The Australia & New Zealand Society of Respiratory Science
and The Thoracic Society of Australia and New Zealand
(ANZSRS/TSANZ) Annual Scientific Meeting

23–27 March 2018
Adelaide, Australia

Disclaimer
This abstract book has been produced using author-supplied copy. Editing has been restricted to some corrections
of spelling and style where appropriate. The publisher assumes no responsibility for any claims, instructions,
methods or drug dosages contained in the abstracts. It is recommended that these are verified independently.

The contents contained herein are correct at the time of printing and may be subject to change.

WILEY
Contents

ANZSRS Oral Abstracts
New Investigators Awards (AO 001 – AO 005)
ANZSRS Oral Abstracts Part (AO 006 – AO 012)

ANZSRS Poster Abstracts
ANZSRS Poster Abstracts (AP 001 – AP 016)

TSANZ Oral Abstracts
TSANZ Respiratory Nurses SIG Symposium 1 (TO 001 – TO 002)
TSANZ Respiratory Nurses SIG Symposium 2 (TO 003 – TO 005)
TSANZ Respiratory Nurses SIG Symposium 3 (TO 006 – TO 007)
Asthma and Allergy 1 (TO 008 – TO 013)
Paediatric (TO 014 – TO 019)
Asthma and Allergy 2 (TO 020 – TO 025)
Cystic Fibrosis 1 (TO 026 – TO 031)
Occupational & Environmental Lung Disease / Population Health (TO 032 – TO 037)
Primary Care / Palliative Care / Tobacco (TO 038 – TO 043)
Cell Immunology & Molecular Biology of the Lung 1 (TO 044 – TO 049)
Chronic Obstructive Pulmonary Disease [COPD] 1 (TO 050 – TO 055)
OLIV 1 (TO 056 – TO 061)
TSANZ Ann Woolcock Young Investigator Awards (TO 062 – TO 067)
Late Breaking Abstracts (TOL 001– TOL 004)
Cystic Fibrosis 2 (TO 068 – TO 073)
Interventional Pulmonary / Bronchology 1 (TO 074 – TO 079)
Pulmonary Physiology & Sleep 1 (TO 080 – TO 085)
Asthma and Allergy 3 (TO 086 – TO 091)
Cell, Immunology & Molecular Biology of the Lung 2 (TO 092 – TO 097)
Chronic Obstructive Pulmonary Disease [COPD] 2 (TO 098 – TO 103)
Pulmonary Physiology & Sleep 2 (TO 104 – TO 109)
Respiratory Infectious Diseases (TO 110 – TO 115)
Asthma and Allergy 4 (TO 116 – TO 121)
Cell, Immunology & Molecular Biology of the Lung 3 (TO 122 – TO 127)
Chronic Obstructive Pulmonary Disease [COPD] 3 (TO 128 – TO 133)
Interventional Pulmonary / Bronchology 2 (TO 134 – TO 139)
Lung Cancer (TO 140 – TO 145)
OLIV 2 (TO 146 – TO 151)
Evidence-Based Medicine and Practice (TO 152 – TO 155)

TSANZ Poster Abstracts
Asthma and Allergy 1 (TP 001 – TPL 002)
Cell, Immunology & Molecular Biology of the Lung 1 (TP 011 – TPL 003)
Chronic Obstructive Pulmonary Disease [COPD] 1 (TP 023 – TPL 006)
OLIV (TP 033 – TPL 047)
Respiratory Infectious Diseases (TP 048 – TPL 007)
Cystic Fibrosis (TP 060 – TPL 072)
Evidence-Based Medicine & Practice (TP 073 – TPL 082)
Asthma and Allergy 2 (TP 083 – TPL 008)
Chronic Obstructive Pulmonary Disease [COPD] 2 (TP 096 – TPL 010)
Paediatric (TP 108 – TPL 070)
Primary Care / Palliative Care / Tobacco (TP 121 – TPL 009)
Asthma and Allergy 3 (TP 131 – TPL 010)
Cell, Immunology & Molecular Biology of the Lung 2 (TP 144 – TPL 155)
Interventional Pulmonary / Bronchology (TP 156 – TPL 167)
Lung Cancer (TP 168 – TPL 181)
Occupational & Environmental Lung Disease / Population Health (TP 182 – TPL 194)
Pulmonary Physiology & Sleep (TP 195 – TPL 011)
WINDS OF CHANGE: BRONCHODILATOR RESPONSIVENESS FROM MORE THAN ONE DIRECTION

PLOEN L1, SOUTHWELL P2, MICALOS P3, SWANNEY M1
1Canterbury District Health Board, Christchurch, New Zealand, 2Charles Sturt University, Orange, Australia, 3Charles Sturt University, Bathurst, Australia

Introduction: Positive bronchial responsiveness (BR) using current American Thoracic Society and European Respiratory Society (ATS/ERS) criteria, purportedly ensures spirometric variability is significantly exceeded. The ATS/ERS guidelines acknowledge there is no clear consensus about what constitutes bronchIAL responsiveness in subjects with airflow obstruction.

Aim: This study investigated the individual variability in multiple spirometric parameters in patients having reversibility tests. We address how spirometric variability can inform current guidelines for identifying a clinically significant bronchial responsiveness response.

Method: 102 consenting participants performed slow vital capacity (SVC) and flow volume loops (FVL) before and after Salbutamol administration. Measurement of symptom control used the clinical chronic obstructive pulmonary disease questionnaire and dyspnoea and wheeze used the visual analogue scale. Two determinants of BR: ATS/ERS criteria and a t-score calculation were compared by correlation with the subjective measurements of respiratory impairment.

Results: 63 participants had positive bronchial responsiveness by t-score calculation compared with 16 by current ATS/ERS guidelines. T-scores showed a weaker correlation with subjective measures of respiratory impairment than per cent and absolute change. Inspiratory vital capacity (IVC), SVC, and inspiratory capacity (IC) correlated more strongly with symptom control, wheeze and dyspnoea than FEV1 or FVC. The mean individual variability and standard deviation (SD) for each parameter is shown in the table.

<table>
<thead>
<tr>
<th>Pre-bronchodilator</th>
<th>Post bronchodilator</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>n</td>
</tr>
<tr>
<td>Mean, SD (L)</td>
<td>Mean, SD (L)</td>
</tr>
<tr>
<td>*CV, SD (%)</td>
<td>*CV, SD (%)</td>
</tr>
</tbody>
</table>

FEV1 101 2.58 (0.98) 1.89 (1.46) 2.74 (1.00) 1.67 (1.45) 1.23 (0.98)
FVC 101 3.60 (1.09) 1.64 (1.27) 3.71 (1.06) 1.35 (1.45) 1.61 (0.98)
SVC 97 3.57 (1.06) 2.29 (2.06) 3.63 (1.07) 1.89 (1.61) 1.61 (1.07)
IC 100 3.56 (1.08) 1.91 (1.22) 3.74 (1.03) 1.45 (1.04) 1.61 (1.03)

Conclusion: The low individual variability may explain the poorer discriminatory ability of BR by t-score because a smaller change is required to be considered significant. T-scores may overestimate bronchial responsiveness, particularly in patients with normal spirometry at baseline. Spirometry values that are less influenced by dynamic compression have potential utility in bronchial responsiveness testing. Ongoing recruitment will allow further investigation into the utility of t-scores and alternative spirometry values for participants with airflow obstruction.

Key Words: Spirometry, variability, bronchial responsiveness
Nomination for New Investigator Award
Grant Support: Nil

ASSESSING THE SUITABILITY OF FRACTIONAL EXHALED NITRIC OXIDE (FeNO) CUT-OFF RANGES FOR ABORIGINAL AND/OR TORRES STRAIT ISLANDER CHILDREN AND YOUNG ADULTS

BLAKE T1,2,3, CHANG A2,3, CHATFIELD M1, PETSKY H1, MCCLEARY M1,2,3
1Centre For Children’s Health Research, South Brisbane, Australia, 2Indigenous Respiratory Outreach Care (IROC) Program, Chermside, Australia, 3Department of Respiratory and Sleep Medicine, LCHC, South Brisbane, Australia, 4QIMR Berghofer Medical Research Institute, Herston, Australia, 5School of Nursing and Midwifery, GU, Nathan, Australia

Introduction/Aim: Fractional exhaled nitric oxide (FeNO) is used as a non-invasive measure of eosinophilic airway inflammation. It is unknown how appropriate the recommended FeNO cut-off ranges are for Aboriginal and/or Torres Strait Islander patients. Our aim was to assess the distribution of healthy Aboriginal and/or Torres Strait Islander FeNO results according to current American Thoracic Society cut-off guidelines.

Methods: We measured FeNO (using Aerocrine NioxMINO) in 991 Indigenous children and young adults (aged 3 to 25 years) from seven Queensland communities. Questionnaires and medical charts were reviewed to identify healthy participants (no respiratory and/or atopic illness ever).

Results: Acceptable FeNO measurements were achieved by 553 children (≤12 years) and 288 adults (>12 years). Participants with a history of respiratory and/or atopic conditions were excluded resulting in a healthy cohort of children (n=401, 72.5%) and adults (n=193, 67%). The geometric mean FeNO results for children and adults were 11.1ppb and 12.5ppb respectively. Table 1 summarises the distribution of healthy FeNO results for each ethnic group according to current cut-off ranges.

<table>
<thead>
<tr>
<th></th>
<th>Child ≤12 years (ppb)</th>
<th>Adult &gt;12 years (ppb)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Normal Int=20 Inflam ≥21</td>
<td>Normal Int=25 Inflam ≥26</td>
</tr>
<tr>
<td></td>
<td>≤20 21-34 ≥35</td>
<td>≤25 26-49 ≥50</td>
</tr>
<tr>
<td>Aboriginal</td>
<td>88% 7% 5%</td>
<td>(n=112) 90% 6% 4%</td>
</tr>
<tr>
<td>Torres Strait Is</td>
<td>83% 6% 11%</td>
<td>(n=134) 87% 10% 7%</td>
</tr>
<tr>
<td>Both</td>
<td>85% 8% 7%</td>
<td>(n=155) 87% 9% 4%</td>
</tr>
</tbody>
</table>

Conclusion: Although the majority of participants had FeNO results within the age-respective normal ranges, we found a proportion of healthy participants with elevated FeNO results in all groups. The greatest proportion of elevated results was seen in Torres Strait Islander children and adults, and Aboriginal/Torres Strait Islander children. This suggests that the recommended cut-off ranges may not be appropriate for these groups. Further investigation is still needed.

Key Words: FeNO, Aboriginal and/or Torres Strait Islander, cut-off ranges
Nomination for New Investigator Award: Yes
Grant Support: IROC Program (Old Health), CRE for Indigenous Lung Health in Children and TPCH Foundation. NHRMC PhD Scholarship (TB), NHMRC Practitioner Fellowship (AC).
COMPARISON OF METHODS FOR POOLING MULTIPLE BREATH NITROGEN WASHOUT DATA

URROZ P1,2, ROBINSON P1,3, KING G1,3, THAMRIN C1
1Woolcock Institute Of Medical Research, Missenden Road, Australia, 2Respiratory Medicine, Campbelltown Hospital, Campbelltown, Australia, 3Children’s Hospital at Westmead, Westmead, Australia

Introduction/Aim: The multiple breath nitrogen washout (MBNW) test measures ventilation heterogeneity in the small airways. Analysis of how the concentration-normalised phase III slope (SnIII) of the expirogram progresses through the washout can provide further insight. This partitions ventilation heterogeneity into a convection-dependent component, primarily reflecting conductive airways (Scond), versus a diffusion-convection-dependent component, primarily reflecting acinar airways (Sacin). Current ERS/ATS consensus[1] recommends SnIII values from three technically acceptable washouts be pooled for reliable estimation of Scond and Sacin. We aimed to compare current methods for pooling MBNW data, to provide evidence to guide ongoing standardisation efforts.

Methods: Three methods were examined: (i) AllBreaths: using all breaths from all three washouts[2], (ii) AvgSlopes: analysing each washout separately and averaging the three Scond and Sacin values [unpublished, default method in commercial MBNW software], (iii) AvgBreaths: averaging each corresponding breath of the 3 tests to produce an average breath 1, 2, etc[3]. Data were collected using an Exhalyzer D system (Eco Medics AG, Duernten, Switzerland).

Results: Data from 10 healthy subjects (3 males, mean±SD age 25±3 years, height 171.1±7 cm, weight 72.2±13.8 kg) were analysed. AvgBreaths tended to yield lower Scond (mean±SD shown in Table), but this was not statistically significant (one-way repeated measures ANOVA, p=0.17). There were no differences seen in Sacin across all methods (p=0.12).

<table>
<thead>
<tr>
<th>Parameter</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>AllBreaths AvgSlopes AvgBreaths</td>
<td></td>
</tr>
<tr>
<td>Scond, L-1</td>
<td>0.017±0.009</td>
</tr>
<tr>
<td>Sacin, L-1</td>
<td>0.061±0.020</td>
</tr>
</tbody>
</table>

Conclusion: In this preliminary analysis, no differences were apparent between the three methods of pooling MBNW data. Further work will examine a wider range of Scond and Sacin values in health and disease. These results help identify any potential sources of differences between laboratories performing MBNW.


Key Words: Multiple breath nitrogen washout, SnIII analysis, ventilation heterogeneity

Grant Support: N/A

IS THE DESATURATION PROFILE APPARENT DURING A 6 MINUTE WALK TEST CONSISTENT WITH THE PROFILE ESTABLISHED DURING A MAXIMAL EXERCISE TEST?

MADIGAN S1, CAFARELLA P1,2, SCHEMBRI D1
1Respiratory Research Unit, Southern Adelaide Local Health Network, Adelaide, Australia, and 2School of Medicine, Flinders University, Adelaide, Australia

Introduction/Aim: To corroborate previous findings that patients desaturate more during six minute walk tests (6MWT) than incremental cardiopulmonary exercise tests (CPET). Secondary aim was to explore predictive characteristics for exercise desaturation.

Method: Retrospective data analysis of patients completing pulmonary rehabilitation (PR) between 2014 and 2016. Inclusion criteria: primary diagnosis of respiratory disease, completed both CPET and 6MWT. Significant exercise desaturation defined as ≥4% change in SpO2 from rest. Chi-squared analysis was undertaken to investigate whether DLCO, EqCO2, P(A-a)O2 or the VE/VCO2 slope were predictive for exercise desaturation. Wilcoxon signed rank test was used to establish differences between resting and minimum saturation levels on pre and post PR 6MWTs.

Results: A total of 35 patients (of 387) met the inclusion criteria. Mean age 60.1 (±SD 11.57) years and FEV1% predicted of 63% (±SD 17.14). Eight patients did not desaturate during either test, 12 desaturated during both tests, 14 desaturated during the 6MWT only and one desaturated during the CPET only. Detailed results are presented in Table 1. CPET achieved a higher peak HR than 6MWT (p-value 0.000). Only DLCO less than 55% predicted desaturation during CPET alone. Markers of gas exchange were not able to predict significant desaturation. Resting and minimum 6MWT SpO2 measurements obtained before and after PR were not significantly different (p-value 0.760 and 0.577 respectively).

Table 1 Predictors of significant desaturation

<table>
<thead>
<tr>
<th>Parameter</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>A-a gradient above ULN (n=30)</td>
<td>0.654</td>
</tr>
<tr>
<td>VE/VCO2 slope above 34 (n=34)</td>
<td>1.00</td>
</tr>
<tr>
<td>EqCO2 (n=34)</td>
<td>0.508</td>
</tr>
<tr>
<td>DLCO 55% predicted or less CPET (n=29)</td>
<td>0.010 *</td>
</tr>
<tr>
<td>DLCO 55% predicted or less 6MWT (n=29)</td>
<td>0.227</td>
</tr>
</tbody>
</table>

*p-value significant.

Conclusion: Consistent with other reports, more patients demonstrated significant desaturation during 6MWT than CPET. Gas exchange parameters failed to predict exercise desaturation during CPET. In agreement with other studies, low DLCO was predictive of desaturation during CPET.

Key Words: Desaturation, Cardiopulmonary exercise test (CPET), Six minute walk test (6MWT).

Nomination for New Investigator Award: Yes

Grant Support: Nil
DO EXERCISE PROTOCOLS INFLUENCE CLINICAL DECISIONS?

WELCH R1, FRANCIS A1, COLLINGWOOD A2, WHYTE K1, KELLY B1, ELLYETT K1
1Auckland District Health Board, Auckland, New Zealand, 2Counties Manukau District Health Board, Auckland, New Zealand

Introduction/Aim: Cardiopulmonary exercise testing (CPET) is an important component of patients’ work-up for lung resection surgery for lung cancer. A peak VO2 (VO2peak) <15 mL·min⁻¹·kg⁻¹ is classified as high risk (1), thus a patient is required to exceed this threshold to be eligible for lung resection surgery.

In 2007 the Auckland District Health Board changed its CPET exercise protocol from an in-house developed treadmill based ramp protocol (Whitlock-Harris (WH)) to a standardised exponential exercise protocol (STEEP) (2). Our study aimed to compare the VO2peak outcomes from these two different protocols to determine if there was a difference in the number of patients achieving >15 mL·min⁻¹·kg⁻¹ threshold, and thus determine if the protocol used influenced the measure of VO2peak used for assessing fitness for surgery.

Method: A retrospective analysis was performed on 159 patients who had been referred for CPET testing for fitness for lung resection surgery between 2004-2010 excluding 2007. Comparisons between the mean VO2peak and proportion of those achieving > 15 mL·min⁻¹·kg⁻¹ were made for those tested with the WH and STEEP protocol.

Results: Those tested with the WH (n=86) achieved mean VO2peak of 17.5 mL·min⁻¹·kg⁻¹ whilst those tested with the STEEP (n=73) achieved mean VO2peak of 20 mL·min⁻¹·kg⁻¹. (p=0.002). There were no significant differences in age, weight or BMI between groups. For those tested with the WH protocol 30% achieved VO2peak < 15 mL·min⁻¹·kg⁻¹ compared to 18% of those tested with STEEP.

Conclusion: Our findings suggest that the exercise protocol used significantly affects the VO2peak attained during testing, and can therefore ultimately influence the decision for lung resection surgery.

Key Words: CPET, VO2, lung cancer, oxygen consumption, lung resection

Nomination for New Investigator Award
I would like to be considered for the new investigator award.

Grant Support: N/A

REFERENCES

LUNG VOLUME PLETHYSMOGRAPHY OCCLUSION TECHNIQUES: PANTING TO TIDAL BREATHING COMPARISON

KIDD P1, JURISEVIC M1, KEATLEY D1, SMITH B1,2
1The Queen Elizabeth Hospital, Adelaide, Australia, 2Clinical Practice Unit, The Basil Hetzel Institute for Translational Health Research, Adelaide, Australia

Introduction/Aim: Lung volumes plethysmography (LVpleth) requires a paning manoeuvre of around 0.5-1.0 Hz (~± 10 cmH2O)during a 2-3 second occlusion obtaining a pressure at functional residual volume (FRC), with a vital capacity manoeuvre to calculate total lung capacity (TLC).

The aim was to determine if there was a difference in test method; and whether there was a preferred technique by patients.

Method: Stratified recruitment occurred for patients already attending a full lung function test at The Queen Elizabeth Pulmonary Function Laboratory. Each patient performed spirometry (pre- and post-bronchodilator), gas transfer, LVpleth (panning, followed by the tidal breathing method). Patients were asked which technique was preferable to perform, and which test instructions were easier to follow.

Data was analysed to determine whether tidal TLC & FRC data fell within ±5% of the GOLD standard panning technique. Paired sample t-tests were used to determine significanceMicrosoft Excel 2010 was used for analyses.

Results: 27 patients were tested (55.6% new patients, 51.9% male, mean age 59yrs, mean BMI of 31.67). Based on clinical diagnosis (by a respiratory consultant following American Thoracic Society guidelines), 37% were normal, 33.3% obstructive, 26% restrictive, 3.7% mixed.

Of 15 patients asked (40% new patients), 40% preferred performing the panting technique, 26.7% tidal breathing, 26.7% indifferent. Tidal breathing was identified as easier to follow. FRC loops were of similar quality, correlating with tidal TLC and FRC analysis and within 5% agreement of the panning technique with no significant difference.

Conclusion: Tidal breathing was identified as easier to follow by patients and had a higher preference. However this may have been bias as the panting was performed first and the ease may be a result of a learned effect. For patients that become overwhelmed with the panting technique, tidal breathing may be a good alternative to obtain FRC values.

Key Words: FRC, TLC, lung volumes plethysmography
Grant Support: None
ASSESSING THE 2017 ERS/ATS SINGLE-BREATH DIFFUSING CAPACITY ACCEPTABILITY AND REPEATABILITY CRITERIA
SMITH E1, BODGER A1
Heart Lung Institute, The Prince Charles Hospital, Brisbane, Queensland, Australia

Introduction/Aim: The 2017 European Respiratory Society/American Thoracic Society standards for single-breath carbon monoxide uptake in the lung propose several changes to acceptability and repeatability criteria.

The aim of this study was to assess current patient results against three of the new criteria – an inspired volume of test gas (VI) greater than 90% of the largest VC, VI >85% and alveolar volumes (VA) within 200mLs or 5%, and DLCO measurements within 2ml/min/mmHg of each other.

Method: The results of 965 consecutive single-breath diffusion measurements (490 male; mean±SD age 65±14 years; DLCO 16.88±6.61 ml/min/mmHg) from July-September 2017 were analysed, all of which were acceptable and repeatable per the 2005 standards.

Results: 97% of tests met the new repeatability criteria for DLCO, while 79% of tests had both inspiratory efforts meeting the new VI acceptability criteria. When taking into account the 200 tests with at least one VI ≥85% and <90% of the largest VC, only 37 did not meet the criteria for a repeatable VA.

Conclusion: The 2017 ERS/ATS DLCO acceptability and repeatability criteria should be easily achievable by the majority of patients.

Key Words: Single breath diffusing capacity, DLCO, technical standards
Grant Support: N/A

PREVALENCE OF ABNORMAL HAEMOGLOBIN LEVELS IN A LUNG FUNCTION LABORATORY POPULATION: IMPACT ON TLCO INTERPRETATION
ROCHFORD P1,2, LANTERI C1,2, BRAZZALE D1,2
1Department of Respiratory and Sleep Medicine, Austin Hospital, Heidelberg, Victoria, Australia, and 2Institute for Breathing and Sleep, Heidelberg, Victoria, Australia

Introduction/Aim: The effect of abnormal haemoglobin (Hb) concentration, and anaemia in particular, on TLCO is well understood. The ERS/ATS 2017 standard recommends Hb correction as optional, leaving open the question of when to apply it. We determined the prevalence of abnormal Hb concentrations in patients attending a public hospital laboratory. We also evaluated the frequency with which correcting for Hb changed TLCO interpretation from normal to reduced (from above to below the lower limit of normal) and from reduced to normal.

Method: 4390 consecutive TLCO measurements performed since January 2016 were analysed. Hb was measured in all patients. TLCO was corrected for Hb using the ERS/ATS recommended equations (to 14.6 for males>14 years and 13.4 gm/dL for females and children<15 years).

Results: The prevalence of Hb<12, <10 and >18 gm/dL was 26.3, 4.8 and 0.6%. Table 1 shows the distribution of Hb’s and change in TLCO after corrected for Hb. Table 2 illustrates the impact of Hb correction on TLCO interpretation.

Table 1

<table>
<thead>
<tr>
<th>Hb (gm/dL)</th>
<th>median</th>
<th>5th-95th perc.</th>
<th>range</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>13.2</td>
<td>10.1 to 15.8</td>
<td>6.1 to 22.1</td>
</tr>
<tr>
<td>ΔTLCO (ml/min/mmHg)</td>
<td>+0.4</td>
<td>-0.8 to +2.6</td>
<td>-2.7 to +8.4</td>
</tr>
<tr>
<td>ΔTLCO (% pred)</td>
<td>+1.5</td>
<td>-2.8 to +9.4</td>
<td>-8.8 to +37.4</td>
</tr>
</tbody>
</table>

Table 2

<table>
<thead>
<tr>
<th></th>
<th>n</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unchanged</td>
<td>4160</td>
<td>95%</td>
</tr>
<tr>
<td>Normal → reduced</td>
<td>40</td>
<td>1%</td>
</tr>
<tr>
<td>Reduced → normal</td>
<td>190</td>
<td>4%</td>
</tr>
</tbody>
</table>

Conclusion: A small but significant proportion of patients referred for TLCO measurements have levels of Hb that require correction in order to avoid misdiagnosis of abnormality. These results suggest a role for routinely correcting for Hb when TLCO is measured.

Key Words: TLCO, haemoglobin correction, CO transfer factor
SMALL AIRWAY FUNCTION IMPROVEMENT WITH MEPOLIZUMAB IN SEVERE EOSINOPHILIC ASThma

ROGERS PG1, SECCOMBE LM1,2, REED N1, BADAL T1,2, THAMRIN C1,2, KING GO1,2,3, PETERS MJ1,2,4, FARAH CS1,2,3,4
1Department of Thoracic Medicine, Concord Hospital, New South Wales, Australia, 2Sydney Medical School, The University of Sydney, New South Wales, Australia, 3The Woolcock Institute of Medical Research, New South Wales, Australia, 4Faculty of Medicine and Health Sciences, Macquarie University, New South Wales, Australia, and 5Department of Respiratory Medicine, Royal North Shore Hospital, New South Wales, Australia

Introduction/Aim: Mepolizumab is a monoclonal antibody against interleukin-5 that was recently approved in Australia for severe eosinophilic asthma. In clinical trials, monthly treatment with mepolizumab results in clinically significant reductions in exacerbation rates, coupled with modest improvements in symptom control scores and FEV1. The acute effects of this biologic treatment on small airway function have not been previously described. The aim of this study is to describe changes in acute effects of this biologic treatment on small airway function have not been previously described. The aim of this study is to describe changes in ventilation inhomogeneity as a marker of small airway function after the commencement of mepolizumab in adult with severe eosinophilic asthma.

Methods: This is a prospective case series of 5 patients (3 males) commencing mepolizumab for severe eosinophilic asthma according to the Pharmaceutical Benefit Scheme pre-specified criteria. At each monthly visit, patients underwent lung function testing including exhaled nitric oxide (eNO), spirometry and the multiple breath nitrogen washout test to measure functional residual capacity (FRC) and global (Lung Clearance Index, LCI) and regional indices of ventilation inhomogeneity attributed to the acinar (Sac in) and conducting (Scond) airways. Results at baseline and four weeks after the first injection are reported.

Results: Mean (range) age of patients was 61 (41-76) years, BMI 23.6 (23-25) kg/m2, post bronchodilator FEV1 50 (36-61) %predicted, FEV1/FVC ratio 50 (31-68) % and median (IQR) eNO 42 (32-75) ppb. One month after the first injection, post bronchodilator FEV1 improved only by 56 (27-151) mL. However, mean FRC improved by 800mL, falling from 3.87 to 3.07 L. Measures of ventilation inhomoegeneity were abnormal in all 5 patients and all improved at one month: LCI 17.6 (13.5-21.6) down to 12.0 (8.96-19.43), Sac in 0.380 (0.247-0.600) /L down to 0.256 (0.140-0.399) /L, Scond 0.075 (0.053-0.100) /L down to 0.061 (0.036-0.105) /L.

Conclusion: Our initial observation suggests an improvement in small airway function as early as four weeks after the first injection of mepolizumab in patients with severe eosinophilic asthma. Measures of ventilation inhomogeneity appear to have greater sensitivity to these improvements than traditional forced manoeuvres.

Key Words: severe asthma, nitrogen washout, small airways, ventilation heterogeneity

Grant Support: Nil

POOR LUNG FUNCTION TRACKS FROM CHILDHOOD TO YOUNG ADULTHOOD, AND IS ASSOCIATED WITH PERSISTENT ASThma IN 22 YEAR OLD PARTICipants OF THE WESTERN AUSTRALIAN PREGNANCY (RAINE STUDY) COHORT

WHITE E1, DEKLERK N1, HOLLAMS E1, HOLT P1, SLY P2, HALL G1,3
1Telopehon Kids Institute, University of Western Australia, Perth, Western Australia, Australia, 2University of Queensland, Brisbane, Queensland, Australia, and 3University of Queensland, Brisbane, Queensland, Australia

Introduction: Impaired lung function in childhood is recognised as a risk factor for impaired lung function and asthma in adulthood.

Aim: This study aimed to explore how lung function tracks through childhood and into young adulthood and identify whether poor lung function in childhood is associated with asthma at age 22 years in a community cohort.

Methods: Participants performed spirometry at 6, 14 and 22 years of age. Quartiles for FEV1 and FEV1/FVC z scores were calculated at age 6 years and lung function at each follow-up was tracked within each quartile group. Associations between childhood low lung function and bronchial hyper-responsiveness, wheezing, asthma medication use, hay fever and asthma outcomes of persistence, remittance and later-onset at age 22 years were investigated.

Results: Participants with FEV1 and FEV1/FVC in the lowest quartile at age 6 years demonstrated persistently reduced lung function at all ages compared to those with lung function in the highest quartile (p<0.00). Low lung function at age 6 years was significantly associated with persistent asthma (p=0.021), current wheeze (p=0.031) and use of asthma medications at age 22 years (p=0.049).

Conclusions: We found that poor lung function in childhood was significantly associated with persistent asthma and asthma symptoms in early adulthood. We also found evidence of lung function tracking from childhood into early adulthood. These results suggest that poor lung function, and an increased risk of asthma in adulthood may be established in early life.

Grant Support: The 22 year Raine Study follow-up was funded by NHMRC grant 1021858 and project grants 1027449, 1044840.

Copyright of individual abstracts remains with the authors.

Respirology (2018) 23 (Suppl. 1), 4–9
REPEATABILITY OF PULSE OXIMETRY MEASUREMENTS RECORDED ON PATIENTS PERFORMING THE SIX MINUTE WALK TEST AFTER PULMONARY REHABILITATION

MADIGAN S1, SCHEMBRI D2, CAFARELLA P1, 2
1Southern Adelaide Local Health Network, Adelaide, Australia 2School of Medicine, Flinders University, Bedford Park, Adelaide, South Australia, Australia

Introduction/Aim: The aim of this study was to assess repeatability of pulse oximetry measurements obtained from repeat 6 minute walk tests (6MWTs). This evaluation would validate if changes in SpO2 reflect variations in physiological factors rather than methodological artefact.

Method: Retrospective analysis of 6MWT oximetry data from pulmonary rehabilitation (PR) program patients (2014 - 2016). Inclusion criteria were: two post PR 6MWTs (ATS/ERS standards), 30 minutes rest between tests, not on supplemental oxygen, reliable oximetry as reported by supervising scientist and no rest periods during test. Differences between SpO2 on repeat walks were tested using Wilcoxon signed rank test. Differences between resting heart rate (HR), peak HR and walk distance between walks were measured by paired t-test.

Results: A total of 103 patients met the inclusion criteria, mean age 70 years (±SD 9.03) with mean FEV1 % predicted 64.87 % (±SD 21.05). Minimum SpO2 was not different between walks. Although statistical difference for distance, resting SpO2, HR and end test HR were found, the absolute differences were not clinically important.

Table 1 Summary results of clinical assessments

<table>
<thead>
<tr>
<th>Clinical measure</th>
<th>Walk 1</th>
<th>Walk 2</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Distance (m)*</td>
<td>424 (97)</td>
<td>431 (99)</td>
<td>0.000</td>
</tr>
<tr>
<td>Resting SpO2 % #</td>
<td>97 (96-98)</td>
<td>97 (96-98)</td>
<td>0.045</td>
</tr>
<tr>
<td>Minimum SpO2 % #</td>
<td>94 (90-96)</td>
<td>94 (91-95)</td>
<td>0.141</td>
</tr>
<tr>
<td>Resting HR BPM *</td>
<td>83 (14)</td>
<td>85 (14)</td>
<td>0.006</td>
</tr>
<tr>
<td>Maximum HR a</td>
<td>113 (101-130)</td>
<td>115 (102-131)</td>
<td>0.003</td>
</tr>
</tbody>
</table>

*data displayed as mean (±sd)
#data displayed as median (lower quartile - upper quartile). Median reported as data not uniformly distributed.

Conclusion: Despite there being a statistical difference between tests for resting SpO2, this is not clinically important. Minimum SpO2 was not different. The repeatability of minimum SpO2 suggests observed desaturation is likely due to physiological factors and not a result of measurement artefact. This is reinforced by the repeatability of HR results and small changes in walk distance between tests.

Key Words: Oxygenation, Six minute walk test (6MWT), oximetry

Grant Support: Nil

VENTILATORY LIMITATION DURING EXERCISE IN PHYSICALLY ACTIVE ADOLESCENT FEMALES

ELLYETT K1, KELLY B2, MCGORAM A2
1Auckland District Health Board, Auckland, New Zealand, and 2University of Melbourne, Melbourne, Australia

Introduction/Aim: This study aimed to determine to what extent ventilatory limitation exists in a population of physically active adolescent females and to correlate this with exertion induced dyspnoea (EID).

Method: Females (n=24) aged 12 to 18 who were participating in regular organised physical activity (> 4h/week) were recruited. Participants underwent pulmonary function assessment and, if prescribed short acting β-agonist, a post-bronchodilator response. A cardiopulmonary exercise test was then carried out during which inspiratory capacity manoeuvres were performed and dynamic flow-volume loops were recorded. At the end of the exercise test Borg score was recorded to assess EID. Flow-volume loops were analysed, using a novel technique to quantify remaining flow reserve, to determine the presence of expiratory flow limitation (EFL), whilst the IRV/FVC ratio calculated to determine presence of an inspiratory limitation (i.e. IRV/FVC <0.1).

Results: Demographic data and peak oxygen consumption data are described in table below.

<table>
<thead>
<tr>
<th>n=24</th>
<th>Mean</th>
<th>SD</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y)</td>
<td>14.3</td>
<td>2.1</td>
<td>12-18</td>
</tr>
<tr>
<td>BMI (kg/m2)</td>
<td>20.4</td>
<td>2.5</td>
<td>17-24.2</td>
</tr>
<tr>
<td>Peak V'O2 (mL/min/kg)</td>
<td>46.5</td>
<td>5.3</td>
<td>35.6-59.2</td>
</tr>
</tbody>
</table>

Five participants were prescribed with β-agonists, however none demonstrated post-bronchodilator effect. 12 of the 24 participants demonstrated EFL during exercise, when combining this group with those whose IRV/FVC were <0.1, 16/24 participants demonstrated some form of ventilatory limitation during exercise. Ventilatory limitation was not correlated with peak V'O2. Only subjects who demonstrated ventilatory limitation during exercise reported a post exercise Borg score >4 (p<0.05).

Conclusion: A significant majority of participants (67%) demonstrated ventilatory limitation during exercise, and this was highly correlated with their sensation of breathlessness. Whilst EID was observed this did not appear to effect peak performance. This study demonstrates that ventilatory limitation in active adolescent females is common and is highly correlated with EID.

Key Words: Exercise, Flow Limitation, Peak V'O2

Nomination for New Investigator Award: NA

Grant Support: Auckland District Health Board A+ Trust, Greenlane Research and Education Fund

Declaration: Authors have no conflicts to declare.
ANZSRS POSTER PRESENTATIONS

SURVEILLANCE OF HIGH ALTITUDE SIMULATION TEST PROTOCOLS IN AUSTRALIA AND NEW ZEALAND
ISAAC A1, GRIFFIN H2, NOFFSINGER W1, SINGH B1,2,3
1Sir Charles Gairdner Hospital, Perth, Australia, 2Hampshire Hospitals NHS Foundation Trust, Basingstoke, United Kingdom, 3West Australian Sleep Disorders Research Institute, Nedlands, Australia, 4Faculty of Science, University of Western Australia, Crawley, Australia

Introduction: Popularity of air travel and an ageing population with respiratory disease has led to an increased need for High Altitude Simulation Tests (HAST). This test is routinely performed across major hospitals in Australia and New Zealand. Despite the abundance of testing, there is a lack of consensus on the method of testing. The British Thoracic Society guidelines do not require exercise during testing1.

Aim & Hypothesis: To determine the most common HAST protocol in respiratory function laboratories in Australia and New Zealand. We hypothesised that the most common protocol included use of a 15% oxygen(O2) mixture, assessment at rest and during exercise, and use of O2 supplementation at rates of 2 and 4L/min.

Method: SurveyMonkey® was used to survey respiratory function laboratories on HAST protocols. Questions included mask type, fraction of inspired oxygen (FiO2), hypoxic gas mixture flow, delivery method, supplemental O2 flow and whether the test involved patient exercise.

Results: Responses were received from 45 respiratory function laboratories and 36 (80%) performed HAST. Among these 36 laboratories, a gas mixture with FiO2=15.0-15.1% was used at 34 (94.4%) laboratories; a protocol using a mask/reservoir bag was used at 12 (33%) laboratories; supplemental O2 was used at 25 (69.4%) laboratories mostly (22, 88%) by nasal prongs; O2 flow rates of both 2 and 4L/min were used at 10 (27.8%) and flow rates of only 2L/min at 9 (25%) laboratories; and patients were exercised during testing at 11 (30.6%) laboratories and this exercise consisted of stepping at 5 (45.5%) of these laboratories.

Conclusion: Various HAST methods are used in respiratory function laboratories in Australia and New Zealand. The commonest protocol used a 15% O2 mixture with supplemental O2 at 2 and 4L/min and did not require the patient to exercise. Increasing HAST protocol consistency between laboratories should be considered in the future.

Key Words: HAST, Survey Monkey®, oxygen, supplemental, mask, titration

REFERENCE

MAGNETIC VERSUS ELECTRICAL PHRENIC NERVE STIMULATION: COMPARISON OF RELIABILITY, SUBJECT DISCOMFORT AND NERVE/MUSCLE LATENCY
ISAAC A1, HARRISON L1, NOFFSINGER W1, SINGH B1,2,3
1Pulmonary Physiology & Sleep Medicine, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia, 2West Australian Sleep Disorders Research Institute, Nedlands, Western Australia, Australia, and 3Faculty of Science, University of Western Australia, Crawley, Western Australia, Australia

Introduction: In patients with diaphragm weakness, unilateral phrenic nerve stimulation can be used to determine the integrity and conduction properties of each phrenic nerve. Phrenic nerve latency is typically 6-8 milliseconds in adults and may be delayed in demyelinating polyneuropathies e.g. Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy. The phrenic nerve can be stimulated either electrically or magnetically.

Aim & Hypothesis: To compare the reliability, subject discomfort and phrenic nerve/diaphragm latency of the magnetic versus electrical phrenic nerve stimulation. We hypothesised that compared to electrical stimulation, magnetic stimulation was more reliable, less distressing to the subject, and produced identical nerve/diaphragm latencies.

Method: In 8 healthy male subjects, each phrenic nerve was stimulated at the neck electrically (150 V, duration 0.1 ms., delay 0.01 ms., rate 0.5 Hz) and magnetically (MagStim) at 30, 50, 70 and 90% maximum output. Compound muscle action potentials (CMAP) were detected using surface electrodes placed in the mid-axillary line at the 8th and 9th rib interspaces, and displayed on a digital chart recorder (PowerLab). We measured the number of stimulations required to elicit an analysable CMAP, the degree of discomfort (using a Borg CR-10 questionnaire), and nerve/muscle latencies. Data are expressed as mean ± SD and were compared using paired t-tests. Significance was defined as p<0.05.

Results: Subjects were aged 36.1±15.3 years and had BMI 25.2±2.8 kg/m².

<table>
<thead>
<tr>
<th>Output (%)</th>
<th>Electrical</th>
<th>Magnetic</th>
</tr>
</thead>
<tbody>
<tr>
<td>30%</td>
<td>1.0±0*</td>
<td>1.0±0</td>
</tr>
<tr>
<td>50%</td>
<td>1.0±0*</td>
<td>1.0±0</td>
</tr>
<tr>
<td>70%</td>
<td>1.0±0*</td>
<td>1.0±0</td>
</tr>
<tr>
<td>90%</td>
<td>1.0±0*</td>
<td>1.0±0</td>
</tr>
</tbody>
</table>

*p<0.05 difference from electrical stimulation

Conclusions: Compared to electrical phrenic nerve stimulation, magnetic stimulation was more reliable and, except at high output, caused less discomfort and obtained similar latencies.

Key Words: phrenic nerve stimulation, electrical, magnetic, latency, discomfort, Borg score
COUGH SENSITIVITY TO MANNITOL INHALATION CHALLENGE IDENTIFIES SUBJECTS WITH COUGH
BRANNAN J1, LAKE C2, WONG K2, KOSKELA H3
1John Hunter Hospital, Newcastle, Australia, 2Royal Prince Alfred Hospital, Camperdown, Australia, 3Kuopio University Hospital, Kuopio, Finland

Introduction/Aim: It is unknown whether cough sensitivity to mannitol identifies subjects with cough and whether it correlates with subjective cough severity.

Method: Subjects with cough as the primary symptom (n=17), with other airway symptoms (n=52) and healthy subjects (n=15) performed mannitol challenge and completed the Leicester Cough Questionnaire (LCQ).

Results: The mean (95%CI) number of provoked coughs divided by the cumulative dose of mannitol (CDR) was 21.1 (12.6 – 35.4) in subjects with cough, 6.25 (4.15 – 9.40) in those with other symptoms and 2.80 (1.3 – 6.10) coughs/100 mg in the healthy subjects (p<0.001). Area under the receiver-operating characteristic curve comparing cough subjects against healthy subjects was 0.95 and when comparing cough subjects against healthy controls and subjects with other symptoms it was 0.80. There was a significant correlation between CDR and LCQ total score (rs= -0.50, p=0.04) within the cough group, as well as when combining both subjects with cough and other airway symptoms (rs= -0.43, p<0.001).

Conclusion: Cough sensitivity to mannitol identifies subjects with cough and correlates with subjective cough severity. Since mannitol challenge can be performed without complicated equipment or trained personnel in a standardised fashion, it is a promising diagnostic test for cough hypersensitivity syndrome.

Key Words: cough hypersensitivity, mannitol

Grant Support: Nil

GASTRIC-OESOPHAGEAL (GOR) REFLUX DURING SPIROMETRY. PREVALENCE AND EFFECTS
BRANNAN J1, ZHOU J2, HO V3, TEO M4
1John Hunter Hospital, Newcastle, Australia, 2University of Western Sydney, Campbelltown, Australia, 3Blacktown Hospital, Blacktown, Australia

Introduction: Variability during spirometry can persist despite control of technical and personal factors. We hypothesised that spirometry may induce GOR which may influence upper airway variability leading to variability of spirometry.

Aim: Pilot study assessing prevalence of GOR during spirometry and its effects on spirometry variability in subjects having outpatient GOR assessment.

Method: At the end of oesophageal manometry and 24hr pH monitoring, 56 subjects performed 2 sets of spirometry separated by 10-minutes. The De-Meester score quantified 24hr GOR (≥ 14.72 in significant GOR). Assessment for GOR during spirometry started with 1st spirometry and ends with 2nd spirometry manoeuvres. Variability of spirometry was assessed between those with GOR and no GOR.

Results: In 26 subjects (44%) had GOR during spirometry assessment: 18 during the 10-minute break with 3 persisting into the 2nd spirometry, 5 throughout assessment, and 3 during spirometry only. They tended to have higher De-Meester scores (mean 39.8 vs 26.8, t-test p=0.13) and were more likely have a GOR event preceding the 1st spirometry (median time interval [min] 8.5 [IQR 5 – 12] vs 25 [IQR 10 – 70]), compared to 30 subjects without GOR during spirometry assessment. In the GOR group both FEV1 and PEF were reduced in the second spirometry set; FEV1 by 84mL (p<0.05), PEFR by 0.5L/s (p<0.001). FVC was not changed. Mean variability of spirometry (%) ± SD was similar between GOR and non-GOR groups as described in Table below.

<table>
<thead>
<tr>
<th>GOR Present (n=25)</th>
<th>No GOR (n=30)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Spirometry 1st</strong></td>
<td><strong>2nd</strong></td>
</tr>
<tr>
<td>FVC variability</td>
<td>6.8 ± 7.3</td>
</tr>
<tr>
<td>FEV1 variability</td>
<td>9.7 ± 11.3</td>
</tr>
</tbody>
</table>

Conclusion: GOR occurs during and following spirometry in subjects having outpatient GOR assessment, but does not significantly impact spirometry variability over 10-minutes in this patient population.

Key Words: spirometry, gastric oesophageal reflux
Better Incremental Workload Equations Are Needed to Predict Maximal Workload for Cardiopulmonary Exercise Tests (CPET) Performed in an Optimal Test Time

MASCARENHAS S1, SCHOFFEL R1, HANDLEY B1, WALLIS R1, KING G1,2,3
1Royal North Shore Hospital, St. Leonards, Australia, 2Woolcock Institute of Medical Research, Glebe, Australia, 3Northern Clinical School, University of Sydney, Australia

Introduction/Aim: Cardiopulmonary Exercise Tests provide a global assessment of multi-organ system function. In order to obtain optimal results and ensure accurate interpretation, it is advantageous to perform the CPET with an appropriate workload protocol and incremental phase lasting 8-12 minutes. This study aimed to determine which of 6 progressive workload equations best predict the maximal workload during an ideal test time of 10 minutes.

Method: 50 patients aged 23-82 (M=23, F=27) were referred to the Laboratory for cardiopulmonary assessment. The maximal CPET included Spirometry in all, Maximal Voluntary Ventilation (MVV) in 15 patients, and used an incremental ramp protocol. Paired T tests compared the achieved workload of each subject to six progressive workload equations. Bland-Altman analysis was applied to this comparison to determine the average bias. For equations 4-6 which predict a ramp increment, a multiplier of 10 was applied to achieve a predicted maximum workload (wmax) at 10 minutes.

<table>
<thead>
<tr>
<th>Equation Number</th>
<th>Sample size</th>
<th>Mean wmax achieved ± SD (watts)</th>
<th>Mean wmax predicted ± SD (watts)</th>
<th>T-test (achieved wmax vs. predicted wmax)</th>
<th>Mean Differences ± SD (watts)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>n=50</td>
<td>141 ± 77</td>
<td>128 ± 59</td>
<td>NS</td>
<td>13 ± 51</td>
</tr>
<tr>
<td>2</td>
<td>n=19</td>
<td>152 ± 91</td>
<td>270 ± 100</td>
<td>p= 5.015E-06</td>
<td>-118 ± 78</td>
</tr>
<tr>
<td>3</td>
<td>n=15</td>
<td>162 ± 90</td>
<td>234 ± 107</td>
<td>p= 0.001</td>
<td>-72 ± 66</td>
</tr>
<tr>
<td>4</td>
<td>n=50</td>
<td>141 ± 77</td>
<td>109 ± 47*</td>
<td>p= 3.07E-06</td>
<td>32 ± 49</td>
</tr>
<tr>
<td>5</td>
<td>n=21</td>
<td>131 ± 59</td>
<td>112 ± 46*</td>
<td>p=0.03</td>
<td>19 ± 37</td>
</tr>
<tr>
<td>6</td>
<td>n=50</td>
<td>141 ± 77</td>
<td>131 ± 56*</td>
<td>NS</td>
<td>10 ± 51</td>
</tr>
</tbody>
</table>

# ramp-10 to predict wmax at 10 minutes.

Results:

Conclusion: This study demonstrated that wmax predicted by Equations 1 and 6 best correspond to the achieved workload in this patient group due to minimal bias. These equations utilise age, height and either ideal or measured weight. Inclusion of FEV1 to predict MVV (2), actual measured MVV (3), FEV1 coupled with anthropometric data (4), and diffusion capacity (5) all measures of the individual's respiratory health, did not further improve the prediction of wmax.


Key Words: Cardiopulmonary Exercise Test, Workload, Ramp

Nomination for New Investigator Award: No

Grant Support: No
A COMPARISON OF MEDGRAPHICS AND JAEGER LUNG
FUNCTION EQUIPMENT WITH SPIROMETRY, DIFFUSING
CAPACITY AND BODYPLETHYSMOGRAPHY PARAMETERS
BY LUNG FUNCTION BIOCONTROL MEASUREMENTS
LIU X1, JURISEVIC M1, KEATLEY D1, KIDD P1, SMITH B1
1The Queen Elizabeth Hospital Of South Australia, Adelaide, Australia

Introduction/Aim: There may be inherent variability in the measurement of respiratory manoeuvres between different lung function equipment. Therefore, it is important to use biological controls to prospectively detect any variability upon a lab’s replacement of lung function testing equipment.

The aim of this study was to compare variability in measurement of spirometry, diffusing capacity and body plethysmography between Medgraphics and Jaeger equipment by using biological control data.

Method: Spirometry, diffusing capacity and body plethysmography parameters, from four healthy, non-smoker technicians (three female & one male), were collected using Medgraphics Elite Full Body Plethysmograph and Jaeger Master Screen Body Plethysmograph with MS-PFT Analyser Unit lung function equipment. These results were compared to detect variation between Medgraphics and Jaeger systems.

All of the biocontrol data were collected within the same calendar year. Means of FEV1, FVC, DLCO, VA, FRC and TLC of individual subject were compared using t-test. Coefficient of variation in percentage (CV%) were compared using the Mann-Whitney U test.

Results: The comparison of CV% between Medigraphic and Jaeger systems showed no significant statistical differences in any of the investigated parameters. Spirometry: FEV1 (2.41% vs 2.35%, p>0.05) and FVC (2.12% vs 2.33%, p>0.05), DLCO (5.12% vs 4.4%, p>0.05) and VA (2.27% vs 2.69%, p>0.05) and TLC (2.61% vs 1.93%, p>0.05) and FRC (5.7% vs 5.19%, p>0.05).

The mean of individual subject’s above lung function parameters did not show significant differences.

Conclusion: The results showed no statistically significant differences in spirometry, diffusing capacity and body plethysmography parameters between Medigraphics Elite Body Plethysmograph and Jaeger Master Screen Body Plethysmography with MS-PFT Analyser Unit.

Key Words: biological control, spirometry, diffusing capacity, body plethysmography

Nomination for New Investigator Award: No
Grant Support: None
LUNG FUNCTION BEFORE AND AFTER TREATMENT OF VOCAL CORD DYSFUNCTION (VCD)

RUANE L1, BAXTER M2, LEAH E1, HEKE E1, BARDIN P1

1Monash Lung & Sleep, Monash Medical Centre and University, Melbourne, Victoria, Australia, and 2Monash ENT and Speech Therapy, Monash Health, Melbourne, Victoria, Australia

Introduction/Aim: Vocal cord dysfunction (VCD) often accompanies asthma. Effective treatment of VCD may improve lung function, especially measures of airway resistance. As part of a multidisciplinary VCD clinic, patients with confirmed VCD (via endoscopy and/or CT larynx) were evaluated before and after speech therapy and botulinum toxin injection.

Method: Patients with confirmed VCD (n=35) were assessed. Diagnosis of VCD was based on detection of inspiratory paradoxical vocal cord movement (PVCM) on at least on occasion. Pre and post spirometry were done, we also conducted resistance measurements and measured lung volumes via body plethysmography before and after treatments. Results were compared using paired t-tests.

Results: Speech therapy was provided to 35 patients and botulinum toxin injections were administered to 22 patients. Baseline patient demographics are shown in Table 1. All results reported are post bronchodilator (except LV). There were no significant changes to lung function or resistance measures after either speech therapy or botulinum toxin injection. There were changes in sGaw after both treatments that approached statistical significance.

Conclusion: Treatment of VCD with speech therapy and botulinum toxin injection do not improve airway function. However, absence of changes in physiology does not preclude improvements in symptoms and other features of VCD.

Grant Support: Monash Lung & Sleep Institute, Monash Health

Table 1. Patient demographic data pre and post speech therapy and botulinum toxin injection

<table>
<thead>
<tr>
<th></th>
<th>Speech Tx (n=35)</th>
<th>Botulinum Toxin (n=21)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pre</td>
<td>Post</td>
</tr>
<tr>
<td>Age</td>
<td>60.29±13.12</td>
<td>-</td>
</tr>
<tr>
<td>BMI</td>
<td>30.84±7.32</td>
<td>-</td>
</tr>
<tr>
<td>FEV1 (% pred)</td>
<td>78.50±21.62</td>
<td>81.0±22.0</td>
</tr>
<tr>
<td>TLC (% pred)</td>
<td>99.92±14.93</td>
<td>102.12±14.39</td>
</tr>
<tr>
<td>Raw</td>
<td>4.39±3.27</td>
<td>3.45±3.13</td>
</tr>
<tr>
<td>sGaw</td>
<td>0.11±0.07</td>
<td>0.16±0.10</td>
</tr>
</tbody>
</table>
OUTCOMES IN VOCAL CORD DYSFUNCTION (VCD) AFTER SPEECH THERAPY AND BOTULINUM TOXIN INJECTION TREATMENTS
RUANE L1, BAXTER M2, LEAH E1, HEKE E1, BARDIN P1
1Monash Lung & Sleep, Monash Medical Centre and University, Melbourne, Melbourne, Victoria, Australia, and 2Monash ENT and speech Therapy, Monash Health, Melbourne, Victoria, Australia

Introduction/Aim: Vocal cord dysfunction (VCD) causes vocal cord narrowing during inspiration resulting in airflow obstruction and may contribute to breathlessness in asthma. Treatment is difficult, however speech therapy and botulinum toxin (Botox) injections can be effective. As part of a multidisciplinary VCD clinic, patients undergoing treatment were evaluated for symptom and healthcare outcomes.

Method: Patients with confirmed VCD (n=35) were assessed. VCD was diagnosed by detection (CT larynx and/or laryngoscopy) of inspiratory paradoxical vocal cord movement (PVCM) on at least one occasion. Patients were then treated with speech therapy (n=35) and if this failed with botulinum toxin injection (n=21). They were assessed pre and post treatment. Patient symptoms were evaluated using standardised asthma, dysfunctional breathing and VCD questionnaires (ACT, ACQ, Nijmegen, VCDQ). Health care outcomes were assessed by questionnaire to determine emergency department (ED) and general practitioner (GP) visits in the year prior to and after treatment.

Results: There were no significant differences in the standardised questionnaires post speech therapy (ACQ: p=0.19; ACT: p=0.28; VCDQ: p=0.66; Nijmegen: p=0.68). Although GP visits were not significantly reduced post treatment (p=0.07), ED visits were significantly reduced post speech therapy (p=0.01). The 21 patients who had botulinum toxin injection had a significant reduction in GP visits (p=0.05) but no reduction in ED visits (p=0.11). There was also no significant difference in questionnaires (ACQ: p=0.13; ACT: p=0.14; VCDQ: p=0.66; Nijmegen: p=0.37).

Conclusion: Speech therapy and botulinum toxin injection did not improve patient symptom scores linked to asthma and VCD. However, important health outcomes (GP visits and ED admissions) were reduced. The reasons for the discordance between symptoms and health outcomes are unclear.

Grant Support: Monash Lung & Sleep Institute, Monash Health

AUDIT TO MONITOR AND IMPROVE THE QUALITY OF RESPIRATORY FUNCTION REPORTS AT EASTERN HEALTH
DEL COLLE E1, HARTLEY F1, HUSBAND A1, HUANG P1, AMINAZAD A1, THIEN F1,2
1Eastern Health, Box Hill, Australia, 2Monash University, Clayton, Australia

Introduction/Aim: To address errors identified in respiratory function reports (RFRs) during TSANZ Laboratory Accreditation, we developed an audit tool to identify systematic or random errors, to monitor and improve the quality of our reports. Audit items included: demographic, clinical notes, technical comments, feasibility of results, transcription errors as well as interpretation concordance against current ATS/ERS interpretation guidelines.

Method: Eighty randomly selected RFRs (two/day for 8 weeks) from June to August 2016 were subsequently reviewed by both one of three Physicians and one of two Scientists. The auditing Physician/Scientist did not review their own reports to eliminate potential conflict of interest. The audit tool consisted of 49 questions including “Critical questions” eg gender correct? interpretation correct? and “Non-critical questions” eg spelling mistakes?

Results: Of the 80 randomly selected RFRs reviewed, we identified 0.6% errors (22 errors / (49 total no. questions x 80 reports). When we included methodical checking of lung volume subdivisions as part of their reporting strategy. The audit results and areas for improvement were discussed with the Physicians / Scientists. The Physicians have now included methodical checking of lung volume subdivisions as part of their reporting strategy. The audit was a useful tool given that we had recently recruited new Physicians which not only consolidated their training in reporting, but an excellent opportunity to ensure their reporting style was standardized for Eastern Health. This audit will now be conducted annually.

Key words: respiratory function reporting, audit
Nomination for New Investigator Award
Grant Support:
FEV1 reproducibility during bronchial challenge to inhaled mannitol in relation to severity of bronchial hyperresponsiveness (BHR)

MANSOUR N1, BRANNAN J2, PERRY C1, WHEATLEY J1,3,4
1Westmead Hospital, Westmead, Australia, 2John Hunter Hospital, New Lambton, Australia, 3Westmead Institute of Medical Research, Westmead, Australia, 4University of Sydney, Westmead, Australia

Introduction: Protocols measuring BHR by administering methacholine using deep inhalations can lead to negative tests in mild BHR. Repeated deep inhalations may reduce bronchoconstriction due to airway smooth muscle (ASM) stretch. Measuring BHR using FEV1, also a deep inhalation manoeuvre, may possibly cause ASM stretch leading to improved subsequent FEV1 values in protocols where repeated FEV1 values are required after each provoking dose.

Aim: To determine if there is evidence of increases in FEV1 following provoking dose steps during a mannitol challenge in subjects with different severities of BHR.

Method: Subjects for occupational assessment for asthma using inhaled mannitol (n=67; median age 20yrs, range: 16-48yrs; 58M:9F) had FEV1 manoeuvres assessed for quality, and the difference of the best second FEV1 compared to best first FEV1.

Results: Subjects were analysed who had either moderate (n=20) or mild (n=30) BHR documenting a 15% fall in FEV1, as well as subjects with borderline BHR who documented a maximum fall in FEV1 of between 10%-15% (n=17).

<table>
<thead>
<tr>
<th>BHR Level</th>
<th>Mannitol Dose (mg)</th>
<th>Difference in First FEV1 to Best FEV1 (% change)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moderate</td>
<td>35mg</td>
<td>+0.40.8</td>
</tr>
<tr>
<td></td>
<td>75mg</td>
<td>+0.50.8</td>
</tr>
<tr>
<td></td>
<td>155mg</td>
<td>+0.51.1</td>
</tr>
<tr>
<td></td>
<td>315mg</td>
<td>+0.70.9</td>
</tr>
<tr>
<td></td>
<td>475mg</td>
<td>+1.11.5</td>
</tr>
<tr>
<td></td>
<td>635mg</td>
<td>+1.92.7</td>
</tr>
<tr>
<td></td>
<td>875mg</td>
<td>+0.71.5</td>
</tr>
<tr>
<td>Borderline</td>
<td>35mg</td>
<td>+0.51.2</td>
</tr>
<tr>
<td></td>
<td>75mg</td>
<td>+1.31.4</td>
</tr>
<tr>
<td></td>
<td>155mg</td>
<td>+1.92.1</td>
</tr>
<tr>
<td></td>
<td>315mg</td>
<td>+2.12.9</td>
</tr>
<tr>
<td></td>
<td>475mg</td>
<td>+2.11.6</td>
</tr>
</tbody>
</table>

Data in table are presented as mean±SD. *p<0.05, **p<0.01, ***p<0.001.

The best second FEV1 was consistently higher compared to the first FEV1 at all doses in all severities of BHR, with larger differences observed in the final 3 (mild) provoking dose steps. Thus, if % fall in FEV1 was calculated using the first FEV1, 53% of subjects with borderline BHR (n=9) would be reclassified as having mild BHR.

Conclusion: There are small increases in FEV1 with repeated FEV1 manoeuvres for all severities of BHR, with larger changes seen in those with borderline BHR. This suggests an FEV1 manoeuvre may cause ASM stretch in asthmatics.

Key Words: mannitol, bronchial hyperresponsiveness

Feasibility of lung function testing & results in children with spinal muscular atrophy type II & III

DEEGAN S1, SHACKLETON C2, KAPUR N1,3,4, GAULD L1
1Department of Respiratory & Sleep Medicine, Lady Cilento Children’s Hospital, Brisbane, Brisbane, Queensland, Australia, 2UQ Child Health Research Centre, University of Queensland, Brisbane Queensland, Australia, 3School of Medicine, University of Queensland, Brisbane, Queensland, Australia

Introduction/Aim: Respiratory function testing is important for children with spinal muscular atrophy (SMA) as a way of monitoring disease progression and timing of interventions. However, it is unclear which tests are most appropriate for this patient group. Our objectives were (1) to assess feasibility of a variety of lung function tests in children with SMA type II and III, and (2) establish baseline data in this unique cohort for future clinical research.

Method: Subjects (n=18) were prospectively recruited when they had a respiratory outpatient appointment or overnight sleep study. Forced oscillation technique (FOT), Lung clearance index (LCI) via Multiple breath washout, spirometry, peak cough flow (PCF), sniff nasal inspiratory pressure (SNIP), maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) were attempted on all subjects.

Results: Subjects able to perform and achieve results with PCF, MIP and MEP were comparatively lower so data was excluded from analysis. Table highlights the difference in the number of patients able to adequately perform each test and subsequently achieve acceptable results. Median of all results reported (IQR).

<table>
<thead>
<tr>
<th>Lung Function Test</th>
<th>Number Tested</th>
<th>No Results</th>
<th>Achieved Results</th>
<th>Results Median (IQR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FOT</td>
<td>15</td>
<td>5</td>
<td>10</td>
<td>2.4 (2.11 - 3.75)</td>
</tr>
<tr>
<td>FOT Rrs z score</td>
<td>15</td>
<td>5</td>
<td>10</td>
<td>-2.03 (-2.51 - -0.86)</td>
</tr>
<tr>
<td>FOT Xrs z score</td>
<td>15</td>
<td>5</td>
<td>10</td>
<td>7.34 (6.96 - 8.16)</td>
</tr>
<tr>
<td>MBW</td>
<td>16</td>
<td>5</td>
<td>11</td>
<td>84 (34.8 - 92.9)</td>
</tr>
<tr>
<td>LCI</td>
<td>16</td>
<td>2</td>
<td>14</td>
<td>-2.4 (-3.1 - -1.5)</td>
</tr>
<tr>
<td>Spirometry FVC (%)</td>
<td>9</td>
<td>0</td>
<td>9</td>
<td>-</td>
</tr>
</tbody>
</table>

Conclusion: Establishing which tests are more appropriate for children with SMA will help to improve the quality of lung function results and better optimise patient management. While MIP, MEP and PCF may have clinical relevance, subjects ability to perform these tests were more variable compared with reported results. This suggests that these tests may not be useful for monitoring patient progress.

Key Words: Respiratory function, Spinal muscular atrophy, feasibility

Nomination for New Investigator Award: No
Grant Support: None
USING IDEAL BODY WEIGHT TO ADJUST PREDICTED VO2
SMITH I1, SMITH E1
1Heart Lung Institute, The Prince Charles Hospital, Chermside, Australia

Introduction: Peak VO2 is used to stratify patients with diagnosed chronic heart failure (CHF). CHF patients with a VO2%pred <50% or <14ml/kg/min have a three-fold increased risk of death within 6 months1.

Aim: To assess whether adjusting predicted VO2 for ideal body weight (IBW) results in an increase of patients with a VO2 <50% predicted.

Method: A retrospective analysis of cardiopulmonary exercise tests (CPET) results between June 2014 and June 2017 was performed. 306 subjects (184 male) underwent CPET within the respiratory department. 107 of these subjects had a body mass index (BMI) > 30. A paired t-test and a chi-squared analysis were used to assess the difference between VO2% predicted using actual body weight and IBW.

Results: Without adjusting for IBW, 15 subjects had a VO2 <50% predicted. After adjusting for IBW, 40 patients had a VO2 <50% predicted. Significant differences were found in VO2% predicted between actual body weight and IBW (p<0.01).

Conclusion: Adjusting for IBW in patients with a BMI >30 results in an increase of patients with a VO2 <50% predicted, assisting with additional stratification for patients diagnosed with CHF.

Key Words: cardiopulmonary exercise test, VO2, IBW

Nomination for New Investigator Award: Grant Support:

A CULTURALLY APPROPRIATE INDIGENOUS SPIROMETRY TRAINING PROGRAM—A MEANS TO IMPROVE QUANTITY AND QUALITY OF SPIROMETRY PERFORMED IN PRIMARY CARE
RODWELL L1, SCHNEIDER I1, MCELREA M1, BROWN M3
1Respiratory Laboratory, Lady Cilento Children’s Hospital, QLD Health, Brisbane, Queensland, Australia, 2Respiratory Investigation Unit, The Prince Charles Hospital, QLD Health, Chermside, Queensland 4032, Australia, and 3Respiratory Laboratory, Royal Brisbane & Women’s Hospital, QLD Health, Herston, Queensland Australia

Introduction: Health workers (HW) trained and mentored in the Indigenous Health Worker spirometry training program (STP) and who are supported by their managers are more likely to do spirometry (spiro) and achieve quality test results.

Aim: To assess the quantity & quality of spiro performed by HW after attending the STP.

Method: HW in Indigenous primary care who were either already performing spiro or were being required to commence performing spiro attended our 2 day culturally appropriate STP. A number of tests performed before training (PreSTP) and after training (PostSTP) were submitted for quality assessment which included patient demographics, test acceptability and repeatability and technical comment inclusion (a total score out of 8). The average quality test score was calculated for a HW’s portfolio and the mean±SD quality score was calculated for the group PreSTP & PostSTP.

Results: 28 HW submitted spiro tests either PreSTP and/or PostSTP (16 Indigenous). There was an increase in the number of HW doing spiro testing.

<table>
<thead>
<tr>
<th>Quality score</th>
<th>Pre STP</th>
<th>Post STP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean</td>
<td>4.5</td>
<td>5.3</td>
</tr>
<tr>
<td>±SD</td>
<td>1.78</td>
<td>1.57</td>
</tr>
<tr>
<td>n</td>
<td>8</td>
<td>25</td>
</tr>
</tbody>
</table>

(*n = HW’s who submitted spiro test results)

Conclusion: The Indigenous Health Worker spirometry training program increases the number of HW doing spiro. There is a trend towards improved quality of spirometry after training. Post workshop telehealth mentoring may further improve spiro quality.

Key Words: Spirometry training, Indigenous Primary Care

Nomination for New Investigator Award: No

Grant Support: Nil
VARIABILITY OF COMPUTER ADJUSTMENT OR SCIENTIST ADJUSTED PHASE 3 SLOPES OF SCOND & SASCIN SLOPES IN ECO MEDICS EXHALYZER MULTI BREATH NITROGEN WASHOUT

HANDLEY B1, MASCARENHAS S1, SCHOEFFEL R1, FARROW C2, MILNE S2,3, TONGA K2,3, KING G1,2,3
1Royal North Shore Hospital, Sydney, Australia, 2Woolcock Institute of Medical Research, Sydney, Australia, 3University of Sydney, Sydney, Australia

Introduction/Aim: The use of multi-breath nitrogen washout (MBNW) for the calculation of parameters of airways heterogeneity, Sacin and Scond is increasing in both adult and paediatric respiratory function laboratories. These indices may help detect early onset of diseases affecting small airways. Software within new MBNW device’s calculates the slope of phase 3 of the washout curve. Software in earlier in-house equipment required the investigator to manually adjust slopes. This study aims to determine the difference in Scond and Sacin adjusted manually compared to those indices generated by the software with no manual adjustment.

Method: 3 groups ( Normal, Asthma & COPD) with a smoking history <5pk yrs performed MBNW with controlled tidal breathing of 1L to 1.3L x 3 with FRC within ±10% using the Eco Medics Exhalyzer® D Nitrogen Washout Bypass System. Scond and Sacin were compared when the slope phase 3 was manually adjusted by the same investigator and unadjusted, using mean differences and paired t test.

Results: 8 Normal, 8 Asthmatics and 8 COPD were studied. A paired T test showed that there was no statistically significance difference between adjusted and unadjusted Scond for any group (p=0.065, 0.169, 0.645). However for all groups Sacin showed a significance difference (p=0.003, 0.007, 0.010) between adjusted and unadjusted values.

<table>
<thead>
<tr>
<th></th>
<th>Scond</th>
<th>Sacin</th>
<th>Mean difference Scond Adjusted vs Unadjusted</th>
<th>Mean difference Sacin Adjusted vs Unadjusted</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(±SD)</td>
<td>(±SD)</td>
<td>(±SD)</td>
<td>(±SD)</td>
</tr>
<tr>
<td>Normal</td>
<td>0.018</td>
<td>0.084</td>
<td>0.002</td>
<td>0.024</td>
</tr>
<tr>
<td></td>
<td>(0.006)</td>
<td>(0.046)</td>
<td>(0.003)</td>
<td>(0.018)</td>
</tr>
<tr>
<td>Asthma</td>
<td>0.032</td>
<td>0.186</td>
<td>-0.154</td>
<td>0.046</td>
</tr>
<tr>
<td></td>
<td>(0.022)</td>
<td>(0.078)</td>
<td>(0.066)</td>
<td>(0.034)</td>
</tr>
<tr>
<td>COPD</td>
<td>0.046</td>
<td>0.437</td>
<td>0.002</td>
<td>0.067</td>
</tr>
<tr>
<td></td>
<td>(0.018)</td>
<td>(0.216)</td>
<td>(0.010)</td>
<td>(0.055)</td>
</tr>
</tbody>
</table>

Conclusion: This data suggests that adjustment of the phase 3 slope is not required for calculation of Scond but as Sacin differed significantly when adjusted by the investigator, compared to the unadjusted values, manual adjustment continues to be indicated. Although seeing a significant difference within this small group data, the effect is yet to be seen in larger groups.

Key Words: Multi-Breath Nitrogen Washout (MBNW), FRC, Phase 3 Slope

Nomination for New Investigator Award: No
Grant Support: No
A REVIEW OF LUNG FUNCTION TESTS IN PATIENTS WHO HAVE UNDERGONE ENDOBRONCHIAL VALVE INSERTION

PRETTY J1, DIMITRIADIS T1, RAMONDETTA L1, SAYKAO O1, EDMONDSTONE S1, STEINFORT D1
1Royal Melbourne Hospital, Melbourne, Victoria, Australia

Background: Endobronchial valves can help emphysema patients who suffer from hyperinflation by reducing lung volumes using minimally invasive procedures, rather than undergoing lung reduction surgery (Frank C. Sciurba et al. 2010, p.1233-1244).

Aim: To assess lung function improvement with physical functional improvement in patients who have had recent endobronchial valve insertion.

Method: Eight patients mean aged 72 ± 7.5 years, 7 male and 1 female, were assessed over the course of 4 months pre and post endobronchial valve insertion. Lung function testing including Spirometry, Body plethysmography and 6 minute walk test distance were performed. The lung function tests were then analysed to determine if any results had an improvement greater than 12%, which is considered substantial.

Results: Table below contains the percentage change.

<table>
<thead>
<tr>
<th>Patient</th>
<th>TLC%</th>
<th>RV%</th>
<th>RVITLC%</th>
<th>FVC%</th>
<th>FEV1%</th>
<th>FVC/FEV</th>
<th>6MWT/M</th>
<th>SpO2%</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>-17.87</td>
<td>-32.7</td>
<td>-18.5</td>
<td>80</td>
<td>64</td>
<td>-8.3</td>
<td>7.1</td>
<td>2</td>
</tr>
<tr>
<td>2</td>
<td>-5.56</td>
<td>-24.3</td>
<td>-19</td>
<td>51</td>
<td>31.1</td>
<td>6.67</td>
<td>-12.5</td>
<td>-1.04</td>
</tr>
<tr>
<td>3</td>
<td>-1.85</td>
<td>5.12</td>
<td>5.88</td>
<td>-6.67</td>
<td>0</td>
<td>12</td>
<td>0</td>
<td>0.06</td>
</tr>
<tr>
<td>5</td>
<td>-1.43</td>
<td>-10</td>
<td>-10</td>
<td>6.79</td>
<td>1.33</td>
<td>-3.57</td>
<td>-14.29</td>
<td>0</td>
</tr>
<tr>
<td>6</td>
<td>-12.01</td>
<td>-14.82</td>
<td>-1.64</td>
<td>-10.28</td>
<td>0</td>
<td>14.81</td>
<td>100</td>
<td>2.2</td>
</tr>
<tr>
<td>7</td>
<td>-19.3</td>
<td>-28.89</td>
<td>-11.11</td>
<td>-3</td>
<td>100</td>
<td>51.52</td>
<td>-37.5</td>
<td>0</td>
</tr>
<tr>
<td>8</td>
<td>-2.67</td>
<td>-2.22</td>
<td>1.67</td>
<td>-3.33</td>
<td>0</td>
<td>3.85</td>
<td>-14.29</td>
<td>-1.06</td>
</tr>
</tbody>
</table>

For all the patients p=0.1503. For the three patients improvements p=0.2576.

Results: Table below contains the percentage change.

Mean change in FEV1 was 20±39% (median=0.6). Only patients 1, 2 and 7 achieved some improvement in their FEV1 values, with all three demonstrating a small reduction in hyper-inflation, as demonstrated by reduced RV values.

Whilst the three patients did show some improvement in their results, statistical analysis suggested no significant improvement occurred in these parameters (p=0.2574). There was also no functional improvement in the six minute walk distance (p=0.404).

Conclusion: Functional improvement was not achieved even in patients demonstrating some reduction in hyperinflation. However, given this small sample group, more studies regarding the mechanism for improvement following endobronchial valve treatment are required.

Key Words: Spirometry, Body Plethysmography, 6 Minute walk test, hyperinflation, Endobronchial valves

REFERENCE
SUPPORT FOR SPIROMETRY OPERATORS BY AN ON-LINE SPIROMETRY ASSESSMENT TOOL
PARSONS R1,4, WHITINGTON M3,4, HANCOCK K5, LONERGAN A2,4, SCHEMBRI D1,4
1Respiratory Function Laboratories, Adelaide, Australia, 2Centre for Nursing & Midwifery Education & Research, Adelaide, Australia, 3Intermediate Care Services, Adelaide, Australia, 4Southern Adelaide Local Health Network, Adelaide, Australia, 5Chandlers Hill Surgery, SA, Adelaide, Australia

Introduction: A Spirometry Assessment Tool (SAT) has been developed within the Spirometry Learning Module (SLM) training program allowing for remote evaluation of spirometry test quality by a designated respiratory scientist incorporating ongoing feedback to operators over time.

Method: The SAT is an interactive PDF document which allows operators to self-assess spirometry measurements against key ATS/ERS criteria; specifically test performance acceptability, measurement repeatability and spirometry interpretation. The SLM online components are integrated within a Modular Object-Oriented Dynamic Learning Environment (MOODLE) open source software Learning Management System. Participants upload spirometry test reports with accompanying SATs via a drop-box within MOODLE. Submissions are made at regular intervals within the SLM 12-week review period to allow previous reviewer feedback to be incorporated into later spirometry assessments.

Reviewers are designated within MOODLE and receive email notification of submitted SATs. The SAT is opened with a PDF annotator which allows correct and incorrect responses to be ‘marked’ by green ticks and red crosses. Additional comments are added from a drop-down menu. Once reviewed, the operator is notified by email that a marked SAT is available for viewing.

Discussion: Use of the SAT provides an opportunity to positively reinforce the practical aspects of spirometry training with ongoing timely feedback to operators and allows them to identify suboptimal test quality specifically related to poor patient test performance. It also allows the uniform evaluation of test quality across multiple reviewers.

Conclusion: The Spirometry Assessment Tool is a simple, standardized, inexpensive and interactive approach to assess the practical application of operator knowledge seen as central in determining the practical outcomes of spirometry training.

Key Words: spirometry Assessment Tool; spirometry test quality; self-assessment

Nomination for New Investigator Award: No

Grant Support: None
CABRINI SHARED CARE MODEL: EARLY REFERRAL AND ACCESS TO PALLIATIVE CARE FOR PATIENTS WITH COPD

O’DRISCOLL L

1Cabrini Health Respiratory Continuing Care Program, Oakleigh, Australia

Introduction: Chronic obstructive pulmonary disease (COPD) is a significant cause of death in Australia but access to Palliative Care is limited. In addition, previous studies indicate that patients with chronic lung disease are more likely to have their first encounter with palliative care in a critical care setting.

Aim: Cabrini Hospital developed a shared model of early referral and access to palliative care for patients with advanced COPD integrated across the Respiratory Continuing care program and Palliative Homecare team, through: Enabling patients to live as actively as possible with focus on quality of life; Reducing time in hospital and optimizing utilization of continuing care services to support preferred place of care; Optimizing function and comfort physically, psychosocially, emotionally and spiritually; Minimizing physical and psychosocial symptoms.

Providing adequate knowledge and open communication for patients and carers to help timely and informed decision-making; Supporting carers throughout the person’s illness; and Supporting patients and carers when death is inevitable and through the bereavement period.

Preliminary Results: Patient and families reported positive patient experience; improvement in preferred place of death; patients did not feel abandoned or "handed over" to another service; family end of life experience improved due to patient and family being well known to palliative homecare staff and respiratory nurses; direct admission to inpatient palliative care services prevented a visit to emergency; prevention of hospital admission during final year of life improved quality of life; reduction in emergency calls to ambulance service due to breathlessness and anxiety.

Conclusion: A shared model of early referral and access to palliative care markedly improved quality of services for patients with advanced, non-malignant lung disease. Training is required to support palliative homecare nurses to deliver care to patients with non-malignant disease, and equally for chronic disease nurses to support and deliver a palliative care approach.

WITHDRAWING/WEANING NON INVASIVE VENTILATION IN PALLIATIVE CARE PATIENTS WITH RESPIRATORY FAILURE

LAFFERTY, M1, DUNFORD, M2

1St George Hospital, Sydney, New South Wales, Australia

Introduction: Withdrawal of Non Invasive ventilation (NIV) at the end of life is extremely challenging with varying patient experience. There is little evidence describing medication titration prior to weaning/post NIV cessation, increasing the risk of an undignified death. St George Hospital palliative care service (SGHPCS) receives referrals to assist in NIV withdrawal in patients failing to respond to treatment with both malignant and non-malignant disease. It was recognized that there was a need to develop a more consistent way of weaning each patients NIV and titrating their medications depending on their level of dependency on the NIV.

Methods: In 2015/2016, SGHPCS received 64 respiratory failure patient referrals receiving NIV. 35 were specifically referred for end of life care where treatment was deemed futile and there was a change in the direction of care with NIV to be weaned and ceased. We have identified 3 levels of NIV dependency at end of life (EOL) requiring different doses of medications/adjustments to ventilation during the weaning process to ensure a symptom free death. This led to the provision of more specific education to the respiratory medical and nursing staff in the units that use NIV. Effective withdrawal of NIV requires an integrated team approach to provide best practice care

Results: Provision of regular education and support of staff improved staff confidence and competence in caring for patients during the weaning process of NIV. 100% patients dying were on regular opioids and benzodiazepines at time of death. Number of days from referral to death ranged from 0-8 with 25% dying on the referral day.

Conclusion: There is a need for further research and guidelines in palliative care NIV withdrawal with respiratory failure. A consistent collaborative approach from both the respiratory/palliative care services in optimal EOL management is encouraged.

Grant Support: Nil
#O2THEFIX: SWIMMING BETWEEN THE FLAGS
NCUBE N1, CHAPMAN A1, NAND J1
1Waitemata District Health Board, Auckland, New Zealand

Introduction/Aim: Historically it has been common practice to administer oxygen regardless of need, without sufficient monitoring and adjustment. This has been consistently demonstrated by audits carried out at Waitemata District Health Board (Waitemata DHB) and other hospitals in New Zealand1,2.

The Thoracic Society of Australia and New Zealand (TSANZ) recently released guidelines for the acute use of oxygen in adults that promote prescribing of oxygen therapy to target a level between a prescribed range of oxygen saturations3. For example between 92% to 96% is appropriate for most patients. For patients that retain carbon dioxide, such as those with chronic obstructive pulmonary disease (COPD), oxygen should be titrated to 88-92%.

Methods: #O2TheFix: Swimming Between the Flags is an innovative multidisciplinary collaboration to improve the prescribing and safe administration of oxygen at Waitemata DHB. A campaign was planned to showcase the mix of utilising technology via electronic prescribing, social media and educational sessions sporting a catchy phrase: “O2 the Fix, Aim 92-96. If high CO2, Aim 88-92” to improve the awareness of oxygen with improved prescribing and administration.

Results: At baseline, only 12% of patients had their oxygen prescribed. The remaining patients were receiving oxygen without a prescription.

A re-audit six months later showed an increase of oxygen prescribing from 12% to 49%.

Staff also reported increased understanding of important safety concepts regarding oxygen and their delivery devices.

Conclusion: #O2TheFix has improved patient safety by raising awareness of oxygen and device prescribing, including specified target saturations ranges. The #O2TheFix team will continue to monitor oxygen and device prescribing while continuing to spread the important safety message.

Grant Support: nil

REFERENCES
Boyle M, Wong J. “Prescribing oxygen therapy. An audit of oxygen prescribing practices on medical wards at North Shore Hospital Auckland New Zealand” NZ Med J 2006119; U2080

INTEGRATED CARE REVIEW OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE INPATIENT MANAGEMENT
SWAMI V1, SMITH T1,2, CHO J1,3, CHAWLA A1, ROBERTS M1,3, WHEATLEY J1,2,3
1Department of Respiratory and Sleep Medicine, Westmead Hospital, Westmead, Australia, 2University of Sydney at Westmead Hospital, Westmead, Australia, 3Ludwig Engel Centre for Respiratory Research, Westmead Institute for Medical Research, Westmead, Australia

Introduction/Aim: In 2014–15, 66,540 patients were hospitalised with an acute exacerbation of COPD (AECOPD) in Australia. National and international guidelines to optimise inpatient management of COPD exist, however compliance to these remains unclear. In 2015 Westmead Hospital implemented a COPD Integrated Care Team (ICT) to review and optimise inpatient and outpatient management of COPD. To review management of AECOPD in inpatients admitted to a tertiary teaching hospital.

Methods: We developed an evidence-based checklist to monitor the care of inpatients with AECOPD and the adherence to COPD national and international guidelines. We performed a retrospective chart review of checklist adherence for AECOPD admissions at Westmead Hospital from 2016 to 2017. ICT reviewed patients usually within 4 days of hospitalisation or step-down from high dependency, recorded compliance with the checklist, and then provided advice to inpatient teams regarding optimisation of COPD management.

Results: We reviewed 276 inpatients with AECOPD (55% male; mean age 69.9±10.4 years). We identified good adherence to oxygen prescription on medication charts, early antibiotic rationalisation, and sputummetry measurement (all>75% compliance). However, we found inhaler prescription errors in 37% of reviews including incorrect or missing prescriptions and duplication of inhaler classes, 36% of patients were still on nebulised therapy at ICT review, 30% of patients were current smokers and only half had been offered smoking cessation measures. Respiratory vaccinations were not up-to-date in 62% of patients, and only 5% had been offered pulmonary rehabilitation.

Conclusion: ICT has identified areas for improvement in inpatient management of AECOPD including inhaler therapy prescriptions, smoking cessation measures, referral to pulmonary rehabilitation and assessment of immunisation. There is a role for ICT in education, ongoing monitoring, and optimisation of inpatient AECOPD management. Further research is needed to understand the impact of improved compliance to AECOPD guidelines on long-term ambulatory outcomes in patients with COPD.

TO 003

TO 004
INNOVATIVE MULTI-LINGUAL MOBILE APP TO IMPROVE KNOWLEDGE AND UNDERSTANDING OF ASTHMA AMONG INDIGENOUS CARERS OF CHILDREN WITH ASTHMA—PROTOCOL
VERSTEEGH L1, CHANG A1, SAUNDERS J2, CHIRWIG S1, SHARMA T1, MCCALLUM G1
1Menzies School Of Health Research, Darwin, Australia, 2Asthma Foundation Northern Territory, Darwin, Australia

Introduction/Aim: Among Indigenous Australians, asthma is the most common self-reported chronic respiratory problem. Asthma related health outcomes are also poorer among Indigenous than non-Indigenous Australians. To address this, innovative interventions that are culturally-appropriate are needed. We have developed a multi-lingual mobile phone application (App) from our existing asthma flipchart, with ‘voice-over’ in local Indigenous languages, using a mixture of static and interactive formats. This study aims to evaluate whether the App improves health knowledge and understanding of asthma among Indigenous carers of children with asthma.

Methods: Evaluation of the app includes quantitative and qualitative methods in addition to the usability testing scheduled. The quantitative component involves a before and after study on asthma-related knowledge based on our previous flipchart study. Eighty Indigenous carers of children with asthma will be enrolled. Carers will undergo a pre-education questionnaire, followed by asthma education using the App. A post-education questionnaire will be administered immediately post-education session. A subset of carers will repeat the questionnaire two weeks later to determine short-term knowledge retention. In the qualitative component, Indigenous health professionals with and without asthma will participate in semi-structured interviews to ascertain perspectives of the functionality and usability of the App.

Results: Recruitment for this study will commence late October 2017 for 12 months.

Summary: Improving asthma related health outcomes is important, and requires a focused, multidisciplinary approach, particularly for at-risk groups such as Indigenous Australians. Education in the form of mobile Apps is an innovative method of communicating health messages to culturally and linguistically diverse groups, that moves towards reducing language and context barriers particularly faced by Indigenous people in rural or remote settings. The asthma App has the potential to improve community knowledge by increasing access and usability of health education once only delivered in health centres.

Declarations of interest: Nil
Grant Support: Asthma Australia

HARNESSING HOPE, INSTILLING BELIEF: COPD SELF-MANAGEMENT
BAIRD M1, GULLICK J2
1Dubbo Health Service, Dubbo, New South Wales, Australia, and 2Sydney Nursing School, The University of Sydney, Camperdown, New South Wales, Australia

Introduction/Aim: Chronic Obstructive Pulmonary Disease (COPD) has a significant impact on the healthcare system and patient. Although literature worldwide supports the efficacy of self-management, studies are traditionally entrenched in the economic model of supported self-management with the primary outcome of decreasing healthcare utilisation. There is limited literature in a rural setting that explores COPD self-management through the lens of patient experience.

This study aims to explore the concept of self-management through the eyes of the patient with COPD, living in rural Western New South Wales (NSW), what their understanding of self-management is and how they measure it?

Methods: A Heideggerian phenomenological inquiry formed the framework for this research, allowing exploration of the patients lived experience. In depth audio-recorded semi-structured interviews were conducted. A total of eight participants (four male, four female) with a reported diagnosis of COPD living in regional and rural Western NSW met the inclusion criteria. Interviews were transcribed verbatim, data was themed and analysed until thematic saturation was achieved (n=8).

Results: Findings unveiled four emerging themes: Adapt, Pace, Preserve and Ownership. Further exploration identified social, emotional and physical domains within the themes Adapt, Pace and Preserve. Exploring the phenomena through the patient lens, identified the true meaning of self-management and their measures of success.

Conclusion: Exploring the patient’s lived experience of COPD self-management provides a meaningful and context-driven explanation of patient’s perceptions of self-management, opening up the concept of subjective patient measures as an indicator of self-management.

Grant Support: This research was supported by the NSW Ministry of Health, Rural Research Capacity Building Program and Western NSW LHD.

Conflict of Interest: COPD Nurse Presenter for Lung Foundation Australia, funded by Menarini.
ARE INPATIENT SMOKERS CONSISTENTLY IDENTIFIED AND OFFERED SMOKING CESSATION INTERVENTIONS: A QUALITY IMPROVEMENT PROJECT

REED N, CHAN M, BIRD T
Respiratory Nurses Interest group, Sydney, Australia

Introduction/Aim: Each year, smoking kills an estimated 18,000 Australians and costs Australia $31.5 billion in health and economic costs. Smoking harms nearly every organ in the body, causing disease and reducing quality of life and life expectancy. An inpatient care episode represents an opportunity to identify smokers with current health needs and to intervene consistently to improve health care outcomes. NSW Health Policy requires consistent identification of smokers and, as a minimum, brief intervention to manage their nicotine dependence. As health care systems transition from paper to electronic records, it is possible that documentation quality may suffer in areas such as this. The purpose of this audit was to determine the quality of our practice in this important area and whether documentation was compromised in the transition to an electronic medical record (EMR).

Methods: Records of Respiratory Medicine inpatients from January to May 2017 (paper-based) and June-October 2017 (EMR) were analysed for documentation of smoking status on admission to hospital and the offering of brief advice and pharmacotherapy or referral to specialist support services for current smokers.

Results: 61 paper and 61 EMR records were analysed. 56(92%) of paper records identified smoking status. This fell significantly to 41(61%) [p<0.001; chi^2 test] in EMR records. 7 of 13 smokers identified from paper records and 1 of 7 smokers from EMR were offered smoking cessation intervention [p=0.08].

Conclusion: Smoking status could be more consistently identified and recorded. Provision and/or documentation of smoking cessation interventions is poor. Transition to EMR may be a risk for poorer health service provision or documentation.

The audit has shown that there is a need for improvement in documentation by health professionals if smoking interventions as per NSW government guidelines are to be achieved.

Conflict of Interest: There is no conflict of interest.

Grant Support: NIL

IRF7, CXCL9 AND CXCL10 PROTEIN LEVELS IN CHILDREN WITH ASTHMA

COLEMAN L^1, HARRIS L^1, KHOO SF^2,3, FRANKS K^2, BIZZINTINO J^2, PRASTANTI F^2, EVERARD J^2, OQ S^1, MACIEWICZ R^4, MCCRAE C^4, ÖBERG L^1, LE SOUËF P^5, BOSCO A^2, LAING P^2,3

1School of Paediatrics and Child Health, University of Western Australia, Crawley, Australia; 2School of Biological Sciences, University of Western Australia, Crawley, Australia; 3Telethon Kids Institute, University of Western Australia, Subiaco, Australia; and 4Respiratory, Inflammation and Autoimmunity iMed, AstraZeneca, Gothenburg, Sweden

Introduction/Hypothesis: Rhinovirus (RV) species C infection is associated with increased severity of acute wheezing and asthma compared with other RV species. RVC utilises a different host cellular receptor to RVA and B, but the mechanisms and pathways activated by RVC and their contribution to the severity of disease are unknown. We have previously identified gene expression differences in nasal cell samples from children with acute asthma and wheezing who were infected with RVC versus RVA. RVC-specific genes included IRF7, whereas CXCL9 and CXCL10 were identified in the RVA-specific response. We hypothesised that protein levels for each of these genes would be different in nasal fluid from children having a respiratory exacerbation and infected with RVC versus RVA.

Methods: Nasal fluid samples were collected from 21 children with RVA and 37 with RVC presenting to our tertiary children’s hospital Emergency Department with acute respiratory illness. CXCL10 and CXCL9 protein were measured as part of a multiplex ELISA (ThermoFisher), whereas IRF7 protein was measured using a single ELISA kit (Cusabio). Urea was measured using a quantitative chromatic assay (BioAssay Systems) and used to standardise the ELISA measurements (presented here as pg protein per μg urea).

Results: CXCL9 levels were not significantly different (Mann-Whitney U=192, p=0.79) between RVA (median 13.27, range 0.34-159.88, n=14) and RVC cases (median 20.66, range 0.37-248.44, n=29). CXCL10 levels were also not significantly different (Mann-Whitney U=234, p=0.90) between RVA (median 0.48, range 0.04-11.41, n=16) and RVC cases (median 0.46, range 0.02-41.19, n=30). IRF7 levels did not differ (Mann-Whitney U=217, p=0.63) between RVA (median 1.88, range 0.15-6.16, n=17) and RVC cases (median 1.62, range 0.19-21.78, n=28).

Conclusion: CXCL9, CXCL10 and IRF7 gene expression in nasal cell samples collected during RVC vs RVA-induced acute wheezing and/or asthma are different, but this has not translated to alterations in nasal fluid protein levels.

Grant Support: National Health and Medical Research Council, Telethon—Perth Children’s Hospital Research Fund, University of Western Australia, Asthma Foundation of Western Australia, AstraZeneca

Declaration of Interest: none.
INTRODUCTION/AIM: Thickening of the airway smooth muscle (ASM) layer is present in children with asthma which implicates a developmental origin. Little is known about the structural changes that occur in the airway and ASM layer from late gestation to adulthood. The aim of this study was to assess maturational changes in airway wall structure and examine mechanisms of ASM growth in terms of hyperplasia, hypertrophy and extracellular matrix (ECM).

METHODS: Sheep were euthanized at late gestation (128 d), birth (150 d), post weaning (4 months) and sexual maturity (1 year). Lungs were fixed by instillation of formaldehyde and samples obtained from the trachea, main bronchus, segmental bronchus, sub-segmental bronchus and peripheral airways. The area of the ASM layer, inner and outer wall and perimeter of basement membrane (Pbm) were measured by planimetry. The number and size of ASM cells was assessed by stereology and fractions of muscle, ECM and ‘other’ within the ASM layer were determined by point counting.

RESULTS: The predominant period of airway maturation was from birth to 4 months of age. Airway size (Pbm) and airway wall areas (including ASM) were all increased in the trachea (p<0.05), segmental bronchus (p<0.05) and sub-segmental bronchus (p<0.05). When wall areas were normalised to Pbm, there was no effect of age indicating that airway structure grew in proportion to airway size. Changes were less pronounced in more peripheral airways. The mechanism of ASM growth was due only to an increase in cell number and not as a result of cell hypertrophy or changes in the proportion of ECM.

CONCLUSION: Substantial airway growth occurs before weaning and this includes expansion of the ASM layer as a result of cell hyperplasia. Upregulation of ASM proliferation in infancy could facilitate thickening of the ASM layer and the development of asthma in childhood.

Grant Support: NHMRC (1077791)

Declaration of Interest Statement: None.

INTRODUCTION/AIM: FeNO-guided asthma management during pregnancy was associated with a reduction in bronchialitis episodes in the first year of life (Mattes et al., Thorax 2013). The aim of this analysis was to investigate an association between infant lung function at 6 weeks of age and bronchiolitis in the first 6 months of life in a cohort of babies born to women with asthma during pregnancy.

METHODS: Tidal breathing flow-volume loop (TBFVL) measurements were performed during quiet unsedated sleep in infants born to mothers who participated in an ongoing NHMRC-funded multi-centre RCT of FeNO-guided asthma management versus usual care (Breathing for Life Trial). All researchers remain blinded in regards to the pregnancy intervention.

RESULTS: Of 324 babies recruited to date, 289 attended a clinical assessment and 261 remained in quiet sleep during testing. 232 had TBFVL attempted (44% female; age 6 weeks SD 1.2), of which 209 (90%) tests were technically acceptable. At the time of abstract submission, 140/209 (67%) were 6 months old. Infants with one episode of bronchiolitis in the first 6 months of life had a mean of time to Peak Tidal Expiratory Flow/time Expiratory Flow % (tPTEF/tE%) of 28.5 (SD 6.8; n=30) at 6 weeks of age. Infants with >1 episode of bronchiolitis had a mean tPTEF/tE% of 22.79 (SD 4.46; n=6) while those without bronchiolitis had a mean tPTEF/tE% of 32.34 (SD 9.4; n=104). There were no difference in respiratory rate (RR) between groups (1 episode: mean RR 44 breaths per minute; >1 episode: mean RR 42 breaths per minute; no bronchiolitis: mean RR 44 breaths per minute).

CONCLUSION: Lung function may be associated with the risk of developing bronchiolitis which could provide a linking mechanism for the effect of FeNO-guided management on bronchiolitis prevalence.

Grant support: NHMRC, John Hunter Hospital, PRC GrowUpWell, HMRI and HCRF.
ANTI-G-CSFR ANTIBODY TREATMENT SUPPRESSES NEUTROPHILIC AND TYPE-2 LUNG INFLAMMATION IN AN ALLERGIC ASTHMA MODEL WORSENED BY NEONATAL CO-INFECION

WANG H1, FITZPATRICK M2, ANTHONY D3, READING P1, WILSON N4, SATZKE C4,5, DUNNE E4, LICCIARDI P4,5, ANDERSON G2, VLACHOS R1, BOZINOVSKI S1

1Equal contribution

RMIT University, School of Health and Biomedical Sciences, Melbourne, Australia, 2The University of Melbourne, Lung Health Research Centre, Department of Pharmacology & Therapeutics, Parkville, Melbourne, Australia, 3The WHO Collaborating Centre for Reference and Research on Influenza, Victorian Infectious Diseases Reference Laboratory, at The Peter Doherty Institute for Infection and Immunity, Parkville, Melbourne, Australia, 4CSL Limited, Parkville, Melbourne, Australia, 5The University of Melbourne, Department of Microbiology and Immunology, at The Peter Doherty Institute for Infection and Immunity, Parkville, Melbourne, Australia, 6Pneumococcal Research, Murdoch Children’s Research Institute, Parkville, Melbourne, Australia, 7The University of Melbourne, Department of Paediatrics, Parkville, Melbourne, Australia

Introduction/Aim: Early life respiratory infections are associated with the development of severe asthma, where the detection of both respiratory viruses and bacteria occur frequently in children with acute wheeze. However, the mechanistic interaction between neonatal respiratory infections and the establishment of allergic type-2 and neutrophilic lung inflammation remains poorly understood in severe asthma. Our aim is to investigate the role of neonatal exposure to infectious pathogens in the development of allergen-triggered asthmatic pathogenesis and airway remodelling.

Methods: Intranasal inoculation of Streptococcus pneumoniae (2000 CFU, EF3030)/saline and Influenza A virus (500 PFU, HKx31)/saline was performed on neonatal mice (female BALB/c) at the age of 8 days and 15 days respectively. At the age of 21 days, house dust mite (HDM)/saline was administered intranasally daily for 3 weeks. In the therapeutic study, a separate cohort of mice was treated as described above. In the last week of HDM regime, 100 μg of anti-G-CSF receptor (G-CSFR) isotype antibody was injected intraperitoneally every second day.

Results: HDM challenge in mice co-infected as neonates significantly increased pneumococcal lung infection, neutrophilic inflammation and mucus production. Neutrophilic lung inflammation was associated with an increase in interleukin-17A and granulocyte-colony stimulating factor (G-CSF). Blocking G-CSFR significantly reduced neutrophilic inflammation in the bronchoalveolar (BAL)-fluid and myeloperoxidase activity in lung tissue without increasing pneumococcal lung load. In addition, elevated makers of netosis including neutrophil elastase and double-stranded DNA were reduced in the BAL-fluid of anti-G-CSFR treated mice. Anti-G-CSFR therapy also potently reduced type-2 inflammation including BAL eosiophils, IL-33/IL-13 lung transcripts, CD4”IL-4” T effector cells and mucus (muc5ac) production.

Conclusion: Disrupting G-CSFR significantly reduced neutrophil mobilisation and netosis without worsening pneumococcal lung infection and furthermore, reduced type-2 inflammation in allergic airways disease. Monoclonal antibodies against the G-CSFR may represent a novel therapeutic target for mixed granulocytic severe asthma.

Grant Support: This work was supported by National Health and Medical Research Council of Australia (grant number APP1067547) and Australian Research Council (grant number FT130100654).

GENETIC VARIANTS IN HUMAN RESPIRATORY VIRUS RECEPTORS WERE ASSOCIATED WITH INFECTION, RECOVERY AND RECURRENCE OF WHEEZING EXACERBATIONS IN CHILDREN

HARRIS L1,2, ALCOCK R3,4, KRESJOE N5, LE SOUËF P1, LAING I2,3

1Division of Paediatrics, The University of Western Australia, Perth, Australia, 2Telethon Kids Institute, Perth, Australia, 3School of Biomedical Sciences, The University of Western Australia, Perth, Australia, and 4Pathwest Laboratory Medicine WA, QEII Medical Centre, Perth, Australia

Introduction/Aim: Human rhinoviruses (RV) and respiratory syncytial virus (RSV) are common respiratory viruses in children with acute wheezing illnesses. Viruses use human receptors to enter host cells. RSV uses nucleolin (NCL), and RV uses intercellular adhesion molecule 1 - (ICAM1), low density lipoprotein receptor (LDLR) or cadherin related family member 3 (CDH3). Our aim was to assess whether variants in viral receptor genes were associated with asthma severity.

Methods: Cohort: Children who presented to a tertiary children’s hospital emergency department with acute asthma (n=50). Samples: Nasal samples for RV detection. DNA was extracted from peripheral blood. Analysis: Viral receptor genes were sequenced using Ion AmpliSeq primers (Thermo Fisher Scientific). Data collected included: (1) number of hours from presentation to discharge, (2) number of respiratory hospital presentations and admissions from birth and (3) number of salbutamol doses administered in the first 6 hours. Statistical analysis was completed using SPSS version 22. All analyses were adjusted for age and gender.

Results: The mean age of children was 8.44yrs, 60% male, 56% with detectable RV. Children with genotypes CDHR3 rs34426483 GC or CC and NCL rs7598759 CC were 0.161-0.105 fold less likely to have rhinovirus detected at recruitment than children with the other genotypes (95% confidence interval (CI): 0.023-1.11; p-value: 0.064 and 95% CI: 0.009-1.24; p-value: 0.073, respectively). Children with ICAM1 rs281437 TT genotypes had 17.0 fold more hospital visits before recruitment (95% CI: -0.062-23.5; p-value: 0.002) and took 2.52 fold longer to be discharged from hospital (95% CI: 7.81-129; p-value: 0.019) compared to children with CC genotypes. Children with ICAM1 rs5498 GG genotypes had 0.593 fold fewer treatment doses in 6 hours (95% CI: -0.852-12.1; p-value: 0.013) than children with AA genotypes.

Conclusion: Gene variants in viral receptor genes may play a role in viral infection and treatment response, and thus recurrent respiratory illnesses requiring presentation to hospital.

Grant Support: NHMRC #1087700, Financial Markets Foundations for Children #2015-314, University Postgraduate Award, UWA Safety-Net Top-Up Scholarship

Conflict of Interest: No.

Nomination: Nil.
### ABNORMAL LUNG CLEARANCE INDEX (LCI) IN PRESCHOOL YEARS IS ASSOCIATED WITH LOWER SPIROMETRY LATER IN CHILDHOOD IN CYSTIC FIBROSIS (CF) CHILDREN

PANDA H2, HARDAKER K1,2, HULME K2, KENNEDY B1, GUSTAFSSON P1, COOPER P1, FITZGERALD D1,3, PANDIT C1,3, SELVADURAI H1,3, ROBINSON P1,3

1The University of Sydney, Sydney, New South Wales, Australia, 2Department of Respiratory Medicine, The Children’s Hospital at Westmead, Sydney, New South Wales, Australia, 3Discipline of Paediatrics and Child Health, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia, and 4Department of Paediatrics, Central Hospital, Skövde, Sweden

**Introduction/Aim:** Availability of robust commercial multiple breath nitrogen washout (MBNW) equipment offers improved feasibility for widespread preschool lung function testing in Cystic Fibrosis (CF) clinics. Clinical utility is emerging with this commercial equipment but the prognostic value of performing preschool MBW (defined as age 2-6 years) remains unclear. We have previously shown an association between higher preschool Lung Clearance Index (LCI) values and greater medication use and incidence of bacterial isolation within our clinic. This study aimed to explore the association between those preschool LCI values and later spirometry, a well established clinical tool in older CF subjects.

**Methods:** Current spirometry values (FEV1, FEV1/FVC and FEF25-75) were collated on the original 37 preschool children who had MBW performed at mean (SD) age 5.0 (1.2, range 2.8-6.9) yrs: median (range) LCI 8.0 (6.5-14.3). Spirometry results were expressed as z-scores (GLI reference equations). Abnormal preschool LCI was defined based on recently published preschool healthy control data using identical equipment and testing protocol1 (ULN for LCI 8.0).

**Results:** Technically acceptable spirometry data were available in 35/37 (95%) (one had moved out of state, one has autism) at mean (SD; range) age 7.7 (1.4; 4.8-9.8) years, which was 2.7 (0.4; 1.0-3.3) years after the original MBW testing time point.

<table>
<thead>
<tr>
<th>Later spirometry (z scores)</th>
<th>FEV1</th>
<th>FEV1/FVC</th>
<th>FEF25-75</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall cohort (n=35)</td>
<td>-0.18 (1.28)</td>
<td>-0.80 (1.06)</td>
<td>-0.82 (1.43)</td>
</tr>
<tr>
<td>Abnormal preschool LCI (n=17)</td>
<td>-0.53 (1.53)</td>
<td>-1.28 (1.17)</td>
<td>-1.05 (1.63)</td>
</tr>
<tr>
<td>Normal preschool LCI (n=18)</td>
<td>-0.02 (0.91)</td>
<td>-0.62 (0.78)</td>
<td>-0.63 (1.04)</td>
</tr>
<tr>
<td>p value (abnormal vs. normal LCI)</td>
<td>0.07</td>
<td>0.02</td>
<td>0.03</td>
</tr>
</tbody>
</table>

Data presented as mean (SD).

**Conclusion:** Abnormal MBW-derived LCI values in the preschool years are associated with later spirometry deficits. This suggests prognostic utility of MBW testing in this younger preschool age range to predict later spirometry values.

1 Stanojevic et al AJRCCM 2017;195:1216-1225

**Grant Support:** CF fundraising, CHW

**Conflict of interest:** No conflicts of interest to declare.

---

**Abstract withdrawn**
CAN A BRONCHOSCOPICALLY DEFINED BRONCHITIS TOOL IN CHILDREN BE VALIDLY DEVELOPED?

THOMAS R1, EG K1,2, MASTERS I1, MCELREA M1, CHANG A1,3
1Department of Respiratory and Sleep Medicine, Lady Cilento Children’s Hospital, Children Centre for Health Research, Queensland University of Technology, Brisbane, Queensland, Australia, 2Department of Paediatrics, University of Malaya, Kuala Lumpur, Malaysia, and 3Child Health Division, Menzies School of Health Research, Charles Darwin University, Tiwi, Northern Territory, Australia

Introduction/Aim: Despite bronchitis being the most common finding at flexible bronchoscopy (FB) in many paediatric centres such as ours, no validated objective system exists. From previously recorded FB, we: (1) determined the correlation among the different macroscopic findings with airway neutrophilia (2) examined the inter-rater repeatability of these findings and, (3) developed an experimental model of an objective FB-derived bronchitis score (BScoreexp).

Methods: We reviewed 100 consecutive previous recordings (2016) from our database. We excluded FBs if: BAL data was unavailable, incomplete FB recording or FBs were on children who were immune-compromised or had endotracheal tube, tracheostomy or foreign body. FB recordings were assessed (by 2 scorers independently blinded to the clinical history) for 6 components: amount of secretions (scores 1-6 from previous validated score), colour of secretions (0-8 using BronkoTest), mucosal oedema (0-3), ridging (0-3), erythema (0-3) and pallor (0-3), based on pre-determined criteria on a pictorial chart. The various models of BScoreexp were plotted against neutrophil% using a receiver operating characteristic (ROC) curve. Here we report our preliminary findings; on the first 65 children with valid FBs.

Results: Only secretion amount (rs=0.272, p=0.03) and colour (rs=0.342, p=0.005) significantly correlated with BAL %neutrophil but other macroscopic findings correlated with each other. For the 26 FBs examined for repeatability, kappa values for secretions (K=0.86, 95%CI 0.91-1.0) and colour (K=0.84, 95%CI 0.73-0.95) were excellent. Other K ranged from 0.38 to 0.67. Using BAL neutrophilia of 15% to define inflammation, the highest aROC (0.63, 95%CI 0.50-0.76) was obtained by the giving three times weightage to secretion amount and colour and adding it to the other 4 components except pallor.

Conclusion: A repeatable FB-defined bronchitis scoring system can be derived. However, a prospective study needs to be performed with larger numbers to further evaluate the different models to obtain aROC of >0.7.

Grant Support: KPE funded by an APSR Scholarship, ABC by NHMRC Practitioner Fellowship

Declaration of Interest statement: None.

PROTRACED BACTERIAL BRONCHITIS (PBB)—LONG-TERM OUTCOMES AT FIVE YEARS: A COHORT STUDY

RUFFLES T1, MARCHANT J1, BUNTAIN H1, MASTERA I1, UPHAM J2, YERKOVICH S3, GIBSON P1, BAINES K1, SIMPSON J4, PIZZUTO S5, HODGE G6, HODGE S6, CHANG A1,2
1Department of Respiratory and Sleep Medicine, Lady Cilento Children’s Hospital, Children Centre for Health Research, Queensland University of Technology, Brisbane, Australia, 2The School of Medicine, University of Queensland and Princess Alexandra Hospital, Brisbane, Australia, 3The Prince Charles Foundation, The Prince Charles Hospital, Chermside, Brisbane, Australia, 4The Respiratory and Sleep Medicine, School of Medicine and Public Health, Centre for Asthma and Respiratory Disease, The University of Newcastle, Callaghan, Newcastle, Australia, 5Child Health Division, Menzies School of Health Research, Darwin, Australia, 6The Chronic Inflammatory Lung Disease Research Laboratory, Department of Thoracic Medicine, Royal Adelaide Hospital and School of Medicine, University of Adelaide, Adelaide, Australia

Introduction/Aim: PBB is a common cause of paediatric chronic cough and is defined as chronic wet cough (>4-weeks) without specific signs or symptoms of an alternative cause which responds to 2-weeks of appropriate antibiotic therapy. In this first 5-year outcome data on children with PBB, we aimed to describe the long-term clinical outcomes in children with PBB.

Methods: 160 children (median age 25mths, range 2-163mths) were recruited and followed for 5-years with monthly contacts by research staff and when possible, annual physician clinical review. Flexible bronchoscopy, bronchoalveolar lavage and basic immune tests were performed at baseline. During follow-up, chest CT was performed if clinical features were suggestive of bronchiectasis. Bronchiectasis was diagnosed when paediatric radiology criteria and clinical features were present. Spirometry was undertaken at the final follow-up (5-years) when possible. We present data on the initial 101 children (n PBB=82, controls=19) of the cohort with 5-year follow-up data.

Results: Of the 82 children with PBB (median age 23mths, range 5-163mths; 65% boys), CT was undertaken in 26 children during the follow-up period; 7 had bronchiectasis (7/82=8.5%). All were diagnosed within 28-months. The frequency of recurrent PBB (r3/yr) decreased over the duration of the study from 54 (66%) at Yr-1 to 10 (12%) at Yr-5. Fifty-seven (70%) of children with PBB had tracheomalacia and/or bronchomalacia on bronchoscopy, whilst 25 (30%) had visible evidence of bronchitis. At the Year-5 point, the mean FEV1 was 94% predicted (SD 15.8) in both the PBB and control groups.

Conclusion: PBB is associated with a subsequent diagnosis of bronchiectasis in a proportion of children recognised within 28 months of initial PBB diagnosis. While recurrent PBB decreases over time, those with recurrent episodes should be reviewed for bronchiectasis. Spirometry values remains in the normal range in children diagnosed with PBB at long-term follow-up.

Grant Support: This work was supported by the National Health and Medical Research Council (APP1042601). PG, SP, SH and AC are supported by NHMRC fellowships. KB is supported by a lung foundation of Australia Fellowship.
Introduction: Spinomuscular atrophy (SMA) is an uncommon, progressive Neuromuscular Disorder (NMD) with significant respiratory morbidity and eventual respiratory failure. There are currently no clear guidelines for non-invasive ventilation (NIV) instigation in this condition. Newer treatment options are likely to change current clinical practices but improved respiratory assessment methods are needed. Our objectives in this cohort were to (1) analyse the patterns of sleep breathing measured by polysomnography (PSG) and (2) determine early clinical and lung function predictors of nocturnal hypoventilation.

Methods: We retrospectively reviewed clinical records and PSG data of all children with genetically-confirmed SMA II/III living in Queensland. Spirometry, Forced Oscillatory Technique (FOT), Lung Clearance Index (LCI), & respiratory muscle strength testing were prospectively performed/measured. The prospective arm of the study is ongoing with complete data collection expected by November 2017.

Results: 23 children (9F; 17 with SMA II, median age 108 months) were included. Median FVC% predicted (z score) was 61% (n=19, -3.32); Rrs8 z-score: 2.19 (n=11); Xrs8 z-score: -2.03 (n=11); SNIP z-score: -2.53 (n=10) & LCI: 7.36 (n=12). Median (IQR) REM related Apea-hypopnea index (rAHI) was high at 5.9 (2.9-17.5;n=19). 10 children (9 with SMA II) required long-term nocturnal NIV initiated at a median age of 94 months; 5 (50%) after an acute respiratory illness. These children were older (127 vs 84 months; p=0.03) with significantly worse FVC-z scores (-4.8 vs -1.18; p<0.01); rAHI (26.5 vs. 4.2; p=0.05), LCI (8.8 vs. 7.1, p=0.01) & SNIP z-scores (-3.5 vs. -1.47 p=0.001). Predictors of NIV need will be analysed using a logistic regression model once the prospective arm is completed.

Conclusion: Most children with SMA II need nocturnal ventilatory support beginning in early childhood and FVC may be a predictor. FOT, SNIP and LCI were deranged and may help in predicting early respiratory insufficiency, particularly in early years.

Grant Support: None

Declaration of Interest: No conflicts of interest.
CHARACTERISTICS OF CHILDREN WITH CHRONIC SUPPURATIVE LUNG DISEASE (CSLD): A PROSPECTIVE 10-YEAR STUDY

MCCALLUM G1, CHANG A1,2, BYRNEs C, MOBERLEY C2, MORRIS P1, REDDING G1, GRIMWOOD K1, SINGLETON R1

1Menzies School of Health Research, Darwin, Australia, 2Children Centre Australia, 3The University of Auckland and Starship Children’s Hospital, Auckland, New Zealand, 4University of Washington, Washington, USA, 5Griffith University and Gold Coast Health, Gold Coast, Australia, and 6Alaska Native Tribal Health Consortium, Anchorage, AK, USA

Introduction/Aim: While largely preventable, CSLD (including bronchiectasis), remains highly prevalent amongst disadvantaged Indigenous populations in high income countries. Adult studies with CSLD have shown that persistent airway infection and inflammation, and longer duration of chronic productive cough result in poorer clinical outcomes. There are however, no prospective studies in children with CSLD in the last 50-years to help guide long-term clinical care and management. We evaluated the long-term clinical outcomes of Indigenous children with CSLD who participated in our previous study, ‘Multicentre Bronchiectasis Study (BOS)’ (2004-2012).

Methods: During 2015–17, we re-assessed as many children as possible from BOS (Australia n=97, Alaska n=41, New Zealand n=42). Research staff administered standardised questionnaires and undertook medical note review, clinical examination and spirometry. Medical history was extracted from the original dataset and current medical records. Based on their clinical assessment, physicians classified children into 4 overall categories (well, better, stable, worse). There are however, no prospective studies in children with CSLD in the last 50-years to help guide long-term clinical care and management. We evaluated the long-term clinical outcomes of Indigenous children with CSLD who participated in our previous study, ‘Multicentre Bronchiectasis Study (BOS)’ (2004-2012).

Methods: During 2015–17, we re-assessed as many children as possible from BOS (Australia n=97, Alaska n=41, New Zealand n=42). Research staff administered standardised questionnaires and undertook medical note review, clinical examination and spirometry. Medical history was extracted from the original dataset and current medical records. Based on their clinical assessment, physicians classified children into 4 overall categories (well, better, stable, worse).

Results: 120/180 (67%) children (current median age 11.5-years (IQR 5.9-18.6); 46% males) were reviewed. From birth until their current age, children had a median of 20 (IQR 14-30) community-treated acute lower respiratory infections and 4 (IQR 3-7) respiratory hospitalisations. Respiratory infections decreased with age. At examination, wheeze was present in 10%, wet cough in 26% and digital clubbing in 17% of children. The children’s summary clinical status were: well (22%); better (32%); stable (46%) or worse (0%). Airway obstruction on spirometry was present in 36% and restrictive pattern in 19%, with only 45% having normal spirometry values within population norms.

Conclusion: In a 10-year follow-up of children with CSLD and ongoing clinical care, most were stable or improved by adolescence. However, as many still experience respiratory symptoms and demonstrate impaired lung function, clinical follow-up is recommended during adolescence to optimise clinical management.

Declaration of interest: Nil

Grant Support: NHMRC CRE for Lung Health APP1040830; GB and AC are supported by NHMRC fellowships.

FREE FATTY ACID RECEPTORS 1 AND 4 MEDIATE DESENSITISATION-RESISTANT BRONCHODILATION AND ARE EXPRESSED IN ASTHMATIC AIRWAYS

ANGELES R1, DONOVAN C1, ROYCE S1,2, BOURKE J1

1Department of Pharmacology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia, and 2Department of Medicine, Central Clinical School, Monash University, Clayton, Victoria, Australia

Introduction: Salbutamol opposes airway hyperresponsiveness in asthma but its efficacy is limited by β2-adrenoceptor desensitisation. Free fatty acid receptors (FFAR) are expressed in mouse and human lungs (Mizuta et al., AJP Lung, 2015) and their agonists cause relaxation of mouse airways with greater efficacy than salbutamol (Bourke et al., AJRMB, 2017).

Aims: To compare bronchodilation to salbutamol, GW9508 (FFAR1/FFAR4 agonist) and TUG891 (FFAR4 agonist) under conditions of β2-adrenoceptor desensitisation, test potential FFAR1/FFAR4 desensitisation and assess FFAR expression in mouse airways from a model of chronic allergic airways disease and human airways from subjects with and without asthma.

Methods: Precision cut lung slices were prepared from 6-8-week-old male BALB/C mice. Airway relaxation to GW9508, TUG891, and salbutamol were compared after overnight incubation with 10μM salbutamol, 100μM GW9508, or vehicle. Immunohistochemistry for FFARs was performed on lung sections from saline control (C) and ovalbumin (OVA)-sensitised mice and airway biopsies from non-asthmatic (NA) and asthmatic (A) subjects.

Results: Salbutamol and FFAR agonists relaxed airways pre-contracted with methacholine (%relaxation: 10μM salbutamol 50±6%; 100μM GW9508 28±7%; 100μM TUG891 44±10%, n=7,4,6). Overnight incubation with salbutamol reduced subsequent relaxation to salbutamol (to 4±2%, n=7, p<0.0001 cf control), but not to GW9508 or TUG891 (27±6%, 42±10% respectively, n=6,5). GW9508 incubation did not affect salbutamol- or GW9508-mediated relaxation (44±6%, 26±7% respectively, n=6,6). Both FFAR1 and FFAR4 expression was similar in C and OVA mouse airways (FFAR4 positive pixel count/mm2: C 4.4±0.3x106, OVA 5.4±0.7x106, n=5,6) and both receptors were evident in airway smooth muscle and epithelium in NA and A human airways.

Conclusion: Relaxation to FFAR agonists was maintained under conditions of β2-adrenoceptor desensitisation and resistant to homologous desensitisation. Expression of FFAR1 and FFAR4 in asthma context suggests that these receptors may be targeted for alternative or adjunct bronchodilator therapy.
DETERMINANTS OF PHYSICAL ACTIVITY IN OBSTRUCTIVE AIRWAY DISEASES

CORDOVA-RIVERA L1,2, GIBSON P1,2,3, GARDINER P2, MCDONALD V1,2,3,4
1Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute (HMRI), University of Newcastle, Newcastle, Australia, 2Centre of Excellence in Severe Asthma, Newcastle, Australia, 3Department of Respiratory and Sleep Medicine, John Hunter Hospital, HMRI, Newcastle, Australia, 4The University of Queensland, Faculty of Medicine, Brisbane, Australia, and 5School of Nursing and Midwifery, University of Newcastle, Newcastle, Australia

Introduction/Aim: Severe asthma (SA), chronic obstructive pulmonary disease (COPD) and bronchiectasis are obstructive airway diseases (OAD) that share clinical characteristics that are likely to impair patients’ physical activity (PA) level. However, PA has not been extensively studied in OAD, outside of COPD. We aimed to describe the prevalence of PA impairment in different OAD compared to controls, and to test whether in the OAD group, PA is associated with shared clinical characteristics of these diseases.

Method: A cross-sectional study of adults with OAD (SA=62, COPD=67, bronchiectasis=60) and controls (n=63) was conducted. Participants underwent a multimodal assessment involving measurement of body mass index (BMI), lung function, exercise capacity (6-minute walk distance (6MWD)), health status (SGRQ) and systemic inflammation (hsCRP). PA (steps/day) was measured using the ActiGraph wGT3X-BT accelerometer.

Results: The OAD group included 189 participants (58.7% female), median [IQR] age 67 [58-72] years and mean FEV1% predicted 69.4%. The control group included 63 participants (52.4% female), aged 55 [34-64] years. Compared to controls, those with OAD accumulated more steps/day: median difference -4630 (COPD), -2255 (SA), and -2289 (bronchiectasis) (p≤0.001 all results). Compared to COPD, both SA and bronchiectasis accumulated more steps/day: median difference 2375 and 2341, respectively (p≤0.0001). No statistically significant differences were found between the SA and bronchiectasis groups. In separate adjusted regression models, 6MWD, FEV1% predicted and SGRQ were all associated with physical activity in participants with OAD. In the full multivariable model, 6MWD, FEV1% predicted and BMI remained significantly associated, explaining 47.4% of the adjusted variance of PA in people with OAD (p=0.0001).

Conclusion: People with OAD engage in lower levels of PA compared to controls. The degree of activity impairment differs by disease. Despite this, the level of activity is associated with shared clinical characteristics. Interventions to improve PA should be multifactorial, and target the OAD population, irrespective of diagnosis.

Grant Support: NHMRC, John Hunter Hospital Charitable Trust, HMRI

Conflict of Interest: VMM is supported by an NHMRC TRIP fellowship, has participated in educational symposia funded by GlaxoSmithKline, AstraZeneca, Menarini, and Novartis and has participated in advisory boards for GlaxoSmithKline, AstraZeneca and Menarini. PGG holds an NHMRC Practitioner Fellowship, has participated in educational symposia funded by AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Novartis, and has participated in studies funded by GlaxoSmithKline and AstraZeneca. PAG is supported by a NHMRC-ARC Dementia Research Development Fellowship and has participated in an educational symposium funded by Boehringer Ingelheim.

IL-33 AND RHINOVIRUS EFFECTS ON IL-33 RECEPTOR EXPRESSION IN ASTHMA

UPHAM J1,2, JURAK L2, XI Y2
1Princess Alexandra Hospital, Brisbane, Australia, and 2University of Queensland Diamantina Institute, Brisbane, Australia

Background: Epithelial cell-derived interleukin-33 (IL-33) appears to have an important role in polarizing type 2 immune responses to allergens, though whether IL-33 can also modify responses to respiratory viruses in asthma is not clear.

Aim: Examine the effects of IL-33 on anti-viral cellular immunity in asthma, focusing on the role of the two chains of the IL-33 receptor, interleukin 1 receptor like 1 (IL1RL1; also known as ST2) and IL-1 receptor accessory protein (IL1RAP).

Methods: Peripheral blood mononuclear cells were isolated from 16 people with mild/moderate allergic asthma and 16 healthy donors, exposed to IL-33 (10ng/ml) and activated with rhinovirus (RV) serotype 16 for 24h. mRNA and protein expression were assessed by qPCR, flow cytometry and/or ELISA.

Results: In those with asthma, RV + IL-33 induced greater type 2 cytokine production, whereas in control subjects, IL-33 enhanced type 1 cytokine production. Both RV alone and RV + IL-33 induced upregulation of IL1RL1/ST2 mRNA and surface protein expression in asthma (p=0.013 and p=0.034 respectively), but not in healthy participants. This was due to enhanced IL1RL1/ST2 expression on both type 2 innate lymphoid cells (ILC2) and conventional T-cells. In contrast, neither RV nor IL-33 had any effect on expression of IL1RAP expression. ILC2 cells were the major source of IL-13 production.

Conclusion: These findings suggest dysregulation of the IL-33 receptor IL1RL1/ST2 in asthma, and provide a mechanism by which RV infections might exacerbate type 2 inflammation in an IL-33 rich tissue environment.

Grant Support: NHMRC and CRE for Severe Asthma
This abstract has been withdrawn

THE ROYAL MELBOURNE HOSPITAL THUNDERSTORM-ASTHMA COHORT
HARUN N1, LACHAPELLE P1,2, BOWATTE G2, LODGE C3, HINKS T4, BRAITBERG G5, IRVING L2,6, DHARMAGE S3,6, DOUGLASS J1,6
1Department of Respiratory and Sleep Medicine, The Royal Melbourne Hospital, Melbourne, Victoria, Australia, 2Department of Immunology and Allergy, The Royal Melbourne Hospital, Melbourne, Victoria, Australia, 3Allergy and Lung Health Unit, School of Population and Global health, University of Melbourne, Melbourne, Victoria, Australia, 4Respiratory Medicine Unit, Nuffield Department of Medicine, University of Oxford, Oxford, UK, 5Department of Emergency Medicine, The Royal Melbourne Hospital, Melbourne, Victoria, Australia, and 6Lung Health Research Centre, University of Melbourne, Melbourne, Victoria, Australia

Introduction/Aim: We aimed to characterise people affected by the catastrophic thunderstorm-asthma event in Melbourne, Australia in November 2016. We identified individual patient characteristics associated with hospital admission to inform research and practice in the management and prevention of the increasingly recognised and potentially fatal phenomenon of thunderstorm-asthma.

Methods: Cross-sectional, retrospective analysis of demographics of 240 patients presenting to The Royal Melbourne Hospital, an adult metropolitan university teaching hospital in Melbourne, and clinical characteristics of 70 of those patients who subsequently attended an outpatient clinic review.

Results: Patients were generally young adults (mean age 35 years), non-Caucasian (60%), with seasonal rhinitis (96%) and universally (100%) sensitised to ryegrass pollen. Forty-three patients (18%) required hospitalisation. Twenty-six (37%) of these patients had no prior diagnosis of asthma. Amongst known asthmatics, preceding the event, 79% had active asthma symptoms. Forty-four per cent of patients were receiving short-acting β-agonist therapy alone. Hospitalisation was associated with uncontrolled asthma symptoms in the month prior to the event (60%), and more symptomatic allergic rhinitis, lower lung function, higher total and ryegrass-specific IgE and higher peripheral blood eosinophil counts measured at review.

Conclusion: Thunderstorm-asthma affects people with seasonal rhinitis, ryegrass sensitisation and can occur without prior history of asthma, with a dramatic potential to rapidly inundate a healthcare system. Poor asthma control earlier in the hay fever season was associated with hospitalisation and inhaled corticosteroids should be considered prior to the high-risk season in strongly sensitised individuals.

Grant Support: The authors have no potential conflict of interest to disclose.
A SINGLE BOUT OF MODERATE-INTENSITY EXERCISE REDUCES EOSINOPHILIC AIRWAY INFLAMMATION IN INACTIVE ADULTS WITH ASTHMA, WHILE VIGOROUS-INTENSITY EXERCISE HAS NO EFFECT

SCOTT H1,2,3, WOOD L2,4, UPHAM J4
1Lung and Allergy Research Centre, The University of Queensland, Woolloongabba, Queensland, Australia, 2School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, New South Wales, Australia, 3Centre for Healthy Lungs, University of Newcastle, New Lambton Heights, New South Wales, Australia, and 4Diamantina Institute, The University of Queensland, Woolloongabba, Queensland, Australia

Introduction/Aim: Exercise benefits general health, however its impact on asthma has received little attention, with the effects of exercise intensity not having been examined in this population. We previously found a single bout of moderate-intensity exercise decreased exhaled nitric oxide in physically inactive, but not in physically active, adults with asthma. The aim of this study was to examine the acute effects of exercise intensity on airway inflammation in adults with asthma, and to examine whether this differs by usual exercise levels.

Methods: In a randomised controlled trial, adults with asthma were randomised to complete either 45 minutes of moderate-intensity exercise (55-70% HRmax) on a cycle ergometer (n=19), 30 minutes of vigorous-intensity exercise (70-85% HRmax) on a cycle ergometer (n=19) or 30 minutes of rest (n=18). Sputum cell counts were obtained the day prior to and 4 hours-post exercise/rest.

Results: Sputum eosinophil count was lower following moderate-intensity exercise [0 (26, 23)x10^6/mL] versus rest [9 (3, 42)x10^6/mL, p=0.0249]. However, sputum eosinophil count did not change following vigorous-intensity exercise [8 (21, 47)x10^6/mL, p=0.380] versus rest. Participants who reported performing exercise causing breathlessness or sweating more than usual had a significant decrease in sputum eosinophil count [-3 (-89, 0) vs 7 (3, 142)x10^6/mL, p=0.006] and sputum %eosinophils [-0.3 (-0.7, 0)% vs 0.5 (0.1, 2.0)%], p=0.012] following moderate-intensity exercise, compared to rest. Participants who became breathless or sweaty during exercise ≥twice/week had a significant decrease in sputum eosinophil count (p=0.395) or sputum %eosinophils (p=0.449) following the exercise challenge.

Conclusion: This study demonstrates that an acute bout of moderate-intensity, but not vigorous-intensity, exercise reduces sputum eosinophils in adults with asthma. This change was only evident in physically inactive participants, suggesting that regular physical activity may protect against airway inflammation.

Grant Support: TSANZ/Astra-Zeneca Respiratory Research Fellowship; Asthma Australia Project Grant.

Cystic Fibrosis 1

PRELIMINARY SAFETY AND EFFICACY OF TRIPLE-COMBINATION CFTR MODULATOR REGIMENS

TULLIS E1, COLOMBO C2, DAVIES J1, WARK P1, MCKEE C1, DESOUZA C1, WALTZ D3, SAVAGE J1, FISHER M4, SHILLING R1, MOSKOWITZ S5, TIAN S5, TAYLOR-COUSAR J6, ROWE S7
1St Michael’s Hospital, ON, Canada, 2Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, University of Milan, Italy, 3Imperial College & Royal Brompton Hospital, UK, 4Department of Respiratory & Sleep Medicine, John Hunter Hospital, New South Wales, Australia, 5Vertex Pharmaceuticals Incorporated, MA, 6National Jewish Health, CO USA, and 7University of Alabama at Birmingham, AL, USA

Introduction/Aim: Prior studies with cystic fibrosis transmembrane conductance regulator (CFTR) modulators in patients heterozygous for F508del and a minimal function (MF) CFTR mutation (F508del/MF) have failed. One strategy to enhance clinical efficacy is to add a second corrector to established corrector/potentiator regimens. Safety and efficacy of 3 such next-generation (NG) correctors (VX-440, VX-152, VX-659) in triple-combination therapy (TC) with tezacaftor (TEZ) and ivacaftor (IVA) were evaluated in patients with CF with F508del/MF or F508del/F508del genotypes.

Methods: Randomized, double-blind, placebo- or active-controlled studies of VX-440 and VX-152 (phase 2), and VX-659 (phase 1) in TC were conducted in CF patients with F508del/MF (n=80) or F508del/F508del genotypes (n=40; the latter with VX-152 and VX-440 only; after 4 weeks of TEZ/IVA pretreatment). Primary objectives were safety and tolerability; efficacy and pharmacodynamic effects were assessed by absolute change in ppFEV1, and sweat chloride from baseline, respectively.

Results: Baseline characteristics were balanced. NG TC regimens were well tolerated; most adverse events (AEs) were mild or moderate. AEs leading to discontinuation included increased alanine aminotransferase/aspartate aminotransferase (VX-440 TC, n=1), pneumonia (VX-152 TC, n=1), and respiration abnormal/sputum increased (placebo, n=1). After 2 to 4 weeks, significant improvement from baseline in ppFEV1 of 9.6 to 12.0 percentage points was seen with all 3 NG TC regimens in F508del/MF patients, and significant improvement from baseline of 7.3 to 9.5 percentage points was seen with VX-440 or VX-152 TC on top of TEZ/IVA in F508del/F508del patients (vs TEZ/IVA baseline). Significant reductions from baseline in sweat chloride were also seen with TC regimens vs placebo or TEZ/IVA alone.

Conclusion: This is the first demonstration of substantial improvements with NG TC regimens in patients with CF with F508del/MF genotype, in whom previous CFTR modulators have failed, and in patients with CF with F508del/F508del genotype. Ongoing studies will guide development of TC regimens.

Grant Support: Sponsored by Vertex Pharmaceuticals Incorporated.

Conflict of Interest: PW was an investigator for the Next Gen clinical trial and has taken part in advisory boards for Vertex Pharmaceuticals.
A PERIPHERAL BLOOD TRANSCRIPTIONAL PROFILE PREDICTS DISEASE SEVERITY AND THE RISK OF FUTURE EXACERBATIONS IN ADULTS WITH CYSTIC FIBROSIS (CF)

GOON K1, BARAN R1, BAINES K2, WARK P2
1Hunter New England Health, New Lambton Heights, Australia, and 2Hunter Medical Research Institute, New Lambton Heights, Australia

Introduction/Aim: To determine if a blood transcriptional gene signature could be used to predict risk of exacerbations in the next 12 months.

Methods: CF participants (n=21) were recruited when stable at annual review and followed for 12 months. Peripheral blood RNA was collected into Paxgene RNA tubes. RNA was extracted using the Paxgene Blood RNA Kit (Qiagen) and RNA quality and quantity was assessed using the Bioanalyzer (Agilent Technologies). Transcriptional profiles were generated (Illumina HumanRef-8 V4) and analysed using GeneSpring GX14.8.

Results: Participants had mean age 33years (13.5), mean FEV1 65% predicted (sd 22). Unsupervised hierarchical clustering of gene expression profiles revealed 2 distinct clusters. Cluster 2 (n=16) were characterised by significantly lower FEV1% predicted (p=0.036), higher residual volume % predicted (p=0.040), lower BMI (p=0.042), more frequent exacerbations requiring IV antibiotics (p=0.012), and increased residual volume % predicted (p=0.040), lower BMI (p=0.042), more frequent exacerbations requiring IV antibiotics (p=0.012), and increased presence of pseudomonas (p=0.011), compared with cluster 1 (n=5). This more severe phenotype in cluster 2 was associated with a reduction in the expression of 119 entities, including downregulation of immune regulatory genes such as IL-10, IL-17RD, and NLRP8.

Conclusion: Transcriptional profiles of peripheral blood can predict disease severity and future risk of exacerbations in the next 12 months.

Grant Support: n/a

HYPERGLYCAEMIA IN YOUNG CHILDREN WITH CYSTIC FIBROSIS CORRELATES WITH INFECTION AND NEUTROPHIL BURDEN ON BRONCHIALVEOLAR LAVAGE

PRENTICE B1,2, HAMEED S2,3, VERGE C1,2, OOI C1,4, STRACHAN R1, WATERS S1,2, WIDGER J1,2
1Department of Respiratory Medicine, Sydney Children’s Hospital, Sydney, New South Wales, Australia, 2School of Women’s and Children’s Health, The University of New South Wales, Sydney, New South Wales, Australia, 3Department of Endocrinology, Sydney Children’s Hospital, Sydney, New South Wales, Australia, and 4Department of Gastroenterology, Sydney Children’s Hospital, Sydney, New South Wales, Australia

Introduction: Cystic Fibrosis(CF) results in insulin deficiency from birth and progresses to Cystic Fibrosis-related diabetes (CFRD)[1]. CFRD has a significant impact on lung function, respiratory infections, and nutrition, and leads to an increase in mortality[2]. However, the prevalence of early hyperglycaemia and impact on respiratory tract infections in young children with CF remains unknown.

Aims: To determine the prevalence of hyperglycaemia in children with CF using Continuous Glucose Monitoring (CGM) To correlate hyperglycaemia on CGM with presence of CF pathogen and neutrophil percentage in routine bronchoalveolar lavage (BAL).

Methods: A single-centre study of children with CF <5years. The CGM device (CGM Medtronic MiniMed) was inserted when clinically well during routine bronchoscopy/BAL and worn for 3 days. CGM outcomes included peak glucose, time spent >7.8mmol/L and Area Under Curve (AUC) >7.8mmol/L. BAL samples were cultured and cell count and differential determined. A t-test and regression analysis was undertaken to examine the relationship between hyperglycaemia and the presence of CF pathogen, and neutrophil percentage on BAL.

Results: 14 children (3 female) had GMs performed, 12/14 had neutrophil percentage results available. Median age 2.44 years (range 1-5.5). 3 day glucose mean=5.89±0.49mmol/L (mean± SD). 43% (6/14) had diabetic range (≥11.1mmol/L) glucose levels. Participants who had positive cultures spent a greater period of time >7.8mmol/L on CGM (mean time 9.9%) compared with culture negative participants (3%, p=0.02), and had a greater glucose AUC>7.8mmol/L (p=0.04). There was a positive correlation with peak glucose (r²=0.4, p=0.02) and AUC>7.8mmol/L (r²=0.4, p=0.04) with neutrophil burden on lavage.

Conclusion: Young children with CF have demonstrated diabetic range hyperglycaemia on CGM. CF pathogens are more likely to be present when glucose abnormalities are more severe and a significant correlation between neutrophil count and hyperglycaemia was demonstrated. Further research is underway to determine whether abnormalities on CGM in this cohort has an impact on nutrition, pulmonary inflammation and lung function.

REFERENCES
Grant Support/Declaration of Interest: SH and CFV are grateful for funding assistance from the National Health and Medical Research Council of Australia, the Australasian Cystic Fibrosis Research Trust, Regional Diabetes Support Scheme, Sydney Children’s Hospital Foundation, Australasian Pediatric Endocrine Care Grant from Pfizer, and for Industry support from Novo Nordisk, Medtronic, Abbott Diagnostics. BP was awarded the TSANZ/Vertex Cystic Fibrosis Paediatric Clinical fellowship in 2016.
GREATER SLEEP FRAGMENTATION IS ASSOCIATED WITH LESS PHYSICAL ACTIVITY IN ADULTS WITH CYSTIC FIBROSIS

Cox N.1,2, Pepin V.2, Holland A.1,2,4
1La Trobe University, Melbourne, Australia, 2Institute for Breathing and Sleep, Melbourne, Australia, 3Concordia University & Hôpital du Sacré-Cœur de Montréal, Montreal, Canada, and 4Alfred Health, Melbourne, Australia

Introduction/Aim: Sleep quality in people with cystic fibrosis (CF) is known to be poor, while regular physical activity participation is associated with less decline in lung function (FEV1). The relationship between sleep quality and physical activity in people with CF is unknown. We aimed to explore any association between sleep pattern and physical activity participation in young adults with CF.

Methods: This is a secondary analysis of sleep and activity data collected via actigraphy. Adults with CF in stable health, participating in a study of physical activity (including assessment of exercise capacity), completed 7 days of activity and sleep assessment (SenseWear Armband (SWA), Bodymedia USA). Sleep characteristics were derived from accelerometer positional data and registration of sleep state by the SWA, determined by energy expenditure.

Results: Sleep and activity data were available for 47 participants (n=28 male; mean (SD) age 29(8) years; median (IQR) FEV1 60 (50 to 82) %predicted). More fragmented sleep was associated with poorer exercise capacity (r2=0.303, p<0.04), time spent in moderate-vigorous physical activity (MVPA) (r2=0.337, p=0.020), and poorer FEV1 (r2=0.344, p=0.018). In a stepwise multiple regression model that included age, sex, body mass index and FEV1, models including wake after sleep onset (WASO) were significantly predicted more total daily activity time (β=-0.3, SE of β=0.2, p<0.05). Less WASO significantly predicted more total daily activity time (β=1.0, SE of β=0.4, p=0.02), and trended toward significance for predicting greater MVPA time (β=0.3, SE of β=0.26, p=0.08). Greater total sleep time and sleep efficiency were related to better exercise capacity and lung function (p<0.05).

Conclusion: This analysis demonstrated a modest relationship between sleep parameters and physical activity and exercise capacity in adults with CF. Future studies of interventions to promote physical activity participation in this group should consider the relationship between sleep and activity performance.

Grant Support: NHMRC (Early Career Fellowship: 1119970); La Trobe University Research Collaboration Grant 2015

NON-INVASIVE MUCOCILIARY TRANSIT ASSESSMENT IN LIVE PIG TRACHEA

Donnelley M.1,2, Klein M.2, Hausermann D.3, Hall C.3, Maksimenko A.2, Morgan K.4,5, Parsons D.1,2
1Robinson Research Institute and Adelaide Medical School, University of Adelaide, Adelaide, Australia, 2Respiratory and Sleep Medicine, Women’s and Children’s Hospital, North Adelaide, Australia, 3Imaging and Medical Beamline, Australian Synchrotron, Clayton, Australia, 4School of Physics, Monash University, Clayton, Australia, and 5Institute for Advanced Study, Technische Universität München, Munich, Germany

Introduction/Aim: The Imaging and Medical Beamline (IMBL) at the Australian Synchrotron was designed to be the world’s widest synchrotron x-ray beam, to facilitate clinical imaging and therapeutic applications in humans, as well as for imaging large animal models. Our group is currently interested in imaging the airways of newly-developed CF animal models that display human-like lung disease, such as the CF pig. We hypothesise that the ability of the lung to clear inhaled particulates by mucociliary transit (MCT) can be used as an outcome measure for assessing the effectiveness of CF airway therapies. This study extends findings from ex vivo sheep and pig tracheal tissue studies previously performed at the IMBL, and was designed to determine whether the design of the IMBL is suitable for imaging pig airways.

Methods: A small sample of 200 μm diameter high refractive index (HRI) glass bead marker particles were delivered into the tracheal airway surface of eight live piglets. Automated analysis algorithms were used to track and quantify deposited-particle motion, including the response to aerosol delivery of hypertonic saline. A high-resolution computed tomographic (CT) whole-animal post-mortem scan of one pig was also performed to verify the large-sample CT capabilities of the IMBL.

Results: MCT tracking particles were visible in all animals, and our automated MCT tracking algorithms were able to identify and track particles. A CT of the whole animal was successfully acquired, and visualisation was successfully made from the CT dataset. Due to unexpected IMBL technical and equipment issues shuttering of the X-ray beam was sometimes poorly controlled, resulting in high radiation doses for some animals.

Conclusion: This study demonstrated that the IMBL is suitable for large animal tracheal MCT imaging and CT. Radiation doses must be carefully and reliably controlled for future non-recovery studies, and will enable estimation of the minimum achievable doses with this experiment design.

ABSENTEEISM AND PRESENTEEISM IMPACT WORK IN ADULTS WITH CYSTIC FIBROSIS
LIAN R1, CAVALHERI V1,2, WOOD J1,2, JENKINS S1,2, STRAKER L1, HILL K1,2
1Curtin University, Bentley, Australia, 2Institute for Respiratory Health, Sir Charles Gairdner Hospital, Nedlands, Australia, and 3Physiotherapy Department, Sir Charles Gairdner Hospital, Perth, Australia

Introduction/Aim: People with cystic fibrosis (CF) are living longer and thus facing issues related to work. The aims of this study were to, in people with CF living in Western Australia (i) report work status and self-reported absenteeism (absence from work due to illness) and presenteeism (loss of performance at work due to illness); and (ii) explore factors related to work status and absenteeism and presenteeism.

Methods: Secondary analyses of a larger study were conducted. Measures were collected of work status, absenteeism and presenteeism (World Health Organisation’s Health Performance Questionnaire), airflow obstruction (FEV1), health-related quality of life (HRQoL; CF Questionnaire-Revised) and level of education. Adults with CF were grouped by work status (full-time versus part-time/unemployed) and self-reported absenteeism/presenteeism (substantial versus no substantial). Between-group differences were explored and factors related to work status and absenteeism/presenteeism were evaluated using logistic regression.

Results: Of the 50 participants (30 [25-36]yr, percent predicted FEV1 60±18[SD]%), 34 (68%) worked full-time. Participants reported working 30±14[SD]hr/week. Compared to those part-time/unemployed, participants working full-time were older (median [IQR] 33 [27 to 38]yr versus 26 [22 to 32]yr; p=0.048) and had higher levels of education (79% versus 31% completed university or other tertiary studies; p=0.002). Higher education level was associated with reduced odds of working part-time/being unemployed (OR 0.26 95%CI [0.11 to 0.64]). Substantial absenteeism and substantial presenteeism were reported by 47% and 16% of participants, respectively. Those reporting substantial absenteeism had worse HRQoL (median [IQR] role domain score 92 [75 to 100] no substantial absenteeism versus 83 [60 to 90] substantial absenteeism; p=0.018). No associations were found for substantial presenteeism.

Conclusion: Despite moderate disease severity, most participants reported working full-time. Cystic fibrosis may have a greater impact upon absenteeism than presenteeism; however, larger studies are needed to determine the reasons for this greater impact.

Grant Support: This study was partially funded by a Sir Charles Gairdner Group Research Advisory Council Grant.

Declaration of Interest: Nil.

Declaration of Interest: Nil.

Occupational & Environmental Lung Disease / Population Health

SMOKING, FAMILY HISTORY AND ASBESTOS EXPOSURE ARE ASSOCIATED WITH IPF
ABRAMSON M1, MURAMBADORO T1, ALIF S1, BENKE G1, DHARMAGE S2, ELLIS S3, GLASPOLE H4, HOPKINS P5, HOY R1,2, KLEBE S6, MILLER A7, MOODLEY Y8, NG B9, RAWSON S1, REYNOLDS P10, ROUSE H10, WOLFE R11, WALTERS E11, CORTE T12
1Public Health & Preventive Medicine, Monash University, Melbourne, Australia, 2Population & Global Health, University of Melbourne, Parkville, Australia, 3Radiology, The Alfred, Prahran, Australia, 4Respiratory Medicine, The Alfred, Prahran, Australia, 5The Prince Charles Hospital, Chermside, Australia, 6Anatomical Pathology, Flinders Medical Centre, Bedford Park, Australia, 7Radiology, Royal North Shore Hospital, St Leonards, Australia, 8University of Western Australia, Claremont, Australia, 9Royal Adelaide Hospital, Adelaide, Australia, 10Medical Imaging, St Vincents Hospital, Fitzroy, Australia, 11Medicine, University of Tasmania, Hobart, Australia, and 12Royal Prince Alfred Hospital, Camperdown, Australia

Introduction/Aim: Idiopathic Pulmonary Fibrosis(IPF) is a progressive scarring lung disease of unknown cause with limited treatment and a median survival of 2-3 years. Our aim was to identify potential occupational and environmental exposures associated with development of IPF in Australia.

Methods: Cases were recruited by the Australian IPF registry. Patients completed a questionnaire about demographics, smoking, family history, environmental and occupational exposures, and medical history. Clinical, radiological and histopathological data were reviewed by a multidisciplinary panel. Population based controls were recruited by random digit dialling, frequency matched on age, sex and state, and interviewed to collect comparable data. Multivariate logistic regression was used to assess associations with IPF as Odds Ratios(OR) and 95% confidence intervals(95%CI), adjusted for age, sex and smoking.

Results: Data were from 374 cases assessed by multidisciplinary discussion as definite, probable or possible IPF, and 962 controls. The mean±SD age of cases was 71.2±7.8 and controls 70.8±8.4 years. 72% cases and 69% controls were male. Current or past tobacco smoking was associated with increased risk of IPF: OR=2.24 (95%CI 1.72, 2.91), but marijuana use appeared protective: 0.43 (0.26, 0.70). A family history of pulmonary fibrosis was associated with 14.1 (7.14, 27.9) fold increased risk of IPF. No domestic environmental exposures were associated with increased risk, but pet birds or standing water appeared protective (OR=0.51; 0.34, 0.78 and 0.57; 0.36, 0.89 respectively). Self-reported occupational exposure to asbestos was associated with increased risk: OR=1.38 (1.06, 1.79), but silica appeared protective: 0.60 (0.42, 0.85). Self-reported occupational exposures to gases, fumes, chemicals or dust were not associated with IPF.

Conclusion: Preliminary findings suggest that the burden of IPF could be reduced by continued tobacco control measures and preventing ongoing exposure to asbestos. More detailed assessment of occupational exposures will be undertaken using the Finnish job exposure matrix (FINJEM).

Grant Support: NHMRC
LONGITUDINAL SURVEILLANCE OF METROPOLITAN FIREFIGHTERS INDICATES NORMAL LUNG FUNCTION DECLINE
SLATTERY F1, JOHNSTON K2, PAQUET C2, CROCKETT A1
1Alliance for Research in Exercise, Nutrition and Activity (ARENA), Sansom Institute, School of Health Sciences, University of South Australia, Adelaide, Australia, and 2School of Health Sciences, Sansom Institute for Health Research, University of South Australia, Adelaide, Australia

Introduction/Aim: Longitudinal surveillance of firefighter lung function is highly valuable, especially considering its utility in determining changes in function following disastrous exposures. Studies investigating the long-term rate of change in lung function parameters of firefighters, however, have produced mixed findings. We aimed to determine the rate of change in FEV1 and FVC of a contemporary cohort professional South Australian Metropolitan Fire Service (SAMFS) firefighters.

Methods: Spirometry was conducted in 5 stages between 2007 and 2016 on all available and consenting full-time firefighting staff, in accordance with ATS/ERS criteria using a Viasys MasterScreen spirometry system. We examined serial FEV1 and FVC measurements to determine the average rate of change using linear mixed effects modelling.

Results: Participation at each stage of data collection ranged from approximately 48-64%. Data from 838 individual male firefighters, each contributing an average of 2.6 ± 1.1 (range 1-5) measurements, were included in the analysis. Fifty per cent of included firefighters had at least three measurements. Preliminary analyses show that the proportion of firefighters below the lower limit of normal (LLN) at baseline was 0.7% for FEV1, 5.0% for FVC and 14.2% for FEV1/FVC, while longitudinally, FEV1 (adjusted for baseline age and height) declined by 24 (95% CI, 20 to 29) mL/yr while FVC declined by 24 (95% CI, 20 to 29) mL/yr.

Conclusion: The SAMFS firefighters observed in this study showed normal levels of FEV1 and FVC at baseline; unsurprising given that they are selected, in part, based on their physical fitness. Early results indicate that the cohort have a normal rate of change in FEV1 and FVC, suggesting that their lung function remains relatively unaffected by their occupation.

Grant Support: This research was supported by the South Australian Metropolitan Fire Service and an Australian Government Research Training Program Scholarship (FS).

<table>
<thead>
<tr>
<th>Child ≤12 years (ppb)</th>
<th>Adult &gt;12 years (ppb)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal ≤20</td>
<td>Intermediate 21-34</td>
</tr>
<tr>
<td>Aboriginal (n=112)</td>
<td>88%</td>
</tr>
<tr>
<td>Torres Strait Is (n=134)</td>
<td>83%</td>
</tr>
<tr>
<td>Both (n=155)</td>
<td>85%</td>
</tr>
</tbody>
</table>

Is=Islander, Both=Aboriginal and Torres Strait Islander

ASSESSING THE SUITABILITY OF FRACTIONAL EXHALED NITRIC OXIDE (FENO) CUT-OFF RANGES FOR ABORIGINAL AND/OR TORRES STRAIT ISLANDER CHILDREN AND YOUNG ADULTS
BLAKE T1,2,3, CHANG A2,3, CHATFIELD M1, PETSKY H1, MCELREA M1,2,3
1Centre For Children’s Health Research, South Brisbane, Australia, 2Indigenous Respiratory Outreach Care (IROC) Program, Chermside, Australia, 3Department of Respiratory and Sleep Medicine, Lady Cilento Children’s Hospital, South Brisbane, Australia, 4OIMR Berghofer Medical Research Institute, Herston, Australia, and 5School of Nursing and Midwifery, Griffith University, Nathan, Australia

Introduction/Aim: Fractional exhaled nitric oxide (FeNO) is used as a non-invasive measure of eosinophilic airway inflammation. It is unknown how appropriate the recommended FeNO cut-off ranges are for Aboriginal and/or Torres Strait Islander patients. Our aim was to assess the distribution of healthy Aboriginal and/or Torres Strait Islander FeNO results according to current American Thoracic Society cut-off guidelines.

Methods: We measured FeNO (using Aerocrine NioxMino) in 991 Indigenous children and young adults (aged 3 to 25 years) from seven Queensland communities. Questionnaires and medical charts were reviewed to identify healthy participants (no respiratory and/or atopic illness ever).

Results: Acceptable FeNO measurements were achieved by 553 children (≤12 years) and 288 adults (>12 years). Participants with a history of respiratory and/or atopy conditions were excluded resulting in a healthy cohort of children (n=401, 72.5%) and adults (n=193, 67%). The geometric mean FeNO results for children and adults were 11.1ppb and 12.5ppb respectively. Table 1 summarises the distribution of healthy FeNO results for each ethnic group according to current cut-off ranges.

Conclusion: Although the majority of participants had FeNO results within the age- and sex-specific ranges, we found a proportion of healthy participants with elevated FeNO results in all groups. The greatest proportion of elevated results was seen in Torres Strait Islander children and adults, and Aboriginal/Torres Strait Islander children. This suggests that the recommended cut-off ranges may not be appropriate for these groups. Further investigation is still needed.

Grant Support: IROC Program (Qld Health) and CRE for Indigenous Lung Health in Children. NHMRC PhD Scholarship (TB), NHMRC Practitioner Fellowship (AC).
LUNG CANCER SCREENING IN THE WESTERN AUSTRALIAN ASBESTOS REVIEW PROGRAM

HARRIS E1,2, MURRAY C3, FRANKLIN P4, SOOHI-BERRY N5, REID A5, OLSEN N6, HALL D1, DE KLERK N1, MUSK A1,4, BRIMS F1,2,6

1Sir Charles Gairdner Hospital, Perth, Australia, 2Curtin Medical School, Curtin University, Perth, Australia, 3Royal Perth Hospital, Perth, Australia, 4School of Population and Global Health, University of Western Australia, Perth, Australia, 5School of Public Health, Curtin University, Perth, Australia, and 6Institute for Respiratory Health, Perth, Australia

Introduction: Asbestos exposure increases the risk of lung cancer, especially in smokers. Western Australia (WA) has the highest rates of asbestos-related diseases in the world, due to crocidolite mining in the Pilbara town of Wittenoom and the widespread use of asbestos throughout WA. Early diagnosis utilising low dose CT (LDCT) scans have been shown to reduce mortality from lung cancer.

Aim: To analyse the efficacy of LDCT in detection of lung cancer in an asbestos-exposed population over a 5-year period.

Methods: In 2012, the Asbestos Review Program (based at Sir Charles Gairdner Hospital) began performing annual LDCT to screen an asbestos-exposed population for asbestos related lung disease and lung cancer. Population: Wittenoom miners and residents, other individuals with >3 months cumulative full time exposure. All participants had a prone LDCT scan with annual health questionnaire (including smoking status), spirometry and gas transfer.

Results: 5907 LDCT scans were performed on 1760 individuals with a median age of 70 years (IQR 63-76), 1490 (85.1%) were male and 1115 (63.7%) were ever-smokers. Lung cancer was diagnosed in 17 participants (0.97% of the cohort), 15 (pre-operative stage 1a or b) underwent treatment with curative intent, 2 underwent non-curative chemo-radiation. Lung cancer was prevalent in 10 (59%), and incident in 7 (41%) individuals (see Table 1). One participant died 4 months after surgery (found to have M1a disease during operation); no participants treated curatively have had reoccurrence to date. Mesothelioma was diagnosed in 7 other individuals. Asbestosis was present in 40.3% of the ARP population and 64.0% had pleural plaques, confirming significant asbestos exposure. The median radiation exposure per LDCT was 0.20mSv (IQR 0.14-0.52).

Conclusions: A carefully controlled LDCT screening program is effective at diagnosing and treating early-stage lung cancer in this population. Occupational exposure to asbestos should be accounted for in assessing risk for lung cancer.

Table 1. Characteristics of ARP participants diagnosed with lung cancer

<table>
<thead>
<tr>
<th></th>
<th>n=</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Participants</td>
<td>1760</td>
<td></td>
</tr>
<tr>
<td>Total Scans</td>
<td>5907</td>
<td>0.97</td>
</tr>
<tr>
<td>Lung Cancer</td>
<td>17</td>
<td></td>
</tr>
<tr>
<td>Smoking status</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ex</td>
<td>11</td>
<td>64.7</td>
</tr>
<tr>
<td>Current</td>
<td>1</td>
<td>5.8</td>
</tr>
<tr>
<td>Never</td>
<td>5</td>
<td>29.4</td>
</tr>
<tr>
<td>Asbestos Exposure</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lx-Wittenoom Worker</td>
<td>5</td>
<td>29.4</td>
</tr>
<tr>
<td>Lx-Wittenoom Resident</td>
<td>4</td>
<td>23.5</td>
</tr>
<tr>
<td>Other (mixed occupations)</td>
<td>8</td>
<td>47.0</td>
</tr>
<tr>
<td>Histology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adenocarcinoma</td>
<td>11</td>
<td>64.7</td>
</tr>
<tr>
<td>Squamous</td>
<td>4</td>
<td>23.5</td>
</tr>
<tr>
<td>Carcinoid</td>
<td>1</td>
<td>5.9</td>
</tr>
<tr>
<td>Small Cell</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Risk Factors</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lmphysema visible on LDCT</td>
<td>5</td>
<td>29.4</td>
</tr>
<tr>
<td>First degree relative - Lung Cancer</td>
<td>5</td>
<td>29.4</td>
</tr>
<tr>
<td>Obstructive Spirometry*</td>
<td>7</td>
<td>41.2</td>
</tr>
</tbody>
</table>

LOCT = Low dose chest CT scan; *(FEV1/FVC ratio <0.7)
NITROGEN DIOXIDE IS ADVERSELY ASSOCIATED WITH TRANSFER FACTOR OF CARBON MONOXIDE IN A DOSE-RESPONSE MANNER

PERRET J1, BOWATTE G1, KNIBBS L2, LODGE C3, JOHNS D3, LOWE A1, THOMAS P4, GILES G1, MORRISON S5, WALTERS E1, ABRAMSON M1, DHARMAGE S1

1The University Of Melbourne, Melbourne, Australia, 2University of Queensland, Brisbane, Australia, 3University of Tasmania, Hobart, Australia, 4University of New South Wales, Sydney, Australia, 5Cancer Council Victoria, Melbourne, Australia, and 6Monash University, Melbourne, Australia

Introduction/Aim: While air pollution exposure can contribute to the development of chronic obstructive pulmonary disease (COPD), studies have not examined lung function beyond the airways. We aimed to examine relationships between exposure to nitrogen dioxide (NO2, a gaseous air pollutant) and complex post-bronchodilator (post-BD) lung function measures in middle-aged Australians.

Methods: Cross-sectional data were obtained from the Tasmanian Longitudinal Health Study (n=1,389) when participants were 45 years of age. Annual outdoor mean NO2 concentrations at participants’ residential addresses were estimated using a validated satellite-based, land-use regression model. Multivariable regression used post-BD spirometry, carbon monoxide transfer factor (TLCO) and static lung volumes as continuous outcomes.

Results: Median NO2 exposure was 3.66 [interquartile range 2.95, 5.22] parts per billion. Increasing exposure to NO2 was associated with reduced TLco in a dose-response manner [p-for-trend<0.001]. Compared with the lowest quartile of NO2 exposure, the reduction in TLco was equivalent to 7.7% of predicted for the highest NO2 quartile (95%CI: -10.8 to -4.5) independent of smoking, and was significantly lower for those with current asthma [p(interaction)=0.005]. There was a trend to reduced TLC [p-for-trend=0.02], and reductions in post-BD FVC for non- and past but not current smokers exposed to the highest NO2 quartile [non-smokers -2.6% pred, p=0.042, p(interaction)=0.056]. There were no statistically significant relationships with post-BD FEV1/FVC, FEF25-75, or gas trapping (RV/TLC).

Conclusion: We provide evidence for a moderate adverse association between NO2 exposure and TLco at relatively low pollution levels, that varies with current asthma status. Other non-obstructive features favour a lung parenchymal process, although co-existent small airway narrowing may be masked by reduced FVC levels. This new knowledge supports environmental policy to reduce NO2 levels to as low as feasible.

Grant Support: NHMRC including Centre for Air quality, health Research and evaluation (CAR); Clifford Craig Foundation; Asthma Foundations (TAS VIC QLD)

MIDDLE-AGE LUNG FUNCTION DECLINE IS PREDOMINANTLY INFLUENCED BY ADULT FACTORS AND THEIR INTERACTIONS WITH CHILDHOOD AND GENETIC FACTORS

BUI D1, WALTERS H1, BURGESS J1, BUI M1, PERRET J1, BOWATTE G1, LOWE A1, GRAHAM G1, ERBAS B1, MORRISON S1, FEATHER P1, JAMES A1, THOMAS P1, HAMILTON G1, ABRAMSON M1, LODGE C1, DHARMAGE S1

1The University Of Melbourne, Melbourne, Australia, 2Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Australia, 3School of Psychology and Public Health, La Trobe University, Melbourne, Australia, 4University of Queensland, Brisbane, Australia, 5Gold Coast Hospital, Gold Coat, Australia, 6Sir Charles Gairdner Hospital, Perth, Australia, 7University of New South Wales, Sydney, Australia, 8Monash Lung and Sleep, Monash Health, Melbourne, Australia, 9School of Clinical Sciences, Monash University, Melbourne, Australia, and 10School of Public Health & Preventive Medicine, Monash University, Melbourne, Australia

Introduction/Aim: Accelerated adult lung function decline is a major pathway to chronic obstructive pulmonary disease. We sought to investigate associations and interactions between life span factors and lung function decline during middle age.

Methods: Post-bronchodilator lung function was measured at 45 and 53 years in 842 participants from the Tasmanian Longitudinal Health Study. We used multivariate linear regression to investigate associations of factors in adulthood (current asthma, smoking, atopy, BMI, BMI change, occupational exposures and traffic related air pollution), childhood (pneumonia, asthma, parental asthma and parental smoking) and Glutathione S-transferase gene polymorphisms, with the rate of lung function decline between 45 and 53 years. Interactions between factors were also investigated.

Results: Current asthma (-6; 95%CI: -11,-1 mL/year), current smoking (-12; -18,-6 mL/year), atopy (-5; -9,-0.7 mL/year), all at 45 years, lifetime occupational exposure to vapour/gas/dust/fumes (-6; -11,-1 mL/year) and increased BMI during the follow-up period (-2; -2.6,-1.5 mL/year per kg/m2 increase) were independently associated with accelerated FEV1 decline after controlling for age, height, sex, socioeconomic status and lung function at baseline (45 years). Current smoking (-12; -18,-6 mL/year) and BMI change (-2.5; -3.2,-1.9 mL/year per kg/m2 increase) were associated with greater FVC decline. GTTM1 polymorphism modified the effect of occupational exposure (p=0.06 and 0.07), and heavy maternal smoking during childhood modified the effect of personal smoking (p=0.03 and 0.02) on both FEV1 and FVC decline. The effect of occupational exposure was only significant for carriers of the GSTM1 null genotype, and the effect of personal smoking was augmented in those also exposed to maternal smoking.

Conclusion: Lung function decline in this middle-aged sample was predominantly influenced by adult factors. Exposure to maternal smoking during childhood and genetic susceptibility may predispose people to being more susceptible to adulthood exposures.

Grant Support: National Health and Medical Research Council of Australia, Clifford Craig Medical Research Trust of Tasmania; Victorian, Queensland & Tasmanian Asthma Foundations

DECLARATION OF INTEREST STATEMENT

There is no conflict of interest.
PERSONAL VAPORIZER E-JUICE AND AEROSOLS VARY WIDELY IN PHYSICOCHEMICAL PROPERTIES

Chivers E1, Mullins B2, Musk B3, Huxley R4, Franklin P5, Larcombe A1, 2

1Respiratory Environmental Health, Telethon Kids Institute, Perth, Australia, 2Occupation & Environment, School of Public Health, Curtin University, Perth, Australia, 3School of Population Health, University of Western Australia, Crawley, Crawley, Australia, 4College of Science, Health & Engineering, La Trobe University, Melbourne, Australia, and 5Environmental Health Directorate, Department of Health, Perth, Australia

Introduction/Aim: Personal vaporizers (“e-cigarettes”) aerosolise a liquid “e-juice” producing an aerosol which is inhaled. There is no regulation of e-juice ingredients. There are tens-of-thousands of different flavours, nicotine concentrations and excipient blends available from thousands of suppliers. Furthermore, while many ingredients are approved as food additives, inhalation toxicity data may be unavailable. We aimed to test the physico-chemical properties of a range of e-juices and aerosols to (i) identify potentially toxic substances and (ii) to see whether ingredients match labelling.

Methods: 18 e-juices were obtained from Australian and US retailers. E-juice chemistry was analysed via GC-MS. Aerosols were generated using a custom-made device based on an Innokin MVP2 vaporizer / Innokin iClear30 cartomizers set at 2.1Ω and 4.2V. Aerosols were collected for 30 minutes using appropriate filters and collection tubes. We assessed levels of carbonyls, volatile organics, polycyclic-aromatics, nicotine, particulate matter and metals. Aerosol mass and size distributions were measured using an optical particle spectrometer.

Results: 28 different chemicals were detected in e-juices including known respiratory irritants such as 2-chlorophenol and 1,2,3-butanetriol. Nicotine was detected in 6 apparently “nicotine-free” juices. Seven metals were identified in aerosols, including titanium, chromium and nickel. We also identified 7 carbonyls, however only formaldehyde, acetaldehyde and acetic acid were common. Sixteen volatile organics were identified. The solvents hexane and 2-ethoxy ethanol were ubiquitous in all samples. No poly-cyclic aromatics were detected. Aerosols contained particulate matter at hugely varying levels (3.3 to 63mg/m3) and particle size distributions also varied considerably, apparently based on the e-juice mixture.

Conclusion: The physico-chemical properties of e-juices and aerosols vary widely and hence their potential to impact health is also likely to vary. Importantly, nicotine was found in many “nicotine-free” juices, which has implications for addiction.

Grant Support: Department of Health, WA, Telethon Kids Institute, Curtin University, NH&MRC and the ACCC.
PALLIATION AND THE USE OF DIAGNOSTIC TESTS IN PATIENTS DYING IN HOSPITAL FROM COPD

ROSS L1, TAVERNER J1, BARTLETT C1, IRVING L1, PHILIP J2, SMALLWOOD N3
1Royal Melbourne Hospital, Parkville, Australia, and 2St Vincent’s Hospital, Melbourne, Fitzroy, Australia

Introduction/Aim: COPD is an incurable, progressive illness, with associated significant morbidity and mortality. Accurately determining prognosis in severe COPD is well-recognised to be challenging, as is diagnosing “active dying”.

Aim: To audit the use of diagnostic tests in both recognising active dying and after establishing the “Goal of Care” (GOC) was palliation in COPD patients dying in hospital.

Method: A retrospective audit of 475 consecutive patients who died from COPD at an Australian teaching hospital between 2004-2016.

Results: Of 221 patients included: 136 (60%) male, median age 80 years; median respiratory function: FEV1 0.8L (41%), FVC 2.0L (73%) and DLco 9 (41%); and 109 (49%) used home oxygen. 63 (29%) patients had palliative care involvement prior to the final admission.

During the terminal admission patients received on average 7 episodes of venepuncture, 9 Arterial Blood Gas tests and 3 chest radiographs. Receiving increased diagnostic tests was associated with age <70 years, admission under respiratory medicine team, ICU admission, and radiological evidence of pneumonia on admission.

For 187 (85%) patients, the GOC was documented as palliation during the final admission, a median of 1.8 days prior to death. 131 (70%) patients had diagnostic tests performed on the day palliation was initiated, and despite the change in GOC 22 (12%) patients had further tests following palliation. 70 (32%) had tests on the day they died.

Conclusion: Excessive, unnecessary diagnostic tests were performed in one third of inpatients dying from COPD, including those following a clear decision to palliate. Failure to clinically diagnose active dying imposes an unnecessary burden of diagnostic tests on those in their final hours.

Key Words: Palliation, COPD, diagnostic tests

Nomination for New Investigator Award: N/A

Grant Support: N/A
To 042

A CLUSTER RANDOMIZED TRIAL OF AN INTERDISCIPLINARY INTERVENTION FOR COPD IN AUSTRALIAN PRIMARY CARE

LIANG J1, ABRAMSON M2, ZWAR N3, RUSSELL G4, HOLLAND A5, BONEVSKI B2, MAHAL A2, PHILLIPS K6, EUSTACE P3, PAUL E2, GEORGE J1
1Centre for Medicine Use and Safety, Monash University, Victoria, Australia, 2Department of Epidemiology and Preventive Medicine, Monash University, Victoria, Australia, 3School of Medicine, University of Wollongong, New South Wales, Australia, 4School of Primary Health Care, Monash University, Victoria, Australia, 5Department of Physiotherapy, La Trobe University, Victoria, Australia, 6School of Medicine and Public Health, University of Newcastle, New South Wales, Australia, 7Nossal Institute of Global Health, University of Melbourne, Victoria, Australia

Introduction: Interdisciplinary practice-based interventions could potentially benefit patients with COPD in primary care. We describe the RADICALS (Review of Airway Dysfunction and Interdisciplinary Community-based care of Adult Long-term Smokers) model of care delivered in Australian general practices.

Methods: General practices (n=43) were block-randomised into ICG (interdisciplinary care group) or UCG (usual care group). Patient participants with spirometry-confirmed COPD in UCG practices received routine care from their GP and Quitline referral, if appropriate. ICG participants received the RADICALS model of care, coordinated by a research assistant, GPs and staff at each clinic. The model comprised individualised smoking cessation support, a home medicines review (HMR) from a consultant pharmacist, and home-based pulmonary rehabilitation from specifically trained physiotherapists. The primary endpoint is change in Health Related Quality of Life (HRQoL), as measured by the St George’s Respiratory Questionnaire (SGRQ), at 6 months from baseline. Other outcomes include changes in lung function, dyspnoea, COPD assessment test (CAT) score and EuroQol-5D at 6 and 12 months.

Results: A total of 275 patients with COPD were included – 161 in ICG and 114 in UCG. Their mean (±SD) age was 64.4 (±11.0) years; 171 (62%) were male and 168 (61%) were current smokers. Mean/median baseline SGRQ, CAT and mMRC scores were 32.3 (±13.2), 13.1 (±7.8) and 1 [IQR 0-2]. A total of 85 ICG participants received the HMR, 71 completed home-based pulmonary rehabilitation, and 62 received both components. Six month follow-ups are complete (n=208); 12 month follow-ups are in progress and will be completed by February 2018.

Conclusion: An interdisciplinary model of care for COPD has been developed, implemented and evaluated in general practice. HMR and home-based pulmonary rehabilitation had moderate acceptance as interventions by GPs and patients.

Grant/in-kind support: NHMRC, Lung Foundation Australia, Boehringer Ingelheim, Eastern Melbourne PHN, Cyril Tonkin Scholarship

Conflict of Interest: Funding was received from Boehringer Ingelheim.

To 043

LUNG FOUNDATION AUSTRALIA (LFA) CONSUMER SURVEY RESULTS 2017

ALLAN H1, PHILLIPS K, AAMI D, MCDONALD C2
1Lung Foundation of Australia, Brisbane, Queensland, Australia, and 2Faculty of Medicine, University of Melbourne, Melbourne, Victoria, Australia

Introduction: LFA undertook a survey to gain insight into the key issues facing consumers and carers, and to understand how LFA meets - or can better meet – their needs.

Methods: 9,000 surveys were distributed (via email and post) to consumers with any lung disease that subscribe to the LFA network.

Results: 1700 surveys were completed, representing a response rate of approximately 19%. Of these, 65% were female, 57% were aged between 65-79 years, 87% had a lung disease and 13% were carers. Respondents indicated that 39% see family and friends less often, 29% feel isolated from society and 59% do the things they love less often because of their lung disease. When asked specifically about how they felt at time of diagnosis, 30% felt less deserving of help than people with other medical conditions, 23% felt shame, guilt or fear of being discriminated against, 41% felt stigmatised by the view that lung diseases are self-inflicted and smoking-related and 58% felt they had all the support they needed to deal with the diagnosis. Suggestions were received about additional LFA supports; responses highlighted the need for psychosocial support through more telephone, online and face-to-face connection with LFA and other consumers, as well as the need for additional education seminars and webinars, and more information on specific disease treatments and research.

Conclusion: People impacted by lung disease face many challenges. This survey has detailed the effect on community and social interactions, with feelings of isolation and less contact with loved ones highlighted. Also it demonstrates the shame, stigma and guilt some people may experience when diagnosed with a lung disease.

Grant support: LFA receives financial support from donors, philanthropic trusts and foundations, fundraising and corporate partners
HDAC6 promotes DDX1-mediated antiviral immunity and is impaired in COPD

HSU A1, HANSBRO P1, WARK P1,2
1University of Newcastle, Newcastle, Australia, and 2John Hunter Hospital, Newcastle, Australia

Introduction/Aim: COPD primary bronchial epithelial cells (pBECs) are characterised with deficient innate antiviral response to influenza virus infection, leading to heightened viral replication. The molecular mechanisms underpinning this deficiency is unclear. HDAC6 is a unique cytoplasmic deacetylase, its roles in innate immunity is less well characterised. In this study we aim to determine the function of HDAC6 in antiviral immunity, and how HDAC6 expression/function is altered in COPD pBECs.

Methods: CRISPR-Cas9 HDAC6 Knockout plasmid and HDAC6-plasmid was transfected into a human minimally immortalised bronchial epithelial cell line BCi-NS1.1, and infected with H1N1. Protein interactions/expression levels were measured by immunoprecipitation, immunoblotting, and cytometric bead array. Viral replication was measured by plaque assay. pBECs from those with COPD (GOLD III-IV) and healthy controls were infected with H1N1. Similar measurements were performed.

Results: HDAC6 deficiency showed an overall reduction in antiviral response. Immunoprecipitation (IP) of HDAC6, mass spectroscopy, and co-IP identified that DDX1 is a direct binding target. DDX1 is an important viral RNA sensor. We found that HDAC6 deacetylated DDX1 and promoted DDX1-mediated type I and III interferon (IFN) induction. HDAC6 expression, DDX1 deacetylation, and antiviral responses were reduced in COPD pBECs. This reduction in HDAC6 expression in COPD pBECs was due to increased expression of miRNAs miR-141/-200a. Inhibition of miR-141/-200a increased HDAC6-DDX1-mediated antiviral response and decreased viral replication in both COPD and healthy control pBECs.

Conclusion: HDAC6 is essential in DDX1-mediated antiviral signalling to influenza viral infection, reduced HDAC6 expression and DDX1 deacetylation in COPD led to deficient antiviral signalings and increased viral replication, which could be restored by specific inhibition of miR-141/-200a.

Grant Support: Alan Hsu is supported by The Thoracic Society of Australia and New Zealand (TSANZ) / AstraZeneca Respiratory Research Fellowship. This study is funded by University of Newcastle Early Career Research Grant and NH&MRC.

Nontypeable Haemophilus influenzae (NTHi) exploits defects in airway epithelial cell xenophagy as a means of persistence during COPD

ROSCIOLI E1,2, BAC-TRAN H1, KICIC A1, POH M2, JERSMANN H1,2, HODGE S1,2
1Royal Adelaide Hospital, Adelaide, Australia, 2University of Adelaide, Adelaide, Australia, and 3Telethon Kids Institute, Subiaco, Australia

Introduction/Aim: NTHi infection causes approximately 50% of COPD exacerbations, inflammation, and FEV1 decline. Normally intracellular microbes are degraded by microbe-specific autophagy (xenophagy). We hypothesise NTHi exploits defects in xenophagy in COPD, potentially by cigarette smoke, enabling infection and propagation between airway epithelial cells (AEC).

Methods: Cultures of bronchial AEC (bAEC) lines, and from control and COPD donors differentiated at an air-liquid interface (ALI) were exposed to 10% cigarette smoke-extract (CSE) and NTHi. Markers of xenophagic flux and intracellular NTHi were assessed using western analysis, immunofluorescence and transmission electron microscopy (TEM).

Results: AEC exposed to 10% CSE exhibit a block in autophagic flux and down-regulation of the xenophagy-microbial adapter protein NDP52. Immunofluorescence analysis resolved intracellular NTHi within vesicular structures. Conversely, NTHi was readily evident in AEC derived from COPD donors and in close proximity to similar vesicular structures.

Conclusion: NTHi is able to avoid xenophagic degradation in AEC exposed to 10% CSE or in cultures of COPD-derived AEC, and may usurp the defective autophagic apparatus as a mode of persistence and extracellular propagation. Hence, modes of therapeutic intervention which restore normal xenophagic activity in AECs will significant utility to improve the clearance of intracellular NTHi infection, and thereby decrease the influence of this damaging pathogen in the airways afflicted by COPD.

Grant Support: Thoracic Society of Australia and New Zealand / AstraZeneca

Figure 1 TEM of bAEC from control donors revealed no detectable NTHi, and considerable autophagic activity (evidenced by dark electron dense regions) within vesicular structures. Conversely, NTHi was readily evident in AEC derived from COPD donors and in close proximity to similar vesicular structures.

Respirology (2018) 23 (Suppl. 1), 21–103

Editorial material and organization © 2018 Asian Pacific Society of Respirology.
Copyright of individual abstracts remains with the authors.
INTRANASAL DELIVERY OF THE TLR7 AGONIST, IMIQUIMOD, PROTECTS AGAINST INFLUENZA A VIRUS-INDUCED MORBIDITY IN MICE
TO E1,2, ERLICH J1, LUONG R1,2, LIONG F1, HENDRICKS K2, BOZINOVSKI S1, O'LEARY J3, BROOKS D3, VLAHOS R1, SELEMIDIS S1,2
1School of Health and Biomedical Sciences, RMIT University Bundoora, Victoria, Australia, 2Department of Pharmacology, Monash University, Clayton, Victoria, Australia, 3School of Medicine, Trinity Translational Medicine Institute, Trinity College Dublin, Ireland, and 4School of Pharmacy and Medical Sciences, Sansom Institute for Health Research, University of South Australia, Adelaide, 5001, Australia

Introduction/Aim: Influenza is a significant global burden with 5 million cases per year, 10% of which are fatal and thus, there is an urgent need for new therapeutics. Toll like receptor 7 (TLR7) is a pattern recognition receptor, which drives a powerful anti-viral signalling pathway that helps clear virus infections. The aim of the present study was to determine the effect of the TLR7 agonist imiquimod on morbidity, lung inflammation, oxidative stress and antibody production caused by influenza A virus (IAV) infection in mice.

Methods: Saline or imiquimod (50μg/mouse) was delivered intranasally to anaesthetised male C57BL/6J mice one day (d-1) prior to infection with a low (103PFU/mouse) or high dose (105PFU/mouse) of the mouse adapted Hong Kong X31 virus strain and everyday thereafter until mice were culled day 3 (d3) or 7 (d7) post-infection for analysis. Bronchoalveolar lavage (BAL) was performed to assess airways inflammation, and inflammatory cell oxidative burst (by L-012 enhanced chemiluminescence). In addition, BAL fluid and serum was used to determine antibody titres. The lungs were then harvested and used to assess inflammation (H&E staining) and pro-inflammatory cytokine gene expression by qPCR. Bodyweights were recorded daily during the experimental process.

Results: Imiquimod significantly suppressed body weight loss caused by IAV infection with a maximum reduction of ~60% starting from day 4 (d4) (103PFU/mouse, n=7-13, p<0.001). At d3 post infection, imiquimod treatment caused a significant reduction (~50-60%) in airway and peripheral bronchial inflammation and BALF neutrophil populations (105PFU/mouse, n=8-15, p<0.01) but had no effect on macrophage and lymphocyte populations, and the oxidative burst. TNF-α and IL-6 mRNA expression was suppressed by ~60% (p<0.01 and p<0.05, respectively), whilst IFN-β and IL-1β mRNA expression were unaffected. Day 7 data showed a modest but significant increase in IgE, IgG1, and IgG2a (p<0.05) in BALF following imiquimod treatment compared to control. There were no changes in antibody titres within the serum.

Conclusion: Our findings highlight a potential of imiquimod as a therapeutic option for the treatment of influenza disease.

Grant Support: NHMRC Australia (Project Grant ID 1122506, 1128276), ARC (FT120100876)

AIRWAY EPITHELIAL INNERNATE IMMUNE RESPONSES TO CORONAVIRUSES
LOO S1, NICHOL K1, HSU A1, LONDRIGAN S2, READING P2,3, BARTLETT N1, WARK P1,6
1Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute and The University of Newcastle, Newcastle, Australia, 2Department of Microbiology and Immunology, The University of Melbourne, Parkville, Australia, 3WHO Collaborating Centre for Reference and Research on Influenza, Victorian Infectious Diseases Reference Laboratory, North Melbourne, Australia, and 4Department of Respiratory and Sleep Medicine, John Hunter Hospital, Newcastle, Australia

Introduction/Aim: Despite the recurring emergence of novel pathogenic coronaviruses (CoVs) SARS-CoV (2002) and MERS-CoV (2012), there is a lack of understanding of host immunity during respiratory infection with CoVs. In this study, we characterised the innate immune responses of differentiated primary bronchial epithelial cells (pBECs) to infection with related less-virulent OC43-CoV and 229E-CoV.

Methods: Human pBECs were grown at the air liquid interface (ALI) until differentiation was observed (25-30 days), and infected at a multiplicity of infection (MOI) 0.1 with OC43-CoV or 229E-CoV for 0, 24, 96 hours and 7 days. Supernatants and RNA were collected to measure pro-inflammatory- and anti-viral-cytokines and viral replication. Using microarray, the gene expression profile of OC43-CoV and 229E-CoV infection was analysed (n=1). A549 cells transduced to overexpress Interferon-induced transmembrane proteins (IFITM) 1, 2 and 3 were infected with OC43-CoV or 229E-CoV. Viral replication was measured at 0, 8, 24 and 48 hours post-infection.

Results: OC43-CoV and 229E-CoV demonstrated different viral replication kinetics. 229E-CoV replicated earlier and more efficiently, peaking at 24 hours. This was associated with a delayed but robust activation of the innate host response, with induction of type I and III interferons (IFN-β, IFN-λ 1/3), IFN stimulated genes and IP-10. In contrast, replication of OC43-CoV peaked between 96 and 168 hours, with attenuated levels of IFN-β, IFN-λ 1/3 and IP-10. Microarray data also identified IFITM protein upregulation during 229E-CoV infection. In A549 cells over-expressing IFITM 1, 2 or 3, 229E-CoV replication was suppressed by IFITM 1 and 3, while the IFITM2 clone displayed similar replication kinetics to the control. OC43-CoV replication was unhindered by over-expression of all IFITM proteins.

Conclusion: This study demonstrated that both OC43 and 229E-CoVs replicated in differentiated pBECs, but they induce a divergent innate immune response potentially linked to their different replication kinetics. Understanding the host-virus interaction for these less virulent coronaviruses will give insight into pathogenic mechanisms underpinning SARS-CoV and MERS-CoV-induced respiratory disease.

Grant Support: University of Newcastle Research Scholarship UNRSC
INTRODUCTION/AIM: Infective exacerbations of chronic inflammatory lung diseases, such as asthma and chronic obstructive pulmonary disease (COPD), are associated with incremental scarring and fibrosis and gradual decrements in lung function. Central to this pathology is the pleiotropic cytokine transforming growth factor-beta (TGFβ) that regulates cell proliferation, tissue remodelling and lung fibrosis. Our previous studies have demonstrated that TGFβ suppresses the immune response, resulting in enhanced viral infection.

METHODS: We have utilised a transgenic mouse model of lung-specific TGFβ over-expression and established an acute and chronic model of inflammatory lung disease. We infected the mice with influenza A virus (IAV; strain HKx31) and examined disease severity, inflammatory and immune responses, and viral loads.

RESULTS: In the acute model, TGFβ was over-expressed for 2 days prior to IAV infection. These mice experienced more severe bronchitis and pneumonia, increased inflammatory cell infiltrates and enhanced cytokine and chemokine production in bronchoalveolar lavage (BAL) fluid compared to mice with normal TGFβ levels. These mice also demonstrated a suppressed innate immune response that was associated with enhanced viral titres. In the chronic model, TGFβ was over-expressed for 8 weeks, which resulted in thickening of the respiratory bronchiol epithelium and surrounding smooth muscle, and an emphysematous appearance within the airspaces, resembling phenotypic changes characteristic of asthma and COPD. Preliminary results in this model demonstrate that TGFβ infection is more severe compared to mice with normal TGFβ levels.

CONCLUSION: Our transgenic mouse model provides us with a unique tool to evaluate the direct effects of TGFβ on viral infection, or in the context of chronic inflammatory lung disease, and to investigate potential therapeutic strategies to combat viral-induced disease exacerbation.

Grant Support: NHMRC
Declaration of Interest: none.

DIFFERENTIATION BETWEEN APOPTOTIC AND NECROTIC CELL DEATH IN AIRWAY EPITHELIAL CELLS IN RESPONSE TO VIRAL INFECTION AND ANAEROBIC CONDITIONS USING FLOW CYTOMETRY

MONTGOMERY S1, STICK S1,2,3,4, KICIC A1,2,3,4,5
1School of Paediatrics and Child Health, University of Western Australia, Crawley, Australia, 2Telethon Kids Institute, Subiaco, Australia, 3Department of Respiratory Medicine, Princess Margaret Hospital for Children, Subiaco, Australia, 4Centre for Cell Therapy and Regenerative Medicine, School of Medicine and Pharmacology, The University of Western Australia, Crawley, Australia, and 5School of Public Health, Curtin University, Bentley, Australia

INTRODUCTION/AIM: Necrosis of airway epithelial cells (AEC) resulting in airway inflammation is a characteristic finding in cystic fibrosis (CF), driven by mucus obstruction of the airway and previously suggested as a potential response to respiratory viral infection. Current methodologies to measure apoptotic and necrotic cell death using flow cytometry in AEC are not adequate to completely differentiate between the two. The aim here was to determine whether a novel flow cytometry methodology described in other cell types could be optimized and adapted to AEC to sufficiently differentiate apoptotic and necrotic AEC.

METHODS: Non-CF and CF AECs were permeabilised, infected with human rhinovirus for 24 hours (MOI 1 & 3), or incubated in a limited O2 environment (0% O2 for 15 hours). Cells were then collected and stained with Annexin-V (A5) and TO-PRO-3 (TP3) before analysis via flow cytometry. Data was analysed using a seven-step gating process to differentiate six different populations from AEC.

<table>
<thead>
<tr>
<th></th>
<th>Viable</th>
<th>Apoptotic</th>
<th>Necrotic</th>
<th>Apoptotic Bodies</th>
<th>Debris</th>
</tr>
</thead>
<tbody>
<tr>
<td>non-CF Control</td>
<td>82.43%</td>
<td>1.88%</td>
<td>9.82%</td>
<td>3.92%</td>
<td>1.44%</td>
</tr>
<tr>
<td>Permeabilised</td>
<td>83.01%</td>
<td>75.21%</td>
<td>0.23%</td>
<td>18.64%</td>
<td>3.16%</td>
</tr>
<tr>
<td>Virus</td>
<td>76.91%</td>
<td>1.97%</td>
<td>0.49%</td>
<td>11.01%</td>
<td>5.23%</td>
</tr>
<tr>
<td>CF Control</td>
<td>59.46%</td>
<td>8.83%</td>
<td>1.28%</td>
<td>17.92%</td>
<td>6.81%</td>
</tr>
<tr>
<td>Permeabilised</td>
<td>60.43%</td>
<td>2.03%</td>
<td>26.94%</td>
<td>7.51%</td>
<td>0.89%</td>
</tr>
<tr>
<td>Virus</td>
<td>58.10%</td>
<td>9.63%</td>
<td>1.88%</td>
<td>15.51%</td>
<td>8.31%</td>
</tr>
</tbody>
</table>

RESULTS: Flow cytometry using A5 and TP3 was able to differentiate viable, apoptotic, and necrotic cells, plus apoptotic bodies and cellular debris in stimulated and unstimulated epithelial samples.

CONCLUSION: Flow cytometry utilising A5 and TP3 in conjunction with a seven-step gating process is sufficient to differentiate six populations from both stimulated and unstimulated AEC of healthy and diseased individuals. Further studies utilising this technique will allow quantification of AEC necrosis in patients with and without CF, with the aim to investigate differences in mechanisms driving cell death and airway inflammation.

Grant Support: Australian Cystic Fibrosis Research Trust Postgraduate Studentship
SMALL AIRWAY FIBROSIS ASSOCIATED WITH DECREASED LUNG FUNCTION IN COPD

EAPEN M1, WALTERS H2, HACKETT T3, SOHAL S1
1School of Health Sciences, Launceston, Launceston, Australia, 2NHMRC Centre for Research Excellence for Chronic Respiratory Disease, School of Medicine, University of Tasmania, Hobart, Australia, and 3Department of Anaesthesiology, Pharmacology & Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada; and UBC Centre for Heart Lung Innovation, St. Paul’s Hospital, Vancouver, Canada

Aim: The primary source of airflow limitation in COPD is small airway (SA) fibrosis and obliteration. We previously showed that epithelial mesenchymal transition (EMT) is an active process in small airways contributing to fibrotic pathogenesis. Myofibroblast is highly active fibroblastic cells that excessively secrete extracellular matrix (ECM). Here we explore the consequence of SA myofibroblast proliferation and relate them to physiological outcomes and airway remodeling in smokers and COPD patients.

Methods: SA lung resections, from non-smoker controls (NC), normal lung function smokers (NLFS), COPD current (CS) and ex-smokers (ES) were stained with anti-human αSMA, collagen-1, and fibronectin. αSMA+ cells were enumerated in Reticular basement membrane (Rbm), Lamina Propria (LP), and adventitia and represented as per mm of Rbm and mm² of the respective area surveyed. Collagen-1 and fibronectin are represented as a percentage change. All measurements including the sub-epithelial LP and adventitia thickness were measured using Imageproplus 7.0.

Results: We observed a general increase in sub-epithelial LP and adventitia thickness in all pathological groups compared to NC. Similar increases in αSMA+ myofibroblasts was observed in sub-epithelial Rbm, LP, and adventitia in the pathological groups compared to NCs, though the changes were prominently higher in the LP. Further, the increase in myofibroblast population in the LP was strongly associated with a decrease in lung function, and an increase in ECM proteins collagen-1 and fibronectin deposition in the LP. Finally, we observed EMT markers expressed in epithelial basal cells and Rbm, correlated to the increased SA myofibroblasts and airway thickness.

Conclusion: This is the first report that systematically characterizes the myofibroblasts in COPD based on their localization and statistically correlates them to lung function. The increase in myofibroblast population also directly related to pathological changes in ECM proteins. Driving these changes is likely to be EMT activity in the basal epithelial cells.

Grant Support: Clifford Craig Foundation, Launceston
Conflict of Interest: Nil.

SKELETAL MUSCLE REGENERATION AND FUNCTION IS IMPAIRED IN EXPERIMENTAL COPD

CERNI C1, PASSEY S2, SEOW H1, BERNARDI D1, VAN DER POEL C2, DOBRIC A1, BRASSINGTON K1, SELEMIDIS S1, BOZINOVSKI S1, VLHOS R1
1RMIT University, Melbourne, Australia, and 2La Trobe University, Bundoora, Australia

Introduction/Aim: Skeletal muscle wasting is a major comorbidity of COPD and a powerful predictor of mortality. Current therapeutic strategies aim to increase muscle mass by augmenting protein synthesis and reducing protein degradation. Muscle mass can also be increased through the activation of satellite cells, which play a pivotal role in skeletal muscle regeneration. However, the role of satellite cells in COPD is not fully understood. Thus, we explored whether muscle regeneration in response to injuring the Tibialis Anterior (TA) muscle is impaired in mice exposed to cigarette smoke (CS).

Methods: Male BALB/c mice were exposed to room air (sham) or CS generated from 9 cigarettes/day, 5 days/week for 8 weeks. After 8 weeks of CS exposure, the right TA muscle was injured by injection of 40μl barium chloride (BaCl2). The mice were then exposed to CS for another 7, 14 and 21 days at which time the contractile properties of the right TA muscle were measured. Mice were then culled and both the uninjured left TA and injured right TA muscles dissected out, weighed and used to examine the expression of genes associated with muscle regeneration (e.g. Pax 7) and for histological assessment of muscle injury.

Results: BaCl2-induced injury significantly decreased the weight of the TA muscle at 7 days post injury and this was further exacerbated in CS-exposed mice (n=10, p<0.05). BaCl2 also caused significant muscle injury as demonstrated by centrally located nuclei and altered tissue architecture when assessed 7 days post injury. However, muscle injury was even greater in CS-exposed mice when compared to injured sham mice (n=8, p<0.05). Injured TA muscle from CS-exposed mice had at least a two-fold increase in Pax 7 mRNA expression compared to injured TA muscle from sham-exposed mice at 7 days post injury (n=8, p<0.001). Moreover, TA muscle contractile function was significantly impaired in the injured CS-exposed mice compared to the injured sham-exposed mice (n=7, p<0.05).

Conclusion: Skeletal muscle regeneration and function is impaired in experimental COPD.

Grant Support: NHMRC Australia (Project Grant ID 1084627)
TRANSFORMING GROWTH FACTOR ALPHA PRODUCES AIRWAY REMODELLING AND REDUCES AIRWAY DISTENSIBILITY

WANG K1,2, LE CRAS T3, LARCOMBE A4, ZOSKY G2,5, BERRY L2, ELLIOT J2, JAMES A1, NOBLE P1,3

1School of Human Sciences, University of Western Australia, Crawley, Western Australia, Australia, 2Clinical Sciences, Telethon Kids Institute, Subiaco, Western Australia, Australia, 3Division of Pulmonary Biology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA

Introduction/Aim: Airway distensibility is reduced in patients with COPD. Transforming growth factor alpha (TGF-α) is increased in the serum of COPD patients and produces airway remodelling in mouse models. We hypothesised that TGF-α overexpression reduces airway distensibility. Our aim was to determine the effect of TGF-α and its regulatory gene, early growth response one (Egr-1), on airway thickness and distensibility.

Methods: Conditional expression of TGF-α (α) in the airways of transgenic mice (Clara cell secretory protein-rtTA(α)(+/+)(tetO)(α)-TGF-α(α)(+/+)) was induced by doxycycline (Dox). Mice were Egr-1 homozygous (α+/+) or heterozygous (α+/−). At 4 weeks of age, mice were fed Dox in chow or a control diet for 3 weeks and then anaesthetised, mechanically ventilated and fixed for morphometry and stereology. Airway conductance (G) was measured at trans-respiratory pressures of 0 (G0) and 5cmH2O (G5). Distensibility was calculated from the change in conductance (G5-G0). Lungs were fixed for morphometry and stereology.

Results: Dox-fed mice had increased thickness of the airway epithelium, inner and outer wall and airway smooth muscle layer. While the increase in thickness of the epithelium and inner wall was greater in Egr-1 α+/− mice, other changes were not affected by genotype. Dox-fed mice had reduced airway distensibility independent of genotype.

Conclusion: Increased TGF-α expression within the airway wall is associated with increased wall thickness and reduced airway distensibility. The effects of TGF-α were largely unaffected by partial modification of the Egr-1 gene. Findings suggest that TGF-α signaling may contribute to airflow limitation in COPD by reducing airway distensibility.

Grant Support: NHMRC (1090888, 1027218, 1045824)

Declaration of Interest Statement: None.

LIPOSOMAL FORMULATION OF QUERCETIN AND RESOLVIND1 FOR TREATMENT OF STEROID RESISTANT AIRWAY INFLAMMATION

KOMALLA V1,2, MCALINDEN K1,2, RAMACCINI D1,3, SCALIA S3, SHARMA P2,4, OLIVER B2,4, HAGHI M2

1Graduate School of Health, University of Technology Sydney, Sydney, New South Wales, Australia, 2Woolcock Institute of Medical Research, Glebe point Road, Australia, 3University of Ferrara, Italy, and 4School of Life Sciences, University of Technology Sydney, Ultimo, Australia

Introduction/Aim: Steroids are the mainstay treatment targeting airway inflammation. However, in some patients increased oxidative stress could result in resistance to steroid treatment. Therefore, combining anti-inflammatory, resolvind D1 (RvD1), and antioxidant quercetin (Q) could be a promising therapeutic strategy. Here, we aim to prepare liposomal formulation of Q and RvD1 and investigate its effectiveness in human airway epithelial cells (BEAS-2B).

Methods: Blank, Q and QRvD1 liposomes were prepared and characterised. Cell uptake studies were performed using confocal microscope and antioxidant activity of the liposomes was determined.

Results: The results demonstrated a monomodal size distribution of 163.26 ± 1.69 nm, 158.16 ± 1.89 nm, 167.3 ± 0.8 nm for blank, Q and QRvD1 liposomes respectively. The concentration of Q encapsulated was found to be 4.99 ± 2.6 μg/ml and 2.5 ± 1.97 μg/ml in Q and QRvD1 liposomes respectively and concentration of RvD1 in QRvD1 liposomes was found to be 9.57 ± 0.01 pg/ml. There was a time-dependent uptake of liposomes (Q and QRvD1) observed over 6 hours following treatment with liposomes. The antioxidant activity of Q was found to be significantly higher than that of other treatments. The concentration of Q encapsulated was found to be 4.99 ± 2.6 μg/ml and 2.5 ± 1.97 μg/ml in Q and QRvD1 liposomes respectively. The concentration of RvD1 in QRvD1 liposomes was found to be 9.57 ± 0.01 pg/ml. There was a time-dependent uptake of liposomes (Q and QRvD1) observed over 6 hours following treatment with liposomes. The antioxidant activity of Q was found to be significantly higher than that of other treatments.

Conclusion: In conclusion, liposomal formulations demonstrate acceptable characteristics for inhalation with significantly increased antioxidant properties when compared with the free Q. These liposomal formulations could potentially improve the therapeutic outcomes in steroid resistant patients. Further studies will investigate the anti-inflammatory activity of these liposomes in vitro and in vivo.
CHARACTERISTICS OF PATIENTS WITH AND WITHOUT PERIPHERAL EOSINOPHILIA IN PATIENTS PRESENTING WITH AN ACUTE COPD EXACERBATION; GOLD COAST UNIVERSITY HOSPITAL EXPERIENCE

SEMASINGHE BANDARALAGE S1,2, TENG R2, SRIRAM K1,2, SIVAKUMARAN P1,2

1Gold Coast Hospital and Health Services, Southport, Queensland, Australia, and 2School of Medicine, Griffith University, Southport, Queensland, Australia

Introduction/Aim: COPD patients with peripheral eosinophilia may have increased frequency of COPD exacerbations, respond better to oral corticosteroids and reduced mortality. Peripheral eosinophilia in COPD patients (eosinophil count of ≥ 2% of white blood cell count) has a prevalence in the range of 37-45%. To our knowledge, there is little epidemiological data of Australian COPD patients concerning peripheral eosinophilia, its prevalence and its association with rehospitalisation rates, steroid responsive disease and mortality rates. With this literature gap in mind, records of patients presenting with COPD exacerbations were audited retrospectively to determine the prevalence of peripheral eosinophilia in an Australian population.

Methods: Consecutive patients with spirometry confirmed COPD admitted to our institution with a COPD exacerbation during the period of July 2016 – December 2016 were considered for the study. These patients’ records were subsequently followed up until June 2017. The variables recorded were white blood cell count, absolute and relative eosinophil count, readmission rate, decompensated type 2 respiratory failure rate, non-invasive ventilation initiation rate, intensive care admission rate and mortality rate.

Results: 240 patients were included for analysis and of these 37% had peripheral eosinophilia. Using Pearson’s coefficient, there appeared to be a statistically significant correlation between increasing peripheral eosinophil count and increased number of readmissions (R=0.175, p=0.007) but not with decompensated type 2 respiratory failure, non-invasive ventilation initiation rate, intensive care admission rate or mortality rate. Two-sample t-Test for equal means when comparing those with invasive ventilation initiation rate, intensive care admission rate or mortality rate. As such peripheral eosinophilia can be used in Australian COPD patient cohorts to predict rehospitalisation rate. Future studies should look to prospectively evaluate the effect inhaled corticosteroids have on readmission rates in patients with peripheral eosinophilia.

Conclusion: Prevalence of peripheral eosinophilia in Gold Coast patients was similar to overseas cohorts. In congruence with findings in previous overseas studies, Gold Coast patients with eosinophilia were prone to readmission but not increased type 2 respiratory failure, non-invasive ventilation, intensive care admission or mortality. As such peripheral eosinophilia can be used in Australian COPD patient cohorts to predict rehospitalisation rate. Future studies should look to prospectively evaluate the effect inhaled corticosteroids have on readmission rates in patients with peripheral eosinophilia.

Grant Support: None

TARGETING APOPTOSIS SIGNAL-REGULATING KINASE 1 IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE

SHARMA P1,2, DESHPANDE D3, OLIVER B1,2

1Medical Sciences Discipline, University of Technology Sydney, Sydney, Australia, 2Emphysema Centre, Woolcock Institute of Medical Research, Glebe, Australia, and 3Thomas Jefferson University, Philadelphia, PA, USA

Introduction: Increased airway smooth muscle (ASM) mass is part of overall structural changes observed in COPD, and is correlated with severity of the disease and has been found to negatively impact lung function. Thus, there is clear unmet clinical need for finding new therapies for COPD which can target airway remodelling and disease progression. Apoptosis signal-regulating kinase 1 (ASK1) is a ubiquitously expressed MAP3K activated by various stress stimuli, including ROS, TNF-α, and LPS. However, the role of ASK1 in airway remodelling is not established. In this study, we aimed to determine the effects of ASK1 inhibition on ASM growth and pro-mitogenic signaling using ASM cells from well-established COPD patients.

Methods and Results: It is known that ASM cells from COPD patients have greater proliferative capacity to variety of mitogens in vitro. We used human lung tissue samples and primary human ASM cells obtained from COPD patients and healthy controls. IHC revealed increased expression of ASK1 in COPD lung when compared with non-COPD lung. Pre-treatment of human ASM cells with highly selective (IC50: 14 nM) and orally available ASK1 inhibitor; TCASK10 resulted in a dose-dependent reduction in mitogen (FBS, 10%; PDGF and EGF; 10 ng/ml, 72 hours)-induced ASM growth as measured by CyQuant assay. Furthermore, ASK1 siRNA prevented mitogen-induced human ASM cell growth, while immunoblotting revealed that the anti-mitogenic effect of ASK1 inhibition or silencing is mediated by JNK and p38MAP kinase-signalling pathways evident by reduced phosphorylation of downstream effectors JNK1/2 and p38MAP kinase respectively with no effect on ERK1/2 signalling.

Conclusions: Collectively, these findings establish the anti-mitogenic effect of ASK1 inhibition and identify a novel pathway that can be targeted to reduce or prevent excessive ASM mass in COPD.

Key Words: COPD, airway remodelling, mitogen

Grant Support: UTS Chancellors Fellowship and NHMRC
NOVEL ANTI-FXII ANTIBODY INHIBITS FXII-INDUCED PROFI abortIC FUNCTIONS IN LUNG FIBROBLASTS

WONG M1, JAFFAR J2, MCMILLAN L1, WESTALL G2, WILSON N1, PANOUSIS C1

1Translational Research, CSL Ltd, Bio21 Institute, Melbourne, Victoria, Australia, and 2Alfred Hospital, Melbourne, Victoria, Australia

Introduction/Aim: Excessive pro-coagulant activity drives recurrent inflammation and fibrosis in patients with Idiopathic Pulmonary Fibrosis (IPF). Coagulation factors promote healing during damage, but can also exert pro-fibrotic cellular effects. Coagulation factor XII (FXII) has been identified as a potential mediator of lung fibrosis. The aim of this study is to further define a role for FXII in fibrogenesis.

Methods: Blood from 35 IPF patients was collected repeatedly (0-15 months) and compared to age and gender-matched healthy controls. Plasma FXII and IL-6 were measured. Immunohistochemical analysis for FXII was performed on paraffin-embedded lung tissue from IPF patients and non-diseased controls (NDC). In vitro effects of FXII on primary IPF and NDC fibroblasts were evaluated for cytokine production, proliferation and migration. The effect of a novel, fully human monoclonal antibody against FXII (CSL312) was evaluated.

Results: Baseline and longitudinal levels of FXII in IPF patients with progressive disease was elevated compared to those with stable disease (27.7 vs 17.6 μg/ml, p=0.04 baseline; 26.3 vs 20.6 μg/ml, p=0.014 longitudinal) but were not increased in IPF compared to healthy controls. Baseline plasma IL-6 was elevated in IPF patients when compared to healthy controls (3.9 vs 1.5 pg/ml, p=0.001). IHC analysis revealed significant FXII staining in IPF lung tissue with minimal staining observed in non-fibrotic lung tissue. Activated FXII induced IL-6 production and enhanced proliferation and migration in primary lung fibroblasts. Migration and IL6 production were effectively inhibited by CSL312.

Conclusion: FXII is elevated in the lungs of progressing IPF patients and can drive pro-fibrotic and pro-inflammatory functions of fibroblasts. An anti-FXII antibody (CSL312) can inhibit these activities. The ability of FXII to drive IL-6 production in lung fibroblasts may contribute to elevated IL-6 levels seen in IPF patients’ blood. Blocking FXII activity may be novel avenue to treat IPF and other inflammation-driven interstitial lung diseases.

Grant Support: Nil
Conflict of Interest: Employee of CSL Ltd.
EXOSOMES AND PAH: THE ROLE OF CELLULAR COMMUNICATION IN BOTH DISEASE PROGRESSION AND THERAPEUTIC SUCCESS

HARPER R1, MAILOO S1, LIM R2, GREENING D3, COCKSHELL M4, BONDER C4, REYNOLDS P1
1Royal Adelaide Hospital & University of Adelaide, Adelaide, South Australia, Australia, 2Hudson Institute, Monash University, Clayton, Victoria, Australia, 3La Trobe University, Melbourne, Victoria, Australia, and 4Centre for Cancer Biology, University of South Australia, Adelaide, South Australia, Australia

Introduction/Aim: Previously we reported the therapeutic effect of BMPR2 augmented endothelial progenitor cell therapy in a rat PH model. We know there is little direct cell integration into the pulmonary endothe-

ium following intravenous injection, thus we attribute the positive physio-

logical effects of our cell therapy to cell-to-cell communication via secreted factors such as exosomes (exos). In this study we look at com-

paring PAH-EPC and control-EPC protein profiles via mass spectrometry,

and we assess their capacity to interact with and transport BMPR2 into endothelial cells (EC).

Methods: EPCs are isolated and cultured from 15mL of PAH or control peripheral blood. Cells were either transduced with AdBMPR2 or AdTrackLuc, or untransduced for subsequent exo isolations. Exosomes are isolated via differential centrifugation, and characterised with a Nano-

Sight, TEM and SEM. Exosome protein profile was via mass spectrometry.

Exo-Quick™ treated exos and GFP-exos labelled were used to view exo localisation within the target ECs both live and fixed via confocal microscopy. BMPR2-Exos were incubated on ECs for 48hrs before being washed off, and the cells lysed for western blot analysis.

Results: Exosomes were positively identified as 40-200nm via Nano-

Sight, TEM and SEM. Protein profiling of exos showed differential protein expression in the PAH vs control for 326 proteins, including a relative down-regulation of BMPR2 in PAH exos. Exosome interaction with ECs demonstrated localisation around the nucleus of the cell, both in live and fixed EC samples. Additionally, BMPR2 expression was significantly increased in cells treated with BMPR2-Exos.

Conclusion: Differential protein expression between exos derived from PAH compared to control EPCs was shown. Additionally, we have characterised exos interaction with ECs and shown that they are involved in BMPR2 transfer from BMPR2 transduced EPCs to naïve ECs. These results indicate the potential role of exos in our BMPR2-cell therapy.

Grant Support: RAH Research Fund

DORNASE ALFA DURING LOWER RESPIRATORY TRACT INFECTION POST LUNG TRANSPLANTATION

TARRANT B1,2, SNELL G3,4, IVULICH S4, BUTTON B1,4,5, THOMPSON B5,6, HOLLAND A1,2
1Physiotherapy, Alfred Health, Melbourne, Australia, 2La Trobe University, Bundoora, Australia, 3Lung Transplant, Alfred Health, Melbourne, Australia, 4Monash University, Clayton, Australia, 5Pharmacy, Alfred Health, Melbourne, Australia, 6Cystic Fibrosis Service, Alfred Health, Melbourne, Australia, and 7Lung Function Laboratory, Alfred Health, Melbourne, Australia

Introduction/Aim: Lung transplant (LTx) recipients are at a high risk of lower respiratory tract infection (LRTI) secondary to immunosuppres-

sion, while altered respiratory physiology can make it difficult to clear secretions. Inhaled mucoactive agents alter mucus properties and/or facil-

itate mucociliary clearance in suppurative lung disease. However there are no randomised controlled trials (RCTs) studying these effects post LTx. We aimed to evaluate the safety and efficacy of nebulised dornase alfa compared to isotonic saline during LRTI > 2 months post LTx.

Methods: Inpatient adults with LRTI and sputum production following bilateral sequential LTx were eligible for this assessor blinded RCT. Ran-

domisation was stratified by LTx indication (cystic fibrosis (CF)). Participants received either 5ml isotonic saline, or 2.5ml dornase alfa, nebulised once daily for 1 month followed by 2 months symptom diary only. The pri-

mary outcome was change in lung clearance index (LCI) measured by multi-breath washout. Secondary outcomes included adverse events; spi-

rometry; quality of life; readmission; length of stay and self-reported excu-

erations at baseline, 1 month and 3 months.

Results: 32 participated, 16 each group (18M,14F), mean(SD) age 50±14, FEV1% 58±22, median(IQR) length of stay 7±5, days since LTx 1275±2482. LTx indications included CF (n=11) and chronic obstructive pulmonary disease (n=11). There were no significant between-group differ-

ences in LCI at any time point (one month mean difference -0.34, 95% confidence interval (CI) -1.57 to 0.89; three months mean difference -0.76, 95% CI -2.29 to 0.78, both favouring dornase alfa). Secondary out-

comes were not different between groups.

Conclusion: These results do not support the routine use of dornase alfa during LRTI in LTx recipients.

Grants: Alfred Research Trusts Small Project Grant; Professor Carey and Laura Denholm

Conflict of Interest: No conflict of interests to declare.
VARIATION IN SENSITIVITY TO PIRFENIDONE AMONG FIBROBLASTS DERIVED FROM PATIENTS WITH AND WITHOUT IDIOPATHIC PULMONARY FIBROSIS

JAFFAR J1,2, ORGAN L1,2, SYMONS K2, GLASPOLE I2, WESTALL G1,2
1Department of Immunology and Pathology, Monash University; Australia, Melbourne, Australia, and 2Department of Lung Transplant Service, The Alfred, Australia, Australia

Introduction/Aim: Lung fibrosis is the end-stage consequence of interstitial lung diseases (ILDs) which involve excessive numbers of activated lung fibroblasts with elevated alpha-smooth muscle actin (αSMA) expression. Pirfenidone is approved for use in patients with idiopathic pulmonary fibrosis (IPF), the most common and fatal of the idiopathic ILDs. Poor tolerability and large variation in efficacy of pirfenidone is a significant barrier to best patient outcomes. This study aims to investigate whether an in-vitro fibroblast test can identify patients most likely to benefit from pirfenidone therapy.

Methods: Primary lung fibroblasts were derived from the apex and base of the lungs from patients with IPF (N=10), patients with other end-stage non-IPF ILDs (N=10) and normal donors whose lungs were deemed unsuitable for transplantation (NDC)(N=10). Determined by in-cell western, αSMA and GAPDH levels in fibroblasts were measured before and after treatment with pirfenidone (0-1mM) and in the presence/absence of transforming growth factor-β (TGFβ) (0-10ng/mL). Sensitivity to pirfenidone was defined by a decrease in αSMA/GAPDH level from baseline by ≥10%.

Results: Treatment with pirfenidone decreased αSMA levels in N=9 fibroblast lines at 72 hours (Figure 1). Fibroblast αSMA levels correlated with the extent of αSMA decline in response to pirfenidone (Spearman’s R = -0.76, p=0.037). In patients with IPF, basal αSMA level of the fibroblast line correlated with forced vital capacity (FVC, % predicted) of the patient from whom the line was derived (Spearman’s R = 1, p=0.016).

Conclusion: The response of lung fibroblasts to pirfenidone may identify patients with IPF who would benefit from said treatment. Our data suggest that patients who have high numbers of αSMA+ fibroblasts would in particular benefit from pirfenidone therapy, although further screening is required. Variation in αSMA level of fibroblasts may be reflective of the overall lung fibrotic burden as it correlated with FVC.

Grant Support: None

Figure 1 Quantification of αSMA levels in primary lung fibroblasts pre and post Pirfenidone therapy by in-cell western. Primary fibroblasts were derived from N=5 patients with idiopathic pulmonary fibrosis (IPF, red dots) and N=4 donors without lung disease (NDC, blue dots). (A) Fibroblasts derived from patients with IPF express greater levels of αSMA compared to fibroblasts from NDC donors. (B) Treatment with 1mM Pirfenidone (in PBS) decreased αSMA expression in lung fibroblasts. Each dot is an experimental triplicate.

Respirology (2018) 23 (Suppl. 1), 21–103

Copyright of individual abstracts remains with the authors.
RCT OF NHF THERAPY COMPARED WITH NIV IN HYPERCAPNIC COPD

MCKINSTRY S1,2,3, BAARSMA J1,4, SINGER J1, WEATHERALL M3,5, BEASLEY R1,2,3, FINGLETON J1,2,3
1Medical Research Institute of NZ, Wellington, New Zealand, 2Victoria University, Wellington, New Zealand, 3Capital and Coast DHB, Wellington, New Zealand, 4University of Groningen, Groningen, The Netherlands, and 5University of Otago School of Medicine, Wellington, New Zealand

Introduction/Aim: Acute hypercapnic respiratory failure secondary to an exacerbation of COPD is associated with poor clinical outcomes and increased mortality. Non-invasive ventilation (NIV) is part of the standard of care but can be poorly tolerated.

We have shown Nasal High Flow therapy (NHF) produces a small reduction in transcutaneous CO2 tension (PtCO2) in stable COPD.

Our aim was to compare NHF and NIV in hypercapnic COPD.

Methods: Design: Single-blind randomised controlled two-way crossover trial.

Setting: Single centre institute in New Zealand recruiting participants from hospital databases.

Participants: 24 participants with a doctor’s diagnosis of COPD, FEV1/FVC ratio <0.7, ≥40 years, smoking history of >10 pack years, PcapCO2 ≥45.0 mmHg, BMI <35 kg/m2, no recent exacerbations and no diagnosis of obstructive sleep apnea or obesity hypoventilation syndrome.

Interventions: NHF at 45Lmin and BiPAP at 15/4cmH2O, each for 60mins with a 15min washout in between.

Primary outcome measure: PtCO2 at 60mins, adjusted for baseline.

Secondary outcomes included tolerability and the proportion of participants with a decrease in PtCO2 ≥4 mmHg and ≥8 mmHg at 60 minutes.

Results: PtCO2 was 2.5 mmHg (95% CI -4.5 to -0.5) lower with NIV compared to NHF, p=0.016.

The proportion of participants with a reduction in PtCO2 ≥4 mmHg with NIV versus NHF was 45.8% versus 25.0%. For a reduction in PtCO2 ≥8 mmHg it was 25% versus 8.3%. These differences were not statistically significant. Participants rated NHF significantly better for ease of application, comfort, fit and willingness to use in the future.

Conclusion: In stable COPD patients with chronic hypercapnia, NIV resulted in a small reduction in PtCO2 compared with NHF, which is of uncertain clinical significance. NHF was better tolerated. NHF may be a therapeutic option for some people with hypercapnic respiratory failure and studies in acute exacerbations of COPD are required.

Grant Support: Health Research Council (NZ)
Trial Registration: ACTRN12616001701415

MULTIDIMENSIONAL AETIOLOGICAL ASSESSMENT IDENTIFIES CLINICAL PHENOTYPES AMONGST HOSPITALIZED ACUTE EXACERBATIONS OF COPD

MCDONALD M1, OSADNIK C1, KING P1, BARDIN P1
1Monash Health, Melbourne, Australia

Introduction/Aim: Hospitalized AECOPD are heterogenous events of diverse aetiology. We hypothesized that comprehensive AECOPD evaluation would reveal clinical phenotypes amongst AECOPD.

Methods: Nasopharyngeal viral PCR, sputum culture, C-reactive protein, chest X-ray, troponin I (hs-TnI), N-terminal pro brain natriuretic peptide (NT-proBNP) and Hospital Anxiety and Depression Scale (HADS) were used to construct a cumulative aetiological phenotype for each AECOPD using a simple acronym: A=airway viral infection, B=bacterial infection, C=coinfection, D=depression/anxiety, E=embolism (pulmonary), F=failure (cardiac), G=general environment, X=unknown.

Results: Aetiologies identified among 155 unique AECOPD admissions were diverse (viral=35, bacterial=61, coinfection=8, no infection=44) and often multifactorial, with 1 aetiology in 31%, 2 in 48.4%, 3 in 5.2% and no identifiable aetiology in 5.8%.

Baseline lung function and symptoms were similar across exacerbation subtypes. Infective exacerbations were associated with lower eosinophils (p<0.001) and non-infective exacerbations with lower pH (p<0.004). NIV requirement was higher in non-bacterial v bacterial (p<0.03). AECOPD patients with no identifiable aetiology (X) were generally “frequent exacerbators” with severe acute presentations but prompt stabilization. Admissions ≥4 days were most common in non-infective groups (viral 22.9% v bacterial 39.3% v co-infection 12.5% v non-infective 47.7%, p=0.06). Subclinical cardiac dysfunction was highly prevalent in both infective and non-infective AECOPD with elevated hs-TnI in 27.3% and elevated NT-proBNP in 61.7% overall. Anxiety/depression was prevalent in all aetiological subgroups (overall population HADS mean/SD =16.7/8.7). Survival at 12 months post discharge was lower in non-viral versus viral AECOPD (p<0.03).

Conclusion: Hospitalized AECOPD are multidimensional and multifactorial. Subtyping by infection type identified significant differences in comorbidities, health care utilization, laboratory parameters, inpatient management and post exacerbation survival. Anxiety/depression and cardiac dysfunction appear prevalent but underdiagnosed. Our clinically oriented methodology provides a feasible framework for clinicians and researchers to address AECOPD complexity and target therapeutic interventions.

Grant Support: This project was supported by an unrestricted educational grant from GlaxoSmithKline.
RELAXIN POTENTIATES SALUTAMOL-MEDIATED AIRWAY RELAXATION IN MULTIPLE SPECIES

LAM M1, BOURKE J1, ROYCE S1, SAMUEL C1, DONOVAN C1, JELINIC M2, PARRY L2

1Monash University, Melbourne, Australia, and 2University of Melbourne, Melbourne, Australia

Introduction: Treatment with β-adrenoceptor agonists may not overcome symptoms of severe asthma. Relaxin (rhRLX), an RXFP1 receptor agonist, exerts cardioioprotective effects in acute heart failure and elicits vascular relaxation via RXFP1 and nitric oxide signalling. Although we have previously established its bronchodilator efficacy in rat airways (Lam et al., 2016), its effects in other species and its potential to enhance β-adrenoceptor-mediated relaxation have yet to be explored.

Aim: To compare the bronchodilator effects of relaxin alone and in combination with the β-adrenoceptor agonists, isoprenaline (ISO) or salbutamol (SAL) in multiple species.

Methods: Tracheal rings or bronchi were dissected and/or precision cut lung slices (PCLS) containing intrapulmonary airways were prepared from mice, rats, guinea pigs and marmosets and human lungs (unused donor). rhRLX alone and in combination with ISO or SAL were added to airways pre-contracted to MCh.

Results: rhRLX (100 nM) elicited partial relaxation in rat airways that was more rapid in PCLS than trachea but was ineffective as a direct bronchodilator in guinea pig trachea or mouse PCLS. rhRLX markedly increased the potency of ISO by 10-fold in rat PCLS without increasing maximum relaxation, and of SAL by 27-fold in guinea pig trachea. SAL only elicited partial relaxation in mouse PCLS but synergism was evident between rhRLX and SAL (maximum relaxation: rhRLX no response; SAL 41±5%; rhRLX/SAL 90±8%; n= 4-7; P<0.001). Preliminary data showed rhRLX elicited relaxation and potentiated SAL-mediated relaxation in marmoset and human small airways.

Conclusion: rhRLX elicits airway relaxation in some species and enhances responsiveness of both small and large airways to salbutamol across all species tested. Since rhRLX increases the potency of salbutamol, further investigations are warranted to define its therapeutic potential as an add-on asthma therapy in human lungs, particularly when responsiveness to current dilator therapy is limited.

Grant Support: NHMRC Project Grant (1041575)

ENDOSOMAL NOX2 OXIDASE INHIBITOR PROTECTS AGAINST HIGHLY PATHOGENIC INFLUENZA VIRUS MORBIDITY

TO E1,2, LUONG R1, LIONG F1, DIAO J2, BOZINOVSKI S1, PORTER C2, QUACH T2, O’LEARY J3, BROOKS D2, VLAHOS R1, SELEmidIS S1,2

1RMIT University, Bentley, Australia, 2Monash University, Clayton, Australia, 3Monash Institute of Pharmaceutical Sciences, Parkville, Australia, 4Trinity Translational Medicine Institute, Ireland, and 5University of South Australia, Australia

Introduction/Aim: Influenza A viruses cause respiratory tract infections that can lead to fatal outcomes when the virus spreads to the alveolar space, more predominantly observed with high pathogenic influenza virus strains. We have shown that influenza A viruses, irrespective of strain, cause a burst of reactive oxygen species (ROS) production via NOX2 oxidase that occurs in endosomes. Evidently, an endosome targeted NOX2 oxidase inhibitor called cholesterol conjugated gp91ds-TAT (Cgp91) abrogated disease caused by a seasonal strain of influenza A virus (IAV) in mice (1). The aim was to determine the effect of Cgp91 treatment on the lung pathology induced by a highly pathogenic strain of IAV.

Methods: Male C57Bl/6J mice were treated daily via intranasal administration with Cgp91 (0.2mg/kg) or DMSO (2%; control) over a 4-day period. Mice were infected with the PR8 (H1N1; 500 PFUs) strain of IAV or PBS control, one-day post initial drug treatment and analysed at day 3 post-infection. Bronchoalveolar lavage (BAL) fluid collected from mice was used to assess airway inflammation. Histopathological analysis of lung was assessed using H&E stain and scored for alveolitis, in addition, Cgp91 attenuated ROS generation and inflammatory cell infiltration and peribronchiolar inflammation. Superoxide generation in the BAL was measured using L-012 enhanced chemiluminescence and changes in cytokine and viral mRNA expression in the lung were quantified using real-time QPCR.

Results: Cgp91 treatment significantly (P<0.05) reduced airway inflammation, neutrophil influx, and pulmonary inflammation as measured by the degree of alveolitis, inflammatory cell infiltrate and peribronchiolar inflammation. Additionally, Cgp91 attenuated ROS generation and influenza viral mRNA expression in PR8-infected mice.

Conclusion: The spatial inhibition of NOX2 in endosomal compartments with Cgp91 could be used as a potential treatment strategy for highly pathogenic influenza A virus infections.

Grant Support: NHMRC Australia (Project Grant ID 1122506, 1128276), ARC (FT120100876)

AMOXICILLIN-CLAVULANATE VS AZITHROMYCIN FOR RESPIRATORY EXACERBATIONS OF BRONCHIECTASIS IN CHILDREN: A MULTI-CENTRE DOUBLE BLIND NON-INFERIORITY RCT

GOYAL V1,2,3, GRIMWOOD K1, MASTERS I1,2, BRYNES C5, MARCHANT J1,2,3, MORRIS P4,7, WARE R4, VAN ASPEREN P4, O'GRADY K1,2, TORZILLO P1, MCCALLUM G2, CHAMPION A10, BUNTAIN H1, MACKAY P1, SLOOTS T11, UNGERER J10, BINKS M6, CHANG A1,2,3,6
1Lady Cilento Children’s Hospital, Brisbane, Australia, 2University of Queensland, Brisbane, Australia, 3Centre for Children’s Health Research, Queensland University of Technology, Brisbane, Australia, 4Menzies Health Institute Queensland, Griffith University and Gold Coast Health, Southport, Gold Coast, Australia, 5Department of Paediatrics, Unit of Auckland & Starship Children’s Hospital, Auckland, New Zealand, 6Menzies School of Health Research, Charles Darwin University, Darwin, Darwin, Australia, 7Department of Paediatrics, Royal Darwin Hospital, Darwin, Australia, 8Department of Respiratory Medicine, The Children’s Hospital at Westmead, , Sydney, Australia, 9Royal Prince Alfred Hospital, Sydney, Australia, 10Department of Pharmacy, Lady Cilento Children’s Hospital, Brisbane, Australia, 11Forensic and Scientific Services, Department of Health, Coopers Plains, Australia, and 12Department Chemical Pathology, Queensland Pathology, Royal Brisbane Hospital, Brisbane, Australia, 

Introduction: Based on limited available data, amoxycillin-clavulanate is the current recommended first-line empirical oral-antibiotic treatment for non-severe bronchiectasis exacerbations in children. Azithromycin is an attractive alternative because of its long half-life, reduced dosing schedule, and good safety profile in children. We tested our primary hypothesis that oral azithromycin is non-inferior (within 20% margin) to amoxycillin-clavulanate at achieving resolution of exacerbation by day-21. Secondary outcomes were cough-specific quality of life (PC-QoL) and duration of exacerbation. Generalised linear model was used to calculate relative differences between groups.

Methods: We conducted a multicentre, parallel group, double-dummy, double-blind placebo-controlled RCT trial in 4 centres. At the start of an exacerbation, 179 children were randomised to receive either amoxycillin-clavulanate (22.5 mg/kg bd)/placebo or azithromycin (5mg/kg/day)/placebo for 21-days. Our primary outcome was resolution of exacerbation (defined as ‘return to baseline’) by day-21. Study was powered for 90% (α=0.05, 1-sided) with 20% non-inferiority margin to detect 80% resolution rate by day-21. Secondary outcomes were cough-specific quality of life (PC-QoL) and duration of exacerbation. Generalised linear model was used to calculate relative differences between groups.

Results: Baseline characteristics of the 2 groups (amoxycillin-clavulanate n=97 and azithromycin n=82) were similar. By day-21, resolution was comparable between groups, relative risk 0.99 95%CI 0.84-1.17, falling within the a-priori calculated 20% non-inferiority margin. Between group differences for duration of exacerbation (2 days 95%CI -1.7, 5.3) and PC-QoL at day-21 compared to beginning of exacerbation was also within our non-inferiority margin (0.42, 95%CI -0.06, 0.89).

Conclusion: Azithromycin is non-inferior to amoxycillin-clavulanate for treating non-severe exacerbations of bronchiectasis in children. Azithromycin may be preferred to amoxycillin-clavulanate in selected settings e.g. adherence. However, its use needs to be balanced with risk of treatment failure (within 20% compared to amoxycillin-clavulanate) and inducing macrolide resistance.

Grant Support: NHMRC project grant (number 1019834). VG was supported by NHMRC PG scholarship. ABC is supported by a NHMRC practitioner fellowship.

LUNG ELASTIC RECOIL, INFLAMMATION AND PERSISTENT AIRFLOW LIMITATION IN ASTHMA

TONGA K1,2,3,4, FARAH C1,2,3, THAMRIN C1,2, TANG F1,4, SANTOS J5,6, SHARMA P1,2, OLIVER B1,7, KING G1,2,3,4

1Woolcock Institute Of Medical Research, Glebe, Australia, 2Sydney Medical School, University of Sydney, Sydney, Australia, 3Concord Hospital, Concord, Australia, 4Royal North Shore Hospital, St Leonards, Australia, 5School of Life Sciences, University of Technology, Broadway, Australia, 6CIRIMAT, University of Toulouse, Toulouse, France, and 7Faculty of Sciences, University of Technology Sydney, Broadway, Australia

Introduction/Aim: Persistent airflow limitation (PAL) may develop in older non-smokers with asthma however the mechanism is unknown. Reduced lung elastic recoil may contribute as this occurs with age and may occur in asthma. Neutrophilic airway inflammation is also more common in older people with asthma. We aimed to determine the relationship between lung elastic recoil, airway inflammation and airflow limitation. We hypothesised that reduced lung elastic recoil and neutrophilic airway inflammation are associated with PAL in older non-smoking asthmatics.

Methods: Non-smoking adults with asthma, treated with standardised high dose inhaled corticosteroid/long acting beta agonist for two months, underwent standard lung function, lung elastic recoil measurement using an oesophageal balloon to derive indices of loss of lung elastic recoil (increased K and reduced B/A), and bronchoscopy to obtain bronchoalveolar lavage fluid (BAL) for differential leukocyte count and TNF-17 cytokine measurement. Spearman correlations were assessed and multiple linear regressions were used to adjust for age, BMI and disease duration.

Results: Nine non-smoker (11 male; mean±SD age 63±9 years, asthma duration 38±22 years) demonstrated moderate PAL ([mean±SD z-score] −2.05±0.75, FVC -0.61±0.95, FEV1/FVC -2.46±0.90). Reduced lung elastic recoil was demonstrated in 8/18 subjects (median (IQR) z-score K 1.57(-1.08–3.43), B/A -1.18(-1.65–0.02)), FEV1/FVC correlated negatively with K ( r=-0.53, p=0.023) independent of age, BMI and disease duration. Neutrophilic airway inflammation was not demonstrated (mean±SD: neutrophils 9.1±18.1%, n=10). Lung elastic recoil did not correlate with BAL neutrophil count or TNF17 cytokines.

Conclusion: Loss of lung elastic recoil contributes to PAL in older non-smokers with asthma. This may be due to lung tissue changes in addition to airway remodeling. Despite the lack of relationship with airway inflammation in this exploratory study, the underlying cellular mechanisms require further investigation. An alternate paradigm of ‘lung remodeling’ would have potential implications on preventing PAL in this population.

Grant Support: University of Sydney Bridging Grant

Editorial material and organization © 2018 Asian Pacific Society of Respirology. Copyright of individual abstracts remains with the authors.

Respirology (2018) 23 (Suppl. 1), 21–103
LUNG CELLS FROM PEOPLE WITH COPD ARE HYPER RESPONSIVE TO E-CIGARETTE VAPOUR

BOZIER J,1,2 XENAKI D,1,2 ADCOCK I,1 OLIVER B,1,2
1University of Technology Sydney, Sydney, Australia 2Woolcock Institute of Medical Research, University of Sydney, Sydney, Australia

Introduction/Aim: E-cigarettes are proposed as an alternative to smoking and as nicotine replacement therapy. There is confusion around the safety and efficacy of E-cigarettes as smoking cessation aids stemming from contradictory findings across multiple studies. The aim of this study was to determine the inflammatory response of both Chronic Obstructive Pulmonary Disease (COPD) and non-COPD cells to E-vapour under realistic physiological conditions.

Methods: Primary human airway smooth muscle cells were stimulated with increasing concentrations of 18mg/ml nicotine and 0mg/ml nicotine (tobacco and menthol flavoured, Vaper empire) E-vapour extract for 24 hours. An MTT assay was performed to determine cytotoxicity and ELISA was used to assess IL-6 and CXCL8 production. Cells were isolated from explanted and resected lung tissue from COPD patients and smokers without COPD.

Results: All 4 E-vapour extracts were cytotoxic to cells (n=9-14, p≤0.0001), cytotoxicity of E-vapour was increased in aerosols created at higher temperatures. All 4 E-vapour extracts stimulated CXCL8 production compared to unstimulated controls (n=14, p<0.05). Cells from people with COPD were hyperresponsive to E-vapours, with 18mg/ml nicotine tobacco flavoured E-vapour stimulating significantly greater CXCL8 production from COPD cells compared to non-COPD cells (n=7, p<0.05). IL-6 production was not stimulated.

Conclusion: E-cigarettes have the potential to contribute to the pathology of COPD. Cytotoxicity can cause cell death and ineffective repair, as seen in both the airways and parenchyma in COPD. Increased CXCL8 would contribute to the proinflammatory environment in the lung. Our data suggests that COPD patients should not use them as a smoking cessation aid or cigarette replacement.

Grant Support: None

DOES ASTHMA CONTROL IN PRESCHOOLERS PREDICT THE LIKELIHOOD OF DISEASE REMISSION?

DUCHARME F,1 BLAIS L,1 BROWNELL M,2 QUAIL J,2 SADATSFAV M,2 FORGET A,2 NIE Y,2 LI W,2 QUTUYBA H,2 FAN Y,2 PLATT R,2
1University of Montreal, Montreal, Canada, 2University of Manitoba, Winnipeg, Canada

Introduction/Aim: Many preschoolers with asthma experience disease remission. As the first 5 years of life may offer a window of opportunity to modify long-term outcomes, we explored the relationship between the likelihood of remission and asthma control in the two years following the diagnostic of asthma in preschoolers.

Methods: We assembled a retrospective birth cohort of children born between 1990-2013 in four Canadian provinces (Quebec, Manitoba, Saskatchewan, British Columbia). Preschool asthma was defined by one hospitalisation or 2 medical visits within a 2-year period for asthma in children aged less than 5 years. Remission was assumed after two years without any asthma-related drug claims, medical visit or hospitalization. The main exposure was asthma control in the 2 years following diagnosis, measured on the validated 4-level Pediatric Pharmacoepidemiology Asthma Control Index (PPACI) and ascertained over 4 consecutive 6-month periods. Cohort exit occurred at death, loss of medical or drug coverage, or date of last available data. Within each province, a Cox regression model served to estimate the strength of association between the PPACI stability over 2 years post diagnosis and remission, after adjusting for potential confounders and covariates, namely demographics (e.g., sex, social assistance), disease characteristics (e.g., age, atopy), therapy (e.g., first controller therapy). A random-effects meta-analysis aggregated the province-specific results.

Results: Of 1.3 million live births in the 4 provinces, 118,785 children less than 5 years met the definition of asthma; 63% were male, 69% were aged less than 5 years at diagnosis. The pooled rate of remission was 7.74 (95% CI: 7.67, 7.81)/100 person-years. Poorer asthma control over the 2 years following diagnosis was associated with incrementally lower likelihood of asthma remission (Table).

<table>
<thead>
<tr>
<th>PPACI</th>
<th>2 years post-dx</th>
<th>Adjusted HR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controlled throughout</td>
<td>reference</td>
<td></td>
</tr>
<tr>
<td>Improving control</td>
<td>0.80 (0.68, 0.95)</td>
<td></td>
</tr>
<tr>
<td>Varying control</td>
<td>0.59 (0.52, 0.68)</td>
<td></td>
</tr>
<tr>
<td>Worsening control</td>
<td>0.50 (0.42, 0.59)</td>
<td></td>
</tr>
<tr>
<td>Out of control throughout</td>
<td>0.31 (0.27, 0.36)</td>
<td></td>
</tr>
</tbody>
</table>

*Adjusted for demographic and disease characteristics (3 provinces)

Conclusion: Poorer asthma control in the two years following diagnosis is associated with an incrementally lower rate of remission. Better asthma control appears as a promising target to modify long-term outcomes of asthmatic preschoolers.

Grant Support: This study was funded by the Canadian Respiratory Research Network. The Canadian Respiratory Research Network (CRRN) is supported by grants from the Canadian Institutes of Health Research (CIHR)—Institute of Circulatory and Respiratory Health; Canadian Lung Association (CLAA)/Canadian Thoracic Society (CTS); British Columbia Lung Association; and Industry Partners Boehringer-Ingelheim Canada Ltd, AstraZeneca Canada Inc., and Novartis Canada Ltd. The funders had no role in the study design, data collection and analysis, or preparation of the manuscript.

Respirology (2018) 23 (Suppl. 1), 21-103
AN ASSESSMENT OF EARLY LIFE EXPOSURE TO COAL MINE FIRE SMOKE AND CHILDREN’S LUNG HEALTH

SHAO J1, ZOSKY G2, HALL G2, WHEELER A1, DALTON M2, DHARMAGE S3, FOONG R1, WILLIAMSON G2, O’SULLIVAN T1, JOHNSTON F1
1Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, 2School of Medicine, Faculty of Health, University of Tasmania, Hobart, Australia, 3Children’s Lung Health Telethon Kids Institute, School of Physiotherapy and Exercise Science Curtin University, Centre for Child Health Research, University of Western Australia, West Perth, Australia, 4Allergy and Lung Health Unit, Melbourne School of Population and Global Health, University of Melbourne, Carlton, Australia, 5School of Biological Sciences, University of Tasmania, Hobart, Australia

Introduction/Aim: In 2014, emissions from a fire in an open cut coal mine caused markedly increased concentrations of fine particulate matter (PM2.5) in the Latrobe Valley of Victoria, Australia, for approximately six weeks. We aimed to evaluate the impacts of infant (<2 years of age) exposure to mine fire emissions on lung function measured three years after the fire.

Methods: Hourly PM2.5 from the fire at 1x1 km2 was derived from an atmospheric transport model. Daily average and maximum PM2.5 were assigned to participants’ residential address during the fire. Lung function was evaluated using the forced oscillation technique (FOT), which generated z scores for resistance (Rrs) and two measures of reactance as follows: (1) Reactance at a frequency of 5Hz, (Xrs) and (2) area under the reactance curve (AX). We used generalised linear models, adjusted for maternal smoking in pregnancy and maternal stress during the first year of life.

Results: 71 children, with a mean age of 4.3 ± 0.6 (SD) years were included. Median [IQR] daily PM2.5 exposures were 6.8 [1.9-12.7] μg/m3 (average) and 107.4 [60.4-167.0] μg/m3 (maximum). The baseline mean (SD) z scores were Rrs 0.6 (0.8), Xrs 0.8(0.9) and AX 0.7(1.0). A 10μg/m3 and 100μg/m3 increase in average and maximum PM2.5 respectively was independently associated with z scores for AX coefficient (95%CI): Average PM2.5: 0.23 (0.02 to 0.44); Maximum PM2.5: 0.13 (0.00 to 0.25), but not with the other measures of lung function. Maternal smoking was strongly associated with Xrs: 1.15 (0.60 to 1.69) and AX: 0.89 (0.30 to 1.48), while maternal stress during the fire was protective for Xrs: -0.62 (-1.19 to -0.06).

Conclusion: Exposure to coal mine fire emissions during infancy may be associated with reduced lung reactance. Further research is required to validate these findings.

Grant Support: Department of Health & Human Services, Victoria

Declaration of Interest Statement: The authors declared no competing interests.

LUNG DIFFUSING CAPACITY IN YOUNGER SMOKERS WITH NORMAL SPIROMETRY

YONG T1, CHEUNG T1, PAPANIKOLOAU V1,2, FINLAY P1,2, BARDIN P1,2, KING P1,2
1Monash Health, Clayton, Australia, 2Monash University, Clayton, Australia

Introduction/Aim: The prevalence of Chronic Obstructive Pulmonary Disease (COPD) has been extensively studied, however limited evidence exists for the role of lung diffusing capacity for carbon monoxide (DLCO) in the management of COPD. Various predicted equations have been used in the interpretation of DLCO. Recently the Global Lung Initiative (GLI) has been established with new reference equations for calculating DLCO. We aimed to assess the prevalence of low DLCO in younger smokers with normal spirometry using the GLI predicted equations.

Methods: We performed a cross-sectional analysis of subjects who have had both spirometry and TLCO measured at the Respiratory Laboratory at Monash Lung and Sleep, Monash Health. Subjects included males and females, aged 40 to 60 years with normal spirometry and significant smoking history. As sub-study, CT scanning was used to assess the prevalence of parenchymal lung diseases in this group. Initially, the ROCA (Roca J, 1990) predicted equations were used in the calculation of lower limit of normal (LLN). Subsequently the results were reanalysed with the GLI equations and both sets of data were compared.

Results: We screened 15,226 lung function tests and identified 470 subjects aged between 40 and 60 with normal spirometry and a significant smoking histories. Of this cohort, 290 subject (60% of the group) had a TLCO below their lower limit of normal when using the ROCA equations. Subjects with the low DLCO had higher prevalence of emphysema and bronchiectasis on CT scanning. When GLI equations were applied, there was a markedly lower prevalence of low DLCO, with 24.3% of subjects in this cohort having a DLCO below LLN.

Conclusion: A low transfer factor for carbon monoxide (DLCO) is prevalent amongst younger smokers with normal spirometry. This low TLCO may be an important early indicator of potential lung damage in COPD.

Grant Support: NA
EFFECT OF LUMACAFTOR/IVACAFTOR ON CT SCORES:
EXPLORATORY IMAGING SUBSTUDY

WAINWRIGHT C1, BRODY A2, NAGLE S3, HUG C4, MARIGOWDA G4, WALTZ D5, GOLDIN J6, RATJEN F7, WANG L8
1Lady Cilento Children’s Hospital, South Brisbane, Australia, 2Department of Radiology, Cincinnati Children’s Hospital Medical Center, OH, USA, 3Departments of Radiology, Medical Physics, and Pediatrics, University of Wisconsin-Madison, WI, USA 4Vertex Pharmaceuticals Incorporated, MA, USA 5Department of Radiologic Sciences, David Geffen School of Medicine, CA, USA and 6Hospital for Sick Children, University of Toronto, Canada

Introduction/Aim: To evaluate lumacaftor (LUM) and ivacaftor (IVA) combination therapy on lung morphology with CT scanning in patients aged 6-11 years with cystic fibrosis (CF) homozygous for the F508del-CFTR mutation.

Methods: Baseline CT scans were obtained in 19 patients (12 LUM/IVA, 7 placebo) from the phase 3 trial (NCT02514473), and 24-week CT scans were completed in 7 active treatment and 3 placebo patients. CT scans were obtained at total lung capacity and at residual volume (RV). CT scans were scored by 2 independent readers blinded to all patient and time point information using the Brody score, which evaluates extent and severity of multiple aspects of CF lung disease, including bronchiectasis and air trapping. Scores are presented as mean ± SD; no statistical testing was performed for this preliminary study.

Results: Mean total CT score (sum of the subcomponent scores) decreased from 20.6 to 12.5 (mean change ± SD, 8.1±13.6) in the LUM/IVA group and increased from 32.8 to 41.4 (8.6±14.6) in the placebo group. Mean bronchiectasis score decreased from 3.2 to 2.5 (0.7±1.3) in the LUM/IVA group and increased from 6.4 to 8.1 (1.7±2.1) in the placebo group. Additionally, there was a suggestion that several ectatic bronchi decreased in size in patients on active treatment. Mean air trapping score decreased from 7.8 to 5.9 (1.9±6.8) in the active group and increased from 9.8 to 14.5 (4.7±11.7) in the placebo group.

Conclusion: This is the first report to describe CT lung findings after CFTR corrector/potentiator therapy in patients 6-11 years of age homozygous for F508del. In this 24-week exploratory analysis, bronchiectasis and air trapping scores improved in patients treated with LUM/IVA and worsened in the placebo group. These data suggest that LUM/IVA may reduce CF disease-related changes in lung morphology and support the need for further study.

Grant Support: Sponsored by Vertex Pharmaceuticals Incorporated.

Conflict of Interest: CEW received grant income on a per patient basis for conducting studies, personal fees, and travel support from Vertex Pharmaceuticals Incorporated during the conduct of the study. She also received personal fees and travel support from Novartis Pharmaceuticals, a research grant from Novo Nordisk, and grant income on a per patient basis for conducting studies from Vertex Pharmaceuticals Incorporated, Boehringer-Ingelheim, and Ablynx NV outside the submitted work.
SCHOOL-AGED OUTCOMES OF INFANT LUNG FUNCTION IN CYSTIC FIBROSIS

FOONG R1,2, RAMSEY K1,2, ZAJAKOVSKI N4,5, SKORIC B4,5, KING L1,2, TURKOVIC L1, HARPER A1, STICK S1,6, HALL G1,3, RANGANATHAN S4,5
1Telethon Kids Institute, Perth, Australia, 2Curtin University, Perth, Australia, 3Bern University Hospital, Bern, Switzerland, 4Murdoch Children’s Research Institute, Melbourne, Australia, 5Royal Children’s Hospital, Melbourne, Australia, and 6Princess Margaret Hospital, Perth, Australia

Introduction/Aim: Studies show that a significant proportion of infants with cystic fibrosis (CF) have diminished lung function within the first 2 years of life. However, it is unknown whether lung function tests in infancy have the potential to predict worse prognosis and determine which infants are most likely to benefit from treatment early in life. This study aims to investigate whether diminished lung function detected in infants diagnosed following newborn screening is associated with worse lung function when re-measured at school-age.

Methods: Lung function was assessed in 58 individuals with CF diagnosed after newborn screening (0-2 years) and again at school-age (7-10 years). The raised volume rapid thoraco-abdominal compression (RVRTC) technique and multiple breath washout (MBW) test was performed at infancy, and spirometry and MBW performed again at school-age. Mixed-effects models were used to determine if outcomes from RVRTC such as forced expiratory volume in 0.5 second (FEV0.5) and FVC, as well as lung clearance index (LCI) from the MBW test were associated with zFEV1, zFVC and zFEV1/zFVC measured by spirometry, and LCI at school-age.

Results: Age and height-adjusted FEV0.5 and FVC and height-adjusted LCI at infancy were not associated with zFEV1, zFVC and zFEV1/zFVC and LCI at school-age. The coefficients, 95% confidence intervals and p-values of the mixed-effects models are shown below.

<table>
<thead>
<tr>
<th></th>
<th>Infant LCI</th>
<th>Infant FEV0.5</th>
<th>Infant FVC</th>
</tr>
</thead>
<tbody>
<tr>
<td>zFEV1</td>
<td>0.13</td>
<td>-0.27</td>
<td>0.25</td>
</tr>
<tr>
<td></td>
<td>(-0.66, 0.91)</td>
<td>(-1.66, 1.12)</td>
<td>(-1.40, 1.91)</td>
</tr>
<tr>
<td>p</td>
<td>0.742</td>
<td>0.696</td>
<td>0.760</td>
</tr>
<tr>
<td></td>
<td>(-0.22, 1.12)</td>
<td>(-1.18, 1.13)</td>
<td>(-1.63, 1.11)</td>
</tr>
<tr>
<td>zFVC</td>
<td>0.45</td>
<td>-0.02</td>
<td>-0.26</td>
</tr>
<tr>
<td></td>
<td>(0.186)</td>
<td>(0.967)</td>
<td>(0.703)</td>
</tr>
<tr>
<td>p</td>
<td>0.300</td>
<td>0.206</td>
<td>0.065</td>
</tr>
<tr>
<td></td>
<td>(-0.55, 1.74)</td>
<td>(-4.85, 1.08)</td>
<td>(-6.80, 0.21)</td>
</tr>
<tr>
<td>LCI</td>
<td>0.60</td>
<td>-1.89</td>
<td>3.29</td>
</tr>
<tr>
<td></td>
<td>(0.300)</td>
<td>(0.206)</td>
<td>(0.065)</td>
</tr>
</tbody>
</table>

Conclusion: Lung function measured in infancy is not associated with lung function outcomes at school-age. Other factors such as respiratory infections and clinical status should be investigated and may be better predictors of worse lung function at school-age.

Grant Support: NHMRC APP1020555

Conflict of Interest: All authors have no conflict of interest to declare.

PREVALENCE OF NONTUBERCULOUS MYCOBACTERIA (NTM) IN POTABLE WATER

STOCKWELL R1,2, LEONG L3, WOOD M1,2,4, SHERRARD L1,5, THOMSON R6, ROGERS G3, BELL S1,2,4
1Lung Bacteria Group, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia, 2Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia, 3Microbiome Research, South Australia Health and Medical Research Institute, Adelaide, South Australia, Australia, 4Adult Cystic Fibrosis Centre, The Prince Charles Hospital, Brisbane, Queensland, Australia, 5School of Pharmacy, Queen’s University Belfast, Belfast, UK, and 6Respiratory Research Unit, Greenslopes Medical Research Institute, Brisbane, Queensland, Australia

Introduction/Aim: NTM is an emerging respiratory infection in people with cystic fibrosis (CF) with one species, Mycobacterium abscessus complex (MABC), causing concern. The mode of acquisition is unknown but their prevalence in potable water may be a risk factor in people with CF. This study is investigating if NTM can be recovered from the potable water systems of The Prince Charles Hospital (TPCH) and Queensland homes.

Methods: Water was collected from showers and sink taps of two respiratory wards at TPCH across five time points (2014 to 2017). Water was collected from homes in Queensland from four groups: 1) People with CF who had active MABC respiratory infection (<2 years since positive sputum culture); 2) People with CF and past MABC respiratory infection (>2 years since positive sputum culture); 3) People with CF never infected with NTM; 4) People with no lung disease. The hospital and home water samples were filtered, inoculated into growth media and incubated for 8 weeks. DNA was extracted from presumptive NTM isolates and sent for whole genome sequencing.

Results: The water sampling recovered 257 presumptive NTM isolates (hospital, n=69; home, n=188). To date, 94 presumptive NTM isolates have been sequenced. Two isolates were contaminants. Thirty-nine isolates from the hospital water were identified as Mycobacterium kansasii (n=25), MABSC (n=7), unidentified Mycobacterium (n=5) and Mycobacterium avium (n=2). Fifty-five isolates from the home water were identified as MABC (n=29), M. kansasii (n=10), unidentified Mycobacterium (n=10) and M. avium (n=4). These water isolates are being compared to CF MABC respiratory isolates as well as other environmental isolates.

Conclusion: NTM species can be found in potable water systems of homes and a hospital. The most dominant NTM species were M. kansasii in the hospital water and MABC in the home water.

Grant Support: Cystic Fibrosis Foundation Therapeutics (USA), The Prince Charles Hospital Foundation (Australia), Advance Queensland.
HIGH FREQUENCY HEARING LOSS IN CYSTIC FIBROSIS ADULTS
SONG Y1,2, LENNON J1,2, BURNS T1,2, MIDDLETON P1,2,3
1Department of Respiratory and Sleep Medicine, Westmead Hospital, Westmead, Australia, 2Ludwig Engel Centre for Respiratory Research, Westmead Institute for Medical Research, Westmead, Australia, and 3Sydney Medical School, University of Sydney at Westmead Hospital, Westmead, Australia

Introduction/Aim: Cystic Fibrosis (CF) is characterised by chronic lung infections often with Pseudomonas aeruginosa, requiring repeated aminoglycoside therapy. Aminoglycosides are recognised to cause both acute and chronic damage to the inner ear with sensorineural hearing loss (SNHL), especially of the higher frequencies. This study examined hearing in CF adults at Westmead Hospital, comparing pure tone audiometry (PTA) with high frequency audiometry (HFA).

Methods: Asymptomatic CF adults were recruited from the outpatient CF clinic. In a quiet room, PTA examined frequencies of 500Hz to 6000Hz, whilst HFA tested frequencies of 8000Hz to 16000Hz. Hearing loss severity was categorised as follows: 26-40dB (slight), 41-60dB (moderate), 61-80dB (severe), and 81+dB (profound), recording the worst 2 consecutive frequencies in standard and high ranges.

Results: A total of 134 CF adults, mean (SD) age 26.7 (8.7) years were recruited. Standard PTA detected hearing loss in both ears with 5 showing slight, 3 moderate and 2 severe impairment. HFA detected more hearing loss with 20 having slight, 16 moderate, 9 severe and 4 profound impairment. All those with hearing loss at standard frequencies exhibited similar or worse abnormalities at high frequencies. Older patients showed more hearing abnormalities both at standard and high frequencies.

Conclusion: These preliminary results suggest that HFA is more sensitive than standard PTA for measurement of potential hearing loss in the CF population. Comparison of these results with the cumulative doses of aminoglycosides is being undertaken in this cross-sectional study.

Grant Support: This study was supported by a Novartis Grant-in-Aid.

A REVIEW OF PERIPHERALLY INSERTED CENTRAL CATHETER-ASSOCIATED DEEP VENOUS THROMBOSIS IN ADULT CYSTIC FIBROSIS PATIENTS IN WESTERN AUSTRALIA
MOORE I1, TAI A1,2,3, MOREY S1,2, MULRENNAN S1,2,3
1Sir Charles Gairdner Hospital, Perth, Australia, 2Institute of Respiratory Health, Perth, Australia, and 3School of Medicine, University of Western Australia, Perth, Australia

Introduction: Peripherally inserted central catheters (PICC) have an integral role in managing pulmonary exacerbations in Cystic Fibrosis (CF). They allow effective delivery of intravenous antibiotics both in inpatient and outpatient settings. With repeated use of PICC lines, however, the incidence of complications rises. One such complication is deep venous thrombosis (DVT) and treatment with anti-coagulation can prove challenging in the setting of haemoptysis or CF related liver disease.

Aim: A retrospective audit was undertaken at Sir Charles Gairdner Hospital of all PICC line insertions in patients with CF between January 2016 and February 2017. The objectives were (i) to assess current practice of PICC insertion and (ii) to determine the frequency of PICC-associated DVT.

Methods: Information was obtained through computer records and included basic patient demographics, prior history of haemoptysis or venous thrombosis, complications and outcomes.

Results: A total of 121 4Fr PICC insertions in 63 patients (33 males and 30 females) took place during the study period. Twenty-eight percent of patients had a history of haemoptysis and one fifth (13/63; 20.6%) had a prior history of DVT or pulmonary embolus. The majority of patients had PICC lines inserted by a Radiologist (55.4%) and the rest were performed by Nurse Practitioners (44.6%). Symptomatic DVT (or pulmonary embolism) occurred in 6/121 (4.96%).

Conclusion: Our audit shows that the rate of PICC-associated DVT in adults attending the WA adult CF centre is equivocal to that reported in the literature of between 3.5 – 16.4%. It is well recognised that factors including PICC size, the thrombotic state of patients with CF and history of DVT can impact the likelihood of PICC-associated DVT. Following this audit we plan to assess the role of enoxaparin prophylaxis, particularly in the outpatient setting, aiming to further minimise the risk of PICC associated DVT.

Grant: Dr Anna Tai is the recipient of the following grants: Glenn Brown Memorial Grant, Institute of Respiratory Health, WA; Conquer CF Program Grant, Institute of Respiratory Health, WA TSANZ Vertex Adult Cystic Fibrosis Fellowship
Conflict of Interest: Nil.
Grant Support:
PLEURAL EFFUSION AND SYMPTOM EVALUATION (PLEASE) STUDY ON THE PATHOPHYSIOLOGY OF BREATHLESSNESS IN PATIENTS WITH SYMPTOMATIC PLEURAL EFFUSIONS

MURUGANANDAN S1,2,3, AZZOPARDI M4, THOMAS R1,2, FITZGERALD D1,2, KOCK Y5, READ C, MURRAY K1,5, BUDGEON C1,5, JENKIN S1,2,5, SINGH B3,4,10, EASTWOOD P8,9,10, LEE Y1,2,3
1Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, Australia, 2Pleural Medical Unit, Institute for Respiratory Health, Nedlands, Australia, 3Centre for Applied Statistics, University of Western Australia, Nedlands, Australia, 4School of Population and Global Health, University of Western Australia, Nedlands, Australia, 5Pulmonary Physiology & Sleep Medicine, Sir Charles Gairdner Hospital, Nedlands, Australia, 6Department of Radiology, Sir Charles Gairdner Hospital, Nedlands, Australia, 7Centre for Respiratory Health, School of Medicine & Pharmacology, University of Western Australia, Perth, Australia, 8Department of Respiratory Medicine, Sunshine Coast University Hospital, Sunshine Coast, Australia, 9Department of Radiology, Sir Charles Gairdner Hospital, Perth, Australia, 10Pulmonary Physiology & Sleep Medicine, Sir Charles Gairdner Hospital, Nedlands, Australia, 11Physiotherapy Unit, Institute for Respiratory Health, Perth, Australia, and 12Physiotherapy Department, Sir Charles Gairdner Hospital, Perth, Australia

Introduction/Aim: Breathlessness is common in patients with pleural effusion, but its pathophysiology is unclear. PLEASE is a comprehensive study assessing physiological and symptom responses to pleural effusion drainage and aims to: 1) identify etiologic factors that correlate with breathlessness and 2) determine incidence and factors influencing symptomatic benefit from fluid drainage.

Methods: Consecutive patients with symptomatic pleural effusion undergoing therapeutic drainage were recruited. Pre- and Post-measurements included 1) Patient and effusion-related characteristics; 2) Degree of breathlessness using three separate grading systems; 3) 6-minute Walk Distance (6MWD) capacity; 4) Spirometry; and 5) Diaphragm morphology and motion with ultrasoundography.

Results: The 145 patients (median age 69; 55% male) most commonly (63%) had malignant effusions and heart failure effusions (15%). Most (93%) effusions were moderate- or large-sized (<25% hemithorax on CXR) and had 1680 [median, IQR 1100–2600] mL drained.

All breathlessness measurements improved significantly after effusion drainage: Visual Analog Score by 30.0mm (minimal clinical important difference=14mm); Dyspnoea-12 score by -10; Borg score by 0.62 (all p<0.05). Respiratory and heart rates, 6MWD, FEV1, FVC (by 8% and 6.6%) all improved (p<0.05). Abnormal diaphragmatic morphology (flattened or inversion, 50%) and motion (paralysed or paradoxical, 48%) were common pre-drainage, and normalized in 94% and 73% of patients, respectively, post-drainage. Most (73%) reported significant relief of breathlessness (by VAS).

Conclusion: The pathophysiology of breathlessness in patients with pleural effusion is complex and multifactorial. Drainage of pleural effusion improves symptoms, functional capacity, and spirometry and normalises diaphragm morphology and motion.

Grant Support: NHMRC Fellowships (RT, YCGL, SJ, PE), WA Cancer Council (RT, YCGL), WACPCN Fellowship (MA, SM).

Conflict of Interest: All authors declare no conflict of interests.

RELATIONSHIPS OF PLEURAL FLUID pH AND GLUCOSE LEVELS: A MULTI-CENTRE STUDY OF 2971 CASES

FITZGERALD D1,2, LEONG S1,2, BUDGEON C1,5, MURRAY K1,5, ROSENSTENGEL A9, SMITH N2, BIELSA S5, CLIVE A, MASKELL N2, PORCEL J1, LEE Y1,2,3
1Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, Australia, 2Pleural Medical Unit, Institute for Respiratory Health, Nedlands, Australia, 3Centre for Applied Statistics, University of Western Australia, Nedlands, Australia, 4School of Population and Global Health, University of Western Australia, Nedlands, Australia, 5Holy Spirit Northside Hospital, Brisbane, Australia, 6Wellington Regional Hospital, Wellington, NZ, 7Pleural Diseases Unit, Arnau de Vilanova University Hospital, Lleida, Australia, 8North Bristol Lung Centre, Bristol, UK, and 9School of Medicine and Pharmacology, University of Western Australia, Nedlands, Australia

Introduction/Aim: Pleural fluid pH and glucose levels are both recommended in current guidelines as investigations in the workup of pleural effusions. Both parameters are reduced in inflammatory and/or metabolically active conditions. Whether pleural fluid pH and glucose levels provide duplicated information or independent knowledge is unclear. We aimed to investigate the relationships between pleural fluid pH and glucose levels in unselected pleural effusions, and the incidences of discordance in their levels.

Methods: Setting: Pleural services of three centres in Spain, UK and Australia.

Data: Clinical information and pleural fluid pH and glucose levels were collected.

Analyses: 1) To assess the relationship between pH and glucose using smooth curves from restricted cubic spline models; 2) Concordance between pH and glucose for varying cut-off levels was assessed.

Results: Pleural fluid samples (n=2971) were separated into four categories: malignant (n=1045), bacterial infection (n=1133), TB pleuritis (n=544) and other benign effusions (n=249). The mean pH was 7.38 (SD 0.22) and median glucose was 5.99 (range 0-29.4) mmol/L. Linear regression modelling of the relationship between glucose (log-transformed) and pH with a restricted cubic spline showed linear (p<0.01) and nonlinear effects (p<0.01). Most (91.6%; n=2720) of the samples were concordant in pH and glucose levels (i.e. at cutoffs of 7.20 and 3.3mmol/L, respectively).

Concordance was the lowest in the TB group (80.7%) and highest in the other benign effusion group (98.2%). Patients with a low pH but high glucose (n=99) were more likely to be diabetic (31% were diabetic vs 8% of those with low pH and high glucose), p<0.001, and have bacterial infection.

Conclusion: Pleural fluid pH and glucose correlate and are concordant in the majority of cases. Either test below its cut-off level can be used to aid diagnosing infection. Pleural fluid glucose should be interpreted with care in diabetic/hyperglycaemic patients.
COMPARISON OF THE 19-GAUGE AND THE 21/22-GAUGE ASPIRATION NEEDLE IN ENDOBRONCHIAL ULTRASOUND-GUIDED TRANSBRONCHIAL NEEDLE ASPIRATION (EBUS-TBNA) IN DIAGNOSING MEDIASTINAL LESIONS

HSU K, TAN E, KARUNARATHNE S
1Royal Adelaide Hospital, Adelaide, Australia, and 2Lyell McEwin Hospital, Adelaide, Australia

Introduction/Aim: This study aims to examine whether there is a difference between the 19 and 21/22-G EBUS-TBNA needles in obtaining adequate tissue for diagnosis and ancillary testing, as well comparing their safety.

Methods: This was a retrospective review of EBUS-TBNA cases done at the Lyell McEwin Hospital between June 2016 to September 2017. We included 25 cases done with the 19-G needle. For comparison, we randomly selected the same number of cases using the 21 or 22-G needle. Data collection included the patients’ demographic data, diagnosis based on fine needle aspiration (FNA) samples, average size of lymph nodes biopsied, number of needle passes, sample adequacy for immunohistochemistry (IHC) and molecular mutation testing in cases of primary lung adenocarcinoma (EGFR and ALK), sample quality and procedure complication data. Results were analysed and compared statistically using the Fisher’s test.

Results: With the 19-G needles, the diagnostic yield was 96% and 80% with the 21/22-G needles (p= 0.19). Sample adequacy was obtained with IHC in 90% in the 19-G group compared to 50% in the 21/22-G group (p=0.04). In both groups, molecular mutation testing was achieved in 100% of patients with primary lung adenocarcinoma. Average size of lymph nodes biopsied, number of needle passes, sample adequacy for immunohistochemistry (IHC) and molecular mutation testing in cases of primary lung adenocarcinoma (EGFR and ALK), sample quality and procedure complication data. Results were analysed and compared statistically using the Fisher’s test.

Conclusion: There was no significant difference between the 2 needle sizes used in EBUS-TBNA with regards to diagnostic yield and sample adequacy for molecular mutation testing. However, in this study, there was a significant difference between sample adequacy for IHC testing. This comes at a slight increased risk of bleeding.

Grant Support: Nil
Declaration of Interest: Nil
References: Nil

INTRAPLEURAL TPA WITH DNASE FOR IPC RELATED PLEURAL INFECTION

FITZGERALD D, POPOWICZ N, MURUGANANDAN S, THOMAS R, LEE Y, MURUGANANDAN S
1Pleural Medicine Unit, Institute for Respiratory, Perth, Western Australia, Australia, 2School of Medicine & Pharmacology, University of Western Australia, Perth, Western Australia, Australia, 3Department of Pharmacy, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia, and 4Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia

Introduction/Aim: Indwelling pleural catheter (IPC) is an effective treatment for recurrent, especially malignant, pleural effusions. Pleural infection, though uncommon, remains physicians’ major concern in the use of IPCs. Intrapleural IPA/DNase therapy has revolutionized care of pleural infection, but its use in IPC-related pleural infection has not been the subject of prior reports.

Methods: Single centre, retrospective review of patients with IPC-related pleural infection treated with IPA/DNase in our tertiary pleural unit. Demographics, interventions and outcomes of treatment were described. Treatment success is defined as survival to hospital discharge and avoidance of surgery. Data are presented as percentages or median [IQR] as appropriate.

Results: Nineteen patients (63% male, age 68 [59-73] years) received intrapleural IPA/DNase. Most had malignant effusions from mesothelioma (68.4%) or non-small cell lung carcinoma (15.8%). Median time from IPC insertion to diagnosis of pleural infection was 162 [57-363] days. Median follow-up was 262 [124-453] days. One patient died before 30-day follow up from cancer progression. Fever (73.7%), dyspnoea (42.1%) and decreased fluid drainage (36.8%) were the commonest presenting complaints. Staphylococcus aureus and gram-negative bacilli were the most common organisms found in pleural fluid culture. IPA/DNase therapy successfully cured 90% (17/19) of cases. The remaining two patients underwent surgery because of inadequate clinical improvement. Three patients required additional chest drain or thoracentesis. tPA/DNase therapy were observed.

Conclusion: Intrapleural IPA/DNase therapy can be safely administered via IPC for pleural infection and provides a high cure rate.

Grant Support: NHMRC Fellowships (RT, YCGL), WA Cancer Council (RT, YCGL), WACP CN Fellowship (SM).

Declaration: Rocket Med Ltd has provided free IPC drainage kits and Sequana Med Ltd has served on advisory boards of Carefusion/BD, Lung Therapeutics Inc. and Sequana Med Ltd.

Respirology (2018) 23 (Suppl. 1), 21-103

Copyright of individual abstracts remains with the authors.
PREVIOUS PLEURAL INJURY INCREASES PNEUMOTHORAX RISK POST-ENDOBRONCHIAL VALVE INSERTION FOR BRONCHOSCOPIC LUNG VOLUME REDUCTION

OH A1,2, GROSSER D2, NGUYEN P3, HNIN K2, SMITH B1
1The Queen Elizabeth Hospital, Woodville South, South Australia, Australia, 2Royal Adelaide Hospital, Adelaide, South Australia, Australia, 3Ashford Hospital, Ashford, South Australia, Australia

Introduction/Aim: Bronchoscopic lung volume reduction (BLVR) via endobronchial valve (EBV) insertion is an accepted treatment for patients with severe emphysema. The most common complication of EBV insertion is pneumothorax, with a reported incidence of up to 25%. The aim of this study was to determine if previous pleural injury, or paraseptal/panlobular emphysema morphological subtype, would contribute to pneumothorax risk post-EBV insertion.

Methods: EBV insertion for BLVR that occurred in Adelaide, South Australia over the period 2014 to September 2017 were examined in 3 centres: the Royal Adelaide Hospital, The Queen Elizabeth Hospital, and ChestCare Clinic.

Emphysema subtype was determined by evaluating pre-EBV CT chest scans. The presence of pleural injury was determined by assessing patients for previous pneumothorax, pleural instrumentation, and pleural plaques/nodules in their pre-EBV CT chest scans.

Results: 86 procedures were completed within the study timeframe. 13 (15.1%) procedures resulted in pneumothorax. Mean age at EBV insertion was 67.31 years. 54.6% (47/86) of EBV insertions occurred in male patients. Statistical analysis was undertaken via logistic regression.

Previous pleural injury significantly increased the risk of pneumothorax post-EBV (OR 22.55: 95% confidence interval 2.51-202.51, p = 0.005). Gender, age at EBV insertion, and paraseptal/panlobular emphysema subtypes did not significantly increase pneumothorax risk.

Conclusion: This is the first Australian study to examine risk factors for pneumothorax incidence in EBV insertion. Previous pleural injury significantly increases the pneumothorax risk after EBV insertion. This data will contribute to our ability to predict pneumothorax in patients evaluated for EBV insertion, thus allowing improved risk assessment, and facilitating discharge planning post-EBV insertion. We plan further studies evaluating other possible risk factors, including quantitative CT scoring of pleural adhesions.

Grant Support: None

EPITOME (EARLY PLEURODESIS VIA INDIWELLING PLEURAL CATHETER WITH TALC FOR MALIGNANT EFFUSIONS): A PILOT STUDY OF THE STATE-OF-THE-ART MANAGEMENT ALGORITHM

FITZGERALD D1,2,3, MURUGANANDAN S1,2,3, STANLEY C2,3, READ C2,3, THOMAS R1,2, LEE Y1,2,3
1School of Medicine and Pharmacology, University of Western Australia, Australia, Nedlands, Australia, 2Respiratory Department, Sir Charles Gairdner Hospital, Nedlands, Australia, 3Pleural Medicine Unit, Institute for Respiratory Health, Nedlands, Australia

Introduction: Talc pleurodesis (TP) and indwelling pleural catheter (IPC) are recognized treatments for malignant pleural effusions (MPEs); each with its own advantages. Combining them can potentially provide best fluid control, facilitate early IPC removal, minimize re-intervention, hospitalization, long term IPC costs and complications.

Methods: A single-centre pilot study of a new treatment algorithm, EPIToME. All patients with symptomatic MPEs requiring definitive treatment were offered inpatient IPC (unless contraindications) insertion. Upon complete drainage (usually overnight), CXR was performed. If the lung full re-expanded, talc slurry (4g) was instilled via the IPC and patient discharged the following day with daily IPC drainage using suction-bottle for 10-14 days (longer if continual reduction of drainage volumes). IPCs were removed if pleurodesis was successful (defined as fluid drainage <50ml for 3 consecutive drainages without significant residual effusion on imaging). Patients with trapped lung, or contraindication to talc, were discharged with IPC and drainage when symptomatic. Data were presented as median (IQR).

Results: Patients with MPE (n=40: 60% male, median age 70) from metastatic cancers (47.5%) or mesothelioma were included. A median volume of 2.5 [1.9-3.5] litres were drained within 24 hours of IPC insertion. Sixteen patients fulfilled the criteria and received talc instillation via the IPC, usually one day post-IPC insertion. The median total hospitalization was 3 [2-3] days. Nine patients (56%) achieved pleurodesis after median of 14 days [11-27] and underwent catheter removal with no evidence of recurrence; median follow-up 116 [81-55] days. Talc was not administered in 24 patients due to trapped lung (50%), prior failed talc pleurodesis (21%), etc. Complications of talc included reversible tube blockage (n=2), self-limiting fever (n=2) and subsequent development of symptomatic loculations (n=3 successfully managed tube drainage + intrapleural IPA).

Conclusion: The EPIToME protocol combining IPC and talc pleurodesis is feasible, safe and has potential advantages over individual therapies.

Grant Support: NHMRC Fellowships (RT, YCGL), WA Cancer Council (RT, YCGL), WACPCN Fellowship (SM)

Declaration: Rocket Med Ltd has provided free IPC drainage kits and a unrestricted educational grant for previous trials led by YCGL. YCGL has served on advisory boards of Carefusion/BD and Sequana Med Ltd.
Obstructive Sleep Apnoea Epidemiology in the Busselton Healthy Ageing Study (BHAS)

Cunningham J1, James A1, Knimian M2, Singh B1, Murray K2, Hunter M2,3
1Sir Charles Gairdner Hospital, Perth, Western Australia, Australia, 2University of Western Australia, Perth, Western Australia, Australia, and 3Busselton Population Medical Research Institute, Perth, Western Australia, Australia

Introduction/Aim: Obstructive sleep apnoea (OSA) is common and associated with significant morbidity and mortality. There are few objective prevalence data in Australia, particularly for women. In Busselton, Western Australia, the prevalence of OSA (respiratory disturbance index >15) was estimated in 1990 at 4.7% in men, and in 2007 (N=793) at 12.4% in men and 5.7% in women (apnea-hypopnea index (AHI)>15 in participants without known OSA). We assessed OSA prevalence in the Busselton Healthy Ageing Study, a comprehensive health study of both sexes aged 46-64 years.

Methods: Between 2010 and 2015, all residents on the Busselton Shire electoral roll born 1946 to 1964 were invited to participate, with 75% participation (N=5,082). Dual channel ApneaLink devices for home sleep study were issued to 3,745 participants (73.7%) and 2,707 (53.3%) collections were suitable for analysis. The prevalence of OSA was defined by the AHI obtained from the ApneaLink automated event scoring algorithm, and its relation to demographic data and co-morbidities was assessed. Moderate and severe OSA were defined as AHI>15 and >30 respectively.

Results: The prevalence of OSA (AHI>15) 20.4% in men and 10.1% in women (see table). Increasing OSA severity was associated with increased BMI and alcohol use in both sexes, and with sleepiness in men only.

Conclusion: The prevalence of OSA in Busselton has increased, and the prevalence in women is higher than previously reported. Sex-based differences in comorbidities are observed.

Grant Support: National Health and Medical Research Council (NHMRC); The Office of Science and Department of Health of the Government of Western Australia; in-kind equipment and consumable support from ResMed Science Centre.

Compared with AHI<15, an AHI>15 was associated with hypertension in both sexes (p<0.001); with current depression in men only (20.3% vs 13.3%, p=0.005); and with diabetes (11.3% vs 5%, p=0.002) and cancer (22.5% vs 14.9%, p=0.014) in women only.

<table>
<thead>
<tr>
<th>AHI</th>
<th>Men</th>
<th>p</th>
<th>Women</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&lt;15</td>
<td>15-29.9</td>
<td>≥30</td>
<td>15-29.9</td>
</tr>
<tr>
<td>n (%)</td>
<td>958 (79.6)</td>
<td>183 (15.2)</td>
<td>63 (5.2)</td>
<td>1352 (90)</td>
</tr>
<tr>
<td>BMI, kg/m2</td>
<td>27.9 ±3.7</td>
<td>29.7 ±4.4</td>
<td>31.3 ±5.3</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Alcohol, glasses/wk</td>
<td>15.1 ±14.5</td>
<td>17.4 ±21.8</td>
<td>19.3 ±13</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>ESS</td>
<td>6.0 ±3.7</td>
<td>6.6 ±4.1</td>
<td>7.2 ±4.0</td>
<td>0.01</td>
</tr>
</tbody>
</table>
CORTICAL CONTRIBUTION TO QUIET BREATHING IN COPD IS ASSOCIATED WITH AGEING

Hudson A1,2, Nguyen D1,2, Boswell-Ruys C1,2,3, McBain R1,2,3, Eckert D1,2, Gandelia S1,2, Butler J1,2
1Neuroscience Research Australia, Randwick, Australia, 2University of New South Wales, Sydney, Australia, and 3Spinal Injuries Unit, Prince of Wales Hospital, Randwick, Australia

Introduction/Aim: Current evidence indicates that inspiratory loads engage cortical mechanisms to defend ventilation. A cortical contribution to breathing is determined via the presence of a Bereitschafts (readiness) potential – a low amplitude negativity which begins ~1s before inspiration. In chronic obstructive pulmonary disease (COPD), changes in the lung, chest wall and respiratory muscles induce an inspiratory load. We hypothesised that there is a cortical contribution to quiet breathing in COPD and that a cortical contribution to inspiratory threshold loading is related to dyspnoea – a major symptom of COPD.

Methods: Electroencephalographic activity (EEG) was recorded in 15 COPD patients (10 males; age: 57-87) and 30 healthy controls (15 age-matched and 15 young) during quiet breathing and inspiratory threshold loading (10% maximal inspiratory pressure). Two blinded observers evaluated the presence of Bereitschaftspotentials prior to inspiration from ensemble averages of 80 or more epochs of EEG at Cz and FCz. Dyspnoea was rated using a modified Borg scale.

Results: The incidence of a cortical contribution to quiet breathing was significantly greater in the COPD patients (7/15) than the young (3/15) (P < 0.01), but not the age-matched (5/15) (P = 0.46), controls. A cortical contribution to inspiratory threshold loading was associated with higher Borg scores in the young (P < 0.05), but not the age-matched controls (P = 0.25) or the COPD patients (P = 0.43).

Conclusion: This study provides evidence that age, rather than COPD, is associated with a cortical contribution to quiet breathing. A cortical contribution to inspiratory threshold loading may be associated with more severe dyspnoea, at least in healthy young people.

Grant Support: A.L. Hudson is supported by a Lung Foundation Australia/Boehringer Ingelheim COPD Research Fellowship.

USE OF CLOUD BASED TECHNOLOGY TO OPTIMISE CPAP INITIATION IN OSA

Georgiou H1, Kee K1, Goldin J1
1Royal Melbourne Hospital, Melbourne, Australia

Introduction/Aim: Despite advances in technology of Continuous Positive Airway Pressure (CPAP) in the treatment of Obstructive Sleep Apnea (OSA) and well validated benefits in quality of life and health outcomes, long term adherence remains a major challenge. Remote access cloud based technology has become a standard feature of new CPAP devices. Currently, this feature may not be optimally utilised to improve compliance and patients’ experience with CPAP.

We sought to determine whether, remote based assessment of CPAP usage at regular intervals with follow up telephone assessment could improve CPAP usage and Epworth sleepiness score (ESS) in patients commencing CPAP therapy for OSA through a well-supported sleep service.

Methods: We sought to prospectively assess 50 consecutive patients commencing CPAP therapy for OSA. Each patient had CPAP usage remotely assessed at weeks 1, 3, 6 and 9 post commencement. Telephone assessment with a standardised questionnaire was carried out at each interval if CPAP usage was <4hrs per night. CPAP usage and final ESS were compared to 50 consecutive retrospective controls. Current preliminary data includes 37 of target 50 patients in the intervention group.

Results: The mean age was 56.1±14.5 years (SD) vs 52.5±14.4, Body mass index (BMI) 37.0±9.1 vs 37.7±7.4 kg/m², Apnea Hypopnea Index (AHI) 46.5±29.0 vs 46.2±29.0 events/hour and baseline ESS 8.8±5.3 vs 10.6±5.3 in control and intervention groups, respectively. There was no significant difference in CPAP usage between control group and intervention group at 1week: 5.0±2.6 vs 4.4±2.7 hours (SD) (p=0.55); 3weeks: 4.8±2.6 vs 4.2±2.6 hours (p=0.49); 6weeks: 4.6±2.5 vs 4.4±2.8 hours (p=0.90); or 9weeks: 4.3±2.5 vs 5.2±2.8 hours (p=0.23), respectively. Additionally, there was no significant difference in change in ESS score -0.6±5.6 vs -2.7±4.3 (p=0.24), respectively.

Conclusion: Regular interval remote based assessment of CPAP usage in OSA, in addition to usual care, does not improve 2-month CPAP usage or ESS.

Grant Support: Nil
RETROSPECTIVE CASE-CONTROLLED STUDY OF OBSTRUCTIVE SLEEP APNOEA IN DOWN SYNDROME
SULAIMAN N1, CATCHESIDE P1, MCEVOY D1,2, CHAI-COETZER C1,2
1Sleep Health Services, Southern Adelaide Local Health Network, Adelaide, Australia, and 2Flinders University, Bedford Park, Australia

Introduction/Aim: Down syndrome (DS) is associated with multiple health issues including obstructive sleep apnoea (OSA). Dysmorphic craniofacial features inherent to DS predispose to OSA. The aims of this study were to ascertain the prevalence and severity of OSA in DS adults and identify possible barriers/enablers to treatment by comparing demographic and polysomnography (PSG) indices, continuous positive airway pressure (CPAP) prescription rates and adherence in DS adults matched to a group of non-DS adults referred for a sleep study at Repatriation General Hospital.

Methods: Data were collected from electronic and paper-based records. DS patients with OSA were identified by case review and compared to a randomly selected matched gender, age (±3), body mass index (BMI) (±3kg/m2) and study date (±90 days) (ratio1:3). Between group comparisons were conducted using independent samples t-tests and Mann-Whitney U tests for continuous data and Fisher’s or Chi2 tests for categorical variables.

Results: 30 DS were matched with 58 non-DS patients for gender, age (mean±SD 38.8±12.5 versus 41.4±12.4 years) and BMI (34.9±9.1 versus non-DS 32.8±6.8 kg/m2). 28 (93%) DS had OSA compared to 32 (55%, p<0.001) non-DS patients. 25 DS (92.8%) and 15 non-DS (46.9%) patients with OSA were commenced on CPAP (p<0.001). DS had more severe OSA (total apnoea hypopnoea index 56.4[28-73.8] (median [IQR]) versus controls 15.5[4.4-17.6]). CPAP adherence at 6 months: average hours use DS 4.6±0.7 (mean±SEM) versus controls 6.4±0.6 in controls (p=0.044). There was similar intensity of follow up visits in the first year after CPAP initiation: DS 5.0±0.5 (mean±SEM) versus controls 4.1±0.6 (p=0.288). DS patients with higher intensity of supervision overnight had better CPAP compliance.

Conclusion: DS patients had significantly more severe OSA but reduced CPAP adherence. Further research is required to elucidate barriers to treatment and potential solutions to improve CPAP compliance amongst DS patient with OSA.

Grant Support: Nil
Declaration of Interest: Nil

ARTIFICIAL INTELLIGENCE HELPS DETECTING LUNG DISEASE WITH PULMONARY FUNCTION TESTS
TOPALOVIC M1, DAS N1, TROOSTERS T1, DECRAMER M1, JANSENS W1
1KU Leuven, Leuven, Belgium

Introduction/Aim: Pulmonary function testing (PFT) is a main tool to evaluate the function of the respiratory system. However, used alone, it hardly leads to disease diagnosis. Based on artificial intelligence (AI) we aimed to develop a smart software which improves the clinical reading of a lung function and suggests a respiratory disease diagnosis if possible.

Methods: Data of 1430 subjects with respiratory symptoms were taken from 33 Belgian hospitals to develop the algorithm. The final diagnosis (healthy, asthma, COPD, ILD, neuromuscular disease, chest wall or pleural disease, pulmonary vascular disease, other obstructive disease) was obtained from clinical history, lung function and all additional tests, and confirmed by an expert panel. A cloud-based solution was incorporated into clinical setting to validate the accuracy of the algorithm on a random sample of 136 new subjects. Finally, the software diagnoses were compared with the diagnostic opinions of 85 pulmonologists (from 11 different European hospitals) provided with PFT and clinical data of 50 new subjects.

Results: At development, software presented a high accuracy of 74% after 10-fold cross-validation when detecting lung diseases (8 possible disease categories). During validation, the high accuracy was maintained in a real clinical setting (76%). At the external multicentric validation, the software-based automated diagnoses (82% accuracy) were superior over the suggested diagnoses of 85 pulmonologists (44.6 ± 3.7 % mean accuracy). Great disagreement between readers is observed with a low kappa score of 0.34.

Conclusion: AI can be used to identify different lung diseases. Due to its superiority and work consistency, such software can provide a powerful decision support system in daily clinical routine.

Grant Support: VLAIO Flanders
THE ASSOCIATION BETWEEN REGIONAL LUNG DISTENSION AND GENE EXPRESSION DURING MECHANICAL VENTILATION

YEN S1, PREISSNER M2, BENNETT E1, FOURAS A3, DARGAVILLE P1,3,4, ZOSKY G1

1School of Medicine, University of Tasmania, Hobart, Australia, 24Dx Limited, Melbourne, Australia, 3Neonatal and Paediatric Intensive Care Unit, Royal Hobart Hospital, Hobart, Australia, and 4Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia

Introduction/Aim: Mechanical ventilation, a lifesaving therapy for patients with respiratory failure, contributes to mortality by inducing inflammation, which can lead to multisystem organ failure. Different regions of the lung have been shown to heterogeneously respond to mechanical ventilation, however, the association between this variation in regional lung distension and regional lung inflammation is unknown. The aim of this study was to assess this association in the healthy lung.

Methods: We ventilated two groups of adult BALB/c mice (n = 8 per group) for 2 h using a protective [low tidal volume with moderate positive end expiratory pressure (PEEP)] or injurious [high tidal volume with zero PEEP] ventilation strategy. RNA levels of 19 genes were quantified regionally by qPCR array. Gene expression was correlated with regional FRC, tidal volume and distension (FRC + tidal volume). FRC and tidal volume were obtained from analysis (cross-correlation-based velocimetry) of dynamic high-resolution (phase contrast) 4DCT lung images at baseline and after two hours of ventilation.

Results: Two genes had differential regional expression that varied between ventilation strategies (IL-6, P<0.02 and Ccl-2, P<0.01). The expression of these genes was positively correlated with regional tidal volume and distension (P<0.05 for all correlations). The expression of Cxcl2, Tnfα, Wnt1, c-fos and Nfe2l2 also varied between ventilation strategies (P<0.01), but they did not appear to be associated with FRC, tidal volume or distension.

Conclusion: We have demonstrated associations between regional gene expression and tidal volume. Our results provide critical insight into the regional lung response to mechanical ventilation. In particular, these results highlight the importance of the balance between under-ventilation and over-stretch (tidal volume) and how each of these can contribute to lung inflammation and, potentially, patient outcomes.

Grant Support: This study is funded by NHMRC grant # 1077905

ORAL CORTICOSTEROID USE IN ASTHMA PATIENTS: AN EASY WAY OUT

BRADBURY T1,2, AZZI E1,2, SROUR P1,2, ARMOUR C1,2,3, KRITIKOS V1,2,3, BOSNIC-ANTICEVICH S1,2,3

1Woolcock Institute of Medical Research, Glebe, Australia, 2The University of Sydney, Sydney, Australia, and 3Sydney Local Health District, Sydney, Australia

Introduction/Aim: Although significant progress has been made in asthma management, 5-10% of patients have severe asthma (SA) that is associated with increased morbidity, mortality and an economic burden. Within this group, 30-40% of patients are prescribed continuous or near-continuous oral corticosteroids (OCS) to achieve or maintain asthma control. However, in primary care, a subset of these patients may exist with poor asthma management practices and thus less severe disease, relying on OCS to achieve asthma control instead of regular inhaled preventative medication. The aim of this study is to identify patterns of medication taking behaviour and describe the respiratory status of people with asthma in primary care. This will allow for the development of a framework that identifies patients based on asthma severity through medication records.

Methods: Patient data (n=493) was utilised from a quality-controlled community pharmacy database. Correlational analysis and regression modelling were employed to determine potential predictors of asthmatic oral corticosteroid users (n=72) based on asthma severity, lung function, symptom control, comorbidities, adherence, inhaler technique and medication management.

Results: Fifteen percent of asthmatics recruited were prescribed OCS in the last 12 months. Ninety-three percent of OCS users were classified as having poor asthma control, 96% identified potential barriers to non-adherence (determined by the Brief Medication Questionnaire (Svarstad BL et al. 1999)), and 86% had incorrect inhaler technique. Significant relationships were found between OCS users and ownership of an asthma action plan (p<0.00), the existence of depression (p<0.002) and eczema (p=0.02), potential for non-adherence (p=0.018), poor asthma control (p<0.00), poor lung function test (p=0.04) and a higher prescribed rate of inhaled combination therapy (p<0.000), including a higher rate of visits to the doctor regarding asthma (p=0.044).

Conclusion: This research has uncovered a heterogeneous group of people with asthma in primary care, with less severe disease who put themselves at risk of exacerbations due to their medication taking behaviour. By better understanding the behaviour of individuals in the context of their day-to-day management, we will be able to tailor interventions for these patients reflecting current guidelines.

REFERENCE

WORKING WHILE UNWELL: WORKPLACE IMPAIRMENT IN PEOPLE WITH SEVERE ASTHMA

HILES S1, HARVEY E2,3, MCDONALD V1,2,3, SAWD INVESTIGATORS3, GIBSON P1,2,3

1Centre of Excellence in Severe Asthma, Faculty of Health, University of Newcastle, New Lambton Heights, Australia, 2Department of Respiratory and Sleep Medicine, John Hunter Hospital, Hunter Medical Research Institute, University of Newcastle, New Lambton Heights, Australia, and 3Australian Severe Asthma Network, New Lambton Heights/Glebe, Australia

Introduction/Aim: Severe asthma substantially impairs quality of life and may impair workplace productivity, although this has rarely been quantified. The aim of this study was to compare workplace impairment in severe and non-severe asthma over time, and identify characteristics associated with presenteeism in severe asthma.

Methods: Patients were enrolled in the Severe Asthma Web-based Database (SAWD), an ongoing observational registry of 434 patients with severe refractory asthma and 102 with non-severe controlled asthma from 26 sites across Australia, New Zealand and Singapore (18 to 88 years; 59% female). Participants provided baseline clinical and questionnaire data and were followed-up every 6 months until 24 months. Workplace absenteeism (% time absent from work), presenteeism (% self-reported impairment at work) and activity impairment (% self-reported impairment in daily activities outside work) in the past week were derived from a validated questionnaire.1

Results: Half of participants were employed at baseline. A quarter of workers reported absenteeism and two-thirds reported presenteeism. People with severe compared with non-severe asthma were 3.15 times more likely to report presenteeism (95%CI 1.75-5.69) and 2.26 times more likely to report daily activity impairment (95%CI 1.44-5.54). Workplace absenteeism (% time absent from work), presenteeism (% self-reported impairment at work) and activity impairment (% self-reported impairment in daily activities outside work) in the past week were derived from a validated questionnaire.1

Conclusion: Impaired work and non-work functioning are important components of the disease burden of severe asthma. Optimising workplace productivity requires improvement in asthma control and attention to mental health. Absenteeism and presenteeism may be key metrics for assessing intervention efficacy among people with severe asthma of working age.

Grant Support: SAWD is supported by GSK, Roche, AZ, Novartis and Boehringer Ingelheim.

REFERENCES

A SPUTUM SIX GENE SIGNATURE PREDICTS INFLAMMATORY AND EXACERBATION PHENOTYPES IN UNCONTROLLED MODERATE-TO-SEVERE ASTHMA: AN AMAZES SUB-ANALYSIS

FRICKER M1, POWELL H1, GIBSON P1, BAINES K1
1University of Newcastle, Newcastle, Australia

Introduction/Aim: Improved diagnostic tools for predicting airway inflammatory phenotype and future exacerbation frequency in asthma are required. We previously demonstrated a sputum gene expression signature of 6 biomarkers (6GS) could predict inflammatory phenotype and corticosteroid responsiveness in stable asthma. We recently demonstrated that azithromycin add-on treatment in uncontrolled moderate-to-severe asthma significantly reduced asthma exacerbations (AMAZES clinical trial). We aimed to test whether the 6GS predicts airway inflammatory and future exacerbation phenotypes in a subpopulation of the AMAZES clinical trial. We also tested whether 48 weeks of azithromycin treatment altered 6GS expression compared to placebo.

Methods: 142 patients (73 placebo-treated, 69 azithromycin-treated) produced adequate sputum for differential cell count and PCR of 6GS markers at baseline and after 48 weeks of treatment. Logistic regression and ROC analysis was performed on baseline results to compare the predictive value of 6GS and conventional biomarkers for airway inflammatory phenotype and future exacerbation frequency.

Results: The 6GS significantly predicted airway inflammatory subtype at baseline, outperforming systemic biomarkers peripheral blood eosinophils (PBE) and fractional exhaled nitric oxide (FENO). 6GS significantly predicted future exacerbation phenotype, was numerically superior to all biomarkers examined (sputum eosinophils, sputum neutrophils, PBE and FENO), and identified patients who would go on to experience frequent (≥2/year) severe exacerbations. Azithromycin treatment did not significantly alter 6GS expression compared to placebo, nor did it affect the prediction of exacerbation phenotype using the 6GS.

Conclusion: The sputum 6GS is useful as a diagnostic tool for inflammatory phenotyping and predicting future frequent severe exacerbations. The 6GS retains this predictive capacity in azithromycin-treated asthma, suggesting a novel therapeutic mechanism independent of known exacerbation-associated inflammatory factors.

Grant Support: Work supported by the NHMRC. MF holds an NHMRC post-doctoral research fellowship within the CRE in Severe Asthma. PGG holds an NHMRC practitioner fellowship. KJB holds a Lung Foundation Australia Boehringer Ingelheim COPD research fellowship.

THE EFFECT OF TREATMENT WITH OMALIZUMAB ON ANTIVIRAL RESPONSES IN ADULTS WITH SEVERE ALLERGIC ASTHMA

WARK P1,2, NICHOL K3, DORAHY D1, COLLISON A3, MATTES J3
1Centre for Healthy Lungs, HMRI, University of Newcastle, New Lambton, Australia, 2Department of Respiratory and Sleep Medicine John Hunter Hospital, New Lambton, Australia, and 3Centre for Growing Up Well, HMRI, University of Newcastle, New Lambton, Australia

Introduction/Aim: Severe asthma is characterised by frequent exacerbations, that lead to poor asthma control and worsened quality of life. The majority of these exacerbations are triggered by viral respiratory tract infections. Poorly controlled asthma is associated with impaired antiviral immune responses. Treatment of severe allergic asthma with Omalizumab, a monoclonal antibody against IgE, has been shown to improve asthma control and reduce exacerbation risk. We sought to determine if treatment with Omalizumab resulted in improvement in antiviral innate immune responses to influenza A (IAV) and rhinovirus (RV).

Methods: We recruited 10 adults, with poorly controlled allergic asthma; atopic to one or more aeroallergens, on maximal dose inhaled corticosteroids/long acting bronchodilators, with persisting poor asthma symptom control, exacerbations requiring oral corticosteroids and a serum total IgE >30IU/ml. They were compared to healthy aged matched controls with no asthma or atopy. Participants were assessed prior to commencing treatment with Omalizumab and then 6 months later at the time effectiveness of treatment was assessed. Blood was drawn and peripheral blood monocytes (PBMCs) were isolated. PBMCs were then exposed for 48 hours to IAV, and RV. Response was assessed by ELISAbead array with release of interferon (IFN)-α, IFN-λ, IL-6, IL-10, IL-5 and IL-13.

Results: At baseline visit subjects with severe allergic asthma compared to healthy controls demonstrated impaired IFN-α, and IFN-λ release in response to IAV (p<0.001) and RV (p=0.003). Following 6 months treatment, 9/10 demonstrated an improvement in asthma symptom control to continue treatment. In the clinical responders there was a significant increase seen in IFN-α, and IFN-λ to IAV and a trend towards improvement to RV.

Conclusion: Adults with severe allergic asthma demonstrate impaired systemic innate immune responses to IAV and RV. Treatment with Omalizumab, that results in improved asthma control is associated with improvement in innate antiviral responses.

Grant Support:
**Introduction/Aim:** Treatable traits (TT) have been proposed as a new approach for airway disease management, however supporting data are currently limited. We aimed to determine if identification of TT is possible using a severe asthma registry, to assess their prevalence in severe compared to non-severe asthma, and to assess the relationship between TT and future exacerbation risk.

**Methods:** The Severe Asthma Web-based Database is an observational registry of 434 severe asthma patients and a comparison group of 102 patients with non-severe asthma from 26 sites in Australia (18-88 years, 59% female). Participants were characterised at enrolment and followed for 24 months. Published traits were mapped to registry data fields and prevalence determined. Bayesian model averaging was applied to identify traits that best predicted future exacerbation risk.

**Results:** Seven pulmonary, 13 extrapulmonary and 4 behavioural risk-factor traits were identified. More pulmonary and extrapulmonary traits were expressed in severe than non-severe asthma (p<0.001). Traits significantly more common in severe asthma were incompletely reversible airflow limitation (58% vs. 39%, p=0.002), frequent exacerbations (51% vs 39%, p<0.05), nebulised airway inflammation (23% vs 4%, p=0.023), obesity (49% vs 27%, p<0.001), systemic inflammation (41% vs 13%, p<0.001), reflux (49% vs. 36%, p=0.021), inhaler-device polypharmacy (29% vs 18%, p=0.018) and Aspergillus sensitisation (39% vs 19%, p<0.001). During follow-up, patients with severe asthma reported more exacerbations (median [IQR]: 2 [0-4] vs 3 [0-2]; IRR 2.33, p<0.001). Each additional trait was associated with a 13% increase in exacerbation risk (p<0.001). Previous exacerbations, inhaler-device polypharmacy, sleep apnea and depression best predicted exacerbation risk.

**Conclusion:** A registry-based systematic characterisation of asthma may be used to assess TT. We report traits that predict exacerbation risk and confirm greater burden associated with severe asthma. Trials evaluating the efficacy and cost-effectiveness of the TT approach are needed.


**Grant Support:** SAWD is supported by GSK, Roche, AZ, Novartis and Boehringer Ingelheim.

---

**Introduction/Aim:** Asthma is a chronic inflammatory airway disease which is characterized by recurrent attacks of breathlessness and wheezing. The pathogenesis of asthma is complex and still unclear. The unfolded protein response (UPR) of the endoplasmic reticulum (ER) has recently been identified as playing a decisive role in inflammatory diseases. Worsening of asthmatic condition can be brought on by stimuli such as oxidative stress, pathogenic infection, and allergen exposure. All of which can induce ER stress and activate UPR. Activated arms of UPR induce different inflammatory pathways and dysregulate the innate immune response. However, how UPR is associated with asthma is unclear. Here we investigate the UPR signature in different inflammatory phenotypes of asthma using human clinical samples.

**Methods:** Bronchoalveolar lavage fluid (BALF), endobronchial biopsies and induced sputum samples were collected from eosinophilic, neutrophilic, paucigranulocytic asthma patients, and from healthy individuals. The expression of UPR associated genes in BALF cells, and biopsy samples were analysed by qPCR. UPR related protein expressions was analysed by immunoblot. UPR gene expression in sputum cells were analysed by microarray.

**Results:** UPR genes (GRP78, CHOP, XBP1s, and PDIA4) in lung immune cells were significantly induced (p<0.05) in eosinophilic asthma while neutrophilic asthma demonstrated an increased trend. GRP78 and CHOP protein expression were significantly higher in both eosinophilic and neutrophilic groups. Microarray data from sputum cells demonstrated an upregulation of various UPR genes mostly in the eosinophilic asthma group, but not in paucigranulocytic or mixed granulocytic groups. UPR gene expression in lung biopsies did not show significant differences between groups. However, bronchial epithelial cells (BECs) treated with asthma allergens demonstrated an increased trend of UPR.

**Conclusion:** UPR is heightened in eosinophilic and neutrophilic asthma. Airways immune cells have a major role in regulating UPR in Airways of asthma.
PLASMA CELL AND REGULATORY B CELL-INFILTRATION IN THE LUNGS OF BLEOMYCIN-TREATED MICE
PRELE C,1,2 PEARCE D,2 MILES T1,2 O’DONOGHUE R,4 LUCAS A,2 FEAR M,1,2 ERNST M,1 LAURENT G,1,2 KNIGHT D,2 HOYNE G,2 MCANULTY R,2 MUTSAERS S1,2
1Institute for Respiratory Health, The University of Western Australia, Perth, Australia, 2Centre for Cell Therapy and Regenerative Medicine, School of Biomedical Sciences, The University of Western Australia, Perth, Australia, 3Centre for Inflammation and Tissue Repair, Division of Medicine, University College London, London, UK, 4Olivia Newton John Cancer Research Institute and La Trobe University School of Cancer Medicine, Heidelberg, Australia

Introduction: STAT3 and B cells are implicated in the development of lung fibrosis. We have previously demonstrated that hyper-activated STAT3, B cell deficient gp130757F, MT-/- mice are protected from bleomycin (BLM)-induced lung fibrosis suggesting that B cells are important in the regulation of STAT3-mediated fibrosis.

Hypothesis: We hypothesise that the pro-fibrotic effects of STAT3 involve B cell-mediated immune regulation.

Methods: The effect of anti-CD20 therapy in bleomycin-treated wild-type and gp130757F mice on lung fibrosis and immune cell composition was examined. Mice were given two 100μg doses of anti-CD20 antibody (Genentech Inc USA) or IgG2a isotype control i.p. either 7 days prior to and 7 days after bleomycin or on day 10 and day 19 post-bleomycin treatment (following the initiation of fibrosis), and the extent of fibrosis measured at 28 days.

Results: FACS analysis of blood taken on days 0, 7 and 28 days post-bleomycin treatment revealed an almost complete depletion of CD19+ B cells in the circulation of wildtype mice but not gp130757FMT-/- mice. Treatment with anti-CD20 antibody depletion occurred at 28 days. FACS analysis identified an expansion of CD138+ (plasma cells) in the lungs of the anti-CD20-treated mice. FACS analysis identified an expansion of CD138+ (days 7 and 28) and CD5+ cells in the lungs of bleomycin treated mice at day 28.

Conclusion: Although antibody depletion of follicular B cells had no effect on bleomycin-induced fibrosis, residual CD138+ plasma cells and CD5+ B are abundant in the lungs of bleomycin-treated mice. The activity of these B cell subsets may contribute to the fibrotic phenotype.

Grant Support: This work is funded by NHMRC Project Grant GNT1067511 and British Lung Foundation Grant PPRG15-10.

THE EFFECT OF THE DIETARY ω-6 POLYUNSATURATED FATTY ACID, ARACHIDONIC ACID, ON AIRWAY INFLAMMATION AND REMODELING IN COPD
RUTTING S,1,2 PAPANICOLAOU M,1,2 XENAKI D,1 WOOD L,3 HORVAT J,1 HANSBRO P,2 OLIVER B1,4
1Woolcock Institute of Medical Research, Sydney, Australia, 2Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute and University of Newcastle, Newcaste, Australia, 3School of Biomedical Science and Pharmacy, The University of Newcastle, Newcastle, Australia, 4School of Medical and Molecular Biosciences, University of Technology, Sydney, Australia, and 5Emphysema Centre, Woolcock Institute, Sydney, Australia

Introduction/Aim: Obesity appears to have protective effects on lung pathology and inflammatory responses in COPD, however, the underlying relationships between obesity, diet and disease outcomes in COPD are not fully understood. This study explored the relationship between the dietary ω-6 polyunsaturated fatty acid (PUFA) arachidonic acid (AA) and airway inflammation and remodeling, in primary human pulmonary fibroblasts in vitro from people with and without COPD. Also, the effect of body mass index (BMI) on the inflammatory response was assessed.

Methods: Primary human lung fibroblasts derived from COPD patients and non-COPD patients were challenged with BSA-conjugated AA for 48hr. Release of the pro-inflammatory cytokines, IL-6 and CXCL8, was measured using ELISA. Messenger RNA (mRNA) expression of the extracellular matrix (ECM) proteins, fibronectin (FN), collagen I (COL I) and tenascin (TNC) was measured using quantitative PCR.

Results: We found that challenge with AA results in increased IL-6 (p<0.05) release in COPD cells compared to non-COPD cells (n=24). Regression analysis revealed no relationship between BMI and cytokine release in COPD. AA reduced basal FN (P<0.01) and COL I (P<0.05) mRNA expression in fibroblasts from COPD patients (n=5).

Conclusion: This study demonstrates that AA, commonly found in obese diets, affects inflammatory processes and ECM deposition in COPD. COPD cells compared to non-COPD cells are hypersensitive to AA, suggesting that in COPD meals rich in ω-6 PUFAs are not as potent in the induction of inflammatory responses compared to other lung diseases. However, the reduced capacity to produce ECM proteins could negatively affect healing processes which is likely to manifest as perturbed and excessive tissue remodeling in COPD.

Grant Support: This work is funded by NHMRC Project Grant GNT1067511 and British Lung Foundation Grant PPRG15-10.
Lymphocyte senescence in COPD is associated with decreased SIRT1 expression in steroid resistant pro-inflammatory lymphocytes

HODGE G1,2, JERSMANN H1,2, HOLMES M1,2, REYNOLDS P1,2, HODGE S1,2
1Royal Adelaide Hospital, Adelaide, South Australia, Australia, 2Department of Medicine, University of Adelaide, Adelaide, South Australia, Australia

Introduction: Class III NAD-dependent histone deacetylase (HDAC) sirtuin 1 (SIRT1) is an important regulator of senescence, aging and inflammation through de-acetylation of chromatin histones thereby silencing inflammatory gene transcription. We have reported increased steroid resistant senescent pro-inflammatory CD28nullCD8+ T cells in patients with COPD. We hypothesized that expression of SIRT1 would be reduced in these cells in COPD and that treatment with SIRT1 activators (resveratrol) and agents that prevent NAD depletion (theophylline) would upregulate SIRT1 expression and reduce pro-inflammatory cytokine expression in these steroid resistant cells.

Methods: Blood was collected from COPD patients and aged matched controls and expression of CD28, SIRT1 and pro-inflammatory cytokines determined in CD28+ and CD8- T and NKT-like cells cultured in the presence of 1 μM resveratrol and 5.0mg/mL theophylline. CD28nullCD8+ T cells were identified in patients with COPD.

Results: Decreased SIRT1 expression was identified in CD28nullCD8+ T and NKT-like cells compared with CD28+ counterparts from both patients and controls (eg., CD28null 7±3% vs. CD28+ 55±5%). Loss of SIRT1 was associated with increased production of IFNγ and TNFα and steroid resistance. SIRT1 expression was upregulated in the presence of 1μM resveratrol and 5.0mg/mL theophylline and was associated with a decrease in steroid resistance and IFNγ and TNFα production by CD28nullCD8+ T and NKT-like cells.

Conclusion: Steroid resistance in pro-inflammatory CD28nullCD8+ T and NKT-like cells is associated with decreased SIRT1 expression. Combination resveratrol and/or theophylline treatment increases SIRT1 expression, restores steroid sensitivity and inhibits pro-inflammatory cytokine production from these cells and may reduce systemic inflammation in COPD.

Grant Support:

Estrogen affect the immune system and leads to more severe asthma in females

LEFFLER J1, LAUZON-JOSET J1, ABAD A1, SHORT B1, HOLT P1, STUMBLES P1,2,3, STRICKLAND D1
1Telethon Kids Institute, Subiaco, Western Australia, Australia, 2School of Veterinary and Life Sciences, Murdoch University, Murdoch, Western Australia, Australia, and 3School of Paediatrics and Child Health, The University of Western Australia, Perth, Western Australia, Australia

Introduction/Aim: Women have a higher incidence of asthma compared to men and exacerbations in women are often more severe and correlate with high estrogen levels. Using an experimental animal model for asthma, we have observed that female rats with experimental asthma also develop more severe exacerbations compared to male rats. The aim of the study was to investigate if the female sex hormone estrogen can impact the asthma response and identify the immunological mechanism for this effect.

Methods: By implanting estrogen-releasing pellets into male rats prior to ovalbumin-sensitisation and re-challenge we investigated how estrogen-exposed males responded compared to untreated males and females. We used multi parameter flow cytometry to investigate proportion and activation of antigen presenting dendritic cells, responding T effector and regulatory T cells in airways before and after allergen re-challenge.

Results: We discovered that estrogen was sufficient to induce a female-like disease phenotype during exacerbations in male rats. Interestingly, male and female rats also displayed significant differences in CD4+/CD8+ T cell ratios in airway draining lymph nodes and this was directly impacted by estrogen exposure. In addition, female and estrogen treated male rats, but not male rats, displayed signs of recruitment of CD4+ cells into the airways following allergen re-challenge which most likely contributed to the exacerbated response.

Conclusion: Our data suggest that estrogen is sufficient to induce female-like asthma symptoms in male rats and appears to alter the T cell balance promoting allergic responses.

Grant Support: The study was funded by the Asthma Foundation of Western Australia, the Telethon Kids Institute and the Swedish Society for Medical Research.
PERSONALIZED CELL CULTURE MODEL FOR HIGH-THROUGHPUT SCREENING FOLLOWING CFTR CORRECTION

LOOI K1, GARRATT L1, SUTANTO E1,2, KIDIC A1,3,4, STICK S1,2,3,4, AREST C1,2,5,6
1Telethon Kids Institute, Subiaco, Perth, Australia, 2Department of Respiratory Medicine, Princess Margaret Hospital for Children, Subiaco, Perth, Australia, 3School of Paediatrics and Child Health, The University of Western Australia, Nedlands, Perth, Australia, 4Centre for Cell Therapy and Regenerative Medicine, School of Medicine and Pharmacology, The University of Western Australia, Nedlands, Perth, Australia, 5Department of Respiratory Medicine, Royal Children’s Hospital, Melbourne, Australia, and 6Murdoch Children’s Research Institute, Melbourne, Australia

Introduction and Aims: Small molecules can correct CFTR production or function and greatly improve CF outcomes. Rarer mutations are hindered by the lack of appropriate primary culture models. Modifying primary airway epithelial cells (AECs) from children with CF modified to express a fluorescence marker that allows functional CFTR assessment would provide a culture-based high-throughput screening platform. We compared methodologies to achieve stable fluorescence in primary AEC.

Methods: Primary AECs were obtained from children (CF and non-CF) by bronchial brushing and cultured using a conditional reprogramming methodology. Cells were transfected with a pcDNA3.1 plasmid via Lipofectamine® or Nucleofector™ device. Alternatively, AEC were transduced by a replication-deficient retroviral vector with fluorescent tag. After 48 hours, cells expressing fluorescence were selected by fluorescence activated cell sorting (FACS) flow cytometry and then expanded further in culture to assess stability of gene expression.

Results: Primary AECs were amenable to all three methodologies. Transfection by Lipofectamine® was 24.1% efficient and the best electroporation protocol achieved a slightly higher efficiency (30.0%). Replication deficient retrovirus was most effective with 78.9% positive cells. There was no difference in transfection efficiency observed between non-CF and CF AECs. Cells could be successfully cultured after FACS selection, but only AEC transduced by retroviral vector maintained their fluorescence through two passages of cultures.

Conclusion: Retroviral vector could stably induce fluorescence into primary AECs. We are constructing a retroviral vector containing the YFP gene and validating the CFTR functional assay across a range of CFTR mutations.

Grant Support: BHP Billiton Telethon Kids Institute Blue Sky Research Grant

MANAGEMENT OF ACUTE COPD EXACERBATIONS: DO WE FOLLOW THE GUIDELINES?

COUSINS J1, WOOD-BAKER R1, WARK P3, YANG I1, HUTCHINSON A2, SAJKOV D1, GIBSON P3, MCDONALD V1,3
1School of Nursing and Midwifery, The University of Newcastle; Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute, New Lambton, Australia, 2School of Medicine, University of Tasmania, Hobart, Australia, 3School of Medicine and Public Health, The University of Newcastle; Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute; Department of Respiratory and Sleep Medicine, Hunter Medical Research Institute, John Hunter Hospital, New Lambton, Australia, 1The Prince Charles Hospital and University of Queensland, Brisbane, Australia, 2School of Nursing and Midwifery, Deakin University, Geelong, Australia, and 3Australian Respiratory and Sleep Medicine Institute, Flinders University and Flinders Medical Centre, Bedford Park, Australia

Introduction/Aim: Chronic Obstructive Pulmonary Disease (COPD) is the second leading cause of avoidable hospital admission in Australia, but to date no national data exists that compares the recommendations of clinical practice guidelines for inpatient management of acute exacerbations against actual practice. We aimed to compare contemporary management against the recommendations of the COPD-X guidelines.

Methods: A prospective audit of COPD hospital admissions from five tertiary care hospitals in five states in Australia was conducted. A standardised audit tool was used to collect data. Telephone follow-up at 28 days after discharge assessed readmission and health-status. Data were assessed against the COPD-X guidelines.

Results: Prospective data were obtained for 207 admissions in 171 patients between October 2012–April 2013. The mean±SD age was 70.2±9.9 years, 50.3% were male, and 95.3% caucasian. The mean number of comorbidities per patient was 3.6±1.9, with hypertension (48.5%), gastrointestinal disease (37.5%), ischaemic heart disease (28.5%), psychiatric/anxiety/depression disorders (28.1%) the most prevalent. Over half were ex-smokers (58.6%) and lived at home with another (56.2%). Of the 171 patients, 21.1% were readmitted within 28 days, there were 2 inpatients deaths (1.2%), and a further 9 deaths (5.3%) within 28 days of discharge.

Concordance to the COPD-X recommendations varied. Prescription of oral corticosteroids (95.1% [inter-hospital range 90-100%]), antibiotic therapy (89.2% [42.9-94.9%]), and performance of chest x-ray (99.5% [87.5-100%]) was high. However, performance of spirometry 22.3% (range 0-52.4%), written inpatient prescription of acute oxygen therapy 27% (range 3.2-76.9%), and referral to pulmonary rehabilitation 29.1% (range 10.3-50.8%) were poor.

Conclusion: Important gaps in management were seen nationally when compared against clinical practice guidelines.

Grant Support: Nil

Declaration of Interest: We declare that we have no conflicts of interest related to the above project.
ASSOCIATIONS OF TYPE-SPECIFIC PHYSICAL ACTIVITY WITH MORTALITY RISK IN COPD

CHENG S1, MCKEOUGH Z1, ALISON J2, DENNIS S1, HAMER M2, STAMATAKIS E2
1The University of Sydney, Sydney, Australia, and 2University of Loughborough, Loughborough, UK

Introduction/Aim: To examine the dose-response associations between specific types of physical activity (PA) and mortality risk in people with chronic obstructive pulmonary disease (COPD).

Methods: A prospective cohort study was used. People with COPD aged ≥40 years were identified from the 1997 Health Survey for England and the 1998 and 2003 Scottish Health Survey cohorts. Self-reported walking, domestic PA, and sport/exercise were assessed at baseline, and were classified into three groups: 1) No participation in that type of PA (the referent group); 2) below the median level of activity of the cohort (‘Low’); or 3) equal to or above the median level of activity of the cohort (‘High’). The medians were 5.25 metabolic equivalent (MET)-hours/week for walking, 5.70 MET-hours/week for domestic PA, and 8.00 MET-hours/week for sport/exercise. Cox proportional hazards models were used to examine the association between PA and mortality risk.

Results: 2398 participants with COPD were included in the analysis (mean age (SD) 62.6 (11.5), mean FEV1% predicted 73.4% (25.4), 52% men). Over 8.5 (3.9) years follow-up, there were 571 deaths. Dose-response associations with mortality risk were demonstrated for walking, 5.70 MET-hours/week for domestic PA, and sport/exercise, but not for domestic PA. Compared to the referent group, participants in the ‘High’ walking group had a reduced mortality risk (hazard ratio (HR) 0.70, 95% confidence interval (CI) 0.56 to 0.88), as did participants in the ‘High’ sport/exercise group (HR 0.69, 95% CI 0.51-0.93). No significant mortality risk reductions were observed in the ‘Low’ groups for walking or sport/exercise.

Conclusion: Walking and structured exercise should be encouraged in people with COPD to gain mortality benefit, but the effects of domestic PA on mortality remain unclear.

Grant support: ES is funded by the National Institute for Health Research (UK) (award code: CDF2010-03-30) and the National Health and Medical Research Council (award code: APP1110526) for dataset acquisition, processing and harmonisation.

OXYGEN SUPPLEMENTATION DURING EXERCISE TRAINING IN COPD: A RCT

ALISON J1,2, MCKEOUGH Z1, JENKINS S3,4, HOLLAND A5,6, HILL K4, MORRIS N7,8, LEUNG R7, SPENCER L7, HILL C1,5, LEE A3, SEALE H4, CECINS N2, MCDONALD C1,12
1Discipline of Physiotherapy, Faculty of Health Sciences, University of Sydney, Sydney, Australia, 2Department of Physiotherapy, Royal Prince Alfred Hospital, Sydney, Australia, 3Department of Physiotherapy, Sir Charles Gairdner Hospital, Perth, Australia, 4School of Physiotherapy and Exercise Science, Curtin University, Perth, Australia, 5Discipline of Physiotherapy, School of Allied Health, La Trobe University, Melbourne, Australia, 6Department of Physiotherapy, Alfred Health, Melbourne, Australia, 7School of Allied Health Sciences, Griffith University, Brisbane, Australia, 8Lung Heart Program, The Prince Charles Hospital, Brisbane, Australia, 9Department of Respiratory and Sleep Medicine, Concord Hospital, Sydney, Australia, 10Department of Physiotherapy, Austin Health, Melbourne, Australia, 11Department of Respiratory and Sleep Medicine, Austin Health, Melbourne, Australia, and 12Department of Medicine, University of Melbourne, Melbourne, Australia

Introduction/Aim: Approximately 47% of people with chronic obstructive pulmonary disease (COPD), referred to pulmonary rehabilitation, desaturate during exercise.

The aim was to determine whether supplementary oxygen during exercise training was more effective than medical air in improving exercise capacity and health-related quality of life in people with COPD who desaturated to < 90% during the six-minute walk test.

Methods: Multi-centre randomised controlled trial with randomisation (independent, concealed allocation), blinding (participants, exercise trainers and assessors) and intention-to-treat analysis. Participants were randomised to either an Oxygen Group (OG) or Air Group (AG). Both groups received the respective gas from a concentrator via nasal prongs at 5 litres/minute during exercise training of treadmill and cycle exercise, three times/week for eight weeks. Primary outcome measures were the endurance shuttle walk test (ESWT) and the Chronic Respiratory Questionnaire (CRQ). The study had ethics approval and trial registration.

Results: 111 participants (60 males), mean (SD) age 69 (7) years, mean FEV1/FVC 0.43 (0.13), FEV1 46 (17) % predicted were recruited and 97 completed (OG n=52; AG n=45). Within-group changes at 8 weeks were significant for ESWT, CRQ Total (T), CRQ Dyspnoea (D) (ESWT: OG mean difference [95%CI]: 163 s [76, 249]; AG 149 s [56, 242]; CRQ T: OG 0.4 points (pts) [0.2, 0.7]; AG 0.5 pts [0.2, 0.7]; CRQ D: OG 0.6 pts [0.3, 0.9]; AG 0.7 pts [0.3, 1.0] (all p<0.01). There were no between group differences with p>0.05 for all outcomes.

Conclusion: Exercise capacity and health-related quality of life improved significantly in both groups, with no greater benefit from training with supplemental oxygen than with medical air. This is the largest rigorous RCT to report such findings.

Grant Support: NHMRC Project grant (App1019989)
REDUCTION IN THE RATE AND RISK OF MODERATE OR SEVERE EXACERBATIONS WITH ONCE-DAILY INDACATEROL/GLYCOPYRRONIUM COMPARED WITH TWICE-DAILY SALMETEROL/FLUTICASONE IN A SUBSET OF GOLD GROUP D COPD PATIENTS WITH A HISTORY OF ≥2 EXACERBATIONS OR 1 HOSPITALIZATION: THE FLAME STUDY

BANERJI D1, VOGELMEIER C2, WEDZICHA J3, DONOHUE J4, FUCILE S1, YADO A1, AYERS T1, THACH C1, OLSSON P5, FOWLETTAYLOR A1, FOGEL R1, PATALANO F6

1Novartis Pharmaceuticals Corporation, East Hanover, 2University Medical Center Giessen and Marburg, Marburg, Germany, 3National Heart and Lung Institute, Imperial College London, London, UK, 4Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, 5Novartis Sverige AB, Taby, Sweden, and 6Novartis Pharma AG, Basel, Switzerland

Introduction: The FLAME study demonstrated the superiority of indacaterol/glycopyrronium (110/50 μg, once daily), in reducing exacerbations, improving lung function, and health status versus salmeterol/fluticasone in moderate-to-very severe COPD patients with a history of exacerbations. We assessed the effect of indacaterol/glycopyrronium versus salmeterol/fluticasone on the rate and risk of moderate or severe exacerbations in a subset of GOLD Group D patients who had a history of ≥2 exacerbations or 1 hospitalization for exacerbation from the FLAME study.

Methods: FLAME was a 52-week, randomized, double-blind, double-dummy, parallel-group study. Patients with moderate-to-very severe COPD, post-bronchodilator FEV1 ≥25% to <60% predicted normal, and a history of ≥1 exacerbation in the previous year were randomized (1:1) to receive either indacaterol/glycopyrronium (110/50 μg) once-daily or salmeterol/fluticasone (50/500 μg) twice-daily. The rate and time to moderate or severe exacerbations were analyzed in the subset of GOLD Group D patients.

Results: Of the 3362 patients randomized, 2514 were categorized as GOLD Group D. The mean post-bronchodilator FEV1 was 44.1% of the predicted normal value and 56.3% patients were on ICS at screening. Indacaterol/glycopyrronium demonstrated superior efficacy over salmeterol/fluticasone in reducing the rate of moderate or severe exacerbations (rate ratio, 0.86; Table). The patients treated with indacaterol/glycopyrronium delayed the time-to-first moderate or severe exacerbation compared with salmeterol/fluticasone (median days: 291 versus 215; Table). The patients treated with indacaterol/glycopyrronium had a 19% lower risk of a moderate or severe exacerbation compared with salmeterol/fluticasone.

Conclusion: Indacaterol/glycopyrronium was superior to salmeterol/fluticasone in reducing the rate and risk of moderate or severe exacerbations in subset of GOLD Group D patients with a history of ≥2 exacerbations or 1 hospitalization for exacerbation, confirming its use as a preferred treatment option for COPD patients at high risk of exacerbations.

Grant Support: Novartis Pharma AG, Basel

REFERENCE

Table 1  Effect of indacaterol/glycopyrronium versus salmeterol/fluticasone on moderate or severe exacerbations in the subset of GOLD Group D patients with a history of ≥2 exacerbations or 1 hospitalization for exacerbation

<table>
<thead>
<tr>
<th>Annualized rate</th>
<th>Indacaterol/glycopyrronium (n=531)</th>
<th>Salmeterol/fluticasone (n=503)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rate (95% CI)</td>
<td>1.26 (1.06 to 1.51)</td>
<td>1.47 (1.24 to 1.75)</td>
</tr>
<tr>
<td>Rate ratio* (95% CI)</td>
<td>0.86 (0.74 to 1.00)</td>
<td></td>
</tr>
<tr>
<td>P value</td>
<td>0.05</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time-to-first exacerbation</th>
<th>Indacaterol/glycopyrronium (n=536)</th>
<th>Salmeterol/fluticasone (n=511)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with event, n (%)</td>
<td>281 (52.4)</td>
<td>299 (58.5)</td>
</tr>
<tr>
<td>Patients without event, n (%)</td>
<td>255 (47.6)</td>
<td>212 (41.5)</td>
</tr>
<tr>
<td>Time at risk (days), median (range)</td>
<td>247.5 (1 to 419)</td>
<td>181 (2 to 386)</td>
</tr>
<tr>
<td>Time-to-event (days), median (95% CI)</td>
<td>291 (254 to 352)</td>
<td>215 (175 to 261)</td>
</tr>
<tr>
<td>Hazard ratio* (95% CI)</td>
<td>0.81 (0.69 to 0.96)</td>
<td></td>
</tr>
<tr>
<td>P value</td>
<td>0.013</td>
<td></td>
</tr>
</tbody>
</table>

* indacaterol/glycopyrronium versus salmeterol/fluticasone
PARENTAL RESPIRATORY DISEASE IS ASSOCIATED WITH REDUCED OFFSPRING LUNG HEALTH AT AGE 45 VIA PATHWAY OF MATERNAL AND PERSONAL SMOKING

LI L1, WILLIAMS M1, JOHNSTON K1, FRITH P1, HYPPONEN E1, PAQUET C1
1University of South Australia, Adelaide, South Australia, Australia

Introduction: Familial aggregation of chronic lung conditions may result from a combination of genetic susceptibility and exposure to risk factors throughout life. We used a life-course approach to investigate factors contributing to the relationship between parental respiratory disease history and Reduced Lung Health (RLH) in adulthood using data from the 1968 British Birth Cohort Study.

Methods: Cohort participants (n=6304) were characterised in terms of RLH (presence of respiratory symptoms at 42yrs and airway obstruction [FEV1/FVC<0.7 at 45yrs]) and parental history of respiratory disease (at offspring age 0,11,16yrs).

Life-course factors evaluated were maternal smoking (0yrs), living with smoker (16,23,33,42yrs), social class (0,7,16,23,33,42yrs), respiratory illness (7,11,16,23,33,42yrs), smoking status (23,33,42yrs), and occupational exposure to dust or fumes (33,42yrs), operationalised for life periods (birth, childhood [7,11,16yrs], adulthood [23,33,42yrs]). Path analysis was used to investigate the mediating role of life-course factors in the relationship between parental respiratory disease history and RLH, adjusting for gender, asthma and recent chest infection.

Results: Within this cohort, 3.7% had a parental respiratory history and 6.3% of offspring had RLH. Parental respiratory history was positively associated with RLH (p=0.023). Maternal smoking during pregnancy, personal smoking in adulthood, social class (0, 23 and 42yrs) and occupational exposure to dust or fumes were the only factors related to both parental history and RLH. Mediating pathway testing indicated that the sequence through maternal and adulthood smoking contributed most to parental history and RLH relationship.

Conclusion: An association between parental history of respiratory disease and offspring RLH at 45yrs was partly mediated by a sequence of exposure to maternal smoking and being a smoker during their adulthood. A large proportion of the relationship between parental history-RLH remains unexplained by smoking, suggesting that assessing parental history of respiratory disease may provide insights into earlier diagnosis and intervention.

Grant Support: Australian Government Research Training Program Scholarship (LSK Li)

ASSOCIATIONS OF ACTIVITY PHENOTYPES WITH HEALTH OUTCOMES IN COPD

MCKEOUGH Z1, CHENG S1, ALISON J1,2, JENKINS C3, STAMATAKIS E1
1Discipline of Physiotherapy, The University of Sydney, Sydney, New South Wales, Australia, 2Allied Health Professional Unit, Sydney Local Health District, Sydney, New South Wales, Australia, 3Respiratory Discipline, The University of Sydney, Sydney, New South Wales, Australia, and 4School of Public Health, The University of Sydney, Sydney, New South Wales, Australia

Introduction/Aim: To examine the association of four activity phenotypes with mortality and cardiometabolic risk factors in people with Chronic Obstructive Pulmonary Disease (COPD).

Methods: A prospective cohort was analysed. People with COPD aged >40 years who were current or ex-smokers were identified from the 2003 Scottish Health Survey and grouped into one of the following activity phenotypes based on their self-reported activity levels: 1) ‘Couch Potatoes’: insufficiently active with high leisure-based sitting time and/or no domestic physical activity (PA); 2) ‘Light Movers’: insufficiently active with some domestic PA; 3) ‘Busy Bees’: sufficiently active with low leisure-based sitting time; or 4) ‘Sedentary Exercisers’: sufficiently active with high leisure-based sitting time. ‘Sufficiently active’ involved adhering to PA recommendations of ≥7.5 metabolic equivalent (MET) hours per week. ‘Low leisure-based sitting time’ was defined as ≤200 minutes of recreational screen time per day. Associations between the phenotypes with mortality and cardiometabolic outcomes was made using Cox proportional hazards models or binary logistic regression models respectively.

Results: The sample comprised 584 participants (mean age (SD) 63.8 (11.5) years, 52% male). Over 5.5 (1.3) years follow-up, there were 81 all-cause deaths from 433 COPD participants with available data. Compared to the ‘couch potatoes’, there was a reduced risk of all-cause mortality in the ‘busy bees’ (hazard ratio 0.26, 95% confidence interval (CI) 0.11-0.65) with a trend towards a reduction in mortality risk in the other phenotypes (p-trend = 0.02). There was a reduced risk of diabetes compared to the ‘couch potatoes’ (odds ratio 0.14, 95% CI (0.03 to 0.67)).

Conclusion: This analysis demonstrated a mortality benefit and reduced risk of diabetes in people with COPD when leisure-based sitting time was low and PA guidelines were adhered to, indicating the health benefits of PA and the importance of measuring these activity outcomes in the COPD population.

Grant Support: Nil
Declaration of Interest: Nil.
Nomination for Awards: Physiotherapy.
Conflicts of Interest: Nil
THE PHYSIOLOGICAL PROPERTIES OF THE KANGAROO AIRWAY

WONG J1, WANG K1,2, HENRY P3, MALONEY S1, NOBLE P1,4
1School of Human Science, The University of Western Australia, Perth, Australia, 2Clinical Sciences, Telethon Kids Institute, Subiaco, Australia, 3School of Medicine and Pharmacology, The University of Western Australia, Crawley, Australia, and 4Centre for Neonatal Research and Education, School of Pediatrics Child Health, The University of Western Australia, Crawley, Australia

Introduction/Aim: Comparative physiology is a powerful approach to help understand the relationship between structure and function. The kangaroo exhibits a unique breathing mechanism when hopping: respiration depends more on motional forces and less on active contraction of the diaphragm. We asked how structural and mechanical properties of the kangaroo airway might accommodate the respiratory pressures generated during hopping. This study compared mechanical and structural properties of airways from kangaroos and sheep, the latter of which is not subject to the same motion-driven movement of air.

Methods: Bronchial segments from kangaroos (n=8) and sheep (n=12) were mounted in an organ bath chamber. Pressure-volume curves were obtained between -10 and 20 cmH2O before and after theophylline. Airway stiffness was calculated from the change in pressure over normalized volume (A volume/initial volume). Closing pressure (pressure required for airway collapse) and airway wall morphology were also assessed. Data is mean±SEM.

Results: The stiffness of kangaroo airways was less than in sheep (kangaroo, 6±2 cmH2O; sheep, 16±4 cmH2O; p<0.05). Theophylline caused a reduction in sheep airway stiffness (p<0.05) but had no effect on kangaroo airway stiffness, suggesting a role for smooth muscle tone in the former. Kangaroo airways also required a less negative pressure for collapse compared with sheep airways (kangaroo, -15±3 cmH2O; sheep, -30±3 cmH2O; p<0.05; Kangaroo airway had a thicker inner (p<0.05) and thinner outer wall (p<0.05) compared with the sheep airway. While the total thickness of cartilage was comparable between groups, there were a greater number (p<0.05) of smaller (p<0.05) cartilage plates in the kangaroo airway.

Conclusion: Kangaroo airways have low stiffness and are more collapsible compared with sheep airways. Fragmented cartilage plates and absence of smooth muscle tone contributes to the lower stiffness. Low airway stiffness may maintain functional residual capacity during hopping in response to large variations in respiratory pressures.

Grant Support: N/A
Declarations of Interest Statement: None.
FORCED OSCILLATION TECHNIQUE REFLECTS COMMUNICATING LUNG VOLUME (VA/TLC RATIO), BUT NOT TOTAL LUNG CAPACITY, IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE

MILNE S1,3,4,8, CHAPMAN D1,2, FARAH C1,4,8, THAMRIN C1, KING G1,3,8

1 Woolcock Emphysema Centre, Woolcock Institute of Medical Research, University of Sydney, Glebe, Australia, 2 Department of Respiratory and Sleep Medicine, Royal North Shore Hospital, Northern Sydney Local Health District, St Leonards, Australia, 3 Department of Respiratory Medicine, Concord Repatriation General Hospital, Sydney Local Health District, Concord, Australia, 4 Northern Clinical School, Sydney Medical School, University of Sydney, Campden Park, Sydney, Australia, 5 Central Clinical School, Sydney Medical School, University of Sydney, Campden Park, Sydney, Australia, and 6 School of Life Sciences, University of Technology Sydney, Ultimo, Australia

Introduction/Aim: The lung in COPD demonstrates expiratory flow limitation, airway closure and ventilation heterogeneity. Reactance at 5 Hz (X5) measured by the forced oscillation technique (FOT) is influenced by each of these pathophysiological phenomena, but is also dependent on lung volume. In the presence of airway closure, where oscillating pressure waves are not able to penetrate all lung segments, X5 may not relate to total thoracic gas volume. Single-breath alveolar volume (VA), measured during the diffusing capacity test, estimates the communicating gas volume by dilution during a breath hold. The ratio of VA to plethysmographic total lung capacity (TLC), or VA/TLC, is therefore reduced in obstructive airways disease due to incomplete gas mixing and gas trapping. We hypothesised that X5 would relate to VA/TLC but not TLC in COPD.

Methods: 15 subjects with mild-moderate COPD (11 male, mean (range) age 68 (58-79), mean ± SD %pred FEV1 64 ± 17) were tested using FOT (Thorasys tremoFlo c100) during 60 s normal tidal breathing. Spirometry, body plethysmography and the single-breath diffusing capacity test were then performed according to standard quality criteria. Spearman rank correlation coefficients were determined before and after adjustment for known covariates from published reference equations.

Results: X5 was moderately correlated with VA/TLC (r = 0.66, p = 0.008) and VA (r = 0.58, p = 0.03) but not with TLC. After adjustment for known covariates, X5 Z-score remained moderately correlated with VA/TLC (r = 0.60, p = 0.02) but not VA or TLC Z-scores. VA/TLC correlated with the severity of airflow obstruction measured by FEV1/FVC ratio Z-score (r = 0.77, p = 0.001).

Conclusion: In COPD, X5 measured by FOT during normal tidal breathing reflects the communicating lung volume rather than the total lung volume. FOT therefore may compliment traditional lung function measurements.

PHYSIOLOGICAL RESPONSES TO THE SIX MINUTE WALK TEST AND MAXIMAL EXERCISE TESTING IN PULMONARY HYPERTENSION

MORRIS N1,3,4, LIN A1,3,4, HARRIS J1,4, SABARATNAM M1, FEENSTRA J4, SEALE H4

1 School of Allied Health Sciences, Griffith University, Gold Coast, Australia, 2 Allied Health Research Collaborative, The Prince Charles Hospital, Brisbane, Australia, 3 Menzies Health Institute, Griffith University, Gold Coast, Australia, 4 Heart Lung Institute, The Prince Charles Hospital, Brisbane, Australia

Introduction/Aim: The six minute walk test (6MWT) remains the most commonly used clinical measure of exercise capacity in pulmonary hypertension (PH). Whilst maximal exercise testing using a cardiopulmonary exercise test (CPET), remains the gold standard estimate of exercise capacity, this test is much less common in clinical practice. The purpose of this study was to compare the physiological responses to the 6MWT and CPET in a group of PH subjects.

Methods: Eighteen individuals with Group I/IV PH patients (Functional Class I-III) completed a CPET on a cycle ergometer and a 6MWT on separate days. During both tests, gas exchange was measured using a calibrated portable metabolic system (Cortex, Metamax). Oxygen uptake (VO2), carbon dioxide production (VCO2), ventilation (Vt), heart rate (HR), oxygen (O2) pulse, VO2/VCO2, end tidal carbon dioxide (PetCO2), oxygen saturation (Spo2), and breathlessness (Borg, 0-10) were averaged over the final 30s and compared between the 6MWT and CPET. In a subgroup of 8 participants, end exercise lactate (HLa) was also measured using a portable lactate analyser (Lactate Scout).

Results: The mean peak power achieved by participants was 74 ± 20 W, whilst the mean 6MWT distance was 574 ± 89m. There was no significant difference between CPET and the 6MWT for peak VO2 (CPET: 15.5 ± 3.8 ml.kg⁻¹.min⁻¹), Vt (54.7 ± 13.8 vs 49.7 ± 15.8 L.min⁻¹), HR (136 ± 22 vs 143 ± 27 beats.min⁻¹), O2 pulse (6.8 ± 1.3 vs 7.0 ± 1.7 ml.beat⁻¹), VO2/VCO2 (35 ± 6 vs 36 ± 5), PetCO2 (30 ± 5 vs 29 ± 4 mmHg) or Spo2 (88 ± 11 vs 87 ± 14%). Peak VCO2 (1.4 ± 0.4 vs 1.2 ± 0.31 L.min⁻¹), breathlessness (5.5 ± 2.2 vs 3.6 ± 1.9) and lactate (8.5 ± 1.5 vs 5.0 ± 1.9) were all significantly higher (p<0.05) with CPET.

Conclusion: We found that the physiological responses to CPET and 6MWT in our group of PH participants were similar. This would suggest that the 6MWT is similar to a peak exercise challenge the PH population.

Grant Support: Office for Health and Medical Research, Queensland

Respirology (2018) 23 (Suppl. 1), 21–103

Copyright of individual abstracts remains with the authors.
EFFECTIVENESS OF A SUBMAXIMAL CYCLE TEST TO PRESCRIBE TRAINING INTENSITY

DOWMAN L1,2,3, RINGIN C1, GERGELY K1, HILL C1,3
1Physiotherapy, Austin Health, Heidelberg, Victoria, Australia, 2Department of Respiratory & Sleep Medicine, Austin Health, Heidelberg, Victoria, Australia, and 3Institute for Breathing and Sleep, Heidelberg, Victoria, Australia

Introduction/Aim: In pulmonary rehabilitation (PR), cycle training is recommended at 60% peak oxygen uptake measured during cardiopulmonary exercise testing (CPET). However, access to CPET is limited and estimation of an equivalent intensity from the 6-minute walk distance (6MWD) using published equations is associated with substantial variation. This study aimed to investigate whether a submaximal cycle exercise test (SMCT) can prescribe appropriate cycle training intensity and whether initial training intensity estimated from 6MWD and SMCT is similar.

Methods: Retrospective data was collected from patients who attended PR over the previous 12 months. Each patient routinely performed a 6-minute walk test at baseline and completed a SMCT during the second exercise session. In the subsequent exercise session, cycle training was prescribed at 50% of peak work (Watts) achieved on SMCT. Initial intensity was considered appropriate if the patient could complete 15 minutes as prescribed with a reported dyspnoea and/or RPE score of 3-4 on the Borg 0-10 score.

Results: Forty-three patients (23 male) with chronic lung disease (23 COPD, 10 ILD, 10 other) were included, with mean (SD) age of 70(11), 6MWD 437(86) metres and SMCT peak work of 60(22) watts. Eight one percent of patients achieved the target intensity, 16% found the initial workload too easy and 2% were unable to maintain the target intensity. There was a moderate correlation between work rate predicted from 6MWD 35(8) Watts and SMCT 30(11) Watts (r= 0.71, p<0.001). Estimating cycle training intensity from 6MWD over-predicted (>5 Watts) appropriate training in 44% patients and under-predicted in 7%.

Conclusions: In chronic lung disease, prescribing cycle exercise intensity at 50% of SMCT peak work achieves an appropriate training intensity that was tolerated by > 80% of patients. Prescribing work rate from SMCT and 6MWD results in similar training loads, although SMCT may provide more accurate cycle training intensity.

Grant support: nil

FATTY ACIDS DO NOT ALTER BOVINE TRACHEALIS MUSCLE CONTRACTILITY

CHAPMAN D1,2,3, BAROFFIO M4, CHIAPPORI A4, IRVIN C2, BRUSASCO V4
1University Of Technology Sydney, Ultimo, Australia, 2University of Vermont, Burlington, USA 3Woolcock Institute of Medical Research, Glebe, Australia, and 4University of Genoa, Genoa, Italy

Introduction/Aim: Increased dietary fat is associated with an increased risk of asthma and airway hyperresponsiveness. A single high fat meal reduces the efficacy of salbutamol, suggesting that dietary fatty acids may alter airway smooth muscle (ASM) contractility. Therefore our aim was to determine the effect of fatty acids on in vitro bovine trachealis smooth muscle responsiveness to relaxant and contractile stimuli.

Methods: Oleic acid, linoleic acid, alpha-linolenic acid, palmitic acid, stearic acid and elaidic acid were compared at 10-5M. Bovine trachealis muscle strips (n = 7/group/experiment) were mounted in tissue baths with warmed, aerated Krebs solution. All experiments were done in the presence of tetrodotoxin (10-6M). To test sensitivity to relaxant stimuli, muscle strips were contracted with acetylcholine (half maximal effective concentration, EC50) before addition of vehicle or fatty acid and cumulative dose-response curves to isoproterenol (10-9Mt o1 0-4M) performed. To test sensitivity to contractile stimuli, separate muscle strips were incubated with vehicle or fatty acid for 20min before cumulative dose-response curves to acetylcholine (10-7M to 10-5M) were performed.

Results: In the relaxation experiment, ASM force following acetylcholine was not affected by addition of any of the fatty acids. Similarly, there was no effect of fatty acid on the EC50 concentration to isoproterenol (RANOVA p = 0.52). In the contraction experiment, baseline force was unaltered by addition of any of the fatty acids. Similarly, there was no effect of fatty acid on the EC50 to acetylcholine (RANOVA p = 0.86).

Conclusion: Dietary fatty acids do not alter bovine trachealis ASM function.

Grant Support: DGC was supported by a European Respiratory Society Short-term Research Fellowship (STRTF 2015 – 8388)
QUANTIFICATION OF PIPERACILLIN AND TAZOBACTAM IN PLASMA AND PLEURAL FLUID MEASURED BY A NOVEL LC-MSMS ASSAY

POPOWICZ N1,2,3, H’ALLORAN S2,4, FITZGERALD D5, LEE Y1,2,5, JOYCE D2,4

1Pleural Medicine Unit, Institute for Respiratory Health, Perth, Western Australia, Australia, 2School of Medicine, University of Western Australia, Perth, Western Australia, Australia, 3Department of Pharmacy, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia, 4PathWest, Clinical Pharmacology and Toxicology, Perth, Western Australia, Australia, and 5Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia

Introduction: Piperacillin (PIP) with tazobactam (TAZ) is commonly used for treatment of pleural infection, the pleural pharmacokinetics however, have not been reported. We developed and validated a rapid and sensitive ultra-performance liquid-chromatography with tandem mass-spectrometry assay for quantification of PIP/TAZ.

Methods: Both drugs were extracted from human plasma and pleural fluid by protein precipitation in methanol containing internal standards (IS) piperacillin-d5 and sulbactam. 5uL of sample was mixed with 125uL of methanol containing IS, vortexed and centrifuged. Supernatant was diluted into mobile phase containing 10mM of ammonium bicarbonate and water. The chromatographic separation was achieved using an Acquity BEH C-18 column.

This method was applied to two patients with pleural infection. Six pleural fluid and blood samples were obtained at steady-state before and over 6-hours post-infusion of 4500mg-PIP/TAZ.

Results: Electrospray ionisation in positive mode and multiple reaction monitoring (MRM) were used for PIP and piperacillin-d5 at the transitions m/z 518.2—143.2 and m/z 523.2—148.2 respectively and in negative mode for TAZ and SUL at the transitions m/z 299.1—138.1 and m/z 232.4—140.1. Linearity was observed over the concentrations of 0.25-352mg/L and 0.25-50.5mg/L for PIP and TAZ respectively. Complete method validation was performed according to US FDA guidelines for selectivity, specificity, precision, accuracy, matrix effects and stability; results were within acceptable limits.

In both patients, the time to maximum concentration (Cmax) for PIP and TAZ in pleural fluid were delayed compared to plasma. The Cmax for PIP in pleural fluid reached 63mg/L and 59mg/L at 90 and 150-minutes in each patient. This was 77% and 52% of the Cmax achieved in plasma for each patient respectively.

Conclusion: The two cases had notably different concentration-time profiles for both drugs in pleural fluid but did not differ in systemic elimination of PIP/TAZ. The assay is feasible to use for future pharmacokinetic studies.

Grant Support: NHMRC; Cancer Council WA; Cancer Australia; NSW Dust Diseases Board (YCGL); Sir Charles Gairdner Research Advisory Group (NP, YCGL, SQ, DAJ); WA Cancer & Palliative Care Network (DF).
HIGH LEVELS OF HOSPITAL HEALTH CARE UTILIZATION ASSOCIATED WITH BRONCHIECTASIS

MAGUIRE G1, KING P2, WONG C2, MORGAN L4, MIDDLETON P5
1Baker Heart and Diabetes Institute, Melbourne, Australia, 2Monash Medical Centre, Clayton, Australia, 3Middlemore Hospital, Auckland, New Zealand, 4Concord Hospital, Sydney, Australia, and 5Westmead Hospital, Sydney, Australia

Introduction/Aim: Bronchiectasis not related to cystic fibrosis (non-CF BEx) is an increasingly recognised cause of chronic lung disease that can occur in isolation or with other lung diseases including asthma and COPD. In other settings bronchiectasis is associated with significant health care utilisation but its impact in both Australia and New Zealand is poorly understood, including for Indigenous populations. We aimed to described the impact of non-CF BEx on inpatient hospital care in this setting.

Methods: A multicentre Australian and New Zealand retrospective audit of hospital admission data relating to patients with non-CF BEx admitted once or more to five hospitals in Melbourne, Sydney and Alice Springs (Australia) and Auckland (New Zealand) was undertaken. The number and length of stay (LOS) of respiratory admissions was determined. For Melbourne, Alice Springs and Auckland additional information was obtained regarding the requirement for ventilatory support.

Results: Data regarding hospitalisation are presented below.

<table>
<thead>
<tr>
<th></th>
<th>Australian Indigenous</th>
<th>Australian non-Indigenous</th>
<th>New Zealand Indigenous</th>
<th>New Zealand non-Indigenous</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of participants</td>
<td>85</td>
<td>157</td>
<td>85</td>
<td></td>
</tr>
<tr>
<td>Admission (no/pers.yr)</td>
<td>2.9</td>
<td>0.7</td>
<td>0.4</td>
<td>0.7</td>
</tr>
<tr>
<td>LOS (day/pers.yr)</td>
<td>16.9</td>
<td>6.4</td>
<td>3.1</td>
<td>4.1</td>
</tr>
<tr>
<td>LOS (med, IQR)</td>
<td>(16.4-17.3)</td>
<td>(6.1-6.7)</td>
<td>(2.9-3.3)</td>
<td>(4.0-4.3)</td>
</tr>
<tr>
<td>Ventilate %</td>
<td>50.6</td>
<td>19.0</td>
<td>6.7</td>
<td>7.6</td>
</tr>
<tr>
<td>non-invasive</td>
<td>37.6</td>
<td>17.7</td>
<td>6.7</td>
<td>1.2</td>
</tr>
<tr>
<td>invasive</td>
<td>8.2</td>
<td>5.1</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>(95% CI)</td>
<td>(3.4-16.2)</td>
<td>(1.4-12.5)</td>
<td>(0.0-2.3)</td>
<td>(0.0-4.2)</td>
</tr>
</tbody>
</table>

Conclusion: Health care utilisation for non-CF BEx is substantial. The number of admissions varies substantially by site as does the cumulative LOS. Average LOS also varies and Australian patients have longer LOS compared to NZ patients. Indigenous Australian patients have a shorter LOS compared with non-Indigenous counterparts despite more frequent admission and overall greater hospitalisation days. LOS is comparable to COPD (ranging from 4.1-7.3 days in Australia) and the frequency of admission for non-CF BEx is likely to be the major factor driving hospital-based health care utilisation. The utilisation of ventilatory support varies by country and is particularly high in Indigenous Australians. The impact and optimal level of admission frequency, LOS and ventilatory support on subsequent representation to hospital, quality of life and survival should be a focus of further investigation.

Grant Support: Australia Bronchiectasis Consortium – Lung Foundation of Australia.
RIFAMPICIN MONO-RESISTANT TUBERCULOSIS IN QUEENSLAND, AUSTRALIA

GIBSON J1,2, EATHER G1,2
1Respiratory and Sleep Medicine Department, Princess Alexandra Hospital, Brisbane, Australia, and 2Metro South Clinical Tuberculosis Service, Princess Alexandra Hospital, Brisbane, Australia

Introduction/Aim: Drug resistant tuberculosis (TB) is an emerging problem. Rifampicin resistance is rare and is usually seen in multi-drug resistant (MDR) TB. Rifampicin mono-resistant (RMR) TB is less common.

The World Health Organization recommends RMR-TB should be treated as per MDR TB guidelines. This requires prolonged treatment with second line agents including intravenous aminoglycosides, and is associated with increased risk of toxicity and cost. The evidence to support this recommendation in RMR-TB is lacking.

We predicted MDR TB regimens are not commonly used in Queensland for RMR-TB and to confirm this we carried out a study to examine the clinical features, treatment regimens and outcomes of RMR-TB in Queensland, Australia.

Methods: This retrospective case series identified all cases of RMR-TB in Queensland from 2000 to 2016. Data was gathered through the Notifiable Conditions System database with cross-reference using medical records.

Results: Twelve cases of RMR-TB were identified. The mean age was 29.1 years. All patients were overseas born. Nine cases (75%) had pulmonary disease.

Drug susceptibility testing confirmed isolates were resistant to Rifampicin and sensitive to other first line agents (Isoniazid, Pyrazinamide and Ethambutol).

Complete data on treatment and outcomes were available for 8 cases. No patients were treated with a MDR TB regimen. All patients who completed treatment in Queensland were cured. The mean duration of treatment was 14.6 months. The majority of patients were treated with the first line agents plus Moxifloxacin was added to the regimen in 5 cases. Only 1 patient received intravenous Amikacin.

Conclusion: This study confirms RMR-TB is rare in Queensland but is not being managed with MDR TB regimens. Generally an extended regimen with first line agents +/- a Fluoroquinolone was used. These regimens achieved good outcomes with 100% cure rates. Management of RMR-TB requires further studies to determine the optimal treatment regimens are not necessary.

Grant Support: Nil

5-YEAR OUTCOME AND RAPID SCORE: AN AUSTRALIAN PLEURAL INFECTION COHORT

GODDARD J1, LAW B2, AZZOPARDI M3
1Respiratory Department, Sunshine Coast University Hospital, Birtinya, Queensland, Australia

Introduction/Aim: Mortality from pleural infection (PI) remains high. Many patients die after successful treatment of their PI. Few studies report on longer term outcomes and cause of death; one US study reported 76% 5-year mortality. The RAPID score is a recently introduced risk stratification tool for PI, encompassing 5 parameters - age, renal function, pleural fluid purulence, infection source and serum albumin. We aimed to validate the RAPID score in our single centre cohort, and examine longer term outcomes and cause of mortality.

Methods: All cases of PI treated at Nambour General Hospital 1st July 2007 – 1st July 2012 were reviewed. PI was defined by positive pleural fluid gram stain or culture or complicated parapneumonic effusion. Data until date of censor (1st July 2017) was extracted from hospital records and electronic pathology database. In-hospital and 5-year mortality was 17.1% and 5-yr mortality 46.3%. Most cases were stratified as medium-risk by RAPID score (low n=12, medium n=21, high n=8). In-hospital mortality for low-, medium- and high-risk groups was 0%, 28.6%, 12.5%. 5-yr mortality for low-, medium- and high-risk groups was 0%, 66.7%, 62.5%. Cause of death for cases that were discharged but deceased at 5 years (n=12) included chronic liver disease, malignancy, myocardial infarction, bowel obstruction, cellulitis and aspiration pneumonia. These patients had a median of 4 comorbidities at the time of their PI.

Results: 41 cases where included. Mean age was 58 (18). 68% were male. 61% were hospital-acquired PI. 76% were culture positive. In-hospital mortality was 17.1% and 5-yr mortality 46.3%. Most cases were stratified as medium-risk by RAPID score (low n=12, medium n=21, high n=8). In-hospital mortality for low-, medium- and high-risk groups was 0%, 28.6%, 12.5%. 5-yr mortality for low-, medium- and high-risk groups was 0%, 66.7%, 62.5%. Cause of death for cases that were discharged but deceased at 5 years (n=12) included chronic liver disease, malignancy, myocardial infarction, bowel obstruction, cellulitis and aspiration pneumonia. These patients had a median of 4 comorbidities at the time of their PI.

Conclusion: In our cohort, the RAPID score accurately stratified the low risk group.

Poor longer term outcomes post PI likely relates to significant patient co-morbidities. Addressing co-morbidity management at the time of PI is important.
HIGH IMPACT OF INFLUENZA ON HOSPITALISATION RATES IN CHILDREN WITH CHRONIC LUNG DISEASES: A POPULATION-BASED STUDY

HOMAIRA N1,2, BRIGGS N1, OEI J1, HILDER L3, BAJUK B6, SNELLING T4,5, JAFFE A1,2
1Discipline of Paediatrics, School of Women’s and Children’s Health, UNSW, Sydney, New South Wales, Australia, 2Respiratory Department, Sydney Children’s Hospital, Randwick, Australia, 3Stats Central, Mark Wainwright Analytical Centre, UNSW, Sydney, New South Wales, Australia, 4Department of Newborn Care, Royal Hospital for Women, Randwick, Australia, 5Centre for Big Data Research in Health UNSW Sydney, New South Wales, Australia, Randwick, Australia, 6NSW Pregnancy and Newborn Services Network, Sydney Children’s Hospitals Network, Randwick, Australia, 7Princess Margaret Hospital, Perth, Australia, 8Wesfarmers Centre of Vaccines & Infectious Diseases, Telethon Kids Institute, University of Western Australia, Perth, Australia, and 9Menzies School of Health Research, Charles Darwin University, Darwin, Australia

Introduction/Aim: Severe influenza infection in children with chronic lung diseases results in, unscheduled hospital presentations and substantial burden to the health system. National influenza burden data in children with chronic lung diseases are limited. Such data are crucial to monitor burden of disease and evaluate effectiveness of influenza vaccination program. We conducted a retrospective population-based cohort study to measure the impact of influenza on hospitalisation rates in children with chronic lung diseases.

Methods: We performed a retrospective cohort study using population-based linked administrative data for all children born in New South Wales between 2001-2010 with complete follow-up until December 31st 2011. The cohort was divided into two groups: i) children with chronic lung diseases including all children with asthma, bronchopulmonary dysplasia, cystic fibrosis, and congenital lung disorders; and ii) all other standard-risk children.

The primary outcome was any episode of influenza associated hospitalisation (ICD codes J.09-J.11). Incidence rates for influenza hospitalisation were calculated for 2001-2011. We used Poisson estimation to calculate 95% confidence interval around incidences.

Results: Our cohort comprised of 9,708 children with chronic lung diseases and 877,240 standard-risk children. The adjusted rate/1000 child-years of influenza hospitalisation in children with chronic lung diseases was 5.21 (95% CI 2.57-7.84) and for all other standard-risk children was 0.92 (95% CI 0.46-1.38). During 2001-2011, the rate in children with chronic lung diseases ranged between 0.20-12.57/1000 child-years. The rate/1000 child-years was similar in male and female children with chronic lung diseases and was 5.45 (95% CI 2.63-8.26) for boys and 5.15 (95% CI 2.41-7.89) for girls.

Conclusion: Our study has demonstrated that children with chronic diseases are at least five times more at risk of being hospitalised with influenza than standard-risk children. Future studies investigating the effectiveness of universal vaccination program for these and all other children may help reduce the burden.

Grant Support: This work was funded by Rotary club of Sydney Cove and Cerebral Palsy Alliance

Conflict of Interest: The authors have no conflict of interest.

THE SPREAD OF PSEUDOMONAS AERUGINOSA INFECTION IN BRONCHIECTASIS AND COPD

STOCKWELL R1,2, CHIN M2, WOOD M1,2, JOHNSON G4, SHERARD L5, JABBOUR N1, KNIBBS L2, MORAWSKA L1, BELL S1,2
1Lung Bacteria Group, QIMR Berghofer Medical Research Institute, Brisbane, Australia, 2Faculty of Medicine, The University of Queensland, Brisbane, Australia, 3Adult Cystic Fibrosis Centre, The Prince Charles Hospital, Brisbane, Australia, 4International Laboratory for Air Quality and Health, Queensland University of Queensland, Brisbane, Australia, 5School of Pharmacy, Queen’s University Belfast, Belfast, UK, and 6School of Public Health, The University of Queensland, Brisbane, Australia

Introduction/Aim: Pseudomonas aeruginosa (Pa) is the dominant respiratory pathogen in people with cystic fibrosis (CF) and can be released as viable aerosols during coughing. These aerosols can travel for at least 4 metres and remain airborne for at least 45 minutes. There is no research to determine if people with other chronic lung conditions can release Pa in cough aerosols. This project aimed to determine if people with non-CF bronchiectasis (nCFB) and chronic obstructive pulmonary disease (COPD) release Pa aerosols during cough.

Methods: Twenty participants with nCFB (n=16) and COPD (n=4) and Pa lung infection were recruited. Participants underwent testing in two validated aerosol-sampling devices to measure Pa viability at 2 and 4 m (distance) and at 5, 15 and 45 min (duration) during voluntary cough. Aerosols from each test were sampled using a 6-stage Andersen Cascade Impactor. Quantitative sputum counts and aerosol cultures were performed with the total number of colony forming units (CFUs) determined.

Results: Twenty participants with mean (SD) age of 62.5 (11.0) years, FEV1 56.7 (20.7)% predicted and BMI 25.3 (4.3) kg/m2 were recruited. On the day of testing, 1 participant did not culture Pa in their sputum. Nine participants completed all five cough tests. Viable Pa was detected in cough aerosols from 6/19 (31.6%) participants at 2m, 6/19 (31.6%) participants at 4m, 2/15 (13.3%) participants at 5 minutes and 2/15 (13.3%) participants at 15 minutes. No participants produced Pa cough aerosols at 45 minutes. The concentration of Pa in the sputum did not correlate with the Pa CFU in the aerosol cultures.

Grant Support: The Prince Charles Hospital Foundation, Advance Queensland
DISCORDANT PERCEPTIONS OF ASTHMA CONTROL AND RELIEVER DEPENDENCE AMONG USERS OF SHORT-ACTING BETA-AGONISTS

VYAS-PRICE B1, AMPON R1, PETERS M2, SAWYER S3, REDDEL H1
1Woolcock Institute of Medical Research, Sydney, Australia, 2Concord Repatriation General Hospital, Concord, Australia, and 3Centre for Adolescent Health, Royal Children’s Hospital, Department of Paediatrics, Melbourne, Australia

Introduction/Aim: Overuse of short-acting beta-agonists (SABA) can compromise asthma control and increase burden of disease, especially among those with poorly-controlled symptoms. This study assessed perception of control and dependence on reliever medication among users who were taking SABA alone.

Methods: Cross-sectional population-based internet survey of participants with current asthma aged >16 years. Using Likert-type questions (ranging from strongly disagree to strongly agree), the survey captured attitudes about asthma and asthma treatment. Asthma control was assessed using the Asthma Control Test (ACT: Poorly-controlled <20; Well-controlled 20-25).

Results: SABA-only respondents who had poor symptom control (n=374) compared with SABA-only users with well-controlled symptoms (n=632) were almost 3 times more likely to agree/strongly agree that they felt anxious without a reliever when out (30.6 vs. 11.6%, respectively; p<0.0001), and almost twice as likely to feel anxious when without a reliever around triggers (36.9 vs. 19.2%, respectively; p<0.0001). Half of SABA-only respondents who had poor symptom control (n=632) were almost 3 times more likely to agree/strongly agree that they relied on their reliever for their asthma (50.9% vs. 39.9%, respectively; p<0.0001), and that their reliever was “a life-saver” (43.6% vs. 24.4%, respectively; p<0.0001). Half of respondents in both groups agreed/strongly agreed that their reliever gave them control over their asthma (49.7% vs 52.2%, respectively; p=0.74).

Conclusion: Patients with poor symptom control appeared overly reliant on SABA compared to patients with well-controlled asthma. While optimal asthma control in this population requires preventative treatment, half of SABA-only respondents viewed their reliever as their means of achieving control over their asthma. Given this, public messages such as “you can control your asthma” that are aimed at encouraging preventer use may inadvertently give the opposite message to many people. These data call into some question the preventer-reliever-control paradigm as currently used. Terminology that interacts better with patients’ thoughts and beliefs may be more effective.

Grant Support: AstraZeneca

Conflict of Interest: This study was funded by a research grant from AstraZeneca. In the last 3 years, BV-P has provided medical writing support through medical communication agencies to Boehringer Ingelheim and Novartis unrelated to the topic of her present research.
INTRINSIC AIRWAY SMOOTH MUSCLE TONE IN PERIPHERAL AIRWAYS IS DETERMINED BY THE VOLUME FRACTION OF MUSCLE AND EXTRACELLULAR MATRIX

Cairncross A1, Sanai F2,3, McFarland B4, King G5, McFawson P1, Elliot J6, James A1,6, Noble P1,2,1

1 School of Human Sciences, University of Western Australia, Crawley, Australia, 2 Woolcock Institute of Medical Research, University of Sydney, Glebe, Australia, 3 School of Medical Sciences and Bosch Institute, University of Sydney, Sydney, Australia, 4 Department of Pulmonary Physiology and Sleep Medicine, Sir Charles Gairdner Hospital, Nedlands, Australia, 5 School of Medicine and Pharmacology, University of Western Australia, Crawley, Australia, and 6 Centre for Neonatal Research and Education, School of Paediatrics and Child Health, University of Western Australia, Crawley, Australia

Introduction/Aim: Abnormalities in small airways are implicated as a primary cause of functional impairment in obstructive airway disease. Contraction of the airway smooth muscle (ASM) layer in the absence of an exogenous stimulus is termed ‘intrinsic tone’ and may contribute to airflow limitation. The aim of this study was to assess the underlying structural determinants of ASM intrinsic tone in peripheral human airways.

Methods: Subjects (12M:6F, 37-85 years) undergoing lung resection surgery were recruited and baseline lung function assessed prior to surgery. Peripheral airways were dissected from resected tissue and further cut into bronchial rings (1-4 rings/subject) for measurement of force in organ bath chambers. Length-tension curves were constructed to KCl (60 mM) to establish optimum length (L0) for contraction and subsequently adapted to repeated KCl stimulation. All experiments were performed at L0. Tension (nN/mm) in the ring was determined before and after complete relaxation to theophylline (10−2M) and then fixed for stereology. Sections (0.5 μm) were stained using Masson’s trichrome technique and relative fractions of ASM (VVASM) and ECM (VVECM) within the ASM layer measured by point counting. Muscle tension was converted to stress (nN/mm²) after normalising to muscle thickness.

Results: Subjects had a pre-bronchodilator FEV1(%Pred) of 89.4±4.5 and FEV1/FVC of 0.72±0.03. Bronchial rings exhibited a mean intrinsic stress of 20.1±3.4mN/mm². Intrinsic stress (n=18) was negatively correlated with VVECM (r=-0.47, p<0.05) and positively correlated with VVASM (r=0.51, p<0.05). There was also a non-significant trend for a decrease in FEV1 (%Pred) with increasing intrinsic stress (r=0.56, p=0.07). There was no association between lung function and VVECM or VVASM.

Conclusion: The presence of intrinsic stress in the peripheral ASM layer is determined by the underlying layer composition, increasing with greater muscle fraction and decreasing with ECM fraction respectively. We propose that muscle composition affects lung function through regulation of intrinsic tone.

Grant Support: NHMRC (1063068, 1045824)

ASSOCIATIONS BETWEEN THE DIETARY INFLAMMATORY INDEX AND LUNG FUNCTION IN MIDDLE-AGE DIFFER BY ASThma STATUS

Byrne S1, Milanzi E1, Burgess J1, Jenkins M2, Abramson M2, Walters E1,2, Shrivappa M3,5,6, Hebert J1,5,6, Hodge A1,2,7

1 Centre for Epidemiology and Biostatistics, The University of Melbourne, Melbourne, Australia, 2 School of Public Health & Preventive Medicine, Monash University, Melbourne, Australia, 3 School of Medicine, University of Tasmania, Hobart, Australia, 4 Cancer Prevention and Control Program, University of South Carolina, Columbia, USA, 5 Department of Epidemiology and Biostatistics, University of South Carolina, Columbia, USA, 6 Connecting Health Innovations LLC, Columbia, USA, and 7 Cancer Council Victoria, Melbourne, Australia

Introduction/Aim: A pro-inflammatory diet may contribute to poor lung function and, in turn, the development and/or progression of chronic inflammatory lung diseases. Few studies have assessed the relationship between the dietary inflammatory index (DII3), a literature-derived measure of the inflammatory potential of the diet, and lung function. We aimed to investigate this relationship in a population-based sample of middle-aged adults.

Methods: A random sample of middle-aged adults (45–72 years) from inner south-east Melbourne were assessed by spirometry and questionnaires (n=1183). An energy-adjusted DII was calculated for each participant from a semi-quantitative food frequency questionnaire. Regression methods were used to model relationships between DII quintiles and lung function outcomes, adjusting for age, gender, height, energy intake, BMI, asthma, atopy and smoking. Asthma status was also examined as an effect modifier.

Results: Associations between DII and FEV1 and between DII and FVC differed by asthma status (p=0.001 and <0.001, respectively). Current asthmatics with a diet in the highest DII quintile had a mean FEV1 516ml lower than those in the lowest DII quintile (95%CI 212, 819ml; P=0.003) and a mean FVC 588ml lower (95%CI 249, 926ml; P=0.006). Remitted asthmatics with a diet in the highest DII quintile had a mean FEV1 364ml lower than those in the lowest DII quintile (95%CI 81, 646ml; P=0.02) and a mean FVC 391ml lower (95%CI 76, 706ml; P=0.01). For those who had never had asthma, there were no associations between DII and any of the lung function measures. There were also no associations between DII and FEV1/FVC in any asthma category.

Conclusion: A pro-inflammatory diet was associated with poorer lung function in current and remitted asthmatics. If this association is causal, it argues for a low inflammatory diet for people with a history of asthma.

Grant Support: NHMRC, NIDDK (USA)
A MULTIDISCIPLINARY TEAM (MDT) CLINIC FOR VOCAL CORD DYSFUNCTION (VCD)

BARDIN P1, BAXTER M2, RUANE L1, LEAHY E1, PHYLAND D2
1Monash University & Hospital, Melbourne, Australia, and 2Monash ENT and Speech Therapy, Melbourne, Australia

Introduction/Aim: Vocal cord dysfunction (VCD) is often mistaken for severe asthma and accurate diagnosis is crucial – but difficult. Treatment is complex and dedicated follow-up is essential. To examine optimal overall management of VCD a Multidisciplinary Team (MDT) clinic was initiated and operationalized. This type of clinic has not yet been described.

Methods: Patients with suspected VCD (n=80) were referred by Respiratory physicians (n=76) and ENT surgeons (n=4). The clinic was staffed by a Respiratory physician, ENT surgeon (laryngologist), Speech therapist and Respiratory Nurse specialist. Patients completed questionnaires, had spirometry and dynamic CT larynx prior to review. At review by the team a history was obtained, physical examination conducted and laryngoscopy performed. Diagnosis of VCD was based on detection (CT larynx or laryngoscopy) of inspiratory paradoxical vocal cord movement (PVCM) on at least one occasion. The team finally reviewed all data, a likely diagnosis was formulated and treatment was selected in consultation with the patient.

Results: A total of 80 patients are reported of whom 61 (76%) had established asthma. A diagnosis of VCD was established in 53/80 cases (67%) and 44 elected to access speech therapy services. Based on symptoms speech therapy was gauged unsuccessful in 29/44 patients (65%) and 22/29 individuals elected to have botulinum toxin injection. In a second group of 17/80 cases (21%) a diagnosis of VCD was considered unlikely. In this group 13/17 patients had poorly controlled asthma and 4/17 patients had other diagnoses. In a third group of 10/80 patients (12%) VCD was strongly suspected but not confirmed. All patients were offered speech therapy and success was achieved in 7/10 cases.

Conclusion: A VCD MDT clinic was established providing an integrated multidisciplinary approach to diagnosis and management of VCD. Our experience indicates that this strategy is feasible and can be employed to optimise management of this problematic condition.

Grant Support: Monash Lung & Sleep Institute, Monash Health

MULTIDIMENSIONAL ASSESSMENT OF TREATABLE TRAITS IN SEVERE ASTHMA AND COPD

CLARK V1,2,4, GIBSON P1,3,4, CORDOVA-RIVERA L1,4, WARK P1,3,4, MCDONALD V1,2,4
1Centre of Research Excellence in Severe Asthma, Newcastle, Australia, 2School of Nursing and Midwifery, University of Newcastle, Callaghan, Australia, 3Department of Respiratory and Sleep Medicine, John Hunter Hospital, HMRI, New Lambton Heights, Australia, and 4Priority Research Centre for Healthy Lungs, University of Newcastle, Newcastle, Australia

Introduction/Aim: Treatable traits have been proposed as a new paradigm for airway disease management. Our aim was to determine the prevalence of traits in severe asthma and COPD compared to healthy controls and to compare trait prevalence by diagnostic label.

Methods: Participants with severe asthma, COPD and age-matched healthy controls were recruited to this cross sectional study and underwent a clinic-based multidimensional assessment to characterise their treatable traits.

Results: Recruited were 140 severe asthma, 45 COPD and 67 healthy control participants. Overall the mean±SD age was 56.6±16.2 years, and 57.5% were female. COPD participants were older compared to those with severe asthma and healthy controls, p<0.001. Post-bronchodilator FEV1 % predicted was lower in COPD (53.0±19.8) compared to severe asthma (74.7±21.1) and healthy controls (99.0±13.8); p<0.001. Of the 23 possible traits, significantly more were identified in COPD (10.6±2.4) and severe asthma (9.0±2.8) compared to healthy controls (2.4±1.4); p<0.001, with a significant difference between COPD and severe asthma, p<0.001. However, the number of comorbidities was not different between disease groups (COPD 6.8±3.1 versus severe asthma 5.9±2.7). Traits that were more prevalent in COPD compared to severe asthma were dyspnoea; p<0.01, exertional O2 desaturation; p<0.001, mucous-hypersecretion; p<0.05 and airflow limitation; p<0.001. Those with severe asthma had significantly more daytime-sleepiness; p<0.01, musculoskeletal problems; p<0.01, obesity; p<0.05, upper-airway diseases; p<0.001 and dermatitis; p=0.001. Airway-eosinophilia was more common in severe asthma and airway-neutrophilia and systemic inflammation in COPD, p<0.05, p<0.001, respectively. The prevalence of frequent chest infections, pathogen colonisation, smoking, non-adherence, inhaler-polypharmacy, dysfunctional breathing, reflux, anxiety or depression did not differ between COPD and severe asthma.

Conclusion: This study confirms the heterogeneity of COPD and severe asthma. Multidimensional assessment in chronic airway disease allows for the detection of traits that can be targeted using a precision medicine approach. Trials testing these approaches are needed to advance management.

Grant Support: NHMRC, Hunter Medical Research Institute, University of Newcastle, John Hunter Hospital Charitable Trust

Declaration of Interest: No interest to declare.
MICRORNA SIGNATURES IN MALIGNANT PLEURAL MESOTHELIOMA EFFUSIONS

BIRNIE K1, PRELE C2, MUSK A3,4, DE KLERK N1,5, LEE Y1,4, ALLOCRO R6, BASS P7, THOMPSON P1, BADRIAN B1, MUTSAERS S1,2

1Institute For Respiratory Health, Perth, Australia, 2Occupational Respiratory Epidemiology, School of Population and Global Health, University of Western Australia, Perth, Australia, 3Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, Australia, 4Telethon Kids Institute, WA, Australia and Centre for Child Health Research, Perth, Australia, 5School of Pathology and Laboratory Medicine, University of Western Australia, Perth, Australia, 6Department of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands, and 7Centre for Cell Therapy and Regenerative Medicine, Perth, Australia

Introduction/Aim: Malignant pleural mesothelioma (MPM) is an incurable cancer of the pleura that can be difficult to diagnose. Biomarkers for an earlier and/or easier diagnosis are urgently needed. The powerful gene regulators microRNA, have become popular diagnostic targets due to their stable expression within the body. Studies have examined microRNA in MPM and control samples, however it is still unclear which microRNA are potential biomarkers for MPM. Approximately 90% of patients develop pleural effusions which are an ideal source of diagnostic targets as sample collection is minimally invasive. The biomarker potential of microRNA in MPM and control samples, however it is still unclear which microRNA are potential biomarkers for MPM. Approximately 90% of patients develop pleural effusions which are an ideal source of diagnostic targets as sample collection is minimally invasive. The biomarker potential of microRNA in MPM frozen/fresh effusions is yet to be determined. We hypothesise that microRNA expressed in effusions are potential biomarkers for MPM.

Methods: Taqman OpenArray profiling and real-time quantitative PCR were used to analyse microRNA in a cohort (Cohort 1) of 48 effusion cell and supernatant samples from MPM, lung adenocarcinoma and benign pleural disease patients. The potential microRNA biomarkers were then analysed in a second cohort (Cohort 2) of 60 MPM and lung adenocarcinoma samples.

Statistics: MicroRNA expression was determined to be significantly different between diseases on a volcano plot with a 2 or more-fold change and a p< 0.05. MicroRNA combinations were analysed using logistic regression and diagnostic efficiency was assessed using receiver operating characteristic curves.

Results: An effusion cell signature based on the combination of miR-143, miR-210 and miR-200c for the diagnosis of MPM was identified in Cohort 1 (AUC – 0.92) and validated in Cohort 2 (AUC – 0.71).

Conclusion: MicroRNA expressed in effusion cells are potential biomarkers for differentiating MPM from lung adenocarcinoma.

Grant Support: This work was supported by grants from Dust Diseases Board N.S.W, Maurice Blackburn and Sir Charles Gairdner Hospital Research Committee. S Mutsaers was supported on a Cancer Council WA Research Fellowship.

Declaration of Interest: No conflicts of interest.

TRANSCRIPTIONAL PROFILING OF EPITHELIUM REVEALS SIMILAR COMPOSITION, BUT PARTIALLY DIFFERING ORGANIZATION BETWEEN THE UPPER AND LOWER AIRWAY

DE JONG E1, LING K1, NICHOL K6,7, ANDERSON D1, WARK P1,2, KNIGHT D1,2,3, BOSCO A1, STICK S1,2,3,4, KICIC A1,2,3,4,5

1Telethon Kids Institute, Perth, Australia, 2School of Paediatrics and Child Health, The University of Western Australia, Perth, Australia, 3Department of Respiratory Medicine, Princess Margaret Hospital for Children, Perth, Australia, 4Centre for Cell Therapy and Regenerative Medicine, School of Medicine and Pharmacology, The University of Western Australia and Harry Perkins Institute of Medical Research, Perth, Australia, 5Occupation and Environment, School of Public Health, Curtin University, Perth, Australia, 6School of Medicine and Public Health, University of Newcastle, Australia, 7Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute, Newcastle, Australia, and 8Department of Anaesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, Canada

Introduction/Aim: Emerging evidence suggests that the upper and lower airway are unified and that under disease settings, a pathological process in one region of the airway would affect the function of the entire airway. However, direct evidence supporting this is extremely limited and only inferred by the fact that the respiratory tract is continuously lined with epithelial cells and clinical observations of improved outcomes for lower airway disease following management of upper airway disease.

Methods: Here, we directly tested this hypothesis by performing RNA-sequencing on predominantly matched nasal and bronchial epithelial brushings from 63 children with or without atopy or asthma. We then used a combination of differential gene expression, and gene co-expression analyses to determine similarity of the transcriptional landscape between the upper and lower airway.

Results: Overall, we report ~50% homology and ~50% divergence between the two sites, independent of disease phenotype and atopy. We identified sixteen modules of co-expressed genes (enriched for specific biological functions) to be conserved across nasal and bronchial epithelium. However, almost half of these were differentially expressed between the two regions.

Conclusion: Our findings suggest that in part the upper and lower airway do share a similar transcriptional composition, but also exhibit significant differences that is reflective of their region-specific functions. With significant interest in biomarker development, our data suggests that in certain settings nasal epithelial cells, may inform on lower airway disease and thus has considerable clinical implications.

Grant Support: Asthma Australia

Conflict of Interest: No conflict of interest.
MITOCHONDRIAL DYSFUNCTION REINFORCES THE SENESCENT PHENOTYPE IN IPF LUNG FIBROBLASTS

SCHULIGA M1, WATERS D1, BLOKLAND K1,2, JAFFAR J3, WESTALL G3, BURGESS J4, PRELE C1, MUTSAERS S3, GRAINJE C1, KNIGHT D1,5
1University of Newcastle, Callaghan, Australia, 2University of Groningen, Groningen, Netherlands, 3Alfred Hospital, Prahran, Australia, 4University of Western Australia, Nedlands, Australia, and 5University of British Columbia, Vancouver, Canada

Introduction/Aim: Increasing evidence highlights that cellular senescence contributes to idiopathic pulmonary fibrosis (IPF). The DNA damage response (DDR) in senescence also leads to escalated mitochondrial superoxide production to reinforce senescence. This study characterises senescence in lung fibroblasts from IPF patients (IPF-LFs) and age-matched controls (Ctrl-LFs), delineating the role of mitochondria in senescence stabilization.

Methods: Fibroblast senescence was assessed using a composite set of markers, including p21 expression and senescence-associated β-galactosidase activity, which were measured by PCR and cytochemical staining, respectively. The DDR was detected by formation of phosphorylated-p53 nuclear foci using immunofluorescence. A senescent-associated secretory phenotype (SASP) was characterised by measuring increases in cytokine production and inflammatory gene expression with ELISA and Nanostring technology, respectively. Mitochondrial dysfunction was monitored by increased mitochondrial stress, mass and superoxide using the fluorogenic dyes, n-nonyl-acridine orange, Mitotracker Green and MitoSOX, respectively.

Results: Even at early passage, IPF-LFs were more senescent-like than Ctrl-LFs, exhibiting an intensified DDR, a SASP and mitochondrial dysfunction. The DNA damaging agent etoposide augmented senescence in Ctrl-LFs accompanied by heightened mitochondrial stress, mass and superoxide production. However, it had no effect on IPF-LFs. Mitochondrial perturbation by rotenone also evoked a DDR and senescence in Ctrl-LFs. Inhibition of mTORC1, a regulator of mitochondrial function or mitochondrial perturbation by rotenone also evoked a DDR and senescence in Ctrl-LFs. Mitochondrial superoxide production to reinforce senescence. This study characterised senescence in lung fibroblasts from IPF patients (IPF-LFs) and age-matched controls (Ctrl-LFs), delineating the role of mitochondria in senescence stabilization.

Conclusion: If IPF-LFs exhibit senescent-like features and mitochondrial dysfunction reinforces the senescent phenotype. Understanding the mechanisms by which mitochondria contribute to fibroblast senescence in IPF has potentially important therapeutic implications.

Grant support: NHMRC research grant #1099569

NOTCH3 INHIBITION SIGNIFICANTLY REDUCES MUC5AC IN HUMAN AIRWAY EPITHELIAL CELLS

REID A1,2, NICHOL K1,2, WEI L1,2, MOHEIMANI F1,2, BARTLETT N1,2, HANSBRO P1,2, WARK P2,3,4, GRAINJE C1,2, KNIGHT D1,2,5
1School of Biomedical Sciences and Pharmacy, University Of Newcastle, Callaghan, Australia, 2Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute (HMRI), The University of Newcastle, Newcastle, Australia, 3Department of Respiratory and Sleep Medicine, John Hunter Hospital, Newcastle, Australia, 4School of Medicine and Public Health, University of Newcastle, Callaghan, Newcastle, Australia, and 5Department of Anaesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, Canada

Introduction: Mucus overproduction in patients with asthma is linked to increased hospitalisations and morbidity. The Notch family of receptor proteins regulate airway mucus production via differentiation mechanisms that direct cells towards secretory or ciliated morphology. However little is known regarding Notch’s role during mucus production, following differentiation.

Aim/Hypothesis: To examine the impact of inhibiting Notch signalling on mucus production in fully differentiated primary bronchial epithelial cells (pBECs) from control subjects as well as patients with asthma. We hypothesise that Notch inhibition will downregulate mucus production.

Methods: pBECs from 5-6 donors of each cohort were grown at air-liquid interface (ALI) culture for 25 days to promote multicellular differentiation. At this time, cells were treated with dibenzazepine (DBZ), a potent inhibitor of Notch signalling for a further 96h during which, apical lining fluid was collected every 24h for assessment of MUC5AC release. At the completion of the experiment, samples were also collected for protein, mRNA and histological analysis. To assess the direct role of NOTCH3 on MUC5AC, siRNA knockdown of Notch3 was also performed in monolayer cultures of human epithelial cells.

Results: DBZ treatment significantly reduced MUC5AC expression and release in all phenotypes as assessed by qPCR, ELISA and IHC. Western blotting/qPCR revealed significant reduction of NOTCH3 intracellular domain (NICD3) and Notch3 mRNA in pBECs from all donor phenotypes. Notch3 siRNA knockdown significantly reduced MUC5AC protein. Finally, the goblet cell marker protein CLCA1 was unchanged across all treatments.

Conclusion: Notch3 inhibition reduced MUC5AC expression and secretion from differentiated pBECs, independent of goblet cell number. This reduction is NOTCH3 dependent and occurs in pBECs from asthematics and non-asthmatics. This suggests that Notch3 regulates MUC5AC production outside of Notch’s well characterised role during secretory cell differentiation.

Grant Support: NHMRC project grant #1064405.
INVESTIGATING THE ROLE OF HISTONE ACETYLATION IN TGF-INDUCED FIBROSIS IN COPD

ZAKARYA R1,2, CHEN H1, BRANDSMA C3, ADCOCK I4, OLIVER B1,2
1School of Life Sciences, University of Technology Sydney, Australia, 2The Molecular Pathogenesis Group, Respiratory Cell and Molecular Biology, Woolcock Institute of Medical Research, Sydney, Australia, 3Department of Pathology and Medical Biology, University of Groningen, Groningen, University Medical Center Groningen, Groningen, The Netherlands, and 4Airways Disease, Imperial College London, UK

Introduction/Aim: Fibrosis and thickening of the airway smooth muscle (ASM) layer are components of airway remodeling and have been attributed to an increase in the ECM fraction in the ASM layer. It has been shown that epigenetic changes occur in COPD (immune cells and peripheral lung tissue) but it is not known if airway mesenchymal cells are reprogrammed. This project aims to identify differentially expressed ECM proteins and investigate the effect of epigenetic inhibition on protein expression.

Methods: Primary human ASM cells were isolated from lung tissue of COPD and non-COPD smoking patients. ASM cells were grown in culture and stimulated with TGF-β (10ng/ml) +/- histone deacetylase inhibitor Trichostatin A (TSA), bromo- and extra terminal domain (BET) protein inhibitor (+)JQ1, or histone acetyltransferase inhibitor Curcumin. Cell lysates were collected after 48 hours of treatment. Microarray analyses were carried out to identify basal differences in expression of ECM and epigenetic gene targets between COPD and non-COPD smokers. qPCR carried out to confirm microarray analyses and determine effect of epigenetic inhibitors.

Results/Conclusion: ASM cells from COPD patients show augmented col5a1, col15a1 and TNC expression in response to stimulation with TGF-β when compared to cells of smokers without COPD. Inhibition with TSA had no effect on col5a1, or TNC expression in cells from both patient groups, whilst inhibiting col5a1 expression in COPD. (+)JQ1 treatment significantly abrogated expression of col5a1 in COPD and non-COPD groups, whilst col5a1 expression was abrogated in COPD and TNC in non-COPD. Col5a1 expression was significantly repressed with Curcumin treatment in non-COPD group only. The different responses between non-COPD susceptible smokers and COPD group highlights the epigenetic differences in disease, and that targeting histone acetylation may be a therapeutic option of small airway fibrosis in COPD.

DYSREGULATED NOTCH SIGNALING DURING ASTHMATIC AIRWAY EPITHELIAL REPAIR

IOSIFIDIS T1,2, SUTANDO E3,4, LING K2, LOOI K2, GARRATT L2, MARTINOVICH K2, KICIC-STARCEVICH E3,4, SHAH N2, MONTGOMERY S1,3, LANNINGAN F1,5, RIGBY P2, KNIGHT D1,3,4, STICK S1,2,3,5, KICIC A1,2,3,4,5
1School of Paediatrics & Child Health, The University of Western Australia, Perth, Australia, 2Centre for Cell Therapy & Regenerative Medicine, Perth, Australia, 3Telethon Kids Institute, Perth, Australia, 4Department of Respiratory Medicine, Princess Margaret Hospital for Children, Perth, Australia, 5School of Medicine, Notre Dame University, Fremantle, Australia, 6Centre for Microscopy, Characterisation and Analysis, Perth, Australia, 7School of Biomedical Sciences & Pharmacy, University of Newcastle, Newcastle, Australia, 8Priority Research Centre for Asthma & Respiratory Disease, Hunter Medical Research Institute, Newcastle, Australia, 9Department of Anaesthesiology, Pharmacology & Therapeutics, University of British Columbia, Vancouver, Canada, 10Occupation and Environment, School of Public Health, Curtin University, Bentley, Australia, 11School of Medicine, University of Western Australia, Perth, Australia, and 12St John of God Hospital, Subiaco, Australia

Introduction/Aim: The airway epithelium is a key driver in asthma pathogenesis, partly due to its dysregulated response to injury. Notch signalling and potential crosstalk with integrins, modulate epithelial cell migration and repair. Therefore, it was hypothesised that aberrant Notch signalling in asthmatic epithelium would result in defective repair by airway epithelial cells(AEC) via regulation of integrins.

Methods: Tracheobronchial airway brushings of non-asthmatic (n=18; age range: 1.2-15.6yr; 8 males) and asthmatic (n=14; 3.3-16.9yr; 12 males) children were utilised for AEC isolation and culture. Notch receptor and ligand gene expression was investigated by qPCR (mean ±SEM; arbitrary units, AU). Notch signalling in cultures was inhibited with gamma secretase inhibitor, DAPT[N-(3,5-Difluoro-phenacetyl)-L-alanyl]-S-phenylglycine-t-butyl ester) over a dose-range (1nM-10μM). Linear wounds were performed on AEC to assess repair (IncuCyte ZOOM®, Essen Bioscience). Integrin α5β1 protein expression was investigated by In-Cell™ Western.

Results: Notch receptors (NOTCH1-4) and ligands (JAG1-2, DLL1, 3, 4) were found to be expressed in ex vivo AEC from non-asthmatic and asthmatic children, however only NOTCH2 and JAG1 gene expression were differentially expressed in AEC from asthmatic children (NOTCH2, 10-fold downregulation[p<0.01]; JAG1, 3.5-fold upregulation[p<0.01]; n=6). Following in vitro wounding, NOTCH2 (2.92±0.11AU) and JAG1 (3.35±0.14AU) mRNA levels were induced within 48hr in AEC of non-asthmatic children. However, an earlier induction of both NOTCH2 (2.58±0.10 AU) and JAG1 (4.19±0.09 AU) at 24hr post wounding was observed in AEC from asthmatic children. Global inhibition of Notch signalling resulted in a 40% reduction in wound repair and an inability to close the wound, observed at the maximal dose, 10μM. Furthermore, Notch signaling inhibition resulted in a reduction of α5 integrin protein expression of 30% at 500 nM DAPT, but not β1 integrin protein expression.

Conclusion: Findings suggest dysregulated expression of Notch signalling molecules, in conjunction with its role in regulating integrin expression, contribute to the defective wound repair of the asthmatic airway epithelium.

Grant Support: NHMRC(#1048910), APA(UWA), Centre for Cell Therapy & Regenerative Medicine PhD Top-Up Scholarship, Fiona Staniforth Asthma Foundation WA PhD Top-Up Scholarship.
PULMONARY REHABILITATION DOES NOT IMPROVE OBJECTIVE MEASURES OF SLEEP QUALITY IN PEOPLE WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

COX N1,2, PEPIN V3, BURGE A1,4, MAHAL A2, HILL C1-5, LEE A1-2,4, MOORE R1, NICHOLSON C1-4, O’HALLORAN P4, LAHMAM A1,2, GILLIES R2,6, MCDONALD C1,2,5,6, HOLLAND A1-2,4
1La Trobe University, Melbourne, Australia, 2Institute for Breathing and Sleep, Melbourne, Australia, 3Concordia University & Hôpital du Sacré-Coeur de Montreal, Montreal, Canada, 4Alfred Health, Melbourne, Australia, 5University of Melbourne, Melbourne, Australia, and 6Austin Health, Melbourne, Australia

Introduction/Aim: More than 50% of people with chronic obstructive pulmonary disease (COPD) report poor sleep quality which has been associated with increased morbidity and mortality. There are varying reports of the effect of pulmonary rehabilitation (PR) on self-reported sleep quality. We aimed to assess the effect of PR on objectively measured sleep quality in people with COPD.

Methods: This is a secondary analysis of data collected as part of an RCT comparing home-based to centre-based PR for COPD. Sleep quality was assessed objectively using the SenseWear Armband (SWA, Bodymedia USA), worn for 7 days before and after an 8-week PR programme. Sleep characteristics were derived from accelerometer positional data and registration of sleep state by the SWA, determined from energy expenditure.

Results: 33 participants (17 male; mean±SD age 68±11 years, FEV1 56±21 %predicted) had paired pre and post PR sleep data. Twenty participants received centre-based PR and n=13 were allocated to home-based PR.

Pre-PR median [interquartile range] sleep onset latency (SOL) was 25 [9, 41] minutes, total sleep time (TST) 390 [339, 421] minutes and wake after sleep onset (WASO) 74 [43, 106] minutes. Sleep efficiency (SE) was low (75% [64, 84]).

No significant differences were seen in any sleep parameter (SOL, TST, WASO, SE) after PR (all p>0.10), between intervention groups (all p>0.20), or within PR groups (all p=0.13). There was no association between sleep parameters and measures of quality of life or function before or after PR. Attendance at a greater proportion of PR sessions was moderately associated with more TST at end rehabilitation (r=0.5, p=0.009).

Conclusion: Sleep quality, measured objectively using actigraphy, did not improve after an 8-week PR programme in individuals with COPD. Whether ongoing participation in regular exercise training beyond the duration of PR may influence sleep quality is yet to be determined.

Grant Support: NHMRC (Project Grant: 1046353; Early Career Fellowship: 1119970); Lung Foundation Australia; La Trobe University Research Collaboration Grant 2015
TO 129

IMPACT OF THE 2017 GOLD STRATEGY ON Tiotropium + Olodaterol Response

LANGTON D1, FERGUSON G2, VOSS F3, MALTAIS F4, GRÖNKE L3, BUHL R5, WATZ H6

1Thoracic Medicine, Frankston Hospital and Monash University Faculty of Medicine, Nursing and Health Sciences, Australia, 2Pulmonary Research Institute of Southeast Michigan, USA 3Boehringer Ingelheim Corporation, Ingelheim, Germany, 4Institut Universitaire de Cardiologie et de Pneumologie de Québec, Canada, 5Johannes Gutenberg University Mainz, Mainz, Germany, 6Pulmonary Research Institute at LungClinic Grosshansdorf Pulmonary Research, Grosshansdorf, Germany

Introduction/Aim: In the 2017 GOLD COPD strategy, treatment choices are guided by patient classification based on assessment of symptoms and exacerbation history. The previous strategy also included lung function. Here, we investigated the effect of the 2017 classification on an analysis of the efficacy of tiotropium+olodaterol (T+O) in GOLD stage A/B patients with COPD.

Methods: Patients from the Phase III, replicate 52-week TONADO studies (NCT01431274, NCT01431287), who received T+O or the mono-components, were classed as GOLD A/B or C/D by the 2017 (exacerbation history) or 2014 (lung function and exacerbation history) criteria. Distinction between A and B was not possible as mMRC Dyspnoea Scale and COPD Assessment Test had not been used. St. George’s Respiratory Questionnaire (SGRQ) and transition dyspnoea index (TDI) were analysed.

Results: More patients are classified as GOLD A/B with 2017 criteria than with 2014 guidelines. T+O was superior to monotherapy for SGRQ and TDI in 2017 A/B population (Table).

Conclusion: Using exacerbation history alone (GOLD 2017), rather than combined with lung function, results in more patients classified as GOLD A/B, leading to more statistical power to investigate differences between T+O and monotherapies. Using the 2017 strategy, T+O had a greater impact on SGRQ and TDI than monotherapies in GOLD A/B patients.

Table

<table>
<thead>
<tr>
<th></th>
<th>2017 GOLD A/B</th>
<th>2014 GOLD A/B</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>Adjusted mean ± SEM</td>
</tr>
<tr>
<td><strong>SGRQ total score change from baseline</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T+O 5/5μg</td>
<td>739</td>
<td>–6.9±0.4</td>
</tr>
<tr>
<td>Tiotropium 5μg</td>
<td>719</td>
<td>–5.0±0.4</td>
</tr>
<tr>
<td>Olodaterol 5μg</td>
<td>744</td>
<td>–5.1±0.4</td>
</tr>
<tr>
<td><strong>Mahler TDI focal score</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T+O 5/5μg</td>
<td>751</td>
<td>1.95±0.11</td>
</tr>
<tr>
<td>Tiotropium 5μg</td>
<td>737</td>
<td>1.50±0.11</td>
</tr>
<tr>
<td>Olodaterol 5μg</td>
<td>768</td>
<td>1.51±0.11</td>
</tr>
</tbody>
</table>

aSGRQ is ≥4.0 units better than baseline; bMahler TDI is ≥1.0 unit better than baseline

Declaration of interest statement:
DL has no conflict of interest to declare in relation to this presentation. GTF has served as a consultant for AstraZeneca, Boehringer Ingelheim, Meda, Mylan, Novartis, Pearl Therapeutics, Sunovion, Theravance and Verona. He has also received honoraria from Boehringer Ingelheim, GlaxoSmithKline, Sunovion and Meda. FV and LG are employees of Boehringer Ingelheim. FM has nothing to disclose. RB has received reimbursement for attending scientific conferences, and/or fees for speaking and/or consulting from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Nycomed and Pfizer. HW has received grants/research support from Almirall, AstraZeneca, AB2BIO, Cilag Jansen, Chiesi, Boehringer Ingelheim, Bayer, GlaxoSmithKline, Novartis, Roche, Takeda, Stema Pharmaceuticals, as well as honoraria or consultation fees from Almirall, AstraZeneca, Boehringer Ingelheim, BerlinChemie, Chiesi, GlaxoSmithKline and Novartis.

Grant Support: The study was funded by Boehringer Ingelheim.

Editorial material and organization © 2018 Asian Pacific Society of Respirology. Copyright of individual abstracts remains with the authors.
THE IMPACT OF PULMONARY REHABILITATION ON PEOPLE WITH MILD CHRONIC OBSTRUCTIVE PULMONARY DISEASE: A RANDOMISED CONTROLLED TRIAL

LAHHAM A1,2, MCDONALD C2,3, COX N1,2, RAWLINGS S5, NICHOLS A1, MOORE R2, LIACOS A1,7, HOLLAND A1,2,7
1Department of Physiotherapy, La Trobe University, Melbourne, Australia, 2Institute for Breathing and Sleep, Melbourne, Australia, 3Respiratory & Sleep Medicine, Austin Health, Melbourne, Australia, 4Department of Medicine, The University of Melbourne, Melbourne, Australia, 5Department of Physiotherapy, Monash Health, Melbourne, Australia, 6Department of Physiotherapy, Austin Health, Melbourne, Australia, 7Department of Physiotherapy, Alfred Health, Melbourne, Australia

Introduction/Aim: People with mild chronic obstructive pulmonary disease (COPD) experience exercise intolerance, dyspnoea and poor health-related quality of life. However, the role of pulmonary rehabilitation in this group is unclear. This randomised controlled trial aimed to explore effects of home-based pulmonary rehabilitation (PR) in people with mild COPD.

Methods: People with mild COPD (FEV1/FVC<70%; FEV1>80%predicted) with smoking history of ≥10 packet years were randomised to either 8-weeks of home-based PR (one home visit and seven once-weekly telephone calls) or attention control (weekly social telephone calls). Six-minute walk distance (6MWD), modified Medical Research Council (mMRC) dyspnoea score and Chronic Respiratory Questionnaire (CRQ) scores were compared between groups post intervention and at 6-months.

Results: A total of 58 participants (34 females, mean age 68 (SD 9) years, FEV1 90 (7)%predicted, 6MWD 496 (105) metres) were included with 29 participants randomised to home-based PR. Participants attended an average of 6.8 of the eight scheduled sessions, ranging from three to eight sessions. Both groups showed improvements in exercise capacity, symptoms and health-related quality of life over time, however there was no between-group differences in the primary outcome of 6MWD at end-intervention (mean difference 1.4 metres, 95% confidence interval (CI) -28.7 to 31.4 metres) or six months (9.8 metres, 95% CI -30.5 to 50.2 metres). At 6-months follow-up home-based PR participants were more likely to have clinically important improvements in CRQ emotional function (50% of home PR vs 0% control, p<0.001) and CRQ total score (45% vs 17%, p=0.05), however there were no other differences in symptoms or other aspects of health-related quality of life.

Conclusion: For people with mild COPD, home-based pulmonary rehabilitation did not improve exercise capacity or health-related quality of life more than weekly social telephone calls.

Grant Support: The Eirene Lucas Foundation and Institute for Breathing and Sleep.

NO ADDITIONAL BENEFITS FOR PULMONARY REHABILITATION INCLUDING COGNITIVE BEHAVIOURAL THERAPY

WILLIAMS M1, PAQUET C1, JOHN D1, CAFARELLA P2, FRITH P1,3
1University of South Australia, Adelaide, Australia, 2Flinders University of South Australia and Southern Adelaide Local Health Network, Adelaide, Australia, and 3Respiratory Laboratories Southern Adelaide Local Health Network, South Australia, Adelaide, Australia

Aim: This pragmatic randomised controlled trial aimed to determine whether comprehensive pulmonary rehabilitation (CPR) including cognitive behaviour therapy (CBT) for the sensation of breathlessness significantly improved health outcomes beyond those achieved with CPR alone.

Methods: People with COPD (FEV1<80% pred, FEV1/FVC<70%, GOLD Grade ≥2) were block randomised to eight weeks of CPR with or without CBT (BREVE). Primary (six minute walk test (6MWT), Hospital Anxiety and Depression scale (HADS)) and secondary outcomes (breathlessness in daily life (Dyspnoea-12 (D-12), Multidimensional Dyspnoea Profile (MDP), quality of life (Chronic Respiratory Questionnaire (CRQ) and habitual daily activity (accelerometry)) were assessed before and one, six and 12 months post intervention. Differences between groups were assessed with latent growth models (non-linear change) with and without covariates (age, sex, BMI, GOLD grade, comorbidity, smoking status and CPRP attendance) using both intention to treat (ITT) and per protocol (PP: commenced intervention and valid 6MWT) approaches with ps<0.05 significant.

Results: 101 participants (mean age 70 ± 8.5, 54 males, FEV1 % pred 47.7 ± 16.3) enrolled in the trial (n=88 for PP analysis). With the exception of CRQ and MDP subdomain scores, groups did not differ significantly in either trajectory or assessment points for primary or secondary outcomes (ITT, PP with and without covariates). For ITT, improvements in CRQ-Dyspnoea favoured CPRP + BREVE (unadjusted model p = 0.03) whereas reductions in MDP-Emotional Response favoured CPRP alone (adjusted model p = 0.03). For PP with and without adjustment for covariates, differences between groups for CRQ and MDP favoured CPRP alone (CRQ-Mastery p = 0.04; MDP-Immediate Perception p = 0.03; MDP-Emotional Response p = 0.04).

Conclusion: In this cohort of people participating in CPRP, there was no clear additional short or longer term benefit of combining CPRP with CBT for breathlessness.

Grant Support: This study was supported by a National Health and Medical Research Council Project Grant (# 1010309).

Clinical Trial registration: Australian New Zealand Clinical Trials Registry (ANZCTR12611000292976)
Introduction/Aim: There is a paucity of literature documenting Respiratory High Dependency Unit (HDU) outcomes. We present demographic and outcome data for patients undergoing care in the Austin Hospital Respiratory HDU, which provides single organ support for patients with acute respiratory failure.

Methods: This retrospective audit describes all admissions to the Respiratory HDU during January to December 2016. Logistic regression was used to identify factors related to in-hospital mortality.

Results: 82 patients, mean age 67.3 years (SD 16.83,) underwent 83 HDU admissions. 53% (44 patients) were male. Mean HDU length of stay (LOS) was 2.17 days (SD 2.15, 95% CI 1.71-2.63.) The main precipitating causes for respiratory failure were exacerbation of chronic obstructive pulmonary disease (n=25, 30.12%) and infection (n=23, 27.7%). 25 admissions (30.12%) were for management of hypoxic respiratory failure, 9 of which were treated with non-invasive ventilation (NIV). N=18 (21.69%) admissions occurred following a ward MET call and had an average HDU LOS of 1.5 days (SD 0.99, 95% CI 1.11-2.03.) 7 patients (8.4% of admissions) did not survive to hospital discharge. A higher age-adjusted Charlson comorbidity score was associated with higher in-hospital mortality (OR 1.41, p=0.021, 95% CI 1.05-1.89.)

Conclusion: The HDU has a high turnover of patients, including post-MET call care. Outcomes are generally good, however increased comorbidity as reflected by a higher age-adjusted Charlson score was associated with in-hospital mortality. A proportion of hypoaemic patients received NIV, raising an opportunity for review of current practice.

Grant Support: None.

Introduction/Aim: Patients with alpha-1 antitrypsin deficiency (AATD) develop pulmonary emphysema prematurely. RAPID, a randomized placebo-controlled trial, showed that treatment with Aα-PI (Zemaira/Respreeza) slows emphysema progression. Based on observational data, which showed a reduced loss in FEV1 in a subgroup of patients, current guidelines recommend treatment with Aα-PI when FEV1 is between 30 and 65% predicted. However, the relationship between the effect of treatment on lung structure preservation and FEV1 is unclear. The aim was to assess the effect of treatment in relation to baseline FEV1% predicted as measured by change in computed tomography (CT) lung density in 180 patients randomized in RAPID with baseline FEV1% between 27% and 79% predicted.

Methods: Changes in annual CT lung density decline rates for both active and placebo treated patients were calculated at 2 years. A random slope intercept model with baseline FEV1% and treatment group as covariates was used to analyse the influence on treatment effect.

Results: Baseline lung function impairment did not affect long-term changes in lung density (p=ns); the regression line was flat. Active treatment was associated with lung density preservation (P<0.0001) and the regression line was parallel to that of placebo treated patients. The regression line for rate of annual lung density decline vs baseline FEV1% was flat with no interaction between treatment group and baseline FEV1%.

Conclusion: These data demonstrate that patients with AATD who are treated with Aα-PI therapy derive an equal benefit in terms of lung tissue preservation over 2-years that is independent of their pre-treatment FEV1%.

Grant Support: The RAPID trial programme and preparation of this abstract was supported by CSL Behring.
DIAGNOSTIC ACCURACY OF BRONCHOSCOPY WITH CONSCIOUS SEDATION VERSUS GENERAL ANAESTHETIC IN A RANDOMISED PROSPECTIVE COHORT

S values were compared for Charlson Comorbidity Index. GA was defined as the use of a Laryngeal mask airway and/or propofol usage. Diagnosis obtained at bronchoscopy was compared to the final clinical diagnosis.

Methods: We report on a further analysis of a prospective randomised patient group. Patients undergoing therapeutic and diagnostic procedures within the RBWH were considered for trial entry and randomization. Procedures included standard bronchoscopy, endobronchial ultrasound (EBUS) with transbronchial node aspiration (TBNA) or EBUS Guide Sheath. Patients were randomized to either CS or GA, stratified for Charlson Comorbidity Index. GA was defined as the use of a Laryngeal mask airway and/or propofol usage. Diagnosis obtained at bronchoscopy was compared to the final clinical diagnosis.

Results: 93 patients were randomised. 49 of these received CS of which 32 were diagnostic procedures, with 14 being EBUS TBNA s. In the GA group these numbers were 44, 32 and 14 respectively. A final diagnosis of malignancy was made in 12 cases in the CS group (38%) and 18 cases in the GA group (56%). For all diagnostic procedures there was no significant difference in diagnostic accuracy between CS and GA, 93.3 vs 97.5% (p=0.67). Regarding EBUS TBNA diagnostic accuracy was 100 vs 92.9% (p=1.00). 24 lymph nodes were sampled in the CS group, 46% paratracheal, 17% subcarinal and 38% hilar. 21 nodes were sampled in the GA group, 24% paratracheal, 29% subcarinal and 48% hilar. Average passes per node were 3.28 ±0.79 and 3.00 ±1.00 respectively (p=0.29). For the CS cases only 2 drugs were used: Midazolam (mean dose 4.4mg ±1.0) and Fentanyl. A variety of anaesthetic agents were used in the GA group. There was no significant difference regarding mean fentanyl dosage of 90.6mcg ±16 for CS vs 86.2mcg ±52.9 for GA (p=0.60).

Conclusion: CS is not inferior to GA in terms of diagnostic accuracy, including EBUS TBNA from a wide range of nodal stations.

Grant Support: Nil

Interventional Pulmonology / Bronchology 2

SAFETY AND DIAGNOSTIC PERFORMANCE OF CRYOBIOPSY IN MELBOURNE, AUSTRALIA

DONOVAN C 1, SLEEP L 1, SEE K 1, IRVING L 1,2, LEONG P 1, STEINFORT D 1,2

1Royal Melbourne Hospital, Parkville, Australia, and 2University of Melbourne, Australia

Introduction/Aim: Cryobiopsy is an emerging technique with mounting utilisation in the settings of diffuse parenchymal lung disease (DPLD) and neoplasia. The safety and usage pattern of cryobiopsy is not well established in the Australian setting. At our tertiary institution, we routinely perform cryobiopsy with general anaesthesia, endotracheal intubation and fluoroscopy guided 1.9mm cryoprobe via ERBECRYO 2 with routine bronchial blocker balloon deployment. We thus set out to establish the safety and usage patterns of our cryobiopsy service.

Methods: Following institutional ethics approval, we conducted a retrospective audit of our institution’s cryobiopsy register (November 2015-September 2017). Records missing from our electronic records were supplemented by a hand search, and by contacting referees. Results were cross-checked by two authors (CD, LS), verified by a third (PL) and are presented as mean±SD.

Results: 49 patients underwent cryobiopsy in the audit period, with 2.6±1.1 biopsies performed per patient, and targets as follows: right lower lobe 23, right upper lobe 15, left lower lobe 11, left upper lobe 11 and endobronchial 4. The predominant indication for cryobiopsy was suspected DPLD (43/49) with possible malignancy accounting for the remaining cases. The mean FVC was 88±17% predicted (lowest 57%) and DLCO 59±17% predicted (lowest 35%). Same day discharge was achieved in 42/49, with 2 further uncomplicated cases staying overnight for social reasons. There were no cases of severe bleeding. Bleeding was moderate (controllable with endobronchial interventions) in 5 cases; 4 cases had pneumothoraces of whom 2 required intercostal catheter insertion. Physicians agreed or strongly agreed that cryobiopsy was helpful in 45/49 patients. Cryobiopsy was suggestive or diagnostic of DPLD in 39, infection in 1 and malignancy in 6. No abnormality was present in 2, 1 of whom was referred for surgical lung biopsy.

Conclusion: Cryobiopsy appears to have an acceptable safety profile with a good diagnostic yield.

Key Words: cryobiopsy, bronchoscopy, interstitial lung disease

Grant Support: Nil
UTILITY OF RADIAL EBUS CRYOBIOPSY IN DIAGNOSIS OF SOLITARY PULMONARY NODULES
TAN S1, ING A1,2,3, SAGHAIE T1,2,3
1Concord General Repatriation Hospital, Sydney, Australia, 2The Faculty of Medicine, University of Sydney, Australia, and 3Faculty of Medicine and Health Science, Macquarie University, Australia

Introduction/Aim: Forceps biopsy through a guide sheet after locating the lesion using radial probe EBUS is an established technique in diagnosis of solitary pulmonary nodules (SPN). The yield, however, drops significantly if the lesion is not concentric. Furthermore, the 1.7mm forceps often provide small samples which occasionally fall short of providing all the information required in malignancies. Using a cryoprobe in combination with radial EBUS could potentially provide larger samples and increase the yield in non-concentric lesions.

Methods: All patients who underwent radial EBUS cryobiopsy for diagnosis of SPN at Concord and Macquarie University hospitals in Sydney were included in this study. A retrospective audit was undertaken to obtain demographic, baseline physiological and procedural data. Complications and length of stay were recorded. Yield was determined by histopathology and clinical data.

Results: A total of 9 patients (3 female, mean age 73.4 years) have so far been included in the study. All procedures were performed under general anesthesia, with rigid intubation used in 8 cases. The lesion was located in all cases using an EBUS radial probe with only one eccentric lesion. Most targets were located in the upper lobes (66.6%). An average of 3.1 biopsies were obtained. No cases of pneumothorax or severe bleeding were observed. Only two patients stayed overnight after the procedure. Average diameter of specimens was 5mm. Definite malignant pathology was diagnosed in 5 cases with an overall yield of 7/9 (77.7%)

Conclusion: Radial EBUS cryobiopsy is a feasible alternative in diagnosis of SPN. The yield is comparable to previously reported techniques, however the larger specimens obtained by cryobiopsy could potentially provide invaluable data in malignant conditions.

Grant Support:

TRANSBRONCHIAL CRYOBIOPSY IN INTERSTITIAL LUNG DISEASE—A RETROSPECTIVE AUDIT
SHE S1, WILLIAMSON J2,3, ING A1,3,4, ING M1, IRANDOOST P5, SAGHAIE T1,3,4
1Faculty of Medicine, University of Sydney, Australia, 2Department of Thoracic Medicine, Liverpool Hospital, Australia, 3Faculty of Medicine and Health Science, Macquarie University, Australia, 4Concord General Repatriation Hospital, Concord, Australia, 5Laverty Pathology, North Ryde, Australia

Introduction/Aim: Histopathology is often required to achieve a multidisciplinary diagnosis in diffuse parenchymal lung disease. Surgical lung biopsy (SLB) remains the gold standard but is associated with significant morbidity and mortality. Recent emergence of transbronchial cryobiopsy (TBCB) as a potential alternative to SLB, promising less complications and a comparable yield, has divided the world of interventional pulmonology. There have been numerous publications reporting different and occasionally contradicting outcomes. Despite relative popularity of TBCB in our region, so far there have not been any published series from Australia.

Methods: All patients who underwent TBCB at Concord, Macquarie University and Liverpool Hospitals in Sydney for diagnosis of diffuse parenchymal lung disease between August 2013 and June 2017 were included. A retrospective audit was undertaken to obtain demographic, baseline physiological and Procedural data. Complications and length of stay were recorded. Diagnostic value of TBCB was assessed by its histopathological and clinical impact. All biopsy specimens were reviewed by a single investigator to record size, presence of artefact, percentage of alveolar area and presence of pleura or proximal airway structures.

Results: A total of 46 patients (25 male, average age 62.2) were enrolled in this study. All cases were performed under general anesthesia with rigid bronchoscope access. An average of 6.1 biopsies were obtained from 1-3 lobes. Most patients were discharged home the same day (65.7%) with average length of stay of 1.05 nights. Pneumothorax was observed in 10.5% of the patients with severe endobronchial bleeding in 5.2%. There were no deaths reported within 30 days of the procedure. Histopathological data as well as yield are currently being analysed.

Conclusion: Our preliminary data suggests that TBCB is a relatively safe procedure with an acceptable yield which could be considered as an alternative to SLB.

Grant Support:
STUDY OF ENDOBRONCHIAL VALVES INSERTION FOR ADVANCED EMPHYSEMA AT THE ROYAL BRISBANE AND WOMEN’S HOSPITAL IN QUEENSLAND AUSTRALIA

BILAL A1, RATHNAYAKE A1, BASHIRZADEH F1
1Royal Brisbane and Women’s Hospital, Brisbane/Herston, Australia

Introduction/Aim: Emphysema is a leading cause of disability and death. Its current medical treatment shows certain limitations in the advanced stage of the disease. Also, there is limited evidence in the Australian setting regarding therapeutic interventions for reducing hyperinflation, including endobronchial valves insertion (EBV). This study examined the outcomes of EBV insertion in patients with severe emphysema at the Royal Brisbane and Women’s Hospital.

Methods: This is a retrospective review of patients with severe emphysema who underwent EBV insertion from 2011-2017. The primary outcomes were change in exercise tolerance as measured by the six-minute walk test (6MWT) and quality of life (QoL) as measured by the St. George’s Respiratory Questionnaire (SGRQ) and direct questioning. Variables of interest were measured pre- and post-EBV placement.

Results: Of the 31 patients included in the study, 15 were females. Age ranged from 50 to 80 years (median age=67 years). Sixteen patients had no complications, and 9 patients had multiple complications. Three patients were readmitted within 30 days and 2 died mainly due to old-age co-morbidities. Ninety-day mortality rate was 0%. Pre and post values for 6MWT were obtained for 18 patients, SGRQ for 10 patients, and QoL data for 24 patients. Patients with complete data (25) showed improved mean values of SGRQ, 6MWT, and lung function. Mean SGRQ was reduced by 24 units (p=0.001), and 6MWT was increased by 78 metres (p=0.001). Mean FEV1 was increased by 4% (p=0.006), and residual volume and TLC were reduced by 25% and 11% (p=0.009 and 0.01), respectively. Significant improvement in QoL was reported in 13 patients while 11 reported improvement/slight improvement.

Conclusion: EBV is an effective and safe therapy that improves lung function, exercise capacity, and QoL in selected patients with emphysema. Further studies on a larger population need to confirm our findings.

Grant Support: Nil

Conflict of Interest: None.

Keywords: Severe emphysema, endobronchial valve, quality of life

BRONCHIAL THERMOPLASTY REDUCES GAS TRAPPING IN SEVERE ASTHMA

LANGTON D1,2, ING A1,2, BENNETTS K1, THIEN F3,4, PETERS M3,4, WANG W2, FARAH C2,4
1Frankston Hospital, Melbourne, Australia, 2Macquarie University, Sydney, Australia, 3Monash University, Clayton, Australia, 4Macquarie University Hospital, Sydney, Australia, and 5Eastern Health, Box Hill, Australia

Introduction/Aim: In randomized controlled trials, bronchial thermoplasty (BT) has been proven to reduce symptoms in severe asthma. The mechanisms by which this is achieved are still uncertain as no improvement in spirometry is observed in most studies. We postulated that BT might improve lung mechanics by altering airway resistance in the small airways of the lung in ways not measured by FEV1. This study aimed to evaluate changes in measures of gas trapping particularly the Residual Volume (RV).

Methods: A prospective cohort of 32 consecutive patients with severe asthma who were listed for BT at two tertiary institutions (Frankston Hospital and Macquarie University Hospital) were evaluated at three time points, namely baseline, and then 6 weeks and 6 months post completion of all procedures. At each evaluation, medication usage, symptom scores (Asthma Control Questionnaire, ACQ-5) and exacerbation history were obtained, and lung function was evaluated by (i) spirometry (ii) gas diffusion (DLCO) and (iii) static lung volumes by body plethysmography.

Results: ACQ-5 improved from 3.0±0.8 at baseline to 1.5±0.9 at 6 months (mean±SD, p<0.001). Daily reliever salbutamol usage improved from 8.3±5.6 to 3.5±4.3 puffs per day (p<0.001). Exacerbation frequency and maintenance oral corticosteroid usage also significantly declined (p<0.001), but no changes in any spirometric parameter were demonstrated. DLCO was also unaltered by BT treatment. However, a significant reduction in gas trapping was observed with RV falling from 146±57 to 136±31% predicted (p<0.001, paired t test). Significant improvements in TLC and FRC were also observed. These changes were evident at the 6 week time period and maintained at 6 months. The change in RV was negatively correlated with the baseline FEV1, r=0.474, p=0.006, indicating that the greatest improvement was evident in the most obstructed patients.

Conclusion: Bronchial thermoplasty appears to improve gas trapping and this effect is greatest in the most severely obstructed patients. The improvement may relate to changes in the mechanical properties of small airways that are not measured with spirometry.

Grant Support: Nil
Lung Cancer

EPITHELIAL MESENCHYMA TRANSITION (EMT) AND NON-SMALL CELL LUNG CANCER (NSCLC): A MUTUAL ASSOCIATION WITH AIRWAY DISEASE

MAHMOOD M1, WARD C2, MULLER H3, SCHAL S4, WALTERS E5

1NHMRC Centre for Research Excellence in Chronic Respiratory Disease and Lung Ageing, School of Medicine University of Tasmania Hobart, Australia, 2Institute of Cellular Medicine Newcastle University Newcastle upon Tyne, Tyne and Wear, UK, and 3Faculty of Health, School of Health Sciences University of Tasmania Launceston, Australia

Introduction/Aim: COPD and smoking play a vital role in development of NSCLC. Local progression and metastasis of NSCLC is associated with epithelial mesenchymal transition (EMT), which is implicated in COPD pathogenesis.

Methods: We have investigated EMT biomarkers (S100A4, Vimentin, and N-cadherin), an epithelial activation marker (EGFR) and a vascularity marker (Type-IV collagen) in surgically resected tissue from patients with NSCLC (adenoc- and squamous cell carcinoma), and compared them with corresponding non-tumorous airways.

Results: EGFR, S100A4, vimentin, N-cadherin expression was higher in tumour cells, at the peripheral leading edge of NSCLC when compared with centrally located tumour cells of same subjects (P<0.01). Same was with Type-IV collagen expressing blood vessels. EGFR and S100A4 expression was related to differentiation status (P<0.05) and TNM stage (P<0.05) of NSCLC. Moreover, EMT markers in the leading edge were significantly related to airway EMT activity, while peripheral edge vascularity of squamous cell carcinoma only was significantly related to large airway Rbm vascularity (P<0.05).

Conclusion: EGFR and EMT-related protein expression was remarkably high at peripheral leading edge of NSCLCs and related to tumour characteristics associated with poor prognosis. The relationships between EMT-related tumour bio-marker expression and those in the airway epithelium and Rbm, provides a background for utility of airway changes in clinical settings.

Grant Support: This study was funded by National Health and Medical Research Council (NHMRC) grant 1001062

Conflict of Interest: Authors declare no conflict of interest.

HEALTH-RELATED QUALITY OF LIFE - QUEENSLAND LUNG CANCER SCREENING STUDY

MARSHALL H1, PASSMORE L1, ELIZABETH M1, YANG I1, BOWMAN R1, FONG K1

1The University of Queensland Thoracic Research Centre, Department of Thoracic Medicine, The Prince Charles Hospital, Brisbane, Australia

Introduction/Aim: Lung cancer screening has a high false positive rate, carrying the potential for negative psychological impact. We report health-related quality of life (HRQoL) from the first year of screening in the Queensland Lung Cancer Screening Study (QLCSS).

Methods: QLCSS screened 256 healthy volunteers aged 60-74 with extensive current or former smoking history (pack years ≥30, quit <15 years prior). Scan results were defined based on 12 months follow-up: false-positive scans (FP) were lung cancer-free at 1 year; true-positives (TP) were not. There were no false negatives. Global health status (physical and mental function) was assessed using a 4-week recall period at baseline (pre-screening), 1 month, 6 months and 12 months after baseline screening scan using the Short Form 12 version 2.0 (SF-12). SF-12 contains twelve questions. Aggregate summary measures (Mental Component Summary (MCS) and Physical Component Summary (PCS)) were calculated using factor weights derived from a 1998 US general population sample. MCS and PCS range between 0 and 100; higher values indicate better health. The Minimally Important Difference determined clinically meaningful differences (MID = half of a standard deviation (SD) of the mean).

Results: Response to each questionnaire was ≥88% (table 1). Baseline mean (SD) for MCS and PCS were 54.82 (6.83) and 49.90 (7.72) respectively. MCS was above or at the norm in 76%. Small changes, below MID, were seen in FP and Negative groups at most time-points (Figure 1). Larger changes were seen in TP group, however, the number of responses was very small.

Conclusion: Screening was associated with small measurable changes in global HRQoL. There was no clinically meaningful difference between participants with negative or FP scans.

Grant Support: NHMRC, Queensland Government Smart State grant, The Prince Charles Hospital Foundation.

Table 1 Respondents, time point by baseline scan result

<table>
<thead>
<tr>
<th>Scan result</th>
<th>Baseline</th>
<th>1 month</th>
<th>6 month</th>
<th>12 month</th>
</tr>
</thead>
<tbody>
<tr>
<td>False Positive</td>
<td>123</td>
<td>112</td>
<td>112</td>
<td>115</td>
</tr>
<tr>
<td>Negative</td>
<td>127</td>
<td>120</td>
<td>111</td>
<td>119</td>
</tr>
<tr>
<td>True Positive</td>
<td>5</td>
<td>5</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Missing</td>
<td>1</td>
<td>19</td>
<td>32</td>
<td>20</td>
</tr>
<tr>
<td>Response rate %</td>
<td>100</td>
<td>93</td>
<td>88</td>
<td>92</td>
</tr>
</tbody>
</table>

Figure 1 Mean change in Physical Component Score and Mental Component Score from baseline.
PLEURAL FLUID CHOLESTEROL IS USEFUL IN DISTINGUISHING EXUDATES FROM TRANSUDATES

THOMAS R1,2, CHEAH H2,3, MURUGANANDAN S2,3, KENDREW P4, CREANEY J2,3, LEE Y1,2,3

1Pleural Medicine Unit, Institute for Respiratory Health, Perth, Western Australia, Australia, 2School of Medicine, University of Western Australia, Perth, Western Australia, Australia, 3Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia, 4School of Medicine, University of Western Australia, Nedlands, Australia, 5National Centre for Asbestos Related Diseases, Nedlands, Australia, and 6National Centre for Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, Australia

Introduction/Aim: Light's criteria is the gold standard for distinguishing between exudative and transudative pleural effusions (98% sensitivity, 80% specificity). The usefulness of pleural fluid cholesterol to improve diagnostic accuracy compared to Light's criteria is unclear. This study aims to determine i) the level of pleural fluid cholesterol and triglyceride and b) its use in distinguishing exudates from transudates.

Methods: Pleural fluid was prospectively collected from 110 consecutive pleural effusion cases. The fluid was analysed by an accredited laboratory (PathWest, WA) for protein, lactate dehydrogenase (LDH), cholesterol and triglycerides. Aetiology of the effusion was independently verified based on clinical, radiological and pathological assessment. The effusion was classed as an exudate (89) or transudate (21) based on final aetiology.

Results: Exudates were mainly due to malignancy (68 including 13 lung, 6 breast, and 26 mesothelioma effusions), pleural infections (6) and benign pleuritis (5). Transudates were secondary to heart failure (16), hepatic hydrothorax (4) and peritoneal dialyses (1). Exudates had higher pleural fluid protein [median 41.5 (IQR 36-46) g/dL], LDH [314 (203-611) mmol/L] cholesterol [2.08 (1.67-2.61) mmol/L] and triglycerides [0.36 (0.24-0.57) mmol/L] compared to transudates with fluid protein [21 (13-26)], LDH [88 (72-115)], cholesterol [0.66 (0.45-0.97)] and triglycerides [0.2 (0.16-0.33)]. Cholesterol and triglyceride were highest in malignant [mean 2.18 (SD 0.76) and 0.47 (0.36), respectively] and parapneumonic [1.93 (0.47) and 0.35 (0.09)] effusions. Strong Spearman correlation was found between fluid cholesterol and protein (0.798, p<0.0001) as well as fluid:serum protein ratio (0.752, p=0.0001). Exudates were identified with a high discrimination (accuracy 95.5%, sensitivity 96.7% and specificity 99.0%) when fluid protein >35, LDH >225 and cholesterol >1.5 with modified cut-offs were combined.

Conclusion: Pleural fluid cholesterol and triglyceride levels are higher in exudates, particularly malignant and parapneumonic effusions. A combined fluid protein, LDH and cholesterol criteria is useful in distinguishing exudates from transudates.

Conflict Support: NHMRC; Cancer Council WA (RT, YCGL, JC); Cancer Australia; NSW Dust Diseases Board (YCGL, JC); Sir Charles Gairdner Research Advisory Group (YCGL).

Conflict of Interest: All authors declare no conflict of interests.

SIX-WEEK EXERCISE INTERVENTION IN PATIENTS WITH MALIGNANT PLEURAL DISEASE IMPROVES PHYSICAL FUNCTION, MUSCULAR STRENGTH AND APPENDICULAR LEAN MASS

PEDPLE-MCINTYRE C1, JEFFERY E1, LEE G2,3,4, NOWAK A5,6, NGUYEN B6, NEWTON R1,3

1Exercise Medicine Research Institute, Edith Cowan University, Joondalup, Australia, 2Respiratory Department, Sir Charles Gairdner Hospital, Nedlands, Australia, 3Institute for Respiratory Health, Nedlands, Australia, 4School of Medicine and Pharmacology, University of Western Australia, Nedlands, Australia, 5Medical Oncology Department, Sir Charles Gairdner Hospital, Nedlands, Australia, 6National Centre for Asbestos Related Diseases, Nedlands, Australia, and 7UQ Centre for Clinical Research, The University of Queensland, Herston, Australia

Introduction/Aim: To investigate the feasibility and efficacy of exercise to improve physical functioning, body composition, and patient-rated outcomes in patients with malignant pleural disease (MPD).

Methods: Thirty-three patients with MPD were recruited to complete an exercise training intervention. The exercise intervention included progressive resistance exercise training three times/week for six weeks. Outcomes assessed at baseline and post-intervention included muscular strength (1-repetition maximum leg press), functional capacity (6-Minute Walk Test), physical functioning (Timed Up and Go), body composition (DXA scan), quality of life (Short-Form 36 Health Survey), ratings of intervention burden and acceptability (7-point Likert scale; 1, not at all, to 7, very much). Paired T-test or Wilcoxon Signed Rank Test was used to assess changes over time.

Results: Mean participant age was 64 (SD =11) years. The majority had mesothelioma (93%), ECOG performance status 0-1 (97%), and were male (70%), and sarcopenic (56%). Twenty-six participants (79%) completed the intervention; 24 (73%) completed all post-intervention assessments. Median adherence to supervised exercise was 100% (range 6%-100%). Median ratings of trial evaluation were high (i.e., 7/7 for all measures) and intervention burden were low (i.e., <1.5/7 for all items). Post intervention, significant improvements were found for mean six-minute walk distance (+59 m; 95% CI 24-93; p<0.05), 1-repetition maximum leg press (+17 kg; 95% CI 11-23; p<0.001), timed up and go (-0.51 sec; 95% CI -0.94 - -0.08; p<0.05), chair rise (+1.6 sec; 95% CI -2.2 - -0.9; p<0.001), and appendicular lean massheight squared (+0.19 kg/m2; 95% CI 0.04 – 0.34; p=0.05). For patient-rated outcomes, only the mental health subscale of SF-36 changed significantly (median change +2.6, IQR 0.0, 5.2; p<0.05).

Conclusion: Progressive resistance exercise training is a feasible intervention with measurable health benefits for patients with MPD.

Conflict Support: Cancer Council Western Australia, Edith Cowan University

Conflict of Interest: All authors declare no conflict of interests.
TARGETED PROFILING OF EBUS BRUSHINGS IDENTIFIES MOLECULAR DRIVERS IN NSCLC
VANINATAMBY A1, MAKADIA T1, IRVING L2, STEINFORT D2, BOZINOVSKI S1
1RMIT University, Bundoora, Australia, and 2Royal Melbourne Hospital, Parkville, Australia

Introduction/Aim: Radial Endobronchial Ultrasound (EBUS) bronchoscopy in conjunction with rapid-on-site examination (ROSE) is a procedure that routinely achieves an adequate diagnostic yield to identify malignant cells. This study aims to improve the diagnostic value of EBUS bronchial brushings by screening these specimens for molecular changes that can identify therapeutic targets. More specifically, to assess the feasibility of using EBUS bronchial brushings to detect differentially expressed tumour markers using Taqman Low Density Array (TLDA) RT-qPCR.

Methods: Single pass radial EBUS brushings from Non-Small Cell Lung Cancer (NSCLC) patients (n=15) were collected following ROSE confirmation of the malignant site at the Royal Melbourne Hospital. Final diagnoses included adenocarcinoma (n=10) and squamous cell carcinoma (SCC, n=5). As a control, benign brushings were collected from clinic-radiologic confirmed interstitial lung disease patients (n=14). Isolated DNA and RNA from individual brushings were used for TLDA gene expression analysis to determine the fold change of several tumour markers (FGFR1, PD-L1, PTEN, RICTOR, MET and MMP-9) and Next Generation Sequencing (NGS) using the Illumina TruSight 15 panel. Statistical significance was assessed by performing Mann Whitney t tests to compare unpaired groups.

Results: Fold change values were higher for PD-L1 (mean±SEM: 6.24±1.73, p<0.04), FGFR1 (3.44±1.30, p<0.02), RICTOR (1.51±0.23, p<0.02) and MMP-9 (33.79±7.38, p<0.0001) in the malignant brushings relative to the benign brushings. According to tumour type a fold increase in PD-L1 (8.50±2.26, p<0.02), RICTOR (1.84±0.28, p<0.003) and MET (3.51±1.38, p<0.005) were observed in adenocarcinomas vs. SCCs. FGFR1 levels were higher (6.86±4.5 fold, p<0.02) and PTEN levels were lower (0.64±0.12 fold, p<0.001) in SCCs vs. adenocarcinomas. The malignant nature of the lesions were confirmed by NGS, identifying common mutations in p53 (10/15 patients), Kras (2/15), EGFR (2/15) and PI3K (3/15).

Conclusion: These findings demonstrate that targeted RT-qPCR profiling can identify molecular abnormalities in EBUS bronchoscopy brushings collected from ROSE confirmed malignant lesions. Further investigation is warranted as to whether RT-qPCR can be used clinically to guide individualised therapeutic options.

Grant Support: National Health and Medical Research Council (NHMRC) and Australian Research Council (ARC).

RADIATION THERAPY AUGMENTS THE EFFICACY OF IMMUNOTHERAPY IN NON-SMALL CELL LUNG CANCER: A CASE-CONTROLLED STUDY
SAMARANAYAKE C1, COUCHER J2, MCCAFFREY E3, LEHMAN M4, MURPHY M4
1Department of Respiratory and Sleep Medicine, Princess Alexandra Hospital, Brisbane, Australia, 2Department of Radiology, Princess Alexandra Hospital, Brisbane, Australia, 3Department of Medical Oncology, Princess Alexandra Hospital, Brisbane, Australia, and 4Department of Radiation Oncology, Princess Alexandra Hospital, Brisbane, Australia

Introduction/Aim: Preclinical studies have demonstrated that radiation acts as an immune stimulus, facilitating immune mediators to enable anti-tumour responses. Impact of previous radiation therapy to the chest on the efficacy and safety of nivolumab in patients with advanced non-small cell lung cancer (NSCLC) is unknown.

Methods: Consecutive series of patients who received nivolumab for advanced NSCLC on an intention-to-treat basis over a 30 months period between January 2015 and June 2017 at a large thoracic-oncology unit were identified. Outcomes in patients who had received radiation therapy to the chest as part of previous treatment prior to commencing nivolumab (RT group, n=20) were compared to an age, gender, tumour histology and performance status matched cohort of patients who did not receive previous radiation therapy (non-RT group, n=20).

Results: The RT group had received a mean 53.3Gy (SD 12.3) at a median of 12.4 months prior to commencing nivolumab. The median progression free survival (PFS) was 3.4 months (95%CI 2.2-4.5) in the RT group compared to 1.3 months (95%CI 1.0-1.7) in the non-RT group (p<0.01). The median overall survival was 8.4 months (95%CI 5.1-11.6) in the RT group compared to 4.2 months (95%CI 1.0-7.7) in the non-RT group (p=0.08). The disease response on the initial assessment following starting nivolumab included nine (45%) patients who had stable disease and five (25%) in the non-RT group. The rate of immune related complications was 35% (n=7) and 15% (n=3) in the RT and non-RT groups respectively (p=0.1). The RT group had a higher mean smoking pack years.

Conclusion: This study demonstrates a novel finding of previous radiation therapy to the chest resulting in significantly higher PFS in patients treated with nivolumab for advanced NSCLC. A trend towards a higher rate of immune related adverse effects seen in the RT group may due to increased activity of the immunotherapy in these patients.

Grant Support: Nil
NINTEDANIB LONG-TERM EFFICACY IN IPF IS MAINTAINED IRRESPECTIVE OF DOSE

GON N1, CRESTANI B2, KOLB M3, WALLAERT B4, QUARESMA M5,6, STANSEN W7, RICHELDI L1

1Austin Health, Australia, 2Hôpital Bichat, Pneumologie, Paris, France, 3McMaster University, Hamilton, Canada, 4University Hospital of Lille, Lille, France, 5Center for Interstitial and Rare Lung Diseases, Pneumology, Thoraxklinik, University of Heidelberg, and Translational Lung Research Center Heidelberg, German Center for Lung Research, Heidelberg, Germany, 6Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany, 7Catholic University of the Sacred Heart, Rome, Italy

Introduction:Aim: In Phase III INPULSIS® trials, nintedanib significantly reduced annual rate of FVC decline versus placebo in patients with IPF (−113.6 versus −223.5 mL/year). In an extension trial (INPULSIS-ON), patients who completed treatment and follow-up visit in INPULSIS® could receive open-label nintedanib. In INPULSIS-ON, patients receiving nintedanib or placebo 150mg twice-daily (bd) at the end of INPULSIS® received nintedanib 150mg bd; patients receiving nintedanib or placebo 100mg bd received nintedanib 100mg bd or 150mg bd, based on discussion between the patient and the investigator. Dose reduction to 100mg bd was allowed to manage adverse events; re-escalation to 150mg bd was permitted. We assessed the influence of nintedanib dose on FVC decline in INPULSIS-ON.

Methods: Annual rates of FVC decline over 96 weeks in INPULSIS-ON were assessed in patient subgroups (treated with nintedanib 150mg bd, 100mg bd or both). Slope of FVC decline was calculated using all available FVC measurements collected between baseline and week 96 in INPULSIS-ON. The first patient was enrolled in July 2012: Analyses were descriptive, based on a data snapshot in October 2015.

Results: Of 734 patients treated, 436 (59.4%), 53 (7.2%) and 245 (33.4%) received 150mg bd, 100mg bd and both doses, respectively. Adjusted annual rates ±SEM of FVC decline over 96 weeks were −116.4±8.9, −79.0±30.1 and −126.2±11.4 mL/year in patients treated with nintedanib 150mg bd, 100mg bd and both doses, respectively. Annual rates of FVC decline in all subgroups were consistent with annual rate of FVC decline over 96 weeks in all treated patients (−117.8±6.6 mL/year).

Conclusion: Annual rate of FVC decline was similar in patients treated with nintedanib 150mg bd, 100mg bd or both. Long-term efficacy of nintedanib in reducing disease progression was maintained in patients with IPF who required dose adjustments to manage adverse events.

Grant Support: The INPULSIS-ON trial was funded by Boehringer Ingelheim.

Declaration of interest statement: NG has received speaker fees from Boehringer Ingelheim, AstraZeneca, Menarini and Novartis and consultation fees from Boehringer Ingelheim and Roche. BC has received grants, personal fees and non-financial support from Roche/InterMune and Boehringer Ingelheim; personal fees and non-financial support from Sanofi; grants from Cardiff, LVL and MedImmune, and personal fees from AstraZeneca. MK has received grants and personal fees from Roche, Boehringer Ingelheim, GlaesoSmithKline, Gilead, Prometic and Alkermes; grants from Actelion, Respivert and Synairgen; and personal fees from AstraZeneca and Genoa. BW has nothing to disclose. MQ and WS are employees of Boehringer Ingelheim. LR served on the scientific advisory boards of InterMune, Boehringer Ingelheim, FibroGen, GlaesoSmithKline, Sanofi-Aventis, Anthera, Genentech, MedImmune, Takeda, UCB, and Promedior and as a trial Principal Investigator for Boehringer Ingelheim, InterMune, Gilead, Roche, Takeda, and UCB; received research grants from InterMune, Biogen, Italian Ministry of Health, Italian National Drug Agency, and Wellcome Trust and speaker’s fees from InterMune, Boehringer Ingelheim and Cipla.

HIGH RESOLUTION CT-BASED CHARACTERIZATION ANALYSIS OF IDIOPATHIC PULMONARY FIBROSIS

ZHANG Y1, CLARK A2, KUMAR H3, MILNE D4, WILSHER M5, BARTHOLMAI B5, TAHWAI M6

1Auckland Bioengineering Institute, University of Auckland, Auckland, New Zealand, 2Auckland City Hospital, Auckland, New Zealand, and 3Department of Radiology, Mayo Clinic, Rochester, USA

Introduction:Aim: Idiopathic pulmonary fibrosis (IPF) is the most aggressive and frequent form of idiopathic interstitial pneumonias. Progression of IPF is variable between individuals and no established quantitative tools exist to assess its development. This work aims to integrate information from volumetric imaging with pulmonary function tests using a predictive computational model under the hypothesis that abnormalities on volumetric are not sufficient to explain increased lung stiffness and decreases in DLCO.

Methods: Tissue regions in HRCT images from 8 patients with IPF were quantitatively analysed. Tissue abnormalities were classified using CALIPER (Computer-Aided Lung Informatics for Pathology Evaluation and Ratings) software. Tissue density (TD) distribution and volume of tissue (classified as reticular, ground-glass, normal and emphysema in each lung) were calculated. The classified data were mapped to a statistical shape model, which allows consistent comparison of regional tissue properties between patients or within one patient at different time points. Ventilation distribution and gas exchange were simulated in a computational model that was parameterised to each subject’s lung tissue characterisation, to predict the relationship between V-Q matching, DLCO and disease distribution.

Results: Fibrosis usually has a consistently higher TD (0.34±.41 for reticular/ground-glass) compared to normal tissue (0.28), and presents predominantly in lower lobes (72%, 58%, 65% for honeycomb, reticular, ground-glass). In contrast, emphysema has lower density (0.08) and appears predominantly in upper lobes (73%). Model predictions of ventilation distribution and DLCO show that V-Q mismatch occurs due to redistribution of ventilation away from diseased regions, contributing to observed DLCO decreases.

Conclusion: A quantitative analysis of the spatial distribution of IPF disease coupled with functional models provides a potential tool to improve assessment of the contributors to decline in IPF patient status over time. Decline in DLCO is a function of regional lung stiffness due to disease location combined with a redistribution of ventilation to ‘normal’ lung tissue.

Grant Support:
THE INTERSTITIAL LUNG DISEASE MULTI-DISCIPLINARY MEETING: 3 YEAR REVIEW OF A NOVEL STATEWIDE TELEMEDICINE MODEL

BALZAT L1, CHAMBER D1,2, GODBOLT D3, REDDY T4, KEIR G5, SIVAKUMARAN S6, BINT M7, BANCROFT S1, HOPKINS P1,2

1Queensland Lung Transplant Service, The Prince Charles Hospital, Brisbane, Australia, 2School of Medicine, University of Queensland, Brisbane, Australia, 3Anatomical Pathology, The Prince Charles Hospital, Brisbane, Australia, 4Radiology Department, The Prince Charles Hospital, Brisbane, Australia, 5Department of Respiratory Medicine, The Princess Alexandra Hospital, Brisbane, Australia, 6Department of Respiratory Medicine, Gold Coast University Hospital, Gold Coast, Australia, and 7Department of Respiratory Medicine, Sunshine Coast University Hospital, Sunshine Coast, Australia

Introduction/Aim: A multidisciplinary meeting (MDM) model of care is recommended by TSANZ for the diagnosis and initial management of interstitial lung disease (ILD). In order to ensure equity of access to the required expertise, we established an ILD-MDM at Prince Charles Hospital (TPCH) in Brisbane which facilitated telemedicine and active participation of sites from elsewhere in Queensland.

Methods: We reviewed all cases presented at the ILD-MDM from July 2014 to June 2017. The ILD-MDM included a minimum of 2 expert thoracic physicians, 1 radiologist and 1 histopathologist.

Results: 313 referrals from 38 clinicians and 11 institutions were discussed. 38.3% were female, mean age 67 years, and 24.9% were from outside TPCH. Mean FVC was 74.0% and carbon monoxide diffusion capacity 51.5%. Overall, 111 cases (35.5%) were classified as idiopathic pulmonary fibrosis (IPF) and 17 (5.4%) as combined pulmonary fibrosis and emphysema, with the majority eligible for antifibrotic medication. 18 (5.8%) were classified as connective tissue disease, 12 (3.8%) chronic hypersensitivity pneumonitis, whilst 18.2% remained unclassifiable. There were 105 (33.5%) patients surgical lung biopsies (SLB) reviewed with 79% performed prior to first MDM presentation. In patients with a first presentation diagnosis of IPF, 65.6% had not had a prior SLB. 71 cases (22.7%) had high-resolution computed tomography (HRCT) reported as usual interstitial pneumonia (UIP), a further 130 (41.5%) as possible UIP and 4.5% had inadequate imaging. Of 61 SLB showing definitive pattern, 63.9% had possible UIP and 19.7% UIP pattern on HRCT. In 22% of initial case presentations (n=69), further investigations were recommended including surgical lung biopsy (n=30), HRCT (n=26), bronchoscopy (n=4) and extended autoimmune screen (n=9).

Conclusion: A telemedicine model is feasible and can facilitate equity of access for patients and clinicians where a low volume ILD caseload &/or absence of expertise precludes local establishment of the ILD-MDM.

Grant Support: Roche Pharmaceuticals $20,000.

Declaration of interest: None.
CARDIOVASCULAR SAFETY OF NINTEDANIB IN SUBGROUPS BY BASELINE CARDIOVASCULAR RISK

COTTE T¹, NOTH F², WIJSENBEEK M³, KOLB M⁴, BONELLA P⁵, MOROS L⁶, WACHTLIN D⁶
¹Royal Prince Alfred Hospital, Sydney, Australia, ²Pulmonary and Critical Care Medicine, University of Chicago, Chicago, USA ³Erasmus MC, University Medical Centre, Rotterdam, Netherlands, ⁴McMaster University, Hamilton, Canada, ⁵Interstitial and Rare Lung Disease Unit, Ruhrlandklinik, University Hospital, University of Duisburg-Essen, Essen, Germany, and ⁶Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany

Introduction/Aim: Tyrosine kinase inhibitors may be associated with an increased risk of arterial thromboembolic events. The efficacy and safety of treatment with nintedanib versus placebo in patients with idiopathic pulmonary fibrosis were assessed in the Phase II TOMORROW trial and 2 Phase III INPULSIS® trials. Exclusion criteria included: myocardial infarction in the previous 6 months, unstable angina in the previous month or stroke in the previous year. We assessed the effect of cardiovascular (CV) risk at baseline on the CV safety of nintedanib 150mg twice-daily.

Methods: Incidence rates of major adverse CV events (MACE) in subgroups of patients with a history of atherosclerotic CV disease (CVD) and/or ≥1 CV risk factor (hypertension, dyslipidemia, body mass index >30 kg/m², current/former smoking and diabetes) at baseline (higher CV risk) and patients with no history of atherosclerotic CVD and no CV risk factors at baseline (lower CV risk) were analysed using pooled data from the TOMORROW and INPULSIS® trials.

Results: At baseline, 1107 (89.9%) patients (656 nintedanib, 451 placebo) had higher CV risk and 124 (10.1%) patients (67 nintedanib, 57 placebo) had lower CV risk. In patients with higher CV risk, incidence rates (95% CI) of MACE were 3.88 (2.58, 5.84) and 3.49 (2.10, 5.79) per 100 patient–years in the nintedanib and placebo groups, respectively (Figure). In patients with lower CV risk, incidence rates (95% CI) of MACE were 4.78 (1.54, 14.82) and 5.37 (1.73, 16.65) per 100 patient–years in the nintedanib and placebo groups, respectively (Figure).

Conclusion: In pooled data from the TOMORROW and INPULSIS® trials, the incidence of major adverse CV events was similar between nintedanib and placebo groups both in patients with higher and lower CV risk at baseline.

<table>
<thead>
<tr>
<th>CV Risk</th>
<th>Patients with events, n (%)</th>
<th>Rate per 100 patient-years (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Higher CV risk</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nintedanib</td>
<td>556</td>
<td>2.20 (2.08, 2.34)</td>
</tr>
<tr>
<td>Placebo</td>
<td>451</td>
<td>3.44 (3.14, 3.78)</td>
</tr>
<tr>
<td>Lower CV risk</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nintedanib</td>
<td>67</td>
<td>4.70 (1.54, 14.83)</td>
</tr>
<tr>
<td>Placebo</td>
<td>57</td>
<td>5.37 (1.73, 16.65)</td>
</tr>
</tbody>
</table>

Figure 1
MULTIPLE PROGRESSION EVENTS IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF)

NATHAN S1, COSTABEL U2, GLASPOLE I2, GLASSBERG M2, LANCASTER L1, J. LEDERER D3, A. PEREIRA C1, TRZASKOMA B4, LIMB B5, U. WELLS A6

1Inova Fairfax Hospital, Falls Church, USA, 2Ruhrlandklinik, University Hospital, University of Duisburg-Essen, Germany, 3Alfred Hospital and Monash University, Melbourne, Australia, 4University of Miami Miller School of Medicine, Miami, USA, 5Vanderbilt University Medical Center, Nashville, USA, 6Columbia University Medical Center, New York, USA, 7Paulista School of Medicine, Federal University of São Paulo, São Paulo, Brazil, 8Genentech, Inc., South San Francisco, USA, and 9Royal Brompton Hospital, Interstitial Lung Disease Unit, London, UK

Introduction/Aim: Declines in forced vital capacity (FVC), declines in 6-min walk distance (6MWD) and respiratory hospitalizations are events associated with disease progression and mortality in IPF. The incidence of multiple events in the context of a 52-week study and in patients (pts) receiving antifibrotic treatment with pirfenidone (PFD) is unknown. To determine the incidence of multiple progression events and the proportion of pts with death subsequent to a progression event in the first 12 months of PFD treatment vs placebo (PBO).

Methods: All pts from the pooled Phase III trials (PFD n = 623; PBO n = 624) were analyzed for incidence of events, defined as relative decline in %predicted FVC ≥10%, absolute decline in 6MWD ≥50 m; respiratory hospitalization, or death due to any cause.

Results: The incidence of progression events was driven by declines in FVC (total events, 202 PFD vs 304 PBO) and 6MWD (285 PFD vs 348 PBO). A lower proportion of pts had > 1 event with PFD vs PBO (17.0% vs 30.1%; P < 0.0001; Figure 1). Death following ≥1 progression event occurred less often with PFD vs PBO (2.1% vs 6.3%; P = 0.0002).

Figure 1 Multiple progression events and death as a first or subsequent progression event in the pooled CAPACITY and ASCEND phase 3 trials (N = 1247). CAPACITY-004, NCT00287716; CAPACITY-006, NCT00287729; ASCEND, NCT01366209.

Conclusion: PFD significantly reduced the incidence of multiple progression events and death subsequent to a progression event at 12 months vs PBO. A multiple events–driven approach may have relevance for the design of future IPF clinical trials.

Grant Support: F. Hoffmann-La Roche Ltd./Genentech, Inc.
PERIPHERAL VENOUS BLOOD GAS ANALYSIS VERSUS ARTERIAL BLOOD GAS ANALYSIS FOR THE DIAGNOSIS OF RESPIRATORY FAILURE AND METABOLIC DISTURBANCE IN ADULTS

BYRNE A, BENNETT M3, PACE N4, THOMAS P3,6, SYMONS R3,6, CHATTERJI R6
1Heart Lung Clinic, St Vincents Hospital, Darlinghurst, Australia, 2Blacktown Hospital, Sydney, Australia, 3Department of Anesthesia, Prince of Wales Clinical School, University of NSW, Sydney, Australia, 4Department of Anesthesiology, University of Utah, Salt Lake City, USA, 5Department of Respiratory Medicine, Prince of Wales Hospital, Sydney, Australia, and 6University of New South Wales, Sydney, Australia

Introduction/Aim: Whilst arterial blood gas (ABG) is the gold standard for the diagnosis of respiratory failure and metabolic disturbance, the peripheral venous blood gas analysis (PVBG) is increasingly being used. We sought to compare the performance (accuracy) of both tests to diagnose these target conditions.

Methods: We performed an extensive electronic and manual search of the literature for case-control or consecutive series studies that directly compared the index test (PVBG) to the reference standard (ABG). No language restrictions were applied. Included studies provided outcome data for specified target conditions (pO2, pCO2, pH, HCO3) using generally accepted cut points. Quality assessment was conducted using the QUADAS-2 tool. The statistical analysis utilized 2x2 tables for each outcome's positive and negative results and Stata 12 software (Statacorp 2017). The published protocol is available at the Cochrane Database of Systematic Reviews. Article No:CD010841.

Results: We identified 7207 articles with our search strategy following the removal of duplicates. There were 16 studies meeting the inclusion criteria, however only 6 could provide sufficient data for the statistical analysis. Two authors evaluated the quality for these studies which were generally considered a low risk of bias. For (any) respiratory failure, 2 studies demonstrated poor accuracy of the PVBG compared to the ABG. The diagnostic odds ratio (DOR) was 2.73 with 95% confidence intervals 0.14-55.2. For isolated hypercapnia (6 studies) and metabolic disturbance (3 studies), the PVBG performed well (DOR 35.5 with 95% CI 9.7-130.2 and DOR 5.8 with 95% CI 1.5-22.2). Meta-analysis was only able to be performed for hypercapnia. The PVBG showed high sensitivity (95.4%) but low specificity (33.6%) with a high false positive rate (45.8%).

Conclusion: Limited data suggests the PVBG is useful in diagnosing metabolic disturbance but not respiratory failure. For isolated hypercapnia the PVBG has high sensitivity but poor specificity.

Grant Support: Nil

Diagnostic Yield and Appropriateness of Computed Tomography Pulmonary Angiography

ONG Q1, CHEN C1, MCANULTY K2, GALLAGHER H1
1Waikato Hospital Respiratory Department, Hamilton, New Zealand, 2Waikato Hospital Radiology Department, Hamilton, New Zealand

Introduction/Aim: International guidelines recommend Computed Tomography Pulmonary Angiography (CTPA) as the gold standard imaging modality for suspected Pulmonary Embolism (PE). Royal College of Radiologist suggests PE should be detected in 15% of CTPA scans. Appropriate requesting of CTPA is important to both establishing an accurate diagnosis and minimizing unnecessary testing and radiation exposure. International and Waikato Hospital guidelines recommend pre-test probability scoring and D-dimer assay to stratify patients prior to performing CTPA.

We aimed to determine the overall and departmental diagnostic yield of CTPA at Waikato Hospital. We also aimed to identify whether CTPA were ordered according to current guidelines.

Methods: Medical records of 200 consecutive patients who underwent CTPA for suspected PE from 01 March to 31 May 2017 were retrospectively reviewed. Patient demographics, referral source, clinical risk factors, D-dimer levels, diagnostic yield and additional CTPA findings were recorded. We utilized an age-adjusted D-dimer cut-off. CTPA images were obtained using either a Siemens 128 or 256 slice multi-detector CT scanner. Results were compared with international guidelines as well as similar local studies.

Results: 41 (20.5%) patients had PE. Orthopaedics had the highest yield (36.4%), followed by Respiratory (32.9%) and General Surgery (18.8%). According to the Wells Score, 74 (37%) patients were low risk while 134 (63%) were High Risk. D-dimer was done in 108 (54%) patients. 34 (44.7%) patients in the low-risk group did not have D-dimer. Two patients who had low wells score and negative D-dimer received CTPA, neither had PE. Of the 14 patients referred by cardiology, none had positive scans. On review, only one patient had CTPA requested inappropriately (low wells score, D-dimer not done).

Conclusion: Diagnostic yield of CTPA in Waikato Hospital is consistent with international standard. D-dimer has not been adequately used as a rule out test. Adherence to diagnostic protocol could potentially improve positive yield.

Grant Support: No funding or financial support was received from any organization.

This abstract has been withdrawn
Introduction/Aim: Severe asthma exacerbations are common and have major impacts on outcomes. The 2017 Lancet Asthma Commission\(^1\) called for zero-tolerance on exacerbations and has recommended replacing the terms ‘exacerbation’ or ‘flare-up’ with ‘attack’. The aim of this study was to explore patients’ perspectives on episodes of severe asthma and the terminology used.

Methods: Semi-structured qualitative interviews were conducted with 14 adults with severe asthma. Interviews explored individuals’ experiences with severe asthma episodes and their perspective on language used. Sampling was purposive and interviews continued until no new themes emerged. Data were analysed using a modified thematic analysis.

Results: Participants had a mean±SD age of 59±12 years and 57% were female. Mean±SD FEV\(_1\)% predicted and ACQ6 were 61±25% and1.8±1.2 units, respectively. Most (71%) lived with family. Participants described attacks of asthma as frightening events that had major impacts on their lives: ‘it’s an attack on your life’. The use of the term ‘exacerbation’ was perceived as being used by health professionals to ‘medicate’ their asthma. Patients considered exacerbations and flare-ups as a transient, often common increase in their symptoms that might last hours or days but generally led to a return to baseline. These were viewed as being less severe events. The term ‘attack’ however had a different meaning. Participants used this to describe serious life-threatening events: ‘it’s an attack when it’s completely out of control’. The use of the term exacerbation by health professionals was described as ‘insulting’ as it trivialised their experience.

Conclusion: Exacerbation and flare-up have a different meaning to patients with severe asthma than how they are intended. These data provide important person-centred support to the recommendations of the Lancet commission\(^1\) in regard to the use of the term attack. The term attack better reflects the severity of events from the patient perspective.


Grant Support: The study was supported by the Centre of Excellence in Severe Asthma and the John Hunter Charitable Trust.

Declaration of Interest Statement: Nothing to declare

Asthma & Allergy 1

PATIENT PERSPECTIVES ON SEVERE ASTHMA EPISODES: ATTACKS, FLARE-UPS OR EXACERBATIONS?

MCDONALD V\(^1\), YORKE J\(^3\), NIVEN P\(^2\), SMITH A\(^1\), GIBSON P\(^1\)

\(^1\)Centre of Excellence in Severe Asthma and Priority Research Centre for Healthy Lungs, University of Newcastle, Newcastle, Australia, \(^2\)Department of Respiratory and Sleep Medicine, John Hunter Hospital, New Lambton Heights, Australia, \(^3\)School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK, \(^4\)Manchester Academic Health Sciences Centre, University of Manchester, Manchester, UK, and \(^5\)MAHSC; University of Manchester and Manchester Foundation Trust, Manchester, UK

ASTHMA SELF-MANAGEMENT FOR AUSTRALIAN CHILDREN AND THE ROLE OF APPS?

GARDNER C\(^1\), MOLLOY C\(^1\), WILES L\(^1\), FOSTER J\(^3\), JAFFE A\(^4\)

\(^1\)Center for Population Health Research, University of South Australia, Adelaide, Australia, \(^2\)Australian Institute of Health Innovation, Macquarie University, Macquarie University, Australia, \(^3\)Clinical Management Group, Woolcock Institute of Medical Research, The University of Sydney, Glebe, Australia, and \(^4\)School of Women’s and Children’s Health, University of New South Wales, Randwick, Australia

Introduction/Aim: Smartphone apps can deliver self-management programmes for children with asthma, however the literature reports heterogeneous outcomes. Consumers’ perspectives are yet to be investigated despite being crucial for uptake and effectiveness. This project aimed to: 1. explore the self-management strategies and needs of children with asthma and their carers; and 2. understand the content, design features and usability of existing asthma apps.

Methods: Children with asthma aged 6-11 years and their carers participated in focus groups which incorporated a group discussion followed by user-testing of 7 asthma apps. Focus groups were recorded, transcribed and analysed thematically.

Results: Participants (children: n=41, carers: n=38) took part in one of 31 focus groups. Carers reported being heavily involved in self-management activities including symptom and medication management and communication with health professionals. Carers wanted children to take on more self-management responsibility but expressed concern about relinquishing control. Carers and children both expressed frustration over asthma negatively impacting social factors including a strong desire to not be seen as different. Most carers felt positive about the potential of an app to build awareness of their child’s experience of asthma and to improve their child’s asthma self-management. App features found particularly useful by participants included customisation, recording and tracking information (e.g. symptom monitoring), education, reminders (e.g. medication), icons and visuals and information sharing with health professionals. Missing, desired features included multiple personnel entry options, automation, intuitive design for young children to navigate, parent and child portals, information sharing between child and carer, and social networking. No single asthma app tested met all needs identified as important by participants.

Conclusion: These findings have significant implications for the future design and implementation of acceptable and effective asthma self-management apps, and indicate the need for greater end-user involvement in app design.

Grant Support: This study was supported by NHMRC Partnership Grant no.1065898.
PREVALENCE OF DIFFERENT TREATABLE TRAITS IN SYMPTOMATIC AIRWAYS DISEASE
FINGLETON J1,2, WILLIAMS M1, TRAVERS J4, WEATHERALL M3,5, BEASLEY R1,2,3
1Medical Research Institute of New Zealand, Wellington, New Zealand, 2Victoria University Wellington, Wellington, New Zealand, 3Capital and Coast District Health Board, Wellington, New Zealand, 4Hutt Valley District Health Board, Lower Hutt, New Zealand, and 5University of Otago Wellington, Wellington, New Zealand

Introduction/Aim: The concept of treatable traits has been proposed as an alternative approach to the classification of airways diseases. This approach does not rely on diagnostic labels such as asthma or COPD but on the presence of specific treatable characteristics to guide management. Many candidate treatable traits have been suggested but their prevalence among people with symptoms of airways disease is unknown.

Methods: Data on the presence of treatable traits were derived from the previously reported New Zealand Respiratory Health Survey. Participants aged 18-75 with symptoms of wheeze and breathlessness, recruited from a random population sample, underwent detailed characterisation including symptom and medical history questionnaires, measurement of lung function, gas exchange, and biomarkers including blood eosinophils and exhaled nitric oxide (FeNO). Participants were not required to have a previous diagnosis of asthma or COPD.

Results: 389 participants had complete data and were included in the analysis.

Airflow limitation, defined as a baseline FEV1:FVC ratio <0.7, was present in 161/389 (41%) of participants. 108/389 (28%) demonstrated ≥12% reversibility to salbutamol. Impaired gas exchange corrected KCO <80% predicted was seen in 77/389 (20%). Elevated blood eosinophils (≥0.3) were seen in 133/389 (33%) and a raised FeNO (≥50) was present in 68/389 (17.5%).

The prevalence of other treatable traits was as follows: rhinitis 74%, reflux 50%, obesity (BMI ≥30) 37%, recurrent chest infections 22%, biomass exposure 19%, workplace-related symptoms 16%, current cigarette smoking 15% (ex-smoker 34%), non-steroidal anti-inflammatory use 13%, beta-blocker use 4%. Rates of doctor diagnosed co-morbidities were: hypertension 26%, depression 21%, anxiety 17%, cardiovascular disease 15%.

Conclusion: Retrospective review of data from participants with symptoms of wheeze and breathlessness has allowed the prevalence of multiple treatable traits to be determined.

Grant Support: HRC(NZ)

Cough Sensitivity to Mannitol Inhalation Challenge Identifies Subjects with Cough
BRANNAN J1, LAKE C2, WONG KC, KOSKELA H2
1John Hunter Hospital, Newcastle, Australia, 2Royal Prince Alfred Hospital, Camperdown, Australia, 3Kuopio University Hospital, Kuopio, Finland

Introduction/Aim: It is unknown whether cough sensitivity to mannitol identifies subjects with cough and whether it correlates with subjective cough severity.

Method: Subjects with cough as the primary symptom (n=17), with other airway symptoms (n=52) and healthy subjects (n=15) performed mannitol challenge and completed the Leicester Cough Questionnaire (LCQ).

Results: The mean (95%CI) number of provoked coughs divided by the cumulative dose of mannitol (CDR) was 21.1 (12.6 – 35.4) in subjects with cough, 6.25 (4.15 – 9.40) in those with other symptoms and 2.80 (1.3 – 6.10) coughs/100 mg in the healthy subjects (p<0.001). Area under the receiver-operating characteristic curve comparing cough subjects against healthy subjects was 0.95 and when comparing cough subjects against healthy controls and subjects with other symptoms it was 0.80. There was a significant correlation between CDR and LCQ total score (rs= -0.50, p<0.04) within the cough group, as well as when combining both subjects with cough and other airway symptoms (rs= -0.43, p<0.001).

Conclusion: Cough sensitivity to mannitol identifies subjects with cough and correlates with subjective cough severity. Since mannitol challenge can be performed without complicated equipment or trained personnel in a standardised fashion, it is a promising diagnostic test for cough hypersensitivity syndrome.

Key Words: cough hypersensitivity, mannitol

Grant Support: Nil
PRESENCE OF DYSFUNCTIONAL BREATHING IS ASSOCIATED WITH WORSE ASTHMA STATUS AND MORE COMORBIDITIES IN A DIFFICULT ASTHMA POPULATION
DENTON E1, BONDARENKO J2, RADHARIKRISHNA N1, TAY T1, LEE J1, HORE-LACY F1, HOY R1, O’HEHIR R1, DABSCHECK E1, HEW M1
1Respiratory Medicine, Alfred Hospital, Melbourne, Australia, and 2Physiotherapy Department, Alfred Hospital, Melbourne, Australia

Introduction/Aim: Dysfunctional breathing (DB) is poorly defined however it is a common and potentially treatable comorbidity in difficult asthma patients and confers significant morbidity. Little is known about the factors associated with DB in a difficult asthma population and we hypothesized that these patients are likely to have poorer baseline asthma status and more frequent comorbidities. This study aimed to better define the DB population within a difficult asthma cohort.

Methods: 163 consecutive patients evaluated through a systematic difficult asthma assessment in a teaching hospital were identified. DB was assessed using the Nijmegen Questionnaire (scores >23 indicating DB). Patient demographics, baseline asthma status, lung function, and comorbidities (allergic rhinitis, anxiety, depression, chronic rhinosinusitis, obstructive sleep apnoea, reflux) were evaluated.

Results: 73 patients with elevated Nijmegen scores were identified. They were predominantly females (70%) with elevated BMI (32kg/m² +/-8) and compared to those without DB were significantly more likely to be unemployed (66% versus 39%, p=0.04), have poorer asthma control (AQLQ 2.8 versus 2.1 p=0.001), more exacerbations in the prior 6 months (3 versus 2.3 p=0.037) and poorer quality of life (AQLQ 3.8 versus 4.6 p=0.001). There was no difference in IgE, blood eosinophils, age or lung function. DB patients were also more likely to have comorbid sleep apnoea, reflux, current symptoms of allergic rhinitis and chronic rhinosinusitis, a psychiatric history, and current symptoms of anxiety and depression.

Conclusion: Patients with DB in a difficult asthma population have worse asthma control, more exacerbations and worse quality of life. The presence of DB is associated with other asthma comorbidities.

Grant Support: Nil funding

PARENT’S PERSPECTIVES ON ASTHMA MEDICATION MANAGEMENT: A SOCIAL NETWORK ANALYSIS
SROUR P1, AZZI E1, CVETKOVSKI B1, CHEONG L2, RAND C3, BOSNICK-ANTICEVICH S1
1Woolcock Institute of Medical Research, The University of Sydney, Sydney, Australia, 2Faculty of Health, University of Canberra, Canberra, Australia, and 3Pulmonary and Critical Care Medicine Department, John Hopkins University, Baltimore, USA

Introduction/Aim: Despite the input of multiple health care professionals (HCPs), patients often establish their own health sources, health advice and support outside the HCP domain1. The overall aim of this study was to gain an understanding of the relative significance of health care professionals, personal contacts and any other sources of advice/information on the parent’s asthma medication management of their child’s asthma.

Methods: In-depth, semi structured interviews were conducted with parents of children (aged 4 to 18 years) with asthma (self-reported) from Sydney, Australia. Participants were recruited from several points including asthma clinics, general practice clinics and community pharmacies. Quantitative social network analysis provided structural insight into the asthma networks while qualitative social network analysis assisted in interpretation of network data.

Results: A total of 26 interviews were conducted. A wide variety of individuals and resources were identified by all parents to be part of their ongoing management of their child’s asthma medications. Figure 1. represents the collated asthma networks of these parents. While general practitioners (GPs) and paediatricians were participant’s principal choice of healthcare professionals (HCPs), community pharmacists were less regarded. Each parent included at least one family member, friend or other mother with a child who has asthma in their asthma networks, with 9 of the parents mentioning their spouse as a significant contributor to their child’s asthma medication management.

Conclusion: Parents have developed their own health networks to aid them in the management of their children’s asthma medications, often consisting of multiple individuals and resources apart from the traditional HCPs. This research highlights the need to consider parent’s health contacts and how they may drive and influence children’s asthma outcomes. Further research is required to explore factors impacting parent’s network choices and their influence on their management of their children’s medications.

REFERENCES
PATTERNS OF PRESCRIBED ASTHMA MEDICINE USE IN AUSTRALIAN CHILDREN: A POPULATION-BASED STUDY
HOMAIRA N1,2, DANIELS B3, PEARSON S3, JAFFE A1,2
1UNSW, Sydney, Australia, 2Respiratory Department, Sydney Children’s Hospital, Randwick, Australia, and 3Medicines Policy Research Unit, Centre for Big Data Research in Health UNSW, Sydney, Australia

Introduction/Aim: Despite the widespread availability of asthma management guidelines, variation in asthma medicine prescribing practices has been observed in the paediatric population. We aimed to characterise the utilisation of asthma medicines subsidised by the Pharmaceutical Benefits Scheme (PBS) in Australians aged ≤18 years.

Methods: We used a 10% sample of individual-level PBS claims (July 2012-December 2016) for Australian children dispensed asthma medicines to examine annual trends in incident and prevalent use (for 2014-2016). We used a 12-month lookback period to define incident use and applied one tenth of the Australian Bureau of Statistics midyear population of residents ≤18 as the denominator for incidence and prevalence per 100 estimates.

Results: During 2014-2016, 160,632 children were dispensed an asthma medicine; 72,159 (45%) were girls and the median age was 5 years (IQR 2-10 years). Annually, an average of 81,404 children were dispensed at least one asthma medicine. The annual incidence of asthma medicines use ranged from 8.5-8.9% and annual prevalence’s ranged from 13.5-14.6%.

The proportion of children who initiated fixed dose combination inhalers (FDC) annually was 1.2%, 1.1% and 1.0% for 2014, 2015 and 2016 respectively. Similarly the proportion of children who initiated inhaled corticosteroid (ICS) was 1.7%, 1.9% and 1.8% for 2014, 2015 and 2016. The proportion of children who initiated FDC without ICS in the preceding 12 months was around 1% annually. The total market share for inhalers (FDC) annually was 1.2%, 1.1% and 1.0% for 2014, 2015 and 2016.

Conclusion: Our data suggest that while the proportion of Australian children using asthma medication remained constant, a large proportion of children initiated FDC without a preceding ICS indicating prescribing of asthma medications not consistent with national guidelines.

Grant Support: This work was funded by Rotary Club of Sydney Cove.

EOSINOPHILIA AS A TREATABLE TRAIT IN THREE PATIENTS WITH ASTHMA/COPD
RAMSAHAI J1,2, SIMPSON J1, WARK P1
1HMRI/University of Newcastle, New Lambton, Australia, and 2University of Calgary, Calgary, Canada

Introduction/Aim: The combination of asthma and COPD in an individual presents significant challenges to achieving satisfactory outcomes. Recently, the concepts of precision medicine and the treatable trait, as opposed to homogenous management based on disease labels, have arisen as promising tools to improve care for this group of patients. In this series, we present three cases of patients with features of both asthma and COPD, in addition to peripheral blood eosinophilia, which was successfully targeted as a treatable trait.

Methods: We performed a retrospective chart review of three patients with chronic airways disease, with features of both asthma and COPD. These patients were selected for this case series based on prior therapeutic choices targeted at suppressing peripheral blood eosinophil count. Medical records were reviewed to compare the outcomes featured in Table 1 reported for each patient before and after the initiation of targeted treatment.

Results: All three patients were male ex-smokers, aged 68-74, with severe airflow obstruction, and CT evidence of emphysema, with either a positive response to bronchodilator on spirometric testing or demonstrating excess variability of FEV1 between visits, and peripheral blood eosinophilia. Oral corticosteroids were successfully used in all three to suppress peripheral blood eosinophil counts below 0.4x10^9 cells/L, and titrated down to the lowest dose to accomplish this. This resulted in significant benefits to all three patients, including improvements in symptoms (using CAT scores), and lung function, and, a marked decline in hospital admission and exacerbation rates, as demonstrated in Table 1.

Conclusion: This case series demonstrates the ability to apply the concept of the treatable trait in the real world to the complex population of patients with chronic airways disease with features of both asthma and COPD. Importantly, this highlights the need to see through the labels of these diseases to the individual traits that reflect therapeutic targets.

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Case</th>
<th>Pre-OCS</th>
<th>Post-OCS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Post-BD FEV1 (L) and (% predicted)</td>
<td>1</td>
<td>0.54 (18)</td>
<td>2.27 (74)</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>0.54 (17)</td>
<td>0.74 (27)</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>1.23 (43)</td>
<td>2.03 (71)</td>
</tr>
<tr>
<td>Exacerbation rate</td>
<td>1</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>8</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Hospital admission rate</td>
<td>1</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>8</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>CAT Score</td>
<td>1</td>
<td>26</td>
<td>11</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>28</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>24</td>
<td>16</td>
</tr>
<tr>
<td>6MWD</td>
<td>1</td>
<td>343</td>
<td>520</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>256</td>
<td>466</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>50</td>
<td>505</td>
</tr>
</tbody>
</table>

Post-BD = Baseline post-bronchodilator

Grant Support: None
A RETROSPECTIVE REVIEW OF THE MANAGEMENT OF HOSPITAL PRESENTATIONS DUE TO EXACERBATIONS OF ASTHMA
COOK A1, BASHAM J1, SIVAKUMARAN P1
1Queensland Health, Brisbane, Australia

Introduction/Aim: Effective asthma management involves addressing educational, environmental, pharmacological, and psychosocial factors, and this also applies to inpatient management of acute exacerbations. Hospital admission provides a good opportunity to clarify a patient’s diagnosis and optimise their long-term control. Society guidelines recommend that a review of the patient’s medications, and inhaler technique, and provision of an action plan, should be performed prior to discharge, and failure to do so may contribute to future risk of exacerbation and fixed airway obstruction. This study aims to evaluate the management of patients with acute asthma presenting to the Gold Coast health service, with particular attention to diagnostic clarification and the evaluation of patient self-management skills.

Methods: A retrospective review of patients presenting to hospitals within the Gold Coast health service, with a diagnosis of an acute asthma exacerbation, from July 2016, to June 2017, was performed.

Results: 149 presentations with acute asthma were evaluated (80% female). 47 patients (32%) were managed by a specialist respiratory team, and 102 (68%) were manged by general medicine or emergency medicine. Patients under the care of a respiratory team at the time of discharge were more likely to have diagnosis clarified (82% vs 25%; P = <0.001) and their written action plan reviewed (60% vs 28% P = <0.001), and more likely to receive education from a specialised respiratory nurse (57% vs 23%; P = <0.001).

Conclusion: Referral of patients presenting to the Gold Coast health service with acute asthma exacerbations to an inpatient respiratory team improved adherence to guideline recommendations regarding inpatient asthma management, including diagnostic clarification and self-management strategies. The institution of a formal acute asthma management pathway would be expected to improve adherence further.

PREGNANCY, LUNG FUNCTION AT 6 WEEKS OF AGE AND BRONCHIOLITIS IN BABIES BORN TO MOTHERS WITH ASTHMA DURING PREGNANCY
JESSON K1, DE GOUVEIA BELIELO P1, R.S. SENA C1, COLLISON A1, MURPHY V1, ROBINSON P2, SLY P3, MATTES J1, HARDAKER K1, GIBSON P4,5
1Priority Research Centre GrowUpWell—The University of Newcastle (Australia), Newcastle, Australia, 2Department of Respiratory Medicine, The Childrens Hospital Westmead, Westmead, Australia, 3Centre of Childrens Health Research, University of Queensland, South Brisbane, South Brisbane, Australia, 4Priority Research Centre healthy Lungs, Hunter Medical Research Institute—The University of Newcastle, Newcastle, Australia, 5Respiratory and Sleep Medicine Department, John Hunter Hospital, Newcastle, Australia, and 6Paediatric Respiratory and Sleep Medicine Department, John Hunter Childrens Hospital, Newcastle, Australia

Introduction/Aims: Asthma is common during pregnancy and can result in adverse pregnancy outcomes. The aim of this analysis was to explore for an association between preterm delivery, infant lung function at 6 weeks of age and the development of bronchiolitis in the first 6 months of life in a cohort of babies born to women with asthma during pregnancy.

Methods: We performed tidal breathing flow-volume loop (TBFVL) measurements during quiet unsedated sleep in infants born to mothers who participated in an ongoing multi-centre RCT of FeNO-guided asthma management versus usual care (Breathing for Life Trial). All researchers remain blinded in regards to the pregnancy intervention.

Results: 324 babies have been recruited to date, of which 289 attended clinical assessment and 261 remained in quiet sleep during testing. 232 TBFVL were attempted (44% female; mean (SD) age 6 (1.2) weeks and 209 (90%) tests were technically acceptable. Mean time to Peak Tidal Expiratory Flow/time Expiratory Flow % (tPTEF/tE%) in preterm infants (n=19) was 25.9 (SD 4.8) versus those who were born at term 32.6 (SD 9.9). Mean respiratory rate (RR) was 47 breaths/ per minute in preterm babies vs 44 breaths/ per minute in fullterm babies. At the time of abstract submission, 140/209 (67%) were 6 months old and 36/209 (17%) had at least one bronchiolitis episode. 37% of preterm babies developed bronchiolitis during the first 6 months of life compared to 22% full-term babies.

Conclusion: Prematurity resulted in lower tPTEF/tE% at 6 weeks of age in babies born to asthmatic mothers which may be associated with the subsequent development of bronchiolitis.

Grant support: NHMRC, John Hunter Hospital, PRC GrowUpWell, HMRI and HCRF.
12-MONTH FOLLOW-UP OF 2016 EPIDEMIC THUNDERSTORM ASTHMA PATIENTS WITHOUT PRIOR DIAGNOSIS OF ASTHMA ASSESSING SYMPTOMS, PREVENTER USE, ASTHMA ACTION PLAN OWNERSHIP AND HEALTH CARE UTILISATION

FOO C1, YEE E2, YOUNG A1,2, THIEN F1,2
1Department of Respiratory and Sleep Medicine, Eastern Health, Box Hill Hospital, Melbourne, Australia; 2Eastern Health Clinical School, Monash University, Melbourne, Australia

Introduction/Aim: Epidemic thunderstorm asthma (ETSA) severely affected Melbourne in November 2016. There is scant literature on the natural history of individuals affected by ETSA. This is a 12-month follow-up study of Eastern Health ETSA patients without prior asthma diagnosis assessing their symptomology and behaviours.

Methods: A standardised telephone questionnaire was developed and administered between 4th–15th December 2017 to individuals affected by 2016 ETSA (n=232). The questionnaire assessed asthma symptoms, preventer prescription and adherence, asthma action plan ownership and healthcare utilization.

Results: 86.2% (n=200) of individuals responded. 57.5% (115) had never been diagnosed with asthma before. On follow-up, 21.7% (25) were asymptomatic, 48.7% (56) described infrequent episodic symptoms (up to 1/month), 10.4% (12) had frequent episodic symptoms (>1/month but <1/week) and 19.1% (22) reported persistent symptoms (>1/week).

Preventer prescription was 54.5% (12) in patients with persistent symptoms and <40% in the other groups. Adherence was poor with only 58.3% (7) of patients with persistent symptoms using their inhaler for ≥5 days/week, and none of the patients in the asymptomatic group.

Asthma action plan ownership was <50%, with only 22.7% (5) ownership in patients with persistent symptoms. Urgent visits to GP, ED or hospitalization was required in 12.5% (7) of the infrequent episodic group, 25% (3) of the frequent episodic group and 31.8% (7) of the persistent group.

67.3% (33) of patients who had never experienced wheeze, chest tightness or dyspnoea prior to November 2016 had developed asthma symptoms during follow-up. This compared with 86.4% (57) of patients who reported at least one symptom prior to November 2016.

Conclusion: Majority of patients affected by 2016 ETSA without a prior diagnosis of asthma reported symptoms suggestive of current asthma on follow-up. This included the majority of patients who had never experienced prior symptoms suggestive of asthma. Preventer use and asthma action plan ownership were low, even in patients with persistent symptoms. Concerningly, a significant proportion sought urgent health care over the follow-up period. Better recognition of undiagnosed asthma and optimisation of asthma management may help to improve symptom control and healthcare utilization before and after an ETSA event.

Grant Support: Nil

RESIDENTIAL NO2 EXPOSURE IS ASSOCIATED WITH RECENT URGENT HEALTHCARE UTILISATION IN CURRENT ASTHMATICS ADMITTED TO EASTERN HEALTH DURING A THUNDERSTORM ASThma EPIDemic

LAI V1, BOWATTE G2, KNIBBS L3, RANGAMUWA K4, YOUNG A1,4, DHARMAGE S2, THIEN F1,4
1Monash School of Medicine, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Australia; 2Allergy and Lung Health Unit, Centre for Epidemiology and Biostatistics, School of Population & Global Health, The University of Melbourne, Melbourne, Australia; 3School of Public Health, The University of Queensland, Brisbane, Australia; 4Box Hill Hospital, Eastern Health, Box Hill, Australia

Introduction/Aim: There is increasing interest in the role of traffic-related air pollution (TRAP) in allergic airway diseases. The Melbourne ‘thunderstorm asthma’ event in November 2016 provided an opportunity to investigate the relationship of annual average residential NO2 exposure and living closer to major roads, proxy markers of TRAP exposure, with risk of recent asthma exacerbation requiring urgent health care utilisation for the last 12 months in those with current diagnosed asthma.

Methods: Patients who presented to the three Eastern Health Emergency Departments with asthma symptoms on the 21st or 22nd November 2016 were identified and contacted using a standardised questionnaire. Current asthma was defined as diagnosed asthma with symptoms within the last 12 months, with further identification of urgent healthcare utilisation for asthma within this period. Residential addresses were geocoded and the annual average NO2 exposure for each patient was assigned through a validated satellite-based land use regression model. Residential distance to the nearest major road was calculated using ArcGIS.

Results: A total of 88 patients with current asthma were analysed from 263 thunderstorm asthma patients. The mean (SD) annual residential NO2 exposure for patients with urgent health care utilisation was 6.7 (1.5) ppb, compared with 5.8 (1.7) ppb in those without (p=0.02). The difference in the mean (SD) distances to nearest road for patients with health care utilisation was 321 (262) m, compared with 411 (609) m in those without health care utilisation, respectively, was not significant.

Conclusion: Annual average residential NO2 exposure was associated with asthma exacerbation requiring urgent health care utilisation for asthma exacerbation in the last 12 months amongst Eastern Health thunderstorm asthma patients with current diagnosed asthma. While those who required urgent health care utilisation lived closer to a major road, the difference was not statistically significant, which may be related to the study power.

Grant Support: Nil
PHYSIOLOGICAL STIFFNESS IS CRITICAL FOR EMULATION OF GLUCOCORTICOID RESPONSES
CHEN Q1, LI M1, WU Y1, XIA Y1, LANGENBACH S1, LEE P1, STEWART A1
1University of Melbourne, Melbourne, Australia

Introduction/Aim: Respiratory diseases, including severe asthma and chronic obstructive pulmonary disease (COPD), are conditions with significant unmet need. However, many drug developments have failed, despite showing impressive efficacy in preclinical models. Biomechanical characteristics of the preclinical in vitro models have been highlighted as important influences on cell morphology, proliferation, and other physiological functions, including the homeostasis of matrix stiffness in respiratory system. We provide evidence in the current study that the glucocorticoid response of airway epithelial cells is conditioned by the stiffness, with softer microenvironments showing more relevance to the pattern of responses in animal models.

Methods: Cells were cultured in plates of defined stiffness for 24h, and treated with Dexamethasone (Dex) for 4h. Mice were treated with bleomycin and/or Dex for 14 days. GC-responsive gene expression was measured by RT-qPCR. Lung sections were stained with ENaC antibodies.

Results: Glucocorticoids induced expression of GILZ and MKP-1 in culture settings across the range of stiffness from physiological (0.5-1.0 kPa) to fibrotic (16-64 kPa). However, the induction of ENaCα was attenuated in softer culture microenvironments and the baseline level of expression was increased 10 fold. These latter findings with ENaCα emulate the elevated expression and lack of GC response in mouse lung.

Conclusion: GC response is related to extracellular matrix stiffness; culture on a physiologically soft substrate is inherently more likely to provide physiological relevance and better predictive value for drug screening.

Grant Support: Asthma Australia, NHMRC (Peter Doherty Fellowship to Yuval C. Xia)

The Effect of Dietary Fatty Acids on Inflammation in Primary Lung Mesenchymal and Epithelial Cells
RUTTING S1,2, XENAKI D1, WOOD L1, HORVAT J2, HANSBRO P2, OLIVER B1,4,5
1Woolcock Institute of Medical Research, Sydney, Australia, 2Priority Research Centre for Asthma and Respiratory Disease, The University of Newcastle, Newcastle, Australia, 3School of Life Sciences, University of Technology Sydney, Sydney, Australia, 4School of Biomedical Science and Pharmacy, University of Newcastle, Newcastle, Australia, and 5Emphysema Centre, Woolcock Institute, Sydney, Australia

Introduction/Aim: Obesity is an important risk factor for developing severe asthma. Dietary fatty acids which are increased in sera of obese individuals and after high fat meals, activate the innate immune system, induce inflammation and impair responses to treatment in the airways. This study investigated whether dietary fatty acids directly cause inflammation and/or synergise with obesity-induced cytokines in primary human pulmonary fibroblasts in vitro and the underlying mechanisms.

Methods: Fibroblasts were challenged with BSA-conjugated ω-6 polyunsaturated fatty acids (PUFAs), ω-3 PUFAs or saturated fatty acids (SFAs) with or without TNFα. Release of the pro-inflammatory cytokines, IL-6 and CXCL8, was measured using ELISA. To investigate underlying mechanisms, specific inhibitors were used to block signalling pathways. Activation of two main pathways, p38 and NF-κB, were investigated using western blotting. To investigate whether other structural lung cells respond the same as pulmonary fibroblasts, selected experiments were repeated in airway smooth muscle (ASM) cells and human bronchial epithelial cells (BEAS-2B).

Results: We found that ω-6 PUFA arachidonic acid (AA), but not ω-3 PUFAs or SFAs up-regulates IL-6 and CXCL8 release from fibroblasts. Combined AA and TNFα challenge resulted in substantially greater IL-6 and CXCL8 release than either alone, demonstrating synergy. Synergistic upregulation of IL-6, but not CXCL8 was mainly mediated via cyclooxygenase (COX). Inhibition of p38 mitogen-activated protein kinase reduced CXCL8 release induced by AA and TNFα alone, but not in combination. Synergistic CXCL8-release following AA and TNFα challenge was not mediated via a single signaling pathway (MEK1, JNK, PISK and NF-κB), nor by hyperactivation of NF-κB or p38. Similar effects in ASM were found, but not in epithelial cells.

Conclusion: This study suggests that diets rich in ω-6 PUFAs might promote airway inflammation via multiple pathways, including COX dependent- and independent pathways, and in an obese person may lead to more severe airway inflammation.
THE CD1B LIPID ANTIGEN PRESENTATION PATHWAY IN COPD IS ASSOCIATED WITH OXIDIZED AIRWAY LIPIDS AND SPHINGOLIPID SIGNALING
WEEN M1,2, WHITTALL J1,2, JONES C2, BAC TRAN H1,2, HODGE S2
1Royal Adelaide Hospital, Adelaide, Australia, and 2School of Medicine, University of Adelaide, Adelaide, Australia

Introduction/Aim: Reduced alveolar macrophage (AM) clearance of apoptotic cells and a build-up of oxidised lipid in the airway have been described in COPD. We showed that CD1b, a lipid antigen presenting molecule, is altered in COPD AM, and by oxidised airway epithelial cell lipid. We hypothesised that CD1b contributes to defective macrophage function and that this occurs via sphingolipid signalling.

Methods: CD1b expression by (a) AM from never-smoker, ex-smoker and current-smoker controls, and current- and ex-smoker COPD patients and (b) MDM exposed to cigarette smoke (CS)/C6 FDA approved sphingo-lipid modulator FTY720 was measured by flow cytometry/immuno-fluorescence. Oxidation states of lipid films produced from mechanically detached and CS-exposed 16HBE bronchial epithelial cells were measured by spectrophotometry. Phagocytosis was measured by flow cytometry using the intracellular pH-sensitive pHrodo stain.

Results: AM from COPD patients and smokers showed higher expression of CD1b than controls (current-smoker COPD 15.8%; ex-smoker COPD 9.6% vs. control 1.8%). CD1b expression significantly correlated with FEV1. Epithelial-derived lipids were oxidised by CS (average increase of 272% vs. controls). Treatment with CS-oxidised airway epithelial lipid increased CD1b in MDM (87% vs. 69%) and also significantly decreased phagocytosis (8.7% vs 16.5%). FTY720 reversed these effects.

Conclusion: A build-up of oxidised lipids from uncleared apoptotic airway cells may cause decreased phagocytosis in COPD and be presented by CD1b, potentially identifying an autoimmune-like component which could be exploited in future treatment strategies targeting the sphingolipid pathway.

TOLL-LIKE RECEPTORS IN VIRUS-INDUCED STEROID RESISTANCE IN BRONCHIAL EPITHELIAL CELLS
XIA Y1, RADWAN A1, LANGENBACH S1, GUALANO R1, STEWART A1
1The Department of Pharmacology & Therapeutics, The University of Melbourne, Parkville, Australia

Introduction/Aim: Airway viral infection is a major cause of acute respiratory disease, which responds inadequately to anti-inflammatory glucocorticoids (GC). Virus can be recognised by pattern recognition receptors, including the Toll-like receptors (TLRs). TLR2 and TLR4 can be activated by viral protein; TLR3 recognizes viral double-strand (ds) RNA intermediate; and TLR7 recognizes viral single-strand (ss) RNA. We recently found that the virus-induced glucocorticoid (GC) resistance in human bronchial epithelial cells was mediated by TLR3 dependent release of TGF-β (Xia, 2017). The present study explores the presence and function of other TLRs members to GC response in bronchial epithelial cells.

Methods: The expression of TLRs (TLR1-TLR10), on bronchial epithelial cell line BEAS-2B cells was examined by RT-PCR. The cells were challenged with TLR2 agonist Zymosan A, TLR3 agonist polyinosinic-polycytidylic acid (Poly (I:C)), TLR4 agonist lipopolysaccharide (LPS) and TLR7 agonist imiquimod for 24 hours. Glucocorticoid transactivation was measured through examination of GC Response Element (GRE)-dependent promoter activity with 24 hours dexamethasone treatment; and GC-responsive gene expression with 4 hours dexamethasone treatment.

Results: All the ten members of TLRs were detectable expressed in BEAS-2B cells albeit at varying levels. Activation of TLR3 inhibited GC-induced GRE activation and impaired the GC-responsive genes. Activation of TLR4 also impaired the GC activity, but to a lesser extent than TLR3, whereas activation of TLR2 and TLR7 had no detectable effect on GC-induced GRE activity or GC-responsive gene expression in the BEAS-2B cells.

Conclusion: The bronchial epithelial cells express various TLRs, which are important in airway inflammation and immunity. Activation of TLR3 and TLR4, but neither TLR2 nor TLR7 impaired the GC activity in bronchial epithelial cells. Better understanding of the viral infection pathway that is involved in the GC resistance may provide new targets for treating viral infection-induced bronchiolitis or asthma/COPD exacerbations.

Grant Support: NHMRC and National Asthma Research Trust Grant
**IN VITRO EXPOSURE OF AIRWAY EPITHELIAL CELLS TO SOY BIODIESEL EXHAUST IS LESS TOXIC COMPARED WITH MINERAL DIESEL EXHAUST**

LANDWEHR K1,2, HILLAS J3, O’LEYAR R4, KNOTHE G5, KIFIC A1,2,3,4,7, MULLINS B1, LARCOMBE A1,2

1School of Public Health, Curtin University, Perth, Australia, 2Respiratory Environmental Health, Telethon Kids Institute, Subiaco, Australia, 3Department of Respiratory Medicine, Princess Margaret Hospital, Perth, Australia, 4Department of Primary Industries and Regional Development, Perth, Australia, 5USDA, Pecoria, 6School of Paediatric and Child Health, The University of Western Australia, Perth, Australia, and 7Centre for Cell Therapy and Regenerative Medicine, The University of Western Australia, Perth, Australia

Introduction/Aim: As biodiesel usage increases worldwide, concerns have been raised over the impact of exhaust exposure on human health. The aim of this study was to compare the effects of exposure to exhaust generated by the combustion of mineral diesel (ULSD), 100% soy biodiesel (B100) or a blend of 20% biodiesel to 80% ULSD (B20) on human airway epithelial cells in vitro.

Methods: Human airway epithelial cells obtained from 6 healthy volunteers (2-7.5 yrs; 4 males) were exposed for 1, 2 or 4 hours to diluted exhaust generated by a diesel engine running on ULSD, B100 or B20 fuel. Exhaust was characterised for toxic gas levels and the physicochemical properties of the particulate matter were analysed. Cells were incubated for 24 hours after exposure before health outcomes were assessed.

Results: All exposures resulted in cell death and the release of inflammatory mediators compared to untreated controls, however there were few overt trends with respect to exposure time. Across all time-points, cells exposed to ULSD exhaust were significantly less viable compared with cells exposed to soy diesel exhaust (e.g. ~50% cell death for ULSD exhaust exposure compared with ~25% cell death for B100). The majority of cell death was via apoptosis, with a smaller proportion of cells undergoing necrosis.

Exhaust gases varied significantly with respect to gas levels. B100 exhaust contained the highest concentrations of NOx, CO2 and SO2 (p<0.01) all of which are known respiratory irritants. Particle size spectra also varied between exhaust types.

Conclusion: Soy biodiesel exhaust exposure was less harmful to human airway epithelial cells in vitro compared with ULSD exhaust exposure. This is contrary to our previous findings for canola based biodiesel (which was more toxic than ULSD), suggesting that the base-oil biodiesel is made from can significantly impact health outcomes.

Grant Support: ARC Discovery Project DP170104346

**ESTABLISHMENT OF A DOXORUBICIN DETOXIFICATION ASSAY TO MEASURE ATP BINDING CASSETTE SUBFAMILY A MEMBER 3 (ABCA-3) FUNCTION IN NASAL EPITHELIAL CELLS DERIVED FROM CHILDREN WITH ABCA-3 DEFICIENCY**

SHAW N1, KIFIC A1,2,3,4,5, FLETCHER S1,2, WILTON S1,2, STICK S1,2,3,4, SCHULTZ A1,2

1University of Western Australia, Perth, Australia, 2Telethon Kids Institute, Perth, Australia, 3Princess Margaret Hospital for Children, Perth, Australia, 4Curtin University, Perth, Australia, 5Centre for Cell Therapy and Regenerative Medicine, Perth, Australia, 6Pemmon Institute for Neurological and Translational Science, Perth, Australia, and 7Centre for Comparative Genomics, Perth, Australia

Introduction/Aim: The ABCA3 gene encodes a lipid transporter, expressed in respiratory epithelial cells, essential for pulmonary surfactant homeostasis. Children with disease-causing mutations in ABCA3 suffer severe respiratory disease, and this rare condition is often fatal. Development of potential therapeutic agents targeting ABCA-3, requires the in vitro demonstration of ABCA-3 function before and after drug exposure. The transporter function of ABCA-3 confers resistance to the antineoplastic chemotherapy drug, doxorubicin and has been used previously to demonstrate decreased viability in HEK293 cells expressing mutant ABCA-3. The present study aimed to adapt and optimise the doxorubicin detoxification assay for application in patient-derived nasal epithelial cells, as we have previously demonstrated ABCA3 gene expression in nasal epithelium.

Methods: Nasal epithelial cells were obtained by cytological brushing of the nasal turbinate from children with (n=2; median (range) age 4.9 (2.2-7.6) years; males: 1) and without (n=4; age 2.9 (2.7-5.4) years; males: 4) ABCA-3 deficiency and used to establish conditionally-reprogrammed primary cultures. Mutations in ABCA3 were confirmed and identified: c.920C>T/c.920C>T in Patient 1 and c.838C>T/c.3997_3998delAG in Patient 2. Cell viability after three-hour exposure to doxorubicin (0 – 10 μM) was assessed using the MTS assay.

Results: Over the concentration range assessed, there was no significant effect of doxorubicin on cell viability in healthy control cells, 0.50<0.80 (n=12). Cell viability for Patient 1 (n=3) was reduced by 25.2% ± 2.7% (SD), p=0.001, and 30.35% ± 2.6% (SD), p=0.001, after treatment with 5 μM and 10 μM doxorubicin, respectively, compared to healthy controls. Cell viability for Patient 2 (n=3) was reduced by 11.3% ± 0.3% (SD), p=0.02, by 5 μM doxorubicin and 7.8% ± 8.1% (SD), p=0.24, by 10 μM doxorubicin compared to healthy controls.

Conclusion: Doxorubicin detoxification function was impaired in ABCA-3 deficient nasal epithelial cells, relative to cells from healthy controls. Effects were patient-specific, indicating that genotype may influence effect size.

Grant Support: N/A
Introduction/Aim: Asthma affects more than 300 million people worldwide and poses a huge economic burden on the healthcare system. Current anti-asthma therapies are effective in ameliorating asthma-related symptoms but fail to target structural changes in the lung also known as airway remodelling. Airway remodelling in patients with asthma has been associated with progressive loss of lung function. Macroautophagy (autophagy) is a fundamental process that occurs in all eukaryotic cells and can be referred to as the cell recycling mechanism. Autophagy regulation is linked to fibrotic remodelling in the heart, liver and kidneys. The aim of our study is to explore the role of autophagy in asthma by investigating autophagy markers in the epithelium of large airways of asthmatics. Our study is the initiation of our ongoing research into the role of autophagy in asthma.

Methods: Tissue from asthmatics and non-asthmatics were immunostained for autophagy markers; ATG5, Beclin1 and p62. The percentage area of positive staining was enumerated in the epithelium using ImageJ software.

Results: Expression of Beclin-1 was significantly higher (p<0.05) in the epithelium of non-asthmatic tissue compared with asthmatic tissue. These tissues showed a significantly higher (p<0.05) expression of Beclin-1 in the epithelium of non-asthmatic patients. Comparatively, the epithelial cells in non-asthmatic patients completely lacked Beclin-1 staining.

Conclusion: The reduction in expression of Beclin-1 indicates that autophagy-dependent regulation of cilia (ciliophagy) may be active in asthma. Our study is the initiation of our ongoing research into the role and effect of autophagy in asthma.

Figure 1 Cilia in the large airways of asthmatics (A) are positively stained for the autophagy marker Beclin-1, whilst cilia in the large airways of healthy patients (B) are devoid of Beclin-1 staining.
TRACE ELEMENT CONCENTRATIONS IN HUMAN PLEURAL EFFUSIONS

POPOWICZ N1,2, FITZGERALD D1, JOSEPH JF, LIM E2, CHEAH H1,2, BUTCHER S1, CREANEY JF3, LEE Y1,2,4
1Sir Charles Gairdner Hospital, Perth, Australia, 2School of Medicine, University of Western Australia, Perth, Australia, 3Department of Pharmacy, Sir Charles Gairdner Hospital, Perth, Australia, 4Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, Australia, 5PathWest Laboratory Medicine, QE II Medical Centre, Perth, Australia, 6School of Medicine, University of Notre Dame Australia, Perth, Australia, and 7National Centre for Asbestos Related Diseases, Perth, Australia

Introduction/Aim: Pleural effusions are common and contain abundant nutrients and growth factors. Trace elements are increasingly recognized for their potent and diverse range of biological roles. For example, we recently found that manganese is important in Streptococcus pneumoniae proliferation in empyema. Trace elements have rarely been investigated in pleural diseases. This study aimed to determine the presence and concentrations of trace elements in human pleural effusions.

Methods: We analysed 119 pleural fluid samples which included 71 malignant (39 mesothelioma), 16 parapneumonic (including empyema), 14 heart failure and 16 other miscellaneous benign effusions. Iron (Fe), manganese (Mn), copper (Cu), zinc (Zn), cobalt (Co) and molybdenum (Mo) were assayed by a NATA accredited hospital laboratory (PathWest, WA). Clinical diagnoses of the effusions were verified by a respiratory specialist.

Results: All trace elements were detected in the pleural effusions: median (IQR) levels of Fe 8.02 (3.96-16.60) umol/L, Mn 10.71 (5.84-18.04) umol/L, Cu 9.95 (5.98-14.77) umol/L, Zn 5.84 (3.26-8.67) umol/L, Co 1.58 (1.05-2.63) nmol/L and Mo 7.91 (5.38-15.82) nmol/L. Strong (Spearman) correlations were found between Fe and Mn as well as Zn and Cu levels (0.742 and 0.745, both p<0.000001). Pleural fluid protein correlated weakly with Zn and Cu (Spearman 0.442 and 0.506, both p<0.000001) but not with other elements. No strong correlations were found between pleural fluid pH or glucose with any trace elements measured. Fe levels were significantly higher in malignant than benign effusions (median 10.07 vs 5.54 umol/L, p<0.001). Conversely, benign pleural fluids contained higher levels of Mo (median 12.18 vs 6.96 nmol/L, p<0.001) and Co (1.84 vs 1.58 nmol/L, p<0.001) than malignant effusions. Co levels were higher in parapneumonic effusions than in other etiology groups.

Conclusion: Trace elements are present (and differentially accumulated) in various pleural effusions. Their roles in normal and pathological pleural conditions need investigations.

Grant Support: NHMRC; Cancer Council WA; Cancer Australia; NSW Dust Diseases Board (YCGL, JC); Sir Charles Gairdner Research Advisory Group (NP, YCGL); WA Cancer & Palliative Care Network (DF).

Declaration: All authors declare no conflict of interests.

THE EFFECT OF VIRAL INFECTION ON GLUCOCORTICOID SENSITIVITY IN BRONCHO-ORGANOIDS

XIA Y1, CHEN Q1, LI M1, WU Y2, STEWART A1
1The Department of Pharmacology and Therapeutics, The University of Melbourne, Parkville, Australia, and 2The Department of Biomedical Engineering, The University of Melbourne, Parkville, Australia

Introduction/Aim: Viral infection, such as respiratory syncytial virus (RSV) and rhinovirus (RV) is a major cause of acute respiratory disease, which responds inadequately to anti-inflammatory glucocorticoids (GC). We recently found that the endogenous TGF-β partially explained virus-induced GC resistance in human bronchial epithelial cell line BEAS-2B cells and in the air-liquid interface (ALI) differentiated primary human bronchial epithelial cells (HBEC) (Xia, 2017). We further investigate virus-induced GC resistance in the broncho-organooids.

Methods: Immortalized human airway basal cell line, BCI-NS1 (expression of hTERT), or primary bronchial epithelial cells (Lonza) were mixed with 5% Corning® Matrigel® in bronchial epithelial cell growth medium (BEGM™, Lonza), seeded on a layer of 25% or 40% Matrigel® in BEGM, to enable the formation of the broncho-organooids. The cell viability of the organoids was tested by CellTiter-Glo® luminescent assay. The organoids were infected with virus for 48 hours by microinjection. The selective ALK5 (TGFβRI) inhibitor, SB431542 was used to test the involvement of TGF-β. Glucocorticoid transactivation was measured through examination of GC-responsive gene expression with the last 4 hours dexamethasone treatment.

Results: Formation of the broncho-organooids was observed within approximately one week. The size of the organoids increased in the first week. The lumen was visible within two weeks. The cells within the organoids maintained a differentiated state with a pseudostratiﬁed epithelial structure with the apical surface projecting towards the lumen by week two to three. Beating cilia and mucus were visualized under microscope. The effect of virus infection on the broncho-organooids in terms of GC sensitivity is being investigated.

Conclusion: Virus infection impairs GC-inducible genes and protein expression in BEAS-2B cells and ALI-HBECs. The effect of virus infection to the bronchial epithelium was further investigated in a newly established physiologically relevant model, broncho-spherical organoids.

Grant Support: NHMRC and National Asthma Research Trust Grant...
PROGNOSTIC SIGNIFICANCE OF THE NEUTROPHIL-TO-LYMPHOCYTE RATIO IN PLEURAL FLUID

POPOWICZ N1,2,3, GREGORY C1, MIRANDA A4,5, CHEAH H1,2, DICK i1,2, LEE Y1,2,5,7, CREANEY J1,2
1Pleural Medicine Unit, Institute for Respiratory Health, Perth, Australia, 2School of Medicine, University of Western Australia, Perth, Australia, 3Department of Pharmacy, Sir Charles Gairdner Hospital, Perth, Australia, 4National Centre for Asbestos Related Disease, School of Medicine, University of Western Australia, Perth, Australia, 5School of Biomedical Sciences, Curtin University, Perth, Australia, 6Centre for Asthma, Allergy & Respiratory Research, School of Medicine, University of Western Australia, Perth, Australia, and 7Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, Australia

Introduction/Aim: Predicting survival of patients with malignant pleural effusions (MPEs) is notoriously difficult. A robust prognostic marker can guide clinical decision making. The neutrophil-to-lymphocyte ratio (NLR) in blood has been shown to predict survival in many cancers. Pleural fluid bathes the malignant pleural tissues, thus the NLR of the pleural fluid may closer reflect the local tumour environment.

Methods: Setting: tertiary pleural referral service at SCGH. Subjects: patients who had pleural fluid drained and a matching blood leucocyte count (within 24 hours of the fluid collection) were included. Those with recent chemotherapy or pleurodesis were excluded.

Data: Neutrophil and lymphocyte counts in effusions were performed by manual review of cytospin cell preparations by trained observers. Clinical data were extracted from a state-wide hospital database.

Results: Paired blood and effusion samples (n=141: 117 malignant and 24 benign) were analysed. Mesotheiloma accounted for 55% of cases. There were significantly fewer neutrophils (expressed as percentage of total leukocyte count) in pleural fluids than in blood (9% vs 73%; p<0.001). The NLR was significantly lower in pleural fluids than in corresponding blood: median [IQR] = 0.20 [0.04-1.18] vs 4.9 [3.0-8.3]; p<0.001. In univariate analysis, NLR in malignant pleural fluid was predictive of survival (HR=1.026 [1.004-1.048]; p=0.018), and remained significant after adjustment for age, sex, presence of chest drain and cancer type (1.07 [1.005-1.050]; p=0.021). The NLR in blood was also predictive of survival (1.05 [1.02–1.07]; p<0.001) in MPE patients. Patients with blood NLR ≥5 had a median survival of 130 (95%CI 64-195) days from sample collection, vs 479 (95%CI 289-669) days if NLR ≤5, p<0.001. No correlation was observed between the NLR of pleural fluids and blood.

Conclusion: This is the first study to show that NLR in malignant effusions can predict survival, despite no correlation with blood NLR.

Grant Support: NHMRC; Cancer Council WA; Cancer Australia; NSW Dust Diseases Board (YCGL, JC); Sir Charles Gairdner Research Advisory Group

SHORT TERM EXPOSURE TO WILDFIRE SMOKE EXTRACT POTENTIATES AUTOPHAGIC INSUFFICIENCY AND BARRIER DYSFUNCTION IN EX VIVO MODELS OF THE AIRWAY EPITHELIUM

ROSCIOLI E1,2, HAMON R1, JERSMANN H1,2, HODGE S1,2
1Royal Adelaide Hospital, Adelaide, Australia, and 2University of Adelaide, Adelaide, Australia

Introduction/Aim: Climate change wildfire events are becoming more frequent and increasingly encroaching on urban areas. Thus, many more individuals are likely to be exposed to wildfire smoke than ever before, yet the body of evidence on the health consequences of such exposure remains small. Here we examine markers of fragility and barrier function in models of human airway epithelium exposed to wildfire smoke-extract (WFSE).

Methods: Submerged cultures of Small Airway Epithelial Cells (SAEC) and differentiated air-liquid interface (ALI) cultures of bronchial AEC (bAEC) were exposed for up to 6h with 1-10% WFSE generated from plant species found in the Australian bushland. Autophagy (LC3-II and Sequestosome), apoptosis (Poly-(ADP)-Ribose Polymerase cleavage) and tight junction proteins were measured using western analysis. Barrier function was assessed using fluorescein tracers and trans-epithelial resistance (TER). The production of inflammatory cytokines were assessed using ELISA.

Results: SAEC exposed to 10% WFSE exhibited a significant blockade in autophagy as evidenced by an increase in LC3-II coupled with a concomitant elevation in Sequestosome abundance (both P<0.05). These conditions also induced significant PARP cleavage indicative of apoptotic changes. ALI cultures of bAEC treated with 5% WFSE demonstrated barrier dysfunction with significant increases in paracellular molecular permeability and ionic conductance (both P<0.001), and a reduction in the abundance of the tight junction proteins ZO-1 and Claudin-1 (both P<0.01). These cultures also exhibited an increase IL-6 secretion, which is consistent with an epithelial inflammation and repair response. The responses to WFSE were consistently elevated in comparison to parallel exposures of cigarette smoke-extract.

Conclusion: Relatively short exposures to WFSE potentiated a block in autophagic flux and barrier dysfunction in models of human airway epithelium. This scenario is commonly observed in the airways during COPD. As autophagy is a central regulator of cellular repair, viability, and inflammation, targeting the block in autophagic flux may ameliorate the consequences of wildfire smoke-exposure, particularly for individuals with pre-existing respiratory conditions.

Grant Support: Thoracic Society of Australia and New Zealand / Astra Zeneca, Royal Adelaide Hospital Research Fund.

COI Statement: The authors have no conflicts of interest to declare.
Introduction/Aim: Mucopolysaccharidoses type IIIA (MPSIIIA) is a lysosomal storage disorder caused by a deficiency in the activity of the lysosomal hydrolase sulphamidase, normally involved in heparan sulphate (HS) degradation. This results in primary storage of partially lysosomal hydrolase sulphamidase, normally involved in heparan sulphate in lung tissue. Here we determine the in vitro surface activity of alveolar surfactant harvested by bronchoalveolar lavage of normal (Norm), heterozygous (Het) and MPSIIIA mice.

Methods: Bronchoalveolar lavage fluid (BALF) (4-6 mice/genotype) was centrifuged to remove immune cells and the supernatant frozen and shipped on dry ice to Madrid. Samples were sequentially defrosted and centrifuged at 105,000g to pellet surfactant material. The pellets were reconstituted in 0.9% NaCl to a final concentration of 20mg/ml phosphatidylcholine and analysed fresh on a Captive Bubble Surfactometer.

Results: For all measurements, results for MPSIIIA animals were more variable, with many individuals performing more poorly. Nevertheless, under static conditions, surfactant demonstrated similar initial adsorption among all genotypes lowering equilibrium surface tension ($\gamma_{eq}$) to ~20mN/m. However, under dynamic conditions (30 cycles/min) surfactant from MPSIIIA animals was unable to reach a low surface tension at minimum bubble size ($\gamma_{min}$) even after 20 cycles compared with Norm and Het animals ($\gamma_{min}$: Norm: 1.6±0.7; Het: 1.3±0.3; MPSIIIA: 8.6±6.0mN/m; mean±SD, p<0.001). Similarly, the surfactant of MPSIIIA animals also had a higher $\gamma_{max}$ at maximum bubble size ($\gamma_{max}$: Norm: 29.0±0.8; Het: 29.6±1.6; MPSIIIA: 36.8±8.5mN/m; mean±SD; p<0.001). In addition, the change in area required to reach $\gamma_{min}$ was significantly greater in MPSIIIA animals ($\Delta A$area): Norm: 0.10±0.06; Het: 0.09±0.02; MPSIIIA: 0.38±0.16; mean±SD, p<0.001).

Conclusion: These data show that surface activity in MPS IIIA mice is inhibited either by changes in surfactant protein composition (lipids are unchanged) or by factors in the alveolar compartment. The latter likely relates to increased storage of heparan sulphate in lung tissue, which may enter the alveolus and either inhibit surface activity directly or indirectly by eliciting an immune reaction. A reduction in surfactant activity has significant implications for the lung function of MPSIIIA patients.

Introduction/Aim: Few data are available describing use-of-time patterns in people with COPD and the relationship between use of time and COPD severity remains unclear. This study aimed to describe use-of-time patterns across a typical day for a person with COPD and to explore associations between BODE index scores and time use patterns.

Methods: Using a cross-sectional design, people with clinically stable moderate to severe COPD had their demographics, objective measures of function, and self-reported COPD-related impairment recorded. Habitual activity was recorded using a seven-day accelerometer protocol and use-of-time recall interviews. Use-of-time recall interviews record 24-hour habitual activity profiles, combining activities that share similar context into one of eight domains. Compositional profiles were created using both energy expenditure bands (accelerometer data) and activity domains (use-of-time data). Compositional linear regression models described the relationship between BODE index scores and the compositional profiles. Models also predicted time use (min/d) across BODE index scores.

Results: 135 people were recruited (Age 70.7 ± 8.1 yrs., FEV1 50% ± 17%, females 40%[n=57]). In both accelerometer and use-of-time compositional models, significant differences in time use were observed across the BODE index. Relative to remaining components, as BODE index scores increased so did time spent in sedentary activities, quiet time and screens. The cumulative increases were strongly significant (p<0.001) and totalled 296 min/d (sedentary), 131 min/d (quiet time) and 155 min/d (screens). Corresponding cumulative and significant reductions in chores and household administration totalled 206 min/d (p<0.001) and 50 min/d (p=0.015) respectively were also observed.

Conclusion: In people with COPD, use-of-time patterns differ across BODE index scores. BODE index scores correlated strongly with time spent in chores, screen and/or quiet time.

Grant Support: Mr Hunt and Ms Dumuid are supported by Australian Government Research Training Program Scholarships. This study includes NHMRC Project Grant data (# 1010309).
PARTICIPATION IN PULMONARY REHABILITATION DID NOT SIGNIFICANTLY ALTER TIME USE PATTERNS IN PEOPLE WITH COPD
HUNT T1, WILLIAMS M1, OLDS T1, DUMUID D1
1University of South Australia, Adelaide, Australia

Introduction/Aim: Whether participation in comprehensive pulmonary rehabilitation programs (CPRP) changes habitual time use in people with COPD is equivocal. This study aimed to explore whether time use patterns changed in the twelve months after CPRP participation.

Methods: Using a non-randomised clinical trial design, adults with clinically stable moderate to severe COPD were recruited into an eight-week CPRP or Usual Care cohort. Baseline demographics, objective measures of function, self-reported COPD-related impairment and use-of-time recall interviews (24-hour profiles of habitual activity) were assessed at baseline and one, six and 12 months post CPRP. Activities sharing similar context were grouped into one of eight domains (chores, household administration, quiet time, screen time, self-care, sleep, socio-cultural, sports/exercise), which were then used to create compositional profiles representing an average day. Between compositions and between compositional components (at group and time point level) comparisons were conducted using ANOVA models and isometric log ratio differences respectively.

Results: 89 people (mean age 69.7 ± 9.7 yrs. FEV1 51% ± 9%) were recruited into CPRP (n=49) or Usual Care (n=40). With the exception of FEV1 %pred (CPRP 47% ± 19% vs. Usual Care 55% ± 16% [p=0.032]), baseline demographics were similar. Both cohorts exhibited similar time use patterns where there were no statistically significant differences in time use patterns evident between cohorts or time points.

Conclusion: This study found CPRP did not significantly influence patterns of habitual time use in people with COPD. Given the observed similarities in use-of-time profiles between cohorts, this data suggests changing habitual patterns of time use in people with COPD requires more than enrolment, and participation in, an eight week CPRP.

Grant Support: Mr Hunt and Ms Dumuid are supported by Australian Government Research Training Program Scholarships. This study includes NHMRC Project Grant data (# 1010309).

‘LET’S START THE CONVERSATION...’—THE PERSPECTIVES OF HEALTH CARE PROFESSIONALS ON PHYSICAL ACTIVITY PRESCRIPTION FOR PEOPLE WITH COPD
LAHHAM A1,2, BURGE A1,2,3, MCDONALD C2,4,5, HOLLAND A1,2,3
1Department of Physiotherapy, La Trobe University, Melbourne, Australia, 2Institute for Breathing and Sleep, Melbourne, Australia, 3Department of Physiotherapy, Alfred Hospital, Melbourne, Australia, 4Respiratory & Sleep Medicine, Austin Health, Melbourne, Australia, and 5Department of Medicine, The University of Melbourne, Melbourne, Australia

Introduction/Aim: Clinical practice guidelines recommend that people with chronic obstructive pulmonary disease (COPD) should be encouraged to be more physically active. However, it is not clear how guidelines are applied in practice. Reporting the perspectives of respiratory health care professionals (HCP) regarding physical activity (PA) advice and prescription would assist translation of PA recommendations into clinical practice.

Methods: An interview-based qualitative study including 30 respiratory HCP was conducted. Interviewed HCP (12 physicians, 10 physiotherapists, four nurses and four exercise physiologists) all provide care for patients with COPD. Semi-structured interviews were conducted, transcribed verbatim and analysed by two independent researchers using thematic analysis.

Results: Six overarching themes emerged from synthesis of the interviews. (1) Respiratory HCP acknowledged the importance of PA for people with COPD and identified it as a key component of management. (2) HCP were conscious of low PA levels; however, few specifically address this issue in practice. (3) Physicians described limitations including time constraints, pharmacological treatment prioritisation and perceived lack of expertise; as a result they preferred to refer to physiotherapists or nurses for more comprehensive assessment and advice regarding PA. (4) Most HCP viewed pulmonary rehabilitation as an essential intervention to enhance COPD outcomes, but PA was poorly differentiated from exercise training. (5) Although HCP were aware of guidelines regarding prescription of PA, few were able to recall specific recommendations for people with COPD. (6) HCP perceived that there were few evidence based strategies to enhance PA.

Conclusion: Respiratory HCP perceive that enhancing PA is a key element of COPD care, however this is not always addressed in practice. A structured approach to assessment and prescription of PA could assist HCP to discuss PA during clinical consultations.

Grant Support: None to declare.
PULMONARY REHABILITATION AND SLEEP QUALITY IN PATIENTS WITH COPD

ROBERTS M1,2, CHO J1,2,3, WHEATLEY J1,2,3

1Westmead Hospital, Wentworthville, New South Wales, Australia, 2Ludwig Engel Centre for Respiratory Research, Westmead Institute of Medical Research, Westmead, New South Wales, Australia, and 3University of Sydney at Westmead Hospital, Westmead, New South Wales, Australia

Introduction/Aim: Poor sleep quality is a common complaint reported by patients with COPD. Exercise has been shown to improve sleep quality. However, the relationship between pulmonary rehabilitation (PR) and improved sleep quality is unknown. We examined sleep quality in patients with COPD before and after PR, to identify factors associated with improvement in sleep quality following PR.

Methods: We performed a retrospective chart review of all patients with COPD who completed PR in Western Sydney from January 2012 to May 2017. Our primary outcome was sleep quality measured by Pittsburg Sleep Quality Index (PSQI). We identified patients with poor sleep quality at baseline (PSQI≥5 units), and compared baseline and post-PR characteristics of patients whose PSQI improved following PR by ≥3 units (responders) with those who did not (non-responders). Data were compared using paired t-tests within group, and Mann-Whitney tests between groups. Data presented as mean±SD. p<0.05 was significant.

Results: Data were available for 329 patients (52% male, 69.5±8.9 years, FEV1% predicted 48±16%). 219 (67%) had poor sleep quality. Following PR, group mean PSQI decreased by 0.95±3.14 units (p<0.0001). 88 of 219 patients with poor sleep quality at baseline improved PSQI by ≥3 units following PR. There was no difference at baseline between responders and non-responders for age, gender, lung function, 6MWD, mood or quality of life (QOL) (all p>0.05). However, following PR, responders had a greater 6MWD compared with non-responders by 38.3m and an improved QOL score by 5.3 units (both p<0.005).

Conclusion: Sleep quality improves following PR for COPD, but is highly variable between individuals. Greater gains in 6MWD and QOL were also seen in association with a clinically significant improvement in sleep quality following PR. Future intervention studies targeting improved sleep quality for patients with COPD may help to maximise the benefits of a PR program.

Grant Support: Nil

FEASIBILITY AND EFFICACY OF NOVEL TRANSITIONAL RESPIRATORY EXERCISE GROUP

AMIRMALEK S1, CHAO C1, RUDD P1,2, KENNEDY M1,3, BUCKLEY S1, GRANT E1, HOUGHTON B1

1Department of Respiratory Medicine, Port Macquarie Base Hospital, Port Macquarie, Australia, 2Department of Physiotherapy, Port Macquarie Base Hospital, Port Macquarie, Australia, 3Respiratory Educator, Specialist Team, Mid North Coast Local Area Health Network, Port Macquarie, Australia, and 4Department of Medical Records, Port Macquarie Base Hospital, Port Macquarie, Australia

Introduction/Aim: Pulmonary rehabilitation programs (PRPs) are integral in the care of chronic respiratory disorders for improvements in quality of life, exercise capacity and reduction in hospitalisations. Exercise is a key component of PRP but the efficacy of other components is yet to be determined. Port Macquarie Base Hospital (PMBH) has developed an abridged PRP, without education, to provide greater access to PRPs for in a timely fashion with limited resources. The Transitional Respiratory Exercise Group (TREG) is a hospital based program incorporating 6 weekly exercise sessions with rolling intake.

We aimed to assess the feasibility and efficacy of performing TREG.

Methods: We conducted a retrospective review of outcome data for all patients enrolled in TREG March 2016 - August 2017. This was compared to data from the PMBH PRP for the 12 months prior to TREG. The mean difference between 6MWT, oxygen saturations were determined using the Paired T-Test.

Results: 50 COPD admissions for occurred between March 2015 and March 2016. 12 (24%) were enrolled into the traditional PRP. 46 COPD admissions for occurred between March 2016 and March 2017. 29 (63%) were enrolled in TREG. Another 30 participants were referred to TREG from external sources to make up 59 patients total. Average time from hospital discharge to enrolment in TREG was 30 days with an average completion rate of 81%.

TREG group had significant improvement in 6MWT with mean increase of 42.5 m (p < 0.05). Oxygen saturations had a mean decrease of 0.004% (p < 0.05).

40 readmissions (Range 0-2) occurred following TREG (9 month average follow-up post, range 5-12m) compared to 61 readmissions (Range 0-3) in the 12 months prior to TREG (p = 0.05).

Conclusion: TREG is a feasible and efficacious means to provide timely access to an exercise rehabilitation program following hospitalisation.

Grant Support: No grant support was received for this project.

REFERENCES


PAIN COEXISTING WITH CHRONIC LUNG DISEASE ASSOCIATED WITH EMPLOYMENT STATUS

LEWTHWAITE H1, WILLIAMS G2, WILLIAMS M1, BALDOCK K3

1Health and Alliance for Research in Exercise, Nutrition and Activity (ARENA), Sansom Institute for Health Research, School of Health Sciences, University of South Australia, Adelaide, Australia; 2School of Health Sciences, University of South Australia, Adelaide, Australia, and 3Centre for Population Health Research, Sansom Institute for Health Research, School of Health Sciences, University of South Australia, Adelaide, Australia

Aim: Australian data on pain prevalence among those with chronic lung disease (CLD) is limited. This study aimed to: 1) determine pain prevalence for people with and without self-reported CLD in Australia; and 2) identify respondent characteristics associated with the presence of pain among people with self-reported CLD.

Methods: A cross-sectional analysis was undertaken on data obtained from adult respondents to the Australian Bureau of Statistics National Health Surveys in 2011/12 (n=15,136) and 2014/15 (n=14,510). Participants who self-reported a diagnosis of chronic bronchitis or emphysema lasting at least six months were classified as having CLD. A single survey item recorded the severity of any and all pain experienced by respondents in the previous four weeks, which was dichotomised as: 1) no pain/pain; 2) none-mild pain/moderate-very severe pain. Logistic regression was used to assess age- and sex-adjusted associations between pain and respondent socio-demographic characteristics for those with CLD.

Results: Overall prevalence of CLD across both surveys was 3.6% (95% CI 3.4%-3.9%; n=1,081). Those with CLD more commonly reported any pain compared to those without (83.5% (95% CI 49.8-55.8) vs. 68.9% (95% CI 68.4-69.4), p<0.001), and more commonly reported moderate to severe pain compared to those without CLD (52.8% (95% CI 49.8-55.8) vs. 27.4% (95% CI 26.9-27.9), p<0.001). Among those with CLD, being employed was associated with a lower probability of experiencing at least moderate pain (2011/12: OR=0.51, 95%CI 0.34-0.80, p =0.002; 2014/15: OR=0.52, 95%CI 0.34-0.80, p =0.003), after accounting for age and sex. No other factors were consistently associated with pain in adjusted models.

Conclusion: Pain was commonly experienced by people with CLD. In addition, employment was the only factor consistently associated with the experience of at least moderate pain among people with CLD. This finding may indicate functional impairment contributing to an inability to work among those experiencing pain and CLD.

Grant Support: Hayley Lewthwaite is supported by an Australian Government Research Training Program Scholarship

LIMITED SPECIFIC GUIDANCE FOR PAIN IN COPD CLINICAL PRACTICE GUIDELINES

LEWTHWAITE H1, WILLIAMS G2, WILLIAMS M1, BALDOCK K3

1Health and Alliance for Research in Exercise, Nutrition and Activity (ARENA), Sansom Institute for Health Research, School of Health Sciences, University of South Australia, Adelaide, Australia; 2School of Health Sciences, University of South Australia, Adelaide, Australia, and 3Centre for Population Health Research, Sansom Institute for Health Research, School of Health Sciences, University of South Australia, Adelaide, Australia

Aim: Pain is highly prevalent in people with moderate to severe COPD, with up to 85% of people experiencing pain in everyday life. This systematic review aimed to describe how pain (prevalence, assessment, management) is reported in COPD clinical practice guidelines (CPGs).

Methods: A systematic search of databases (Medline, Scopus, CINAHL, EMbase, clinical guideline), reference lists and websites identified current versions of CPGs for the management of COPD published in any language from 2006 to 2016. Two independent reviewers extracted data on frequency and context (verbatim) of the word “pain”. Pain context was synthesised into common categories including statements of prevalence, and strategies for assessment and management.

Results: 39 CPGs were included in this review (English n=20; translated n=19). “Pain” was mentioned 55 times across 24 CPGs; ranging from no (15 CPGs) to 11 mentions within a single CPG (Dutch). Three CPGs reported “pain” in the context of prevalence: 30-70% in advanced COPD (Finnish); ‘main symptom in year before death’ (German); ‘patients believe that they will experience less pain than people with other chronic conditions’ (Dutch). In the context of pain assessment, there were 13 mentions across nine CPGs (23%); as a need for differential diagnosis (n=12) or self-report questionnaires for problematic sputum causing painful cough (n=1). In the context of pain management, there were seven mentions across six CPGs, all suggesting palliation as the management strategy, of which two specifically suggested opioids. Further mentions of “pain” related to adverse drug reactions (n=22), contraindications to lung function assessments (n=6), or specific to surgical management (n=4).

Conclusion: Pain is common in people with COPD and has negative consequences for symptoms and quality of life. While the majority of COPD management CPGs (62%) mention pain, there was limited specific guidance for the assessment and management of pain over the life-course of COPD.

Grant Support: Hayley Lewthwaite is supported by an Australian Government Research Training Program Scholarship
HOME-BASED PULMONARY REHABILITATION IN THE “REAL” WORLD

BONDARENKO J1,2, BORGHAMS F2, BRYAN C2, BURGE A1,3,4, HOLLAND A1,3,4
1Physiotherapy, Alfred Health, Melbourne, Australia, 2Hospital Admissions Risk Program, Alfred Health, Melbourne, Australia, 3Physiotherapy, La Trobe University, Melbourne, Australia, and 4Institute for Breathing and Sleep, Melbourne, Australia

Introduction: Pulmonary rehabilitation is an effective intervention for people with chronic lung disease; however, centre-based program access and uptake are poor. A home-based model has demonstrated equivalent outcomes in a clinical trial; this study aimed to evaluate the clinical implementation of this model.

Methods: Since December 2016, Hospital Admissions Risk Program (HARP) clients with chronic lung disease referred for pulmonary rehabilitation have been offered the option of a home-based program (one home visit in week 1, 7 once-weekly phone calls); or a traditional centre-based program (8 weeks, twice-weekly sessions). Baseline and end-rehabilitation assessments include exercise capacity (6-minute walk test) and health-related quality of life. Home-based program completion was defined as participating in 70% of phone calls and attending a final assessment.

Results: Of the 110 clients referred, 34 (31%) chose to undertake a home-based program (21 female, mean age 69 [SD 13] years, FEV1 59 [24] % predicted, baseline 6-minute walk distance 375 [179] metres). Diagnoses included chronic obstructive pulmonary disease (n=23), bronchiectasis (n=5), asthma (n=3) and interstitial lung disease (n=3). Reasons for choosing the home-based program included transport issues (n=16) and work commitments (n=11); of these working clients, none had been previously able to undertake pulmonary rehabilitation. Twenty-seven participants stated that they would not have attended a centre-based program. To date, 30 people have attended an initial assessment for the program, and 21 people have completed the program. There was a significant improvement in 6-minute walk distance following home-based pulmonary rehabilitation (mean 23 [CI 7-38] metres).

Conclusion: Home-based pulmonary rehabilitation provides access to an effective intervention alternative for people with chronic lung disease who are not able to participate in a centre-based model.

Grant Support: None to declare

PHYSICAL EXERCISE DURING ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE: A SURVEY OF AUSTRALIAN PHYSIOTHERAPY PRACTICE

DEGARIS J1, OSADNIK C1
1Department of Physiotherapy, Monash University, Melbourne, Australia

Introduction/Aim: Some debate surrounds the role of physical exercise for patients admitted to hospital due to acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Little is known regarding the practice and opinions of physiotherapists regarding exercise and physical activity prescription and evaluation for this patient group. This study aimed to evaluate current Australian physiotherapy practice.

Methods: A national paper-based survey of 123 ‘large’ or ‘principal referral’ Australian public hospitals was conducted in 2016-17. The custom survey evaluated rates of prescription, outcomes used to measure treatment effectiveness, referral practices to pulmonary rehabilitation and factors related to service delivery. Response options were typically multi-choice or Likert scales. Results were compared between groups defined according to >/>5 years cardiorespiratory experience via Chi square test.

Results: 176 physiotherapists from 89 hospitals returned surveys (response rate 72%). Most physiotherapists (n=161, 91%) prescribed physical exercise for 60-100% of patients and felt their role was very or fairly important (n=42, 81%). The most frequently prescribed exercise modalities were non-treadmill walking (n=165, 94%), sit-to-stand lower limb endurance training (n=156, 89%), and non-equipment based lower limb strengthening (n=138, 78%), while aerobic capacity (n=127, 72%) and function (n=121, 69%) were most common assessed via the 6-minute walk test (n=69, 39%) and sit-to-stand tests (n=55, 31%). Most physiotherapists (n=97, 55%) did not offer physiotherapy evaluation during follow-up outpatient clinic reviews but frequently referred patients to follow-up pulmonary rehabilitation (n=121, 69%). The rate of referral was higher in those with less experience compared to those with greater experience (p=0.031).

Conclusion: Australian physiotherapists frequently prescribe simple physical exercise training modalities for patients with AECOPDs and perceive their role to be important in their overall management.

Grant Support: N/A
Conflicts: None to declare

Grant Support: None to declare

Conflicts: None to declare
CLINICIAN AND PATIENT TREATMENT PREFERENCES FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN AUSTRALIA: A DISCRETE CHOICE EXPERIMENT

HAMROSI K1, FIFER S1, ZEKAN A2
1Community and Patient Preference Research (CaPPRe), Sydney, Australia, and 2AstraZeneca, Macquarie Park, Australia

Introduction/Aim: To identify patient and clinician preferences for the treatment of chronic obstructive pulmonary disease (COPD) and the significance of attributes and values on decision making.

Methods: An online discrete choice experiment was conducted between July and October 2017 to evaluate patient and clinician preference for bronchodilators that co-administer long-acting antimuscarinic agent (LAMA) and long-acting beta 2-agonist (LABA) fixed dose combination (FDC) as inhaled therapy. A total of 200 patients with COPD currently taking a LAMA/LABA FDC; 40 respiratory specialists and 100 General Practitioners (GPs) participated in the survey. The survey evaluated hypothetical treatments of ten attributes derived from the literature. For each scenario, patients were asked to choose between their current treatment and three new treatment options based on mode of administration. GPs and respiratory specialists were asked to choose between their most prescribed treatment and three new treatment options based on mode of administration. A latent class model was used to estimate the relative priority patients and clinicians place on different attributes and estimate their willingness to pay for new treatments.

Results: Cost, improvement in symptoms and side effects primarily influenced the treatment decisions of clinicians. This was similar for the majority of COPD patients. Mode of administration (metered dose inhaler) and the ability to use a spacer were significant determinants of choice for a proportion of patients and a smaller segment of clinicians.

Conclusion: The results of this study suggest that whilst patients and clinicians share similar treatment preferences in COPD, differences were observed. Patients are more willing to trade off other attributes, risks and cost when considering a new mode of administration for COPD medications.

Grant Support: This study was supported by AstraZeneca.

ADVANCE CARE PLANNING IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE ASSESSED FOR LONG TERM OXYGEN THERAPY

HILDEBRAND F1, KEIN C1, DENTON E1, MILLER B1, KOHV S1
1Respiratory Medicine Department, Alfred Hospital, Melbourne, Australia

Introduction/Aim: An Advance Care Plan (ACP) is a communication between patient and clinician about end-of-life care, and has been shown to improve outcomes for patients and their families. Despite the incurable nature of Chronic Obstructive Pulmonary Disease (COPD), poor long term prognosis and proven benefit of ACP, uptake in this patient group is low, and discussion surrounding patients’ values, goals and palliative care are rarely addressed in an outpatient setting. This study examined patients with COPD on Long Term Oxygen Therapy (LTOT) to determine rates of uptake of ACP and factors associated with presence of an ACP in this population.

Methods: Data was retrospectively collected from consecutive patients with COPD assessed for continuation or commencement LTOT who attended Oxygen Clinic at a tertiary hospital in Melbourne between 1st July 2015 and 30th June 2016. Factors recognised to be associated with ACP were analysed using independent t-tests for continuous variables and Chi-squared tests for ordinal variables.

Results: 79 patients were included; age (mean ± SD) 71 ± 11 years, FEV1%predicted 38 ± 15%, PaO2 60 ± 11 mmHg, PaCO2 45 ± 10 mmHg, arterial pH 7.43 ± 0.04, Body Mass Index 28 ± 8 kg/m². 21.5% had an ACP. 40.5% were on continuous home oxygen, 36.7% intermittent oxygen, 11.4% nocturnal oxygen and 11.4% did not qualify/oxygen not advised for safety reasons/refused oxygen. 43.0% lived at home with community supports, 35.9% home with family, 12.7% family and supports, 3.8% home alone, 5% not known. 26.6% died within the study period. The only factor significantly associated with the presence of an ACP on univariate analysis was number of hospital admissions within the preceding 12 months (p<0.002).

Conclusion: This study demonstrated a low ACP rate, despite high mortality, in patients with COPD assessed for LTOT. Patients who were hospitalised within the last 12 months were more likely to have an ACP in place.

Grant Support: None
EXACERBATION STATUS IS LINKED TO DYSFUNCTIONAL PHAGOCYTOSIS IN STABLE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PATIENTS BUT NOT TO PULMONARY FUNCTION
LEE K1,2, LEE H2, MUNNIS S2, RUSH C1, NOLAN G1,2
1 College of Public Health, Medical and Veterinary Sciences, James Cook University, Townsville, Queensland, Australia, 2The Respiratory and Sleep Unit, Townsville Hospital and Health Services, Townsville, Queensland, Australia

Introduction/Aim: Chronic obstructive pulmonary disease (COPD) is a significant and increasing public health challenge. Much of the disease burden and economic cost of COPD is associated with acute exacerbations and resulting bacterial colonisation of the airways. The aim of this study is to determine whether the bactericidal functions of phagocytic cells (monocytes and neutrophils) are impaired, predisposing COPD patients to increased bacterial infections.

Method: Spirometry and venous blood were collected from COPD patients across the GOLD2015 spectrum and a group of healthy controls were recruited for comparison. Flow cytometry was used to determine differential counts for a range of leukocytes and internalisation of fluorescently labelled Streptococcus pneumoniae in whole blood phagocytes. Groups were compared by ANOVA and post hoc tests.

Results: Results demonstrated that peripheral blood monocytes (p=0.04) and neutrophils (p=0.0005) in exacerbation prone COPD patients had significant reductions in both bactericidal activity against S. pneumoniae (p=0.01) and internalisation of inert microparticles (p=0.01) compared to healthy controls and also stable COPD patients. Data collection remains ongoing.

Conclusion: This study has demonstrated that defective phagocytosis in COPD patients prone to exacerbations is irrespective of disease severity (according to GOLD2015). Thus dysfunctional cellular activity of blood monocytes and neutrophils, and a failure to mount an appropriate immune response to infection, may enable bacteria to overwhelm host defences leading to further lung tissue damage.

Grant Support: Institutional (JCU) funds to CR supported this project.

Declaration of interest: all of the named authors have no significant competing financial, professional or personal interests that might have influenced the performance or presentation of the work described in this submission.

COMMENCEMENT OF PULMONARY REHABILITATION DURING HOSPITAL ADMISSION INCREASES RATES OF ATTENDANCE AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD):
TANG C1,2, SOUTHCO TGD, BARKER K1, PAZSA F1, SKINNER EH1, BLACKSTOCK FC2,4
1Physiotherapy Department, Western Health, Victoria, Australia, 2School of Allied Health, La Trobe University, Victoria, Australia, 3Department of Respiratory and Sleep Disorders, Western Health, Victoria, Australia, 4Physiotherapy, School of Science and Health, Western Sydney University, NSW, Australia

Introduction: Early implementation of pulmonary rehabilitation (PR) after an Acute Exacerbation of COPD (AECOPD) is safe and effective, however the optimal time to implement PR remains unknown.

Aim: To compare PR attendance and completion rates for participants commencing PR at various time points relative to a hospital admission for AECOPD.

Methods: Participants admitted to hospital with an AECOPD were randomly allocated to commence PR either (i) at time of hospital admission, (ii) four weeks or (iii) eight weeks post discharge. Primary outcome measures were attendance and completion rates. Secondary outcome measures include 6-minute walk test (6MWT) and hospital re-presentation within 8 weeks post discharge. Primary outcomes were analysed using Chi Square and odds ratio. Secondary outcomes were analysed with ANCOVA. Significance was set at p<0.05.

Results: Sixty-two participants (mean(SD) age 68(12.9), baseline FEV1%predicted 47(19.4)) were recruited to the trial. 80% of those commencing PR at time of hospital admission attended at least one session of PR, compared to 65% of those commencing at 4 weeks post, and 50% of those commencing at 8 weeks post discharge (X²(df)=4.1(2), p=0.1). Participants were more likely to attend PR at time of hospital admission compared to 4 weeks (OR(95% CI)=0.5(0.1 to 1.9), p=0.3) and 8 weeks (OR(95% CI)=0.25(0.1 to 0.9), p=0.048) post discharge. 60% of participants commencing PR at time of hospital admission completed the program, compared to 40% of the 4 weeks group, and 46% of the 8 weeks group (X²(df)=1.7 (2), p=0.4). There were no significant differences in hospital presentations (F=1.2, p=0.3) or readmissions (F=0.7, p=0.5), and all groups showed a tendency for improvement in 6MWT (F=1.6, p=0.22).

Conclusion: Patients who commence PR at time of hospital admission are significantly more likely to attend, but just as likely to complete and improve exercise capacity, as those commencing at 8 weeks post admission.

Grant Support: Western Health Research Grant

Declaration of Interest Statement: We hereby declare that there are no known conflict of interest in this project.

Word count: 300 words
OLIV

TP 033

CXCR4 AND SDF-1 ARE EXPRESSED IN THE HONEYCOMB CYSTS OF PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS

JAFFAR J1, ORGAN L1, GRIFFITHS K2, FOLEY M2, WESTALL G1

1Department of Immunology and Pathology, Monash University; Australia and Department of Lung Transplant Service, The Alfred, Australia, Melbourne, Australia, and 2AdAlta Limited, 15/2 Park Drive Bundoora, Australia 3083 and Department of Biochemistry and Genetics, La Trobe University, Bundoora, Melbourne, Australia

Introduction/Aim: The presence of “honeycomb lung” on CT is a diagnostic most commonly but not exclusively associated with idiopathic pulmonary fibrosis (IPF). CXCR4 is a transmembrane-receptor activated by SDF-1 and present on epithelial cells. Conflicting reports in the literature, describing honeycomb cysts as having both airway origin and parenchymal/alveolar origin highlights the need for further investigation into the cells of the honeycomb cysts and their immediate microenvironment.

Methods: Sixty paraffin embedded samples of human lung tissue (n=30 (non-diseased control, NDC, n = 10; IPF, n = 10 and non-IPF interstitial lung disease, n = 10) from patients were included in this study. Staining patterns of CXCR4, SDF-1, CD20, CD45, E-Cadherin, and alpha-smooth muscle actin (α-SMA) were determined by immunohistochemistry. Total collagen in the tissue sections was determined by Masson’s trichrome staining. Regions of examination on the apical and basal lobes of each patient included distal airways, small blood vessels, and alveolar spaces of the parenchyma where honeycombing is found.

Results: Brightfield microscopy performed on (N=4) patients with IPF and (N=4) non-diseased control (NDC) donors demonstrated strong CXCR4 and SDF-1 expression in honeycomb regions of IPF tissue compared to mild or absent staining in the normal parenchyma of NDC tissue (Figure 1). Prominent CXCR4 expression was also observed in distal airway epithelium. Co-staining of CXCR4 and e-cadherin or CD45 by immunofluorescence suggested the presence of 2 populations of CXCR4 + cell; one epithelial (CXCR4+/e-cadherin+) and one bone marrow derived (CXCR4+/CD45+).

Conclusion: Honeycomb changes are most commonly, but not exclusively seen in patients with IPF. CXCR4 expression within both honeycomb cysts and distal airway epithelium is suggestive of an airway origin of honeycombing, however, CXCR4 expression was also observed occasionally in small vessels within fibrotic interstitial tissue.

Grant Support: This work was supported by AdAlta and an Innovation Connection Grant

Figure 1 Immunohistochemistry on lung tissue from patients with/without idiopathic pulmonary fibrosis (IPF). Tissue sections were probed with antibodies to CXCR4 and SDF-1.
CYCLOPHOSPHAMIDE FOR CONNECTIVE TISSUE DISEASE–ASSOCIATED INTERSTITIAL LUNG DISEASE
BARNES H1, GOH N2, WESTALL G1, HOLLAND A1,2,3, GLASPOLE I1
1Alfred Hospital, Melbourne, Australia, 2Respiratory and Sleep Medicine, Austin Hospital, Melbourne, Australia, 3Institute for Breathing and Sleep, Melbourne, Australia

Introduction/Aims: Decision-making in the treatment of connective tissue disease associated interstitial lung disease (CTD-ILD) is difficult due to lack of evidence of benefit and high risk of side effects.

The objectives were to assess the efficacy and safety of cyclophosphamide in the treatment of CTD-ILD.

Methods: Searches for randomised controlled studies on CENTRAL, MEDLINE, EMBASE, CINAHL, and Web of Science to May 2017 were performed.

Results: Four trials with 495 participants (mostly systemic sclerosis) were included. The evidence was low quality, as participants had mostly non-progressive disease, the withdrawals were high in the intervention groups, and there were wide confidence intervals with small effect sizes.

There was a small significant impact on lung function using cyclophosphamide compared with placebo (FVC% mean difference (MD) 2.83; 95% CI 0.80 to 4.87; p=0.006) but not in DLCO % (MD -1.68; 95% CI -4.37 to 1.02; p=0.25; two trials, 182 participants).

There was a clinically and statistically significant improvement in breathlessness and in quality of life in one trial favouring cyclophosphamide compared with placebo. There was an increased risk of adverse events.

There was no significant impact on lung function using cyclophosphamide compared with mycophenolate (FVC% MD -0.68; 95% CI -5.44 to 4.08; p=0.78; two trials, 149 participants), however there was an increased risk of adverse events.

Conclusions: Further studies are required, adequately powered to compare outcomes within different subgroups, including by radiological severity, and in other forms of CTD; with cyclophosphamide compared with other anti-fibrotic agents, and in those with evidence of progressive fibrotic disease, who may benefit the most.

Grant Support: Cochrane Airways/Lung Foundation Australia Scholarship 2017

ANTIFIBROTICS FOR TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS IN THE REAL WORLD: A SINGLE CENTRE EXPERIENCE
SANTOS C1, WOODS A1, JO H1,2, JEE A1,2, WEBSTER S2, CORTEY1,2
1University of Sydney, Sydney, New South Wales, Australia, and 2Respiratory Department, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia

Introduction/Aim: Idiopathic Pulmonary Fibrosis (IPF) is the most common interstitial lung disease (ILD), however until recently, there was no effective treatment. In May 2014, landmark trials of antifibrotic medications (nintedanib and pirfenidone), demonstrated slowing of disease progression in IPF. There is however, limited data outside of clinical trials regarding long-term effects of these medications. In this study, we describe the experience with these medications in the population of IPF patients at Royal Prince Alfred Hospital (RPA).

Methods: We retrospectively reviewed the ILD multidisciplinary meeting (MDM) diagnosis of all patients and included any patient with a diagnosis of IPF. All patients received follow-up with serial pulmonary function and six-minute walk tests. Patients on antifibrotic medications had doses and adverse events recorded at each clinic appointment.

Results: Of the 500 patients reviewed, IPF was the most common diagnosis with 32% (n=160). They were mostly male (115, 71.9%), older (71.3±9.7 years) with mild impairment (FVC 73.65±19.5%; DLCO 55.75±18.17%. 36% (n=57) of these IPF patients received antifibrotic treatment (pirfenidone n=29; nintedanib n=28). This population was largely similar to those who did not start treatment. 7 patients reported no side-effects. Severe side-effects occurred in 12 resulting in a cessation of antifibrotic. 24 had a pause in treatment and then restarted at the same dose. 6 patients were switched from one antifibrotic to the other. The most common adverse events for both medications combined included weight loss / anorexia (52.4%), nausea (49.2%) and diarrhoea (36.5%).

Conclusion: IPF was the most common diagnosis made at the RPA ILD-MDM. 36% of IPF patients commenced antifibrotic therapy. Side effects were common but only led to treatment changes in 57.1% (n=36).
Overall, there appeared to be more side effects in this population compared with clinical trials.

Grant Support: Nil
IDENTIFYING INTERSTITIAL LUNG DISEASE PATIENTS WHO PRESENT WITH AUTOIMMUNE FEATURES
MAHMOOD A1, LIMAYE S1, RIDLEY L1, LEE K1, VEITCH E1
1Concord Repatriation General Hospital, Sydney, Australia

Introduction/Aim: A long recognised subgroup of patients with interstitial lung disease (ILD) and autoimmune features don’t fit into a specific autoimmune disease diagnosis. Recently, scoring criteria have been proposed to categorise these patients, who are said to have interstitial pneumonia with autoimmune features (IPAF).

Aim: We sought to determine how many ILD patients presented at our ILD multidisciplinary meeting fulfil the criteria for this designation, and describe their features.

Methods: A retrospective study was performed of patients presented in the ILD multidisciplinary meetings at Concord Hospital from 2014 to 2017. Case summaries from the meetings were reviewed and IPAF patients were identified using a data collection checklist.

Results: 200 cases were reviewed, of which 24 patients (12% of cases) satisfied the criteria for IPAF. The mean age was 69.5 (range 50 to 88 years), and 14 were female. The diagnosis of ILD was overwhelmingly based on HRCT abnormality, only 1 patient underwent a surgical lung biopsy. Clinical criteria for IPAF were only present in 2 patients but all had serological abnormalities. The most common serological abnormality was positive ANA in 15 cases. The most common chest HRCT appearance was NSIP (16 cases), followed by OP (6 cases). A retrospective analysis of serology in patients with an NSIP pattern on chest CT scanning. At presentation, most were deemed sufficiently well to monitor only. The appropriateness of this and further information on disease trajectory in this group is required.

Conclusion: The diagnosis of IPAF is heavily based on abnormal serology in patients with an NSIP pattern on chest CT scanning. At presentation, most were deemed sufficiently well to monitor only. The appropriateness of this and further information on disease trajectory in this group is required.

COMPOSITE PHYSIOLOGIC INDEX IN IDIOPATHIC PULMONARY FIBROSIS: EFFECTS OF NINTEDANIB
GLASPOLE I1, WELLS A2, BEHR J3, STANSEN W4, STOWASSER S5, MAHER T5
1The Alfred Hospital and Monash University, Melbourne, Australia, 2National Institute for Health Research Respiratory Biomedical Research Unit, Royal Brompton and Harefield NHS Foundation Trust, and National Heart and Lung Institute, Imperial College, London, UK, 3Medizinische Klinik und Poliklinik V, University of Munich and Asklepios Klinik München-Gauting, Member of the German Center for Lung Research, Munich, Germany, and 4Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany

Introduction/Aim: In the Phase III INPULSIS® trials, nintedanib 150mg twice daily slowed disease progression in patients with idiopathic pulmonary fibrosis (IPF) by significantly reducing the annual rate of decline in FVC. Patients with FVC ≥50% predicted, diffusing capacity of the lung for carbon monoxide (DLco) 30–79% predicted and FEV1/FVC ≥0.7 were eligible for inclusion. The composite physiologic index (CPI), calculated based on percent predicted values for FVC, DLco and FEV1, is a measure of the extent of pulmonary fibrosis in patients with IPF. We assessed the effect of nintedanib on change in CPI.

Methods: The measures required to calculate CPI were taken at baseline, Week 24 and Week 52. Post-hoc analyses were conducted on the effect of nintedanib on change from baseline in CPI at Weeks 24 and 52 using pooled data from both INPULSIS® trials. Adjusted mean difference versus placebo at Week 52 was assessed based on a mixed model for repeated measures (MMRM).

Results: 1061 patients were treated in the INPULSIS® trials (638 with nintedanib, 423 with placebo). Mean±SD CPI at baseline was 45.9±10.9 and 46.3±11.0 in the nintedanib and placebo groups, respectively. At Week 24, mean±SD changes from baseline in CPI were 2.1±8.3 in the nintedanib group and 2.2±7.0 in the placebo group. Based on MMRM, the adjusted mean±SEM change from baseline in CPI at Week 52 was 2.8±0.4 in the nintedanib group and 3.9±0.5 in the placebo group (difference −1.1 [95% CI: −2.3, 0.1]; p=0.0676).

Conclusion: Based on data from the INPULSIS® trials, nintedanib was associated with a marginal treatment effect on change from baseline in CPI at Week 52. This may be due to the high variability in DLco assessments in multi-centre clinical trials and the influence of factors other than extent of fibrosis on DLco.

Grant Support: The study was funded by Boehringer Ingelheim.

Declaration of Interest Statement: IG has received speaker fees and unrestricted educational grant from Roche and speaker fees and equipment grant from Boehringer Ingelheim. He is also an advisory board member for Roche and Boehringer Ingelheim. AW has nothing to disclose. JB has received lecture fees from Actelion, Altana, AstraZeneca, Bayer Schering Pharma, Boehringer Ingelheim, Encysive, GSK, InterMune, Merck, Nycomed, Pfizer, Schering, Zambon and ZLB Behring; he is involved in consultancies with Actelion, Bayer Schering Pharma, Pari, Zambon and he has industry grants from Actelion, Bayer, Mondobiliotech and Mygene. He has received reimbursement of conference fees and travel expenses from Boehringer Ingelheim, Actelion and InterMune. WS and SS are employees at Boehringer Ingelheim. TMM has received consultancy fees from GSK, Actelion, Boehringer Ingelheim and Philips Respironics. He has received an unrestricted academic-industry research grant from GSK.
CHRONIC HYPERSENSITIVITY PNEUMONITIS: A PROSPECTIVE COHORT ANALYSIS OF AN UNDER-RECOGNISED CLINICAL ENTITY

BARNES H1, WATSON A2, ELLIS S1, GOH N1, WESTALL G1, HOLLAND A1,2,6, GLASPOLE I1
1Alfred Hospital, Melbourne, Australia, 2School of Physiotherapy, La Trobe University, Melbourne, Australia, 6Department of Physiotherapy, Alfred Health, Melbourne, Australia, and 7Institute for Breathing and Sleep, Melbourne, Australia

Introduction/Aim: Chronic hypersensitivity pneumonitis (CHP) is an immune mediated interstitial lung disease, caused by an antecedent exposure to an offending agent. It can be difficult to accurately diagnose, but may improve with immunomodulatory treatment. Little is currently known about patient characteristics and prognosis.

We sought to determine what characteristics accurately conferred a diagnosis of CHP, and what factors might influence disease trajectory and mortality.

Methods: We collected data from all patients with a consensus diagnosis of CHP from the Alfred ILD Registry: a prospective, longitudinal cohort registry commenced in 2002.

Results: Fifty-five patients with a consensus diagnosis of CHP were identified (mean age 55±10ys; 43% male). Dyspnoea was the most common symptom at disease onset, clubbing likely (40%) but not crackles (9%). Over 50% had a clinical exposure identified, including 30% with avian exposure, however only 37% underwent avians precipitans testing and none were positive. Multi-disciplinary meeting (MDT) clinical diagnostic confidence was only definite in 10%, probable in 61% and equivocal in 30%. Ground glass changes were the most common radiological feature. Multinucleated histiocytes the predominant histopathological feature on biopsy (27%) or explant (21%). Immunomodulatory treatment was used in 70% of patients, mostly commonly prednisolone (45%). Oxygen supplementation was used in 20%. Nine-percent were deceased at time of follow-up, and 5% underwent lung transplantation. The average rate of decline per year was FEV1 150±10mL, FVC 117±29mL, and %TLCO 2±18%. The rate of decline was not affected by identification of clinical exposure (p=0.7) or immunomodulatory treatment (p=0.4).

Conclusion: This data describes the natural history of CHP patients, however is limited by small patient numbers. Further larger registry research is required to aid more accurate MDT diagnosis, predict prognostic factors, and response to treatment.

Grant Support

LONG-TERM NINTEDANIB TREATMENT IN IPF: NEW DATA FROM INPULSIS-ON

TROY L1, CRESTANI B2, QUARESMA M2-4, KAYE M6, STANSEN W3, STOWASSER S3, KREUTER M7
1Royal Prince Alfred Hospital, Australia, 2Pneumologie, Hôpital Bichat, Paris, France, 3Thoraxklinik, University of Heidelberg, and Translational Lung Research Center Heidelberg, German Center for Lung Research, Heidelberg, Germany, 4Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany, and 5Minnesota Lung Center, Minneapolis, Minnesota, USA

Introduction/Aim: The efficacy and safety of nintedanib 150 mg twice daily in patients with idiopathic pulmonary fibrosis were assessed in the 2 Phase III INPULSIS® trials. Patients who completed the 52-week treatment period and follow-up visit 4 weeks later in INPULSIS® could receive open-label nintedanib in the extension trial INPULSIS-ON. We assessed the long-term efficacy and safety of nintedanib based on an interim analysis of INPULSIS-ON in October 2016.

Methods: Patients treated with placebo in INPULSIS® initiated nintedanib in INPULSIS-ON; patients treated with nintedanib continued nintedanib.

Results: 734 patients were treated in INPULSIS-ON (430 continuing nintedanib; 304 initiating nintedanib). At this interim analysis, mean±SD exposure in INPULSIS-ON was 27.7±15.1 months. Mean±SD (minimum–maximum) total exposure for patients treated with nintedanib in INPULSIS® and INPULSIS-ON was 40.7±14.6 (11.9–63.1) months. In INPULSIS®, mean±SD change in FVC from baseline to Week 52 was −89.2±264 mL in the nintedanib group and −203.2±293 mL in the placebo group; the annual rate±SEM of decline in FVC was −114.1±11 mL/year and −224.1±13 mL/year in these groups, respectively. In all patients treated in INPULSIS-ON, mean±SD change in FVC from baseline of INPULSIS-ON to Week 144 of INPULSIS-ON was −30.5±365 mL; the annual rate±SEM of decline in FVC over 144 weeks was −131±6 mL/year. The adverse event profile of nintedanib in INPULSIS-ON was consistent with that in INPULSIS®.

Conclusion: Data from INPULSIS-ON indicated that the effect of nintedanib on reducing disease progression is maintained over the long term. Nintedanib treatment (up to 63 months) had an acceptable safety and tolerability profile.

Grant Support: The study was funded by Boehringer Ingelheim.

Declaration of Interest Statement: LT has previously received speaker’s fees from Boehringer Ingelheim, along with travel support for attendance at investigator meetings from Roche/InterMune, Celgene and Bayer. BC has received grants, personal fees and non-financial support from Roche/InterMune and Boehringer Ingelheim; personal fees and non-financial support from Sanofi; grants from Cardif, LVL and MedImmune, and personal fees from AstraZeneca. MQ, WS and SS are employees of Boehringer Ingelheim. MKaye has nothing to disclose. MKreuter has received fees for speaking and/or organising education from ERS, Almirall, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, GlaxoSmithKline, InterMune, Novartis, Nycomed, Pfizer and Roche and consulting fees from Boehringer Ingelheim, InterMune, GlaxoSmithKline and Roche.
1-YEAR GOOD, 5-YEARS NOT SO: ERA EFFECT ON SHORT AND LONG TERM SURVIVAL AFTER LUNG TRANSPLANTATION

WILSON B1, GLANVILLE A1
1St Vincents Hospital, Sydney, New South Wales, Australia

Introduction/Aim: While short term survival after lung transplantation has improved over time, mortality at 5 years remains higher than other solid organ transplants. We examine the effect of era on 30-day, 1-year and 5-year conditional survival after lung transplantation.

Methods: We compared baseline characteristics, 1-year survival and 5 year conditional survival in adult lung transplant recipients at St Vincent’s Hospital across 3 decades: 1990-1999, 2000-2009, 2010-2016. We also examined the change in cause of death at 1 year over time.

Results: A total of 860 patients met our inclusion criteria. Survival was 96%, 88% and 61% at 30 days, 1 year and 5 years respectively. There was a strong association between improved 30-day mortality rate and increasing era of transplantation (85.8/100 patient years (pyrs) in 1990-1999, 36.3/100pyrs in 2000-2010, 27.0/100pyrs in 2010-2016, p=0.006). There was also a strong association between increasing era of transplantation and 1-year mortality rates (19.4/100pyrs in 1990-1999, 11.23/100pyrs in 2000-2010, 9.7/100pyrs in 2010-2016, p=0.0045). However, there was no association between transplantation era and 5-year conditional survival (7.6/100pyrs in 1990-1999, 6.3/100pyrs in 2000-2010, 8.2/100pyrs in 2010-2016, p=0.97). Causes of death at 1 year have also evolved over time, with more technical failures occurring in the early era compared to the more recent era.

Conclusion: While there have been significant improvements in short term survival after lung transplantation over time, there have been no significant improvements in conditional 5-year survival. In order to improve conditional 5-year survival, we must focus on optimal candidate selection and improving the prevention, detection and management of (a) chronic allograft dysfunction, in its various phenotypes, (b) acute cellular and antibody mediated rejection (c) infection prophylaxis and (d) post-transplant malignancy.

IN SIGHT BUT OUT OF MIND: THE HIDDEN RISK OF HUMAN PAPILLOMA VIRUS IN MALES AFTER LUNG TRANSPLANTATION

BENZIMRA M1, MALOUF M1, MITCHELL A1, PEARSON R1, ABELSON D1, GLANVILLE A1
1St Vincent’s Hospital, Sydney, New South Wales, Australia

Introduction/Aim: In contrast to other solid organ transplant recipients, lung transplant (LTX) patients are often within their reproductive years. We reported previously that high grade human papilloma virus (HPV) lesions are more frequent in females after LTX. Herein we explored factors which influence rate and severity of HPV related morbidity in male LTX recipients including the potential role of HPV vaccination.

Methods: Single centre, anonymous, cross sectional survey to ascertain sexual health experiences of male LTX recipients.

Results: 101 consecutive bilateral LTX recipients (age 47±15 years, mean±SD, range 21-77 years) attending outpatient clinic were recruited at 5.9±5.9, range 0.5-23 years post LTX. Indications were cystic fibrosis (n=32), interstitial lung disease (n=29), emphysema (n=28) and other (n=12). Only 1% had completed HPV vaccination. 9% reported penile lesions comprising warts (n=6) and penile intraepithelial neoplasia (PIN) / cancer (n=3). Therapy comprised topical preparations (33%), ablation (33%) and partial penectomy (33%). Only 24% recorded always using barrier prophylaxis with a casual partner while 49% recorded no use. In comparison, 10% recorded always using barrier prophylaxis with a stable partner while 53% recorded no use. Traditional risk factors, including age of first sexual intercourse and number of partners were not significant nor was time post LTX.

Conclusion: Even accounting for recollection bias, HPV causes significant and diverse morbidity after LTX occasionally requiring extensive surgery. In addition to HPV vaccination in both males and females, an ongoing education and surveillance program is critical to limit morbidity, prevent mortality and preserve reproductive potential with a focus on self-examination and prompt reporting to effect successful therapies.

Grant Support: Nil
OUT OF SIGHT, OUT OF MIND: THE HIDDEN RISK OF HUMAN PAPILLOMA VIRUS IN FEMALES AFTER LUNG TRANSPLANTATION
MALOUF M1, PEARSON R1, MITCHELL A1, ABELSON D1, BENZIMRA M1, GLANVILLE A1
1Lung Transplant Unit, St.Vincent’s Hospital, Sydney, New South Wales, Australia

Introduction/Aim: Unlike other solid organ transplant recipients, lung transplant (LTX) patients are often females with reproductive potential. We reported previously that high grade human papilloma virus (HPV) lesions are more frequent after LTX. Hence we explored factors which influence rate and severity of HPV related morbidity including the role of HPV vaccination.

Methods: Single centre, anonymous, cross sectional survey, to ascertain sexual health experiences of female LTX recipients.

Results: 143/144 consecutive LTX recipients attending clinic (bilateral: heart lung = 140:3) (age 47 ± 15 years, mean ±SD) were recruited at 5.9 ±4.2, range 0.5-23 years post LTX. Indications were cystic fibrosis (n=48), interstitial lung disease (n=16), emphysema (n=49) and other (n=30). 17% had completed HPV vaccination. 30% reported abnormal Pap smears. Rates of warts, vulval intraepithelial neoplasia, vaginal intraepithelial neoplasia, and anal intraepithelial neoplasia were 4.9%, 4.2% and 3.5% respectively. Therapy comprised observation (33%), loop excision of the transformation zone (LETZ) / long LETZ (23%), cervical cone biopsy (22%) and hysterectomy (5%). Traditional risk factors, including age of first sexual intercourse (p=0.001) and number of partners (p<0.001) were significant as was time post LTX (p=0.020). Smoking history was not (p=0.444). Only 48% recorded always using barrier prophylaxis with a casual partner while 47% recorded no use. In comparison, 16% recorded always using barrier prophylaxis with a stable partner while 47% recorded no use.

Conclusion: Even accounting for recollection bias, HPV causes significant and diverse morbidity after LTX. In addition to HPV vaccination, an ongoing education and surveillance program is critical to limit morbidity, prevent mortality and preserve reproductive potential.

Grant Support: Nil

WHAT A CHANGE A FEW DECADES CAN MAKE: IMPROVEMENTS IN 1-YEAR SURVIVAL AFTER LUNG TRANSPLANTATION
WILSON B1, GLANVILLE A1
1The Lung Transplant Unit, St Vincent’s Hospital, Sydney, New South Wales, Australia

Introduction/Aim: Post-transplant survival in adult lung transplant recipients has improved over time. We examine the effect of era on survival after lung transplantation, adjusting for baseline donor and recipient factors.

Methods: We compared baseline characteristics and 1-year survival in adult lung transplant recipients at St Vincent’s Hospital across 3 decades: 1990-1999, 2000-2009, 2010-2016. We used a Cox proportional hazards model to determine risk-adjusted era effect on mortality.

Results: Of 860 patients meeting inclusion criteria, 826 had sufficient follow-up data for 1-year survival analysis. Survival was 88% at 1 year. There was a strong association between transplant era and 1-year mortality (RR 0.58 in 2000-2009 with p=0.02 and RR 0.50 in 2010-2016 with p=0.005 compared to 1990-1999). Other predictors of 1-year mortality on crude analysis included older age, gender, higher patient baseline BMI, transplant type, indication for transplantation, operation duration, older donor age, increased donor to recipient weight ratio, and female donor to male recipient transplants. Patients in more recent years were also older and more overweight/obese. In multivariate regression, the association between era of transplant and 1-year mortality was even stronger (HR 0.35 in 2000-2009 and HR 0.17 in 2010-2016 compared to 1990-1999, p<0.0001). Other variables included in multivariate regression for prediction of 1-year mortality were older patient age at transplant (HR 0.82 in 2000-2009 and HR 0.77 in 2010-2016 compared to 1990-1999, p=0.0001). Other variables included in multivariate regression for prediction of 1-year mortality were older patient age at transplant (HR 1.40, p=0.079), older donor age (HR 2.31 for donors aged >56 vs 0-17 years, p=0.063), longer operation duration (HR 1.39, p=0.006) and transplantation for interstitial lung disease (HR 2.31 compared to cystic fibrosis, p=0.042).

Conclusion: Despite increasing baseline risk profiles of patients, risk-adjusted mortality at 1-year post-transplant has improved over time.
RETROSPECTIVE RISK STRATIFICATION PREDICTS EVENTUAL OUTCOMES IN PATIENTS PRESENTING WITH ACUTE PULMONARY EMBOLISM

COOK A1, GAO D2, SINGH M1, SRIRAM B1, SINGH M1
1Queensland Health, Gold Coast, Queensland, Australia, 2Griffith University, Gold Coast, Queensland, Australia

Introduction/Aim: The Pulmonary Embolism Severity Index (PESI) score is a risk prediction score that estimates the 30 day mortality risk of a patient presenting with an acute pulmonary embolism (PE), as well as identifying low risk patients who may be a candidate for early discharge and home therapy. This study aims to audit the adherence to society guideline recommendations that a risk assessment score should be performed for patients presenting with acute PE, and to retrospectively calculate the patient’s risk to assess how this correlated with eventual outcomes, including length of stay (LOS), and mortality.

Methods: A retrospective review was performed of adult patients presenting the Gold Coast Health Service, with acute PE over a two year period. Patients with incidentally-detected PE, or those who developed a PE while an inpatient for another reason, were excluded. The PESI score was calculated from clinical information documented at admission.

Results: 288 patients were included (60% male). 14 (5%) had a PESI score documented by the treating team. There is a significant correlation between retrospectively calculated PESI score and length of stay (R² = 0.312; P = <0.001). Average LOS (days) for each PESI category was Very Low = 3.5, Low = 4.3, Intermediate = 5.7, High = 7.8, Very High = 9.1. There is a correlation between PESI score and mortality at 30 days (R² 0.286; P = <0.001), 90 days (R² 0.373; P = <0.001), and 1 year (R² 0.439; P = <0.001).

Conclusion: This study demonstrates that a PESI score calculated from clinical parameters at admission for acute PE predicts length of stay and mortality, and is therefore a useful risk stratification tool which could encourage early discharge for low risk groups, or more intense observation, investigation, and counselling for high risk groups.

A CASE OF DYSPNOEA—HEPATOPULMONARY SYNDROME

GHIMIRE R1, WELGADARA S1, TANG T1
1Gold Coast University Hospital, Gold Coast, Australia

Introduction: Hepatopulmonary syndrome (HPS) is characterized by abnormal arterial oxygenation from intrapulmonary vascular dilatations (IPVD) in the setting of chronic liver disease particularly those with portal hypertension or congenital portosystemic shunts and rarely in acute liver disease. Its prevalence ranges from four to 47 percent.

Method/Case Report: A 61 years old male presented with progressively worsening shortness of Breath for years. He was found to have platypnoea and orthodeoxia and was diagnosed to have Child pugh B chronic liver disease secondary to alcohol excess.

He had long standing background history of anaemia and thrombocytopenia under investigation, subdural haematomas and asbestos exposure. He was an ex-smoker with ten pack year history of smoking.

Preliminary investigations for chest pain and dyspnoea were negative. He was discharged with home oxygen. Patient continued to drink alcohol despite constant encouragement to quit and wasn’t interested for liver transplant.

Results: Transthoracic echocardiogram Exercise stress test and myocardial perfusion scan were unremarkable. Spirometry and lung volumes within normal limits however there was severe reduction in CO diffusion which didn’t correct for alveolar volume. There was no evidence of CT pulmonary thromboembolism and significant parenchymal lung disease. Ultrasound liver showed fatty liver with possible cirrhosis but normal spleen size. Agitated saline test did not show any interatrial shunt, however left atrial opacification occurred only after seven cardiac cycles post initial right atrial opacification.

Conclusion: Development of HPS doesn’t correlate with the severity of the liver disease so recognising this condition early will prevent concerns and minimise excessive investigations.

Grant Support: none
A COORDINATED MULTIDISCIPLINARY CLINIC MODEL OF CARE FOR CHILDREN AND ADULTS WITH PRIMARY CILIARY DYSENESIA (PCD) IN SYDNEY, AUSTRALIA

PRENTICE B1,2, FITZGERALD D1,4, MIDDLETON P3,6, BIRMAN C7,8, DOUMIT M1, SILVA Y3, WALES S1, BUBBLE L3, MORGAN L3

1Department of Respiratory Medicine, Sydney Children’s Hospital, Sydney, Australia, 2School of Women’s and Children’s Health, The University of New South Wales, Randwick, Australia, 3Department of Respiratory Medicine, The Children’s Hospital at Westmead, Westmead, Australia, 4Discipline of Paediatrics and Child Health, Sydney Medical School, The University of Sydney, Sydney, Australia, 5Ludwig Engel Centre for Respiratory Research, Westmead Institute of Medical Research, Australia, 6ENT Department, Royal Prince Alfred Hospital, Camperdown, Australia, 7The University of Sydney, Camperdown, Australia, and 8Department of Respiratory Medicine, Concord Repatriation General Hospital, Australia

Introduction: Diagnosing and treating a rare multi-system disease such as Primary Ciliary Dyskinesia (PCD) requires specialist expertise and multidisciplinary support. A multidisciplinary service for children and adults with PCD was established in 2013 at Concord Hospital, Sydney to provide patients with an annual health review and plan. The clinic aims to ensure patients are managed according to PCD guidelines, and have access to coordinated specialist respiratory, ear nose and throat, audiology, and physiotherapy expertise on an annual basis. The clinic was established through a collaboration of paediatric and adult respiratory physicians and physiotherapists, ENT specialists, nursing and respiratory scientists. The clinic is conducted quarterly at Concord Hospital and the Children’s Hospital at Westmead, Westmead, Australia.

Aims: To describe the proportion of paediatric patients that will be seen within the clinic

To describe the proportion of paediatric patients that will be followed through the transition period to adult services.

Methods: A retrospective review of clinic bookings over a 4 year period (January 2014 to October 2017) was undertaken. The number of patients seen in clinic were determined and results presented using descriptive statistics.

Results: Within the 4 years examined, 57 patients with PCD have been seen (19/57, 30% children). 34/57 (60%) of all patients were seen on more than one occasion.

Conclusion: This clinic model has established a transition pathway for multidisciplinary care for patients with PCD. This may be a useful model for other complex, rare chronic conditions requiring care from multiple services. Further research is being undertaken to examine quality of life around the time of transition within this clinic model.

Grant Support: nil

RANDOMISED CONTROLLED TRIAL OF AMBULATORY OXYGEN VERSUS AIR VIA PORTABLE CONCENTRATOR IN CHRONIC INTERSTITIAL LUNG DISEASE

KHOR Y1,2,3,4, GOH N1,2,4, MILLER B5,6, GLASPOLE I5,6, HOLLAND A6,4,6, MCDONALD C7,8,9

1Austin Health, Heidelberg, Australia, 2Institute for Breathing and Sleep, Heidelberg, Australia, 3University of Melbourne, Melbourne, Australia, 4Alfred Health, Melbourne, Australia, 5Monash University, Melbourne, Australia, and 6La Trobe University, Melbourne, Australia

Introduction/Aim: Ambulatory oxygen therapy (AOT) is often provided to patients with interstitial lung disease (ILD) and exertional desaturation, although evidence supporting benefit is limited. Lightweight portable oxygen concentrators are an alternative to portable compressed oxygen cylinders and are more acceptable to people with ILD. This study aims to examine the impacts of ambulatory oxygen using portable concentrators on health outcomes in people with ILD who experience dyspnoea and exertional desaturation.

Methods: This double-blind, placebo-controlled trial aims to recruit 73 participants with ILD from two tertiary institutions. Participants are randomised to 3-month supplemental oxygen or air delivered via portable concentrators at the maximal setting of six. Assessments are performed at baseline, during intervention (Week 4), post intervention (Week 12) and at follow-up (Week 18). The primary outcome is change in 6-minute walk distance (6MWD) post intervention. Additional outcome measures include disease-related symptoms, health-related quality of life, physical activity, systemic oxidative stress and inflammatory markers, and device utilisation. The feasibility of study design and recruitment strategies will also be evaluated.

Results: To date, 17 participants (four idiopathic pulmonary fibrosis) have been randomised, with median FVC 68% (range 50-92%) predicted and TLCO 33 (28-62)% predicted. The median baseline 6MWD was 466 (209-663) m. The median resting and nadir oxyhaemoglobin saturation during 6MWT at baseline were 96 (93-99)% and 84 (74-89)%, respectively. The median duration of device usage at Week 4 was 101 (19-864) minutes per week. Three participants withdrew from the study after randomisation: two due to clinical deterioration, and one for personal reasons.

Conclusion: This prospective study will provide important information regarding the role of AOT in ILD, with the potential to influence clinical practice and facilitate evidence-based discussion with patients.

Grant Support: NHMRC Postgraduate scholarship, Austin Medical Research Foundation, Institute for Breathing and Sleep, Lung Foundation Australia, Air Liquide, Boehringer Ingelheim
Respiratory Infectious Diseases

PASTEURELLA MULTOCIDA PNEUMONIA—COMING BACK TO BITE?
MUNISIF M1,2, MAHBOUB A2
1Alfred Health, Melbourne, Australia, and 2Mildura Base Hospital, Mildura, Australia

Introduction: Pasteurella multocida is a zoonotic infectious organism that is most-commonly associated with animal bites and local soft-tissue infections. P multocida has been isolated in the human respiratory tract as a commensal and rarely causes serious infections such as pneumonia, empyema and abscesses. In patients with an underlying lung disease such as COPD, infection has a high mortality rate approaching 30%1.

Case Report: We present a case of a 78-year-old man admitted with a three-day history of dyspnoea and low-grade fever, on a background of COPD on continuous home oxygen. He had a chronic cough productive of yellow sputum but no previous documentation of Pseudomonas spp. or Pasteurella spp. He was in type 1 respiratory failure but blood tests failed to show a raised white cell count (6) or C-reactive protein (26.9) and his chest x-ray showed only a few increased markings bilaterally. He was treated as per a non-infective exacerbation of COPD. Subsequent sputum cultures grew Pasteurella multocida and on day 2 of the admission, he deteriorated with oxygen saturations down to 62% on a FiO2 of 28%. He was promptly commenced on intravenous antibiotics with Benzylpencillin and Doxycycline and made a rapid recovery with discharge on day 5. On further history, he revealed he had close contact with his two dogs and a cat. There was no history of bites or scratches.

Conclusion: We associate Pasteurella infections with animal bites but there have been cases of serious infections after non-bite exposure usually with close animal contact and inhalation of secretions. Obtaining a detailed history of animal exposures especially in our chronic lung disease patient group is essential to promptly diagnose and treat with a penicillin-based agent. We need to advice patients with underlying lung disease to avoid close contact with pets for preventing serious, life-threatening infection.

Grant Support: Nil

USE OF INTERFERON GAMMA RELEASE ASSAYS (IGRA) IN A REGIONAL HOSPITAL
WATSON N1, SIMPSON G2
1Respiratory Department, Cairns Hospital, Cairns, Queensland, Australia

Conflicts of interest: none

Introduction/Aim: IGRAs represent an alternative to the tuberculin skin test (TST) in diagnosing latent tuberculosis (TB). All guidelines emphasise that it should not be used to test for active TB due to poor sensitivity and specificity. As with the TST, results should be interpreted with other relevant information (e.g. age, Bacillus Calmette–Gueurin status, country of origin, travel history and contact with TB). This audit examines the use of IGRAs in a regional hospital and thus identifies gaps in clinicians’ knowledge in regards to these guidelines.

Methods: Retrospective audit of patients who had IGRA performed at Cairns hospital from 1/1/16 to 1/1/17. Patients were identified by Auslab records. Clinical notes were reviewed to assess indications for the test, documentation of other relevant factors and actions taken on the IGRA result.

Results: 190 tests were performed. 37.4% of the cases were attempting to diagnose active TB, 60% latent TB and in 2.6% the reason was unclear or insufficient history was documented. Of the patients that were tested to investigate latent TB, 20/114 (17%) were inappropriate e.g.: screening for patients on insufficient immunosuppression to risk conversion to active tuberculosis. In only 36.6% cases was appropriate history taken. General medicine, infectious diseases, neurology and gastroenterology specialties were most likely to use the test inappropriately. Worryingly, even if results were positive, the majority were overlooked; 10/15 cases that were positive and 15/16 ‘indeterminate’ results were never further investigated.

Conclusion: IGRAs are widely used by non-respiratory specialists in our regional hospital and seem to be poorly understood, often being used inappropriately to diagnose active TB. Frequently no further action is taken even if the result of the test is positive.

Grant Support: NA
LOW UTILITY OF MICROBIOLOGY TESTING IN COMMUNITY ACQUIRED PNEUMONIA
Kudo M1,2, Johnson J1, Burke A1,2
1Thoracic Medicine Department, The Prince Charles Hospital, Chermside, Australia, and 2School of Medicine, University of Queensland, Herston, Australia

Introduction/Aim: Community-acquired pneumonia (CAP) is a common cause of admission to Australian hospitals. The aim of this study was to evaluate yield and utility of microbiological investigations in the management of patients who presented to a tertiary cardio-thoracic hospital with a diagnosis of CAP.

Methods: A retrospective audit was performed on patients who presented to the Prince Charles Hospital (TPCH) from 1st July 2016 to 31st March 2017 with a discharge diagnosis of pneumonia. The following data were gathered:— patient demographics, antimicrobial allergy, microbiology results including sputum, blood cultures, urine antigens for Streptococcus pneumoniae and Legionella, nasopharyngeal swab for respiratory viruses and atypical serologies including Mycoplasma, Chlamydophila and Legionella species.

Results: 85 cases were identified for audit. Mean age was 70 with 49% being male. 99% had either radiographical or clinical signs consistent with pneumonia. 39% of cases had documented allergies to first line beta lactam antimicrobials. The yield of microbiology investigations for identifying a respiratory pathogen were as follows: sputum culture 8%, blood cultures 4.5%, nasopharyngeal swab 6%, urine pneumococcal antigen 7%, Mycoplasma serology 11%. There were no positive results for urine Legionella antigen, Chlamydophila serology and Legionella serologies. Overall, causative pathogens were identified in only 16.4% of cases.

Conclusion: Microbiology investigations performed for patients who present to TPCH with a discharge diagnosis of CAP showed low yields. This result indicates that these investigations should be performed on a more selective group of patients to aid aetiological diagnosis and management.

Grant Support: NIL

LEPTOSPIROSIS-ASSOCIATED PULMONARY HAEMORRHAGE IN FAR NORTH QUEENSLAND: A CASE SERIES
Williams K1
1Queensland Health, Sunshine Coast, Australia

Introduction/Aim: This is an observational, descriptive study of all cases of pulmonary haemorrhage admitted to the Cairns Hospital between 1998-2016. This study aims to describe the prevalence of pathognomonic presenting features of those with Leptospirosis-associated pulmonary haemorrhage, including demographics and serovar. The prevalence of those requiring intensive care admission, vasopressor therapy and intubation is also described.

Method: Retrospective chart review of 24 cases of pulmonary haemorrhage admitted to the Cairns Hospital

Results: 22 cases were male (92%). Median age was 37yrs. The most prevalent serovar was Leptospira sp. Australis in 9 cases (36%). At presentation, 19 (79%) of cases had low platelets (<150 x10^9/L), 20 (83%) had elevated creatinine and 13 (54%) had elevated bilirubin. 17 (71%) had positive findings on chest auscultation and 16 (67%) had an abnormal chest radiograph. 22 (92%) had >10x10^6/L erythrocytes on urinalysis. At any time during admission, 22 (92%) cases were admitted to the intensive care unit, half of these required vasopressor therapy and 7 (29%) required intubation. There were no deaths from pulmonary haemorrhage in this cohort.

Conclusion: Pulmonary haemorrhage is a serious complication of leptospirosis, a zoonotic infection of global importance and most commonly encountered in Australia in the states of Queensland and Victoria. This case series describes the prevalence of common presenting features of the disease in 24 cases who developed pulmonary haemorrhage in the last 2 decades in Far North Queensland.

Key Words: Leptospirosis, pulmonary haemorrhage, tropical infections, diffuse pulmonary airspace opacities, thrombocytopenia

Grant Support: Nil

Declaration of Interest: Nil
RESPIRATORY INFECTIONS WITHOUT RADIOLOGICAL FINDINGS - ARE WE OVER TREATING THEM?
MUNISIF M1, TAN S2, NAGALINGAM V1, AUNG A1,2, GIBBS H1, NEWNHAM H1, JANARDAN J1
1Department of General Medicine, Alfred Hospital, Melbourne, Victoria, Australia, 2Medical School, Monash University, Melbourne, Victoria, Australia, and 3School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia

Introduction/Aim: Lower respiratory tract infection(LRTI) is a common reason for hospital admission. Adherence to Australian therapeutic guidelines for antibiotic selection is variable. Data is lacking for inpatients with LRTI without radiological findings. The DISPNEOA study evaluated antibiotic use in non-immunosuppressed patients without chronic lung disease admitted with LRTI and normal chest x-ray(CXR).

Methods: Retrospective audit of patients admitted to Alfred Hospital in 2016 with discharge diagnoses of LRTI, chest infection, bronchitis, pneumonia or influenza. Patients with COPD, emphysema, bronchiectasis, asthma, cystic fibrosis, immunosuppression and hospital acquired pneumonia were excluded. Patient demographics, SMART-COP and CORB scores, laboratory results and antibiotics were reviewed.

Results: For 231 patients, median age was 82 years with average LOS of 3 days. The mean Charlson score was 5. The discharge diagnosis was LRTI in 60% and pneumonia in 35%. The median white cell count and C-reactive protein was 9 and 39 respectively. Sputum samples were obtained in only 44 patients yielding no growth(n=18) or oral flora (n=13), allowing targeted therapy in 13 patients only. Nasopharyngaeal viral PCRs were performed in 64 patients with 40 positive results (influenza in 8). The mean total length of antibiotics was 7 days with an average of 2 days of intravenous antibiotics followed by 5 days of oral therapy. 85.3% were classified as low severity by the SMART-COP score. Despite this, 91.3% were started on intravenous therapy including ceftriaxone with azithromycin(n= 67) or ceftriaxone with doxycycline(n= 35) or benzylpenicillin with doxycycline(n=34). There were no admissions to intensive care and a mortality rate of 3.5%.

Conclusion: Inpatients with LRTI with low severity scores and normal CXR were often over-diagnosed as pneumonia and over-treated with intravenous antibiotics. Few patients were treated as per the therapeutic guidelines and this study highlights the importance of using severity scores to guide treatment.

Grant Support: Nil

IDENTIFYING THE GAPS: BRONCHIECTASIS CARE IN A GENERAL RESPIRATORY UNIT
LIU B1, SMALLWOOD N1,2, REES M1,2,3
1Department of Respiratory Medicine and Sleep Disorders, Melbourne Health, Australia, 2Department of Respiratory and Sleep Disorders Medicine, Western Health, , Australia, 3The University of Melbourne, , Australia

Introduction: Bronchiectasis is a heterogeneous condition associated with high mortality, morbidity and reduced quality of life. TSANZ Bronchiectasis Guidelines1 suggest optimal management involves specialised multidisciplinary care; however, many patients attend general respiratory clinics.

Aim: To describe patient characteristics and review current bronchiectasis management at an Australian teaching hospital.

Methods: A retrospective medical record audit was undertaken for all patients with a diagnosis of bronchiectasis, excluding traction bronchiectasis, attending respiratory outpatient clinics at the Royal Melbourne Hospital, between 1/1/2015 and 31/12/2016.

Results: Of 145 patients with bronchiectasis, aetiology was documented for 58 (40%) patients. The cohort was predominantly female (54%), of mean age 65 years (range 21-93), and mean Body Mass Index 26.1 (range 15.6-57.9). Comorbid asthma or chronic obstructive pulmonary disease was present for 87 (60%). Smoking status was documented for 139 (96%), with 60 (43%) current or previous smokers.

Patients had a mean of 1.4 exacerbations per year with 70% of exacerbations managed in the community. Modified Medical Research Council dyspnoea scores were inferred for 126 patients (86%), with 43 patients (34%) scoring 3-4. Spirometry was available for 142 (97%) patients. The mean FEV1 was 70% predicted (SD 28.8%), and mean 6MWT distance 383m (SD 191m). Chest Computerised Tomography was available for 131 (90%) patients, of which 59 (45%) had 3-5 lobes involved. Immunoglobulin levels were measured in 74 (52%). Of 117 (80%) patients with sputum microbiology available, 26 (22%) were colonised with P. aeruginosa.

Long term antibiotics were prescribed for 56 (38%) patients. Few had documentation of accessing chest physiotherapy (n=78, 54%) or pulmonary rehabilitation (n=28, 19%). Vaccination status was infrequently documented against Influenza (n=73, 50%) and Pneumococcus (n=37, 26%). Action plans were documented for 43 (30%) patients.

Conclusion: While many aspects of care were good, a significant proportion did not appear to receive all recommended elements of multidisciplinary care, particularly physiotherapy.

Grant Support: Nil

CHARACTERISING THE TREATMENT AND PREVENTION OF DRUG RESISTANT TUBERCULOSIS IN NSW
CHANG W1,2, LING R2, CHIAM D2, BRITTON W2,3, FOX G2,4
1The Sutherland Hospital, Sydney, Australia, 2The University of Sydney, Camperdown, Australia, 3Immunology Medicine, Immunology and Infectious Disease, The Royal Prince Alfred Hospital, Australia, and 4Department of Respiratory Medicine, The Royal Prince Alfred Hospital, Australia

Introduction/Aim: Management of Multidrug-resistant tuberculosis (MDR-TB) is a major challenge for clinicians including the need for prolonged treatment, worse treatment outcomes, risk of treatment-related toxicity and increased cost of treatment for individuals and public health systems. A recent study identified discordance between current International standards of care and clinical practices in four countries of Europe. This highlighted the importance and need to evaluate practice and ensure the translation of policies into practice in order to optimise MDR-TB case management, prevention and control.

Methods: The 1st part of the study is a retrospective cohort study to analyse the demographics, TB diagnosis, treatment, outcomes and treating facility information for patients with bacteriologically confirmed MDR-TB diagnosed between 2000 and 2016 in NSW. 2nd part of the study is a cohort study of contacts of patients with MDR-TB identified by index patients during the contact investigation. It aims to evaluate the characteristics of the index and contact patients and the prevalence of latent TB infection (LTBI). The quality of the MDR-TB cases management will be assessed by an Expert Clinical Panel and compare with identified international standards to achieve improvements to MDR-TB control and management in Australia.

Results: 76 patients with MDR-TB diagnosed between 2000 and 2016 are identified via The Institute for Clinical Pathology and Medical Research (ICPMR) Mycobacterium Reference Lab from 6 hospitals in NSW. The demographics, duration of treatment, outcomes of the patients and the infection control facilities of the treating facility are presented. We also described the prevalence of LTBI and management of the contact patients.

Conclusion: The study highlighted the importance of adopting health system approaches to improve management of MDR-TB. Contact investigation provides an important opportunity for prevention of drug resistant disease in Australia.

Grant Support: Nil

IN ADULTS HOSPITALISED WITH COMMUNITY-ACQUIRED PNEUMONIA STEP COUNT IS REDUCED IN THOSE WITH GREATER CLINICAL FRAILTY AND THOSE WHO HAVE A PLEURAL EFFUSION
RICE H1,2, HILL K1,2,3, FOWLER R1,2, WATSON C2, WATERER G2,4, HARROLD M1
1School of Physiotherapy and Exercise Science, Curtin University, Perth, Australia, 2Department of Physiotherapy, Royal Perth Hospital, Perth, Australia, 3Institute for Respiratory Health, Perth, Australia, and 4University of Western Australia, Perth, Australia

Aim: In adults hospitalised with community acquired pneumonia, to explore relationships between daily step count and possible influencing factors of; (i) clinical frailty, (ii) pleural effusion and, (iii) occasions of physiotherapy service.

Methods: A prospective observational study design. Adults hospitalised with community acquired pneumonia were identified from electronic databases. Throughout their admission, participants wore a StepWatch Activity Monitor. Details related to clinical management were recorded. For analyses, participants were grouped according to disease severity using pneumonia-specific CURB score (scores of 0 and 1 = less severe disease and 2 and 3 = more severe disease) and clinical frailty scores (scores of 1 to 3 = mild frailty and 4 to 7 = moderate-to-severe frailty).

Results: Of the 148 participants recruited to the study, 88 wore the StepWatch for more than 24 hours. These participants were aged 66±18 (SD) years and had a length of stay of 3 [IQR] days. Daily step count was 883 [1008] steps. In a logistic regression model three variables were found to influence daily step count. Higher frailty, the presence of a pleural effusion and two or more occasions of physiotherapy service were associated with lower step count. Overall these variables contributed to 25% of the variance with clinical frailty being the main contributing factor (15%).

Conclusion: Greater clinical frailty and the presence of a pleural effusion were associated with lower daily step counts, suggesting that physiotherapy should target frailer patients and those with a pleural effusion for mobilisation programs. Current physiotherapy practice is targeted at those patients who are less mobile.

Grant Support: Australian Government Research Training Program Scholarship.

Declaration of Interest Statement: No conflicts of interest to declare.
TP 056

MICROBIOLOGICAL PROFILE AND LONG-TERM ANTIBIOTIC USE IN A LARGE NSW METROPOLITAN COHORT OF ADULT PATIENTS WITH BRONCHIECTASIS: EARLY DATA FROM THE AUSTRALIAN BRONCHIECTASIS REGISTRY

S VISSER1, D JACKSON2, M PETERS2, P BYE1, L MORGAN3
1Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital Sydney, The University of Sydney, 2Lung Foundation Australia, and 3Department of Respiratory and Sleep Medicine, Concord Hospital Sydney, The University of Sydney

Introduction/Aim: The burden of bronchiectasis for Australians is not well described. As part of the ABR we recruited from 2 tertiary centres in Sydney to describe the severity of disease, impact of airway microbiology, and antibiotic use.

Methods: Eligible participants (bronchiectasis on CT, no CF) were recruited from Concord and Royal Prince Alfred Hospitals. Data were collected into the ABR dataset. Recruitment began in April 2015.

Results: 243 patients have been recruited to date; 71% female, mean age 64.2 years [95% CI 62.66]. Aetiology was mainly post-infective (26.8%) or idiopathic (24.7%). 51% had FEV1/VC <0.7, and mean FEV1 was 74%pred [70.5,77.7]. The mean number of affected lobes was 2.96 [2.7-3.2]. 66% produced sputum daily/mean sputum/day 33mls [25-42]. Mean exacerbations/year were 1.6 [1.3,1.8], mean hospitalisations/year 0.44 [0.32,0.57]. 23% were taking long-term macrolides (azithromycin 29%, clarithromycin 25%), 9% were on alternative long-term oral antibiotics (doxycycline) and 4% were on nebulised antibiotics. 21% had chronic Haemophilus influenzae, HI, 20.5% had chronic Pseudomonas aeruginosa (PA) and 8.2% had chronic NTM (93% female;75%MAC;1 MABSC).

Patients with chronic PA had significantly (p<0.05 for all) lower lung function (mean FEV1 69%pred [52.5,73.6]), higher sputum volumes (mean 49mls/day [23.2,75.0]), more exacerbations/year (mean 3.1 [2.4,3.8]), hospitalisations/year (mean 1.9 [1.5,2.4]), and lobes affected (mean 4.3 [3.8,4.8]). They were more frequently taking macrolide (42%) and/or nebulised antibiotics (21%).

Patients with chronic HI, compared to those with PA, were younger (mean 54.4ys [48.6,60.1]), with less exacerbations/year (mean 2.2 [1.8,2.6]) and hospitalisations/year (mean 1.2 [1.1,1.3]), however had no significant differences in lung function, number of lobes affected, sputum volume, QOLB or mMRC scores. They were more frequently taking doxycycline (19.4%);36% on macrolide, 8% on nebulised antibiotic.

Conclusion: PA colonisation is associated with greater disease burden, supporting a role for sputum surveillance and attempted eradication. HI is an important colonising organism in younger patients.

Grant Support: The ABR is a Lung Foundation Australia initiative, supported by COPD Foundation, EMBARC, Bayer Healthcare, Insmed, Aradigm, Pfizer, Novartis and bioCSL.

TP 057

COMPARISON OF PAST AND PRESENT PLEURAL INFECTION MICROBIOLOGY AND OUTCOMES

GODDARD J1, LAW B1, STIGWOOD D1, AZZOPARDI M1
1Respiratory Department, Sunshine Coast University Hospital, Birtinya, Queensland, Australia

Introduction/Aim: Pleural infection (PI) rates are increasing and mortality remains high despite intrapleural tPA/DNase and surgery. Microbiological patterns vary worldwide and may influence outcome, and few Australian studies have reported data. We aimed to 1) examine microbiology at our centre in Queensland and 2) compare outcomes past and present.

Methods: All PI cases treated at Sunshine Coast Hospital and Health Service between 1st July 2007 – 1st July 2012 (period A) and 1st October 2016 – 1st October 2017 (period B) were reviewed. PI was defined by positive pleural fluid culture or complicated parapneumonic effusion. Cases were identified by ICD coding and review of positive pleural fluid cultures on a pathology database.

Results: 67 cases were included; period A n=41, period B n=26. Mean age was 63 (17). Community-acquired PI accounted for 56.7%. 65.7% of cases were culture positive. The commonest pathogens of community-acquired PI were Streptococcal species (29.0%), especially Streptococcus milleri; Staphylococcal species (34.5%), especially Staphylococcus aureus, were most common in hospital-acquired PI.

Patients in Period B were older (71(13) vs 58(18) years, p<0.05) and had more community-acquired PI (84.6 vs 39.0%; p<0.05). The culture positive rate was lower in period B (53.9 vs 76.0%). Of positive cultures, Period B had a greater percentage of gram negative organisms (42.9 vs 23.3% p=0.51). In Period B, 46.2% of cases were treated with intrapleural tPA/DNase. Compared to Period A, surgical referral was lower, 4.8 vs 29.2%; p=0.04. However, median hospital stay (16(9-27) vs 21(10-37) days) and in-hospital mortality (14.3 vs 17.1%) were not significantly changed.

Conclusion: The incidence of pleural infection has increased. Mortality rate remains high in the modern era.

Surgical referrals have significantly reduced following introduction of an IPA/DNase protocol. Streptococcal species were the most common community-acquired PI and Staphylococcal species the most common hospital-acquired PI.

Grant Support

Respirology (2018) 23 (Suppl. 1), 104–215

Copyright of individual abstracts remains with the authors.
MYCOBACTERIUM TUBERCULOSIS COMPLICATED BY EMPYEMA NECESSITANS
MAHER A1, SELLARS R1,2
1Darling Downs Hospital and Health Service, Queensland, Toowoomba, Australia, and 2University of Queensland Rural Clinical School, Toowoomba, Australia

Empyema necessitans is a rare complication of a complicated pleural effusion and describes the extension of purulent pleural fluid through the parietal pleura with resultant formation of an abscess in the extrathoracic soft tissues (1). Factors influencing the development of empyema necessitans include the virulence of the organism, or previous trauma or thoracic surgery (2). Pleural effusion with associated empyema necessitans is typically caused by Mycobacterium tuberculosis, accounting for 70% of cases (3). Other causative organisms include Actinomycetes spp, Blastomyces spp, Aspergillus and Nocardia.

Empyema necessitans secondary to pleural tuberculosis is rarely seen in the twenty-first century, particularly in an immunocompetent host situated in a geographical area with a low prevalence of tuberculosis. We present the case of a 37 year old female who presented with back pain and a subcutaneous lump of 12 months duration. Subsequent investigations, including imaging with plain films, computed tomography and magnetic resonance imaging demonstrated a small pleural collection with extension through the intercostal space in the absence of parenchymal lung disease. A biopsy confirmed fully sensitive Mycobacterium tuberculosis. Management included standard short course antituberculous chemotherapy and was complicated by drug induced liver injury and rupture of the collection through the chest wall within 2 weeks of commencing therapy.

Mycobacterium tuberculosis infection is uncommon in non-indigenous Australian born patients with no known exposure history. This organism needs to be considered when evaluating patients with pleural effusions.

ANTIPHOSPHOLIPID SYNDROME PRESENTING WITH LARGE CAVITATING PULMONARY EMBOLISM IN A TEENAGER
SARWAR G1, CROCKER H1
1Flinders Medical Centre, Bedford Park, South Australia, Australia

Introduction/Aim: Antiphospholipid syndrome is associated with arterial and venous thromboembolic disease. Pulmonary embolism is quite common in patients with antiphospholipid syndrome but large pulmonary embolism leading to infarction and systemic inflammatory response are quite rare. We report a case of large cavitating pulmonary embolism in a teenager due to previously undiagnosed antiphospholipid syndrome.

Methods: An 18 year old man presented with pleuritic chest pain, fever and haemoptysis. Chest X-ray revealed a consolidation and it was initially thought to be a bacterial pneumonia. No response to appropriate antibiotics led to a CT scan which confirmed large pulmonary embolus and cavitary infarct. A bronchoscopy was performed for microbiological sampling with no particular growth. Serological test confirmed presence of the lupus anticoagulant. Very low positive titre of anti GBM antibody prompted renal assessment for any involvement. There was no evidence of microscopic haematuria or proteinuria. A transcutaneous core lung biopsy did not reveal any vasculitis in the lung lesion. A repeat sample of anti GBM antibody from a different laboratory was negative and a diagnosis of Goodpasture disease was refuted.

Results: Systemic anticoagulation with enoxaparin followed by warfarin lead to resolution of his symptoms along with clinical and radiological improvement.

Conclusion: A teenage presenting with large pulmonary embolus leading to infarction and cavitation. Such unusual presentation should raise possibility of underlying systemic disorders and should be appropriately investigated and treated.
IMPACT OF THE 2017 INFLUENZA SEASON IN A VICTORIAN RURAL HOSPITAL

MUNSIF M1, WHYLER N1, COOK T1, RUSSELL J2
1Department of General Medicine, Mildura Base Hospital, Mildura, Australia, 2Acting Director of Medical Services, Mildura Base Hospital, Mildura, Australia

Introduction/Aim: Influenza activity in Australia was highest in 2017 since 2009. Overall, severity was lower, however, with 8.9% of hospitalised patients admitted to ICU nationally based on sentinel hospital data. Limited data exists on the impact of influenza on rural hospitals. We report our experience of the 2017 influenza season at Mildura Base Hospital (MBH), a 165-bed rural Victorian hospital with 5 intensive care beds. This information may contribute to future pandemic planning in resource-limited settings in Australia.

Methods: We conducted a retrospective audit of patients hospitalised during the period 01/04/17 to 07/10/17 with positive influenza PCR. Patient demographics, influenza subtype, oseltamivir and antibiotic use, biochemical markers and outcome were recorded and severity scores (SMART-COP, CURB-65) were calculated. Data was analysed using SPSS.

Results: 58 patients (median age 67) with average LOS 7 days were identified. Influenza A (non-subtyped) was the predominant infection (65.5%) with 8.6% H1N1 subtype, and 25.9% influenza B. Community acquisition accounted for 72.6%, with 13.8% acquired in hospital/facility. Median SMART-COP and CURB-65 scores were 1 and 1. 41.4% cases were appropriately isolated on/before influenza diagnosis. 55.2% received oseltamivir with median time to commencement 2.5 days. 84.5% received concurrent antibiotics. 32.8% required ICU admission; 34.5% had pre-existing lung disease. Mean Charlson co-morbidity index was 4. 86.2% patients were discharged home, with 4 deaths and 1 transfer.

Conclusion: Influenza burden was high, consistent with national trends; our centre experienced higher use of ICU resources. Understanding factors affecting the rural experience of influenza season is essential with future planning in resource-limited settings.

Grant Support: Nil

References

Cystic Fibrosis

INFECTION CONTROL IN AUSTRALIAN AND NEW ZEALAND CYSTIC FIBROSIS CENTRES

STOCKWELL R1,2, WOOD M1,2,3, MOORE V3, BELL S1,2,3
1Lung Bacteria Group, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia, 2Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia, and 3Adult Cystic Fibrosis Centre, The Prince Charles Hospital, Brisbane, Queensland, Australia

Introduction/Aim: In people with cystic fibrosis (CF), new research has demonstrated that the spread of respiratory infections may be via aerosol transmission. To prevent the spread of aerosol transmission in people with CF, updated infection control guidelines for managing people with CF during hospital visits have been published. We wanted to investigate the current infection control practices used in CF centres in Australia and New Zealand.

Methods: Two online surveys were developed for distribution to the Australian and New Zealand CF centres. One survey was developed for the Medical Directors and CF Lead Nurse and the second survey was developed for the CF Lead Physiotherapists. Both surveys included sections on general demographics, outpatient care infection control guidelines, inpatient care infection control guidelines and mask wearing protocols (if used).

Results: The surveys were distributed to 50 centres providing CF care. The surveys opened on 27th September 2017 and to date, a total of 45 responses (medical and nursing responses, n=39; physiotherapy responses, n=6) have been received. The final results will be presented at TSANZ Conference.

Conclusion: The high response rate for this survey within a short opening time (<3 weeks) demonstrates that understanding infection control practices in CF centres is a priority.

Grant Support: Cystic Fibrosis Foundation Therapeutics USA, The Prince Charles Hospital Foundation, Advance Queensland
TREATING PARENTS OF CHILDREN WITH CYSTIC FIBROSIS WITH UNRESOLVED GRIEF

BRANCH-SMITH C1, BARRETT A2, BALDING E3, GROVER Z4, YIKILMAZ G2, BOURKE C2, DEPIAZZI J3, SANDER N2, FOSTER J3, ZEPF F1, SCHULTZ A1,2,5

1Telethon Kids Institute and University of Western Australia, Perth, Western Australia, Australia, 2Prince Margaret Hospital for Children, Perth, Western Australia, Australia, 3Woolcock Institute of Medical Research, University of Sydney, Sydney, New South Wales, Australia, 4Centre & Discipline of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, School of Medicine, University of Western Australia, Perth, Western Australia, Australia, and 5School of Paediatric and Child Health, University of Western Australia, Perth, Western Australia, Australia

Introduction/Aim: Diagnosis of CF in a child can cause parental grief, and if parents do not adjust well the grief can remain unresolved. Parental unresolved grief may be associated with emotional distress, and may impact on a child’s health outcomes.

Aims were: to identify parents with unresolved grief, depression and anxiety at an Australian paediatric CF centre; to compare the effectiveness of insight oriented therapy vs. CF education for the treatment of unresolved diagnosis grief (UDG).

Method: Parents of children with CF aged 6months-18years were screened for UDG and randomised to receive either 5 hours of insight oriented therapy or 5 hours of disease and treatment related education from a multi-disciplinary CF team over 5 weeks. UDG, anxiety and depression were measured before and after the intervention with the Reaction to Diagnosis Interview (RDI), the Depression, Anxiety, Stress Scale (DASS), the Parent Stress Index (PSI) and the Impact of Events Scale-Revised questionnaire (IES-R).

Results: Overall, 44 parents were screened, of which 21(48%), 15(34%), 13(30%) had UDG, anxiety and depression, respectively. Anxiety and depression were significantly more prevalent in parents with UDG n=10 (48%), n=8 (38%) respectively (p=0.0002). The median duration of UDG was 5 years. Fourteen parents with UDG received intervention: six received insight-oriented therapy and eight received education. Grief resolved in 3 (50%) parents with insight-oriented therapy and 6 (75%) parents who received education. Levels of anxiety and/or depression reduced in 3 (50%) parents receiving insight-oriented therapy and 5 (63%) parents receiving education.

Conclusion: Unresolved grief around CF diagnosis remains prevalent for parents well after diagnosis of their child and is significantly associated with anxiety and depression. This preliminary interim analysis suggests that parental insight-oriented therapy and/or CF education may partially mitigate the parental grief and emotional distress associated with a child’s CF diagnosis.

Key Words: unresolved grief, parents, Reaction to Diagnosis Interview, trauma

Grant Support: Circle of Care, Verlex Pharmaceuticals

PERCEPTIONS OF BODY MASS INDEX AMONG YOUTH WITH CYSTIC FIBROSIS: AN EXAMINATION OF ACCURACY AND ITS RELATION TO QUALITY OF LIFE

DUNCAN C1, DURKIN K1, SIMON S2, FERRIS K1, WILLIFORD D1, RIEKERT K1

1Department of Psychology, West Virginia University, Morgantown, WV, USA, 2University of Colorado Denver & Children’s Hospital Colorado, Aurora, CO, USA, 3University of Chicago, STEM Education, Chicago, IL, USA, and 4Johns Hopkins University, Pulmonary & Critical Care Medicine, Baltimore, MD, USA

Introduction/Aim: Adherence to the dietary regimen is a crucial aspect of managing cystic fibrosis (CF). Our primary aim was to examine the accuracy in youths’ perceived body image compared to Body Mass Index (BMI) and its relation to quality of life (QOL) in youth with CF.

Methods: A total of 54 patients with CF (Mage=13.61, SD=2.32; 53.7% female) were recruited from two pediatric pulmonary clinics. Anthropomorphic data and pulmonary function test results were obtained via medical chart review. BMI percentile was classified using CDC weight status categories. Patients completed the Figure Rating Scale (FRS) to assess body size perception and the Cystic Fibrosis Questionnaire—Revised to measure quality of life (QOL).

Results: Paired-samples t-tests revealed a significant difference between observed BMI percentile scores (M = 44.67%, SD = 29.48%) and BMI percentile scores converted from the FRS (M = 31.04%, SD = 12.90%) across all youth, t (53) = 4.14, p < .05. Results of independent samples t-tests indicated a significant difference in respiratory-related QOL scores between participants who underestimated and those who overestimated their BMI, t (51) = 2.67, p = .01. Youth who underestimated their BMI reported significantly higher respiratory-related QOL scores (M = 82.26, SD = 14.87) compared to youth who overestimated their BMI percentile scores (M = 67.49, SD = 24.10).

Conclusion: Results indicate that youth were not very accurate in identifying their actual BMI compared to objective measurement. Further, findings suggest among youth with CF, those with higher QOL related to respiratory function tend to underestimate their BMI. Future research is needed to evaluate the relation between perceived body size and adherence to medical regimens.

Grant Support: NA
COMPARATIVE EFFICIENCY OF HA AND VSV-G PSEUDOTYPED LENTIVIRAL VECTORS FOR CYSTIC FIBROSIS AIRWAY GENE THERAPY
CARPENTERI C1,2,3, FARROW N1,2,3, MCKINTYRE C1,2,3, CMIELEWSKI P1,2,3, ROUT-PITT N1,2,3, PARSONS D1,2,3, DONNELLEY M1,2,3
1Robinson Research Institute, Adelaide, South Australia, Australia, 2Adelaide Medical School, Adelaide, South Australia, Australia, 3Department of Respiratory and Sleep Medicine, WCH, Adelaide, South Australia, Australia

Introduction/Aim: Lentiviral (LV) vectors are a promising option for treating cystic fibrosis airway disease by delivering a functional copy of the CFTR gene into airway epithelial cells. We have developed a unique dosing technique that involves conditioning the airway with lysophosphatidylcholine (LPC) prior to LV vector delivery. However, the choice of vector pseudotype is important to ensure that the correct cells are efficiently targeted. The aim of the project was to examine the gene transfer levels that result when the LV vector is pseudotyped with the VSV-G or HA envelope proteins, which target airway receptors on the basolateral and apical surfaces, respectively.

Methods: The lungs of normal C57Bl/6 female mice were conditioned with 10 μl of LPC (n=12) or PBS (control; n=12), followed one hour later by two 15 μl aliquots of a VSV-G (n=12) or HA (n=12) pseudotyped LV vector containing the Luciferase reporter gene. Bioluminescence imaging (BLI; Xenogen, IVIS) was performed at 1 week, 1, 2, 3, 4 and 5 months after LV vector instillation to assess lung luciferase gene expression levels over time.

Results: Lung luminescence was detected by BLI at all imaging time points in the LPC and PBS conditioned mice that received either pseudotyped LV vector. At one week, the VSV-G pseudotype group had significantly higher expression levels that the HA group, regardless of whether LPC airway conditioning was used (p<0.0001, Tukey’s multiple comparison). From the 1-5 month time points there was no quantifiable difference in luminescence between LPC and PBS, or VSV-G and HA.

Conclusion: The addition of LPC conditioning has shown not to be more effective in targeting basolateral or apical airway cell receptors in lung airways of mice for up to 5 months. Monthly imaging of the treated mice will continue to occur for approximately 12-18 months.

Grant Support: Project supported by the Channel 7 Children’s Research Foundation.

DOES EPITHELIAL ABLATION IN THE NASAL AIRWAYS OF MICE IMPROVE STEM CELL ENGRAFTMENT?
FARROW N1,2,3, CMIELEWSKI P1,2,3, DONNELLEY M1,2,3, BERTONCELLO I4, PARSONS D1,2,3
1Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia, 2Robinson Research Institute, University of Adelaide, Adelaide, South Australia, Australia, 3Department of Respiratory and Sleep Medicine, Women’s and Children’s Hospital, Adelaide, South Australia, Australia, 4Lung Health Research Centre, Department of Pharmacology and Therapeutics, University of Melbourne, Melbourne, Victoria, Australia

Introduction/Aim: Cell transplantation therapy has proven successful for treating some immune disorders and this approach has potential to correct the airway disease phenotype associated with cystic fibrosis. This project assessed whether conditioning the mouse nasal airway with the agent polidocanol (PDOC) enhanced the rate of human basal epithelial cell (HBEC) engraftment.

Methods: Normal HBEC (LONZA, USA; CC-2540S) were seeded onto collagen-coated flasks, expanded to 75% confluence, and exposed to a lentiviral vector containing the luciferase transgene at a MOI of 10. To prepare the mouse nasal epithelium for cell transplantation the airway epithelium was first exposed to 2% PDOC (Polyoxyethylene-9 lauryl ether), which removes most of the epithelial cell layer. Normal female C57Bl/6 mice received 4 μl of either PBS (control (n=10)) or PDOC (n=7) into the right nostril. Two hours later, three 10 μl aliquots of HBEC-Luciferase were delivered to the treated nasal passage within a period of 30 mins. Bioluminescence imaging (BLI; Xenogen, IVIS) of animals was performed at 1, 3, 5 and 8 weeks after cell transplantation to assess HBEC engraftment via luminescence of Luc-expressing cells.

Results: Mice that received PDOC ablation prior to HBEC-Luciferase cell transplantation showed significant luminescence for up to 3 weeks (p<0.01, RM ANOVA vs PBS control), as detected by BLI. Nasal luciferase gene expression declined at the 5 week time point, and was below detectable levels by 8 weeks. No luciferase expression was detected by BLI at any time point in the PBS conditioned (control) animals.

Conclusion: This data suggests that the PDOC airway conditioning procedure can produce initial and persisting Luc-expressing cell engraftment in the airways. While these results are encouraging, further studies are warranted to confirm cell engraftment using histological analyses before testing the potential of a therapeutic cell therapy in a CF animal model.

Grant Support: Studies supported by the USA CF Foundation and the Cure 4 Cystic Fibrosis Foundation.
ADHERENCE TO A SMARTPHONE APPLICATION FOR REPORTING SYMPTOMS IN CF

WOOD J1,2,3, JENKINS S1,2,3, PUTRINO D4, MULRENNAN S3,5, MOREY S3,5, CECINS N2, HILL K1,3
1School of Physiotherapy and Exercise Science, Curtin University, Perth, Western Australia, Australia, 2Physiotherapy Department, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia, 3Institute for Respiratory Health, Perth, Western Australia, Australia, 4Rehabilitation Medicine, Mount Sinai Hospital, New York, USA and 5Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia

Introduction/Aim: In people with cystic fibrosis (CF), respiratory exacerbations impair lung function and health-related quality of life, and increase healthcare costs. Delayed reporting of symptoms can result in more severe exacerbations and worse outcomes. We have developed a smartphone application used to report symptoms suggestive of a respiratory exacerbation, and are now investigating its impact on health outcomes in a randomised controlled trial (RCT). As part of this study, we report on the current adherence to the weekly use of the smartphone application amongst participants.

Methods: Participants in the intervention group of the RCT were required to use the smartphone application weekly, or sooner if they felt their symptoms had worsened. If the smartphone application responses were not received during any given week, a text message reminder was sent to the participant. Adherence, defined as the number of weeks used versus number of weeks enrolled in the RCT (as a percentage), is reported on participants who have used the smartphone application for a minimum of 6 months.

Results: Twenty-nine participants (17 female, aged (mean ± SD) 31 ± 10 years, FEV1 58 ± 18% predicted) were allocated to the intervention group. Nineteen participants (66%) have completed the 12 month intervention, with a further 10 having used the smartphone application for a minimum of 6 months. Adherence to the weekly use of the smartphone application was mean (range) 77% (31 to 100%). Adherence was greater than 90% in 8 (28%) participants, and less than 50% in 2 (7%) participants.

Conclusion: We have demonstrated, on average, good adherence to the weekly use of a smartphone application used to report symptoms to the CF team. Complete adherence data will be available at the end of the RCT.

Grant Support: This research was supported by a Sir Charles Gairdner Group Research Advisory Council Grant.

AIRWAY CLEARANCE BY EXERCISING IN MILD CYSTIC FIBROSIS: CLINICAL OUTCOMES

WARD N1,2, STILLER K1, ROWE H1, MORROW S1, MORTON J1, GREVILLE H1, HOLLAND A1,2,3
1Royal Adelaide Hospital, Adelaide, Australia, 2La Trobe University, Melbourne, Australia, and 3Alfred Health, Prahran, Australia

Introduction/Aim: Guidelines generally recommend that patients with CF perform daily airway clearance techniques. Many patients report using exercise as one of their forms of airway clearance despite there being a paucity of studies supporting this practice. This study aimed to determine the feasibility of a research protocol investigating the medium-term effectiveness of exercise as a stand-alone form of airway clearance, and collect preliminary data on clinical outcomes.

Methods: A prospective, single blinded, randomised controlled feasibility trial was conducted at the Royal Adelaide Hospital with recruitment open for 12 months for adults with mild CF (FEV1%pred > 70%). All participants completed a wash-in period comprising four weeks of PEP and exercise. Participants who adhered with the wash-in protocol were randomised to a three month intervention period of either PEP and exercise or exercise alone for airway clearance. Clinical outcomes were respiratory function, respiratory exacerbation rates and quality of life as measured by the Cystic Fibrosis Questionnaire (Revised) (CFQR) and the Leicester Cough Questionnaire (LCQ).

Results: 57 eligible patients were identified. 17 were recruited (59% male, mean±SD age 25±5yrs, FEV1%pred 93±12%, 41% F508del homozygote). Of the 17 recruited, 13 (76%) were randomised after the four week wash-in period and 13 completed the final assessment. The changes (mean±SD) in clinical outcomes over the three month intervention period were:

<table>
<thead>
<tr>
<th>Outcome</th>
<th>PEP + Exercise (n=6)</th>
<th>Exercise Only (n=7)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FEV1 (L)</td>
<td>0.03±0.21</td>
<td>0.12±0.54</td>
</tr>
<tr>
<td>Total number of exacerbations</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>CFQR (respiratory)</td>
<td>7.6±4.5</td>
<td>7.9±12.8</td>
</tr>
<tr>
<td>LCQ (total)</td>
<td>1.0±1.6</td>
<td>0.6±0.4</td>
</tr>
</tbody>
</table>

Conclusion: Clinical outcomes appeared similar between groups. Given the recruitment and randomisation rates observed, further refinement of the protocol is required prior to expansion to a multi-centre study.

Grant Support: This study received financial support from the Royal Adelaide Hospital Research Committee and was supported by an Australian Government Research Training Program Scholarship.
ULTRASHORT ECHO TIME MRI CAN EVALUATE TREATMENT EFFECT OF LUMACAFTOR/IVACAFTOR
WAINWRIGHT C1, NAGLE S2, BRODY A3, WOODS J4, JOHNSON K5, WANG L5, MARIGOWDA G2, WALTZ D6, GOLDIN J6, RATJEN F7, HUG C8
1Lady Cilento Children’s Hospital, Queensland, Australia, Queensland, Australia, 2Departments of Radiology, Medical Physics, and Pediatrics, University of Wisconsin-Madison, USA, 3Department of Radiology, Cincinnati Children’s Hospital Medical Center, USA, 4Department of Medical Physics, University of Wisconsin-Madison, 5Vertex Pharmaceuticals Incorporated, USA, 6Department of Radiologic Sciences, David Geffen School of Medicine, USA, and 7Hospital for Sick Children, University of Toronto, Canada

Introduction/Aim: To evaluate feasibility of ultrashort echo time (UTE) MRI in a subset of patients aged 6-11 years with cystic fibrosis (CF) who were homozygous for the F508del mutation treated with lumacaftor (LUM) and ivacaftor (IVA) combination therapy in a phase 3 trial (NCT02514473).

Methods: UTE MRI scans were obtained at study baseline (n=10); a second scan was completed at week 24 in 9 patients (4 LUM/IVA, 5 placebo) at 3 institutions using MRI hardware from 2 vendors. One vendor platform was 3D radial UTE1; the other was 3D “stack of stars” UTE.2 Scans were obtained during 5 minutes of tidal breathing without use of IV contrast. MRI scans were scored by 2 independent readers using the Brody score after supervised training on UTE MRI scans. Readers were blinded to time point and treatment arm. Scores are presented as mean ± SD; no statistical testing was performed.

Results: Despite the lower image quality of MRI compared with CT, potential treatment effects were seen on UTE MRI. Mean total Brody score with treatment decreased from 41.1 to 32.5, a change from baseline (± SD; %) of 8.4±11.2 but increased from 31.3 to 34.6, a change from baseline of 3.3±8.2 with placebo. Mucus plugging subscore decreased by 5.0±5.1, from 8.5 to 3.5 with treatment but increased by 1.4±4.4 from 4.2 to 5.6 with placebo. There were no noticeable changes in other subscores (bronchiectasis, peribronchial thickening, parenchymal opacities, or hyperinflation).

Conclusion: In this analysis from an exploratory substudy in patients with CF aged 6-11 years homozygous for F508del, UTE MRI was a feasible approach for detecting the effect of LUM/IVA, despite the small sample size, short duration of treatment, and limitations in image quality. As optimization of UTE MRI technology improves image quality, monitoring disease course in patients with CF may also improve.

REFERENCES

Grant Support: Sponsored by Vertex Pharmaceuticals Incorporated.

SAFETY AND EFFICACY OF LUMACAFTOR/IVACAFTOR IN PEDIATRIC CYSTIC FIBROSIS PATIENTS
WAINWRIGHT C1, CHILVERS M2, HUG C3, MARIGOWDA G3, TIAN S3, SOLOMON M3, BLACK P3, ROSENFIELD M3, SAWICKI G4, HOPPE J5, HUG C6
1Lady Cilento Children’s Hospital, Queensland, Australia, 2British Columbia Children’s Hospital, British Columbia, Canada, 3Vertex Pharmaceuticals Incorporated, MA, USA, 4The Hospital for Sick Children, Ontario, Canada, 5The Children’s Mercy Hospital, USA, 6Seattle Children’s Hospital, University of Washington School of Medicine, USA, 7Harvard Medical School, USA, and 8Children’s Hospital Colorado, University of Colorado School of Medicine, USA

Introduction/Aim: Lumacaftor/ivacaftor (LUM/IVA) was well tolerated and improved lung function and other efficacy endpoints in patients with cystic fibrosis (CF) aged ≥6 years homozygous for F508del in two 24-week phase 3 studies (NCT01897233; NCT02514473). A preplanned interim analysis was conducted after all patients reached week 24 of a subsequent 96-week open-label extension (OLE; NCT02544451).

Methods: Patients continued LUM/IVA (LUM 200 mg/IVA 250 mg q12h [6-11 years] or LUM 400 mg/IVA 250 mg q12h [≥12 years]), or if previously receiving placebo, were assigned to LUM/IVA regimens by age. Primary endpoint was safety (up to OLE week 72); secondary endpoints included absolute change from baseline in lung clearance index (LCI2.5), sweat chloride, body mass index (BMI), and percent predicted FEV1 (ppFEV1).

Results: Of 260 eligible patients, 240 enrolled in the OLE and 229 completed ≥24 weeks. Most adverse events (AEs) were mild (36.8%) or moderate (48.5%); the most common were cough (47.3%), infective pulmonary exacerbation (30.1%), pyrexia (18.6%), nasal congestion (16.3%), and headache (15.5%). Serious AEs were reported in 40 patients (16.7%); 6 (2.5%) discontinued because of AEs. Predefined respiratory events were more frequent in placebo patients initiating LUM/IVA vs those continuing LUM/IVA (19.8% vs 8.4%); all were mild or moderate, and none led to discontinuation. Twenty-eight patients (11.7%) had AST or ALT >3×ULN. LCI2.5 and ppFEV1 improvements were maintained after 48 weeks in patients continuing LUM/IVA: absolute mean change from week 0 (95% CI): -1.07 (-1.49, -0.65), P<0.0001 and 2.8 (0.7-4.9), P=0.0090, respectively; patients previously receiving placebo had similar significant, rapid, sustained improvement in LCI2.5 -0.97 (-1.48, -0.47); P=0.0002. Improvements in sweat chloride and BMI occurred in all patients.

Conclusion: LUM/IVA treatment for up to 48 weeks was well tolerated and led to durable improvements across multiple endpoints. Safety profile was consistent with phase 3 studies, with no new safety concerns.

Grant Support: Sponsored by Vertex Pharmaceuticals Incorporated.
Introduction: For young children with cystic fibrosis (CF), bacterial surveillance is commonly performed using oropharyngeal swabs (OPS). We evaluated the associations between *P. aeruginosa* (PsA) from OPS and lung disease in young children with CF.

Method: Paired OPS, bronchoalveolar lavage (BAL) samples were obtained annually in children in the AREST CF program between 2005 and 2017. Test characteristics of OPS were calculated using BAL as gold standard. Culture results were related to lung inflammation (BAL neutrophil elastase and interleukin-8), structural lung disease (chest CT scored using PRAGMA CF method) and hospital admissions for respiratory exacerbations, accounting for repeated measurements and adjusting for age and pancreatic insufficiency.

Results: Six hundred and ninety paired OPS-BAL cultures were obtained from 181 patients. Prevalence of PsA in BAL was 7.4%. Sensitivity of OPS for BAL result was 23.5% (CI95% 12.8%-37.5%), specificity 90.9% (CI95% 86.4%-93.0%), the post-test probability of positive BAL activity of OPS for BAL result was 23.5% (CI95% 12.8%-37.5%), specificity changed only marginally on the basis of OPS results (from 7.4% to 6%). PsA on OPS was not associated with increased risk for BAL PsA the following year (odds ratio (OR) 2.03 CI95% 0.85-4.87, p=0.11). PsA on OPS was not associated to any lung disease parameter studied. In contrast, PsA on BAL was associated with positive neutrophil elastase (OR 4.6 CI95% 2.14-9.88, p<0.001), increased interleukin-8 (p<0.001), increased PRAGMA-CF CT scores at baseline (p<0.001) and progression of PRAGMA-CF CT scores in the following year (p<0.05). Patients with PsA on BAL but not OPS had an increased risk of admission for respiratory exacerbations in the following year (Incidence Rate Ratio 3.73 CI95% 2.06-6.76, p<0.001).

Conclusion: OPS were not associated with current or progression of lung disease or an increased risk for exacerbations in young children with CF. Alternative non-invasive techniques are required for early detection of lower airway PsA infection.

Key Words: Cystic Fibrosis, oropharyngeal swabs, *P. aeruginosa*

Nomination for New Investigator Award: No

Grant Support: OB has been supported by a Lowy Foundation Paediatric Fellowship arranged by AUSiMED (Australia/Israel Medical Research).

Introduction/Aim: Animal models are fundamental to the development of therapies for cystic fibrosis (CF). A major disadvantage of CFTR-defective mouse models has been the lack of CF pathology in the lungs. The first CF knock-out rat model was reported to have excessive mucus production that was later shown to enable development of lung pathology (Birket S, 2015; Tuggle K, 2014). We have established a Sprague Dawley strain CF rat model in collaboration with the Australian Phonemics Network (Monash University).

Method: Founder animals were generated using CRISPR/Cas9 genome editing, with HDR used to delete the codon aligning to 508 in the human CFTR gene sequence (Phe508del, the most common human CF-causing mutation). Two animals harbouring the targeted mutation and one animal harbouring an off-target mutation (causing termination early in the coding sequence), were selected as colony founders. The CF rat colony is maintained through the breeding of mutation-matched CF-heterozygous pairs, and a limited number of animals have been used for post-mortem analyses to date.

Results: To date the Adelaide CF rat colony has generated more than 50 CF-affected individuals; most survive past the age of weaning, while approximately 25% succumb to gut complications within their first few weeks. Observed out to 12 weeks of age, the CF rats that reach adulthood typically appear active, without signs of distress, although they are considerably smaller than their unaffected littermates and they show abnormal tooth development. Consistent with reports on the USA-based CF rats, the respiratory histology of the Australian CF rats remains similar to normal at 8 weeks old.

Conclusion: By March 2018 we expect to report on respiratory outcomes out to 6 months of age. Once established and characterised, the Australian CF rat will be used in our studies of CF airway gene correction, and will be available to other research groups.

Key Words: Animal models, cystic fibrosis, CRISPR/Cas9, genome editing.

Grant Support: Channel 7 Children’s Research Foundation, Fay Fuller Foundation, Cystic Fibrosis South Australia, Cure 4 CF Foundation
PARAPNEUMONIC EFFUSION IN AN ADULT WITH CYSTIC FIBROSIS (CF): A CASE STUDY
TAI A1,2,3, MOREY S1,2, WOOD J1,2,4, POPOWICZ N1,2,3, MULRENNAN S1,2,3
1Sir Charles Gairdner Hospital, Perth, Western Australia, Australia, 2Institute of Respiratory Health, Perth, Western Australia, Australia, 3School of Medicine, University of Western Australia, Perth, Western Australia, Australia, and 4School of Physiotherapy, Curtin University, Perth, Western Australia, Australia

Introduction: We report an uncommon case of complicated parapneumonic effusion in an adult with CF managed with intercostal catheter and intravenous antibiotics.

Method: Retrospective review of clinical notes.

Result: SH is a 23-year-old man with moderate CF lung disease and chronic infection with Pseudomonas aeruginosa and Methicillin resistant Staphylococcus aureus. He presented with a three-day history of breathlessness, left-sided pleuritic chest pain, fevers and night sweats. On examination, he had a low grade temperature with bilaterally reduced breath sounds, increased vocal resonance and percussion dullness in the left base. Chest X-ray showed left lingular and lower lobe consolidation and a small left-sided pleural effusion. The patient was treated with intravenous timentin and tobramycin but continued to spike temperatures. CT chest on day 3 showed a large, complex loculated pleural effusion adhered to the left superior anterior chest wall with underlying consolidation. A pigtail catheter was inserted with drainage of 500 millilitres of straw-coloured exudate. No bacteria were cultured. Intravenous Vancomycin was added. Repeat CT after 10 days of drainage showed persistence of multiple thick-walled pleural locules which was managed conservatively. The patient improved and was discharged after 19 days. Subsequent X-rays demonstrated resolution of the effusion and consolidation.

Discussion: Parapneumonic effusions/empyemas are rare complications in adults with CF pre-transplant. In our patient, the loculated effusion on the initial X-ray was obscured by underlying lobar consolidation which further delayed diagnosis. The negative bacterial culture on pleural fluid analysis was attributable to the delay in diagnostic aspiration after commencement of antibiotics. Given a high rate of discordance between sputum and pleural microbiology has been reported in CF empyemas, timely diagnostic aspirate is crucial for microbiological identification and antibiotic optimization in CF empyemas. Our case highlights the importance of vigilant detection, early diagnosis and treatment for this rare, but serious, CF complication.

Grant Support: Glenn Brown Memorial Grant, Institute of Respiratory Health, WA
Conquer CF Program Grant, Institute of Respiratory Health, WA
Vertex Adult Cystic Fibrosis Fellowship

Declaration of Conflict of Interest: Nil

PATIENT PERCEIVED EFFECTIVENESS OF AUTOGENIC DRAINAGE COMPARED WITH OTHER AIRWAY CLEARANCE TECHNIQUES IN CYSTIC FIBROSIS
LAZARUS R1, BISHOP J1, SONG Y1,2, MIDDLETON P1,2,3
1Department of Respiratory and Sleep Medicine, Westmead Hospital, Westmead, Australia, 2Ludwig Engel Centre for Respiratory Research, Westmead Institute for Medical Research, Westmead, Australia, 3Sydney Medical School, University of Sydney at Westmead Hospital, Westmead, Australia

Introduction/Aim: Cystic Fibrosis (CF), the most common inherited disease in Australia is characterised by abnormally thick airway secretions causing chronic lung infections. Airway clearance techniques have been shown to maintain lung function and slow the progression of lung disease in children and adults with CF. Autogenic drainage (AD) is an effective technique for mobilising peripheral sputum up the airway and can be performed without the use of any devices. However, AD can be difficult for both the physiotherapist and patient to learn and teach effectively. This study aimed to compare the patient perceived effectiveness of AD with other airway clearance techniques used on a daily basis.

Methods: Adults with CF at outpatient physiotherapy appointments or admitted into hospital were taught AD in multiple sessions. Once familiarised, the AD technique was used in comparison to their usual airway clearance technique such as positive expiratory pressure (PEP) or percussion with postural drainage. A questionnaire using a visual analogue scale (VAS) was completed for the different physiotherapy techniques used in each session, where 0 indicates a positive perception towards treatment whilst 10 a negative perception.

Results: 16 adults with CF were recruited, median age of 24.6 (range 19-35). 15 adults found AD to be more effective than their previous treatment. The vast majority of adults with CF (14 of the 16) indicated that AD required higher concentration than their previous technique and 10 adults found their previous treatment regimen easier to perform. However, because of its perceived effectiveness, despite these difficulties 13 of the 16 adults still chose to continue with AD.

Conclusion: AD was perceived to be effective in clearing sputum in the recruited cohort. Patients found AD difficult to complete as it required high concentration levels, but once they felt the benefits of this technique they were more motivated to continue with this treatment.

Grant Support: Nil
Evidence-Based Medicine & Practice

PULMONARY EMBOLECTOMY: AUDIT OF PATIENT CHARACTERISTICS AND OUTCOMES
RAMAKRISHNAN S1, SANDERS L1, LAKE P1,2, MULRENNAN S1,2
1Sr Charles Gairdner Hospital, Nedlands, Australia, and 2School of Medicine and Pharmacology, University of Western Australia, Crawley, Australia

Introduction/Aim: Optimal management of high-risk submassive and massive pulmonary embolism (PE) is unclear with treatment options including systemic anticoagulation, catheter directed lysis, systemic thrombolysis and surgery. Until evidence is available to recommend a specific therapy for each circumstance, we have taken a multidisciplinary approach. Patients who underwent pulmonary embolectomy after the introduction of a PE management pathway at a tertiary centre were audited.

Methods: Retrospective review of medical records of all pulmonary embolectomies done at Sir Charles Gairdner Hospital between January 2016 and February 2017.

Results: 13 pulmonary embolectomies were undertaken during audit period. Median age was 65 (37-79) and median body mass index was 34 kg/m². Most patients had a PE severity index of 4 or 5 (n=8) and European Society of Cardiology Risk Class of Intermediate-high or High (n=11), 2 patients had surgery provoked PE, 3 had immobility provoked PE and 1 had a thrombophilia. 5 required cardio-pulmonary resuscitation pre-operatively with 1 undergoing thrombolysis. 12 underwent a CT pulmonary angiogram; all showed features of right heart strain. 12 had a pre-operative echocardiogram (ECHO) which showed right heart failure. Estimated pulmonary artery systolic pressure ranged from 44-105 mmHg (n=5). Median intensive care length of stay (LOS) was 5 days (2-22 days) and median hospital LOS was 20 days (7-35 days). Patients needed endotracheal intubation and an intercostal catheter for a median of 3 days and 3 had acute kidney injury post-operatively. 1 patient died during hospital stay. Of those discharged, all survived at 6 month follow up. At hospital discharge, 8 patients had normal or mild impairment of right ventricular (RV) function. 8 had ECHO at clinic follow up and all had normal RV function.

Conclusion: Pulmonary embolectomy is associated with morbidity but has a clear place in the management of high-risk PE. A multidisciplinary team approach may assist in ensuring the best treatment is matched to individual patients. Comparison with a non-surgical series on RV outcomes is needed.
THROMBOEMBOLIC DISEASE: UNDER-DIAGNOSED IN CLINICAL PRACTICE
MYAT L1
1Cardiology Department, The Prince Charles Hospital, Brisbane, Queensland

Introduction: CTEPH is a largely underdiagnosed disorder and majority of cases had ineffective clot resolution from acute PE.3

Aim: To improve awareness of early diagnosis needed for this unique, fatal but potentially curable condition.

Case 1: A 47-year-old man presented with a week history of exertional dyspnoea. He has hypertension, hypertensive heart disease and chronic renal impairment. His troponin assay was elevated at 0.102 (less than 0.01 ng/ml) with recent normal coronary angiogram. Myocardial perfusion scan and cardiac MRI which did not identify the cause. Sub-segmental left lower lobe pulmonary emboli were found on V/Q scan. There was no features of pulmonary hypertension or right heart dysfunction. He was commenced on oral anticoagulant and to be followed up at thoracic outpatient.

Case 2: An 80-year-old lady presented with rapid atrial fibrillation, dyspnoea and right sided chest pain. Her medical history includes chronic atrial fibrillation, hypertension, moderate aortic stenosis, renal impairment, metastatic ovarian cancer. V/Q scan revealed multiple segmental pulmonary emboli in right upper lobe. Given her risks of recurrent thromboembolism and CTEPH, lifelong anticoagulation with warfarin was recommended.

Discussion: The natural history of CTEPH remains unclear1. Progressive pulmonary hypertension, right ventricular dysfunction and death ensure if the condition is left untreated1. V/Q scan and echocardiography are initial screening investigations in suspected cases followed by pulmonary angiography and right heart catheterization to confirm the diagnosis and assess the surgical suitability2. In patients with operable CTEPH, pulmonary endarterectomy is the treatment of choice2. All patients should receive lifelong anticoagulant treatment with warfarin or its equivalent2.

REFERENCES
Keith McNeil, Chronic thromboembolic pulmonary hypertension (CTEPH) Heart 2007;93:1152–1158
Ivan M.Robbins, Update on chronic thromboembolic pulmonary hypertension Trend in cardiovascular medicine 27 (2017) 29-37

CTPA PRACTICE AT A REGIONAL NZ HOSPITAL: PE YIELD, ALTERNATIVE DIAGNOSES AND INCIDENTAL FINDINGS
HALL A1
1Lakes DHB, Rotorua, New Zealand

Introduction: CT Pulmonary Angiography (CTPA) is the most commonly used investigation to diagnose a pulmonary embolus (PE). There is an ongoing global initiative to reduce unnecessary tests across all specialties5. The aim of this study was to determine the usefulness of CTPA in a real world setting.

Methods: All inpatient CTPA requests at Rotorua Hospital during 2016 were included. Radiology reports, blood test results, discharge summaries and clinic letters were reviewed for each patient.

Results: 197 CTPAs were included for analysis. Of these 33 (16.8%) were positive for PE. In 50 of the other 164 scans (30.5%) an alternative diagnosis was evident that was not reported in the preceding chest x-ray. Most commonly these were infective changes. 86.8% of all the CTPA reports yielded additional findings compared with the chest x-ray. The majority of these were not clinically relevant and unrelated to the current presentation.

12 patients (6.1%) had follow up imaging arranged for incidental findings unrelated to the admission diagnosis (5—Lymphadenopathy, 4—Nodules, 1—Kidney lesion, 1—Thymus mass, 1—Thyroid mass).

121 patients had a D-Dimer performed as part of their initial workup. The PE yield significantly increased with the D-Dimer value:

<table>
<thead>
<tr>
<th>D-Dimer (ug/L)</th>
<th>PE positive/Total scans</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤999</td>
<td>0/36 (0%)</td>
</tr>
<tr>
<td>1000-1999</td>
<td>2/45 (4.4%)</td>
</tr>
<tr>
<td>2000-4999</td>
<td>12/26 (46.2%)</td>
</tr>
<tr>
<td>≥5000</td>
<td>8/14 (57.1%)</td>
</tr>
</tbody>
</table>

Conclusion: The PE yield of CTPA at Rotorua Hospital is comparable to similar studies in Australasia with a significant amount of alternative diagnoses and a low rate of incidental findings requiring follow up. The PE yield increased significantly with higher D-Dimer values. This information can be used to better inform clinicians and patients of the possible outcomes of a CTPA request.

REFERENCES
Choosing Wisely. An initiative of the ABIM foundation.

No grant support
No conflicts of interest
An Audit of Non-Invasive Ventilation Use in a Regional Hospital: A Clinical Outcomes and Resource Utilisation Analysis

Jeganathan V1,2, Lim W2, Chimunda T1, Fletcher J1, Broadfield E1

1Intensive Care Unit, Bendigo Health, Bendigo, Victoria, Australia, and 2Department of General Medicine, Bendigo Health, Bendigo, Victoria, Australia

Introduction/Aim: The advent of non-invasive ventilation (NIV) has reduced intubation rates and mortality in acute respiratory failure. This audit aims to look at clinical outcomes, adherence to practice guidelines, and resource utilisation in a Victorian regional hospital.

Methods: A retrospective analysis of all patients >18 years of age receiving NIV as an inpatient over a 3-month period (01 January to 31 March 2017) was performed. We excluded patients receiving home NIV who did not receive additional NIV.

Results: A total of 34 patient were included in the audit. The most frequent indications were acute pulmonary oedema (47%), pneumonia (28%), and exacerbation of chronic obstructive pulmonary disease (COPD) (21%). 97% of patients received NIV in the emergency department, intensive care unit, or both, with 3% receiving it on the ward. Of the COPD exacerbations, 57% were confirmed to have acute hypercapnia. In terms of duration of NIV use, 50% received <4 hours, 41% between 4-48 hours, and 9% >48 hours. With regards to guiding ongoing therapy, 62% of patients did not have documented oxygen saturation targets and 32% did not get repeat blood gases. In terms of clinical outcomes, 76% of patients were weaned off NIV, 18% intubated and 6% palliated. None of the patients that received NIV for 4-48 hours required intubation.

Conclusion: Our avoidance of intubation rate is similar to published data. Our indications for using NIV align with established guidelines, however better patient selection would have avoided unnecessary application of NIV, particularly in patients who did not have acute hypercapnia. Compliance with setting oxygenation targets and monitoring response with repeat blood gases was poor. These issues could be addressed by provider education. The group of patients receiving NIV for 4-48 hours are a potential target for patients who could be managed on the ward.

Grant Support: Nil

Priorities and Expectations of Patients Attending a Multidisciplinary Interstitial Lung Disease Clinic

McLean A1,2, Webster S1, Fry M6, Lau E1,2, Cortez P1, Torzillo P1,2, Troy L1,3, Jo H1,2, Geis M1, Rhodes J1, C Lear S1, Spencer L1,2, Cortez T1,2

1Department of Respiratory Medicine, Royal Prince Alfred Hospital, Sydney, Australia, 2Faculty of Medicine, University of Sydney, Sydney, Australia, 3Discipline of Physiology, Faculty of Health Sciences, University of Sydney, Sydney, Australia, 4Faculty of Health, University of Technology Sydney, Sydney, Australia, 5Department of Physiotherapy, Royal Prince Alfred Hospital, Sydney, Australia, 6Northern Sydney Local Health District, Sydney, Australia

Introduction/Aim: A sub-specialist multidisciplinary interstitial lung disease (ILD) clinic was established at the Royal Prince Alfred Hospital (RPAH) in 2010. The RPAH-ILD clinic is a referral centre for patients with suspected ILD from throughout NSW, enabling patients to see expert physicians, specialist nurses and physiotherapists in the one visit. Our study aimed to determine the expectations and priorities of patients attending the RPAH-ILD clinic. In particular, we sought to determine how important the multidisciplinary aspect of the clinic was to the patients, and which aspects were most valued.

Methods: An 18 item survey was sent to a sample of 100 patients who had previously attended the RPAH-ILD clinic. The survey collected anonymous demographic data as well as both quantitative and qualitative data regarding patient’s experiences when attending the RPAH-ILD clinic.

Results: To date, 38 (41%) patients have returned the survey (age 66 ± 13 yrs; male 21 (55%)). 23 (63%) of patients were from Sydney, with the remaining patients from other areas of NSW and ACT. ILD diagnoses ranged from IPF (n=12, 31.6%) to connective tissue disease associated ILD (n=7, 18.4%) and 14 patients (37%) were uncertain of their ILD diagnosis.

Obtaining an accurate diagnosis, multidisciplinary care, education and access to medications all ranked very highly, with 76%, 66%, 67% and 66% of patients listing these issues as top priority. Patients rated access to a respiratory physician and specialist nurse as extremely important with 84% and 59% listing these as top priority, respectively. Other patient education tools, including written material, attending education courses or enrolling in clinical trials were very important to a subset of patients.

Conclusion: Patients appear to place high value on the multidisciplinary approach to the management of ILD. Further work will focus on thematic analysis of qualitative responses.

Grant Support: Nil

Regional Audit of Non-Invasive Ventilation Use in a Victorian Regional Hospital: A Clinical Outcomes and Resource Utilisation Analysis

Jeganathan V1,2, Lim W2, Chimunda T1, Fletcher J1, Broadfield E1

1Intensive Care Unit, Bendigo Health, Bendigo, Victoria, Australia, and 2Department of General Medicine, Bendigo Health, Bendigo, Victoria, Australia

Introduction/Aim: The advent of non-invasive ventilation (NIV) has reduced intubation rates and mortality in acute respiratory failure. This audit aims to look at clinical outcomes, adherence to practice guidelines, and resource utilisation in a Victorian regional hospital.

Methods: A retrospective analysis of all patients >18 years of age receiving NIV as an inpatient over a 3-month period (01 January to 31 March 2017) was performed. We excluded patients receiving home NIV who did not receive additional NIV.

Results: A total of 34 patient were included in the audit. The most frequent indications were acute pulmonary oedema (47%), pneumonia (28%), and exacerbation of chronic obstructive pulmonary disease (COPD) (21%). 97% of patients received NIV in the emergency department, intensive care unit, or both, with 3% receiving it on the ward. Of the COPD exacerbations, 57% were confirmed to have acute hypercapnia. In terms of duration of NIV use, 50% received <4 hours, 41% between 4-48 hours, and 9% >48 hours. With regards to guiding ongoing therapy, 62% of patients did not have documented oxygen saturation targets and 32% did not get repeat blood gases. In terms of clinical outcomes, 76% of patients were weaned off NIV, 18% intubated and 6% palliated. None of the patients that received NIV for 4-48 hours required intubation.

Conclusion: Our avoidance of intubation rate is similar to published data. Our indications for using NIV align with established guidelines, however better patient selection would have avoided unnecessary application of NIV, particularly in patients who did not have acute hypercapnia. Compliance with setting oxygenation targets and monitoring response with repeat blood gases was poor. These issues could be addressed by provider education. The group of patients receiving NIV for 4-48 hours are a potential target for patients who could be managed on the ward.

Grant Support: Nil

Resource Utilisation Analysis

Jeganathan V1,2, Lim W2, Chimunda T1, Fletcher J1, Broadfield E1

1Intensive Care Unit, Bendigo Health, Bendigo, Victoria, Australia, and 2Department of General Medicine, Bendigo Health, Bendigo, Victoria, Australia

Introduction/Aim: The advent of non-invasive ventilation (NIV) has reduced intubation rates and mortality in acute respiratory failure. This audit aims to look at clinical outcomes, adherence to practice guidelines, and resource utilisation in a Victorian regional hospital.

Methods: A retrospective analysis of all patients >18 years of age receiving NIV as an inpatient over a 3-month period (01 January to 31 March 2017) was performed. We excluded patients receiving home NIV who did not receive additional NIV.

Results: A total of 34 patient were included in the audit. The most frequent indications were acute pulmonary oedema (47%), pneumonia (28%), and exacerbation of chronic obstructive pulmonary disease (COPD) (21%). 97% of patients received NIV in the emergency department, intensive care unit, or both, with 3% receiving it on the ward. Of the COPD exacerbations, 57% were confirmed to have acute hypercapnia. In terms of duration of NIV use, 50% received <4 hours, 41% between 4-48 hours, and 9% >48 hours. With regards to guiding ongoing therapy, 62% of patients did not have documented oxygen saturation targets and 32% did not get repeat blood gases. In terms of clinical outcomes, 76% of patients were weaned off NIV, 18% intubated and 6% palliated. None of the patients that received NIV for 4-48 hours required intubation.

Conclusion: Our avoidance of intubation rate is similar to published data. Our indications for using NIV align with established guidelines, however better patient selection would have avoided unnecessary application of NIV, particularly in COPD patients who did not have acute hypercapnia. Compliance with setting oxygenation targets and monitoring response with repeat blood gases was poor. These issues could be addressed by provider education. The group of patients receiving NIV for 4-48 hours are a potential target for patients who could be managed on the ward.

Grant Support: Nil
CARDIAC EVENTS IN PATIENTS WITH RESPIRATORY INFECTIONS WITHOUT RADIOLOGICAL FINDINGS

MUNSF M1, TAN S1, NAGALINGAM V1, AUNG A1, GIBBS H1, NEWNHAM H2, JANARDAN J1
1Department of General Medicine, Alfred Hospital, Melbourne, Victoria, Australia, 2Medical School, Monash University, Melbourne, Victoria, Australia, and 3School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia

Introduction/Aim: Lower respiratory tract infection (LRTI) is a common reason for hospital admission. Cardiovascular events occur in 14-19% following admissions with community acquired pneumonia (CAP). However there is no similar data for LRTI without radiological consolidation. The DISPNOEA study evaluated the outcomes of patients admitted with LRTI without chronic lung disease and normal chest-xray (CXR).

Methods: Retrospective audit of patients admitted to Alfred Hospital in 2016 with discharge diagnoses of LRTI, chest infection, bronchitis, pneumonia or influenza. Patients chronic lung disease, immunosuppression and hospital acquired pneumonia were excluded. Patient demographics, cardiac history, SMART-COP and CORB scores, in-hospital cardiac events and 30-day re-admission data was obtained from medical records.

Results: For 231 patients (103=Male), median age was 82 years with average LOS of 3 days. The mean Charlson co-morbidity index was 5 with past history of Ischaemic heart disease (IHD) and heart failure documented in 25% and 12% respectively. 34.6% were on anti-platelets on admission. 85.3% were classified as low severity of infection by the SMART-COP score. Inpatient stay was complicated by a cardiac event in 13.9% (n=32) which was a new diagnosis in 24 patients. Other events include bradycardia in 4.8% (n=11) and myocardial infarction in 3.9% (n=9). There were no ICU admissions however inpatient mortality rate was 3.5% (n=8). The 30-day re-admission rate to the same hospital was 13.9% (n=32), 40.6% of them secondary to cardiovascular complications (n=13) of which ADHF was most common (n=10).

Conclusion: Our study revealed that nearly 20% of patients admitted with LRTI with normal CXR suffered subsequent cardiac events, often resulting in high readmission rates. These results are comparable with prior studies of patients with CAP. This highlights the need for close follow-up of these patients post hospital discharge and adequate optimisation of their cardiac risk factors.

Grant Support: Nil

REFERENCES
1. Musher D, Rueda A, Kaka A, Mapara S. Clinical Infectious Diseases, 2007, 45, 158-165

AUDIT OF HIGH FLOW NASAL CANNULAS IN AN AUSTRALIAN TERTIARY HOSPITAL

FANNING M1, LUONG D1, WHITE B1, BURR L1
1Mater Hospital Brisbane, Brisbane, Australia

Introduction: High flow oxygen via nasal cannulas (HFNC) deliver humidification and a higher FiO2 and flow rate than other modalities of oxygen delivery and has been traditionally used in high dependency and intensive care units (HDU/ICU). In recent years use of HFNC has become commonplace in medical and surgical wards,(1) However, evidence for improvement in outcomes over traditional devices is lacking and further large randomised controlled trials are required, particularly outside of the ICU and neonatal setting.(2, 3) Furthermore, the ability to deliver high fractions of inspired oxygen has the propensity to cause harm in patients at risk of hypercapnia.(4)

Methods: The medical records of all patients treated with HFNC during the winter months on the medical and surgical wards was retrospectively reviewed. Patients were excluded if they were immediately admitted to the ICU without first being admitted to a medical or surgical ward.

Results: 55 patients were included. The mean age was 61.6 with 45% males. The most commonly prescribing specialties were General Medicine (23%), Respiratory (18%) and the surgical specialties (36%). The most common indications were hypoxic respiratory failure (22%), Obstructive Sleep Apnoea (22%), for increased work of breathing (18%) and there were two patients treated for hypercapnic respiratory failure with HFNC. 77% of patients had identified risk factors for hypercapnia but only 31% had arterial blood gas measurement before or after starting HFNC. Only 45% of patients had a formal oxygen prescription and 13% were assessed as complying with the oxygen guidelines set out by the Thoracic Society of Australia and New Zealand.

Conclusion: In our cohort of patients there was a wide range of indications for commencing HFNC, many which fell outside the supporting literature. There was poor utilisation of arterial blood gas measurement despite most patients having risk factors for hypercapnia. There was also poor utilisation of formal oxygen prescriptions despite there being a hospital wide mandate for such documentation. Further education of medical staff prescribing HFNC may improve safety and in some cases, result in prescription of more cost-effective delivery devices.

Grant Support: N/A

DIAGNOSIS OF DYSPNEA: A LITERATURE REVIEW
HOMAIRA N1,2,3, CORCORAN K2, BEREND N3, JENKINS C4,5
1UNSW, Sydney, Australia, 2Respiratory Department, Sydney Children’s Hospital, Randwick, Australia, 3Respiratory Unit, The George Institute for Global Health, Newtown, Australia, 4Faculty of Medicine, UNSW, Sydney, Australia, 5Respiratory Department, The Concord Hospital, Australia

Introduction/Aim: Dyspnea or breathlessness is a common presenting symptom among patients attending primary care services. In Australia 1.8 million people have breathlessness that chronically limits exertion. We undertook a narrative literature review to determine if there are clinical tools that can be incorporated into a clinical decision support system for efficient and accurate diagnosis of causes of dyspnea.

Methods: We conducted a systematic search in MEDLINE, EMBASE and Google Scholar of all literature published between 1946-2016. Studies that evaluated a clinical decision support system in assessment of dyspnea in patients of any age group presenting to physicians with chronic dyspnea were included.

Results: We identified 125 abstracts, 44 papers were reviewed, six were included. The age of the patients was between 20-80 years, 60% were women (752 women, 494 men). Duration of dyspnea was three weeks to 25 years. The studies undertook a stepwise or algorithmic approach to assessment of dyspnea. The initial stage included physical examination, history taking, and screening tests such as spirometry, electrocardiography, chest x-ray, thyroid function test and full blood count. If undiagnosed by the initial assessment, the subsequent stage included more specialised investigations such as Echocardiogram, lung volume measurement, bronchial provocation, and cardiac exercise stress test. The third stage of assessment included invasive investigations such as bronchoscopy and cardiac catheterization.

Initial assessment ascertained a cause for dyspnea for 35% of the patients. Stage 1 and stage 2 in combination diagnosed 65% and more than 90% of the dyspnea cases were diagnosed by initial assessment and the advanced invasive tests.

Conclusion: Our review suggest that, while there is a paucity of literature, a stepwise approach using simple tests and then more expensive or invasive tests only when the initial steps fail, can achieve an accurate diagnosis in the majority of patients with dyspnea.

Grant Support: The work was funded by Telstra Health

ASSESSMENT OF NON-CARDIAC PULMONARY HYPERTENSION AT IPSWICH HOSPITAL
GOH T1, THASNEEM A1
1Ipswich Hospital, Australia

Introduction: Pulmonary hypertension (PH) is a heterogeneous condition with a wide range of aetiology. The diagnosis is often delayed or missed. The prognosis is usually poor without appropriate and timely management.

Aim: To evaluate whether patients with evidence of non-cardiac PH are adequately investigated at Ipswich Hospital.

Method: A retrospective audit of patients who underwent echocardiogram between 1st January 2016 to 31st June 2016 was conducted. Patients were screened for echocardiographic signs of PH (right pulmonary systolic pressure of ≥ 40mmHg, right ventricular dysfunction or enlargement, right atrial enlargement and flattening of interventricular septum). Patients with obvious cardiac dysfunction (left ventricular dysfunction, cardiac valvulopathy and congenital cardiac defects) were excluded. A review was conducted to find if these patients had further work up of their PH (pulmonary function test, overnight oximetry or polysomnogram, VQ scan/CTPA and autoimmune tests). A second review was done to identify follow up of these patients.

Results: Of the 851 echocardiograms performed at Ipswich Hospital between January and June 2016, 63 had evidence of non-cardiac PH. The mean age was 70 years with standard deviation of 14 years. 31 (49.2%) patients had no investigations performed. 18 (28.6%) patients had only one investigation and 14 (22.2%) had more than 2 investigations performed. 17 (27%) patients were identified to have a probable aetiology for their PH. 13 patients (20.6%) had appropriate follow up.

Conclusion: In our centre, a considerable number of patients with non-cardiac PH did not get adequate evaluation of their PH in the period audited. Majority of patients were not appropriately followed up or referred to a specialist. Further intervention is necessary to improve our current management strategy of PH.

Grant Support: Nil
NLRC4 GENE VARIANTS ARE ASSOCIATED WITH mRNA EXPRESSION LEVELS IN CHILDREN HAVING AN ASTHMA EXACERBATION

HARRIS L1,2, COLEMAN L1,2, KHOO S2,3, BIZZINTINO J2,3, FRANKS K2,3, PRASTANTI F1, KOO S1, MCCRAE C6, OBERG L5, BORLAND M1,5, MACIEWICZ R6, LE SOUEF P1, LAING I2,3
1Division of Paediatrics, the University of Western Australia, Perth, Australia, 2Telethon Kids Institute, Perth, Australia, 3School of Biomedical Sciences, the University of Western Australia, Perth, Australia, 4Emergency Department, The Princess Margaret Hospital for Children, Perth, Australia, 5Division of Emergency Medicine, School of Medicine, University of Western Australia, Perth, Australia, and 6Respiratory, Inflammation and Autoimmunity, Innovative Medicines & Early Development (IMED) Biotech Unit, AstraZeneca, Gothenburg, Sweden

Introduction/Aim: Asthma results from interactions between environmental and genetic risk factors. We identified five genes (NLRC4, MNDA, THBS1, CD163 and IFTIM3) that fulfilled at least two criteria including: altered mRNA expression in peripheral blood mononuclear cells (PBMC) and/or nasal epithelial cells in children with asthma and/or wheezing exacerbations compared to (1) convalescence and/or (2) healthy controls; and/or (3) contained rare variants associated with recurrent asthma exacerbations. During asthma and/or wheezing exacerbations, we found children with minor homozygote genotypes in these genes had altered asthma severity, incidence of rhinovirus infection and recurrent hospital visits compared to common genotypes. We aimed to identify whether these genotypes had altered mRNA expression in PBMC collected during asthma and wheeze exacerbations.

Methods: Cases were children who presented to hospital with an asthma or wheezing exacerbation (n=85). PBMC were isolated from peripheral blood samples, RNA was extracted and mRNA expression measured by microarray using Affymetrix U133 Plus 2.0. In these five genes, 39 variants were genotyped by Australian Genome Research Facility. Statistical analysis was completed using R version 3.2.2.

Results: Mean age was 2.91 years and 32.9% were male. Children with NLRC4 rs212721 TT genotypes had lower mRNA expression (mean 5.14) than children with CT (mean 5.93; p=0.024) and CC genotypes (mean 5.90; p=0.028). Children with NLRC4 rs212736 AA genotypes had lower mRNA expression (mean 4.68) than children with AG (mean 5.99; p<0.001) and GG genotypes (mean 5.78; p=0.003). Children with NLRC4 rs7562653 TT genotypes had lower mRNA expression (mean 4.58) than children with the CT (mean 6.07; p=0.001) and CC genotypes (mean 5.78; p<0.001). No association was observed in the other four genes.

Summary/Conclusion: NLRC4 is involved in intracellular pathogen detection and inflammasome complex formation. Taken together, our results suggest NLRC4 gene variants alter gene expression and may contribute to asthma and wheezing exacerbations in children.


COMBINED FLOW CYTOMETRY AND GENE EXPRESSION PROFILING OF MAST CELLS AND BASOPHILS IN ASTHMATIC SPUTUM

FRICKER M1, QIN L1,2, ERRIAH M1, BROOKS C3, SIMPSON J1, BAINES K1, GIBSON P1
1University Of Newcastle, Newcastle, Australia, 2Respiratory department, Xiangya Hospital, Central South University, Changsha, China, and 3Centre for Public Health Research, Massey University, Wellington, New Zealand

Introduction/Aim: Quantification of immune cell populations in sputum can inform asthma prognosis and treatment. Mast cells (MCs) and basophils are pathophysiologically relevant cells present in low numbers in sputum, making their study challenging. MCs and basophils express both unique and overlapping surface markers and gene signatures, which may be useful for development of biomarkers of their activity. Indeed, MC and basophil-associated genes are often amongst the most differentially expressed in transcriptomic analyses of sputum and bronchial brushings in asthma. Here, we aimed to use flow cytometry and mRNA profiling to develop reliable biomarkers for these two cell types in sputum.

Methods: Sputum cell suspensions were prepared using conventional dispersion methods and undispersed sputum plugs were stored for subsequent RNA isolation and analysis. MC and basophil populations were identified using flow cytometry. Sputum microarray data was used to test for differential expression of published MC and basophil gene signatures across asthma inflammatory phenotypes. Differentially expressed MC and basophil genes were selected for qPCR analysis in matched flow cytometry-characterised sputum samples.

Results: MCs and basophils were increased in eosinophilic asthma compared to both healthy control and non-eosinophilic asthma. Sputum microarray analysis of published MC and basophil gene signatures revealed upregulation in eosinophilic asthma. qPCR measurement of these genes in sputum samples also tested by flow cytometry allowed ranking of these genes as sputum biomarkers for MCs and basophils.

Conclusion: Here we combine flow cytometry with microarray and qPCR analysis for the first time to develop reliable, potentially clinically applicable biomarkers of MCs and basophils in induced sputum. We show that MCs and basophils are increased in eosinophilic asthma. Further analysis will focus on the clinical outcomes associated with MC/basophil-high asthma, and aim to characterise the functional roles of these cells in driving inflammation and pathology in asthma.

Grant Support: Work supported by the NHMRC. MF is an NHMRC-funded post-doctoral fellow within the CRE in Severe Asthma. KJB holds a Lung Foundation Australia Boehringer Ingelheim COPD research fellowship. PGG holds an NHMRC practitioner fellowship.
ABNORMAL miRNA-22 EXPRESSION AFTER INFLUENZA INFECTION FACILITATES EPITHELIUM REMODELING IN ASThma

MOHEIMANI F1,2, WILLIAMS T1,2, REID A1,2, HANSBRO P1,2, WARK P1,2,3, KNIGHT D1,2,4

1 School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, Australia, 2 Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute, New Lambton Heights, Australia, 3 Department of Respiratory and Sleep Medicine, John Hunter Hospital, New Lambton Heights, Australia, and 4 Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, Canada

Introduction/Aim: Specific miRNAs play essential roles in airway remodelling in asthma. Influenza A virus-induced exacerbations may also magnify pre-existing airway remodelling in asthma. Epithelium of asthmatics display dysregulated differentiation. miR-22, is a differentiation specific miRNA and has been proposed to suppress different genes with potential roles in airway remodelling including, CD147(a MMP inducer) and HDAC4 (an epigenetic regulator of EMT). We hypothesised that the potential roles in airway remodelling including, CD147(a MMP inducer) and HDAC4 (an epigenetic regulator of EMT). The consequent magnify pre-existing airway remodelling in asthma. Influenza A virus-induced exacerbations may also indicate a self-defence mechanism against further epithelium aberrations which is not present in asthmatics.

Methods: Primary bronchial epithelial cells (pBEC) obtained from severe asthmatics were cultured under ALI condition. Cells were incubated with H1N1 (MOI 5). miRNAs and mRNA were isolated using RNAeasy mini kit with some modifications and subjected to Taqman miR-22 and mRNA assays.

Results: Basal expression of miR-22 was similar in pBEC of asthmatics and non-asthmatics. However miR-22 expression increased significantly at 24 h after H1N1 infection in pBECs from non-asthmatics but expression was unchanged in asthmatics. mRNA expression of the miR-22 targets, CD147 and HDAC4 were reduced during infection cells from non-asthmatics. CD147 expression increased whereas HDAC4 remained un-changed in asthmatics. The expression of regulators of miR-22 and its targets; c-Myc and SP1, also increased during H1N1 infection in pBEC of asthmatics which may result in induction of CD147.

Conclusion: The different profile of miR-22 expression in differentiated epithelial cells from asthmatics and non-asthmatics highlight a novel mechanism through targeting CD147 and HDAC4. The consequent reduction of CD147 and HDAC4 following H1N1 infection in healthy cells may indicate a self-defence mechanism against further epithelium aberrant responses which is not present in asthmatics.

Grant Support: TSANZ/AstraZeneca Grant in Aid for severe asthma-FM. McDonald Jones Homes Group Grant-HMRI-FM & DK. NHMRC(APP1064405)-DK.

CHANGE IN TYPE-2 INFLAMMATORY BIOMARKERS FOLLOWING SEVERE EXACERBATIONS OF ASThma

FINGLETON J1,2, SEMPRI NI R1,2, SHOR TT N1, EBMIEIER S1, SEMPRI NI A1, RACHEL V1, HOLWEG C1, MATTHEWS J2, WEATHERALL M1, BEASLEY R1, BRAITHWAITE I1

1 Medical Research Institute of New Zealand, Wellington, New Zealand, 2 Genentech Inc., San Francisco, CA, USA and 3 Rehabilitation Teaching and Research Unit, University of Otago, Wellington School of Medicine, Wellington, New Zealand

Introduction/Aim: Blood eosinophils, fraction of exhaled Nitric Oxide (FeNO), serum perilostin and serum IgE are biomarkers of Type 2 inflammation in asthma. We aimed to identify the time course of these biomarkers during and after severe exacerbations to understand how a recent exacerbation may affect their clinical utility in identifying patients likely to benefit from monoclonal antibody therapy directed against IgE, IL-4Ra, IL-5 and IL-13.

Methods: 34 adults with asthma were recruited within 24 hours of starting systemic corticosteroid therapy for a severe asthma exacerbation. Blood eosinophils, FeNO, serum perilostin and serum IgE levels were measured at six visits over 12 weeks. Mixed linear models were used to compare reference biomarker measurements at 12 weeks with those at each previous visit, under the assumption that levels would return to previous stable readings by study end.

Results: Mean blood eosinophil level was lowest at week zero (0.07 vs 0.33 x10^9/L), difference 0.25x10^9/L (95% CI 0.15-0.36), P<0.001; median FeNO was lowest at week two (23 vs 33 ppb), ratio of geometric means (RGM) 0.79 (95% CI 0.63-1.01), P<0.06; median serum perilostin was lowest at week one (45.9 vs 50.9 ng/ml), RGM 0.86 (95% CI 0.82-0.92), P<0.001; median serum IgE was highest at week zero (339 vs 249 U/L), RGM 1.32 (95% CI 1 22 to 1.43), P<0.001.

Conclusion: The time course of change for each of these Type 2 biomarkers are different following treatment for severe exacerbations of asthma. A delay of up to four weeks following a severe exacerbation is required if these biomarkers are used to identify patients likely to benefit from monoclonal antibody therapy.

Grant Support: Genentech Inc.

Conflict of Interest: Funding for the study was provided by Genentech Inc.
DE-RECRUITMENT IN ASTHMATIC AND HEALTHY SUBJECTS ASSESSED VIA FOT
NILSEN K1,2, THIEN F1,4, KING G3, THOMPSON B1,2
1Monash University, Melbourne, Australia, 2The Alfred Hospital, Melbourne, Australia, 3Eastern Health, Melbourne, Australia, and 4The Woolcock Institute, Sydney, Australia

Introduction/Aim: De-recruitment plays an important role in asthma given its strong relationship with clinical parameters. Recently, the forced oscillation technique (FOT) has been used to identify surrogate measures of airway closure via reactance (Xrs) lung volume relationships. In this study, we tested the hypothesis that there are two independent lung volume markers of de-recruitment: 1. where de-recruitment is initiated (DR1) and 2. where rapid de-recruitment commences (DR2). We also hypothesize that these lung volumes correlate with different physiological and clinical markers.

Methods: Asthmatic (n=20) and control (n=19) subjects were included in the study. DR1 and DR2 were identified on the Xrs percentage lung volume relationship via an automatic algorithm. DR1 and DR2 were compared to other physiological measurements obtained via spirometry, multiple breath nitrogen washout and the ACQ6 asthma questionnaire, by obtaining the correlation coefficients and p values.

Results: Asthmatics had higher values of DR1 vol and DR2 vol (p<0.001) indicating the de-recruitment was at a higher lung volume. The rate of de-recruitment of the asthmatics was also significantly slower than the control group (p<0.01). In the control group, DR1vol and DR2vol were positively correlated with age (r=0.79 and r=0.73 respectively). In the asthmatic group DR1vol both and DR2vol were highly correlated (r>0.4 and p<0.01) with symptoms and physiological markers of disease (Scond, Sacin, ACQ6), while only DR1vol correlated with spirometry parameters (FEV1, FRC and FER).

Conclusion: This study demonstrates that two different de-recruitment volumes are evident via Xrs percentage lung volume relationships. Also, the initiation and rate of de-recruitment are altered in subjects with asthma.

BELIEFS ABOUT MEDICINES AND ADHERENCE TO ASTHMA MEDICATION IN PREGNANCY
VANESSA E MURPHY1,2, TOMMY B METCALFE1, ANNELES ROBUN1,2, PETER G GIBSON3,4, KIRSTEN MCCAFFERY5, and MEGAN E JENSEN1,2
1Priority Research Centre GrowUpWell, University of Newcastle, Newcastle, New South Wales, Australia, 2Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia, 3Priority Research Centre Healthy Lungs, University of Newcastle, Newcastle, New South Wales, Australia, 4John Hunter Hospital, New Lambton Heights, New South Wales, Australia, and 5University of Sydney, Sydney, New South Wales, Australia

Introduction/Aim: Non-adherence to inhaled corticosteroids (ICS) is a significant issue in pregnancy; however the reasons for this are unknown. This study aims to characterise beliefs about medicines in pregnant women with asthma and determine whether an association with ICS adherence exists.

Methods: Pregnant women (n=284) completed the validated Beliefs about Medicines Questionnaire (BMQ), consisting of 10 questions about asthma medicines (characterised into “necessity” questions about maintaining health, or “concern” questions about adverse effects), and 8 general medicine questions, each scored on a 5-point Likert Scale. The Necessity-Concerns differential (N-C) was calculated, with positive scores indicating that the patient perceives the benefits of medicines to outweigh the costs.

Results: 88 women used ICS, with 46 (52%) self-reporting adherence (>80% of prescribed doses taken in past week) and 42 (48%) non-adherence. 30% of participants agreed or strongly agreed that they sometimes worry about becoming too dependent on their asthma medication. The majority (80%) believed that their asthma medication would protect them from becoming worse. 21.1% believed that doctors use too many medications, and 16% believed that if doctors had more time with patients they would prescribe fewer medicines. The median N-C was 8 and 5 for women who were adherent and non-adherent, respectively (P=0.008).

Conclusion: Approximately half of all pregnant women were non-adherent to ICS. Pregnant women with asthma who report non-adherence to asthma medicines also express negative concerns about their treatment. Interventions which target beliefs and attitudes about asthma medication use in pregnancy are needed.

Grant Support: NHMRC, University of Newcastle
PASSIVE INTRINSIC AND INDUCED ACTIVE TONE TO ACETYLCHOLINE AND HISTAMINE IN HUMAN SMALL AIRWAYS IN VITRO

SANAI F1,2, CAIRNCROSS A3, ELLIOT J4, NOBLE P1, JAMES A1, KING G1, MCPARLAND B2

1Woolcock Institute of Medical Research, University of Sydney, Glebe, Australia, 3School of Medical Sciences and Bosch Institute, University of Sydney, Sydney, Australia, 4School of Human Sciences, The University of Western Australia, Crawley, Australia, and 2Department of Pulmonary Physiology and Sleep Medicine, Sir Charles Gairdner Hospital, Nedlands, Australia

Introduction/Aim: Passive intrinsic tone is the tension generated by the airway smooth muscle in the absence of any exogenous stimuli. Human large airways (3-12mm inner diameter) in vitro exhibit an intrinsic tone of approximately 50 percent of the maximal contractile response. Given the current interest in small airway diseases such as asthma and chronic obstructive pulmonary disease (COPD), it is important to establish what is normal in regards to airway responsiveness and tone in these airways. This study explored the baseline parameters for assessing contraction of small airways in vitro.

Methods: Resected lung tissue was acquired from five adult cancer patients (3 female; age 68±13 years) with normal lung function. Small airway rings (1-4mm) internal diameter; n=17 tissues) were dissected free from the parenchyma and mounted into a wire myograph chamber. Optimal tissue length (L0) was determined by measuring force generated to 60mM KCl at increasing tissue lengths. At L0 concentration-response curves were generated to acetylcholine (ACh) and then to histamine in the presence of atropine (1μM). Finally to determine intrinsic airway tone, theophylline (10mM) was added to fully relax the airways.

Results: Mean internal diameter (ID) at L0 was 2.8±0.9mm. Maximal active wall tension to ACh and histamine were 2.5±0.7mN/mm and 2.4±0.75mN/mm respectively. Active wall tension to ACh and His were highly correlated to each other (P<0.0001). Potency to ACh and histamine were 1.7±M 95% CI [1, 3μM] and 154mM 95% CI [92, 258nM], respectively (histamine approximately 10 fold more potent). Potency/sensitivity for ACh and His were positively correlated with ID, r=0.53 (P<0.03) and r=0.50 (P=0.04), respectively. The intrinsic passive tone as a percentage of maximal active tone was 12±8%.

Conclusion: Small human airways exhibited increased sensitivity to histamine compared with ACh and considerably less intrinsic airway tone (-12%) than that reported previously for large airways (-50%).

Grant Support: NHMRC-1063068

TNF AND LPS EXERT DIFFERENTIAL EFFECTS ON THE REACTIVITY OF INTRAPULMONARY AIRWAYS AND ARTERIES IN MOUSE PRECISION CUT LUNG SLICES

LAMANNA E1, NOLD C2, BOURKE J1

1Monash University, Clayton, Victoria, Australia, and 2Hudson Institute, Clayton, Victoria, Australia

Introduction: Inflammation-induced increases in airway and vascular reactivity contribute to diseases such as asthma and pulmonary hypertension. Whilst in vitro exposure to bacterial lipopolysaccharide (LPS) or the inflammatory cytokine tumour necrosis factor alpha (TNFα) have been shown to affect reactivity of large airways and pulmonary arteries, their influence on small intrapulmonary airways and arteries have yet to be defined.

Aim: To use the precision-cut lung slice (PCLS) technique to determine the effect of in vitro treatment with LPS or TNFα on responses to broncho/vasoconstrictors in intrapulmonary airways and arteries.

Methods: 8-week old male C57BL/6 mice were culled and lungs were inflated with agarose and collected for preparation of PCLS. Multiple PCLS from each mouse were cultured overnight in the absence or presence of 10μg/mL LPS or 10ng/ml TNFα. Contraction of intrapulmonary airways and arteries (80-200μm) in response to the thromboxane mimetic U46619 and endothelin-1 (ET-1) were assessed in situ under phase contrast microscopy and expressed as % reduction in lumen area.

Results: After LPS treatment, contraction to ET-1 increased in both airways (maximum contraction (%): untreated 61±4% n=11; +LPS 81±7% n=4, p<0.05) and arteries (untreated 35±6% n=9; +LPS 33%, 100% n=2). Incubation with TNFα increased vasoconstriction to U46619 (untreated 23±3% n=11; +TNFα 45±10% n=7, p<0.05) but not to ET-1, while artery responses to both contractile agonists were unaltered with TNFα treatment.

Conclusion: This study demonstrates differential effects of inflammatory mediators on airway and artery contractile responses in PCLS. Further insights into the disease-specific drivers and mechanisms underlying altered reactivity may identify novel approaches for therapeutic targeting of small intrapulmonary airways and arteries in lung diseases.
DUPILUMAB IMPROVES ACQ-5 ITEMS IN CRSwNP PATIENTS WITH COMORBID ASTHMA

HELLINGS P1, BACHERT C2, MILLUL J3, HAMilos D4, NACLERIO R6, MANNENT L7, AMIN N1, TANIou A9, PIROZZI G6, GRAHAM N1, KHAN A11, Regeneron Pharmaceuticals Inc., Tarrytown, United States, 2University Limited in Hospitals Leuven, Leuven, Belgium, 3Ghent University Hospital, Ghent, Belgium, 4Hospital Clinic ·IDIBAPS, Barcelona, Spain, 5Massachusetts General Hospital, Boston, USA, 6The University of Chicago, Chicago, USA, 7Sanofi, Chilly-Mazarin, France, 9Experis IT, BU Pharma and Industry, Nanterre, France, 10Sanofi, Bridgewater, USA

Introduction/Aim: Dupilumab is a fully human monoclonal antibody, directed against the shared IL-4Rα and IL-13, which are key drivers of type 2-mediated inflammation. Dupilumab is approved in the USA and EU for the treatment of adults with moderate-to-severe atopic dermatitis. In a phase 2a study (NCT01920893), dupilumab improved endoscopic, radiographic, and clinical endpoints in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP) and comorbid asthma. This post hoc analysis evaluates the effect of dupilumab on each of the 5 items of the Asthma Control Questionnaire (ACQ-5) in patients with CRSwNP and asthma.

Methods: CRSwNP patients refractory to intranasal corticosteroids were assigned to weekly doses of subcutaneous dupilumab 300 mg or placebo, with mometasone furoate IUI, aerosol nasal spray. Asthma control was assessed using ACQ-5 at baseline and at Week 16.

Results: Of 60 patients enrolled, 58.3% had asthma and used asthma medications. Dupilumab showed clinically relevant improvements in total ACQ-5 (Table). Differences vs placebo were significant for each of the 5 items assessing asthma symptoms (shortness of breath; wheezing time; awake in the morning with symptoms; activity limitation; and nighttime awakenings). Asthma-control improvement correlated with improvement in patient-reported outcomes (visual analogue scale; 22-item Sino-Nasal Outcome Test) and nasal polyp volume. Injection-site reactions, headache, and nasopharyngitis were the most frequently reported adverse events with dupilumab.

Conclusion: In CRSwNP patients with asthma, dupilumab significantly improved all asthma-related measures. Improvement correlated with reduced nasal polyp burden.

Acknowledgements: Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ClinicalTrials.gov Identifier: NCT01920893. Support with additional statistical analyses provided by Shymalie Jawa-wardena, Sanofi. Input, interpretation, and critical review provided by Vijay N. Joshi, former employee of Regeneron Pharmaceuticals, Inc., and Adeline Abbe, former employee of Sanofi. Medical writing/editorial assistance provided by Marinella Calle, PhD, of Excerpta Medica, funded by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.


Disclosures: Hellings P: No conflicts of interest to disclose. Bachert C: Principal investigator of the study; Sanofi—consultant. Mullot J: Is or has been a member of national and international scientific advisory boards (consulting); ALK-Abeló, Boehringer Ingelheim, Crucell, Esteve, FAES, GSK, Harlington Pharmaceuticals, Hyphens, Johnson & Johnson, Meda, Menarini, MSD, Novartis, Pierre Fabre, sanofi-aventis, Schering Plough, UCB, Urich—received fees for lectures and grants for research projects. Hamilos D: Genentech, Regeneron Pharmaceuticals, Inc., Sanofi—consultancy for use of biologics for chronic rhinosinusitis and nasal polyposis; Merck—grant support for bench research; UpToDate—royalties. Naclerio R: Genentech, Media, Merck, Sanofi, Teva—advisory board. Mannent L, Pirozzi G, Khan A: Sanofi—employees, may hold stock and/or stock options in the company. Amin N, Graham NMH: Genentech, Regeneron Pharmaceuticals, Inc.—employees and shareholders. Taniou C: Experis IT, BU Pharma and Industry—employee.

<table>
<thead>
<tr>
<th>Measure</th>
<th>Placebo (n = 19)</th>
<th>Dupilumab (n = 16)</th>
<th>Placebo (n = 19)</th>
<th>Dupilumab (n = 16)</th>
<th>LS mean difference (95% CI)</th>
<th>Incidence of patients achieving MCID of 0.5 based on change from baseline to Week 16, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall</td>
<td>1.63 (0.87)</td>
<td>1.55 (1.11)</td>
<td>-0.10 (0.20)</td>
<td>-1.19 (0.19)</td>
<td>-1.09 (-1.54, -0.63)**</td>
<td>3 (15.8)</td>
</tr>
<tr>
<td>1</td>
<td>1.00 (1.10)</td>
<td>0.88 (1.45)</td>
<td>0.08 (0.24)</td>
<td>-0.91 (0.23)</td>
<td>-0.99 (-1.55, -0.42)**</td>
<td>10 (62.5)**</td>
</tr>
<tr>
<td>2</td>
<td>2.00 (1.37)</td>
<td>1.69 (1.25)</td>
<td>0.01 (0.22)</td>
<td>-1.46 (0.20)</td>
<td>-1.46 (-1.94, -0.99)**</td>
<td>10 (62.5)**</td>
</tr>
<tr>
<td>3</td>
<td>1.38 (1.20)</td>
<td>1.25 (1.13)</td>
<td>-0.11 (0.23)</td>
<td>-0.93 (0.21)</td>
<td>-0.83 (-1.34, -0.32)**</td>
<td>10 (62.5)**</td>
</tr>
<tr>
<td>4</td>
<td>2.19 (1.33)</td>
<td>1.94 (1.24)</td>
<td>-0.29 (0.29)</td>
<td>-1.33 (0.27)</td>
<td>-1.04 (-1.77, -0.31)**</td>
<td>10 (62.5)**</td>
</tr>
<tr>
<td>5</td>
<td>1.56 (0.63)</td>
<td>2.00 (1.90)</td>
<td>-0.54 (0.36)</td>
<td>-1.50 (0.34)</td>
<td>-0.96 (-1.81, -0.12)**</td>
<td>10 (62.5)**</td>
</tr>
</tbody>
</table>

*p < 0.05 vs placebo; **P < 0.01 vs placebo; ***P < 0.001 vs placebo. CI, confidence interval; LS, least-squares; MCID, minimal clinically important difference; SD, standard deviation; SE, standard error.

Respirology (2018) 23 (Suppl. 1), 104–215

Editorial material and organization © 2018 Asian Pacific Society of Respirology. Copyright of individual abstracts remains with the authors.
DUPILUMAB IMPROVES FEV1 AND EXACERBATIONS IN ASTHMA WITH ALLERGIC RHINITIS
WEINSTEIN S1, STAUDINGER H2, GUILLONNEAU S3, TANIOU C4, ECKERT L1, MARONI J1, ROWE P3, AMIN N1, PIROZZI G5, GRAHAM NMH1

Introduction/Aim: Allergic rhinitis (AR) is a common type 2 comorbidity in asthma patients. In addition to having higher exacerbation rates and healthcare costs, asthma patients with AR (vs those without AR) have worse asthma disease control, symptoms, and quality of life (QoL). Dupilumab is a fully human monoclonal antibody, directed against the α subunit, that inhibits interleukin (IL)-4 and IL-13, which are key drivers of type 2-mediated inflammation. Dupilumab is approved in the USA and EU for the treatment of adults with moderate-to-severe atopic dermatitis. In a pivotal phase 2b study (NCT01854047), dupilumab improved lung function and QoL measures, reduced severe asthma exacerbations, and was generally well tolerated in adults with uncontrolled persistent asthma on medium-to-high-dose inhaled corticosteroids plus a long-acting β2-agonist (ICS+LABA). This post hoc analysis assessed efficacy findings in asthma patients with self-reported ongoing comorbid AR.

Methods: Patients received dupilumab 200/300 mg every 2 weeks (q2w; currently being investigated in phase 3 [NCT02414854]) or 4 weeks, or placebo. Change from baseline to Weeks 12 and 24 in forced expiratory volume in 1 second (FEV1; L and %) and annualized severe asthma exacerbation rate over the 24-week treatment period are reported.

Results: Dupilumab 200 and 300 mg q2w improved FEV1 (L) (P<0.05 vs placebo) at Weeks 12 and 24. The severe exacerbation rate was lower (P<0.05 vs placebo) with both dupilumab doses (Table).

Conclusion: In asthma patients with ongoing AR, dupilumab added to ICS+LABA improved FEV1, and reduced severe asthma exacerbations. Future studies are required to further investigate the benefit of dupilumab in this subgroup.

Acknowledgments and Funding Sources: Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ClinicalTrials.gov Identifier: NCT01854047. Input, interpretation, and critical review provided by Vijay N. Joish, former employee of Regeneron Pharmaceuticals, Inc. Medical writing/editorial assistance provided by Xiomara V. Thomas, PhD, and Marinella Calle, PhD, of Excerpta Medica, funded by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.


<table>
<thead>
<tr>
<th>Week 12</th>
<th>Week 24</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Placebo</td>
</tr>
<tr>
<td>Patients with ongoing AR at baseline, n</td>
<td>99</td>
</tr>
<tr>
<td>Patients, n</td>
<td>97</td>
</tr>
<tr>
<td>LS mean change from baseline (SE)</td>
<td>0.16 (0.04)</td>
</tr>
<tr>
<td>LS mean difference vs placebo (95% CI) P value vs placebo</td>
<td>0.15 (0.04-0.25)</td>
</tr>
<tr>
<td>LS mean percent change from baseline (SE)</td>
<td>9.13 (2.37)</td>
</tr>
<tr>
<td>LS mean difference vs placebo (95% CI) P value vs placebo</td>
<td>7.88 (1.29-14.47)</td>
</tr>
<tr>
<td>Annualized rate of severe exacerbations Patients, n</td>
<td>-</td>
</tr>
<tr>
<td>≥ 1 exacerbation in the 24-week treatment period, n (%)</td>
<td>-</td>
</tr>
<tr>
<td>Adjusted annualized severe exacerbation event rate estimate (95% CI) P value vs placebo</td>
<td>0.094</td>
</tr>
<tr>
<td>Risk reduction vs placebo, %</td>
<td>-</td>
</tr>
<tr>
<td>P value vs placebo</td>
<td>-</td>
</tr>
</tbody>
</table>

CI, confidence interval; LS, least-squares; SD, standard deviation; SE, standard error.
12-MONTH FOLLOW-UP OF 2016 EPIDEMIC THUNDERSTORM ASTHMA PATIENTS WITH PRIOR ASTHMA DIAGNOSIS ASSESSING SYMPTOMS, PREVENTER USE, ASTHMA ACTION PLAN OWNERSHIP AND HEALTH CARE UTILISATION

FOO C1, YEE E2, YOUNG A1,2, THIEN F1,2
1Department of Respiratory and Sleep Medicine, Eastern Health, Box Hill Hospital, Melbourne, Australia, 2Eastern Health Clinical School, Monash University, Melbourne, Australia

Introduction/Aim: Epidemic thunderstorm asthma (ETSA) severely affected Melbourne in November 2016. There is scant literature on the natural history of individuals affected by ETSA. This is a 12-month follow-up study of Eastern Health ETSA patients with prior asthma diagnosis assessing their symptomology and behaviours.

Methods: A standardised telephone questionnaire was developed and administered between 4th-15th December 2017 to individuals affected by 2016 ETSA (n=232). The questionnaire assessed asthma symptoms, preventer prescription and adherence, asthma action plan ownership and healthcare utilisation.

Results: 86.2% (n=200) of ETSA patients responded. 42.5% (85) had a prior diagnosis of asthma with 70.6% (60) and 29.4% (25) categorized as “current asthma” or “past asthma” (symptoms within or longer than 12 months before ETSA presentation) respectively. 3% (2) of patients with “current asthma” were asymptomatic on follow-up, with 50% (30) reporting infrequent episodic (up to 1/month), 11.7% (4) frequent episodic (1/month but <1/week) and 35% (21) persistent symptoms (>1/week). 12% (3) of patients with “past asthma” remained asymptomatic with 60% (15) reporting infrequent episodic, 12% (3) frequent episodic and 16% (4) persistent symptoms.

Amongst those with a prior asthma diagnosis, 88% (22) of those with persistent symptoms were prescribed preventers, with 72.7% (16) demonstrating adherence (≥5 days/week). This compared with 60% (36) of those in the other groups combined, with 55.6% (20) adherent.

Asthma action plan ownership was 52% (13) in those with persistent symptoms and 43.3% (26) in those without. 32% (8) of patients with persistent symptoms utilised healthcare services (urgent visit to GP, ED presentation or hospitalization) during the follow-up period compared to 20% (12) in the other groups combined.

Conclusion: The majority of patients affected by 2016 ETSA with a prior diagnosis of asthma had ongoing symptoms on follow-up. Those without persistent symptoms had suboptimal preventer use and adherence. Furthermore, nearly a quarter of all patients required urgent healthcare review for asthma in the follow-up period. Optimisation of preventer usage and action plan ownership may improve asthma control and healthcare utilisation in patients with ETSA.

Grant Support: Nil

Chronic Obstructive Pulmonary Disease (COPD) 2

BARRIERS AND FACILITATORS TO THE IMPLEMENTATION OF COPD SCREENING IN AUSTRALIAN PHARMACIES: A QUALITATIVE ANALYSIS

FATHIMA M1, SAINI B2, FOSTER J3, ARMOUR C1,3
1Woolcock Institute of Medical Research, Sydney Medical School, Glebe, New South Wales, Australia, 2Faculty of Pharmacy, University of Sydney, Camperdown, New South Wales, Australia, and 3Central Sydney Area Health Service, Sydney, New South Wales, Australia

Introduction/Aim: Studies demonstrate that COPD case-finding is feasible and effective. A pharmacist-delivered case finding service recently conducted in New South Wales (using evidence based criteria, micro-spirometry and referral of at-risk patients to GPs) produced a diagnostic yield of 15% which may have been limited by not all participating pharmacists reaching the target number of screened patients. We aimed to investigate the barriers and facilitators encountered by the pharmacists in the NSW COPD case-finding service to facilitate the wider adoption of this service model.

Methods: Community pharmacists participated in semi-structured telephone interviews within three months of case-finding service completion. Interviews were recorded and transcribed verbatim. Data were analysed thematically and managed using NVivo version 11 software (QSR International Pty Ltd.).

Results: Fifteen of 21 pharmacists (male 53%; age 39.8 ± 8.6yrs, rural 47%) in the NSW case-finding service participated in a telephone interview. In general, the pharmacists engaged positively with the service. Our analysis revealed three ‘barrier themes’: ‘challenges of patient recruitment’, ‘poor community awareness of pharmacy services’ and ‘poor interdisciplinary collaboration’ and three ‘facilitator themes’: ‘pharmacist adaptation/entrepreneurship’, ‘training opportunities’ and ‘professional satisfaction’. Suggestions for future implementation included training all pharmacy staff (not just the pharmacist providing the service), creating public awareness about pharmacy services to increase their acceptability, providing pharmacists with remuneration, and streamlining referral logistics to improve GP referral uptake.

Conclusion: Improving COPD diagnosis and treatment requires the involvement of all segments of primary health care, including community pharmacy. Data from this study identifies the main barriers and facilitators to provision of a feasible and effective COPD screening service in Australian pharmacies. Future research is recommended into the benefits of digital tools and electronic decision support algorithms for COPD case-finding screening to support service provision.

Grant Support: None

Declaration of Interest Statement: None

Acknowledgements: Pharmacy Guild of Australia, Lung Foundation Australia, participating pharmacists
THE CHRONIC RESPIRATORY QUESTIONNAIRE HAS A HIGHER RESPONSIVENESS TO PULMONARY REHABILITATION COMPARED TO THE COPD ASSESSMENT TEST

PHILIP R1,2, BONDARENKO J1,2, HOLLAND A1,2,3
1La Trobe University, Melbourne, Australia, 2Alfred Health, Melbourne, Australia, 3Institute for Breathing and Sleep, Melbourne, Australia

Introduction/Aim: Assessment of disease-specific quality of life is a key component of pre- and post-pulmonary rehabilitation (PR) outcome measurements. The PR programme at Alfred Health, Melbourne, has traditionally utilised the Chronic Respiratory Questionnaire (CRQ) for this assessment, however recently, the COPD Assessment Test (CAT) has become increasingly popular. Whether the CAT is equally responsive to PR as the more established CRQ, is unclear.

Methods: Over 3-years, CRQ and CAT scores were routinely collected pre and post PR. All PR participants with pre and post CRQ and CAT results were included in the analysis. Mean change scores were compared using paired t-tests. The number of individuals who achieved the minimal important difference (MID) for each measure was calculated, along with correlations between change scores using Spearman’s Rho. Responsiveness of each tool was evaluated using standard response means (SRM).

Results: Participants (n=92) were 49 males, mean age 69 (SD 13) years, COPD n=44 (48%). CAT and CRQ scores improved from baseline (all p<0.05). Only 50% of individuals achieved the MID for the CAT and 45% for the CRQ total score. There was a weak negative correlation between the change scores generated by the CAT and CRQ total (r=0.4, p<0.001). Responsiveness was moderate for CRQ dyspnoea domain (SRM=0.7) and the total CRQ score (SRM=0.6), however the CAT was less responsive to PR (SRM=0.3).

Conclusion: The CRQ demonstrated greater responsiveness compared to the CAT tool in people with chronic respiratory disease undergoing PR. The CRQ and CAT were weakly correlated, suggesting the tools measure different constructs and are not interchangeable. The CRQ may better reflect changes in dyspnoea-related quality of life following PR.

Grant Support: None to declare.

RECRUITING ADULT OFFSPRING OF PEOPLE WITH COPD TO EXPLORE INTERGENERATIONAL LUNG HEALTH: FEASIBILITY STUDY

LI L1, PAQUET C2, JOHNSTON K1, FRITH P1, WILLIAMS M2
1School of Health Sciences, Sansom Institute for Health Research, University of South Australia, Adelaide, Australia, 2School of Health Sciences, Centre for Population Health Research, Sansom Institute for Health Research, University of South Australia, Adelaide, Australia

Introduction/Aim: Parental history of COPD increases the likelihood of the same condition occurring in their adult offspring. Despite this, familial associations have not generally been a focus of early examination of lung health. Proband-initiated recruitment is a screening/case-finding strategy used to recruit family members of people with conditions that have well-known genetic components. This study aimed to test the feasibility of using this recruitment method to investigate lung health in adult offspring of parents diagnosed with COPD.

Methods: People with confirmed COPD (proband) were identified and contacted by mail from four hospital/clinic databases or face-to-face during a pulmonary rehabilitation program. Ethical considerations required that interested probands be invited to pass on study information to their adult offspring, who if interested, could then contact the researchers. Any comments volunteered by potential participants were recorded.

Results: 645 proband were contacted through mail (n= 546) or face-to-face (n=99), resulting in four offspring recruited (1% offspring response rate).

Conclusion: Low recruitment of adult offspring by contacting people with diagnosed COPD indicate that this process was not feasible to investigate offspring exposures and lung health. Some known parent-related barriers were identified that include possible low prioritisation of lung health as an issue but offspring-related barriers remain unknown.

Grant Support: Australian Government Research Training Program (LSK Li); Physiotherapy Research Foundation seeding grant.
DELAYED TIME TO FIRST AND SUBSEQUENT EXACERBATIONS INDEPENDENT OF SEASON WITH INDACATEROL/GLYCOPRYRONIUM COMPARED WITH SALMETEROL/FLUTICASONE: THE FLAME STUDY

BANERJI D1, CHAPMAN K2, KOSTIKAS K3, OLSSON P4, THACH C1, PATALANO F3, FOGEL R1

1Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA 2Department of Medicine, Asthma and Airway Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada, 3Novartis Pharma AG, Basel, Switzerland, and 4Novartis Sverige AB, Taby, Sweden

Introduction: Seasonal differences have been identified in the pattern of COPD exacerbations.1

We compared the efficacy of indacaterol/glycopyrronium (IND/GLY) vs salmeterol/fluticasone (SFC) in reducing exacerbations across seasons and in reducing the risk of multiple exacerbations in patients with moderate-to-severe COPD.

Methods: FLAME was a 52-week, double-blind, double-dummy study, randomised (1:1) patients (with past year history of ≥1 exacerbation) to IND/GLY 110/50 μg once daily or SFC 50/500 μg twice daily2. Here, we assessed the rate of moderate/severe exacerbation, and time to first and subsequent exacerbations.

Results: Of the 3362 patients randomised, 82.2% completed the 52 weeks of study treatment. IND/GLY significantly reduced the rate of moderate/severe exacerbation in both spring/summer and fall/winter seasons vs SFC (Table). IND/GLY significantly delayed the time to 1st, 2nd, and 3rd exacerbation (moderate/severe), with a 22% (95% CI, 14 to 30%; P<0.001), 24% (95% CI, 11 to 34%; P<0.001), and 29% (95% CI, 9 to 44%; P = 0.006) reduction in risk vs SFC, respectively.

Conclusion: IND/GLY was more effective than SFC in reducing COPD exacerbations in both seasons and should be considered as the preferred first-line treatment option in COPD patients at high risk of exacerbations.

Grant Support: Novartis Pharma AG, Basel

REFERENCES

Table 1  Annualized rates of moderate/severe exacerbations during 52 weeks of treatment with IND/GLY vs SFC by season

<table>
<thead>
<tr>
<th>Season</th>
<th>Exacerbation Outcomes</th>
<th>Annualized rate1 (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IND/GLY</td>
<td></td>
</tr>
<tr>
<td></td>
<td>110/50 μg o.d. (N=1675)</td>
<td></td>
</tr>
<tr>
<td>Spring/Summer</td>
<td>Rate of moderate or severe COPD exacerbations</td>
<td>0.79 (0.68-0.92)</td>
</tr>
<tr>
<td>Fall/Winter</td>
<td>Rate of moderate or severe COPD exacerbations</td>
<td>1.11 (0.98-1.26)</td>
</tr>
<tr>
<td></td>
<td>SFC 50/500 μg b.i.d. (N=1679)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rate ratio (95% CI)</td>
<td></td>
</tr>
<tr>
<td>Spring/Summer</td>
<td>0.95 (0.82-1.09)</td>
<td>0.84 (0.73-0.96) P=0.010</td>
</tr>
<tr>
<td>Fall/Winter</td>
<td>1.35 (1.19-1.52)</td>
<td>0.83 (0.74-0.92) P=0.001</td>
</tr>
</tbody>
</table>

1Rate per 365 days of the season group. b.i.d., twice-daily; IND/GLY, indacaterol/glycopyrronium; o.d., once-daily; SFC, salmeterol/fluticasone
POST-HOSPITALISATION SHORT-TERM OXYGEN THERAPY: A RETROSPECTIVE STUDY

WONG R1,2, KHOR Y1, McDONALD C1
1Austin Health, Heidelberg, Australia, and 2Northern Health, Epping, Australia

Introduction/Aim: Home oxygen therapy is commonly prescribed for patients who remain hypoxaemic at hospital discharge, although there is a lack of evidence supporting this practice. The aim of this study was to evaluate the prescription and follow-up of patients who were discharged with home oxygen therapy following hospitalisation in a tertiary hospital setting.

Methods: A retrospective audit of patients who were discharged with home oxygen following hospitalisation from January 2011 to December 2015 was conducted. A designated clinical pathway for prescription of home oxygen therapy and follow-up following hospital discharge was present during the study period. Chart review was performed to collect patient demographics, comorbidities, oxygen assessment and prescription, follow-up re-assessment and mortality.

Results: Over 5 years, 205 patients were prescribed home oxygen therapy at hospital discharge. The study population was male predominant (58%) with a median age of 75 years. The majority of patients were admitted under Respiratory Medicine (29%), General Medicine (20%) and Medical Oncology (20%). Only 71 (35%) patients had detailed oxygen assessments prior to therapy prescription. Common indications for therapy were chronic lung disease (54%) and palliation (26%). Among the 118 patients who attended their scheduled review appointment 4 to 6 weeks after discharge, 47 (40%) did not fulfill the criteria for long-term oxygen therapy. The 1-year cumulative survival rate for the study population was 56%.

Conclusion: For those patients who were discharged with home oxygen therapy, a significant proportion either failed to attend reassessment following hospital discharge or did not fulfill the criteria for long-term oxygen therapy at reassessment. The assessment for patients who were prescribed with home oxygen therapy at hospital discharge was inadequate. Adherence to the clinical pathway and education for both clinicians and patients should be emphasised.

Grant Support: None

OUTCOMES OF IMPLEMENTATION OF AN INTEGRATED MULTIDISCIPLINARY INPATIENT COPD PATHWAY

TOMO Y1, HSU K2, GEAKE J3
1School of Medicine, University of Adelaide, Adelaide, Australia, 2Division of Acute and Complex Medicine, Royal Adelaide Hospital, Adelaide, Australia, and 3Department of Respiratory Medicine, Lyell McEwin Health Services, Elizabeth Vale, Australia

Introduction/Aim: To assess the effect of an integrated clinical management pathway in chronic obstructive pulmonary disease (COPD) exacerbations on hospital length of stay, readmission rate and clinicians and patients’ satisfaction with the pathway.

Methods: A clinical management pathway for COPD exacerbations was developed and implemented at the Lyell McEwin Hospital as a trial from February to December 2016. We evaluated the effectiveness of the COPD pathway by calculating the average length of stay (ALOS) and readmission rate during the implementation of the COPD pathway, and this was compared to baseline data obtained 12 months prior to the trial. Clinicians’ satisfaction was assessed using an online survey and patients’ satisfaction was evaluated by telephone survey 28 days following discharge of patients during the trial.

Results: Baseline data indicated an ALOS for COPD exacerbations of 4.31 days and a 28-day readmission rate of 18.90%. Implementation of the COPD pathway was associated with a reduction in ALOS of 0.31 days and a decrease in readmission rate by 1.3%. Extrapolating this data, in our institution, use of the pathway over the 2016 calendar year would have equated to a possible reduction in 286 occupied bed-days, with indicative savings of approximately $314,000. Survey data collected indicated that staff felt instructions were clear, and patients were confident in using their COPD action plan and emergency pack of medications.

Conclusion: An inpatient multidisciplinary COPD pathway is effective in reducing length of stay for pulmonary exacerbations, and is generally well received by staff and patients. It is less effective in reducing 28-day re-admissions and further work is required for this outcome.
**TP 102**

**BETA-BLOCKER USE IN COPD PATIENTS WITH CARDIOVASCULAR DISEASE IN A MAJOR SYDNEY HOSPITAL**

DI MICHELI J1, JENKINS C1,2

1Concord Repatriation General Hospital, Sydney, Australia, and 2The George Institute for Global Health, Sydney, Australia

**Introduction/Aim:** In Australia, about 30% of patients with Chronic Obstructive Pulmonary Disease (COPD) die from heart disease. Beta-blockers remain one of the most affordable and efficacious classes of medications to reduce cardiac-related morbidity and mortality. However, despite increasing evidence for the safety of beta-blockers in COPD, their use in COPD patients with known cardiac indications remains inconsistent. We reviewed all admissions to a major Sydney hospital in patients with both a history of COPD and co-morbid cardiac disease over a 12 month period to determine beta-blocker prescription rates in COPD patients.

**Methods:** A retrospective cohort study was conducted across all patients admitted to Concord Repatriation General Hospital (CRGH) from May 2016 to May 2017 with a history of either an acute exacerbation or stable COPD, and a known or new cardiac condition for which a beta-blocker is indicated. Patient demographics recorded included age, sex, length of stay, beta-blocker prescription and whether the patient either died in hospital or was readmitted within 28 days.

**Results:** 198 patients meeting criteria were admitted to CRGH within the study period. The mean age was 79 (±10.5) and 59% were male. Overall only 75 (37.9%) of patients with an indication for beta-blocker therapy were prescribed such. The most commonly prescribed beta-blockers were bisoprolol (38.7%), metoprolol (24.0%) and carvedilol (14.7%). Only 4 patients (2.0%) were commenced on beta-blocker therapy during admission. Furthermore, of the 47 patients that were readmitted within 28 days, 32 (68.1%) were still not prescribed a beta-blocker.

**Conclusion:** Our results show that beta blockers are under-prescribed in the COPD population at a major Sydney hospital.

**TP 103**

**FACTORS ASSOCIATED WITH READMISSION AFTER CHRONIC OBSTRUCTIVE PULMONARY DISEASE RELATED HOSPITALISATION**

WEBER N1, LAVERCOMBE M1,2, YANG M1

1The University of Melbourne, Melbourne, Australia, and 2Department of Respiratory & Sleep Disorders Medicine, Western Health, Melbourne, Australia

**Introduction/Aim:** Acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD) are associated with increased morbidity and mortality. Readmission within 30 or 60 days of discharge remains common. The purpose of this study was to identify factors in COPD admissions that are associated with readmission at two Melbourne teaching hospitals.

**Methods:** Admissions where COPD was the principal diagnosis between August 1st and December 31st 2016 were retrospectively reviewed through the electronic database of Western Health. Information pertaining to the patient, COPD severity and treatment, as well as to the admission itself was recorded. Admissions were not recorded if they were incomplete, if follow-up was not possible, or if the admission concluded with death. Data was analysed through STATA (v14.2).

**Results:** 211 admissions were included. The outcome 30-day readmission occurred 39 times (19.0%) and the outcome 60-day readmission occurred 60 times (28.4%). Patients who were readmitted were generally older and male. Univariate analysis demonstrated that the risk of 30-day readmissions was higher in patients with more previous COPD or total admissions, lower FEV1, higher bicarbonate levels, abnormal chest x-rays, admissions to Footscray Hospital, higher number of regular medications, and a recent history of pulmonary rehabilitation or Hospital Admission Risk Program participation. Multivariate analysis showed that a higher number of regular medications, a recent COPD admission, a higher white blood cell count, and higher bicarbonate levels on admission were associated with 30-day readmissions (corrected for age, sex, and hospital site). Similar associations were observed for 60-day readmission.

**Conclusion:** Readmission within 30 and 60 days of discharge after admission for AECOPD are common in the Western Health population. Several factors were significantly associated with readmission, in particular those related to COPD severity.

**Grant Support:** No funding was received.
FEASIBILITY OF NHF FOR ACUTE HYPERCAPNIC RESPIRATORY FAILURE IN COPD
FINGLETON J1,2,3, MCKINSTRY S1,2,3, BAARSMA J1, ALDINGTON S2, ARMSTRONG P3, NGUYEN M4, CROMHOUT A5, WEATHERALL M3,4, BEASLEY R1,2,3
1Medical Research Institute of New Zealand, Wellington, New Zealand, 2Victoria University of Wellington, Wellington, New Zealand, 3Capital and Coast District Health Board, Wellington, New Zealand, and 4University of Otago Wellington, Wellington, New Zealand

Introduction/Aim: Non-invasive ventilation (NIV) is part of the standard of care for the management of acute hypercapnic respiratory failure in patients with acute exacerbation of COPD (AECOPD). However, NIV is often poorly tolerated. Nasal high flow therapy (NHF) is effective in non-hypercapnic respiratory failure but its utility in hypercapnic respiratory failure is unknown. We aimed to determine the feasibility of a randomised controlled trial of NHF in patients with AECOPD and acute hypercapnic respiratory failure.

Methods: Patients presenting to the Emergency Department (ED), Wellington Hospital, were enrolled and received protocolised standard medical care. Baseline paired arterial and venous blood gas measurements were recorded. Participants with an initial pH 7.25 to 7.34 had a further ABG after a 60 minute optimisation period. Enrolment and data collection was by ED staff. Consent to use data was sought once participants had capacity.

Primary outcome: The proportion of patients with protocol defined treatment failure after 60 to 90 minutes. Secondary outcomes included recruitment and eligibility rates.

Results: During the four month study period 120 people were admitted with a primary diagnosis of AECOPD, of whom 56 (47%) received an initial ABG as per study protocol. 7/56 (12.5%) participants were acidic on initial ABG, 4/56 (7%) had an initial pH in range for the study and 3/56 received a second ABG after the optimisation period. Care deviated from the agreed protocol in 1 of 3 enrolled participants. Only 2 enrolled participants received the second ABG after 60 minutes, both had protocol defined treatment failure.

Conclusion: Lower than expected rates of ABG sampling and of hypercapnic respiratory failure mean that an RCT comparing NHF and AECOPD is unlikely to be feasible with this design. Factors which may affect enrolment include the presence of dedicated research staff in the ED and the requirement for ABG sampling.

Grant Support: None

CARDIAC EVENTS AND MORTALITY FOLLOWING ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE: AN AUDIT OF FOUR NEW ZEALAND HOSPITALS
ELLIS H1, CHANG C1, SHAHUDDIN E1, BEASLEY R2, BECKERT L4, WONG C3, HANCOX R1,5
1Respiratory Research Unit, Department of Respiratory Medicine, Middlemore Hospital, Auckland, New Zealand, 2Department of Medicine, University of Otago, Christchurch, New Zealand, 3Department of Respiratory Medicine, Middlemore Hospital, Auckland, New Zealand, and 4Dept of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand

Introduction/Aim: Cardiac comorbidities are common in patients with COPD and COPD exacerbations are often associated with acute cardiac conditions. We assessed the frequency of cardiac events and mortality in the 2-years following admission for an exacerbation of chronic obstructive pulmonary disease (COPD) in four New Zealand hospitals.

Methods: A review of the clinical notes of 100 consecutive patients admitted with a primary diagnosis of an exacerbation of COPD during 2011/2012 was performed at Middlemore, Waikato, Wellington and Christchurch hospital. We recorded subsequent cardiac events, occurring either during or after the index admission, and further hospitalisations for exacerbations of COPD, and mortality of any cause within 2 years of the index admission.

Results: 400 patients’ clinical notes were reviewed. The mean age on admission was 70 years and 54% were women. In total, 19.8% of patients experienced a cardiac event in the 2 years following the index admission and 61% had a further hospitalisation for exacerbation of COPD. Only 3.3% died during the index admission, but 36.5% of patients died within 2 years (Figure).

Figure 1 Survival after COPD exacerbation.

Conclusion: Although the inpatient mortality is low in New Zealand, over a third of patients die within two years of an admission for an acute exacerbation of COPD. Further hospitalisations for COPD exacerbations are very common and one fifth of patients had a cardiac event within 2 years of admission.
POTENTIAL EFFECTS OF REVISED PRESCRIBING CRITERIA ON AMBULATORY OXYGEN TESTING

WONG Y1, REID L1, HARKNESS N1
1Royal Hobart Hospital, Hobart, Australia

Introduction/Aim: Clinical utility of ambulatory oxygen in COPD patients with mild-moderate desaturation is lacking. Furthermore, the use of blinding in walk tests to determine suitability for ambulatory oxygen is variable but still recommended by TSANZ.

The aim is to estimate the effect of revised prescribing and use of ‘gold standard’ testing on respiratory laboratory costs and time.

Methods: A literature review was conducted and identified that the highest quality ambulatory oxygen assessment includes blinded, 3-step testing with room air, medical air and oxygen. Additionally revised prescribing criteria were proposed, based on the recent trial data1 and known testing with room air, medical air and oxygen. Revised pre-testing time was compared with the currently used 2-step room air/oxygen testing method.

Results: Modelling of revised prescribing criteria and adoption of a 3-step ambulatory oxygen test when applied to previous testing may result in a reduction in testing time of 10.3% for COPD and 15% in non-COPD patients. This equates to 10 minutes saved per test for a consecutive testing cohort of 100 patients. Potential cost savings of $13K and $6K in the COPD and non-COPD groups were calculated over a three-year period. Cost savings of $178 per patient from each 100 consecutive tests may be achieved.

Conclusion: Applying best evidence-based practice to ambulatory oxygen testing and prescribing in COPD and non-COPD patients is above cost-neutral, may generate savings of $178 per patient tested with modest improvement in laboratory testing time. Laboratories with higher testing volume may generate even greater efficiencies.

Grant Support: No funding received for this clinical audit.

SAFETY OF BI-WEEKLY INTRAVENOUS THERAPY WITH ALPHA-1 ANTITRYPSIN

BURDON J1, GREULICH T5, THOMPSON P3, CHLUMSKY J4, WENCKER M2, VIT D6, FRIES M2, CHUNG T5, VOGLMEIER C2, CHAPMAN K8, MCELVANEY N10
1St Vincent’s Hospital, Department of Respiratory Medicine, Fitzroy, Australia, 2Department of Internal Medicine, Division for Pulmonary Diseases, Philipps-University Marburg, Marburg, Germany, 3Molecular Genetics and Inflammation Unit, Institute of Respiratory Health and School of Medicine, University of Western Australia, Perth, Australia, 4Thomayer Hospital, First Medical Faculty, Charles University, Department of Pulmonary Diseases, Prague, Czech Republic, 5Medical Affairs, CSL Behring, Marburg, Germany, 6Clinical Research and Development, CSL Behring, Bern, Switzerland, 7Clinical Strategy and Development, CSL Behring, King of Prussia, USA 8Statistics Department, CSL Behring, King of Prussia, USA 9Department of Medicine, University of Toronto, Toronto, Canada, and 10Department of Respiratory Medicine, Beaumont Hospital, Royal College of Surgeons in Ireland, Dublin, Ireland

Introduction/Aim: Infusion of human alpha-1 proteinase inhibitor (A1-PI) effectively slows the progression of emphysema in patients with alpha-1 antitrypsin deficiency (AATD). Nonetheless, weekly infusions of 60 mg/kg body weight are time consuming, costly and inconvenient, particularly when a patient plans to travel. The aim was to assess the safety of bi-weekly infusions of 120 mg/kg A1-PI compared with weekly 60 mg/kg infusions.

Methods: The adverse event (AE) profile 7 days before a 120 mg/kg infusion was compared with the AE profile 7 days after the infusion.

Results: A placebo controlled trial of A1-PI (Zemaira/Respreeza; RAPID-RCT), which randomised 180 patients, was followed by an open-label extension trial (RAPID-OLE) in which bi-weekly treatment with A1-PI was permitted to cover holidays. The infusion adjusted event rate (IAER) of any treatment emergent AE was numerically higher in the 120 mg/kg A1-PI and placebo groups compared with the corresponding 60 mg/kg groups (Table). However, AEs within the first 24 and 72 hours after infusion were comparable between all subgroups. The majority of reported AEs were infections of the upper and lower respiratory tract and exacerbations of COPD.

<table>
<thead>
<tr>
<th></th>
<th>933 infusions in 137 patients</th>
<th>374 infusions in 137 patients</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A1-PI 60 mg/kg</td>
<td>A1-PI 120 mg/kg</td>
</tr>
<tr>
<td>Any TEAE</td>
<td>0.1029</td>
<td>0.1222</td>
</tr>
<tr>
<td>IAER 24 h</td>
<td>0.0354</td>
<td>0.0322</td>
</tr>
<tr>
<td>IAER 72 h</td>
<td>0.0568</td>
<td>0.0579</td>
</tr>
</tbody>
</table>

Conclusion: The IAER was similar between A1-PI and placebo infusions. Doubling the dose, and thus the infusion volume, did not increase the IAERs after 24 and 72 h, the time in which volume effects would be expected to occur. No difference in tolerability between the two doses was detected.

Grant Support: The RAPID trial programme and preparation of this abstract was supported by CSL Behring.
PREDICTORS OF CPAP ADHERENCE IN CHILDREN AND ADOLESCENTS WITH OBSTRUCTIVE SLEEP APNOEA

KAPUR N1,2, WALES P1, GOYAL V1,2
1Lady Cilento Children’s Hospital, Brisbane, Australia, and 2University of Queensland, Brisbane, Australia

Introduction/Aim: Obstructive Sleep Apnoea (OSA) is a common condition effecting 2-4% of children. Children are being increasingly treated with continuous positive airway pressure (CPAP), though its use is limited by poor adherence. The purpose of this study was to identify and describe the factors associated with adherence to CPAP.

Methods: We retrospectively reviewed the records and Polysomnography (PSG) scoring of children on CPAP for OSA during 2016 with a minimum of 6-month of CPAP usage data available. We studied the association of adherence (defined as median CPAP use per night of 4-hours or more for at least 6-months) with age, gender, obesity, Apnoea-Hypopnea Index (AHI) at diagnosis, change in AHI post treatment, socio-economic status (SES) and underlying aetiology.

Results: 85 children (28F) were included with a median age (IQR) at CPAP initiation of 5.8 years (2.6-12.2). 33 (39%) were obese; 12 had Down’s syndrome and 8 had Achondroplasia. AHI at diagnosis (n=76) was 14.35 (6.9-47.9) with a median improvement of 10.7 (4.4-40.8) with treatment. 57/78 (73%) children were considered adherent. Males were more likely to be adherent compared to females (80% adherence vs. 61%). Higher proportion of children with Achondroplasia were non-adherent (38% vs. 27%) though this difference was not statistically significant. Age, obesity, socio-economic status based on postcode, AHI at diagnosis and change in AHI with treatment did not predict adherence to CPAP therapy.

Conclusion: In this retrospective study, CPAP adherence was variable, though high proportion were adherent. Boys reported higher adherence rates though severity of OSA and degree improvement with treatment did not predict adherence. Prospective qualitative research is needed for better understanding of adherence governing factors, including data on patient and parent education at CPAP initiation and follow up.

Grant Support: None

Declaration of Interest: No conflicts of interest

OXYGEN EFFECT ON BREATHING PATTERN IN MULTIPLE BREATH NITROGEN WASHOUT PERSISTS INTO PRESCHOOL YEARS BUT IS OF SMALLER MAGNITUDE THAN FOUND IN INFANTS

ROBINSON P1,2, LINDBLAD A3, WONG A1, COWARD E1, COOPER P1, FITZGERALD D1,2, PANDIT C1,2, SELVADURAI H1,2, GUSTAFSSON P4
1Department of Respiratory Medicine, The Children’s Hospital at Westmead, Sydney, Australia, 2Discipline of Paediatrics and Child Health, Sydney Medical School, University of Sydney, Sydney, Australia, 3Cystic Fibrosis Centre, Queen Silvia Children’s Hospital, Gothenburg, Sweden, and 4Department of Paediatrics, Central Hospital, Skövde, Sweden

Introduction/Aim: Multiple breath inert gas washout (MBW) offers strong feasibility across all age ranges. Inert gas choice includes resident (e.g. Nitrogen, N2) and non-resident gas options (e.g. Sulfur hexafluoride, SF6). We have recently demonstrated detrimental effects of 100% oxygen (O2) exposure on breathing pattern during N2MBW in infants (Gustafsson et al JAP 2017): decreased tidal volume (VT), minute ventilation (VE) and increased end-tidal CO2 (ETCO2) most pronounced during initial O2 exposure. In this study we investigated the persistence of this effect within the preschool age range (defined as 2-6 years of age).

Methods: Preschool subjects, experienced in MBW, were recruited from clinically indicated MBW tests at a tertiary paediatric centre (CHW), N2MBW was performed in triplicate, with facemask interface, using commercial equipment (Exhalyzer D, Eco Medics AG, Switzerland). Standard test protocol (ERS/ATS consensus guidelines) was modified to contain an extended prephase (prior to 100% O2 exposure, 30-60s) to ensure good estimation of baseline breathing pattern. Changes in VT, VE, ETCO2, respiratory rate (RR), Inspiratory drive (Vt/inVT) were examined.

Results: Data collated from 20 subjects to date: mean (SD) age 4.3 (1.1) years, 75% cystic fibrosis, mean (SD) Lung clearance index 8.0 (1.3). Percent change in breathing pattern indices, compared to baseline, during initial O2 exposure, in comparison to previously published infant cohort (tested on identical equipment) summarised below.

<table>
<thead>
<tr>
<th></th>
<th>Infant (n=10)</th>
<th>Preschool (n=20)</th>
</tr>
</thead>
<tbody>
<tr>
<td>VT (%) decline</td>
<td>40%</td>
<td>11%</td>
</tr>
<tr>
<td>VE (%) decline</td>
<td>40%</td>
<td>14%</td>
</tr>
<tr>
<td>RR no change</td>
<td>no change</td>
<td>no change</td>
</tr>
<tr>
<td>Inspiratory drive (Vt/inVT) (%)</td>
<td>25% decline</td>
<td>7% decline</td>
</tr>
<tr>
<td>ETCO2 (%) increase</td>
<td>5% increase</td>
<td>2% increase</td>
</tr>
</tbody>
</table>

Conclusion: Detectable differences in breathing pattern with 100% O2 exposure persist into the preschool age range but are of lesser magnitude than that observed in infants. Further work will examine whether magnitude also decreases with increasing age within this age range.

Grant Support: Vertex Innovation Award, Fundraising CHW.

Conflict of Interest: No conflicts of interest to declare.
SINGLE VERSUS TRIPPLICATE MEASUREMENTS IN ASSESSING DAY-TO-DAY FOT VARIABILITY
WONG A1, HARDAKER K2,3, HUVA NANDANA J3, KOHLHOFF P3, THAMRNIN C3, KING G2, SELVADURAI H1,2, ROBINSON P1,2,3
1Department of Respiratory Medicine, The Children’s Hospital At Westmead, Sydney, Australia, 2Discipline of Pediatrics and Child Health, Sydney Medical School, University of Sydney, Sydney, Australia, and 3Airway Physiology and Imaging Group, Woolcock Medical Research Institute, Sydney, Australia

Introduction: Objective tools for monitoring childhood asthma are urgently required, yet conventional lung function tests (e.g. spirometry, peak flow) are limited in this setting by their effort-dependent nature and limited insight into asthma control. The Forced Oscillation Technique (FOT) is a novel test performed during tidal breathing and assesses airway calibre and lung stiffness by measuring airway resistance (Rrs) and reactance (Xrs), respectively. We previously related day-to-day FOT variability with severe disease; antibiotic courses & clinic visits within a 12 month period.

Methods: Data was analysed from 10 subjects, who performed 3x60-s technically acceptable FOT measurements daily using a commercial FOT system, under parent supervision over a 3-4 month period. FOT outcomes examined were Rrs and Xrs at 5 Hz, AX (area under the reactance curve), and resonant frequency. Variability of Rrs and Xrs was calculated from the running coefficient of variation over the past 7 days. Only technically acceptable runs were included. Values obtained using the first run vs. the mean of triplicate values were compared using Pearson correlations, paired t-tests, and Bland-Altman plots.

Results: Single versus mean-of-triplicate values were strongly correlated across all FOT outcomes (R>0.99, p<0.001). Magnitude and variability of all FOT outcomes obtained from single measurements were statistically higher compared to mean-of-triplicate measurements. The differences, however, were very small (<0.1 cmH2O s L-1 or <4% of mean values for Rrs and Xrs) compared to known day-to-day variability and unlikely to be clinically relevant. Bland-Altman plots revealed no evidence of proportional bias.

Conclusion: A single measurement may be acceptable to quantify day-to-day FOT variability in trained children. This may increase overall feasibility of FOT for monitoring in the home and field settings.

REFERENCE

Key Words: Forced Oscillation Technique, variability, asthma

Grant Support: Asthma Foundation (Ross Trust), Sydney Medical School Foundation Grant

Industry support: Thorasys Ltd, Canada; Adherium, New Zealand

CAN WE DEVELOP A PAEDIATRIC APPROPRIATE BRONCHIECTASIS SEVERITY SCORE?
BELL H1,2, JAKSIC M1,2, PILLARISETTI N2, WAINEVAU U2, BYRNE S C1,2
1University of Auckland, Auckland, New Zealand, and 2Starship Children’s Hospital, Auckland, New Zealand

Introduction/Aim: The ‘Bronchiectasis Severity Index’ (BSI) and the ‘FACED’ scores assess severity of disease in adults with bronchiectasis and have been validated in determining prognosis. However, a number of the clinical parameters are irrelevant to children.

Aims: 1.: To develop a disease severity score relevant for children with bronchiectasis.

2. To determine validity by comparing to other parameters associated with severe disease; antibiotic courses & clinic visits within a 12 month period.

Methods: We adapted the adult scoring systems to children with categories of; age, extension of disease, chronic infection, hospital admissions, presence of co-morbidities (total score 9), with the addition of lung function in a subgroup (total score 11). We separately recorded number of clinic visits within the previous year (scheduled by the clinical team; annual mild, 2 moderate, 4 or more severe) and the numbers of antibiotic courses picked up per year with an apriori definition (mild <2/year, moderate 2-4, severe >4). We then reviewed children in the database under current care at the Starship Bronchiectasis Clinic.

Results: There were 257 children appropriate for scoring, mean age 9.4 years (range 1.7 to 17.5 years) with a mean severity score of 4.4 (range 1-9) with 35 mild, 146 moderate & 76 severe. There was only moderate correlation between these categories and those determined by antibiotic pick-up, and clinic visits. With the addition of FEV1 there were 139 children (mean age 11.9 years, range 4.4 to 17.5 years), with a mean score 4.6 (range 1-11) with 18 mild, 104 moderate, & 17 severe.

Conclusion: In all parameters 28-40%of children have severe bronchiectasis. The clinical score correlated moderately with two other disease severity indicators meaning some adjusted weighting may be needed. The score also needs assessment in determining it ability to predict future outcomes.

REFERENCE

TECHNOLOGY ENABLED LEARNING FOR SCHOOL STAFF

ASThma TRAINING

BURNS C1, GRAY M1, FRANCIS S1, HOMAIRA N1,2, JAFFE A1,2
1Respiratory Department, Sydney Children’s Hospital, Randwick, Sydney, Australia, and 2Discipline of Paediatrics, School of Women’s and Children’s Health, Faculty of Medicine, UNSW, Sydney, Australia

Introduction/Aim: One in 10 children in Australia is diagnosed with asthma. With children spending on average 30% of their day at school, school staff are an important population who may be called upon to provide asthma first aid. Our aim was to investigate whether a technology enabled teaching resource improved asthma first aid knowledge and self-confidence among school staff.

Methods: We conducted a prospective randomised parallel study. School staff across Sydney were randomly assigned to receive asthma management training via the Asthma First Aid Management in Schools eBook, or standard face to face training. Each participant completed a 14 item asthma first aid knowledge questionnaire (AFAKQ) and a 4 item, 10 point Likert scale asthma management self-confidence questionnaire pre and post training.

Results: There was significant increase in mean score in asthma knowledge and 4 areas of asthma management self-confidence post training compared to pre-training in the eBook group (Table 1). There was no significant difference between the mean score changes in asthma knowledge and asthma management self-confidence when comparing both training groups.

Table 1

<table>
<thead>
<tr>
<th>Variable</th>
<th>Pre-training</th>
<th>Post-training</th>
<th>Mean Change</th>
<th>Mean (SD)</th>
<th>Mean (SD)</th>
<th>(95% CI)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Score in AFAKQ</td>
<td>9.78 (3.10)</td>
<td>11.72 (1.67)</td>
<td>1.94</td>
<td>1.20</td>
<td>2.70</td>
<td></td>
</tr>
<tr>
<td>Correctly using a spacer</td>
<td>6.69 (2.97)</td>
<td>9.28 (1.24)</td>
<td>2.59</td>
<td>1.93</td>
<td>3.24</td>
<td></td>
</tr>
<tr>
<td>device with puffer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recognise an asthma attack</td>
<td>6.74 (2.54)</td>
<td>9.14 (1.00)</td>
<td>2.40</td>
<td>1.78</td>
<td>3.02</td>
<td></td>
</tr>
<tr>
<td>Managing an asthma attack</td>
<td>6.29 (2.71)</td>
<td>9.10 (1.07)</td>
<td>2.81</td>
<td>2.20</td>
<td>3.42</td>
<td></td>
</tr>
<tr>
<td>Correct asthma first aid</td>
<td>5.90 (2.81)</td>
<td>9.10 (1.12)</td>
<td>3.21</td>
<td>2.60</td>
<td>3.82</td>
<td></td>
</tr>
</tbody>
</table>

*Mean change significant at p<0.00001

Conclusion: Both the Asthma First Aid Management in Schools eBook and standard face to face training increase asthma knowledge and self-confidence in school staff. The eBook is an effective alternative to face to face training in settings where human resources for health education are limited or for school staff unable to access training due to geographical location.

Grant Support: N/A

SPECIFIC VENTILATION IMAGING USING OXYGEN

ENHANCED MRI IN ADOLESCENTS WITH CYSTIC FIBROSIS

JAYASURIYA G1,2,3, COWARD E1, KENNEDY B1, PRISK K1, ROBINSON P1,2,3, SA R1, SELVADURAI H1,2, THEILMAN R1, WALKER T1, KING G1,2
1Department of Respiratory Medicine, The Children’s Hospital At Westmead, Sydney, Australia, 2The University of Sydney, Sydney, Australia, 3The Woolcock Institute of Medical Research, Sydney, Australia, 4Department of Radiology, University of California, San Diego, CA, and 5Department of Radiology, The Children’s Hospital at Westmead, Sydney, Australia

Introduction/Aim: Specific ventilation imaging (SVI) is a novel pulmonary imaging technique utilising magnetic resonance imaging (MRI) to evaluate the regional distribution of ventilation. The SVI technique developed by Prisk et al in San Diego relies on the paramagnetic properties of oxygen and signal change in MRI seen in the lungs during alternating cycles of room air (21% oxygen) and 100% oxygen. Feasibility to date has been demonstrated only in adults. Our study aims to establish the technique and determine feasibility in both adult and adolescent patients at our center.

Methods: General Electric (GE) 1.5 T MRI SVI sequence used by Prisk et al, was adapted to a Philips 1.5T MRI. To reduce equipment-related dead space volume, a bias flow plumbing circuit with Solenoid switching valve system was developed (including 3-D Printed MRI-safe components) to deliver alternating 100% O2 at 120L/min and room air through a Hans Rudolph face mask, sealed with putty. Chest coil used as receiver.

Results: Adult feasibility was demonstrated in five patients (2 male), age range 27-36 years, with technically acceptable results achieved in all subjects. Adolescent feasibility was demonstrated down to 10 years: Four healthy adolescents (3 male, ages 10-16 years) and four cystic fibrosis patients (4 male, ages 15-18 years) with mild lung disease (abnormal LCI, normal FEV1). SV quantification and mapping able to be performed on all subjects. Differences in vertical distribution in SV seen between healthy and CF participants.

Conclusion: SVI sequence specifications can be translated from GE to Philips MRI scanners. Strong feasibility was demonstrated in adults and, for the first time in adolescents down to 10 years of age at our centre.

REFERENCE
**Introduction/Aim:** Indigenous children in the Northern Territory (NT) have high rates of repeated acute lower respiratory infections, associated with a future diagnosis of bronchiectasis. There is however, little data among non-Indigenous children and the trend over the years is unknown. We aimed to determine whether the clinical profile of children investigated for suspected bronchiectasis has changed between 2007-11 and 2012-17.

**Methods:** Demographics, clinical and medical history were obtained in children aged 3 months to 10 years undergoing FB and CT scans at the Royal Darwin Hospital.

**Results:** 304 children were enrolled (n=126 - 2007-11; n=178 - 2012-17); median age 2.4 years (IQR 1.6-3.9). CT confirmed bronchiectasis and age remained similar. However, the number of children with suppurative airways (p=0.02), chronic cough (p=0.008) and non-Indigenous ethnicity (p=0.04) increased (Table) between the two cohorts. In 2012-17, doctor visits for cough in the past year was high with 75% with >5 visits (5-10 visits=45/127, 35%; 10-20 visits=29/127, 23%; >20 visits=9/127, 7%).

<table>
<thead>
<tr>
<th></th>
<th>2007-11</th>
<th>2012-17</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yrs) (median)</td>
<td>2.4 (1.7-4.2)</td>
<td>2.3 (1.6-3.8)</td>
<td>2.4 (1.6-3.9)</td>
</tr>
<tr>
<td>Indigenous:</td>
<td>116 (92)</td>
<td>150 (84)</td>
<td>266 (88)</td>
</tr>
<tr>
<td>non-Indigenous, n (%)</td>
<td>10 (8)</td>
<td>28 (16)</td>
<td>38 (12)</td>
</tr>
<tr>
<td>Males, n (%)</td>
<td>75 (59.5)</td>
<td>94 (52.8)</td>
<td>169 (56)</td>
</tr>
<tr>
<td>Chronic Cough (&gt;4 weeks)</td>
<td>67/109 (62)</td>
<td>94/167 (56)</td>
<td>161/277 (58)</td>
</tr>
<tr>
<td>CT confirmed bronchiectasis, n (%)</td>
<td>115/125 (92)</td>
<td>155/171 (91)</td>
<td>270/296 (91)</td>
</tr>
<tr>
<td>Suppurative airways, n (%)</td>
<td>88/126 (70)</td>
<td>100/174 (58)</td>
<td>188/300 (63)</td>
</tr>
</tbody>
</table>

**Conclusion:** The persistently high frequency of bronchiectasis in Indigenous children, increasing number of non-Indigenous children with bronchiectasis, higher prevalence of children with chronically cough, suppurative airways and frequent doctor visits in the later cohort require further evaluation and resources in the NT. This includes education at the primary care level for parents/carers and health professionals.

**Grant Support:** NHMRC CRE for Lung Health in Indigenous Children. GB and AC are supported by NHMRC fellowships.

**Conflict of Interest:** None.
THE IMPACT OF THE 13 VALENT CONJUGATE PNEUMOCOCCAL VACCINE ON PNEUMOCOCCAL SEROTYPES CAUSING CHILDHOOD EMPYEMA IN AUSTRALIA

STRACHAN R1, BEGGS S2, FEARON D3, GILBERT G4, HOMAIRA N5, LAMBERT S6, MARSHALL H7, MARTIN A8, MCCALLUM G8, MCCULLAGH A9, MCDONALD T10, McINTYRE P10, OFTADEH S11, RANGANATHAN S12, SURESH S13, TEOH L14, TWAIJ A15, WAINWRIGHT C16, WONG M17, SNELLING T18, JAFFE A1,2

1Sydney Children’s Hospital, Randwick, Australia, 2Department of Paediatrics, Royal Hobart Hospital, Hobart, TAS, Australia, 3Department of Paediatrics, Alice Springs Hospital, Alice Springs, Australia, 4Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, Australia, 5School of Women’s and Children’s Health, University of New South Wales, Randwick, Australia, 6UQ Centre for Child Health Research, The University of Queensland, Brisbane, Australia, 7Department of Paediatrics, Women’s and Children’s Hospital, Adelaide, Australia, 8Department of Paediatrics, Princess Margaret Hospital for Children, Perth, Australia, 9Paediatric Department, Royal Darwin Hospital, Darwin, Australia, 10Respiratory Department, Monash Children’s Hospital, Melbourne, Australia, 11Paediatric Respiratory and Sleep Department, The Canberra Hospital, Canberra, Australia, 12National Centre for Immunisation Research & Surveillance, Children’s Hospital at Westmead, Westmead, Australia, 13Respiratory Department, Royal Children’s Hospital, Melbourne, Australia, 14Respiratory Department, Lady Cilento Children’s Hospital, Brisbane, Australia, 15Department of Immunology, The Children’s Hospital at Westmead, Westmead, Australia, 16Westfarmers Centre of Vaccines & Infectious Diseases, Telethon Kids Institute, University of Western Australia, Perth, Australia

Introduction:
The 13-valent conjugate pneumococcal vaccine (13vPCV) replaced the 7vPCV on the national immunisation schedule in Australia in mid-2011.

Aim:
To determine the impact of 13vPCV on Streptococcus pneumoniae (Sp) serotypes causing childhood empyema.

Methods:
Pleural fluid was collected from children with empyema presenting to 11 paediatric hospitals across Australia before (2007-2009) and after (2015-2017) the introduction of 13vPCV. Sp serotypes were identified on empyema fluid by PCR and sequencing.

Results:
Pre 13vPCV: 143 children, 81 male, median age 4.9 (range 0.4-15.5) years were recruited. Sp was identified by PCR in 73 of 143 (51%) of cases. Post 13vPCV: 167 children, 85 male, median age 3.5 (range 0.6-15.8) years were recruited. Sp was identified by PCR in 95 of 167 (56.9%) of cases (Table).

Conclusion:
The 13vPCV has not been effective against pneumococcal serotypes 3 and 19A. These data will help inform future national pneumococcal vaccination strategies.

Grant Support: NHMRC grant

Declaration of Interest: No

<table>
<thead>
<tr>
<th>Serotype</th>
<th>2007-2009 (N=143)</th>
<th>2015-2017 (N=167)</th>
<th>13vPCV vaccination status</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. (%) specimens</td>
<td></td>
<td>Not (N), Partial (P), Full (F) (%)</td>
</tr>
<tr>
<td>PCV13 serotypes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>18 (32.7)</td>
<td>34 (58.6)</td>
<td>P 2 (6), F 32 (94)</td>
</tr>
<tr>
<td>19A</td>
<td>20 (36.4)</td>
<td>13 (22.4)</td>
<td>P 1 (7.7), F 12 (92.3)</td>
</tr>
<tr>
<td>1</td>
<td>8 (14.5)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>7F/7A</td>
<td>2 (3.6)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>1 (1.8)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>9V/9A</td>
<td>1 (1.8)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Non vaccine serotypes</td>
<td>5 (3.5%)</td>
<td>11 (6.5%)</td>
<td></td>
</tr>
<tr>
<td>11A</td>
<td>0</td>
<td>3 (5.2)</td>
<td>F 3 (100)</td>
</tr>
<tr>
<td>25F/25A, 38</td>
<td>0</td>
<td>3 (5.2)</td>
<td>F 3 (100)</td>
</tr>
<tr>
<td>9N</td>
<td>0</td>
<td>2 (3.4)</td>
<td>N1 (50), F1 (50)</td>
</tr>
<tr>
<td>22F/22A</td>
<td>2 (3.6)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>15A</td>
<td>0</td>
<td>1 (1.7)</td>
<td>F1 (100)</td>
</tr>
<tr>
<td>22F</td>
<td>0</td>
<td>1 (1.7)</td>
<td>F1 (100)</td>
</tr>
<tr>
<td>35B/35C</td>
<td>0</td>
<td>1 (1.7)</td>
<td>P1 (100)</td>
</tr>
<tr>
<td>6C</td>
<td>1 (1.8)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>15F</td>
<td>1 (1.8)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>1 (1.8)</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

The proportions of 13vPCV serotypes were not statistically different in the 2 time periods. (Z-Score = 1.2065, p=0.226).
EVALUATION OF AN INTEGRATED PAEDIATRIC ASTHMA MANAGEMENT PROGRAM: PRELIMINARY DATA
HOMAIRA N 1,2, ALTMAN L 3, WALES S 2, GREY M 2, BURNS C 2, OWENS L 2, BREEN C 3, CORBET M 2, JAFFE A 1,2, WOOFFENDEN S 2
1Discipline of Paediatrics, School of Women’s and Children’s Health, UNSW, Sydney, Australia, 2Respiratory Department, Sydney Children’s Hospital, Randwick, Australia, and 3Integrated Care, Sydney Children’s Hospital Network, Australia

Introduction/Aim: In 2016, The Sydney Children’s Hospitals Network launched the Asthma Follow Up Integrated Care Initiative to address repeated presentations by children with non-complex asthma to the Sydney Children’s Hospital (SCH) Emergency Department (ED). The aim was to reduce ED presentations, through better management of their asthma and increased engagement with their general practitioners (GPs).

Methods: Starting in January 2017, children aged 2-16 years, presenting to SCH ED with non-complex asthma, for ≥4 times in a 12 month period, were approached by Kids GPS Care Coordinators for enrolment in the program. Parents of enrolled children were requested that their child have a review with their GP, and also offered referral to asthma education sessions. An extra layer of support was introduced in April 2017, a letter was sent to the child’s GP advising of the child’s recent hospital presentation. This letter suggested steps to improve the child’s asthma management including influenza vaccination, review of asthma action plan, preventer medication and referral to a paediatrician if necessary. We compared the number of asthma ED presentations for these children six months pre and post enrolment using Wilcoxon signed-rank test.

Results: A total of 51 children have been enrolled in the program; 29 children were enrolled for >6 months. The median age of the children was 4 years (IQR 3-5 years). The median numbers of ED presentations in the six months preceding enrolment in the program was 2 (IQR 2-3) and post enrolment was 1 (IQR 0-1). There was significant reduction in the median frequency of ED presentations post implementation of the Asthma Follow Up Integrated Care Initiative (z=3.25, p =0.001).

Conclusion: Our preliminary data suggest that a comprehensive integrated approach to management of non-complex paediatric asthma may reduce frequent ED presentations due to exacerbation of asthma symptoms in children.

Grant Support: This work was funded by the NSW Health

LUNG CLEARANCE INDEX AS A MARKER OF SEVERE ASTHMA IN A PAEDIATRIC POPULATION
1Priority Research Centre GrowUpWell, The University of Newcastle, Newcastle, Australia, 2Department of Respiratory Medicine, John Hunter Children’s Hospital, Newcastle, Australia, and 3Paediatric Respiratory & Sleep Medicine Department John Hunter Children’s Hospital, Newcastle, Australia

Introduction/Aim: Lung clearance index (LCI) derived from nitrogen multiple breath washout (MBW) ventilation inhomogeneity. LCI airway disease severe asthma severe asthma.

Methods: This retrospective analysis 16 patients reviewed in The Severe Asthma Clinic (SAC) at John Hunter Children’s Hospital between 2014 and 2017 aged 2 to 15 years (6 females). All patients were uncontrolled on maximum doses of inhaled steroids plus long-acting beta agonist or montelukast to meet eligibility criteria. Relevant investigations performed included (where possible) spirometry, body plethysmography, exhaled nitric oxide (FeNO), asthma control test (ACT) scores, and measured in accordance with international recommendations.

Results: Nine of the total 16 patients (56.2%) ean LCI 11.7 (3.68.9-13.1), which was markedly higher than in two cohorts of healthy children at our site (mean LCI 7.1, Dunn et al., Ped Pulmonology 2017; mean LCI 7.3, Mandaliya et al. BMC Pulm Med 2015). Asthma control test scores 14.4 (5.111.0-19.5)FEV1 69.3 (16.957-78) FeNO 26.5 (24.87-38). Preliminary analysis suggest a correlation between improved clinical parameters and reduced LCI.

Conclusion: LCI airways disease in severe asthma in and management of more severe asthma.
**TP 120**

**DEVELOPMENT AND VALIDATION OF A BRONCHOSCOPICALLY DEFINED BRONCHITIS TOOL IN CHILDREN**

EG K1,2, THOMAS R1, MASTERS I1, MCELREA M1, CHANG A1,3
1Department of Respiratory and Sleep Medicine, Lady Cilento Children’s Hospital, Children Centre for Health Research, Brisbane, Australia, 2Department of Paediatrics, University of Malaya, Kuala Lumpur, Malaysia, and 3Child Health Division, Menzies School of Health Research, Charles Darwin University, Tiwi, Australia

**Method:** No validated tool exists for scoring bronchitis (i.e. airway inflammation) during flexible bronchoscopy (FB) despite potential clinical and research usefulness. Thus, we aimed to develop a bronchoscopically defined bronchitis scoring system in children (Bscore).

**Methods:** We used methods from our retrospective study; FB recordings were assessed for 6 components: amount of secretions (scores 1-6), colour of secretions (BronkoTest, 0-8), mucosal oedema (0-3), erythema (0-3) and pallor (0-3) based on pre-determined criteria. Bscore was derived using several models developed from various combinations of the each of the 6 components that best related to airway neutrophilia (in BAL). We also determined the correlations (Spearman) between each component with BAL neutrophilia%. Clinical history was obtained from parent(s) who consented for study inclusion before the FB undertaken. A clinician blinded to the child’s history scored the FB. The various models of Bscore were plotted against neutrophilia% using a receiver operating characteristic (ROC) curve. Here we report our preliminary findings; we plan to enrol >100 children.

**Results:** Chronic/recurrent cough was the commonest indication for FB in the 30 children enrolled (median age=3-years). Secretion amount and colour had the strongest correlation with BAL neutrophilia%, (r=0.409, p=0.025 and r=0.401, p=0.028 respectively). With inflammation defined as BAL neutrophilia >15%, the highest aROC (0.68, 95%CI 0.45-0.91) was obtained by tripling the secretion scores (amount and colour) and excluding pallor. aROC for the model derived from our retrospective study was 0.63 (95%CI 0.50-0.76). The highest aROC (0.86, 95%CI 0.71-1.00) was with neutrophils of >10% using the Bscore obtained by each of the 6 components.

**Conclusion:** A validated bronchoscopic defined bronchitis scoring system can be obtained from visualization of airway secretions (amount and colour) and mucosa appearances (erythema, ridging and oedema). Further data is however required.

**Grant Support:** KPE is funded by an Asia Pacific Society of Respiratory (APSR) Short-term Research/Training Scholarship. ABC funded by a NHMRC Practitioner Fellowship. Declaration of Interest statement: No conflict of interest.

**Primary Care/ Palliative Care/ Tobacco**

**TP 121**

**ASTHMA BEST PRACTICE (ABP): A NATIONAL ASTHMA EDUCATION PROGRAM CHANGING PRIMARY HEALTH CARE PRACTICE**

WICKING J1, GRIFFITH M1, BROPHY S1, CLEVELAND R1, FODERO L2, WHORLOW K1
1National Asthma Council Australia, and 2Health Consult Pty Ltd, Australia

**Introduction/Aim:** In 2001 the Australian Government funded the National Asthma Council Australia (NAC) to establish an ongoing, national asthma education program focused on providing best-practice asthma management guidelines to primary care professionals (PCHP). Aiming to reinforce and increase awareness of best-practice asthma management guidelines by PCHP through provision of peer education, via small group workshops across Australia.

**Methods:** An independent evaluator was appointed to assess program outcomes. Participants were asked to complete an evaluation survey. Follow-up telephone surveys were conducted with volunteer participants 6 months later to assess change in practice.

**Results:** From 2001-2016, 13,333 PHCP attended 828 workshops across Australia. The immediate post-workshop evaluation survey response rate was 78%. Across all workshop types, most respondents (91%) felt attending the workshop had increased their knowledge of evidence-based best practice, 89.4% increased their practical skills to support their application of evidence-based practice in asthma care, and 87% expected improvement in their asthma management practices.

The response rate of the 6-month follow-up survey in the 2013-2016 program was 22%. All responders reported they had ‘entirely’ or ‘partially’ retained knowledge from attending an NAC workshop. Confidence in exercising practical skills six-months post workshop ranged between 78%-97%, depending on skill area and workshop.

**Conclusion:** The ABP education program is a targeted, national program and a successful model for providing evidence-based asthma management guidelines and education to PCHP. It highlights a change in practice following participation.

**Grant Support:** N/A
ARE WE ASKING THE RIGHT QUESTIONS? USING DRAWINGS TO EXPLORE HEALTHCARE PROFESSIONALS’ AND PATIENTS’ PERCEPTIONS OF ASTHMA
CHEUNG M1, SAINI B1, SMITH L1
1The University of Sydney, Camperdown, Australia

Introduction/Aim: Differences between healthcare professionals’ (HCPs) and patients’ views of asthma can influence communication, rapport, treatment provision and consequently clinical and psychosocial outcomes. This study aimed to explore the alignment between HCPs’ and patients’ perceptions of asthma.

Methods: HCPs and adults with asthma independently participated in a one-on-one semi-structured interview which was followed by a creative expression exercise (drawing). A qualitative approach utilising a coding process was used to cluster thematic material. Data were compared between the HCP and patient transcripts and drawings. The HCPs were also shown drawings which were made by patients and feedback regarding their impressions were sought.

Results: HCPs’ drawings (N = 19) were clinically focussed and indicated little evidence of emotional content. In contrast, patients’ drawings and interviews (N = 18) highlighted the prominence of the emotional burden of asthma and its often profound impact on their lives. Of note, the HCP data showed minimal exploration of patients’ psychosocial experiences of being diagnosed with or managing asthma. HCPs revealed that patients would not offer information when it was not directly elicited, and that they frequently received a neutral response when they asked how patients were generally going with their asthma. When viewing the patients’ drawings, HCPs were often surprised by the intensity of the emotions portrayed and expressed that they found this exercise insightful.

Conclusion: HCPs can more effectively explore the patient’s perspective by asking targeted questions, as this may help to reduce patients’ psychological burden and engage them to take an active role in the management of their asthma. This also raises the issue of the expectations that both HCPs and patients have regarding what could be discussed during clinical encounters. Creative methods for eliciting patients’ lived experiences may offer a window into how asthma affects their lives personally.

Grant Support: Asthma Australia Mickie Hardy PhD Scholarship, Australian Government Research Training Program (RTF) scholarship

PALLIATIVE AND SYMPTOMATIC CARE OF PATIENTS WITH FIBROTIC INTERSTITIAL LUNG DISEASE
MANN J1,2, GUO H2, GOH N1,2, SMALLWOOD N3
1Austin Health, Melbourne, Australia, 2Institute of Breathing and Sleep, Melbourne, Australia, and 3The Royal Melbourne Hospital, Melbourne, Australia

Introduction: Fibrotic interstitial lung diseases (ILD) are often progressive and incurable with limited treatment options. Patients experience significant symptom burden with refractory dyspnoea and cough. Current guidelines recommend early palliative care referral.

Aim: To examine the end of life care delivered to fibrotic ILD patients during the terminal hospital admission.

Methods: A retrospective audit was performed for all patients who died from progression of fibrotic ILD, at two Australian teaching hospitals over 5 years from 2012 to 2016.

Results: Of 55 patients who died from fibrotic ILD, 37 (67%) had Idiopathic pulmonary fibrosis. Median age was 78 years and 30 (55%) were male. The average number of comorbid conditions was 4.7. Median respiratory function: FEV1 69.0% predicted (IQR 58.5-79.0%), FVC 64.0% predicted (IQR 58.5-79.0%), DLCO 36.5% predicted (IQR 31.0-45.0%). 37 (67%) patients were prescribed domiciliary oxygen. Prior to the terminal admission, 21 (38%) patients reported severe breathlessness (MMRC score: 3 or 4) and 16 (29%) used outpatient opioids for symptom relief. 25 (45%) patients received specialist palliative care and 18 (33%) had completed Advanced Care Planning.

During the terminal admission: 51 patients (93%) had their goal of care changed to comfort care. Nine patients (16%) were admitted directly under Specialist Palliative Care and 25 (54%) were subsequently referred. Palliative care referral occurred on average 1 day prior to death. 52 (95%) patients received inpatient opioids and 41 (75%) received benzodiazepines for symptom management. Median starting and final doses were 10mg to 20mg oral morphine equivalent/24hr; and 10mg to 12.5mg oral diazepam equivalent/24hr. These were commenced at 1 and 2 days prior to death respectively.

Conclusion: Although most ILD patients were identified as actively dying in the final admission, the referral to Palliative Care and commencement of palliative medications occurred just prior to death. Similarly the minority of patients accessed symptom palliation and palliative care earlier in their illness.

Grant Support: Nil
A NEW INTEGRATED RESPIRATORY AND PALLIATIVE CARE MODEL: PATIENTS/CARERS PERCEPTIONS
MORAN T1, THOMPSON M2, LE B3, IRVING L2, SMALLWOOD N2
1Melbourne Medical School, University of Melbourne, Melbourne, Australia, 2Department of Respiratory Medicine, Melbourne Health, Melbourne, Australia, and 3Department of Palliative & Supportive Care, Melbourne Health, Melbourne, Australia

Introduction/Aim: The Advanced Lung Disease Service (ALDS) is a unique, new model of integrated respiratory and palliative care for patients with advanced, non-malignant, lung disease.

Methods: All current ALDS patients and their carers were invited to complete an anonymous, confidential questionnaire with an independent researcher.

Results: Eighty-eight responses were received, from 24 carers and 64 (80.0%) of 80 eligible patients. Respondent patients’ median age was 75 years, 34 (53.1%) male, 25 (39.1%) lived alone and 58 (90.6%) had severe COPD. The median number of ALDS clinic visits was 9, and 52 (81.3%) patients saw both respiratory and palliative care staff in the clinic.

66 (75.0%) respondents rated the ALDS as excellent, 18 (20.5%) as very good and 85 (96.6%) would recommend the ALDS. 88 (100%) respondents found the ALDS helpful, with 87 (98.9%) feeling more confident managing their symptoms, and 87 (98.9%) reporting the ALDS team listened to them carefully.

Aspects of the ALDS which were important to respondents included: continuity of care from the same doctors and nurses - 82 (93.2%), long term care - 77 (87.5%), access to urgent clinic reviews - 63 (71.6%), and respiratory nurse home visits - 53 (60.2%).

Common themes were staff kindness and friendliness, optimal disease management, self-management education, and opportunities to discuss all aspects of care, including future care wishes.

Conclusion: ALDS patients and their carers express high levels of satisfaction with this model of integrated respiratory and palliative care.

Grant Support: n/a

Declaration of interest: No competing interests.

INVESTIGATION BURDEN IN PATIENTS WITH FIBROTIC INTERSTITIAL LUNG DISEASE IN THEIR TERMINAL ADMISSION
GUO H1, MANN J2,3, SMALLWOOD N1, GOH N2,3
1Royal Melbourne Hospital, Melbourne, Australia, 2Austin Health, Melbourne, Australia, and 3Institute for Breathing and Sleep, Melbourne, Australia

Introduction: The prognosis of fibrotic Interstitial Lung Disease (ILD), in particular idiopathic pulmonary fibrosis (IPF), is poor. Therefore referral to palliative care should be considered early. Patients may still be undergoing burdensome investigations despite being at the end of life.

Aim: To examine the number and types of investigations fibrotic ILD patients experience during their terminal hospital admission.

Methods: A retrospective audit was performed for all patients who died from fibrotic ILD, across two Australian teaching hospitals over 5 years from 2012 to 2016.

Results: Data from fifty-five patients were analysed; median age was 78 years (IQR=74-84 years), 30 (55%) were male and mean number of comorbid conditions was 4.7. Median respiratory function: FEV1 69.0% predicted (IQR=58.5-79.0%), FVC 64.0% predicted (IQR=48.0-76.5%) and DLCO 36.5% predicted (IQR=31.0-45.0%). 37 (67%) patients were prescribed domiciliary oxygen. 25 (45%) patients had previous specialist palliative care involvement.

During the final admission, the average length of stay was 4 days (IQR=2-9 days). For 51 (93%) patients the goal of care was changed to comfort care. Excluding ten patients who died within 24 hours of admission, referral to Palliative Care occurred on average 1 day prior to death. 6 (11%) patients underwent further tests after institution of comfort care.

The mean number of investigations ordered was associated with ICU admission, activation of the Medical Emergency Team response and admitting team, with significantly more investigations when admitted by General Medicine (17.4 tests/person), compared to Respiratory Medicine (9.8 tests/person) and Palliative Care (0.8 tests/person).

Conclusion: Most fibrotic ILD patients received appropriate palliation at the end of life in hospital, however, a significant minority continued to receive unnecessary and burdensome investigations after the decision for comfort care. Practices varied widely between treating units.

Grant Support: Nil
BACTERIAL COLONIZATION OF INDWELLING PLEURAL CATHETERS IN PATIENTS WITH MALIGNANT PLEURAL EFFUSIONS

RANDAZZO S1, AZZOPARDI M2,4, FYSH E1,2,4, THOMAS R1,4,5, LEE Y1,4,5
1School of Medicine and Pharmacology, University of Western Australia, Perth, Australia, 2Department of Respiratory Medicine, Sunshine Coast University Hospital, Birtinya, Australia, 3Respiratory Medicine Department, St John of God Midland Hospital, Perth, Australia, 4Respiratory Medicine Department, Sir Charles Gairdner Hospital, Perth, Australia, and 5Pleural Medicine Unit, Institute for Respiratory Health, Perth, Australia

Introduction/Aim: Indwelling pleural catheter (IPC) is increasingly used in malignant pleural effusion (MPE) care. IPCs often remain in situ for patients’ remaining life, hence bacterial colonization and/or pleural infection can occur. Separating colonization from infection can be challenging. This report is the first to provide clinical data on patients with bacterial colonization of IPCs.

Methods: All patients with MPEs treated with IPCs at our tertiary pleural unit between 26/8/2009 and 31/5/2015 were included. Pleural fluid cultures were collected routinely at clinic follow-up. Clinical and microbiological data up to the censor date (1/12/2016) was retrospectively reviewed. Definitions: Patients with bacterial colonization or infection had at least one pleural fluid culture yielding microbes. Patients included in the Infection Group (IG) had clinical features compatible with active infection and were treated with antibiotics. Those in the Colonization Group (CG) did not require antimicrobial treatment.

Results: 183 MPE patients had IPCs inserted: mean age 69.67% male, 59% right-sided. Of these 52 (28.4%) patients had positive pleural fluid cultures of which 38 (20.7%) were colonization and 14 (7.7%) were pleural infections. Median time to first positive culture was shorter in CG [18 (0-125) vs 97 (39-269) days in IG]. No pre-specified baseline criteria differentiated colonization from infection. Gram-positive organisms (76%) accounted for most cases of colonization. Coagulase-negative Staphylococci (55%), Propionibacterium species (18%) and mixed microbes (13%) were the commonest organisms. The CG has lower inflammatory indices in pleural fluid and blood (vs IG): median pH 7.26 vs 7.05; LDH 535 vs 1630 IU/L; glucose 2.3 vs 0.5 mmol/L; serum CRP 140 vs 150 IU/L and total blood leukocyte count 10 vs 12 x109/L.

Conclusion: Bacterial colonization can occur with IPC use and does not require treatment/eradication. Clinical judgement, blood and pleural fluid parameters can help distinguish colonization from active infection.

Grant Support: NHMRC and Cancer Council WA (RT & YCGL);
NSW Dust Diseases Board (YCGL); Sir Charles Gairdner RAG (YCGL);
Raine Foundation and WA Dept of Health (EF).

Declaration: Rocket Med Ltd has provided free IPC drainage kits for patients.

ELECTRONIC CIGARETTE AWARENESS, USE, AND PERCEPTION OF HARMFULNESS IN MIDDLE-AGED ADULTS: THE BUSSELTON BABY BOOMER STUDY

MUSK B1, HUNTER M2,3, LARCOMBE A3,4, HUI J1,2, JAMES A2,5
1School of Population and Global Health, University of Western Australia, Crawley, Australia, 2Busselton Population Medical Research Institute, Nadelands, Australia, 3Respiratory Environmental Health, Telethon Kids Institute, University of Western Australia, Subiaco, Australia, 4Occupation and Environment, School of Public Health, Curtin University, Perth, Australia, and 5Pulmonary Physiology, Sir Charles Gairdner Hospital, University of Western Australia, Nedlands, Australia

Introduction/Aim: Despite emerging evidence suggesting that chronic e-cigarette use may be harmful to lung development and function, information on contemporary public perception and knowledge about the safety and use of e-cigarettes among Australian adults is not well known. We aimed to assess; 1) awareness, 2) usage (ever or recent) and 3) perceived harmfulness of e-cigarettes among a community sample of middle-aged adults residing in Busselton, Western Australia.

Methods: Adults aged 51 – 71 years attending phase II of the longitudinal Busselton Baby Boomer Study in 2016/17 completed e-cigarette-related items from the US National Tobacco Survey (NATS) 2013-2014 questionnaire.

Results: E-cigarette awareness among 812 Baby boomers surveyed (46.6% never smokers, 48.5% ex-smokers, 4.9% current smokers) was high with over 80% of respondents having heard of them and 30% of current smokers indicating they had tried them. However current or recent usage of e-cigarettes among adult smokers was low with only 3% reporting use over the last 30 days. Over 30% of current smokers believed e-cigarettes were less harmful than regular cigarettes compared with 16% of never- or ex-smokers. 15% of all respondents believed e-cigarettes were equally or more harmful than regular cigarettes. Over 60% of Baby boomer felt they did not know enough information about e-cigarettes to compare harmfulness with regular cigarettes.

Conclusion: These results indicate that despite the sale of e-cigarettes being illegal in Western Australia a high number (1 in 3) of middle-aged smokers have tried e-cigarettes on at least one occasion. Recent or regular use of e-cigarettes among adult smokers in Busselton however is low, possibly reflecting State Government restrictions on sale and supply. The higher prevalence of lower perceived harmfulness of e-cigarettes among current smokers coupled with emerging evidence showing adverse effects on lung function suggest public education campaigns on e-cigarette safety may be warranted.

Grant Support: The Busselton Baby Boomer Study is supported by grants from the WA Government Office of Science and Department of Health.
1Department of Psychology, West Virginia University, Morgantown, USA, 2Nemours/Alfred I. duPont Hospital for Children, Wilmington, USA, and 3West Virginia University Health Sciences Center, Department of Pediatrics, Morgantown USA

Introduction/Aim: The use of electronic cigarettes (e-cigs) among U.S. adolescents has tripled in recent years; however, there is limited research on parent and youth information management strategies (i.e., monitoring, control, knowledge, solicitation, disclosure, and secrecy) as they relate to this use. The current study uses a profile-based analytic procedure (cluster analysis) to explore patterns among these variables and investigate relations to adolescent e-cig use.

Methods: A total of 569 students (ages 13-18) were recruited from four high schools and one adolescent clinic in rural and suburban areas in Ohio, Pennsylvania, and West Virginia. Participants completed the Youth Behavior Risk Survey (YRBS) to assess tobacco use, and measures of parent and youth information management. Responses resulted in 223 youth (Mage = 16.25, SD = 1.16) identified as e-cig users. User status was defined as any use, even one puff, in the student’s lifetime. Analyses include hierarchical and k-means cluster analyses, chi-squares with post-hoc testing, ANOVA, and MANOVA procedures.

Results: Consistent with current literature, 57% (n = 127) of students identified as a dual user (e-cigs & conventional cigarettes) and 43% (n = 96) were identified as e-cig only user. A preliminary cluster analysis suggested a four-cluster solution, with each cluster representing significantly different combinations of parental and youth strategies. User group was found to be significantly related to cluster profile, \( \chi^2(3) = 15.92, p < .001 \), such that patterns of strategies for users particularly related to youth secrecy, youth disclosure, and parental knowledge.

Conclusion: Results suggest the potential of bidirectional associations between parental and youth information management strategies and differences in profiles for e-cig and dual users. These findings have the potential to clarify policy, particularly regarding eliciting parent help in reducing e-cig use among adolescents. Results also have the potential to inform youth-focused education and preventative efforts.

Grant Funding: None.

Expected costs and benefits mediates the relation between peer use and self-reported use of electronic cigarettes in adolescents

WILLIFORD D1, ENLOW P2, DURKIN K1, MANEGOLD E1, BANVARD-FOX C3, MURRAY P3, DUNCAN C1

1Department of Psychology, West Virginia University, Morgantown, USA, 2Nemours/Alfred I. duPont Hospital for Children, Wilmington, USA, and 3West Virginia University Health Sciences Center, Department of Pediatrics, Morgantown USA

Introduction/Aim: Preliminary research has identified peer use as a salient risk factor of adolescent e-cigarette use, but have not expanded on the mechanism of this association. The aim of this study is to examine a mediation model of the effect of adolescent expectations of benefits and costs of e-cigarette use on the relation between peer- and self-reported e-cigarette use.

Methods: For this study, 569 adolescents (Ages 13-18, M = 15.96, SD = 1.38; 43% male) were recruited from an adolescent medicine clinic and schools in rural and suburban areas of the mid-Atlantic U.S. Participants completed the Youth Behavior Risk Survey (YRBS) to assess e-cigarette use, and the Smoking Expectancy Scale for Adolescents (SESA) to measure beliefs about the potential consequences of e-cigarette use. Mediation analyses were conducted in SPSS utilizing the PROCESS version 2.15 add-on (Hayes, 2013).

Results: An analysis of direct and indirect effects demonstrates that peer use has a significant direct effect on self-reported use of e-cigarettes \( b = -.850, p < .05 \). Benefits had an indirect effect of self-reported use, \( b = -.071, 95\% CI [-.118, -.035] \). Costs had an indirect effect of self-reported use, \( b = -.134, 95\% CI [-.197, -.077] \). The effect of the mediator indicates that increased report of costs is associated with a 27% increased rate of being in the non-user group and that an increased report of costs is associated with a 58% reduced chance of being in the non-user group and that an increased report of costs is associated with a 27% increased rate of being in the non-user group.

Conclusion: These findings support previous research claims that peer use is a significant risk factor for adolescent e-cigarette use and adds to the literature by suggesting that expectations about consequences of e-cigarette use (perceived costs and benefits) may play an important role in the association between peer and self-reported use. Additionally, this study informs future targeted strategies (e.g., social pressures or perceptions) to reduce youth e-cigarette use.

Grant Support: Not applicable
‘CIGARETTES OR E-CIGARETTES?’: A SURVEY OF YOUNG AUSTRALIANS ATTITUDES AND PERCEPTIONS OF EMERGING TOBACCO PRODUCTS

BOZIER J1,2, OLIVER B1,2, FOSTER J1,2
1University of Technology Sydney, Sydney, Australia, and 2Woolcock Institute of Medical Research, University of Sydney, Sydney, Australia

Introduction/Aim: Young people are thought more likely to use electronic cigarettes (e-cigarettes) than adults, but their reasons for uptake and their attitudes toward e-cigarette safety and regulation are unknown. This study aimed to explore this.

Methods: An online survey was conducted among Australians aged 18-30 years, recruited through university mailing lists and social media pages. Participants were asked questions about how they first heard of e-cigarettes, the perceived safety of e-cigarettes and the regulations surrounding e-cigarette use.

Results: 124 participants (73% Female, Mean age 21.2 (SD=2.60) years, 95.2% University students) completed the survey, of whom 27% were past/current e-cigarette users and 32% were past/current tobacco cigarette smokers. Participants most commonly reported that their first exposure to e-cigarettes was via social media (56%), friends (54%) and/or the internet (48%). Among past/present users, the most common reason for initiating e-cigarette use was curiosity (94%), friends using them (36%) and/or considering them better for health than tobacco cigarettes (27%). Indeed, 85% of all respondents thought nicotine e-cigarettes had lower health risk than tobacco cigarettes and only half (55%) thought nicotine e-cigarettes could cause similar damage to their lungs. Moreover 53% of participants thought cannabis and 57% thought fast food carried less risk than nicotine e-cigarettes. More respondents agreed nicotine e-cigarettes are bad for your health than non-nicotine e-cigarettes (76% vs 33%). A number of respondents thought e-cigarettes could be used in places where they are currently banned in Australia, such as outdoor dining areas (24%).

Conclusion: Many young people consider e-cigarettes comparatively safe, with lower health risks than smoking, cannabis or fast food. They consider non-nicotine e-cigarettes safer than nicotine e-cigarettes, though current evidence contradicts this. The lack of understanding of potential health risks indicates the poor public health communication and confusion around e-cigarettes which must be urgently addressed.

Grant Support: None

SHORT ACTING BETA AGONIST OVERUSE: AN UNACKNOWLEDGED/MASKED PROBLEM IN AUSTRALIA

AZZI E1, SROUR P1, PETERS M2, KRIKIKOS V1,3, PRICE D4, BOSNIC-ANTICEVICH S1,2
1Woolcock Institute Of Medical Research, University of Sydney, Glebe, Australia, 2Department of Respiratory Medicine, Concord Hospital, Macquarie University, Sydney, Australia, 3Sydney Local Health District, Sydney, Australia, 4Centre of Academic Primary Care, University of Aberdeen, Aberdeen, UK

Introduction/Aim: Research shows that in Australia, approximately 50% of people with asthma are poorly controlled; with overuse of short-Acting Beta Agonist (SABA) being reported. The drivers for overuse of SABA and the interactions between patients and treatable traits in Australia where SABA are available over the counter, is unknown, however, may hold the key to the unsatisfactorily high level of poorly controlled asthma. The aim of this study is to identify and characterise the clinical asthma status, behaviour and attitudinal clusters and patterns of SABA use in the asthma population.

Methods: In this observational study data was collected from people who purchased SABA in the pharmacy along the following domains: asthma control, medication use and side effects, comorbidities, smoking status, action plan ownership, device use, healthcare utilisation. Inclusion criteria was a SABA user over 18 who could self-complete the questionnaire.

Results: Data from 154 community base pharmacy patients were collected, mean age 43.1 (+/- 1.42), with an equal distribution of males and females (51%). Twenty percent had good control and 64 % self-reported good control. The mean number of SABA inhalations used per week was 1-4 puffs, three or more times a week, the proportion of SABA users who reported using a preventer every day was 30%, however 62% acknowledged being prescribed one. Fifty-four percent reported that they have never had their inhaler technique checked by a HCP. There was a statistically significant difference between patients who used preventer versus those who only used SABA in regards to asthma symptom control (p<0.001).

Conclusion: Twenty percent of people using SABA have never had a diagnosis of asthma; 70% have had it confirmed with spirometry. Patients are taking advantage of OTC availability of SABA and this preliminary data suggests that they self-medicate/manage in ways which puts a high proportion of them at risk.
CLINICAL CHARACTERISTICS OF DYSFUNCTIONAL BREATHING IN DIFFICULT ASTHMA

DENTON E1, BONDARENKO J2, HEW M1
1Respiratory Medicine, Alfred Hospital, Melbourne, Australia, and 2Physiotherapy Department, Alfred Hospital, Melbourne, Australia

Introduction/Aim: Dysfunctional breathing (DB) is poorly defined, common in asthma patients and confers worse asthma control and quality of life. Little is known about the phenotypes of asthma patients with DB and we aimed to describe the clinical characteristics of dysfunctional breathers in a difficult asthma cohort to help better define this group.

Methods: Consecutive patients with DB undergoing physiotherapy assessment and breathing retraining referred from the difficult asthma clinic at a university teaching hospital were identified. Asthma control, quality of life and comorbidities were examined. These patients were also evaluated for the presence of common DB features including mouth breathing, thoracic dominance, hyperventilation, musculoskeletal and postural abnormalities. Pre- and post- Nijmegen questionnaires were performed.

Results: Of the 29 patients, 59% were female with mean age 49 years, BMI 31 and FEV1 71% predicted. Asthma control was poor at baseline with mean of 3.1 severe exacerbations in the 6 months prior to review and ACO6 2.4, and quality of life was poor with mean AQLQ 3.9. Comorbidities were common including a psychiatric history in 62% and vocal cord dysfunction in 66%. Mean baseline Nijmegen scores was 28.8. On assessment of breathing pattern thoracic dominance was the most common form of DB, present in 86%. Mouth breathing was present in 28%, hyperventilation 45%, spinal abnormalities 10%, abnormal neck position 10% and scalene muscle use at rest in 24%. All underwent breathing retraining and 59% responded with significant improvement in symptoms and/or reduction in asthma medication requirements. Of those with data available (n=6) there was a significant improvement in mean Nijmegen score post breathing retraining (21.5, p=0.006).

Conclusion: Thoracic dominance is the commonest phenotype seen in the difficult asthma population with DB however this overlaps significantly with mouth breathing and hyperventilation. Postural and musculoskeletal abnormalities are common. The majority of patients responded to breathing retraining.

Grant Support: Nil funding
FVC RESPONSE TO TIOTROPIUM RESPIMAT® IN ADULTS WITH SYMPTOMATIC ASTHMA

FRITH P1, HALPIN D2, MORONI-ZENTGRAF P3, VAN HECKE B3, SIGMUND R4, KERSTJENS H5

1Repatriation General Hospital And Flinders Medical Centre, Adelaide, Australia, 2Royal Devon and Exeter Hospital, University of Exeter Medical School, Exeter, UK, 3Boehringer Ingelheim Pty Ltd, Australia, 4Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riss, Germany, 5Department of Pulmonary Medicine and Tuberculosis, and Groningen Research Institute for Asthma and COPD, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands

Introduction/Aim: To investigate the impact of tiotropium Respimat® (tioR) treatment on different measures of lung function in adult patients with symptomatic asthma across different severities.

Methods: Lung function data from 5 Phase III clinical trials, namely, pooled PrimoTinA-asthma® (severe asthma: 2x48-week, tioR5 μg/placebo, once-daily [QD], added-on to inhaled corticosteroid [ICS] ≥800 μg budesonide/equivalent + long-acting β2-agonist/C6 additional controller medications), pooled MezzoTinA-asthma® (moderate asthma: 2x24-week, tioR2.5 μg/tioR5 μg/placebo QD, added-on to ICS 400–800 μg budesonide/equivalent) and GraziaTinA-asthma® (mild asthma: 12-week, tioR2.5 μg/tioR5 μg/placebo QD, added-on to ICS 200–400 μg budesonide/equivalent) were compared in this post hoc analysis.

Results: TioR provided significant improvements in peak FEV1(0–3h) and trough FEV1 versus placebo in severe (Week 24), moderate (Week 24) and mild (Week 12) asthma (Table). Peak and trough FVC were significantly improved with tioR versus placebo in the severe and moderate groups (Week 24). In patients with mild asthma, FVC improvements following tioR versus placebo were generally smaller; statistical significance was reached for tioR2.5 μg (Week 12).

Conclusion: TioR as add-on to maintenance asthma therapy improves FEV1 and FVC with a greater impact in patients with more severe asthma, possibly due to airway remodelling and hyperinflation seen in more severe persistent disease.

Table 1

<table>
<thead>
<tr>
<th>Lung function analyses</th>
<th>tioR5 μg Adjusted mean difference from placebo, mL(95%CI)</th>
<th>tioR2.5 μg Adjusted mean difference from placebo, mL(95%CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PrimoTinA-asthma® (severe): N=907</td>
<td>Peak FEV1 110(63, 158)***</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Trough FEV1 93(60, 137)***</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Peak FVC 87(26, 148)*</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Trough FVC 118(62, 175)***</td>
<td>-</td>
</tr>
<tr>
<td>MezzoTinA-asthma® (moderate): N=2081</td>
<td>Peak FEV1 185(146, 223)***</td>
<td>223(185, 262)***</td>
</tr>
<tr>
<td></td>
<td>Trough FEV1 146(105, 188)***</td>
<td>180(138, 221)***</td>
</tr>
<tr>
<td></td>
<td>Peak FVC 95(53, 138)***</td>
<td>141(98, 183)***</td>
</tr>
<tr>
<td></td>
<td>Trough FVC 80(35, 125)***</td>
<td>107(62, 152)***</td>
</tr>
<tr>
<td>GraziaTinA-asthma® (mild): N=464</td>
<td>Peak FEV1 128(57, 199)***</td>
<td>159(88, 230)***</td>
</tr>
<tr>
<td></td>
<td>Trough FEV1 122(49, 194)***</td>
<td>110(38, 182)***</td>
</tr>
<tr>
<td></td>
<td>Peak FVC 57(−25, 140)</td>
<td>106(23, 188)*</td>
</tr>
<tr>
<td></td>
<td>Trough FVC 66(−19, 151)</td>
<td>98(13, 183)*</td>
</tr>
</tbody>
</table>

***p<0.0001; **p<0.001; *p<0.05
Results at 1Week 24 and 2Week 12

Grant Support: Funding by Boehringer Ingelheim

Declaration of Interest Statement: PF has received in the past 5 years honoraria for educational and advisory board involvement and/or received conference attendance support for the following: Global Initiative for COPD (GOLD), Improvement Foundation, Lung Foundation Australia, and Remedy Healthcare and AstraZeneca, Boehringer Ingelheim, CSL-Behring, GlaxoSmithKline, Menarini, Mundipharma and Novartis. DH has previously received honoraria for speaking and consultancy from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, InterMune, Napp, Novartis, Nycomed, MSD and Pfizer. PM-Z, BVH and RS are employees of Boehringer Ingelheim. HAK, on behalf of his institution, has received payment for lectures from Boehringer Ingelheim and Pfizer, support from Pfizer, Almirall, GlaxoSmithKline, Takeda, Novartis, Nycomed and Chiesi for his service on advisory boards and from Pfizer, Almirall, GlaxoSmithKline, Novartis, Nycomed, Chiesi, AstraZeneca and Protalinf for consulting work.
"[SEVERE ASTHMA] IS CONSTANTLY WITH ME... EVERY DAY IS A BIT OF A STRUGGLE" A QUALITATIVE STUDY OF PEOPLE’S EXPERIENCES OF LIVING WITH SEVERE ASTHMA

EASSEY D1, REDDEL H2, RYAN K3, SMITH L1
1Faculty of Pharmacy, The University of Sydney, Australia, 2Woolcock Institute of Medical Research, The University of Sydney, Australia, and 3School of Pharmacy, University of Reading, UK

Introduction/Aim: Severe asthma is diagnosed when high doses of conventional treatment are required to prevent it from becoming uncontrolled or it remains uncontrolled despite such treatment and good patient adherence. There is a considerable body of literature on the clinical management of severe asthma, yet there is little empirical data on how it affects patients’ lived experience. We aimed to explore the personal experiences of people living with severe asthma.

Methods: Rigorous qualitative research methods using in-depth semi-structured interviews, collected by maximum sampling variation. Participants were included if they were >18 years old and diagnosed with severe asthma. Participants were asked to give a narrative of their experience living and managing severe asthma. Interviews were mainly conducted in participants’ homes and were video recorded. The data were transcribed and coded into categories and themes. These categories and themes were based on areas that were identified by the participants as important to them.

Results: From twenty-one interviews, our findings revealed that, for most participants, living with severe asthma affects their physical and mental health, relationships with family and friends, and limits work and activities. Participants wrestled with everyday decisions such as taking life-saving medications in the face of experiencing often debilitating side effects. Notably, for some people, their views and understanding of what their respiratory condition meant to them did not align with the diagnostic ‘label’ of severe asthma.

Conclusion: Barriers to self-management of severe asthma include taking medications and communication with healthcare providers. Healthcare providers need to know what people living with severe asthma understand about their condition, how they attempt to self-manage and address their concerns. This could potentially be a barrier to seeking appropriate care.

Grant Support: Seed Grant from the NHMRC Centre for Research Excellence in Severe Asthma.

Declaration of Interest: None.
PEF DIURNAL VARIABILITY WITH TIOTROPIUM RESPIMAT® IN SYMPTOMATIC ADULT ASTHMA

DAVIES H1, AALBERS R1, CASALE T2, MORONI-ZENTGRAF P3, VAN HECKE B4, SIGMUND R2, KERSTJENS H5
1 Repatriation General Hospital and Flinders Medical Centre, Adelaide, Australia, 2 Martini Hospital, Groningen, Netherlands, 3 University of South Florida, USA, 4 Boehringer Ingelheim Pty Ltd, Australia, 5 Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riss, Germany, and 6 Department of Pulmonary Medicine and Tuberculosis, and Groningen Research Institute for Asthma and COPD, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands

Introduction/Aim: We investigated diurnal variability in peak expiratory flow (PEF) following add-on treatment with tiotropium Respimat® (tioR), delivered as two puffs once daily (QD) across asthma severities.

Methods: Post hoc analysis of PEF diurnal variability from 5 Phase III trials was conducted: PrimoTinA-asthma® (pooled 2x48-week trials, tiotropium tioR5μg/placebo QD [morning], added onto maintenance inhaled corticosteroids [ICS]≥800μg budesonide/equivalent+long-acting β-agonists+additional controller medications); MezzoTinA-asthma® (pooled 2x24-week trials, tiotropium tioR2.5μg/placebo QD [evening], added onto maintenance ICS 400–800μg budesonide/equivalent); and GraziaTinA-asthma® (12-week trial, tiotropium tioR2.5μg/placebo QD [evening], added onto maintenance ICS 200–400μg budesonide/equivalent).

Pre-dose PEF was self-monitored at home using the asthma monitor AM2+®.

Results: TioR improved morning and evening PEF in all studies. Mean baseline PEF variability was 14.14%, 13.51% and 12.08% in Severe, Moderate and Mild asthma, respectively. Adjusted mean changes from baseline in PEF variability at Week 24 for tioR2.5μg/placebo were small (Table). Pre-dose PEF was self-monitored at home using the asthma monitor AM2+®.

Conclusion: The differences between tioR and placebo were generally not statistically significant across asthma severities.

Grant Support: The study was funded by Boehringer Ingelheim.

Declaration of Interest Statement: HD is a staff consultant in Respiratory and Sleep Medicine at the Repatriation General Hospital and Flinders Medical Centre, RA has received speaker fees from AstraZeneca, Boehringer Ingelheim and Chiesi. TC reports grants and personal fees from Boehringer Ingelheim, outside the submitted work. PM-Z, BVH, and RS are employees of Boehringer Ingelheim. HAK, on behalf of his institution, has received payment for lectures from Boehringer Ingelheim and Pfizer, support from Pfizer, Almirall, GlaxoSmithKline, Takeda, Novartis, Nycomed and Chiesi for his service on advisory boards and from Pfizer, Almirall, GlaxoSmithKline, Novartis, Nycomed, Chiesi, AstraZeneca and Protalinn for consulting work.

Table 1

<table>
<thead>
<tr>
<th>Study (Asthma severity, Treatment duration)</th>
<th>N</th>
<th>Change in PEF diurnal variability*, % adjusted mean±SEM</th>
<th>Treatment versus placebo, adjusted mean difference±SEM (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PrimoTinA-asthma® (Severe, 24 weeks)</td>
<td>453</td>
<td>−0.33±0.35</td>
<td>0.54±0.50 (−0.44, 1.51)</td>
</tr>
<tr>
<td>tioR5μg</td>
<td>453</td>
<td>−0.67±0.35</td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>454</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MezzoTinA-asthma® (Moderate, 24 weeks)</td>
<td>513</td>
<td>−0.32±0.30</td>
<td>0.70±0.43 (−0.15, 1.54)</td>
</tr>
<tr>
<td>tioR5μg</td>
<td>513</td>
<td>−1.78±0.30</td>
<td>−0.77±0.43 (−1.61, 0.07)</td>
</tr>
<tr>
<td>Placebo</td>
<td>518</td>
<td>−1.01±0.30</td>
<td></td>
</tr>
<tr>
<td>GraziaTinA-asthma® (Mild, 12 weeks)</td>
<td>155</td>
<td>−0.37±0.52</td>
<td>0.15±0.72 (−1.26, 1.56)</td>
</tr>
<tr>
<td>tioR5μg</td>
<td>155</td>
<td>−0.52±0.52</td>
<td>&lt;0.01±0.72 (−1.41, 1.42)</td>
</tr>
<tr>
<td>Placebo</td>
<td>155</td>
<td>−0.62±0.51</td>
<td></td>
</tr>
</tbody>
</table>

*Absolute difference between morning and evening PEF divided by mean of the two values
LOW-DOSE MEPOLIZUMAB EFFECTIVELY TREATS CHRONIC RELAPSING EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
THOMPSON G1, VASILEVSKI N2, RYAN M2, BALTIC S2,3, THOMPSON P2,3,4
1Department of Immunology Sir Charles Gairdner Hospital, Nedlands, Australia, 2The Lung Health Clinic, Hollywood Hospital, Nedlands , Australia, 3The Institute of Respiratory Medicine, University of Western Australia, Nedlands, Australia, and 4Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, Australia

Introduction/Aim: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare systemic vasculitis characterised by asthma, eosinophilia and multi organ disease. In its chronic form long term oral steroid treatment is required. Early evidence suggests Mepolizumab, a monoclonal antibody directed against IL5, may be a useful treatment. A single randomised placebo control trial has shown efficacy for 50% of patients treated with 300mg of Mepolizumab 4 weekly, subcutaneously. We sought to determine the efficacy of 100mg of Mepolizumab in a cohort of patients with chronic relapsing EGPA.

Methods: Six patients with a long term diagnosis (mean 10.7 years) of EGPA (American College of Rheumatology Criteria) who were unable to wean off prednisolone due to multiple episodes of relapse were treated with 100mg of Mepolizumab 4 weekly over a period of 9-11 months. Patients were monitored 4 weekly by asthma control questionnaire (ACQ), clinical review, eosinophil counts, spirometry, exhaled nitric oxide (ExNO) and respiratory resistance using a Forced Oscillometry Technique (FOT). Prednisolone doses were tapered after three months according to clinician discretion.

Results: Pre-treatment, the average prednisolone dose was: 9 mg/day. All patients responded to Mepolizumab and were successfully weaned off prednisolone after 4 to 9 months. Eosinophils fell from an average of 0.7 x 10^9/L to 0.1 x 10^9/L and ExNO fell from 48 ppb to 23 ppb. FEV1 (% predicted) improved by 12% from baseline and airway resistance (FOT R5) improved from 185% to 127%. ACQ improved from a baseline reading of 2.9 to 0.3. There were no episodes of disease relapse, all patients reported improving clinically and Mepolizumab was well tolerated by all.

Conclusion: Mepolizumab therapy is a safe and efficacious therapy for patients with chronic relapsing EGPA at doses of 100mg 4 weekly. Mepolizumab is a more targeted immunomodulatory therapy allowing chronic patients to discontinue and avoid the long term complications of steroid therapy.

Conflict of Interest: No conflicts of interest

ASTHMA MEDICATION MANAGEMENT PRACTICES: UNDERSTANDING THE INFLUENCES ON PARENTS WHEN CARING FOR CHILDREN WITH ASTHMA
SROUR P1, AZZI E1, CVETKOVI SK B1, CHEONG L2, RAND C2, BOSNIC-ANTICEVICH S1
1Woolcock Institute of Medical Research, Sydney Medical School, University of Sydney, Sydney, Australia, 2Faculty of Health, University of Canberra, Canberra, Australia, and 3Pulmonary and Critical Care Medicine Department, John Hopkins University, Baltimore, USA

Introduction: Preliminary research has indicated that parents consult with a range of health care professionals (HCPs) and lay contacts when considering the medication management of their children with asthma; with a preference for general practitioners (GPs), family and spouses. It remains unknown however as to why parents choose specific connections and on what basis parents selected specific sources for health advice. Further, it is unknown as to how parent’s non-HCP advisor’s may impact on the support parents seek or receive advice from HCPs.

Objective: The overall aim of this study was to explore the key elements contributing to the nature and development of parent’s health connections with regards to the management of their children’s asthma medications.

Methods: In-depth, semi structured interviews were conducted with parents of children (aged 4 to 18 years) with asthma (self-reported) from Sydney, Australia. Participants were recruited from several points including asthma clinics, general practice clinics and community pharmacies. Face-to-face interviews were audio recorded, transcribed verbatim, independently reviewed by three authors and analysed using a qualitative approach.

Results: A total of 26 interviews were conducted. Parents established a combination of HCP, personal and impersonal health connections around their perceptions of their children’s medication needs and for advice and support. These needs were based on the provision of effective medications, including their ongoing management and education, regular monitoring of symptoms and physical and emotional support. Parent’s trust in relationships, their circumstances at a present time, the convenience of health advice and their perceptions of the role of specific health connections in the management of their children’s medications contribute towards the nature and development of parent’s health networks.

Conclusion: This research has provided a greater understanding of the dynamics of parent’s health connections and their potential impact on children’s asthma management.
IN PAEDIATRIC ASTHMATIC SUBJECTS, DAY-TO-DAY VARIABILITY IN HOME-BASED FORCED OSCILLATION TECHNIQUE (FOT) MONITORING IS INCREASED IN SUBJECTS EXPERIENCING EXACERBATIONS

WONG A1, HARDAKER K1,2, FIELD P1, FITZGERALD D1,2, JAYASURIYA G1,2, SELVARADH I1,2, KING G3,4, ROBINSON P1,2,3
1Department of Respiratory Medicine, The Children’s Hospital at Westmead, Sydney, Australia, 2Discipline of Pediatrics and Child Health, Sydney Medical School, University of Sydney, Sydney, Australia, 3Airway Physiology and Imaging Group, Woolcock Medical Research Institute, Sydney, Australia, and 4Respiratory Medicine, Royal North Shore Hospital, St Leonards, Sydney, Australia

Introduction/Aim: Objective tools for monitoring childhood asthma are urgently required, yet conventional lung function tests (e.g. spirometry, peak flow) are limited in this setting by their effort-dependent nature and limited insight into asthma control. The Forced Oscillation Technique (FOT) is a novel test, performed during tidal breathing, assessing airway calibre and lung stiffness by measuring airway resistance (Rrs) and reactance (Xrs), respectively. In this study we sought to extend previously published utility of physician-supervised FOT day-to-day variability in the asthma camp setting1 by examining these relationships with asthma control and exacerbations in the parent-supervised home setting over a longer period.

Methods: Asthmatic children (8-18 years) with asthma exacerbations over the preceding year are being recruited from tertiary hospital respiratory clinics (total intended n=25). Following FOT training and device (te-moFloTM, Thorasys Ltd, Canada) set-up in the child’s home, daily FOT was collected over 3-4 months. Rrs and Xrs dy-to-day variability was calculated (as Coefficient of variation, CoV) and compared between and within subjects. Asthma symptoms, control and quality-of-life questionnaires were performed at regular intervals. Medication adherence was assessed using Smartinhalers™ (Adherium, New Zealand).

Results: Recruitment and data collection is ongoing: 12/12 completed home-based monitoring to date. Feasibility rates >90% have been achieved across several subjects. Data collected have highlighted: (1) ability to detect exacerbations, (2) increased day-to-day Rrs and Xrs variability in brittle asthma, compared to well-controlled asthma (R5: CoV 33% vs 17.4%; X5: CoV 41% vs 33%) and (3) detrimental impact of asthma preventer medication non-adherence on day-to-day variability in the asthma camp setting1 by examining these relationships with asthma control and exacerbations in the parent-supervised home setting over a longer period.

Conclusion: Home-based day-to-day FOT variability, under parental supervision, is feasible and observations during initial data collection support potential clinical utility of this approach in paediatric asthma. Ongoing data collection will seek to confirm the above patterns in other subjects.

REFERENCE

Severe eosinophilic asthma in Australia: the Australian Mepolizumab Registry

Harvey E1,2, Langston D, Upham J, Hew M, Rimmer J, Chung L1, Katerlasis G, James A, Gibson P1,2
1Department of Respiratory and Sleep Medicine, John Hunter Hospital, New Lambton Heights, Australia, 2School of Medicine and Public Health, The University of Newcastle, New Lambton Heights, Australia, 3Department of Thoracic Medicine, Frankston Hospital, Frankston, Australia, 4Department of Respiratory Medicine, Princess Alexandra Hospital, Woolloongabba, Australia, 5Allergy, Asthma & Clinical Immunology, Alfred Health, Melbourne, Australia, 6St Vincent’s Clinic, Darlinghurst, Australia, 7Department of Respiratory Medicine, Fiona Stanley Hospital, Murdoch, Australia, 8Department of Respiratory and Sleep Medicine, Campbelltown Hospital, Campbelltown, Australia, and 9Department of Pulmonary Physiology and Sleep Medicine, Sir Charles Gairdner Hospital, Perth, Australia

Introduction/Aim: Mepolizumab is a monoclonal anti-interleukin 5 antibody for the treatment of severe eosinophilic asthma. Aim: to describe the baseline characteristics and clinical responses of patients treated with mepolizumab and entered in the Australian Mepolizumab Registry (AMR).

Methods: AMR, a multi-centre web-based post-marketing surveillance registry, was established to characterise the use, efficacy and adverse effects of mepolizumab (NUCALA) for the treatment of severe eosinophilic asthma. Patients with severe eosinophilic asthma who were prescribed mepolizumab were characterised prior to the commencement of therapy and at predetermined 4 and 7 month follow-up visits.

Results: Of 46 patients registered, the median(Q1,Q3) age was 58 (53,65) years, 23 were male and 61% were never smokers. They had a mean pre-bronchodilator FEV1 %predicted 55.1 58 (53,65) years, 23 were male and 61% were never smokers. They had a mean pre-bronchodilator FEV1 %predicted 55.1 58 (53,65) years, 23 were male and 61% were never smokers. They had a mean pre-bronchodilator FEV1 %predicted 55.1 58 (53,65) years, 23 were male and 61% were never smokers. They had a mean pre-bronchodilator FEV1 %predicted 55.1 58 (53,65) years, 23 were male and 61% were never smokers. They had a mean pre-bronchodilator FEV1 %predicted 55.1 58 (53,65) years, 23 were male and 61% were never smokers. They had a mean pre-bronchodilator FEV1 %predicted 55.1 58 (53,65) years, 23 were male and 61% were never smokers. They had a mean pre-bronchodilator FEV1 %predicted 55.1 58 (53,65) years, 23 were male and 61% were never smokers. They had a mean pre-bronchodilator FEV1 %predicted 55.1 58 (53,65) years, 23 were male and 61% were never smokers. They had a mean pre-bronchodilator FEV1 %predicted 55.1 58 (53,65) years, 23 were male and 61% were never smokers. They had a mean pre-bronchodilator FEV1 %predicted 55.1 58 (53,65) years, 23 were male and 61% were never smokers. They had a mean pre-bronchodilator FEV1 %predicted 55.1 58 (53,65) years, 23 were male and 61% were never smokers. They had a mean pre-bronchodilator FEV1 %predicted 55.1 58 (53,65) years, 23 were male and 61% were never smokers. They had a mean pre-bronchodilator FEV1 %predicted 55.1 58 (53,65) years, 23 were male and 61% were never smokers. They had a mean pre-bronchodilator FEV1 %predicted 55.1 58 (53,65) years, 23 were male and 61% were never smokers. They had a mean pre-bronchodilator FEV1 %predicted 55.1 58 (53,65) years, 23 were male and 61% were never smokers. They had a mean pre-bronchodilator FEV1 %predicted 55.1 58 (53,65) years, 23 were male and 61% were never smokers. They had a mean pre-bronchodilator FEV1 %predicted 55.1 58 (53,65) years, 23 were male and 61% were never smokers. They had a mean pre-bronchodilator FEV1 %predicted 55.1 58 (53,65) years, 23 were male and 61% were never smokers. They had a mean pre-bronchodilator FEV1 %predicted 55.1 58 (53,65) years, 23 were male and 61% were never smokers. They had a mean pre-bronchodilator FEV1 %predicted 55.1 58 (53,65) years, 23 were male and 61% were never smokers. They had a mean pre-bronchodilator FEV1 %predicted 55.1 58 (53,65) years, 23 were male and 61% were never smokers. They had a mean pre-bronchodilator FEV1 %predicted 55.1 58 (53,65) years, 23 were male and 61% were never smokers. They had a mean pre-bronchodilator FEV1 %predicted 55.1 58 (53,65) years, 23 were male and 61% were never smokers. They had a mean pre-bronchodilator FEV1 %predicted 55.1 58 (53,65) years, 23 were male and 61% were never smokers. They had a mean pre-bronchodilator FEV1 %predicted 55.1 58 (53,65) years, 23 were male and 61% were never smokers. They had a mean pre-bronchodilator FEV1 %predicted 55.1 58 (53,65) years, 23 were male and 61% were never smokers. They had a mean pre-bronchodilator FEV1 %predicted 55.1 58 (53,65) years, 23 were male and 61% were never smokers. They had a mean pre-bronchodilator FEV1 %predicted 55.1 58 (53,65) years, 23 were male and 61% were never smokers. They had a mean pre-bronchodilator FEV1 %predicted 55.1 58 (53,65) years, 23 were male and 61% were never smokers. They had a mean pre-bronchodilator FEV1 %predicted 55.1 58 (53,65) years, 23 were male and 61% were never smokers.

Conclusion: People with severe eosinophilic asthma have a high disease burden. Psychological symptoms are worse in people prescribed mOCS. Reducing the use of mOCS may be of benefit in this population.

Grant Support: Funded by the GlaxoSmithKline Investigator-Sponsored Studies program

Copyright of individual abstracts remains with the authors.
COMPARATIVE RESPONSES IN LUNG FUNCTION MEASUREMENTS IN MODERATE SYMPTOMATIC ASTHMA

HALPIN D1, HAMELANN E2, MORONI-ZENTGRAF P3, VAN HECKE B3, UNESSL A3, KERSTJENS H3

1University of Exeter, Exeter, UK, 2Evangelisches Krankenhaus Bielefeld GmbH, Bielefeld, Germany, 3Boehringer Ingelheim Pty Ltd, Australia, 4Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riss, Germany, and 5Department of Pulmonary Medicine and Tuberculosis, and Groningen Research Institute for Asthma and COPD, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands

Introduction/Aim: We investigated (post-hoc) the comparative responses of several lung function measurements in adults and adolescents with moderate symptomatic asthma following tiotropium Respimat® (tioR) treatment.

Methods: Data from Phase III trials in adults (MezzoTinA-asthma®: two replicate, pooled, 24 week trials [NCT01172808/NCT01172821]) and adolescents aged 12–17 years (RubaTinA-asthma®: 48-week trial [NCT01257230]) were analysed. Both trials involved patients with moderate symptomatic asthma. Lung function measurements (FEV1, FVC, FEV1/FVC ratio and peak expiratory flow [PEF]) were analysed at Week 24 from patients receiving tioR2.5 μg/tioR5 μg/placebo once-daily added-on to at least 400–800 μg budesonide/equivalent.

Results: In adults, significant improvements in tioR versus placebo were observed consistently across lung function measurements (Table). In adolescents, while significant improvements in peak FEV1(0–3h) were observed for both tioR doses, the difference for trough FEV1, FEV1/FVC and morning and evening PEF was significant only for tioR5 μg. Peak FVC(0–3h) and trough FVC responses were non-significant for either tiotropium dose in adolescents.

Conclusion: Add-on tioR improves lung function in adults and adolescents with moderate symptomatic asthma. Adolescents demonstrated numerically smaller improvements than adults; statistically significant improvements were noted primarily for FEV1 and PEF, and not for FVC, indicating larger flow than volume response in adolescents compared to adults.

Grant Support: Boehringer Ingelheim

Declaration of interest statement: DH has previously received honoraria for speaking and consultancy from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, InterMune, Napp, Novartis, Nycomed, and Pfizer. EH is a principal investigator for Boehringer Ingelheim. PM-Z and BVH are employees of Boehringer Ingelheim. AU has nothing to disclose. HAK, on behalf of his institution, has received payment for lectures from Boehringer Ingelheim and Pfizer, support from Pfizer, Almirall, GlaxoSmithKline, Takeda, Novartis, Nycomed and Chiesi for his service on advisory boards and from Pfizer, Almirall, GlaxoSmithKline, Novartis, Nycomed, Chiesi, AstraZeneca and Protalief for consulting work.

Table 1

<table>
<thead>
<tr>
<th>Parameter</th>
<th>MezzoTinA-asthma® Adults N=513</th>
<th>RubaTinA-asthma® Adolescents N=134</th>
<th>MezzoTinA-asthma® Adults N=515</th>
<th>RubaTinA-asthma® Adolescents N=125</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peak FEV1(0–3h), mL</td>
<td>185(146, 223)***</td>
<td>174(76, 272)**</td>
<td>223(185, 262)***</td>
<td>134(34, 234)***</td>
</tr>
<tr>
<td>Trough (pre-dose) FEV1, mL</td>
<td>146(105, 188)***</td>
<td>117(10, 223)*</td>
<td>180(138, 221)***</td>
<td>84(25, 194)***</td>
</tr>
<tr>
<td>Peak FVC(0–3h), mL</td>
<td>95(53, 138)***</td>
<td>72(37, 182)</td>
<td>141(98, 183)***</td>
<td>88(24, 200)***</td>
</tr>
<tr>
<td>Trough FVC, mL</td>
<td>80(35, 125)***</td>
<td>35(80, 150)</td>
<td>107(62, 152)***</td>
<td>63(55, 181)***</td>
</tr>
<tr>
<td>FEV1/FVC, %</td>
<td>2.7(1.3, 3.4)***</td>
<td>2.5(0.8, 4.2)*</td>
<td>3.3(2.6, 4.0)***</td>
<td>1.0(0.8, 2.7)***</td>
</tr>
<tr>
<td>PEF morning, L/min</td>
<td>24.3(17.9, 30.7)***</td>
<td>15.8(2.3, 29.3)*</td>
<td>25.4(19.0, 31.7)***</td>
<td>9.7(4.1, 23.5)***</td>
</tr>
<tr>
<td>PEF evening, L/min</td>
<td>23.2(16.9, 29.5)***</td>
<td>16.7(3.4, 30.0)*</td>
<td>22.1(15.8, 28.4)***</td>
<td>12.2(1.3, 25.8)***</td>
</tr>
</tbody>
</table>

***p<0.0001; **p<0.001; *p<0.05
CASE STUDY: MEPOLIZUMAB AND VEDOLIZUMAB EFFECTIVELY, AND SAFELY USED IN A PATIENT WITH SEVERE EOSINOPHILIC ASTHMA AND CROHN’S DISEASE
HARRYANTO H1, LI X1, CHUNG L1
1Fiona Stanley Hospital, Perth, Australia

Introduction: Mepolizumab (IL-5 inhibitor), a newly PBS-approved treatment for severe eosinophilic asthma (SEA) has changed the landscape of severe asthma. However, its safety-profile and potential drug-interactions in real-life patient settings require ongoing surveillance. Here, we present a unique case of a patient safely and effectively treated with dual monoclonal therapies using mepolizumab and vedolizumab (α4β7-integrin blocker).

Case: 30-year-old man with asthma was diagnosed in his early teens with multiple ICU admissions. Deterioration in asthma control was noted in the last 2 years with frequent exacerbations treated with high dose oral steroid with difficult weaning despite optimal adherence to maximal therapy (Seretide, Alvesco, Spiriva and Singularai). In the setting of persistent peripheral-eosinophilia, non-specific HRCT changes, raised ANCA-PR3, the diagnosis of EGPA vasculitis was confirmed on lung biopsy.

He also has Crohn’s disease since age 13, severe, with histologic evidence of pancolitis. Over the last decade, he remained refractory to oral steroids and conventional immunosuppressive medications with abdominal pain and diarrhoea (≥20 bowel motions per day) with persistent weight loss. Vedolizumab was started in November 2016 with gradual but significant symptomatic benefit and well-tolerated.

While high dose oral prednisolone was helpful in alleviating his asthma symptoms, it leads to intolerable side effects. After 6-months therapy of Mepolizumab, improvements noted in asthma symptoms (ACQ 4.5 to 1.6), FEV1 (2.43, 56 %predicted to 3.65, 70 %predicted), FeNO (127 to 3.2, normal<1.8). He became exacerbation-free while prednisolone was weaned.

Both monoclonal therapies were well tolerated with no notable adverse event. His liver function remains stable despite background diagnosis of primary sclerosing cholangitis.

Conclusion: In this case, mepolizumab was highly effective in treatment of SEA secondary to EGPA. More importantly, it was safe to use in combination with vedolizumab (α4β7-integrin blocker) in a patient with multiple autoimmune conditions.

Grant Support: Nil

GAVAGE EXACERBATES AIRWAY HYPER-RESPONSIVENESS IN AN ALLERGIC AIRWAYS DISEASE MODEL
LARCOMBE A1,2, PHAN J1, BERRY L1, NOBLE P3
1Telethon Kids Institute, Subiaco, Australia, 2Curtin University, Bentley, Australia, and 3University of Western Australia, Crawley, Australia

Introduction/Aim: Gavage is the most widely used method for precise oral dosing in experimental studies involving rodents. In the hands of a skilled operator, it is rapid and allows for a precise dose to be delivered directly to the stomach. Gavage requires conscious, or lightly anaesthetised experimental animals to be restrained, and thus it is also technically challenging. Instances of oesophageal trauma, aspiration and other complications are not uncommon. In this study, we aimed to investigate the effects of repeated gavage on lung function in a mouse model of allergic airways disease.

Methods: Adult male C57BL/6 mice were gavaged with saline 3 times per week from week 5 to week 9 of life (total of 15 gavages). Control mice were handled in the same way, but were fed saline by pipetting drops of it into their mouths. Mice were sensitised and challenged with ovalbumin. Seven days after the final gavage/feed, we assessed pulmonary inflammation, lung volume, lung function and responsiveness to the bronchoconstrictor methacholine.

Results: There was no effect of repeated gavage on any cell type identified in lavage fluid (p > 0.214 in all cases). There was no effect of repeated gavage on lung volume (p > 0.657) or any parameter of lung function at FRC (p > 0.243 in all cases). Mice subjected to repeated gavage were significantly more hyper-responsive to methacholine with respect to airway resistance compared with non-gavaged mice (p < 0.016).

Conclusion: Repeated gavage exacerbates measurements of airway responsiveness in a mouse model of allergic airways disease. This may be a result of the gavage needle causing physical trauma to the adjacent trachea, however further research is required to identify the mechanism. The results of this study have important implications for studies assessing lung function after repeated gavage.

Grant Support: None.
TP 143

GENERAL PRACTITIONERS (GPS) EXPERIENCES OF ASTHMA MANAGEMENT IN CULTURALLY AND LINGUISTICALLY DIVERSE (CALD) POPULATIONS

ALZAYER R1, SAINI B1, CHAAR B1, BASHETI I2

1University of Sydney, Sydney, Australia, and 2Applied Science Private University, Amman, Jordan

Introduction/Aim: To explore how Australian GPs deal with CALD patients who have asthma.

Methods: Semi-structured interviews guided by a schedule of questions were conducted with GPs who deal with CALD patients with asthma. These GPs were recruited from medical practices in Melbourne, Australia.

Results: The study included 18 GPs have been interviewed so far. Preliminary thematic analyses of the interview transcripts highlighted five key emergent themes: self-management, miscommunication, accessibility and engagement, trust issues and cultural issues. Many participants highlighted CALD patients do not self-manage their asthma. Miscommunication was mentioned by some participants because of linguistic barriers. Other issues resulting in lower accessibility to health care was social isolation and financial stress. Trust issues among CALD resulted from unfamilarity with the Australian health care system. Cultural attitude of CALD patients affected treatment, for example with conservative CALD patients refusing some physical tests (e.g.: Chest examination).

Conclusion: GPs perceive that treating CALD patients with asthma is difficult and there many key barriers observed to affect treatment. Cultural competence training for health professionals as well as improving asthma and health system awareness in CALD patients with asthma and their carer are key interventions that may address asthma management gaps in CALD patients.

Key Words: CALD, Asthma, General Practitioners, Asthma Management.

Nomination for New Investigator Award

Grant Support: Saudi Arabian government scholarship

TP 101

PROFILING INNATE LYMPHOID CELLS IN THE CORD BLOOD OF INFANTS BORN TO MOTHERS WITH ASTHMA IN PREGNANCY

GOMES G1, STARKEY M2, DE GOUVEIA BELINELO P1, JESSON K1, HANSBRO P2, MURPHY V1, HARDAKER K1, ROBINSON P3, SLY P1, GIBSON P2, MATTES J1,2, COLLISON A1

1Priority Research Centre GrowUpWell, Hunter Medical Research Institute, The University of Newcastle, Newcastle, Australia, 2Priority Research Centre Centre Healthy Lungs, Hunter Medical Research Institute, The University of Newcastle, Newcastle, Australia, 3Department of Respiratory Medicine, The Children’s Hospital at Westmead, Sydney, Australia, 4Centre for Children’s Health Research, University of Queensland, South Brisbane, Brisbane, Australia, 5Sleep Medicine Department, John hunter Hospita, Newcastle, Australia, 6Paediatric Respiratory & Sleep Medicine Department John Hunter Children’s Hospital, Newcastle, Australia

Introduction/Aim: Perinatal risk factors for allergic disease such as maternal asthma, birth season and even birth order can be linked to detectable alterations in cord blood immune cells. Innate lymphoid cells (ILCs), have been implicated in the development of allergic diseases and are capable of regulating eosinophil inflammation. Their potential role in the development of asthma is of great interest but remains poorly understood. Here we examine the cord blood cell profile in infants born to mothers with asthma in pregnancy taking part in the NHMRC funded Breathing for Life Trial (BLT).

Methods: Cord blood from 29 BLT participants was collected into EDTA tubes and processed within 6 hours of birth. Cells were stained in whole cord blood: Eosinophils (CD 45+CD16+CD193+), ILC1 (Lin-CD127+CD161+CD294-), ILC2 (Lin-CD127+CD161+CD294-), ILC3 (Lin-CD127+CD161+CD294+), ILC3 NCR+ (Lin-CD127+CD161+CD294+CD117-CD16-CD294-CD14-CD83-CD103-CD11c-CD11b-CD117-NKp44-). Cells were fixed overnight, samples were acquired on a BD LSRFortessa X-20 flow cytometer and analysed using FlowJo software.

Tidal breathing flow-volume loop (TBFVL) measurements during quiet sleep were performed in infants at 6 weeks of age.

Results: In this preliminary analysis, there were correlations between ILC1, ILC2 and (NCR) ILC3s in cord blood (n=0.54-0.74, p<0.005, n=29). No significant correlations were found with NCR+ positive ILC3. Eosinophils weakly correlated with ILC2 (n=0.36, p=0.04) and were inversely correlated with lung function (PTEF%E%) at 6 weeks (n=0.83, p=0.005, n=10).

Conclusion: The study of ILC subtypes in cord blood is feasible and ILC1, ILC2 and ILC3 NCR+ numbers in cord blood show strong correlations with each other. The apparent correlation between ILC2 and eosinophils in cord blood and the potential association with lung function at 6 weeks of age warrants further investigation in this ongoing study.

Grant Support: The BLT pregnancy RCT and BLT Infant follow-up are funded by NHRMC. This project has received further support from the Hunter Children’s Research Foundation and PRC GrowUpWell®. A.M. Collison is supported by a TSANZ / NAC career development fellowship.


Copyright of individual abstracts remains with the authors.
Introduction/Aim: Mucopolysaccharidosis type IIIA (MPS IIIA) is a lysosomal storage disorder caused by a deficiency in the activity of the lysosomal hydrolase sulphamidase, normally involved in heparan sulphate (HS) degradation. This results in primary storage of partially degraded HS and secondary lipid storage in brain and liver. We recently showed HS storage and increased lipids, including cholesterol and selected species of GM1, 2 and 3, and bis-(monoacylglycero) phosphate (BMP) in MPS IIIA mouse lung tissue. Here we determine the phospholipid composition and rate of newly synthesised phosphatidylcholine in lung tissue and bronchoalveolar lavage fluid (BALF) of normal (Norm), heterozygous (Het) and MPS IIIA mice.

Methods: Mice received 100 μl intraperitoneal injections of methyl-9-deuterated choline chloride (10mg/ml) and were sacrificed at 0, 1.5, 3, 6 and 24h (n = 3-14 per time point/group) after labelling. Phospholipid composition and enrichment of d9 choline in surfactant phosphatidylcholine (BMP) in MPS IIIA mouse lung tissue. Here we determine the phospholipid composition and rate of newly synthesised phosphatidylcholine in lung tissue and bronchoalveolar lavage fluid (BALF) of normal (Norm), heterozygous (Het) and MPS IIIA mice.

Results: At time 0 (no label), there was no difference in PC molecular species composition of either lung tissue or BALF between the three genotypes. Similarly, there was no difference in the overall phospholipid composition (i.e. %phosphatidylcholine, -glycerol, -ethanolamine, -serine or sphingomyelin) between the three genotypes. However, there was an approximate halving in the amount of total phospholipid content (nmol/lung) of the BALF in MPSIIIA animals compared with both normal and heterozygous animals (Norm: 259.9±64.3; Het: 271.4±100.4; MPSIIIA: 134.6±36.7nmol; mean ± SD, n=3-14; ANOVA, p=0.0003). In addition, the % enrichment in d9 choline chloride into newly synthesised PC in lung tissue was reduced at 3h in MPS IIIA animals (Norm: 1.32±0.31%; Het: 1.19±0.14; MPSIIIA: 0.96±0.30; mean±SD, ANOVA, p=0.01).

Conclusion: These data suggest that the pulmonary surfactant synthetic capacity of the lung in MPS IIIA mice is reduced. In addition, there may be changes in the rate of secretion or uptake of phospholipids to and from the alveolar compartment. A halving in the surfactant phospholipid content has significant implications for the lung function of MPS IIIA patients.
Differential Effects of Exogenous IGF-1 Administration on Young Adult and Geriatric Mice Following Pneumectomy

Yasa J1,2,3,4, Huang W5, Liu L1, Engineer D5, Prele C1,2,4, Laurent G1,2,4, Lucas M5, Lucas A1,2,4
1Institute for Respiratory Health, Perth, Australia, 2Centre for Cell Therapy and Regenerative Medicine, Perth, Australia, 3School of Veterinary and Life Sciences, Murdoch University, Perth, Australia, 4School of Biomedical Sciences, The University of Western Australia, Perth, Australia, and 5Centre for Microscopy, Characterization and Analysis, The University of Western Australia, Perth, Australia

Introduction/Aim: The murine unilateral pneumonectomy (PNX) model induces growth of new alveolar tissue in the remaining lung, increasing lung mass and volume 14d after surgery. This compensatory lung growth response declines as mammal’s age. We aimed to determine whether infusion of Insulin-like Growth Factor (IGF)-1 could enhance lung growth in young adult mice and very old mice following PNX.

Methods: Groups of 5 – 8, female C57BL/6J mice aged 12 weeks or 23 months, received both a left sided PNX and also the subcutaneous insertion of an osmotic pump, delivering either rhIGF-1 or PBS. To determine changes in lung volume, mice were imaged by micro-Computerised Tomography at days 4, 7, 14 and 21 and then sacrificed, the right lung inflated, embedded and examined by immunohistochemistry.

Results: Following PNX in 12 week old mice, there is a rapid increase in lung volume which approaches pre-operative volumes by d4. IGF-1 supplementation following PNX in 12 week old mice significantly increased Ki67+ and Ki67/SepC+ lung cell numbers, at day 21 post-surgery, but did not affect magnitude of lung volume change compared to PBS treated mice. In contrast in old mice, there was a much less pronounced increase in total lung volume of the right lung following surgery. IGF-1 supplementation following PNX surgery significantly increased the volume of air in the lungs compared to PBS treated old mice, but not to the level of preoperative lung volumes and had no effect on tissue content or cell proliferation.

Conclusion: Exogenous IGF-1 treatment does not accelerate or increase lung growth in 12 week old mice or induce lung growth in old mice, following PNX. IGF-1 treatment did significantly increase the lung volume and reduce the lung density in old mice.

Grant Support: This work was supported by 2 grants awarded by the Charles Gairdner Osborne Park Health Care Group and by a UWA-Helmholtz Institute/UCL Seed Funding Grant.

Conflict of Interest: Authors declare no conflict of interest.
ESTABLISHING AN EPITHELIAL AIRWAY MODEL OF BACTERIAL-VIRAL POLYMICROBIAL INFECTION

POH M1, FONCECA A1,2, KICIC A1,2,3,4,5, EVERARD M1,2
1Division of Paediatrics and Child Health, University Of Western Australia, Perth, Australia, 2Department of Health, Princess Margaret Hospital, Subiaco, Australia, 3Department of Respiratory Medicine, Princess Margaret Hospital, Subiaco, Australia, 4Telethon Kids Institute, Subiaco, Australia, and 5Center for Cell Therapy and Regenerative Medicine, University of Western Australia, Crawley, Australia

Introduction/Aim: Infections of the respiratory airway rarely involves a single pathogen aetiology. Modelling the human respiratory epithelium has been a challenge due to its complex structure multiple cell types. Using juvenile epithelial brushings, we generated a polarised epithelial layer using the Air-Liquid Interface (ALI) method and infected or inoculated two common but significant respiratory pathogens, namely Respiratory Syncytial Virus (RSV) and non-typable Haemophilus influenzae (NTHi) to assess the impact on respiratory airway epithelial cells of sequential infection by the virus on NTHi biofilms and vice versa, characterise their behaviour through various functional, immunological, bacterial and viral endpoints.

Methods: Red fluorescent tagged RSV (A2 strain, rRSV-BN1, 1 x 10^6 pfu) and Green fluorescent tagged NTHi (86-028 NP, 2.5 x 10^7 CFU) were inoculated individually, concurrently or sequentially onto differentiated and polarised human airway epithelial cells. RSV infection and/or NTHi colonisation were allowed to proceed for 7 days before three washes of 0.2ml 1X PBS were performed on the apical epithelial surface. Washes are used to determine bacterial and viral loads via qPCR, as well as cytokine profiles determined via multiplex. Apical and basal insert surfaces were fixed with Hoechst 33342, excised, mounted cell surface up with ProLong Gold antifade mountant and overlayed with coverslips. Five confocal microscopy field-of-views of the inserts were obtained on a C2+ system (Nikon), and 1.2µm Z-stacks thickness used to reconstruct 3-dimensional images of the epithelium. Biofilm structural analysis was performed using the COMSTAT program. Image stacks were examined for: dimensional images of the epithelium. Biofilm structural analysis was performed using the COMSTAT program. Image stacks were examined for:

Results: Red fluorescence from RSV absent in epithelial cells inoculated four days earlier with NTHi when examined through confocal microscopy (at Day7-post primary inoculation/infection).

Conclusion: Prior NTHi colonisation of respiratory epithelium elicits protection against a secondary RSV infection, but not vice versa.

Grant Support: N/A

IMMUNOFLUORESCENCE IS A USEFUL ADJUNCT TO TRANSMISSION ELECTRON MICROSCOPY FOR THE DIAGNOSIS OF PRIMARY CILIARY DYSKINESIA

CANOY I1, BUDDLE L2, CLARKE C1, HUGHES L1, MACKENNEY K1, MORGAN L2
1Anatomical Pathology Department, Concord Hospital, Concord, Australia, and 2Respiratory Medicine Department, Concord Hospital, Concord, Australia

Introduction/Aim: Primary Ciliary Dyskinesia (PCD) is a rare autosomal recessive disorder characterised by dysfunction of motile cilia. Diagnosis of PCD has historically been made on the basis of the demonstration of impaired ciliary beating (using light microscopy) and abnormal ciliary ultrastructure (using electron microscopy) in patients with a suggestive phenotype and low nNO. Recent advances in molecular genetics have identified that up to 30% of affected individuals demonstrate normal ciliary ultrastructure. Transmission Electron Microscopy (TEM) is costly, labour intensive and limited to specialised units. We have been exploring direct immunofluorescence (IF) as a method for confirming TEM abnormalities with known protein defects with a view to extending to patients with a strong pre-test probability of PCD, but no abnormality demonstrable on TEM.

Methods: Consecutive patients with a history suspicious for PCD were referred for diagnostic ciliary studies. Nasal nitric oxide (nNO) levels were measured. Samples of ciliated nasal epithelium were then obtained using standard methodology using a cytology brush. The cells were suspended in Medium 199 and examined immediately using high-speed video microscopy. Further samples were prepared for IF and labelled using a panel of 4 antibodies (DNAH5, DNALI1, RSPH4 and GAS8). The rest of the cells were fixed with glutaraldehyde and prepared for TEM.

Results: 20 patients had ciliary brushing for TEM and IF.

Results and Table

<table>
<thead>
<tr>
<th></th>
<th>PCD Positive</th>
<th>PCD Negative</th>
<th>Unsatisfactory</th>
</tr>
</thead>
<tbody>
<tr>
<td>Suspicious for PCD</td>
<td>4</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>PCD positive</td>
<td>0</td>
<td>8</td>
<td>3</td>
</tr>
<tr>
<td>PCD negative</td>
<td></td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>Unsatisfactory</td>
<td></td>
<td>2</td>
<td>1</td>
</tr>
</tbody>
</table>

Conclusion: IF demonstrated abnormal axonemal proteins in 1 case where TEM did not.

IF demonstrated normal axonemal proteins in 3 cases where TEM was inconclusive. IF added sensitivity and specificity to our PCD diagnostic algorithm.

Respirology (2018) 23 (Suppl. 1), 104–215

Editorial material and organization © 2018 Asian Pacific Society of Respirology. Copyright of individual abstracts remains with the authors.
CHARACTERISATION OF B CELL SUBSETS IN THE BLOOD AND LUNG OF PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS
PRELE C1,2, LUCAS A1,2, BARRETT L1,2, BALTIC S1, FEAR M6, KNIGHT D1, LAURENT G1,2, MCANULTY R5, MUTSAERS S1,2, HOYNE G2,6

1Institute for Respiratory Health, The University of Western Australia, Perth, Australia, 2Centre for Cell Therapy and Regenerative Medicine, School of Biomedical Sciences, The University of Western Australia, Perth, Australia, 3Burn Injury Research Unit, School of Biomedical Sciences, The University of Western Australia, Perth, Australia, 4School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, Australia, 5Centre for Inflammation and Tissue Repair, Division of Medicine, University College London, London, UK, and 6The University of Notre Dame, Perth, Australia

Idiopathic pulmonary fibrosis is the most common of the idiopathic interstitial pneumonias and is typically associated with prominent lymphoid aggregates of CD3+ T cells and CD20+ B cells within the lung tissue that are located near sites of active fibrosis. The presence of lymphoid aggregates outside of primary and secondary lymphoid tissues is a prominent feature of many autoimmune diseases and the presence of lymphoid foci can precede the onset of clinical disease. We have examined the B cell profile of IPF patients and aged matched healthy controls using multicolour flow cytometry and analysed the serum for the presence of B cell cytokines BAFF and April, and CXCL13 a chemokine that promotes B cell migration to lung tissue. In contrast to healthy controls IPF patients show an accumulation of plasma B cells in the peripheral blood and a subset of patients show a rise in CD5+ CD23+ transitional B cells. Immunohistochemical staining of lung tissue from IPF patients revealed synchronous accumulation of CD138+ plasma cells and CD5+ B cells within the lymphoid aggregates of IPF patients. IPF patients showed a trend toward increased serum levels of BAFF, April and CXCL13. The presence of plasma cells and CD5+ B cells in the blood and lung tissue of IPF patients raises the important question as to the role of B cells in IPF disease pathogenesis.

Grant Support: This work is funded by NHMRC Project Grant GNT1067511 and British Lung Foundation Grant PPRG15-10.

SERUM AMYLOID A (SAA), TNFα AND INTERFERON γ IN SARCOIDOSIS
TAN C1,2, THOMAS P1,2,3, HERBERT C1,2
1Prince of Wales Hospital Clinical School, Sydney, Australia, 2Mechanisms of Disease and Translational Research, Faculty of Medicine, University of New South Wales, Sydney, Australia, and 3Respiratory Medicine, Prince of Wales Hospital, Sydney, Australia

Introduction/Aim: Sarcoidosis is a multisystem inflammatory disorder characterised by non-casing granulomas which express SAA, TNFα and interferon (IFNγ). Definitive diagnosis requires a biopsy. Target organ biomarkers in e.g. exhaled breath condensate (EBC), blood and saliva may aid development of less invasive methods of diagnosis and monitoring. This study compared SAA, TNFα and IFNγ levels in EBC, peripheral blood and saliva of sarcoidosis patients and healthy controls.

Methods: EBC, blood and saliva were collected from sarcoidosis patients and healthy controls. SAA, TNFα and IFNγ expression in EBC, blood and saliva samples from sarcoidosis patients and healthy controls were measured using enzyme-linked immunosorbent assays. Total protein levels in EBC and saliva were measured using the Bradford protein assay.

Results: See table. Results are presented as median (range).

<table>
<thead>
<tr>
<th></th>
<th>Controls</th>
<th>Patients</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma SAA (ng/ml)</td>
<td>357 (124-724)</td>
<td>526 (168-676)</td>
<td>0.034 (&lt;0.05)</td>
</tr>
<tr>
<td>n=13</td>
<td>n=16</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total salivary protein (μg/ml)</td>
<td>464 (313-1036)</td>
<td>759 (313-1697)</td>
<td>0.0276 (&lt;0.05)</td>
</tr>
<tr>
<td>n=16</td>
<td>n=18</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

No differences were seen in levels of TNFα and IFNγ expression in any of the samples, but were generally at the limit of detection of the assays.

Conclusion: SAA was increased in the plasma of sarcoidosis patients, which probably reflects the total body burden of sarcoid granulomas. More sensitive assays may help establish non-invasive patterns of biomarkers that are suitable for the diagnosis and monitoring of sarcoid activity.

Grant Support: None
TRANSCRIPTOMIC ANALYSIS OF HEALTHY PRIMARY TISSUE RESPONSE TO RHINOVIRUS INFECTION

LING K1,2, GARRATT L2, LASSMANN T4, KICIC A1,3,4,5, STICK S1,2,3,4, ARESTCF2,3,6,7, WAERP8,9
1School of Paediatrics & Child Health, The University of Western Australia, Perth, Australia, 2Telethon Kids Institute, Perth, Australia, 3Department of Respiratory Medicine, Princess Margaret Hospital for Children, Perth, Australia, 4Centre for Cell Therapy and Regenerative Medicine, School of Medicine and Pharmacology, The University of Western Australia, Perth, Australia, 5School of Public Health, Curtin University, Perth, Australia, 6Department of Respiratory Medicine, Royal Children’s Hospital, Melbourne, Australia, 7Murdoch Children’s Research Institute, Melbourne, Australia, and 8St John of God Subiaco Hospital, Perth, Australia

Introduction/Aim: Acute respiratory illness (ARI) caused by viral infection is a significant health burden in young children, especially those with underlying respiratory disease such as asthma. Human Rhinovirus (RV) is the most prevalent respiratory virus in children, however, there are no therapeutics effective at minimising adverse outcomes from RV. We aimed to fully describe the normal cellular response as a reference point for future studies.

Methods: Primary airway epithelial cells (AECs) were obtained from 17 healthy children (age 3.8 ± 1.5 years; 9 male). Cells were infected with RV1B (multiplicity of infection: 12.5) for 24 hours. RNA-sequencing was performed using Illumina Hi-Seq2500. Alignment and quality control was performed via an in-house pipeline. Differential gene-expression analysis was then conducted using Ballgown. Gene interaction was modelled by Network Analyst and upstream drivers identified using Ingenuity Pathway Analysis (QIAGEN, Germany).

Results: There were 329 differentially expressed genes in response to RV1B infection, of which 253 were upregulated. Genes not previously reported in RV response studies included interferon signaling mediators EPSTI1, IDO1, CMPK2 and HELZ2. Genes with high connectivity and betweenness which are known as hub—bottleneck nodes include STAT1, ISG15, NFKB2, PML and IRF1. Gene pathways were associated with interferon alpha/beta signaling, negative regulators of RIG-I/MDA5 signaling, interferon signaling, interferon gamma signaling and interleukin-6 signaling. Network analyst identified three key modules namely; interferon signaling, inflammation response and inhibition of viral translation and transcription.

Conclusion: Results demonstrate that applying a systems biology analysis to relevant primary samples uniquely inform whole cell responses to infection and is therefore an ideal platform for identifying new therapeutic targets in respiratory diseases.

Grant Support: NHMRC

STAT3 ACTIVATION REINFORCES SENESCENCE IN HUMAN LUNG FIBROBLASTS

WATERS D1, SCHULIGA M1, BLOCKLAND K1,2, BURGESS J2, GRANGE C1, WESTALL G3, LAURENT G1, PRELE C1, MUTSAERS SM1,2, KNIGHT D1
1School of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, New South Wales, Australia, 2University of Groningen, Groningen, Netherlands,
3School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia, 4Allergy, Immunology and Respiratory Medicine, Alfred Hospital, Prahran, Australia, 5Centre for Cell Therapy and Regenerative Medicine, School of Biomedical Sciences University of Western Australia, Crawley, Australia, and 6Lung Institute of Western Australia and Centre for Respiratory Health, University of Western Australia, Harry Perkins Institute of Medical Research, Nedlands, Australia

Background: Idiopathic pulmonary fibrosis (IPF) is a chronic fibrosing interstitial pneumonia of unknown cause and has a median survival of only 3 years. We have shown that fibroblasts derived from IPF-lungs clearly display characteristics of senescent cells. Senescent cells are crucial for tissue homeostasis but in overwhelming numbers are thought to drive the pathology of diseases such as IPF. The question of what is driving abnormally high numbers of fibroblasts into senescence remains unanswered. Dysregulated activation of the transcription factor STAT3 has previously been shown to correlate with IPF progression and has the potential to drive the phenotypic divergence observed in lung fibroblasts (LFs) in IPF.

Hypothesis: Inhibiting STAT3 activation after oxidant-induced senescence will attenuate characteristics of the senescent phenotype.

Aim: To determine the effect of inhibiting STAT3 activation on the development of fibroblast senescence.

Methods: Primary cultures of LFs were established from macroscopically normal lung tissue of thoracotomy patients. Senescence was induced by exposing cells to H2O2 (150 μM) for 2hr and confirmed by measuring senescence-associated β–galactosidase (SA-β–Gal), IL-6 production, and cell-cycle arrest protein p21 by cytochemistry, ELISA, and immunoblotting respectively. STAT3 activation was inhibited using the pharmacological inhibitor STA-21 (10 μM), cellular characteristics were subsequently assessed via Immunoblot, fluorescence, and the Seahorse Mitochondrial Stress test.

Results: The induction of senescence resulted in increased SA-β–Gal activity, p21 levels, and IL-6 production. Mitochondrial activity revealed increases in mitochondrial volume, superoxide production, and proton leak. Targeting STAT3 activity after senescence induction attenuated IL-6 production and prevented senescence-associated increases in mitochondrial mass, reduced superoxide production, and inhibited proton leak.

Conclusion: Our data suggests that activated STAT3 plays a role in reinforcing fibroblast senescence, particularly through regulating mitochondrial activity.

Grant Support: This research was funded by NHMRC grant 1099569 and by the Lung Foundation Australia David Wilson Scholarship awarded to David W Waters.
EFFECT OF ALTERNATIVE DIESEL FUELS ON HUMAN BRONCHIAL EPITHELIAL CELLS
VAUGHAN A 1, STEVANOVIC S 2, JAFARI M 2, BOWMAN R 1, RISTOVSKI Z 2, FONG K 1, YANG I 1
1UQ Thoracic Research Centre, Brisbane, Australia, and 2The International Laboratory for Air Quality and Health, Brisbane, Australia

Introduction/Aim: A potential alternative approach to reduce air pollution from diesel emissions is to substitute a portion of the diesel fuel with an alternative fuel, such as biodiesel (WCO), other biofuels (butanol) or with an additive (xylene or toluene). However, very little is known about the potential adverse health effects of these alternative fuels. The aim of this study was to compare the effects of diesel and alternative fuel emissions exposure on cell viability and inflammation of primary human bronchial epithelial (pHBECs) cells in vitro.

Methods: pHBECs were cultured at an air-liquid interface (ALI) and exposed to different diesel emissions for 30 minutes. This study compared seven diesel mixes made from four substitutes including butanol (Bu20, 20%), toluene (T20, 20%), xylene (X20, 20%) and waste cooking oil (B20, 20%; B50, 50%; B90, 90%; B100, 100%). As a negative control, pHBECs were exposed to filtered laboratory air for 30 minutes. After exposure, cell viability (cell proliferation, live cell percentage and CASP3 mRNA expression) and inflammation (IL-8 and IL-6 secretion) were measured. Statistical analysis was performed using a one-way ANOVA with a Tukeys multiple comparison post-test.

Results: Exposure to toluene- and xylene-diesel emissions significantly increased cell proliferation and CASP3 mRNA expression. Exposure to waste cooking oil biodiesel significantly increased cell proliferation, decreased live cell percentage, increased CASP3 mRNA expression and increased cytokine secretion.

Conclusion: Exposure to these specific alternative fuel emissions had some adverse effects on cellular responses of pHBECs, compared to diesel emissions. These findings suggest that further research is warranted to characterise health effects of alternative fuels, more importantly biofuels before their implementation in diesel cars.

Grant Support: The Prince Charles Hospital Foundation (AV), NHMRC Career Development Fellowship (IY), NHMRC Practitioner Fellowship (KF), The University of Queensland (IY)

Table 1  pHBEC response data to exposures

<table>
<thead>
<tr>
<th></th>
<th>D100</th>
<th>Bu20</th>
<th>T20</th>
<th>X20</th>
<th>B20</th>
<th>B50</th>
<th>B90</th>
<th>B100</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cell proliferation (%)</td>
<td>40.2±6.4</td>
<td>105.3±5.8</td>
<td>108.5±13.8</td>
<td>130.2±39.8</td>
<td>89.7±23.4</td>
<td>91.0±11.3</td>
<td>220.8±64.1</td>
<td>73.8±18.5</td>
</tr>
<tr>
<td>Live cells (%)</td>
<td>3.7±1.2</td>
<td>7.0±2.5</td>
<td>17.8±17.6</td>
<td>9.4±24.36</td>
<td>26.2±7.8</td>
<td>79.0±53.3</td>
<td>64.8±11.2</td>
<td>53.3±12.4</td>
</tr>
<tr>
<td>CASP3 exp. (Log2 of ΔΔCt)</td>
<td>-9.3±1.1</td>
<td>-1.7±0.9</td>
<td>-6.3±1</td>
<td>3.0±0.6</td>
<td>10.3±0.9</td>
<td>3.3±1.5</td>
<td>4.2±1.1</td>
<td>2.9±0.4</td>
</tr>
<tr>
<td>IL-8 secretion (Log2 fold change)</td>
<td>0.5±0.2</td>
<td>-0.8±0.3</td>
<td>0.8±0.7</td>
<td>-0.4±0.7</td>
<td>1.4±0.2</td>
<td>1.3±0.2</td>
<td>3.1±0.9</td>
<td>2.1±0.4</td>
</tr>
<tr>
<td>IL-6 secretion (Log2 fold change)</td>
<td>0.7±0.5</td>
<td>-0.4±0.1</td>
<td>1.8±0.7</td>
<td>-0.6±0.2</td>
<td>1.4±0.4</td>
<td>0.3±0.6</td>
<td>8.4±3.9</td>
<td>1.3±0.3</td>
</tr>
</tbody>
</table>

*indicates a statistically significant difference when compared to the filtered air control.
#indicates a significant difference when compared to diesel emissions exposure.

*Copyright of individual abstracts remains with the authors.
ALVEOLAR MACROPHAGE ZINC HOMEOSTASIS IS DYSREGULATED BY EXPOSURE TO CIGARETTE SMOKE
HAMON R1,2, TRAN H1,2, ZALEWSKI P3, HODGE S1,2
1Thoracic Medicine, Royal Adelaide Hospital, Adelaide, Australia, and 2Department of Medicine, The University of Adelaide, Adelaide, Australia

Introduction/Aim: Zinc homeostasis in the lung microenvironment is dysregulated in chronic inflammatory lung diseases associated with decreased zinc in the airways. Cigarette smoke exposure impairs the capacity of alveolar macrophages (AM) to phagocytose apoptotic airway epithelial cells (efferocytosis). We hypothesise that this impairment occurs by dysregulation of zinc homeostasis.

Methods: THP-1 macrophages were differentiated under various zinc conditions (0μM, 4μM or 20μM) and exposed to 10% cigarette smoke extract (CSE). Zinc transporter expression was assessed by qPCR, and intracellular labile zinc (FluoZin-3: Live cell stain) and efferocytosis using flow cytometry. Lung tissue sections from mice chronically exposed to cigarette smoke were examined by confocal microscopy; mean fluorescent intensity (MFI) for labile zinc (Zinpyr-1: Fixed cell stain) and zinc transport protein, ZnT4 (2-fold, p<0.001).

Results: By immunofluorescence, 256±33 to 815±123 (MFI±SEM, p<0.01). AM ZnT4 protein expression was negatively correlated with the ability of AM to efferocytose (R²=0.432; p<0.05) and with Zinpyr-1 staining of labile zinc in the airways (R²=0.723, p<0.001). Airway labile zinc was positively correlated with AM efferocytosis (R²=0.514, p<0.05)

Conclusion: AM zinc homeostasis is influenced by exposure to cigarette smoke, potentially leading to the impaired efferocytosis and increased inflammation in patients with chronic inflammatory lung diseases.

Grant Support: NHMRC

Interventional Pulmonology / Bronchoology

DIAGNOSIS OF PULMONARY EMBOLISM DOES NOT INCREASE LONG-TERM RISK OF ADVERSE CLINICAL EVENTS
LAMBA M1, PICKERING J2,3, THAN M2, ILES S2, BECKERT L1,2
1Department of Respiratory Medicine, Christchurch Hospital, Christchurch, New Zealand, 2University of Otago, Christchurch, New Zealand, and 3Department of Emergency Medicine, Christchurch Hospital, Christchurch, New Zealand

Introduction/Aim: We aimed to assess the long term risk of serious clinical events (SCE) in patients investigated for pulmonary embolism (PE). SCE were defined as composite of mortality, malignancy, cardiovascular events, recurrent venous thromboembolism (VTE) and chronic thromboembolic pulmonary hypertension, and analyse associated risk factors.

Methods: We prospectively recruited 501 consecutive patients presenting with clinical suspicion of PE to Christchurch Hospital in 2002-2003. These patients were followed-up until 01/03/2015. The data were analysed descriptively.

Results: The mean (±SD) age at presentation was 62 (±18) years and 42.1% of patients were male. 104 (20.8%) patients were diagnosed with PE by CT pulmonary angiography or ventilation-perfusion scanning. Of these, 18 (17.3%) patients had un-provoked PE. The median follow-up was 11.9 years, 56.0% patients completing over 10 years of follow-up, and 286 patients developed SCE (61.5% in PE group, 55.9% in Non-PE group, P=0.3).

Two hundred and thirty patients (45.9%) died during follow-up; 43.3% in PE and 46.6% in Non-PE group (P=0.5). Using multi-variate analysis, the predictors of mortality were age (P<0.01 ), diagnosis of malignancy (P<0.01 ) and congestive heart failure (P<0.01 ). Diagnosis of PE itself was not associated with increased risk of death (P=0.62 ). A total of 48 patients (9.6%) developed malignancy during the follow-up period (13.5% in PE compared to 8.6% in Non-PE group, P=0.13), with age being the only risk-factor (P=0.01). Recurrent symptomatic VTE was diagnosed more commonly in patients with PE (10.6%) compared to Non-PE group (1.7%) (P=0.01).

Conclusion: We demonstrate that underlying comorbidities, and not diagnosis of PE is associated with increased risk of serious clinical events. Recognition and management of underlying medical comorbidities is the key to improve long-term outcomes in patients with suspected or proven PE.

Grant Support: Nil
Introduction/Aim: Medical pleuroscopy is often used to investigate undiagnosed pleural effusions. Some of these require definite management using talc pleurodesis or placement of an indwelling catheter. The decision to use talc depends on the proceduralist’s ability to predict lung expansion. This has been proven to be inaccurate in the literature. Simulation of lung expansion has already been described as a technique to directly visualize lung expansion when negative pressure is applied to the pleural space at the end of medical pleuroscopy.

The aim of this study is to demonstrate whether changes in intrapleural pressure during this manoeuvre respond differently in expandable and non-expandable lung.

Methods: Patients undergoing diagnostic medical pleuroscopy for exudative pleural effusions were enrolled in the study. At the end of the procedure a 1.8mm catheter was introduced into the pleural cavity via the semi-rigid pleuroscope’s working channel (Olympus LTF-160) while the pleural space was sealed. Pressure of -50mmHg was applied via wall suction and changes in intrapleural pressure were continuously monitored.

Results: A total of 6 patients have so far been enrolled including 4 expandable and 2 non-expandable lungs on direct visualization during the manoeuvre. The slope of decline in pleural pressure was calculated in two phases: 1) from when the suction is applied to when the suction is released, 2) from when the suction is released to when the seal is broken.

Conclusion: Preliminary results indicate that the gradient of the slope of pleural pressure decline is different during both phases in expandable compared to non-expandable lung. This could further validate the use of visualization of lung expansion simulation during pleuroscopy as a predictor of success of talc pleurodesis.
MASSIVE PULMONARY HAEMORRHAGE WITH A COMPLEX, PLEXIFORM BLOOD SUPPLY

MAHER A1, SELLARS R1,2
1Darling Downs Hospital and Health Service, Queensland, Toowoomba, Australia, and 2University of Queensland Rural Clinical School, Toowoomba, Australia

Massive haemoptysis is a life threatening emergency. It may be defined as >100mL blood in an hour or >500mL in 24 hours. There are a variety of causes, most commonly related to lung cancer, bronchiectasis and in some settings tuberculosis.

Bronchopulmonary sequestration (BPS) is a rare cause of massive haemoptysis. It is a developmental abnormality that comprises between 0.15 to 6.4% of all congenital abnormalities of the lower respiratory tract, which themselves have an incidence ranging from 1 in 10,000 to 1 in 35,000 live births. It is defined as a region of lung parenchyma that has an incomplete or no connection to the airways, and is supplied by an aberrant artery arising from the aorta or one its branches. Most occur in the lower lobes and the commonest form, intralobular sequestration, is equally found in men and women.

BPS is often diagnosed in childhood but may not be detected until adulthood. Presentations include recurrent infection, haemoptysis, or as an incidental finding on chest radiology.

We present the case of a 38 year old male who presented to hospital with life threatening haemoptysis and received immediate care within the limitations of a regional environment prior to transfer to a tertiary centre. This included CT scanning that showed a right lower lobe necrotic lesion supplied predominantly by enlarged bronchial arteries. Following transfer, a bronchial angiogram demonstrated the right lower lobe lesion with a bronchial artery to pulmonary vein shunt and vascular supply originating from the right bronchial artery, right intercostal artery and a branch from the abdominal aorta. Following discussion at multidisciplinary team meeting between the respiratory team, cardiothoracic surgeons and interventional radiologists, embolisation of these vessels was performed.

BRONCHOSCOPIC REMOVAL OF FOREIGN BODIES: PRESENTATION OF TWO UNUSUAL CASES

VAZIRANI J1, HILDEBRAND F2, BARNES H, TAVERNER J1
1Alfred Health, Melbourne, Australia

Introduction/Aim: The incidence of foreign body aspiration is rare, but when occurs, Respiratory Physicians may be expected to manage difficult and unique airway issues. We highlight some of the challenges associated with foreign body removal at our health service.

Methods: We present two case reports of foreign body aspiration over six months at the Alfred Hospital.

Results: Case One: A 42 year old male presented with chest tightness following aspiration of a cockroach. During flexible bronchoscopy under sedation, the cockroach was identified in the ligula and extracted using biopsy forceps. Upon withdrawal of the bronchoscope, the patient had significant oxygen desaturation (nadir 65%) requiring a period of bag mask ventilation. On completion of the procedure, the patient expectorated further segments of the cockroach. Subsequent rigid bronchoscopy extracted a final hind-wing from the trachea.

Case Two: An 89 year old male with a history of dysphagia aspirated a capsule endoscope (‘Pillcam’) whilst being investigated for iron deficiency anaemia. The pillcam lodged in his bronchus intermedius. Flexible bronchoscopy with anaesthetic support and laryngeal mask airway was performed, and extraction of the pillcam was successful using an electrosurgical snare (used in gastrointestinal procedures). This complication of capsule endoscopy is reported with increasing frequency.

Conclusion: Adult respiratory physicians need to have the skills to manage unexpected foreign body aspiration. Our case series highlights the importance of anaesthetic support and airway management skills during foreign body extraction and draws attention to the under recognised issue of capsule endoscope aspiration.

Picture A: Cockroach within lingual
Picture B: Pillcam within right main bronchus

Grant Support: None
HIGH DIAGNOSTIC YIELD OF TRANSBRONCHIAL CRYOBIOPSY INCLUDES FOCAL PATHOLOGIES AND IS ENHANCED BY EBUS

OLIVE G1, BYRNES R1, SINGH M1, BASHIRZADEH F1, FIELDING D1
1Royal Brisbane Hospital, Brisbane, Australia

Introduction/Aim: Transbronchial cryobiopsy is emerging as a minimally invasive technique to bronchoscopically acquire diagnostic tissue samples from lung parenchyma. Most reports focus on yield of interstitial pneumonias however we here audit our experience with both diffuse and localised infiltrates and masses to improve yield. Including the additional use of endobronchial ultrasound to localise the cryoprobe.

Methods: Here, we report on the diagnostic outcomes of an ethics approved prospective series of 24 patients undergoing transbronchial cryobiopsy between July 2016 and October 2017 at The Royal Brisbane and Women’s Hospital. All patients gave informed consent.

Results: Patients were aged 58 years (+/- 14.6 std dev), 42% were female. Radiographic changes showed diffuse abnormality in 13/24 (54%), focal infiltrate in 8/24 (33%) and focal lesion in 3/24 (13%). Radial probe endobronchial ultrasound was used to assist biopsy location in 6/24 (25%). Mean cryobiopsy specimen size was 8mm in maximal dimension. Broncholaveolar lavage was done in 16 cases as well as other conventional biopsies however pathologically the cryobiopsies were the most revealing. Breakdown of final diagnoses by cryobiopsy were diffuse interstitial lung disease 7/24, inflammatory conditions 13/24 (including cases of complex vasculitis, Bronchiolitis Obliterans Organising Pneumonia, and sarcoidosis which had defied previous forms of pathologic diagnosis), malignancy 3/24. Only 3 cryobiopsy biopsy specimens were reported as normal. Two cases had dual pathology with inflammatory and malignant features.

Conclusion: In addition to diffuse processes, cryobiopsy facilitates diagnosis of localised pathologies including complex masses, and is facilitated by EBUS.

Grant Support: Nil

AUDIT OF THORACOSCOPIES PERFORMED IN A NEWLY-ESTABLISHED PLEURAL MEDICINE UNIT

VOON K1, SHRESTHA R1
1Department of Respiratory Medicine, Fiona Stanley Hospital, Perth, Australia

Introduction/Aim: Medical Thoracoscopy is increasingly utilised as a procedure of choice for investigation of undiagnosed exudative pleural effusion. This audit was performed to create a data pool relating to demographics and outcomes of patient undergoing Medical Thoracoscopy at Fiona Stanley Hospital (FSH). This data also serves as an initial comparator for future audits to improve service delivery.

Methods: Data was collected from the hospital database and patient medical records for all patients undergoing thoracoscopy at FSH since its establishment in January 2015 to August 2017. Outcomes assessed included length of inpatient stay, procedure-related complications, diagnosis post-procedure, other procedures performed at time of thoracoscopy, recurrence of effusions and patient mortality.

Results: 30 thoracoscopies were performed on 29 patients in the timeframe assessed. Only 1 of 6 extended admissions (>4 days) was associated with procedure-related complications. All procedures were performed in relation to investigation of pleural effusion. 23 patients (85%) were successfully diagnosed following thoracoscopy, with 16 diagnosed with malignancy, 7 diagnosed with non-malignant process while four patients had no diagnosis found. Only 8 patients received talc pleurodesis during their thoracoscopy, and 50% had recurrence of pleural effusion post-pleurodesis. All patients with recurrence had a diagnosis of mesothelioma. 11 (58%) of the 19 patients with malignant diagnosis have passed away since their procedure, with 6 patients passing away within 6 months of the procedure.

Conclusion: Similar to international data, thoracoscopy at our tertiary centre has been associated with low complication rates, and is effective in establishing the diagnosis of a pleural effusion. Success rate for pleurodesis at our centre is lower than the quoted published success rates (50% vs 77-100%), however our sample size is small in comparison.
MANAGEMENT OF EMPYEMA AND COMPLICATED PARAPNEUMONIC EFFUSION IN CHRISTCHURCH
LIU Y1, BECKERT L1
1Respiratory Services, Canterbury District Health Board, Christchurch, New Zealand

Introduction: Empyema and complicated pleural effusion (CPE) carry significant morbidity and mortality. White cell morphology and pH are used to predict the risk of infected pleural fluid, as microbiological yield is often low. Empiric antibiotic therapy is usually commenced prior to culture results.

Aim: To establish a baseline microbiological yield from pleural fluid culture in patients with empyema/CPE. Secondary aims were to assess factors for empyema/CPE, fibrinolytic therapy use and further surgical intervention.

Methods: This study retrospectively evaluated consecutive patients requiring a chest drain insertion from January 2015 to December 2016. CPE was defined as an exudate by Lights criteria and a pH<7.2. Empyema was defined as gram stain or culture positive, or frank pus.

Results: Thirty eight patients from 333 had an empyema/CPE. Forty-five total chest drains were inserted, n=28(62.2%) left and n=17(37.8%) right. Patient age ranged from 17 to 91 years (median 69). The majority of chest drains were 12 French n=26(57.8%). Twenty five cases had more than 50% polymorphic white cells and gram stain was positive in 17(38%) cases. Organisms were cultured in 19(42%) cases, however antibacterial activity was detected in 16 out of 25(64%). Risk factors for developing an empyema/CPE included underlying lung disease n=22(58%), diabetes mellitus n=5(13%), immunosuppression n=5(13%), and current/ex-smoker n=24(63%). Fibrinolytic therapy was used in 26(57.8%) cases and surgical intervention was required for 3(7.9%) cases but 2 had prior fibrinolysis.

Conclusion: In our setting, 38 patients had an empyema/CPE; gram stain was positive in 38% and an organism was identified in 42% of cases. Polymorphic white cells is a strong marker for empyema/CPE. Lung disease and smoking history appears to have an associated risk for empyema/CPE. Surprisingly, immunosuppression and diabetes mellitus were less so. Very few patients required surgical management post fibrinolytic therapy.

Grant Support: Nil
No interest to declare

MEDICAL CHEST DRAIN INSERTIONS IN CHRISTCHURCH HOSPITAL
LIU Y1, GOH Z2, BECKERT L1
1Respiratory Medicine, Canterbury District Health Board, Christchurch, New Zealand

Introduction/Aim: With the event of more effective therapeutic interventions like tunneled pleural catheters (TPC), talcum pleurodesis and fibrinolytic therapy; the number of chest drain insertions appears to have increased. The aim is to review local chest drain insertions, use of fibrinolitics, the success rate of talcum pleurodesis, and compare this to international data.

Methods: This observational study included all patients admitted to the respiratory unit from January 2015 to December 2016 requiring chest drain insertion. We analysed patient characteristics, type of drain inserted, pleural fluid biochemistry, culture, cytology, pleurodesis and fibrinolytic therapy(alteplase and dornase).

Results: A total of 486 chest drains were inserted for 333 patients, with a median age of 69 years. The majority were male n=201(60%). Of these drains, 227(46.7%) were inserted on the left and 259(53.3%) on the right. The main indications for chest drain insertion were malignancy n=260(53.5%), non-malignant pleural exudate n=97(20%) and pneumothorax n=70(14.4%). Drain size was 12 French n= 303(62.4%), central venous catheters n=69(14.2%), TPC n= 53(10.9%), 24 French n=25(5.1%), 18 French n=15(3.1%), 16 French n=20(4.2%), 28 French n=1(0.2%), and surgical drain n=2(0.4%). Interventional radiology inserted n=16(3.3%).

Talcum pleurodesis for malignant pleural effusion was used in 43 cases with a success rate of 72.1%. Fibrinolitics were used for 31(32%) cases of non-malignant pleural exudates. Twenty two patients required surgical intervention; pneumothorax n=14(4.2%), empyema/CPE n=3 (0.9%), hydro pneumothorax n=3(0.9%) and other indications n=2(0.6%).

Conclusion: Mainly 12 French drains or central venous catheter lines were used in Christchurch whilst large bore drains were reserved for empyema, complicated pleural effusions and post thoracoscopy. Fibrinolitics were used for parapneumonic effusions and empyema. Our success rate of talc pleurodesis is in keeping with international data.

Grant Support: Nil
No interests to declare
PULMONARY ARTERIO-VENOUS MALFORMATIONS: THE PRINCE CHARLES HOSPITAL EXPERIENCE
GERHARDY B1, KREBS L1, MASEL P1,2
1The Prince Charles Hospital, Brisbane, Australia, and 2University of Queensland, Brisbane, Australia

Introduction/Aim: Pulmonary Arterio-Venous Malformations (pAVMs) are an uncommon lung pathology that can be isolated or associated with hereditary haemorrhagic telangiectasia (HHT). They may present with symptoms including dyspnoea, orthodeoxia and life-threatening haemoptysis, or incidentally found on thoracic imaging. They may also present due to complications including cerebrovascular accidents or abscess due to their right-to-left shunt function. Management approaches include expectant, intravascular coiling or resection. Regardless patients with pAVMs benefit from multi-disciplinary management involving respiratory physicians, cardiologists, interventional radiologists, clinical geneticists and specialist nursing staff.

Methods: We performed a literature review and retrospective analysis of all individuals with International Classification of Disease codes of either HHT or peripheral arteriovenous malformation who presented to the Prince Charles Hospital between July 1999 and July 2014 to gain further insight into their spectrum of symptoms and complications, biochemical markers, extent of association with HHT and management strategies.

Results: 62 unique patients presented during this interval. Data was available for 46 patients with the remainder excluded due to incorrect coding, chart loss or destruction.

Our data demonstrates that 45% of patients had a confirmed diagnosis of HHT. The most common presenting complaints were epistaxis and haemoptysis, with the incidence of complications including need for nasal cautery, hypoxia and intracranial haemorrhage being seen in 26%, 32% and 6% percentage of people respectively. Of our cohort 41% underwent at least one endovascular intervention with no acute or long-term complications documented within this group. One patient had partial recanalization and was treated with Onyx with good effect.

We have also collated information including demographics, biochemistry, haematocrits and family screening to further explore the characteristics of this patient population.

Conclusion: To our knowledge this is the largest single centre cohort of pAVM patients in the Asia-Pacific region and it represents an insightful resource into common management strategies and complications within this region.

Grant Support: No funding, financial or otherwise, was involved in this project.
Dr B Gerhardy has no conflicts of interest to declare.
Dr L Krebs has no conflicts of interest to declare.
Dr P Masel has no conflicts of interest to declare.

MASSIVE HAEMOPTYSIS IN A PATIENT WITH PROXIMAL PULMONARY ARTERY INTERRUPTION SYNDROME
WASGEWATTA S1, HERAGANAHALLY S2, CARSON P1
1Royal Darwin Hospital, Darwin, Australia

Introduction: Proximal pulmonary artery interruption syndrome (PPAIS) is a rare developmental anomaly which is commonly associated with other cardiovascular abnormalities. It is usually diagnosed in childhood and adult patients are usually asymptomatic. Symptoms can be frequent pulmonary infections or haemoptysis. Diagnosis of this condition can be very challenging. There is no consensus regarding treatment of PPAIS. Aim of this case report is to discuss diagnosis and treatment strategies in this rare entity.

Case report: This case is of a 45 year old previously fit and healthy woman who presented to hospital with 3 episodes of massive haemoptysis of approximately 1000ml. She was haemodynamically stable despite a 30g/L drop in the haemoglobin level. Patient was further investigated with a CT bronchial angiogram which revealed complete occlusion of the lower lobe pulmonary artery with associated bronchial arterial hypertrophy. Given the risk of recurrent life threatening haemorrhage, she underwent an elective left lower lobectomy. Histopathology revealed possible proximal pulmonary artery interruption syndrome.

Conclusion: Patients presenting with massive haemoptysis, even if it has spontaneously resolved, should always be investigated further to determine the aetiology. Medical colleagues are encouraged to publish similar cases in the medical literature to identify different clinical presentations, diagnosis and management strategies on these rare entities.
PARATHYROID ADENOMA DIAGNOSED WITH ENDOSCOPIC ULTRASOUND WITH BRONCHOSCOPE (EUS-B) GUIDED BIOPSY IN ASYMPTOMATIC PATIENT WITH PRIMARY HYPERPARATHYROIDISM

SARWAR G1,2, GRAINGE C1,2, ARNOLD D1,2
1John Hunter Hospital, Newcastle, Australia, and 2The University of Newcastle, Newcastle, Australia

Introduction: Endobronchial Ultrasound (EBUS) is being increasingly used to sample the hilar and mediastinal lymph nodes along with other accessible soft tissue masses through the tracheal and bronchial wall. Some mediastinal lesions are more accessible through the oesophagus. When EBUS scope is passed through the oesophagus to sample mediastinal structures, it is termed as EUS-B (Endoscopic ultrasound with bronchoscope).

Methods: We report a first case of atypical parathyroid adenoma diagnosed using Endoscopic Ultrasound with Bronchoscope (EUS-B) guided biopsy. 48 year old patient presented with dysphagia. A provisional diagnosis of oesophageal intramural mass was made based on a CT scan with subsequent normal oesophagoscopy. EBUS along with EUS-B was performed. Given the location of the lesion just below the vocal cord, it was more accessible through the oesophageal wall using EUS-B. Initial aspiration of the cystic lesion followed by fine needle aspiration (FNA) was performed.

Results: The histology was consistent with parathyroid adenoma. Subsequent biochemical investigations revealed asymptomatic severe hypercalcaemia due to undiagnosed primary hyperparathyroidism which was initially medically managed. Further study with a sestamibi scan showed activity in that lesion which was surgically excised and found to be consistent with atypical parathyroid adenoma. EUS-B is very valuable skill to sample mediastinal lesions which are otherwise difficult to access through the trachea.

Lung Cancer

RISK FACTORS AND RATE OF PNEUMOTHORAX FOLLOWING CT-GUIDED PULMONARY BIOPSY: A RETROSPECTIVE AUDIT OF A SINGLE TERTIARY LUNG CANCER CENTRE

JEFFERIES R1, PADGHAM C1, MANNING L2,3, JOHNSON P1
1Department of Respiratory Medicine, Fiona Stanley Hospital, Perth, Australia, 2School of Medicine, University of Western Australia, Perth, Australia, and 3Harry Perkins Institute of Medical Research, Fiona Stanley Hospital, Perth, Australia

Introduction/Aim: Computer tomographic-guided biopsy (CTGB) is a widely used technique for obtaining a tissue diagnosis of pulmonary lesions, but is commonly complicated by pneumothorax. The aim of this single centre study was to describe the rate, independent risk factors and outcomes of post-procedural pneumothorax following CTGB.

Methods: A retrospective analysis was conducted of all patients undergoing CTGB of pulmonary lesion at Fiona Stanley Hospital during 2016. We excluded patients undergoing pleural or mediastinal biopsies and those in which the procedure was abandoned before introduction of the needle into the pleural space. Data were obtained using electronic medical records and included patient demographics, lesion size and type, needle size and type (co-axial, fine needle aspirate, core), number of passes, length of lung traversed (mm) and post-procedure pneumothorax. Univariate and multivariate analyses were then performed.

Results: One hundred procedures were performed in 94 patients. Forty-nine patients had a post-procedure pneumothorax (any size and defined on any modality), with 24 requiring admission and 12 requiring intercostal chest drain insertion. The presence of emphysema/bullae surrounding the biopsied lesion (aOR 5.11 [1.21-35.0]; p=0.05) and average size of the lesion (0.97 [0.95-0.99; p=0.02) were independent predictors of post procedural pneumothorax. This can be interpreted as a 3% reduction in risk of pneumothorax for each 1mm increase in size of the lesion. No peri-procedural factors were associated with risk of pneumothorax.

Conclusion: In patients undergoing CTGB there is an increased risk of pneumothorax in those with small lesion size and with emphysema/bullae surrounding the lesion. Peri-procedural factors did not appear related to pneumothorax risk in our study. As the main risk factors identified are unmodifiable, careful patient selection is warranted and must be balanced against the potential benefits of new less toxic cancer therapies available.

Key Words: CT-Guided Pulmonary Lesion Biopsy, Pneumothorax.

Grant Support: Nil declared
ACTIVE SCREENING FOR LUNG CANCER INCREASES SMOKING ABSTINENCE—5 YEAR OBSERVATIONAL DATA FROM THE QUEENSLAND LUNG CANCER SCREENING STUDY (QLCSS)
VEMULA M1, MARSHALL H1, YANG I1, BOWMAN R1, FONG K1
1Department of Thoracic Medicine, University of Queensland Thoracic Research Centre, The Prince Charles Hospital, Australia, Brisbane, Australia

Introduction/Aim: Screening for lung cancer promotes smoking cessation behaviours and may represent a “teachable moment” in smoking abstinence. We report 5-year smoking outcomes from the QLCSS.

Methods: The QLCSS screened 256 participants at baseline, Year 1 and 2 using Low-Dose Computed Tomography (LDCT) and collected annual health status questionnaires over 5 years. 121 participants were self-reported current smokers or quit smoking <6 months prior trial enrolment; 135 were former smokers who quit >6 months prior. Smokers received brief intervention (<5mins counselling by the research team plus printed Quitline materials) and were advised to contact their GP and Quitline for further support. Self-reported prolonged smoking abstinence was ascertained annually by the following yes/no questions: “Do you NOW smoke cigarettes (one or more cigarettes per week)?” and “In the past 6 months, have you smoked any cigarettes?”. Quitters were defined as answering “No” to both questions. Complete case analysis was performed. Sensitivity analyses for missing data used two models: 1) missing data coded as current smokers and 2) last observed status carried forward—LOSCF.

Results: Complete case analysis showed an increasing proportion of quitters up to 37% in Year 3 followed by a plateau. Worst case scenario (Model 1) showed a similar trend but overall lower proportion of quitters to Year 3 followed by a reduction. Model 2 suggested a continued increase across 5 years (Table 1).

Table 1 Annual Proportion of Prolonged Smoking Abstinence Analysed in Complete Cases, Cases with Missing Smoking Status Interpreted as Continued Smokers and LOSCF

<table>
<thead>
<tr>
<th>Year</th>
<th>Complete Cases§</th>
<th>Model 1ß</th>
<th>Model 2◊</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Quitters / Smokers n (%)</td>
<td>Quitters / Smokers n (%)</td>
<td>Quitters / Smokers n (%)</td>
</tr>
<tr>
<td>1</td>
<td>18 / 105 (17)</td>
<td>18 / 112 (16)</td>
<td>20 / 112 (18)</td>
</tr>
<tr>
<td>2</td>
<td>29 / 98 (30)</td>
<td>29 / 105 (28)</td>
<td>29 / 105 (28)</td>
</tr>
<tr>
<td>3</td>
<td>34 / 92 (37)</td>
<td>34 / 103 (33)</td>
<td>26 / 103 (25)</td>
</tr>
<tr>
<td>4</td>
<td>30 / 85 (36)</td>
<td>30 / 103 (29)</td>
<td>34 / 103 (33)</td>
</tr>
<tr>
<td>5</td>
<td>19 / 57 (33)</td>
<td>19 / 101 (19)</td>
<td>41 / 101 (41)</td>
</tr>
</tbody>
</table>

§Complete cases: participants who did not develop lung cancer, did not withdraw from study and who completed self-reported smoking status at that time point (had returned follow-up form and had indicated smoking status).
ßModel 1: participants who had missing self-reported smoking status at that time point (either did not return follow-up form or did not fill in smoking status) were counted as continued smokers.
◊Model 2: participants who had missing self-reported smoking status at that time point (either did not return follow-up form or did not fill in smoking status) were assumed to have the same smoking status as at their last prior recorded observation.

Conclusion: Using a stringent definition of prolonged abstinence, we observed high levels of smoking cessation consistent with prior studies and the ‘teachable moment’. Missing data limit the detailed analysis beyond Year 3; however, even in a worst-case scenario the rates of quitting remained high during active LDCT screening. This possibly reflects increased quit motivation through regular contact with the study team which diminished in the passive follow-up phase.
Intraperitoneally in Rats

Hocking A1, Elliot D2, Hua J1, Klebe S1,3
1Department of Anatomical Pathology, Flinders University, Adelaide, Australia, 2Department of Clinical Pharmacology, Flinders Medical Centre, Adelaide, Australia, and 3SA Pathology, Department of Surgical Pathology, Flinders Medical Centre, Adelaide, Australia

Introduction/Aim: Curcumin, a polyphenol found in the spice turmeric, is cytotoxic towards mesothelioma cells in vitro and in vivo stimulating a number of pathways of programmed cell death including apoptosis, autophagy and pyrotosis. Difficulties with clinical translation exist as curcumin is poorly absorbed into the circulation via the intestinal mucosa and undergoes rapid biotransformation in the blood. We propose that curcumin could be instilled into the pleural cavity of patients with mesothelioma through tunneled indwelling pleural catheter for a direct internal topical treatment. Our aim was to evaluate the safety of curcumin treatments in vivo, when applied to the pleural cavity in healthy rats.

Methods: Curcumin (80 mg/kg) was injected into the pleural cavity of male and female Fischer 344 rats (n=6). Blood was taken at 1.5 h, 24 h, 48 h, 7-days, 14 days and 21 days. Rats were euthanized at 48 h, 1 week and 3 weeks (n=2). Parietal pleura, lung, kidney, liver brain and heart tissues were obtained and examined for signs of gross tissue damage and histopathological changes. Ultra performance liquid chromatography - mass spectrometry was used to determine systemic distribution of curcumin following intrapleural treatments.

Results: Encapsulated curcumin deposits were observed in the pleural cavity of rats at 1 and 3 weeks following curcumin administration. Histological analysis revealed focal reactive mesothelial hyperplasia and a histiocytic response towards curcumin. Lung, liver, heart, brain and kidney tissues all display normal histological appearances. Curcumin was detected in the plasma samples of rats receiving intrapleural curcumin with peak concentration observed at 1.5 h post curcumin treatment (387-100 μg/ml). Curcumin could still be detected 2-weeks after curcumin administration.

Conclusion: Preliminary data suggests that intrapleural curcumin treatments could be tolerable in patients with mesothelioma and is under consideration for clinical trial.

Grant Support: Supported by Tour de Cure Australia and the Michael Ely Scholarship.

Exercise Training in Advanced Lung Cancer: A Cochrane Systematic Review

Cavilhaer V1, Singh P2,3, Thomas R1, Newton P2,3, Galvão D2, Peddle-Mcintyre C2
1School of Physiotherapy and Exercise Science, Curtin University, Perth, Australia, 2Exercise Medicine Research Institute, Edith Cowan University, Perth, Australia, 3School of Medical and Health Sciences, Edith Cowan University, Perth, Australia, and 4Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, Australia

Aim: To investigate the effects of exercise training on exercise capacity, health-related quality of life (HRQoL), dyspnoea, fatigue, feelings of anxiety and depression and lung function in people with advanced lung cancer.

Methods: We searched the Cochrane Central Register of Controlled Trials, PubMed, EMBASE, CINAHL, SPORTDiscus and PEDro up to July 2017. Randomised controlled trials (RCTs) were included in which study participants with advanced lung cancer (stage IIIB or IV) were allocated to receive either exercise training or a control group that received usual care. Two review authors independently screened and assessed studies for inclusion. Risk of bias was assessed using the Cochrane seven evidence-based domain table. Meta-analyses were conducted wherever possible.

Results: Five RCTs involving 109 participants were identified. Overall, the risk of bias in the included studies was high. Pooled data from the included studies demonstrated that, compared to usual care, exercise training improved exercise capacity (SMD 0.76; 95% CI 0.30 to 1.23) and HRQoL (SMD 0.41; 95% CI 0.00 to 0.81). No between-group difference was found for dyspnoea (SMD -0.26; 95% CI -0.77 to 0.25), fatigue (SMD -0.12; 95% CI -0.56 to 0.33), feelings of anxiety (SMD -0.38; 95% CI -1.86 to 1.10), depression (SMD -0.46; 95% CI -1.44 to 0.53) or forced expiratory volume in one second (SMD 0.34; 95% CI 0.24 to 0.92).

Conclusion: Exercise training appears to improve exercise capacity and HRQoL in people with advanced lung cancer. The findings of this review should be interpreted with caution due to disparities between the studies, methodological limitations, risk of bias and small sample sizes. This systematic review emphasises the need for larger RCTs.

Grant Support: Vinicius Cavilhaer, Rajesh Thomas and Carolyn Peddle-McIntyre are supported by a Cancer Council WA Postdoctoral Fellowship.

Declaration of interest: Nil.
HOPE: A TERTIARY CENTRE EXPERIENCE WITH INDWELLING TUNNELED PLEURAL CATHETERS

NEWHOUSE S1, KRUAVIT A1, CHENG J1, GRECO K1, DOUGHERTY B1, ROSE A1
1Flinders Medical Centre, Warradale, Australia

Introduction/Aim: Flinders Medical Centre (FMC) is the first tertiary hospital in South Australia with a dedicated pleural service, the HOPE (Home Pleural Effusion) Program, established in 2013. The aim of this study was to determine the complication rate and outcomes of patients with a tunneled indwelling pleural catheter (TIPC) placed at Flinders Medical Centre (FMC).

Methods: A retrospective audit was conducted of all patients undergoing a TIPC insertion at FMC from Sept 2013 to Sept 2017. Time of insertion, TIPC removal and death were recorded along with complication and pleurodesis rates. Statistical analysis was performed using the Fisher’s exact test.

Results: A total of 75 TIPCs were inserted at FMC in 71 patients. Three patients required repeat TIPC insertion after initial drain dislodge-ment (n=2) or removal (n=1) and 2 patients had bilateral TIPCs. The majority of TIPCs were inserted for malignant pleural effusions (n=68) with n=7 inserted for benign recurrent pleural effusions. Average length of stay post insertion was 5.32 (±/5.87 SD) days. The overall survival following TIPC insertion was 104 days (±/117SD). The time from TIPC insertion to removal (n=20) was an average of 156.6 days (±/113.13 SD) with the most common reason being pleurodesis (n=11). The overall rate of pleurodesis was 20% (15/75 TIPCs). Overall infection rate was 12/75 TIPCs with 8 patients developing an empyema, all of which were treated with good outcome. The rate of empyema appeared higher in those patients receiving concurrent chemotherapy (16.7%) compared with 6.3%, however this was not statistically significant (p=0.24).

Conclusion: TIPCs are an effective and safe treatment for recurrent pleural effusions. Our complication rates are similar to those reported in the literature. Our observed rate of pleurodesis is lower than expected which may be due to symptom guided drainage.

Grant Support: None

PREVALENCE AND PET FEATURES OF ANTHRACOSILICOTIC LYMPHADENOPATHY IN PATIENTS UNDERGOING INVESTIGATION FOR MALIGNANCY

DINHAN T1, FOO T2, DE BOER B3, LOH N4, MULRENNAN S1,5, PHILLIPS M1
1Sir Charles Gairdner Hospital, Perth, Australia, 2Department of Anatomical Pathology, Pathwest Laboratory Medicine, Perth, Australia, 3Department of Anatomical Pathology, Pathwest, Fiona Stanley Hospital, Perth, Australia, 4Department of Nuclear Medicine, Sir Charles Gairdner Hospital, Perth, Australia, and 5Medical School, Faculty of Health and Medical Sciences, University of Western Australia, Perth, Australia

Introduction/Aim: Anthracosilicosis is a known cause of FDG-avid thoracic lymphadenopathy in patients under investigation for malignancy. In patients with known or suspected malignancy, we aim to describe the patient factors and PET imaging findings of FDG-avid thoracic lymph nodes proven to contain silica and/or anthracotic material.

Methods: We conducted a retrospective analysis of 66 patients from Sir Charles Gairdner Hospital between 2014 and 2016 who underwent both PET scanning and EBUS-guided biopsy of thoracic lymphadenopathy for known or suspected malignancy, with subsequent biopsy proven anthracosilicosis. Each PET scan was reviewed by a nuclear medicine physician to obtain values for lymph node SUVmax/mean/peak, node SUV compared to liver/mediastinal blood pool/primary lung tumour and nodal stations/distribution.

Results: 22% of patients who underwent EBUS-guided nodal biopsy and PET scan for malignancy were found to have anthracosilicosis. A total of 107 lymph nodes contained anthracosilicosis. Mean age of these patients was 66±11.5 years, M:F = 46:20, 78% current/former smokers. 61% of patients were undergoing investigation for lung cancer, 39% for other malignancies. 71% of patients had both hilar and mediastinal disease, and the PET features listed above do not predict the absence of malignancy in our population, using previously validated criteria. Our results are preliminary at this time, however final results will include greater numbers and a comparison group of malignant lymph nodes.

Conclusion: Anthracosilicosis was prevalent in our Western Australian population, and reinforces the value of invasive staging methods to ensure appropriate cancer treatment. Most patients with anthracosilicosis have both hilar and mediastinal disease, and the PET features listed above do not predict the absence of malignancy in our population, using previously validated criteria. Our results are preliminary at this time, however final results will include greater numbers and a comparison group of malignant lymph nodes.

Grant Support: Nil
NIVOLUMAB: A SINGLE CENTRE EXPERIENCE

INTRODUCTION/AIM: Clinical trials have shown promising results with nivolumab in advanced non-small cell lung cancer (NSCLC), however the efficacy in real-life clinical setting is less well defined. This study aims to determine the efficacy and safety of nivolumab at a large thoracic-oncology unit.

METHODS: Consecutive series of patients who received nivolumab for advanced NSCLC over 30 months period between January 2015 and June 2017 were identified. Main outcomes were overall survival (OS) and progression free survival (PFS). Objective response and complications were also analysed.

RESULTS: Intention-to-treat study population included 54 patients (median age 62 years). Median OS was 8.8 months (95%CI 4.4 to 13.2) and 23 patients (42.6%) were alive at 12 months after initiation of nivolumab. Median PFS was 2.6 months (95%CI 0.9 to 4.4). Patients with better performance status had significantly higher PFS with a median of 4.5 months for ECOG status one and 1.1 months for ECOG status two (p=0.02). Patients who had complications from nivolumab had higher median PFS compared to others (4.3 vs 1.6 months, p=0.049).

CONCLUSION: The survival rates with nivolumab were higher than expected with conventional second line chemotherapy, with a favourable complications rate. The performance status and serum LDH levels predicted PFS. Patients who had a favourable response on initial assessment continued to have a sustained benefit.

Grant Support: Nil
RADIAL-EBUS INVESTIGATION OF PERIPHERAL PULMONARY LESIONS: A NEW ZEALAND PERSPECTIVE

GOOD W1, CHRISTENSEN P2, HERATH S3, DAWKINS P4, YAP E1
1Department of Respiratory Medicine, Middlemore Hospital, Counties Manukau-DHB, Auckland, New Zealand, 2Department of Health Intelligence and Informatics, Ko Awatea, Counties Manukau-DHB, Auckland, New Zealand, and 3Department of Respiratory and Sleep Medicine, Westmead Public Hospital, Westmead, Australia

Background: Radial-probe endobronchial ultrasound (radial-EBUS) is becoming a key investigation for peripheral pulmonary lesions (PPLs), with growing international evidence supporting its use. This approach is still new to New Zealand, performed in only two centres nationally.

Aims: This study aimed to investigate the diagnostic yield (confirmed malignancy or benignity subsequently confirmed), predictors of success and radial-EBUS safety in New Zealand.

Methods: We performed a retrospective analysis of all cases (n=68) from Middlemore Hospital, Auckland, undergoing sheath-guided radial-EBUS for PPL from March 2015 to August 2016. Diagnostic yield from radial-EBUS was determined and associations with demographic and clinical variables were tested for. Logistic regression on complete records (n=54) was used to build a model predicting successful radial-EBUS.

Results: Overall diagnostic yield of radial-EBUS was 66.2% (95% confidence interval (95CI): 53.7-77.2). It was diagnostic in 57.4% (95CI: 43.2-70.8) of malignant cases with 81.0% (95CI: 58.1-94.6) of diagnostic samples sufficient for mutational analysis when required. Pneumothorax occurred in 4.4% (95CI: 0.9-12.4), none requiring chest drain insertion. There were no cases of pulmonary haemorrhage requiring blood transfusion. Distance from hilum (p-value=0.0020), air-bronchogram (p-value=0.0054) and concentric positioning (p-value=0.0054) were individually associated with diagnostic yield. A model predicting diagnostic yield with 85.3% (95CI: 68.9-95.0) sensitivity and 85.0% (95CI: 62.1-96.8) specificity was attained.

Conclusion: Radial-EBUS was shown to be safe with high diagnostic yield, similar to international reports. It should become common practice in the diagnostic work-up of PPLs in New Zealand. There were promising results allowing for the use of models to predict the yield.

Grant Support: There was no funding provided for this study and no conflicts of interest to be disclosed.

ROLE OF PRE-CLINIC MULTIDISCIPLINARY TRIAGE MEETINGS IN LUNG CANCER MANAGEMENT

HUSEINI T1, TOBIN C1, LAM K2, LEONG J1
1Department of Respiratory Medicine, Royal Perth Hospital, Perth, Australia, and 2Department of Radiology, Royal Perth Hospital, Perth, Australia

Introduction/Aim: Lung cancer is one of the leading cause of cancer related morbidity and mortality worldwide. Prolonged waiting periods before diagnosis and treatment can lead to poor outcomes. Our aim is to assess impact of thoracic multidisciplinary triage meetings on time to diagnosis and to treatment.

Methods: We organised thoracic multidisciplinary triage meetings which included respiratory physicians and thoracic radiologist. All referrals with suspected thoracic malignancy were assessed on a weekly basis for three consecutive months; further investigations or procedures were tentatively booked in advance and all patients were seen in clinic before they underwent any further procedures. We assessed impact on time to a) Lung cancer triage category clinic waiting periods and b) Time to diagnosis and relevant specialist appointment for further treatment. Data are expressed as mean±SD and outcomes were compared using unpaired t-test with previous two consecutive years for the same three month period.

Results: We identified 80 patients who were referred over a three month period in 2017; 37% male and age 71±12.6 years. 23.3% had adenocarcinoma, 20% benign, 16.6% squamous cell carcinoma, 3.3% small cell lung cancer and 36.8% other malignancies. Average time to when patients were seen in clinic, time to diagnosis and time to treatment is outlined in table 1.

Table 1

<table>
<thead>
<tr>
<th>Time to Event</th>
<th>2017 (mean±SD)</th>
<th>2016 (mean±SD)</th>
<th>2015 (mean±SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Days</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time to clinic</td>
<td>19±11</td>
<td>19.1±18.8</td>
<td>18.5±35.2</td>
</tr>
<tr>
<td>Time to diagnosis</td>
<td>25±18.1</td>
<td>49.2±59.5</td>
<td>38±48.1</td>
</tr>
<tr>
<td>Time to treatment</td>
<td>52±23.5</td>
<td>74.7±44.7</td>
<td>57.7±56.6</td>
</tr>
</tbody>
</table>

At the end of the three months average time span to diagnosis and treatment reduced by 24.2 (p-value 0.0008) and 22.7 days (p-value 0.01) respectively when compared to 2016 and 13 (p-value 0.03) and 5.7 days (p-value 0.6) respectively when compared to 2015.

Conclusion: Multidisciplinary triage meetings appear to have a useful role to expedite diagnosis and treatment in patients with thoracic malignancy.

Grant Support: Nil
CORE NEEDLE BIOPSY VERSUS FINE NEEDLE BIOPSY IN A LARGE METROPOLITAN HEALTH NETWORK

TAN M1, CUKIERMAN R1, POLKINGHORNE K1, LI X1, LAU K1
1Monash Health, Melbourne, Australia

Introduction: Lung cancer is the world’s leading cause of cancer related death. Early and accurate diagnosis is essential for prompt treatment to reduce morbidity and mortality. The aim of the large retrospective study was to compare the efficacy of radiologically guided core needle biopsy (CNB) and fine-needle aspiration (FNA) of lung lesions by analysing outcomes and complications.

Methods: Study analysis of 241 consecutive CT-guided CNB or FNA performed with the step and shoot approach between January 2007 and December 2013. For core biopsies 16-20G Quickcore needles and for FNA 22G Chiba needles were used. Specimens were sent for histopathological or cytotological analysis. Immediately post procedure, a low dose CT scan was performed to exclude pneumothorax, followed by chest radiography two hours later to assess for complications.

Results: Of the 241 biopsies, 177 (73.44%) were CNB and 64 (26.56%) were FNAs. FNAs were more frequently performed on non-peripheral lesions than peripheral (60.94% vs 39.06%) compared to core biopsies (38.42% vs 61.58%). Core biopsies demonstrated higher yield (90.40% vs 65.63%) and diagnosed malignancy more often (70.06% vs 37.50%). Pneumothorax occurred 75 times (31.12%) and were more common non-peripheral (70.67% vs 29.33%), yet only 5.81% of biopsies and only one peripheral pneumothorax required further management. FNAs had a higher rate of pneumothorax than CNBs (43.75% vs 26.55%). Haemorrhage complicated 7.05% of biopsies and occurred more in CNB than FNA (8.47% vs 3.12%).

Conclusion: Core biopsy appears to be a more efficacious method of sampling tissue in the investigation of a solid pulmonary nodule. Our study demonstrated a higher diagnostic yield, lower pneumothorax rate and overall similar complication rate in CNB compared to FNA.

Grant Support: No Grant Support

INTERSTITIAL LUNG ABNORMALITIES IN THE QUEENSLAND LUNG CANCER SCREENING COHORT

MACKINTOSH J, SLAUGHTER R, MARSHALL H, BOWMAN R, YANG I, FONG K
1Department of Thoracic Medicine, University of Queensland Thoracic Research Centre, The Prince Charles Hospital, Rode Road, Chermside, Australia, and 2Department of Medical Imaging, The Prince Charles Hospital, Rode Road, Chermside, Australia

Introduction/Aim: Non-nodule incidental findings are common in lung cancer screening trials. We present preliminary data on the prevalence and progression of incidentally-detected interstitial lung disease in the Queensland Lung Cancer Screening Study (QLCSS) cohort.

Methods: 256 healthy volunteers underwent screening (low-dose, supine) (aged 60-74, >= 30 pack years smoking history and FEV1 >=50% predicted). Electronic search of baseline (T0) and two year follow-up (T2) Computed Tomography reports identified candidate cases using pre-specified interstitial lung disease terms. Candidate CTs were reviewed on PACS workstations in a randomised order by an experienced radiologist and senior respiratory medicine trainee blinded to the existing reports. Scans were scored for the presence and extent of interstitial abnormalities using an in-house score. A provisional diagnosis based on the radiology features was made where possible.

Results: 66 (25%) candidate cases were identified from reports. Single observer (JM) review of CT images of candidate cases identified 42 participants (16%) with an interstitial abnormality. Minor basal reticulation was the most common finding (43%) and usually involved less than 5% of the entire lobe. Fifteen cases (6%) demonstrated evidence of focal or more diffuse ground glass opacity. One participant met ERS/ATS radiological criteria for probable usual interstitial pneumonia with reticulation, traction bronchiectasis and honeycombing. Most participants showed no progressive change on T2 scan.

Conclusion: Minor interstitial abnormalities are common incidental findings in our lung cancer screening cohort. The majority of cases did not progress on short-term interval imaging and are unlikely to be of any clinical significance, however, longer-term assessment would enable more accurate prognostication.

Grant Support: NHMRC, Queensland Government Smart State grants, The Prince Charles Hospital Foundation
CASE REPORT—A PULMONARY GLOMUS TUMOUR WITH MALIGNANT TRANSFORMATION
LIU S1, JONES A1, SIRIWARDANA A2
1Wollongong Hospital, Wollongong, Australia, and 2St George Hospital, Australia

Case Description: A 68-year-old female presented with an increased cough, exertional dyspnoea and chest tightness. A CT chest demonstrated a partially occlusive mass evident in the right bronchus intermedius. A bronchoscopy demonstrated a large, partially necrotic vascular tumour at the origin of the bronchus intermedius. Biopsies demonstrated features suggestive of a Glomus tumour. A PET CT scan of her chest showed a non FDG avid lesion in the right bronchus intermedius with no evidence of locoregional or metastatic disease defined.

She proceeded to an uncomplicated right middle and right lower lobe lobectomy. The histopathological findings were consistent with a malignant glomus tumour. Follow up CT scans now one year after the procedure have not demonstrated evidence of recurrence to date.

Discussion: The Glomus body is a neuromyoarterial apparatus in the dermis and contributes to body temperature regulation. Glomus tumours are rare solitary neoplasms that usually occur in the distal extremities. Occasionally glomus tumours can be found at ectopic sites such as gastrointestinal tract, respiratory system, female reproductive tract and cardiovascular system. Pulmonary Glomus tumours are extremely rare and most commonly arise from trachea and bronchial Airways. There are less than 60 cases reported worldwide. Most pulmonary glomus tumours are benign and from the literature research at the time of writing, only 20% cases were malignant and less than 1% were with distant metastasis.

It is difficult to differentiate glomus tumours from other solid tumours in the lung preoperatively. It is also difficult to differentiate benign and malignant glomus tumours based on imaging features. Therefore the gold standard therapy for suspicious glomus tumour is operative management. The clinical prognosis of benign glomus tumours is excellent, while malignant metastasis.

Conclusion: For glomus tumours that have malignant transformation or malignant potentials, close monitoring with regular follow up is warranted.

Grant Support: Nil
PRELIMINARY OCCUPATIONAL REVIEW OF QUEENSLAND MINERS WITH DUST-INDUCED LUNG DISEASE
CLEVELAND D1, NEWBIGGIN K2, DICKINSON S3, MCBEAN R2, EDWARDS R4
1Sonic HealthPlus, Mackay, Australia, 2Wesley Medical Imaging, The Wesley Hospital, Australia, 3Department of Medical Imaging, The Royal Brisbane and Women’s Hospital, Australia, and 4Genesis Sleep Care, The Wesley Hospital, Australia

Introduction/Aim: To review the occupational history of recently diagnosed cases of dust-induced lung disease in Queensland.

Methods: A single centre, retrospective analysis of 20 current or retired Queensland coal mine workers with a dust-induced lung disease. The workers included had occupational dust exposure in either underground mines or open-cut mines. Occupational histories were collected in consultation with the treating physician.

Results: The majority of workers had a diagnosis of silicosis (40%) or mixed dust pneumoconiosis (40%), reflecting respiratory silica exposure. Four patients (20%) had a diagnosis of coal workers pneumoconiosis, reflecting heavy coal dust exposure. Typically cases occurred in workers who were currently or previously employed in underground coal mining (90%) rather than above ground coal mining (10%). Some workers reported periods of prior employment in non-coal mines, or in the mining industry interstate or overseas. Occupational dust exposure history was broad, ranging from 10 to 42 years. Occupational roles associated with heavy dust exposure such as working at the longwall or coal face; with conveyor belt systems; and roof bolting, were over represented.

Conclusion: This study reviewed the largest case series of dust-induced lung disease in Queensland miners in three decades. Commonalities amongst cases included long dust exposure histories, underground mining and crystalline silica dust exposure. This case series highlights the importance of understanding the complexities and prevalence of occupational lung disease in mining within Australia and the need to better understand the relationship between specific occupational roles and the development of dust-induced lung disease.

The authors have no conflicts of interest to declare.

Grant Support: none at the time of writing

THE RESPIRATORY INFLAMMATORY POTENTIAL OF PYRITE RICH COAL PARTICLES
ZOSKY G1, WILLIAMS L1, BENNETT E1, BEAMISH B2
1University of Tasmania, Hobart, Australia, and 2BD Mining Services Pty Ltd, Toowong, Australia

Introduction/Aim: The resurgence of coal workers’ pneumoconiosis (CWP) in Australia is a significant public health concern. The geographic clustering of cases suggests that the local physico-chemical characteristics of coal dust may be contributing to CWP risk. The aim of this study was to compare the inflammatory potential of Australian coal dust with low and high reactive pyrite content.

Methods: We collected two real-world coal samples with low and high reactive pyrite content. When exposed to ambient air, coal containing reactive pyrite undergoes oxidation to form a range of secondary minerals. We monitored the degradation of the coal samples when exposed to warm ambient air and assessed the pH of the liquid exudates that were produced. We also assessed the cytotoxicity (by LDH assay) and inflammatory potential (cytokine production) in A549 (Type II epithelial cell line) cells in response to particle exposure at a range of concentrations (0, 10, 30, 100 and 300 μg/mL).

Results: The sample with the low reactive pyrite content showed limited reactivity and degradation whereas the high reactive pyrite sample degraded rapidly and produced a liquid exudate with a pH of 0.45. Both the low and high reactive pyrite samples caused dose dependent cytotoxicity (p < 0.001), however the magnitude of the effect was greater in the sample with high reactive pyrite content (p = 0.03). Similarly, both the low and high reactive pyrite content samples caused dose-dependent increases in IL-8 production (p < 0.001), but the magnitude of the effect was greater in response to the high reactive pyrite particles (p < 0.001).

Conclusion: These observations suggest that coal with high reactive pyrite content has the capacity to produce by-products that are likely to cause significant respiratory injury when inhaled. Further studies are required to determine whether this is linked to their fibrogenic potential.
PLEURAL PLAQUES DO NOT INCREASE LUNG CANCER RISK IN ASBESTOS-EXPOSED

KONG K1, HARRIS E2, FRANKLIN P1, OLSSEN N1, REID A2, MUSK B1,2, DE KLERK N2, BRIMS F1,2,5
1School of Population and Global Health, University of Western Australia, Perth, Australia, 2Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, Australia, 3Curtin Medical School, Curtin University, Perth, Australia, 4School of Public Health, Curtin University, Perth, Australia, and 5Institute for Respiratory Health, Perth, Australia

Introduction: Asbestos exposure increases the risk of lung cancer. Pleural plaques (PP) are the most common manifestation of asbestos exposure. There is controversy as to if the presence of PP confers an increased risk for lung cancer.

Aim: To define the relationship between PP and lung cancer risk.

Methods: 1,759 male participants from the Western Australia Asbestos Review Program with occupational exposure to asbestos >3 months cumulative full time exposure (excluding ex-Wittenoom miners and residents) were studied over a 25-year period. All participants were under annual review with chest radiography (CXR) and/or low dose CT (LDCT), with linkage to national cancer and mortality registry data. Subjects were followed up from the date of their latest CXR or LDCT, taken a year or more before the date of death, cancer diagnosis, or end of follow-up. A case was defined as a diagnosis of lung cancer from state cancer registry data. Hazard ratios (HR) for lung cancer were estimated by Cox regression, with age as the underlying matching time variable, and tobacco smoking (ever/never smoker and pack-years), asbestos exposure (using the AsbJEM-derived estimated cumulative exposure), International Labour Organisation CXR readings for asbestosis (defined as profusion score ≥1/0) or LDCT reading score ≥1, and presence of pleural plaques.

Results: Mean age at follow up was 69.1 years. Asbestosis was present in 705 (40.1%) and PP in 811 (46.1%) subjects. Lung cancer was recorded in 58 (3.3%) cases. 1333 (75.8%) subjects were ever smokers. HRs for risk of lung cancer are presented in Table 1. Tobacco smoke exposure, specifically iron ore (magnetite), through a case report. Occupational lung disease secondary to iron ore dusts have been rarely been documented in the current literature.

Summary of the Case Report: The case report is of a 58 year old man, who was previously healthy and a non-smoker, who presented with a 12 month history of dry cough with a 3 year history of occupational exposure to iron ore dust after working in the blast crew of an iron ore mining industry in Western Australia. Computer tomography of the chest demonstrated nodular ground grass opacities in the apical areas of bilateral upper and lower lobes with sparing of the periphery. Pulmonary function tests demonstrated moderate obstructive lung disease with no bronchodilator response and normal diffusing capacity. Bronchoscopy with washings and lavage was inconclusive. Wedge surgical biopsy of the affected lung regions demonstrated frequently scattered non-necrotising epithelioid granulomas suggestive of SLGLD. He had symptomatic response to sarcoidosis therapy however there was no radiological improvement; a suggestion that sarcoidosis was not the culprit for the granulomatous disease.

Conclusion: Reporting case studies of incidents of occupational exposure-related lung diseases including iron ore dust and management strategies is important given the very sparse knowledge and experience in this field.

Grant Support: WA Cancer Council, New South Wales Dust Diseases Care (iCare), NHMRC

Declaration of Interest: We have no conflict of interest to declare.

Intervention: To expand knowledge on sarcoid-like granulomatous lung diseases (SLGLD) secondary to industrial/occupational dust exposure, specifically iron ore (magnetite), through a case report. Occupational lung disease secondary to iron ore dusts have been rarely been documented in the current literature.

SARCOID-LIKE GRANULOMATOUS LUNG DISEASE SECONDARY TO OCCUPATIONAL IRON ORE DUST EXPOSURE

XIAO L1, WAGGEGATTA S1, HERAGANAHALY S1
1Royal Darwin Hospital, Darwin, Australia

Introduction/Aim: The case report is of a 58 year old man, who was previously healthy and a non-smoker, who presented with a 12 month history of dry cough with a 3 year history of occupational exposure to iron ore dust after working in the blast crew of an iron ore mining industry in Western Australia. Computer tomography of the chest demonstrated nodular ground grass opacities in the apical areas of bilateral upper and lower lobes with sparing of the periphery. Pulmonary function tests demonstrated moderate obstructive lung disease with no bronchodilator response and normal diffusing capacity. Bronchoscopy with washings and lavage was inconclusive. Wedge surgical biopsy of the affected lung regions demonstrated frequently scattered non-necrotising epithelioid granulomas suggestive of SLGLD. He had symptomatic response to sarcoidosis therapy however there was no radiological improvement; a suggestion that sarcoidosis was not the culprit for the granulomatous disease.

Conclusion: Reporting case studies of incidents of occupational exposure-related lung diseases including iron ore dust and management strategies is important given the very sparse knowledge and experience in this field.

Grant Support: WA Cancer Council, New South Wales Dust Diseases Care (iCare), NHMRC

Declaration of Interest: We have no conflict of interest to declare.

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Hazard ratios for lung cancer from Cox Regression.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HR Lower 95% CI Upper 95% CI p=</td>
</tr>
<tr>
<td>TSFE (yrs)</td>
<td>≤30 1.00 - -</td>
</tr>
<tr>
<td></td>
<td>30-50 1.13 0.25 5.20 0.87</td>
</tr>
<tr>
<td></td>
<td>≥50 1.42 0.28 7.11 0.67</td>
</tr>
<tr>
<td>Ever smoker</td>
<td>5.30 1.25 22.4 0.02</td>
</tr>
<tr>
<td>Pack years (per 10 pack-years)</td>
<td>1.12 1.05 1.19 &lt;0.01</td>
</tr>
<tr>
<td>Asbestos exposure (f/mly)</td>
<td>2.07 1.20 3.57 &lt;0.01</td>
</tr>
<tr>
<td>Asbestos exposure &gt;5 (f/mly)</td>
<td>1.99 0.99 3.99 0.05</td>
</tr>
<tr>
<td>Any pleural plaque</td>
<td>0.63 0.35 1.11 0.11</td>
</tr>
</tbody>
</table>

(TSFE = Time since first asbestos exposure; f/mly = fibres / ml-years; HR = Hazard Ratio; CI = Confidence Interval)

Conclusion: In this population, the presence of pleural plaques did not increase the risk of lung cancer.

Grant Support: WA Cancer Council, New South Wales Dust Diseases Care (iCare), NHMRC

Declaration of Interest: We have no conflict of interest to declare.


Copyright of individual abstracts remains with the authors.
THE WITTENOOM LEGACY
MUSK A1, REID A2, OLSN N1, HOBBS M1, ARMSTRONG B1, FRANKLIN P1, HUI J2, LAYMAN L3, BRIMS P4, ALFONSO H1, SHILKIN K3, SODHI-BERRY N3, DE KLERK N1
1School of Population Health, University of Western Australia, Nedlands, Australia, 2School of Public Health, Curtin University, Australia, 3PathWest Laboratory Medicine WA, Nedlands, Australia, and 4School of Social Sciences, Murdoch University, Murdoch, Australia

Introduction/Aim: In the fifty years since the Wittenoom crocidolite (blue asbestos) industry ceased operating, the epidemic of asbestos-related diseases in Australia has intensified.

Use of the employment records of the Australian Blue Asbestos Company and records of the Wittenoom township residents has permitted two cohorts of people with virtually exclusive exposure to blue asbestos to be assembled.

Methods: Exposure data have been analysed and follow-up of these two cohorts has been conducted through all available public records including mortality records in all states of Australia and in Italy, cancer registries of Western Australia (WA) and Federal mesothelioma registries.

Results: Although the pattern of occurrence of asbestos-related diseases in the Wittenoom cohorts has changed, there has been an ongoing epidemic of mortality from lung cancer and malignant mesothelioma and also from asbestosis. Benign pleural diseases continue to be seen. Quantitative exposure-response relationships have been established.

Conclusion: The industrial disaster that was Wittenoom has been directly responsible for many deaths as well as ongoing disease and social issues in people who worked in the mine and mill, who lived in the town, were involved in the transport of asbestos or were exposed to the product occupationally, domestically or environmentally subsequently.

The legacy continues. It has prompted the establishment of epidemiological, clinical and scientific research groups in order to understand the biology and behaviour of the various asbestos-related diseases and improve their diagnosis and clinical management, thereby contributing significantly to scientific knowledge.

Grant Support

LONGITUDINAL CHANGES IN PROFESSIONAL FIREFIGHTER LUNG FUNCTION: A SYSTEMATIC REVIEW
SLATTERY F1, JOHNSTON K2, BENNETT H1, CROCKETT A1
1Alliance for Research in Exercise, Nutrition and Activity (ARENA), Sansom Institute, School of Health Sciences, University of South Australia, Adelaide, Australia, and 2School of Health Sciences, Sansom Institute for Health Research, University of South Australia, Adelaide, Australia

Introduction/Aim: Firefighters may be routinely exposed to harmful airborne substances which increase their risk of developing respiratory illness. This systematic review aimed to investigate the rate of change in the forced expiratory volume in one second (FEV1), often used as a marker of chronic obstructive pulmonary disease risk, in urban professional firefighters.

Methods: A systematic search was conducted in four electronic databases. Articles were included for review if they reported FEV1 in the same professional firefighters on ≥2 occasions over ≥1 year. Rate of change in FEV1 was extracted independently by two authors when reported, or manually calculated as the change in FEV1 from baseline to follow-up divided by the time interval.

Results: Twenty-one studies, published between 1974 and 2016 were included. Fifteen studies reported FEV1 in firefighters who performed routine firefighting duties, five of which made comparisons to non-firefighter controls. One study showed an improvement in FEV1, while others reported declines of 27 to 81 mL/yr in never-smokers; typically less than that of smoking firefighters. Studies that compared FEV1 to non-firefighter controls reported conflicting results. A further six studies reported FEV1 declines at 4.8-50.8 % based on variables.

Conclusion: The large degree of heterogeneity across studies as well as lack of clarity in reporting results makes generalisations difficult. However, healthy, non-smoking firefighters who use respiratory protection, and who are not subjected to a disastrous exposure should expect to have a normal rate of FEV1 decline.

Grant Support: This research was supported by the South Australian Metropolitan Fire Service and an Australian Government Research Training Program Scholarship (FS).
HYPERSENSITIVITY PNEUMONITIS ASSOCIATED WITH METASTATIC UROTHELIAL CARCINOMA: A PARANEOPLASTIC PHENOMENON?
DUNN E1, KHAIRA G2, TWADDELL S1
1John Hunter Hospital, Newcastle, Australia, and 2Hunter Histo Pty Ltd, Newcastle, Australia

Introduction: Peripheral eosinophilia and eosinophilic pleural effusions are known to occur in association with malignancy(1-3). We present a case of metastatic urothelial carcinoma(UC) with concurrent hypersensitivity pneumonitis(HP) in the context of minimal exposure history and in the absence of many classical features of HP.

Case Presentation: A 70 year old man presented with a 3 month history of progressive dyspnoea, lethargy, non-productive cough and weight loss.

He had been an oyster farmer for 50 years. Three days annually were spent preparing wooden frames without respiratory protection; an activity which exposed him to mud dust, tar particulates and tar fumes. He experienced acute inhalational effects of exposure to tar fumes but no prolonged respiratory symptoms.

High resolution CT showed honeycombing and interlobular septal thickening with bilateral apicobasal gradient(Fig 1). Lung biopsy showed extensive lymphatic and vascular invasion by metastatic, poorly differentiated UC(Fig 2). There were also changes consistent with HP, with loose non-necrotising peribronchiolar and interstitial granulomata and mixed infiltrates of lymphocytes, histiocytes and eosinophils.

Blood pathology was normal.

Discussion: While HP associated with lung UC has not previously been reported, paraneoplastic peripheral hyper-eosinophilia is well described(1). There has also been a single previous report of metastatic UC to the lung with peripheral eosinophilia, eosinophilic pleural effusion, and neutrophilic and eosinophilic lung infiltrates(3).

Given our patient had no history of respiratory illness, very infrequent exposure to potential inciting antigens, and no peripheral eosinophilia, it is possible that his HP was induced by local or systemic tumour-related factors.

Conclusion: In the absence of peripheral eosinophilia, which would support a diagnosis of true HP, and in the face of extensive interstitial metastatic UC, it is possible that the findings are a local, tumour-induced immune response or paraneoplastic phenomenon. The authors believe this may be the first report of a UC associated paraneoplastic HP without peripheral blood eosinophilia.

REFERENCES

Grant Support: Nil
Conflicts of Interest: Nil

THE MACROPHAGE INFLAMMATORY RESPONSE TO IRON OXIDE AND SILICA
WILLIAMS L1, ZOSKY G2
1University of Tasmania, Sandy Bay, Australia

Introduction and Aims: Previous studies have focused on the effects of urban PM10, however, little is known about the impacts of geogenic (earth-derived) PM10 on respiratory health. In vivo studies suggest that geogenic iron oxide causes inflammation. This study aimed to investigate the in vitro macrophage response to crystalline silica (quartz) and iron oxide (haematite & magnetite).

Methods: The THP-1 human monocyte cell line was differentiated into macrophages prior to exposure to quartz (SiO2), haematite (Fe2O3) or magnetite (Fe3O4) at a range of concentrations (0, 10, 25, 50, 75 & 100 μg/mL). To assess the impact of exposure to the particles on the response to bacterial infection, cells were cultured with or without LPS (10 ng/mL). Interleukin (IL)-1β, IL-6 and IL-8 production in the supernatant was measured by ELISA.

Results: IL-8 was significantly increased with exposure to quartz (10, 25, 50, 75 & 100 μg/mL; p<0.001), haematite (25, 50 & 75 μg/mL; p<0.01) and magnetite (50 μg/mL; p<0.01). When stimulated with LPS, IL-8 production was significantly increased by quartz (10, 25 & 50 μg/mL; p<0.05), haematite (25 & 50 μg/mL; p<0.01) and magnetite (50 μg/mL; p<0.01). In the absence of LPS, IL-6 and IL-1β levels were below the limit of detection. With LPS, IL-6 production was increased by quartz (50 & 75 μg/mL; p<0.01), haematite (50 & 100 μg/mL; p<0.01) and magnetite (10, 25 & 75 μg/mL; p<0.05). Similarly, IL-1β increased with exposure to haematite (50, 75 & 100 μg/mL; p<0.001) and magnetite (50 & 100 μg/mL; p<0.05), but not to quartz, in the presence of LPS.

Conclusion: Our data suggests that quartz, haematite and magnetite can induce a pro-inflammatory response and exacerbate the bacterial response in macrophages. Our data suggest that macrophages may play a pivotal role in the inflammatory response to geogenic particles in vivo.
BACILLUS LICHIENIFORMIS IN GEOGENIC DUST INCREASES INFLAMMATORY RESPONSES IN THE RESPIRATORY EPITHELIUM DURING NON-TYPEABLE HAEMOPHILUS INFLUENZAE INFECTION

CLIFFORD H1, TEO T1, THORNTON R2,3, KIRKHAM L2,3, ZOSKY G4, PICKERING J2

1Telethon Kids Institute, University of Western Australia, Perth, Australia, 2Wesfarmers Centre for Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Perth, Australia, 3School of Biomedical Sciences, University of Western Australia, Perth, Australia, and 4School of Medicine, University of Tasmania, Hobart, Australia

Introduction/Aim: The development and progression of chronic lung diseases such as bronchiectasis involves recurrent episodes of severe respiratory bacterial infections. We have recently shown that exposure to environmental geogenic dust PM10 (particulate matter <10μm) may exacerbate the response to non-typeable Haemophilus influenzae (NTHi) infection in the human airway. The components of geogenic dust that drive these responses are not yet known. Persistent microbial contamination of cultures led us to investigate the bacterial component of geogenic dust.

Methods: Geogenic dust was collected from remote towns in Western Australia, and PM10 was extracted. We assessed the microbial component of this community-sampled dust PM10 using 16S rRNA sequencing. We exposed immortalized human airway epithelial cells (NuLi-1) to increasing doses of our isolated Bacillus licheniformis strain (MOI 0.01, 0.1 and 1:1 bacteria:cells) for 1, 3, or 24 h. B. licheniformis and NTHi infection (association and invasion) was assessed using a standard gentamicin survival assay. Epithelial release of IL-6 and IL-8 was assessed using a bead based immunoassay.

Results: We identified the presence of Bacillus licheniformis, a spore-forming, environmentally abundant bacteria. B. licheniformis was cytotoxic to NuLi-1 cells at 24 h. At 3 h, live and heat-killed B. licheniformis produced high IL-6 and IL-8 inflammatory responses. Co-colonisation of B. licheniformis with NTHi did not increase NTHi infection, but did evoke significantly greater IL-6 and IL-8 inflammatory responses (p<0.0001 and p<0.0001 respectively) compared with PBS control and NTHi-only challenge.

Conclusion: These findings have important implications for lung health in individuals living in and environments such as those in the remote regions of Australia, who are exposed to high loads of geogenic dust. Further investigation into the contribution of B. licheniformis and the wider dust microbiome to respiratory infection is warranted.

Grant Support: BrightSpark Foundation, Raine Medical Research Foundation

Declaration of Interest: All authors declare no conflicts of interest.

CEREBRAL ARTERIAL GAS EMBOLISM IN A SCUBA DIVER WITH A PRIMARY LUNG BULLA

GOFFINET C1, SIMPSON G1

1Cairns Hospital, Cairns North, Australia

Primary lung bullae have been reported to cause pulmonary barotrauma and lead to cerebral arterial gas embolism (CAGE) in the context of SCUBA diving, however a lack of symptoms and often minimal radiographic findings often preclude a diagnosis of lung bullae prior to undertaking SCUBA diving activity. We present the case of a fit and healthy 27 year old Caucasian male who presented following the second of two introductory resort SCUBA dives. He developed chest discomfort and dyspnoea immediately on surfacing, which was followed by left-sided hemiparesis and paraesthesias as well as expressive aphasia. His neurological symptoms completely resolved after 10 minutes. A chest X-ray showed a large bulla in the right upper zone containing an air-fluid level. A CT chest confirmed the presence of a large thin-walled fluid-containing bulla in the right upper lobe with surrounding alveolar shadowing, likely representing pulmonary haemorrhage. There was a smaller bulla in the left lower lobe. The diagnosis was of pulmonary barotrauma secondary to a primary lung bulla leading to CAGE. A review of the literature identified several isolated case reports of pulmonary barotrauma leading to CAGE secondary to asymptomatic primary lung bullae. This case highlights the clinical sequelae of primary lung bullae in the context of SCUBA diving activity.
PREGNANCY ALTERS THE IMMUNE RESPONSE TO PARTICULATE RESPIRATORY INSULTS
THAVER S1, BENNETT E1, FOA L1, RICHARDS S1, LYONS B1, ZOSKY G1
1School of Medicine, Faculty of Health, University of Tasmania, Hobart, Australia

Introduction/Aim: Air pollution is associated with an increased risk of respiratory morbidity and mortality. Identifying susceptible individuals is key to mitigating the health risk associated with exposure to air pollution. While the in utero effect(s) of exposure to inflammatory insults has been studied, there are almost no data on the effect of pregnancy on the respiratory response to air pollution. Therefore, the aim of this study was to determine whether pregnancy alters the inflammatory and immune response to respiratory insults.

Methods: Eight-week-old pregnant C57BL/6J mice were exposed intranasally to saline, iron oxide (Fe2O3) particles or house dust mite (HDM) extract at gestational day (E)7.5, E12.5 and E17.5. Non-pregnant controls were exposed at day (D)0, D5 and D10. Mice were euthanased at E18.5 or D11. A bronchoalveolar lavage sample was collected for assessment of inflammatory cell infiltrate and cytokine production. The spleen and thymus were isolated and processed for flow cytometry for assessment of CD4+, CD8+ and CD4+CD25+ T cell populations

Results: Exposure to Fe2O3 (p < 0.001) and HDM (p = 0.01) reduced the %CD4+ T cells and increased the %CD8+ T cells (Fe2O3, p = 0.002; HDM, p = 0.006) in the spleen of non-pregnant mice but not pregnant mice (p > 0.05 for all comparisons). Exposure to Fe2O3 increased the %CD4+ T cells in the thymus, however this response was not altered by pregnancy (p = 0.17). Pregnancy reduced the %CD4+CD25+ T cells in the spleen (p = 0.007) and %CD8+ T cells in the thymus, however there was no effect of treatment on these cell populations (p > 0.05 for all comparisons).

Conclusion: These results suggest that pregnancy impairs the immune response to particulate respiratory insults. The impact of this on the maternal inflammatory response and fetal immune development is unclear and warrants further investigation.

LUNG HEALTH IN NEW ZEALAND GANG MEMBERS: RESULTS FROM A HEALTH HUI
DUMMER J1, COWAN J1, TEWHAITI-SMITH J1, ALUZAITE K1, FITZGERALD C2, SCHULTZ M1
1University Of Otago, Dunedin, New Zealand, and 2Dunedin Hospital, Dunedin, New Zealand

Introduction/Aim: Little is known about lung health in New Zealand gang members, their whānau (extended family) and affiliates. The prevalence of smoking, asthma and chronic obstructive pulmonary disease (COPD) are unknown in this group. A better understanding of lung health in this group might inform public health policy and facilitate targeted strategies to improve lung health. We aimed to determine the prevalence of smoking, asthma and COPD in a group of New Zealand gang members, their whānau and affiliates at a health hui (meeting).

Methods: We organised a health hui for the Notorious chapter of the Mongrel Mob in the central North Island of New Zealand. We collected demographics, smoking and respiratory history, height and weight from participants, and we performed spirometry and exhaled nitric oxide tests. A respiratory doctor and nurse were available to offer advice and local health contacts for any known or newly-diagnosed lung disease, and smoking cessation advice was available.

Results: We studied 26 Notorious Mongrel Mob gang members, affiliates and their whānau. 19 participants were current smokers (prevalence 73%), 5 were ex-smokers and 2 had never smoked. Two participants had a known history of asthma and a new diagnosis was made in a third. No COPD diagnoses were noted.

Conclusion: We successfully conducted a community-focused, hard-to-reach gang population study, and were able to obtain first-of-its-kind data on smoking, asthma and COPD in this population. The smoking prevalence of 73% in this group was much higher than the average nationally and for Māori of 16% and 39% respectively.

Grant Support: This study was supported by internal departmental funds.
SCREENING FOR SLEEP DISORDERED BREATHING IN HAEMODIALYSIS PATIENTS

CHU G1,2,3, CHOI P1, MCDONALD V2,4,5
1Nephrology Department, John Hunter Hospital, New Lambton Height, Australia, 2School of Nursing and Midwifery, University of Newcastle, Newcastle, Australia, 3Hunter New England Local Health District, New Lambton Height, Australia, 4Priority Research Centre for Healthy Lung, University of Newcastle, Newcastle, Australia, and 5Department of Respiratory and Sleep Medicine, John Hunter Hospital, New Lambton Height, Australia

Introduction: Previous studies suggest that sleep-disordered breathing (SDB) is common in patients with kidney disease; however this is infrequently assessed in practice. We aim therefore was to evaluate the performance of screening tools and the association of SDB and clinical factors in haemodialysis patients.

Methods: A cross-sectional study recruiting 92 haemodialysis patients was conducted. We examined the presence of SDB using the STOPBANG questionnaire, Epworth Sleepiness Scale (ESS) and nocturnal oximetry. Patients with an oxygen desaturation index (ODI) of ≥5 were classified as having SDB. A STOPBANG score ≥3 and or an ESS score ≥10 were used as a risk indicator for SDB. Patient characteristics and pre-dialysis blood samples were collected.

Results: The mean±SD age was 67±15.2 years, and 47% were female. Hypertension (67%) and high body mass index (BMI) (65%, mean 28.9±5.2) were common. The mean ODI of the 77 patients who completed an overnight oximetry was 15.09±17.34, and 65% had an ODI≥5. STOPBANG was abnormal in 89% of participants, but only 17% had an ESS≥10. ODI and STOPBANG were significantly correlated (r=0.46, p<0.001), as were ODI and BMI (r=0.44, p<0.001), neck circumferences (r=0.47, p<0.001) and dialysis adequacy (Average Kt/V: 0.38, p<0.0006), but not ESS (r=0.17, p=0.14). Multivariate analysis showed that neck circumference (OR: 1.17, p=0.03), working (OR: 0.02, p=0.02) and haemoglobin (OR: 0.92, p=0.006) were independently associated with the occurrence of SDB.

Conclusion: The prevalence of SDB in patients receiving intermittent haemodialysis is high. Although patients are not presenting with traditional symptoms of daytime tiredness as reflected in the ESS score; other risk factors such as a high STOPBANG score and large neck circumferences were associated with a high ODI score. Diagnostic testing of SDB using polysomnography can be expensive, STOPBANG and neck size may be useful SDB risk screening tools in the haemodialysis population.

Grant Support: None

DYSFUNCTIONAL BREATHING IN PATIENTS WITH TREATMENT NAÏVE OBSTRUCTIVE SLEEP APOnea

BARNETT A1, SRIRAM K2, SIMPSON G2
1Gold Coast University Hospital, Southport, Australia, and 2Caims Hospital, North Cairns, Australia

Introduction and Aims: Occasionally patients being evaluated for sleep disordered breathing (SDB) report symptoms of breathlessness that is unexplained by standard cardio-pulmonary evaluation. Dysfunctional breathing (DB) has been reported to result in breathlessness in some patients. A previous study by our group identified DB in 22% of patients referred for sleep studies. The aim of this study was to assess the prevalence of dysfunctional breathing in patients with newly diagnosed obstructive sleep apnoea (OSA).

Methods: We conducted a prospective observation study of patients diagnosed with obstructive sleep apnoea (OSA) and had been referred for continuous positive airway pressure (CPAP) therapy. Participants who provided written informed consent were asked to complete the ‘Nijmegen’ questionnaire, a validated tool to assess the subjective/functional dimension of dyspnoea. Participant demographic, Epworth Sleepiness Score (ESS) and polysomnographic data were also collected.

Results: Forty participants (median age 57, 58% male) have been enrolled so far. Eighteen (45%) had a Nijmegen score of ≥23 (i.e. positive for dysfunctional breathing). Participants with dysfunctional breathing were more likely to have an elevated ESS (median 13 versus 9.5, p<0.001). There was no difference in the apnoea-hypopnoea index, oxygen saturation, sleep latency, body mass index, sex or age between patients with normal and patients with elevated Nijmegen scores.

Conclusion: Our pilot study has identified that dysfunctional breathing is very common in patients with newly diagnosed OSA. Ongoing participant recruitment will allow a larger sample size and will address the question of whether CPAP treatment improves dysfunctional breathing in OSA patients.

Grant Support: None
APNEALINK® IN THE DIAGNOSIS OF OBSTRUCTIVE SLEEP APNEOA

SMITH D1, PARK J2, HAY K2, HOEY L1, DOWNEY C1, BROWN G1, WOVENCROFT E1, LEONG M2, CURTIN D1, TAY G1

1The Prince Charles Hospital, Chermside, Australia, 2QIMR Berghofer Medical Research Institute, Herston, Australia, 3Royal Brisbane & Women’s Hospital, Herston, Australia, and 4Thoracic and Sleep Medicine, The Royal Brisbane & Women’s Hospital, Australia

Introduction/Aim: A major impediment to the provision of obstructive sleep apnoea (OSA) treatment is the reliance on labour-intensive and costly, sleep physician-led diagnostic laboratory-based polysomnography (PSG). This study investigated if oximetry and nasal breathing via the ApneaLink® device (AL) could be used to identify patients with moderate-severe OSA in those referred for PSG to a tertiary Sleep Service.

Methods: New referrals to The Prince Charles Hospital Sleep Disorders Centre were assessed for study suitability. Demographics, anthropometrics, Epworth Sleepiness and OSA50 scores were collected. Exclusion criteria included age <18 years, pregnancy, significant cognitive impairment, poorly controlled psychiatric disorder, domiciliary oxygen and prior OSA treatment. Participants underwent concurrent Level 1 PSG and AL assessments.

Results: The 100 participants had a mean age of 55 (SD 17) and were 49% male. 48 (48%) had moderate-severe OSA on PSG. AL 3% oxygen desaturation index (ODI) ≥16 had receiver operator characteristic area under the curve of 0.86, sensitivity of 88% and specificity of 84% for PSG AHI ≥15. Various composites of AL, anthropometric and questionnaire variables did not improve upon the AUC or sensitivity of 3% ODI ≥16 but did improve specificity. There were 6 false negative AL 3% ODI (AL 3% ODI <16 but PSG AHI ≥15). 7 of the 8 false positives (AL 3% ODI ≥16 but PSG AHI <15) had PSG AHI >5 (mild OSA) and 7 had average PSG SpO2 <94%.

Conclusion: AL may play a role in the diagnosis of moderate-severe OSA in those referred for PSG to a tertiary Sleep Service. This could lessen the reliance on PSG for OSA diagnosis, shorten time to treatment initiation, improve waiting lists for PSG and provide significant cost savings. False positive results occurred in those with mild sleep apnoea and/or low baseline oxygen saturations.

Grant Support: Nil.

TEMPORAL METRICS DERIVED FROM ELECTRICAL IMPEDANCE TOMOGRAPHY DEMONSTRATE ABNORMAL REGIONAL VENTILATION DISTRIBUTION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE

MILNE S1,2,3,4, HUVAHANDA J1, NGUYEN C1, SLATTERY A2,3, DUNCAN J3, THAMRIN C1, KING G1,2,3

1Woolcock Institute Of Medical Research, Glebe, Australia, 2Department of Respiratory and Sleep Medicine, Royal North Shore Hospital, Northern Sydney Local Health District, St Leonards, Australia, 3Northern Clinical School, Sydney Medical School, University of Sydney, Sydney, Australia, and 4Central Clinical School, Sydney Medical School, University of Sydney, Camperdown, Australia

Introduction/Aim: Electrical impedance tomography (EIT) is a non-invasive imaging technique which measures dynamic changes in thoracic electrical impedance during the respiratory cycle, with low spatial but high temporal resolution. We aimed to characterise regional ventilation distribution using temporal metrics derived from EIT in subjects with COPD.

Methods: 6 male COPD subjects (median(range) age 72(50-86) years, mean±SD FEV1 Z-score -3.31±1.49) and 8 healthy male controls (median(range) age 32(23-73) years, mean±SD FEV1 Z-score -0.08±1.24) underwent spirometry and EIT testing (Dräger PulmoVista® 500, 16 electrode belt, frame rate 50 Hz, during 30 s tidal breathing in the upright posture). The tidal variations in impedance (VT) for the global signal and for each of 256 regions of interest (ROIs) were examined offline. ROIs were visualised as heat maps based on the following features: 1) mean expiratory time (TE); 2) mean breath full-width-half-max (FWHM); 3) mean phase shift relative to global VT (PHASE). Regional distribution of ventilation for each feature was determined by: mean, variability of frequency histograms; mean anterior-mean posterior difference (AP); and fractal dimension (FDdist, slope of the log-log relationship of the SD of differences between ROI pairs as a function of inter-ROI distance).

Results: There were no significant differences between COPD and controls in histogram mean or variability for any feature. PHASE-AP was lower in COPD compared to controls (0.22±0.06 vs 0.22±0.06, p=0.04). PHASE-FDdist showed expected increasing ventilation phase variability with increasing distance, following a power-law relationship, but was significantly weaker in COPD vs controls (0.12±0.04 vs 0.22±0.06, p=0.004). PHASE-DISTro was correlated with FEV1 and FEV1/FVC ratio.

Conclusion: Using EIT-derived temporal metrics of respiratory cycle phase differences, the organised regional distribution of ventilation appears to be altered in COPD compared to controls and may relate to the degree of airflow obstruction.
PROLONGED RESPIRATORY SUPPORT FOR PATIENTS RECOVERING FROM SEVERE GUILLAIN-BARRE SYNDROME

CHENG M1, MURPHY P1, HART N1, HOWARD R1
1Lane Fox Respiratory Unit, London, UK

Introduction/Aim: Guillain-Barre Syndrome (GBS) is an autoimmune neuropathy which can lead to respiratory failure due to muscle weakness. Recovery can take months to years. In rare cases, it can lead to requirement for prolonged respiratory support. We present the outcomes data from a tertiary referral weaning centre.

Methods: Clinical review of patient records who presented with a diagnosis of GBS between 2006-2016 and were transferred to a 34-bed specialist weaning facility in London, UK. Patient characteristics including age, sex, time to mechanical ventilation and nerve conduction study results were collected. Primary outcome was time to removal of tracheostomy.

Results: 28 patients (21 male) were referred with median age of 60 (range: 18-85). Median time to intubation was 2 days (range: 0-56 days). 9 patients had a demyelinating pattern; 13 with axonal pattern; 6 had equivocal response or results were not available. 19 patients were weaned from mechanical ventilation with a median time of 150 days (range: 50-500); 7 (25%) required long-term non-invasive respiratory support. 1 patient required tracheostomy re-insertion; 1 patient died from hospital acquired pneumonia whilst awaiting placement. Patients with axonal pattern of nerve damage who weaned from invasive ventilation were younger (median: 57 vs. 66) and took longer to wean from mechanical ventilation (median: 183 vs. 137 days).

Conclusion: Guillain-Barre Syndrome can lead to chronic respiratory failure requiring prolonged invasive mechanical ventilation. Our cohort demonstrates that there is potential for long-term recovery and liberation from invasive ventilator support. There is a role for non-invasive ventilation in patients requiring long-term respiratory support allowing them earlier liberation from invasive ventilation.

COMPARISON OF TWO METHODS OF DETERMINING LUNG DE-RECRUITMENT, USING FOT

NILSEN K1,2, THIEN F1,3, GOVE K4, WILKINSON T4, THOMPSON B1,2
1Monash University, Melbourne, Australia, 2The Alfred Hospital, Melbourne, Australia, 3Eastern Health, Melbourne, Australia, and 4University of Southampton, Southampton, UK

Introduction/Aim: Airway closure has proved to be important in a number of respiratory diseases and may be the primary defect in asthma. Closing volume can be identified using the forced oscillation technique (FOT), by performing a deflation manoeuvre and examining the resultant reactance (Xrs) lung volume relationship. This study aims to determine if a simple slow vital capacity (SVC) manoeuvre during a FOT test can be used to determine closing volume and compare it to existing more complex techniques.

Methods: Three subject groups were included in the study; healthy (n=29), asthmatic (n=18), and COPD (n=10) subjects for a total of 57 subjects. Reactance lung volume curves were generated via FOT recordings during two different breathing manoeuvres (both pre and post bronchodilator). The correlation and agreement between the closing volume (Volcrit) and reactance (Xrscrit) at this volume was analysed. The changes in Volcrit and Xrscrit pre and post bronchodilator were also analysed.

Results: Across all three subject groups the two different measures of Volcrit were shown to be statistically equivalent (P>0.05) and demonstrated a strong fit to the data (R² = 0.49, 0.78, 0.59, for asthmatic, COPD and healthy subject groups respectively). A bias was evident between the two measurements of Xrscrit with statistically different means (p<0.05). However the two measurements of Xrscrit displayed the same trends.

Conclusion: In conclusion we have developed a new alternative technique for measuring airway closure from FOT recordings. The technique delivers equivalent and possibly more sensitive results to previous methods while being simple and easily performed by the patient.
A SINGLE CENTRE 6 YEAR AUDIT OF DIAPHRAGM DYSFUNCTION
TAVERNER J1, FULLER L1, SNELL G1,2, HEW M1,2, NAUGHTON M1,2
1Alfred Health, Melbourne, Australia, and 2Monash University, Melbourne, Australia

Introduction/Aim: Diaphragm dysfunction (DD) results from pathology involving the innervation, contractile properties, or mechanical attachments of the diaphragm. Common causes include cardiac surgery, neuropathy and myopathy. The symptoms and course of DD are highly variable. We examined a cohort of patients in a major tertiary trauma centre (520 beds, 110,000 admissions/year) with high volume heart and lung transplant units to ascertain incidence, aetiology, and clinical significance of DD.

Methods: A retrospective medical record audit was performed of patients diagnosed with DD via fluoroscopy or thoracic ultrasound over six years (2011-2017).

Results: Sixty-five patients were identified with DD: 92% unilateral and 8% bilateral. Mean age 56 years, 62% male and mean BMI 24.5. At diagnosis, mean forced vital capacity (FVC) was 2.36 (±0.84L (52%±19%)) and mean PaCO2 was 45.0 (±9.7mmHg). Commonest causes of DD were lung transplant (65%), non transplant cardiothoracic surgery (9%), idiopathic (9%) and cardiac transplant (8%). DD was persistent in 38 patients (59%) and complete resolution occurred in 14 patients (22%). Eighteen patients (28%) required treatment with non-invasive ventilation. Baseline PaCO2 was significantly elevated in patients with bilateral compared to unilateral DD with a trend to lower FVC and greater total sleep time with SpO2<90%.

<table>
<thead>
<tr>
<th></th>
<th>N (N=65)</th>
<th>FVC (%) (N=56)</th>
<th>TST SpO2&lt;90% (N=28)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Latersity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unilateral</td>
<td>60</td>
<td>46.2 (±9.5)</td>
<td>2.30 (±0.85)</td>
</tr>
<tr>
<td>Bilateral</td>
<td>5</td>
<td>55.2 (±9.5)</td>
<td>1.96 (±0.58)</td>
</tr>
<tr>
<td>p value</td>
<td>0.0438</td>
<td>0.3513</td>
<td>0.6811</td>
</tr>
<tr>
<td>Cause</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Post lung</td>
<td>45</td>
<td>47.0 (±9.6)</td>
<td>2.31 (±0.84)</td>
</tr>
<tr>
<td>transplant</td>
<td>13.9 (±26.3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other cause</td>
<td>20</td>
<td>46.4 (±10.2)</td>
<td>2.16 (±0.89)</td>
</tr>
<tr>
<td>p value</td>
<td>0.8066</td>
<td>0.6147</td>
<td>0.1531</td>
</tr>
<tr>
<td>Persistence</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Persistent</td>
<td>38</td>
<td>46.4 (±9.1)</td>
<td>2.17 (±0.76)</td>
</tr>
<tr>
<td>Resolved</td>
<td>21</td>
<td>47.9 (±10.0)</td>
<td>2.40 (±0.97)</td>
</tr>
<tr>
<td>p value</td>
<td>0.5703</td>
<td>0.4980</td>
<td>0.3858</td>
</tr>
</tbody>
</table>

Forced vital capacity FVC, total sleep time TST, peripheral capillary oxygen saturation SpO2

Values are mean (standard deviation)

Conclusion: In a major trauma centre with heart-lung transplant, most cases of DD were caused by lung transplantation. However non-transplant causes accounted for roughly one new diagnosis every three months. Clinicians should be aware of this condition as DD is frequently persistent and over one quarter may require ventilator support.

Grant Support: Nil

EFFECT OF ENDO TRACHEAL TUBE RESISTANCE ON OPTIMIZING MECHANICAL VENTILATION
WIN Z1, CLARK A1, CHASE J2, TAWHAI M1
1Auckland Bioengineering Institute, The University of Auckland, Auckland, New Zealand, and 2Department of Mechanical Engineering, The University of Canterbury, Christchurch, New Zealand

Introduction/Aim: The endotracheal tube (ETT) serves as the connection between the mechanical ventilator (MV) and the patient. Partial occlusion of ETT is common, and the subsequent increase in ETT resistance (RETT) theoretically decreases delivered tidal volume (VT). Although ETT suctioning (removing the blockage) is regularly performed, if MV settings are not adjusted appropriately post-suction the lungs could be subjected to transient or sustained high alveolar pressures (Paw), leading to alveolar injury. Therefore, we aim to develop a model that can quantify the risk of biotrauma (inflammatory response to overstretching) and volutrauma (physical injury by over-distension).

Methods: We present an anatomically-based computational model of ventilation distribution to predict alveolar volume (VA) and Pavl over the breathing cycle of a MV patient driven by MV pressure (oscillated between 7-25cmH2O). The model was fitted to the patient’s flow data, by stiffening alveoli in dependent regions of the lungs, representing a patient with patchy localised atelectasis and/oedema. A 30cm long and 8mm diameter ETT was assumed to be 1) occluded with a 5cm long and 3.6mm diameter occlusion (RETT=10.58cmH2O/L.s), and 2) un-occluded (RETT=5.85cmH2O/L.s).

Results: In post-suctioning simulations, VT and average Paw were increased by ~17%(90mL) and ~15%(2cmH2O), respectively, compared with pre-suctioning simulations. The predicted distribution of increased VA was non-uniform with 16~31% increase in one-third of the lungs and ~1% in the remainder. Volume increase was mainly seen in normal alveoli in dependent regions of the lungs, suggesting that these normally functioning alveoli are most at risk from trauma relating to over-distension.

Conclusion: Prolonged VA increases of ~30% have been linked to biotrauma, and acute VA increases >70% to volutrauma. Our model suggests that suctioning without subsequent adjustment of MV settings is unlikely to result in volutrauma but may increase risk of biotrauma in normally functioning regions of the lung.

Grant Support: The Medical Technologies Centre of Research Excellence
SMALL AIRWAY FUNCTION IMPROVEMENT WITH MEPOLIZUMAB IN SEVERE EOSINOPHILIC ASTHMA

FARAH C1,2,3, SECCOMBE L1,2, ROGERS P1, REED N1, BADAL T1,3, THAMRIN C2,3, KING G1,2,3, PETERS M1,2,4
1Department of Thoracic Medicine, Concord Hospital, Concord, Australia, 2Sydney Medical School, The University of Sydney, Australia, 3The Woolcock Institute of Medical Research, Glebe, Australia, 4Faculty of Medicine and Health Sciences, Macquarie University, Australia, and 5Department of Respiratory Medicine, Royal North Shore Hospital, St Leonards, Australia

Introduction/Aim: Mepolizumab is a monoclonal antibody against interleukin-5 that was recently approved in Australia for severe eosinophilic asthma. In clinical trials, monthly treatment with mepolizumab results in clinically significant reductions in exacerbation rates, coupled with modest improvements in symptom control scores and FEV1. The acute effects of this biologic treatment on small airway function have not been previously described. The aim of this study is to describe changes in ventilation inhomogeneity as a marker of small airway function after the commencement of mepolizumab in adult with severe eosinophilic asthma.

Methods: This is a prospective case series of 5 patients (3 males) commencing mepolizumab for severe eosinophilic asthma according to the Pharmaceutical Benefit Scheme pre-specified criteria. At each monthly visit, patients underwent lung function testing including exhaled nitric oxide (eNO), spirometry and the multiple breath nitrogen washout test to measure functional residual capacity (FRC) and global (Lung Clearance Index, LCI) and regional indices of ventilation inhomogeneity attributed to the acinar (Sacin) and conducting (Scond) airways. Results at baseline and four weeks after the first injection are reported.

Results: Mean (range) age of patients was 61 (41-76) years, BMI 23.6 (23-25) kg/m2, post bronchodilator FEV1 50 (36-61) %predicted, FEV1/FVC ratio 50 (31-68)% and median (IQR) eNO 42 (32-75) ppb. One month after the first injection, post bronchodilator FEV1 improved variably 56 (27-151) mL. Mean FRC improved from 3.87 to 3.07 L. Measures of ventilation inhomogeneity were abnormal in all 5 patients and improved at one month: LCI 17.6 (13.5-21.6) improving to 12.0 (8.96-19.43), Sacin 0.380 (0.247-0.600) /L improving to 0.256 (0.140-0.399) /L, Scond 0.075 (0.053-0.100) /L improving to 0.061 (0.036-0.105) /L.

Conclusion: Our initial observation suggests an improvement in small airway function, i.e. ventilation inhomogeneity, as early as four weeks after the first injection of mepolizumab in patients with severe eosinophilic asthma.

Grant Support: Nil

ACT DOMICILIARY OXYGEN & RESPIRATORY SUPPORT SCHEME PORTABLE OXYGEN CONCENTRATOR TRIAL

VOON W1, MACPHERSON K1, AZZOPARDI D1, FIGURSKI D1, KEEN M2, HUANG H1,2
1The Canberra Hospital, Woden, Australia, and 2College of Medicine, Biology & Environment, Australian National University, Acton, Australia

Introduction/Aim: Ambulant oxygen therapy is routinely offered to patients with chronic severe lung disease. Following significant interest from consumers and advocacy groups regarding the portable oxygen concentrator (POC), the ACT Domiciliary Oxygen and Respiratory Support Scheme (DORSS) aimed to evaluate a protocol for prescribing oxygen via a POC and to determine if these devices are a viable alternative to oxygen cylinders for patients using ambulatory oxygen.

Methods: Twelve volunteer oxygen dependent clients from DORSS were first medically assessed by a Respiratory Physician, followed by spirometry and a 6 minute walk test (6MWT) with portable oxygen cylinder to determine POC prescription. 4 participants were excluded from the trial following initial assessment. 6MWT was repeated with a POC and those without significant oxygen desaturation were provided a loan POC for 3 months. A questionnaire about their POC use was sent fortnightly and pre and post POC St George Respiratory Questionnaires (SGRQ) were also completed.

Results: 8 participants completed the trial (median age 76 years). There was no clinically significant difference between pre-trial SGRQ scores (range 23-77, median 54) and post-trial SGRQ scores (range 22-64, median 52). Participants consistently agreed that the POC was easier and more convenient to use. Many felt more confident leaving home and attending social engagements with a POC. However, some found the POC too heavy to carry. There were no reported adverse events while using a POC.

Conclusion: Our study provides evidence that switching from oxygen cylinders to a POC may be done safely with an appropriate scripting process for ambulatory oxygen users. Participants unanimously found the POC superior to oxygen cylinders in terms of size and convenience. However, given our small number of participants, a larger study would be needed to assess safety and impact of the POC on quality of life.

Grant Support: ACT Domiciliary Oxygen & Respiratory Support Scheme

Respirology (2018) 23 (Suppl. 1), 104–215
EXPLORING THE FACTORS ASSOCIATED WITH FAILURE TO ATTEND SLEEP MEDICINE OUT-PATIENT CLINICS

PRASAD P1, SRIRAM K1,2
1Gold Coast University Hospital, Gold Coast, Australia, and 2Griffith University School of Medicine, Gold Coast, Australia

Introduction/Aim: It is estimated that 10-15% of patients fail to attend (FTA) out-patient sleep medicine clinic appointments. FTA appointments cause considerable disruption to the provision of quality care to patients but the reasons why patients do not attend appointments are poorly understood. The aim of this audit was to evaluate a cohort of patients who FTA sleep medical out-patient clinics in our institution to assess factors associated with non-attendance.

Methods: We identified 100 patients who had FTA a sleep medical appointment during the time period of 2016-2017. Patient demographic and information pertaining to the reason for clinic attendance was gathered from patient electronic medical records.

Results: The mean (±SD) age of the patients was 53±16 years. 63% of patients were male. The median (IQR) of distance of patient residential postcode to clinic site was 10 (3-36) kilometres. Of the 100 appointments, 30% were new clinic appointments and 70% were review appointments. The reasons for clinic appointment were: ongoing management of sleep apnea (69%); evaluation of possible sleep apnea (24%); evaluation of narcolepsy (3%); evaluation of possible parasomnias (2%), insomnia (1%) and respiratory failure (1%). In the electronic medical records, there was no documentation of the reason for the fail-to-attend in 93% of patients; 2% of patients had relocated elsewhere; 2% stated that they were unwell and hence could not attend the appointment and 2% stated that they were not interested in attending sleep medical clinics. 27% of patients had previously failed to attend a previous sleep medical out-patient clinic.

Conclusion: In this pilot study we have identified major gaps in knowledge about the process involved in identifying reasons patients’ FTA clinics. Considerable research is required to develop innovative approaches to reduce patient clinic FTA rates.

Grant Support: NIL
IMPROVED NON-INVASIVE VENTILATION PRESCRIPTION FORM REDUCES ADMINISTRATION ERRORS: A QUALITY IMPROVEMENT SUCCESS

JONES S1, MANNERS D1, PICCOLO F1
1Respiratory Department, St John of God Midland Public and Private Hospitals, Midland, Australia, 2Curtin Medical School, Curtin University, Perth, Australia

Introduction/Aim: Errors in the administration of non-invasive ventilation (NIV) are common. Poor documentation and inappropriate substitution of the values for Positive End Expiratory Pressure (PEEP), Pressure Support (PS), and Inspiratory Positive Airway Pressure (IPAP) contribute to errors. This study aimed to see if implementing a new NIV prescription form would improve prescription documentation and reduce NIV administration errors.

Methods: A multidisciplinary working group designed a new NIV prescription form. Key features allowed clinicians to distinguish between the three pressure values: PEEP, PS, and IPAP. Inpatient NIV episodes were audited pre-intervention (n=62) and post-intervention (n=49) recording 1) absent/incorrect prescription documentation incidence, 2) administration error incidence and 3) location of NIV commencement. Staff in ED and ICU received education prior to both audit periods.

Results: The post-intervention administration error rate was 4.1% (n=2/49), a significant (p=0.04) reduction from the pre-intervention error rate of 16% (n=10/62). The administration error rate was highest among patients who commenced NIV in ED without correct prescription documentation. The intervention appeared to reduce both the absent/incorrect documentation rate and the administration error rate only when NIV was initiated in the ED.

<table>
<thead>
<tr>
<th></th>
<th>Pre-intervention</th>
<th>Post-intervention</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Administration error</td>
<td>16.1% (n=10/62)</td>
<td>4.1% (n=2/49)</td>
<td>0.04</td>
</tr>
<tr>
<td>Absent/incorrect documentation</td>
<td>43.5% (n=27/62)</td>
<td>32.7% (n=16/49)</td>
<td>NS</td>
</tr>
<tr>
<td>When NIV commenced in ED</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Administration error</td>
<td>25.8% (n=8/31)</td>
<td>6.7% (n=1/15)</td>
<td>0.13</td>
</tr>
<tr>
<td>Absent/incorrect documentation</td>
<td>41.9% (n=13/31)</td>
<td>6.7% (n=1/15)</td>
<td>0.02</td>
</tr>
<tr>
<td>When NIV commenced as inpatient</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Administration error</td>
<td>6.5% (n=2/31)</td>
<td>2.9% (n=1/34)</td>
<td>NS</td>
</tr>
<tr>
<td>Absent/incorrect documentation</td>
<td>45.2% (n=14/31)</td>
<td>44.1% (n=15/34)</td>
<td>NS</td>
</tr>
</tbody>
</table>

Conclusion: Errors in the administration of NIV significantly reduced following the implementation of the new NIV prescription form.

Grant Support: No funding was received for this project.

Declaration of Interest Statement: The authors have no competing interests to declare.

Respirology (2018) 23 (Suppl. 1), 104–215 Editorial material and organization © 2018 Asian Pacific Society of Respirology. Copyright of individual abstracts remains with the authors.